Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,29972644,IC50,"Compared with our previous lead compound S-230, our most potent antagonist, S-C025, has an IC50 (120 pM) over 80 times lower and a substantially longer plasma half-life.","Novel Highly Potent and Metabolically Resistant Oxoeicosanoid (OXE) Receptor Antagonists That Block the Actions of the Granulocyte Chemoattractant 5-Oxo-6,8,11,14-Eicosatetraenoic Acid (5-oxo-ETE). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29972644/),pM,120,139,DB01373,Calcium
,29972644,IC50,"A single major metabolite, which retains antagonist activity (IC50, 690 pM) and has a prolonged lifetime in plasma was observed.","Novel Highly Potent and Metabolically Resistant Oxoeicosanoid (OXE) Receptor Antagonists That Block the Actions of the Granulocyte Chemoattractant 5-Oxo-6,8,11,14-Eicosatetraenoic Acid (5-oxo-ETE). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29972644/),pM,690,140,DB01373,Calcium
,21988149,release,"The highest significant release (p < 0.05) was achieved from the lyophilized ternary complex containing 100 mg of Fn in presence of polyvinylpyrrolidone (PVP K(25)), exhibiting a release of 88.25% ± 0.93 after 5 min of chewing.","Immediate release three-layered chewing gum tablets of fenoprofen calcium: preparation, optimization and bioavailability studies in healthy human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988149/),%,88.25,350,DB01373,Calcium
,21988149,relative bioavailability,The relative bioavailability of the selected gum tablet was found to be 166.06% compared to Nalfon(®) 200 mg capsules.,"Immediate release three-layered chewing gum tablets of fenoprofen calcium: preparation, optimization and bioavailability studies in healthy human volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988149/),%,166.06,351,DB01373,Calcium
,15031600,"peak plasma 1,25-D(3) concentrations (Cp(max))","After 0.125 and 0.5 microg dosing, peak plasma 1,25-D(3) concentrations (Cp(max)) were 12.0 ng/ml (CI 95%, 10.8-12.6) and 41.6 ng/ml (CI 95%, 40.8-53.6), respectively.","Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15031600/),[ng] / [ml],12.0,664,DB01373,Calcium
,15031600,"peak plasma 1,25-D(3) concentrations (Cp(max))","After 0.125 and 0.5 microg dosing, peak plasma 1,25-D(3) concentrations (Cp(max)) were 12.0 ng/ml (CI 95%, 10.8-12.6) and 41.6 ng/ml (CI 95%, 40.8-53.6), respectively.","Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15031600/),[ng] / [ml],41.6,665,DB01373,Calcium
,15031600,areas under the curve (AUC(0->24 h)),"The corresponding areas under the curve (AUC(0->24 h)) were 47.0 (CI 95%, 43.2-51.1) and 128.0 (CI 95%, 127.0-130.0) ng.h/ml.","Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15031600/),[h·ng] / [ml],47.0,666,DB01373,Calcium
,15031600,areas under the curve (AUC(0->24 h)),"The corresponding areas under the curve (AUC(0->24 h)) were 47.0 (CI 95%, 43.2-51.1) and 128.0 (CI 95%, 127.0-130.0) ng.h/ml.","Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15031600/),[h·ng] / [ml],128.0,667,DB01373,Calcium
,15365401,percentage of absorption for,"At an ingested calcium load of 3.18 mmol, percentage of absorption for water averaged 22.53 +/- 2.53 (mean +/- SD) for men, 22.57 +/- 2.10 (mean +/- SD) for premenopausal women and 21.62 +/- 3.12 (mean +/- SD) for postmenopausal women.","Calcium bioavailability from a calcium-rich mineral water, with some observations on method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15365401/),,22.53,1333,DB01373,Calcium
,15365401,percentage of absorption for,"At an ingested calcium load of 3.18 mmol, percentage of absorption for water averaged 22.53 +/- 2.53 (mean +/- SD) for men, 22.57 +/- 2.10 (mean +/- SD) for premenopausal women and 21.62 +/- 3.12 (mean +/- SD) for postmenopausal women.","Calcium bioavailability from a calcium-rich mineral water, with some observations on method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15365401/),,22.57,1334,DB01373,Calcium
,15365401,percentage of absorption for,"At an ingested calcium load of 3.18 mmol, percentage of absorption for water averaged 22.53 +/- 2.53 (mean +/- SD) for men, 22.57 +/- 2.10 (mean +/- SD) for premenopausal women and 21.62 +/- 3.12 (mean +/- SD) for postmenopausal women.","Calcium bioavailability from a calcium-rich mineral water, with some observations on method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15365401/),,21.62,1335,DB01373,Calcium
,15365401,Percentage absorption from,Percentage absorption from milk was 23.15 +/- 4.06 (mean +/- SD).,"Calcium bioavailability from a calcium-rich mineral water, with some observations on method. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15365401/),,23.15,1336,DB01373,Calcium
,17174058,flow-rate,"The analysis was carried out on an ACQUITY UPLC BEH C(18) column (50 mm x 2.1 mm, i.d., 1.7 microm) with gradient elution at a flow-rate of 0.35 ml/min.",Determination and pharmacokinetic study of amlodipine in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174058/),[ml] / [min],0.35,1393,DB01373,Calcium
,27671833,C24 h,"However, significant reduction in the trough concentrations of raltegravir was observed: C24 h 0.43 (0.36, 0.51) in the presence of calcium carbonate antacids and 0.42 (0.34, 0.52) in presence of magnesium/aluminium hydroxide, respectively.",Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27671833/),,0.43,2060,DB01373,Calcium
,27671833,C24 h,"However, significant reduction in the trough concentrations of raltegravir was observed: C24 h 0.43 (0.36, 0.51) in the presence of calcium carbonate antacids and 0.42 (0.34, 0.52) in presence of magnesium/aluminium hydroxide, respectively.",Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27671833/),,0.42,2061,DB01373,Calcium
,15492770,clearance,Clevidipine has a high clearance (0.05 L/min/kg) and is rapidly hydrolyzed to inactive metabolites by esterases in arterial blood.,"Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15492770/),[l] / [kg·min],0.05,2194,DB01373,Calcium
>,32647975,serum corrected calcium (cCa),Mean serum corrected calcium (cCa) for all patients was maintained > 2.25 mmol/L.,"Phase 1, single-dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of etelcalcetide in pediatric patients with secondary hyperparathyroidism receiving hemodialysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32647975/),[mM] / [l],2.25,2501,DB01373,Calcium
,12951478,IC(50),"The simultaneous addition of GBE to small intestine and liver microsomes inhibited the formation of N-demethyl DTZ (MA), an active metabolite of DTZ produced by CYP3A, in a concentration-dependent manner, with an IC(50) of about 50 and 182 microg/ml, respectively.",Studies on interactions between functional foods or dietary supplements and medicines. I. Effects of Ginkgo biloba leaf extract on the pharmacokinetics of diltiazem in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12951478/),[μg] / [ml],50,2528,DB01373,Calcium
,12951478,IC(50),"The simultaneous addition of GBE to small intestine and liver microsomes inhibited the formation of N-demethyl DTZ (MA), an active metabolite of DTZ produced by CYP3A, in a concentration-dependent manner, with an IC(50) of about 50 and 182 microg/ml, respectively.",Studies on interactions between functional foods or dietary supplements and medicines. I. Effects of Ginkgo biloba leaf extract on the pharmacokinetics of diltiazem in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12951478/),[μg] / [ml],182,2529,DB01373,Calcium
,28892871,emulsification time,"D-optimal mixture design was used for systematic optimization of L-SNEDDS, which exhibited emulsification time of 131s, globule size <100nm and faster drug release rate >80% in 15min.",Formulation by design approach for development of ultrafine self-nanoemulsifying systems of rosuvastatin calcium containing long-chain lipophiles for hyperlipidemia management. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28892871/),s,131,2566,DB01373,Calcium
,16640453,absolute bioavailability,The absolute bioavailability ranges from 35% to 50%.,Clinical pharmacokinetics of ranolazine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),%,35,3347,DB01373,Calcium
,16640453,absolute bioavailability,The absolute bioavailability ranges from 35% to 50%.,Clinical pharmacokinetics of ranolazine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),%,50,3348,DB01373,Calcium
,16640453,protein binding,Ranolazine protein binding is about 61-64% over the therapeutic concentration range.,Clinical pharmacokinetics of ranolazine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),%,61-64,3349,DB01373,Calcium
,16640453,Volume of distribution at steady state,Volume of distribution at steady state ranges from 85 to 180 L.,Clinical pharmacokinetics of ranolazine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),l,85 to 180,3350,DB01373,Calcium
,16640453,Elimination half-life,"Elimination half-life of ranolazine is 1.4-1.9 hours but is apparently prolonged, on average, to 7 hours for the ER formulation as a result of extended absorption (flip-flop kinetics).",Clinical pharmacokinetics of ranolazine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),h,1.4-1.9,3351,DB01373,Calcium
,16640453,Elimination half-life,"Elimination half-life of ranolazine is 1.4-1.9 hours but is apparently prolonged, on average, to 7 hours for the ER formulation as a result of extended absorption (flip-flop kinetics).",Clinical pharmacokinetics of ranolazine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),h,7,3352,DB01373,Calcium
,16640453,Oral plasma clearance,"Oral plasma clearance diminishes with dose from, on average, 45 L/h at 500 mg twice daily to 33 L/h at 1000 mg twice daily.",Clinical pharmacokinetics of ranolazine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),[l] / [h],45,3353,DB01373,Calcium
,16640453,Oral plasma clearance,"Oral plasma clearance diminishes with dose from, on average, 45 L/h at 500 mg twice daily to 33 L/h at 1000 mg twice daily.",Clinical pharmacokinetics of ranolazine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),[l] / [h],33,3354,DB01373,Calcium
,25234550,relative bioavailability,The mean (SD) relative bioavailability calculated from the ratios (T/R) of AUC0-t was 101.3% (19.7%).,"Comparison of scaled-average, population, and individual bioequivalence on 2 tablets of pitavastatin calcium: a 3-period, reference-replicated, crossover study in healthy Chinese volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25234550/),%,101.3,3384,DB01373,Calcium
,25234550,Tmax,"No significant differences were found among Tmax (0.742 ± 0.276, 0.674 ± 0.202, and 0.689 ± 0.226, respectively) for reference tablet 1, reference Supplemental Table II in the online version at 10.1016/j.clinthera.2014.06.21, and test tablet by a Wilcoxon test (P > 0.05).","Comparison of scaled-average, population, and individual bioequivalence on 2 tablets of pitavastatin calcium: a 3-period, reference-replicated, crossover study in healthy Chinese volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25234550/),,0.742,3385,DB01373,Calcium
,25234550,Tmax,"No significant differences were found among Tmax (0.742 ± 0.276, 0.674 ± 0.202, and 0.689 ± 0.226, respectively) for reference tablet 1, reference Supplemental Table II in the online version at 10.1016/j.clinthera.2014.06.21, and test tablet by a Wilcoxon test (P > 0.05).","Comparison of scaled-average, population, and individual bioequivalence on 2 tablets of pitavastatin calcium: a 3-period, reference-replicated, crossover study in healthy Chinese volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25234550/),,0.674,3386,DB01373,Calcium
,25234550,Tmax,"No significant differences were found among Tmax (0.742 ± 0.276, 0.674 ± 0.202, and 0.689 ± 0.226, respectively) for reference tablet 1, reference Supplemental Table II in the online version at 10.1016/j.clinthera.2014.06.21, and test tablet by a Wilcoxon test (P > 0.05).","Comparison of scaled-average, population, and individual bioequivalence on 2 tablets of pitavastatin calcium: a 3-period, reference-replicated, crossover study in healthy Chinese volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25234550/),,0.689,3387,DB01373,Calcium
<,32786371,blood clearance (t1/2,These studies revealed that [68Ga]Ga-THP-Pam has high in vivo affinity for bone tissue (high bone/muscle and bone/blood ratios) and fast blood clearance (t1/2 < 10 min) comparable to both [68Ga]NO2APBP and [18F]NaF.,[68Ga]Ga-THP-Pam: A Bisphosphonate PET Tracer with Facile Radiolabeling and Broad Calcium Mineral Affinity. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32786371/),min,10,3400,DB01373,Calcium
,12610743,steady-state AUC(0-24),"In subjects with CP-A, and in four of six subjects with CP-B, rosuvastatin steady-state AUC(0-24) and C(max) were similar to subjects with normal hepatic function (geometric mean values 60.7 ng h/ml and 6.02 ng/ml, respectively).",Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610743/),[h·ng] / [ml],60.7,3499,DB01373,Calcium
,12610743,C(max),"In subjects with CP-A, and in four of six subjects with CP-B, rosuvastatin steady-state AUC(0-24) and C(max) were similar to subjects with normal hepatic function (geometric mean values 60.7 ng h/ml and 6.02 ng/ml, respectively).",Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610743/),[ng] / [ml],6.02,3500,DB01373,Calcium
,12610743,AUC(0-24),Two of six subjects with CP-B who had the highest CP scores (i.e. the highest degrees of hepatic impairment) had the highest AUC(0-24) (128 ng h/ml and 242 ng h/ml) and C(max) (23.4 ng/ml and 96.7 ng/ml) values.,Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610743/),[h·ng] / [ml],128,3501,DB01373,Calcium
,12610743,AUC(0-24),Two of six subjects with CP-B who had the highest CP scores (i.e. the highest degrees of hepatic impairment) had the highest AUC(0-24) (128 ng h/ml and 242 ng h/ml) and C(max) (23.4 ng/ml and 96.7 ng/ml) values.,Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610743/),[h·ng] / [ml],242,3502,DB01373,Calcium
,12610743,C(max),Two of six subjects with CP-B who had the highest CP scores (i.e. the highest degrees of hepatic impairment) had the highest AUC(0-24) (128 ng h/ml and 242 ng h/ml) and C(max) (23.4 ng/ml and 96.7 ng/ml) values.,Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610743/),[ng] / [ml],23.4,3503,DB01373,Calcium
,12610743,C(max),Two of six subjects with CP-B who had the highest CP scores (i.e. the highest degrees of hepatic impairment) had the highest AUC(0-24) (128 ng h/ml and 242 ng h/ml) and C(max) (23.4 ng/ml and 96.7 ng/ml) values.,Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610743/),[ng] / [ml],96.7,3504,DB01373,Calcium
,11986913,C-max,"At steady-state regular nimodipine reached a C-max of 10.208 +/- 0.317 ng/ml, at a t-max of 1 h; minimum concentration 6 h after dosage was 1.2929 +/- 0.411 ng/ml, half-life was estimated in 2.9 h.",Comparison of two nimodipine formulations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11986913/),[ng] / [ml],10.208,3661,DB01373,Calcium
,11986913,t-max,"At steady-state regular nimodipine reached a C-max of 10.208 +/- 0.317 ng/ml, at a t-max of 1 h; minimum concentration 6 h after dosage was 1.2929 +/- 0.411 ng/ml, half-life was estimated in 2.9 h.",Comparison of two nimodipine formulations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11986913/),h,1,3662,DB01373,Calcium
,11986913,minimum concentration,"At steady-state regular nimodipine reached a C-max of 10.208 +/- 0.317 ng/ml, at a t-max of 1 h; minimum concentration 6 h after dosage was 1.2929 +/- 0.411 ng/ml, half-life was estimated in 2.9 h.",Comparison of two nimodipine formulations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11986913/),[ng] / [ml],1.2929,3663,DB01373,Calcium
,11986913,half-life,"At steady-state regular nimodipine reached a C-max of 10.208 +/- 0.317 ng/ml, at a t-max of 1 h; minimum concentration 6 h after dosage was 1.2929 +/- 0.411 ng/ml, half-life was estimated in 2.9 h.",Comparison of two nimodipine formulations in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11986913/),h,2.9,3664,DB01373,Calcium
,11986913,C-max,Meanwhile nimodipine AP 120 mg reach a C-max of 11.885 +/- 0.403 ng/ml; a t-max of 1 h with a minimum concentration 24 h after the last dose of 4.2387 +/- 0.353 ng/ml (P < 0.001).,Comparison of two nimodipine formulations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11986913/),[ng] / [ml],11.885,3665,DB01373,Calcium
,11986913,t-max,Meanwhile nimodipine AP 120 mg reach a C-max of 11.885 +/- 0.403 ng/ml; a t-max of 1 h with a minimum concentration 24 h after the last dose of 4.2387 +/- 0.353 ng/ml (P < 0.001).,Comparison of two nimodipine formulations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11986913/),h,1,3666,DB01373,Calcium
,11986913,minimum concentration,Meanwhile nimodipine AP 120 mg reach a C-max of 11.885 +/- 0.403 ng/ml; a t-max of 1 h with a minimum concentration 24 h after the last dose of 4.2387 +/- 0.353 ng/ml (P < 0.001).,Comparison of two nimodipine formulations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11986913/),[ng] / [ml],4.2387,3667,DB01373,Calcium
,11986913,Apparent half-life,Apparent half-life was calculated in 17.8 h (P < 0.001).,Comparison of two nimodipine formulations in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11986913/),h,17.8,3668,DB01373,Calcium
,11986913,Area under the curve,"Area under the curve for the 24 h period was 143.76 ng/ml/min for regular nimodipine and 183.7 ng/ml/min for nimodipine AP 120 mg (P < 0.001), indicating better bioavailability.",Comparison of two nimodipine formulations in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11986913/),[ng] / [min·ml],143.76,3669,DB01373,Calcium
,11986913,Area under the curve,"Area under the curve for the 24 h period was 143.76 ng/ml/min for regular nimodipine and 183.7 ng/ml/min for nimodipine AP 120 mg (P < 0.001), indicating better bioavailability.",Comparison of two nimodipine formulations in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11986913/),[ng] / [min·ml],183.7,3670,DB01373,Calcium
,28508378,clearance,"The clearance and central volume of distribution (Vc) of etelcalcetide were 0.472 L/h and 49.9 L, respectively, while estimates of the turnover half-lives of PTH and Ca were 0.36 and 23 h, respectively.",Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28508378/),[l] / [h],0.472,4395,DB01373,Calcium
,28508378,central volume of distribution (Vc),"The clearance and central volume of distribution (Vc) of etelcalcetide were 0.472 L/h and 49.9 L, respectively, while estimates of the turnover half-lives of PTH and Ca were 0.36 and 23 h, respectively.",Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28508378/),l,49.9,4396,DB01373,Calcium
,28508378,turnover half-lives,"The clearance and central volume of distribution (Vc) of etelcalcetide were 0.472 L/h and 49.9 L, respectively, while estimates of the turnover half-lives of PTH and Ca were 0.36 and 23 h, respectively.",Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28508378/),h,0.36,4397,DB01373,Calcium
,28508378,turnover half-lives,"The clearance and central volume of distribution (Vc) of etelcalcetide were 0.472 L/h and 49.9 L, respectively, while estimates of the turnover half-lives of PTH and Ca were 0.36 and 23 h, respectively.",Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28508378/),h,23,4398,DB01373,Calcium
,32302064,relative oral bioavailability,The relative oral bioavailability of calcium from calcium glucoheptonate as compared to calcium carbonate was 92% within 6 hours and 89% within 12 hours after study drug administration.,Relative bioavailability and pharmacokinetic comparison of calcium glucoheptonate with calcium carbonate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32302064/),%,92,4719,DB01373,Calcium
,32302064,relative oral bioavailability,The relative oral bioavailability of calcium from calcium glucoheptonate as compared to calcium carbonate was 92% within 6 hours and 89% within 12 hours after study drug administration.,Relative bioavailability and pharmacokinetic comparison of calcium glucoheptonate with calcium carbonate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32302064/),%,89,4720,DB01373,Calcium
,19135530,area under the plasma concentration-time curve (AUC),"After oral irinotecan dosing, the mean area under the plasma concentration-time curve (AUC) was found to be 14.03+/-2.18 microgh/ml which was increased significantly, i.e. 61.71+/-15.0 microgh/ml when verapamil was co-administered (P<0.05).","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),[μgh] / [ml],14.03,4808,DB01373,Calcium
,19135530,area under the plasma concentration-time curve (AUC),"After oral irinotecan dosing, the mean area under the plasma concentration-time curve (AUC) was found to be 14.03+/-2.18 microgh/ml which was increased significantly, i.e. 61.71+/-15.0 microgh/ml when verapamil was co-administered (P<0.05).","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),[μgh] / [ml],61.71,4809,DB01373,Calcium
,19135530,maximum plasma concentration,"Similarly, the mean maximum plasma concentration of irinotecan increased from 2.93+/-0.37 microg/ml (without verapamil) to 10.75+/-1.0 microg/ml (with verapamil) (P<0.05).","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),[μg] / [ml],2.93,4810,DB01373,Calcium
,19135530,maximum plasma concentration,"Similarly, the mean maximum plasma concentration of irinotecan increased from 2.93+/-0.37 microg/ml (without verapamil) to 10.75+/-1.0 microg/ml (with verapamil) (P<0.05).","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),[μg] / [ml],10.75,4811,DB01373,Calcium
,19135530,AUC,"On the other hand, the intravenous irinotecan administration with verapamil resulted in small but statistically significant effect on AUC (10.76+/-2.0 to 23.3+/-3.8 microgh/ml; P<0.05) and systemic clearance (1206.4+/-159.7 to 713.5+/-78.2 ml/(hkg)).","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),[μgh] / [ml],10.76,4812,DB01373,Calcium
,19135530,AUC,"On the other hand, the intravenous irinotecan administration with verapamil resulted in small but statistically significant effect on AUC (10.76+/-2.0 to 23.3+/-3.8 microgh/ml; P<0.05) and systemic clearance (1206.4+/-159.7 to 713.5+/-78.2 ml/(hkg)).","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),[μgh] / [ml],23.3,4813,DB01373,Calcium
,19135530,systemic clearance,"On the other hand, the intravenous irinotecan administration with verapamil resulted in small but statistically significant effect on AUC (10.76+/-2.0 to 23.3+/-3.8 microgh/ml; P<0.05) and systemic clearance (1206.4+/-159.7 to 713.5+/-78.2 ml/(hkg)).","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),[ml] / [hkg],1206.4,4814,DB01373,Calcium
,19135530,systemic clearance,"On the other hand, the intravenous irinotecan administration with verapamil resulted in small but statistically significant effect on AUC (10.76+/-2.0 to 23.3+/-3.8 microgh/ml; P<0.05) and systemic clearance (1206.4+/-159.7 to 713.5+/-78.2 ml/(hkg)).","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),[ml] / [hkg],713.5,4815,DB01373,Calcium
,19135530,percent,"The mean percent of irinotecan excreted into bile over 5h following intravenous and oral administration was found to be 8% and 1%, respectively, which was further reduced to half when treated with verapamil.","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),%,8,4816,DB01373,Calcium
,19135530,percent,"The mean percent of irinotecan excreted into bile over 5h following intravenous and oral administration was found to be 8% and 1%, respectively, which was further reduced to half when treated with verapamil.","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),%,1,4817,DB01373,Calcium
,26709596,t(max),"Compared with the IR formulation, median t(max) was longer (0.5 vs. 2 - 10 hours), and mean C(max) was lower for all 5 MR formulations (262 vs. 34 - 78 ng/mL); t(1/2,z) was similar (18 - 21 hours).","Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26709596/),h,0.5,4915,DB01373,Calcium
,26709596,t(max),"Compared with the IR formulation, median t(max) was longer (0.5 vs. 2 - 10 hours), and mean C(max) was lower for all 5 MR formulations (262 vs. 34 - 78 ng/mL); t(1/2,z) was similar (18 - 21 hours).","Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26709596/),h,2 - 10,4916,DB01373,Calcium
,26709596,C(max),"Compared with the IR formulation, median t(max) was longer (0.5 vs. 2 - 10 hours), and mean C(max) was lower for all 5 MR formulations (262 vs. 34 - 78 ng/mL); t(1/2,z) was similar (18 - 21 hours).","Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26709596/),[ng] / [ml],262,4917,DB01373,Calcium
,26709596,C(max),"Compared with the IR formulation, median t(max) was longer (0.5 vs. 2 - 10 hours), and mean C(max) was lower for all 5 MR formulations (262 vs. 34 - 78 ng/mL); t(1/2,z) was similar (18 - 21 hours).","Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26709596/),[ng] / [ml],34 - 78,4918,DB01373,Calcium
,26709596,"t(1/2,z)","Compared with the IR formulation, median t(max) was longer (0.5 vs. 2 - 10 hours), and mean C(max) was lower for all 5 MR formulations (262 vs. 34 - 78 ng/mL); t(1/2,z) was similar (18 - 21 hours).","Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26709596/),h,18 - 21,4919,DB01373,Calcium
>,26709596,relative bioavailability,The relative bioavailability was high (> 75%) for three MR formulations but lower (< 65%) for the other two.,"Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26709596/),%,75,4920,DB01373,Calcium
<,26709596,relative bioavailability,The relative bioavailability was high (> 75%) for three MR formulations but lower (< 65%) for the other two.,"Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26709596/),%,65,4921,DB01373,Calcium
>,26709596,relative bioavailability,The relative bioavailability of omecamtiv mecarbil was high (> 75%) for 3 of the five MR formulations.,"Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26709596/),%,75,4922,DB01373,Calcium
,19033449,AUC,"AUC values were significantly higher for (-)-3S,5R-FV than for (+)-3R,5S-FV (358.20 vs 279.68 ng.h/mL) and for S-LER compared with R-LER (13.90 vs 11.88 ng.h/mL).",Enantioselectivity in the pharmacokinetic interaction between fluvastatin and lercanidipine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033449/),[h·ng] / [ml],358.20,5369,DB01373,Calcium
,19033449,AUC,"AUC values were significantly higher for (-)-3S,5R-FV than for (+)-3R,5S-FV (358.20 vs 279.68 ng.h/mL) and for S-LER compared with R-LER (13.90 vs 11.88 ng.h/mL).",Enantioselectivity in the pharmacokinetic interaction between fluvastatin and lercanidipine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033449/),[h·ng] / [ml],279.68,5370,DB01373,Calcium
,19033449,AUC,"AUC values were significantly higher for (-)-3S,5R-FV than for (+)-3R,5S-FV (358.20 vs 279.68 ng.h/mL) and for S-LER compared with R-LER (13.90 vs 11.88 ng.h/mL).",Enantioselectivity in the pharmacokinetic interaction between fluvastatin and lercanidipine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033449/),[h·ng] / [ml],13.90,5371,DB01373,Calcium
,19033449,AUC,"AUC values were significantly higher for (-)-3S,5R-FV than for (+)-3R,5S-FV (358.20 vs 279.68 ng.h/mL) and for S-LER compared with R-LER (13.90 vs 11.88 ng.h/mL).",Enantioselectivity in the pharmacokinetic interaction between fluvastatin and lercanidipine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033449/),[h·ng] / [ml],11.88,5372,DB01373,Calcium
,19033449,AUC,"The pharmacokinetic parameters of FV were not enantioselective when combined with LER (AUC: (-)-3S,5R-FV: 325.21; (+)-3R,5S-FV: 316.44 ng.h/mL).",Enantioselectivity in the pharmacokinetic interaction between fluvastatin and lercanidipine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033449/),[h·ng] / [ml],325.21,5373,DB01373,Calcium
,19033449,AUC,"The pharmacokinetic parameters of FV were not enantioselective when combined with LER (AUC: (-)-3S,5R-FV: 325.21; (+)-3R,5S-FV: 316.44 ng.h/mL).",Enantioselectivity in the pharmacokinetic interaction between fluvastatin and lercanidipine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033449/),[h·ng] / [ml],316.44,5374,DB01373,Calcium
,19033449,AUC,There was a significant reduction in S-LER (8.06 vs 13.90 ng.h/mL) and R-LER (6.76 vs 11.88 ng.h/mL) AUC values when FV was coadministered.,Enantioselectivity in the pharmacokinetic interaction between fluvastatin and lercanidipine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033449/),[h·ng] / [ml],6.76,5375,DB01373,Calcium
,26558434,AUC(0-72),Mean (SD) AUC(0-72) was 102.7 (26.8) (26.8) μg × h/L for the solution and 108.2 (30.6) μg × h/L for the tablet.,Bioequivalence study of an extemporaneously prepared oral solution of amlodipine suitable for use in pediatric patients compared to commercial tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26558434/),[h·μg] / [l],102.7,5450,DB01373,Calcium
,26558434,AUC(0-72),Mean (SD) AUC(0-72) was 102.7 (26.8) (26.8) μg × h/L for the solution and 108.2 (30.6) μg × h/L for the tablet.,Bioequivalence study of an extemporaneously prepared oral solution of amlodipine suitable for use in pediatric patients compared to commercial tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26558434/),[h·μg] / [l],108.2,5451,DB01373,Calcium
,26558434,Cmax,Mean (SD) Cmax of the solution was 3.11(1.06) μg/L with a median (IQR) t(max) of 4.0 (2.6 - 7.5) hours.,Bioequivalence study of an extemporaneously prepared oral solution of amlodipine suitable for use in pediatric patients compared to commercial tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26558434/),[μg] / [l],3.11,5452,DB01373,Calcium
,26558434,t(max),Mean (SD) Cmax of the solution was 3.11(1.06) μg/L with a median (IQR) t(max) of 4.0 (2.6 - 7.5) hours.,Bioequivalence study of an extemporaneously prepared oral solution of amlodipine suitable for use in pediatric patients compared to commercial tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26558434/),h,4.0,5453,DB01373,Calcium
,26558434,C(max),Mean (SD) C(max) of the tablet was 2.91 (0.84) μg/L with a median (IQR) tmax of 6.0 (4.0 - 14.0) hours.,Bioequivalence study of an extemporaneously prepared oral solution of amlodipine suitable for use in pediatric patients compared to commercial tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26558434/),[μg] / [l],2.91,5454,DB01373,Calcium
,26558434,tmax,Mean (SD) C(max) of the tablet was 2.91 (0.84) μg/L with a median (IQR) tmax of 6.0 (4.0 - 14.0) hours.,Bioequivalence study of an extemporaneously prepared oral solution of amlodipine suitable for use in pediatric patients compared to commercial tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26558434/),h,6.0,5455,DB01373,Calcium
,15108221,terminal half-life,"After intravenous dosing, the plasma concentration of mebudipine declined biexponentially with a terminal half-life of 2.84 h.","Pharmacokinetics of mebudipine, a new calcium antagonist, following single intravenous and oral administrations in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15108221/),h,2.84,6043,DB01373,Calcium
,15108221,blood clearance,The blood clearance was 1.67 l/h/kg and the volume of distribution at steady state was found to be 6.26 l/kg.,"Pharmacokinetics of mebudipine, a new calcium antagonist, following single intravenous and oral administrations in rats. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15108221/),[l] / [h·kg],1.67,6044,DB01373,Calcium
,15108221,volume of distribution at steady state,The blood clearance was 1.67 l/h/kg and the volume of distribution at steady state was found to be 6.26 l/kg.,"Pharmacokinetics of mebudipine, a new calcium antagonist, following single intravenous and oral administrations in rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15108221/),[l] / [kg],6.26,6045,DB01373,Calcium
,15108221,C(max),"After oral dosing (10 mg/kg), the C(max) of mebudipine was 25.9+/-9.79 ng/ml.","Pharmacokinetics of mebudipine, a new calcium antagonist, following single intravenous and oral administrations in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15108221/),[ng] / [ml],25.9,6046,DB01373,Calcium
<,15108221,oral bioavailability,The oral bioavailability was low (< 2%) suggesting a marked first-pass effect.,"Pharmacokinetics of mebudipine, a new calcium antagonist, following single intravenous and oral administrations in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15108221/),%,2,6047,DB01373,Calcium
,22278138,concentrations,"After 4 weeks of treatment, microdialysate aliskiren concentrations (ng/ml) were 2.4 ± 2.1 (adipose) and 7.1 ± 4.2 (skeletal muscle), similar to plasma concentrations (8.4 ± 4.4); tissue concentrations (ng/g) were 29.0 ± 16.7 (adipose) and 107.3 ± 68.6 (skeletal muscle).",Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22278138/),[ng] / [ml],2,7405,DB01373,Calcium
,22278138,tissue,"After 4 weeks of treatment, microdialysate aliskiren concentrations (ng/ml) were 2.4 ± 2.1 (adipose) and 7.1 ± 4.2 (skeletal muscle), similar to plasma concentrations (8.4 ± 4.4); tissue concentrations (ng/g) were 29.0 ± 16.7 (adipose) and 107.3 ± 68.6 (skeletal muscle).",Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22278138/),[ng] / [g],29.0,7406,DB01373,Calcium
,22278138,tissue,"After 4 weeks of treatment, microdialysate aliskiren concentrations (ng/ml) were 2.4 ± 2.1 (adipose) and 7.1 ± 4.2 (skeletal muscle), similar to plasma concentrations (8.4 ± 4.4); tissue concentrations (ng/g) were 29.0 ± 16.7 (adipose) and 107.3 ± 68.6 (skeletal muscle).",Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22278138/),[ng] / [g],107.3,7407,DB01373,Calcium
,22278138,concentrations,"After 4 weeks of treatment, microdialysate aliskiren concentrations (ng/ml) were 2.4 ± 2.1 (adipose) and 7.1 ± 4.2 (skeletal muscle), similar to plasma concentrations (8.4 ± 4.4); tissue concentrations (ng/g) were 29.0 ± 16.7 (adipose) and 107.3 ± 68.6 (skeletal muscle).",Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22278138/),[ng] / [g],29.0,7408,DB01373,Calcium
,22278138,concentrations,"After 4 weeks of treatment, microdialysate aliskiren concentrations (ng/ml) were 2.4 ± 2.1 (adipose) and 7.1 ± 4.2 (skeletal muscle), similar to plasma concentrations (8.4 ± 4.4); tissue concentrations (ng/g) were 29.0 ± 16.7 (adipose) and 107.3 ± 68.6 (skeletal muscle).",Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22278138/),[ng] / [g],107.3,7409,DB01373,Calcium
,12576438,MTD,The MTD for irinotecan administered in combination with cisplatin (30 mg/m(2)) was 50 mg/m(2).,Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576438/),[mg] / [m],50,7517,DB01373,Calcium
,12576438,maximum plasma concentrations (C(max)),"The maximum plasma concentrations (C(max)) for free cisplatin and WR-1065 were 4.5 +/- 1.6 micro M and approximately 89 +/- 10 micro M, respectively.",Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576438/),μM,4.5,7518,DB01373,Calcium
,12576438,maximum plasma concentrations (C(max)),"The maximum plasma concentrations (C(max)) for free cisplatin and WR-1065 were 4.5 +/- 1.6 micro M and approximately 89 +/- 10 micro M, respectively.",Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576438/),μM,89,7519,DB01373,Calcium
,12576438,half-life (t(1/2)),The half-life (t(1/2)) for free plasma cisplatin was 25.4 +/- 5.4 min.,Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576438/),min,25.4,7520,DB01373,Calcium
,12576438,initial t(1/2),The initial t(1/2) for plasma WR-1065 was approximately 7 min and terminal t(1/2) approximately 24 min.,Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576438/),min,7,7521,DB01373,Calcium
,12576438,terminal t(1/2),The initial t(1/2) for plasma WR-1065 was approximately 7 min and terminal t(1/2) approximately 24 min.,Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576438/),min,24,7522,DB01373,Calcium
,24724508,oral bioavailability,Bare PTH 1-34 failed to reach the systemic circulation following oral dosage in rats whereas TCS-PTH 1-34 NPs showed an oral bioavailability of 0.075 microg PTH 1-34 throughout 48 h which is indeed a significant improvement in the half life of this peptide.,PTH 1-34 loaded thiolated chitosan nanoparticles for osteoporosis: oral bioavailability and anabolic effect on primary osteoblast cells. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24724508/),μg,0.075,7720,DB01373,Calcium
,14530750,Total body clearance,"Total body clearance of citrate was normal in noncirrhotic critically ill patients but significantly reduced in cirrhotic patients (710 vs. 340 mL/min, p =.008).",Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14530750/),[ml] / [min],710,7772,DB01373,Calcium
,14530750,Total body clearance,"Total body clearance of citrate was normal in noncirrhotic critically ill patients but significantly reduced in cirrhotic patients (710 vs. 340 mL/min, p =.008).",Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14530750/),[ml] / [min],340,7773,DB01373,Calcium
,23767355,run time,A run time of 4 min made it possible to determine many plasma samples/day.,Development and validation of a liquid chromatography/ mass spectrometry method for the simultaneous quantitation of rosuvastatin and ezetimibe in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23767355/),min,4,8468,DB01373,Calcium
,11736882,Cmax,"Bile acids decreased the Cmax (ng ml(-1)) [control 10.9 +/- 5.8 (mean+/- s.d.), UDCA 5.0 +/- 4.7 (95% confidence interval for difference; 3.9, 7.8, P = 0.0006), CDCA (600 mg) 5.0 +/- 3.9 (2.6, 9.2, P = 0.0059)] and AUC (ng ml(-1) h) [(control; 60 +/- 36, UDCA 15 +/- 13 (20, 73, P = 0.0064), CDCA (600 mg) 19 +/- 19 (21, 63, P = 0.0038)] of nitrendipine, while elimination half-life remained unchanged.",Effect of bile acids on absorption of nitrendipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736882/),[ng] / [ml],10.9,8924,DB01373,Calcium
,11736882,Cmax,"Bile acids decreased the Cmax (ng ml(-1)) [control 10.9 +/- 5.8 (mean+/- s.d.), UDCA 5.0 +/- 4.7 (95% confidence interval for difference; 3.9, 7.8, P = 0.0006), CDCA (600 mg) 5.0 +/- 3.9 (2.6, 9.2, P = 0.0059)] and AUC (ng ml(-1) h) [(control; 60 +/- 36, UDCA 15 +/- 13 (20, 73, P = 0.0064), CDCA (600 mg) 19 +/- 19 (21, 63, P = 0.0038)] of nitrendipine, while elimination half-life remained unchanged.",Effect of bile acids on absorption of nitrendipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736882/),[ng] / [ml],5.0,8925,DB01373,Calcium
,11736882,Cmax,"Bile acids decreased the Cmax (ng ml(-1)) [control 10.9 +/- 5.8 (mean+/- s.d.), UDCA 5.0 +/- 4.7 (95% confidence interval for difference; 3.9, 7.8, P = 0.0006), CDCA (600 mg) 5.0 +/- 3.9 (2.6, 9.2, P = 0.0059)] and AUC (ng ml(-1) h) [(control; 60 +/- 36, UDCA 15 +/- 13 (20, 73, P = 0.0064), CDCA (600 mg) 19 +/- 19 (21, 63, P = 0.0038)] of nitrendipine, while elimination half-life remained unchanged.",Effect of bile acids on absorption of nitrendipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736882/),[ng] / [ml],5.0,8926,DB01373,Calcium
,11736882,AUC,"Bile acids decreased the Cmax (ng ml(-1)) [control 10.9 +/- 5.8 (mean+/- s.d.), UDCA 5.0 +/- 4.7 (95% confidence interval for difference; 3.9, 7.8, P = 0.0006), CDCA (600 mg) 5.0 +/- 3.9 (2.6, 9.2, P = 0.0059)] and AUC (ng ml(-1) h) [(control; 60 +/- 36, UDCA 15 +/- 13 (20, 73, P = 0.0064), CDCA (600 mg) 19 +/- 19 (21, 63, P = 0.0038)] of nitrendipine, while elimination half-life remained unchanged.",Effect of bile acids on absorption of nitrendipine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736882/),[h·ng] / [ml],60,8927,DB01373,Calcium
,11736882,AUC,"Bile acids decreased the Cmax (ng ml(-1)) [control 10.9 +/- 5.8 (mean+/- s.d.), UDCA 5.0 +/- 4.7 (95% confidence interval for difference; 3.9, 7.8, P = 0.0006), CDCA (600 mg) 5.0 +/- 3.9 (2.6, 9.2, P = 0.0059)] and AUC (ng ml(-1) h) [(control; 60 +/- 36, UDCA 15 +/- 13 (20, 73, P = 0.0064), CDCA (600 mg) 19 +/- 19 (21, 63, P = 0.0038)] of nitrendipine, while elimination half-life remained unchanged.",Effect of bile acids on absorption of nitrendipine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736882/),[h·ng] / [ml],15,8928,DB01373,Calcium
,11736882,AUC,"Bile acids decreased the Cmax (ng ml(-1)) [control 10.9 +/- 5.8 (mean+/- s.d.), UDCA 5.0 +/- 4.7 (95% confidence interval for difference; 3.9, 7.8, P = 0.0006), CDCA (600 mg) 5.0 +/- 3.9 (2.6, 9.2, P = 0.0059)] and AUC (ng ml(-1) h) [(control; 60 +/- 36, UDCA 15 +/- 13 (20, 73, P = 0.0064), CDCA (600 mg) 19 +/- 19 (21, 63, P = 0.0038)] of nitrendipine, while elimination half-life remained unchanged.",Effect of bile acids on absorption of nitrendipine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736882/),[h·ng] / [ml],19,8929,DB01373,Calcium
,16411524,maximum serum concentration,"The maximum serum concentration after IP administration of 10 microg OCT was 750 pg/mL after 5 minutes, and remained at 500 pg/mL at 60 minutes.",Pharmacokinetics of calcitriol and maxacalcitol administered into peritoneal dialysate bags in peritoneal dialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411524/),[pg] / [ml],750,9093,DB01373,Calcium
,16411524,maximum serum concentration,"The maximum serum concentration after IP administration of 10 microg OCT was 750 pg/mL after 5 minutes, and remained at 500 pg/mL at 60 minutes.",Pharmacokinetics of calcitriol and maxacalcitol administered into peritoneal dialysate bags in peritoneal dialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411524/),[pg] / [ml],500,9094,DB01373,Calcium
,31250754,encapsulation efficiency (EE),"Additionally, Formulation 3 (F3) has a particle size of 340.40 ± 2.39 nm with narrow uniformity exhibiting encapsulation efficiency (EE) of 72.78 ± 1.25 % produced highest absorption profile of insulin with a bioavailability of 40.23 ±1.29% and reduced blood glucose after its oral administration in rats.",Chitosan-Coated Alginate Nanoparticles Enhanced Absorption Profile of Insulin Via Oral Administration. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31250754/),%,72.78,9201,DB01373,Calcium
,31250754,bioavailability,"Additionally, Formulation 3 (F3) has a particle size of 340.40 ± 2.39 nm with narrow uniformity exhibiting encapsulation efficiency (EE) of 72.78 ± 1.25 % produced highest absorption profile of insulin with a bioavailability of 40.23 ±1.29% and reduced blood glucose after its oral administration in rats.",Chitosan-Coated Alginate Nanoparticles Enhanced Absorption Profile of Insulin Via Oral Administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31250754/),%,40.23,9202,DB01373,Calcium
,16097365,peak concentration (C(max)),Combined treatment with simvastatin and amlodipine increased the peak concentration (C(max)) of HMG-CoA reductase inhibitors from 9.6 +/- 3.7 ng/ml to 13.7 +/- 4.7 ng/ml (p < 0.05) and the area under the concentration-time curve (AUC) from 34.3 +/- 16.5 ng h/ml to 43.9 +/- 16.6 ng h/ml (p < 0.05) without affecting the cholesterol-lowering effect of simvastatin.,Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16097365/),[ng] / [ml],9.6,9523,DB01373,Calcium
,16097365,peak concentration (C(max)),Combined treatment with simvastatin and amlodipine increased the peak concentration (C(max)) of HMG-CoA reductase inhibitors from 9.6 +/- 3.7 ng/ml to 13.7 +/- 4.7 ng/ml (p < 0.05) and the area under the concentration-time curve (AUC) from 34.3 +/- 16.5 ng h/ml to 43.9 +/- 16.6 ng h/ml (p < 0.05) without affecting the cholesterol-lowering effect of simvastatin.,Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16097365/),[ng] / [ml],13.7,9524,DB01373,Calcium
,16097365,area under the concentration-time curve (AUC),Combined treatment with simvastatin and amlodipine increased the peak concentration (C(max)) of HMG-CoA reductase inhibitors from 9.6 +/- 3.7 ng/ml to 13.7 +/- 4.7 ng/ml (p < 0.05) and the area under the concentration-time curve (AUC) from 34.3 +/- 16.5 ng h/ml to 43.9 +/- 16.6 ng h/ml (p < 0.05) without affecting the cholesterol-lowering effect of simvastatin.,Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16097365/),[h·ng] / [ml],34.3,9525,DB01373,Calcium
,16097365,area under the concentration-time curve (AUC),Combined treatment with simvastatin and amlodipine increased the peak concentration (C(max)) of HMG-CoA reductase inhibitors from 9.6 +/- 3.7 ng/ml to 13.7 +/- 4.7 ng/ml (p < 0.05) and the area under the concentration-time curve (AUC) from 34.3 +/- 16.5 ng h/ml to 43.9 +/- 16.6 ng h/ml (p < 0.05) without affecting the cholesterol-lowering effect of simvastatin.,Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16097365/),[h·ng] / [ml],43.9,9526,DB01373,Calcium
,24593819,CLCr,"The patients were 52 +/- 20 years old, their mean body weight was 73 +/- 17 kg and their mean CLCr was 119 +/- 55 mL/min.",Tobramycin exposure from active calcium sulfate bone graft substitute. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24593819/),m,119,10183,DB01373,Calcium
,24593819,absorption rate constant (ka),"With CL equated to CLCr, mean absorption rate constant (ka) was 0.06 h-1, F was 63% or 32% (CV 74%) for 10 and 20 g Osteoset® T respectively, and volume of distribution (V) was 16.6 L (CV 89%).",Tobramycin exposure from active calcium sulfate bone graft substitute. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24593819/),1/[h],0.06,10184,DB01373,Calcium
,24593819,volume of distribution (V),"With CL equated to CLCr, mean absorption rate constant (ka) was 0.06 h-1, F was 63% or 32% (CV 74%) for 10 and 20 g Osteoset® T respectively, and volume of distribution (V) was 16.6 L (CV 89%).",Tobramycin exposure from active calcium sulfate bone graft substitute. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24593819/),l,16.6,10185,DB01373,Calcium
up to,15081140,maximum solubility,"The optimal microemulsion formulation consisted of 8% Labrafil M 1944CS, 30% Cremophor RH 40/ethanol (3:1) and water, with a maximum solubility of NM up to 6.4 mg/ml, droplet size of 30.3 +/- 5.3 nm, and no ciliotoxicity.",Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15081140/),[mg] / [ml],6.4,10186,DB01373,Calcium
,15081140,absolute bioavailability,"After a single intranasal administration of this preparation at a dose of 2 mg/kg, the plasma concentration peaked at 1 h and the absolute bioavailability was about 32%.",Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15081140/),%,32,10187,DB01373,Calcium
,24854296,half-life,These results coupled with a pharmacokinetic half-life of ~24 h suggest that 2MD given either daily or at the time of dialysis may be a superior therapy for secondary hyperparathyroidism in chronic renal failure patients.,"Novel, selective vitamin D analog suppresses parathyroid hormone in uremic animals and postmenopausal women. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24854296/),h,24,12317,DB01373,Calcium
,17161566,oral bioavailability,Nitrendipine is an antihypertensive drug with poor oral bioavailability ranging from 10 to 20% due to the first pass metabolism.,Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17161566/),%,10 to 20,12507,DB01373,Calcium
,24374219,relative bioavailability,"In comparison with the commercial reference tables, the relative bioavailability of the two formulations was 67.0% and 121.1%, respectively, indicating the solid dispersion technique was more efficient than the micronization technique in terms of solubilization capability and absorption enhancement.",A two-step strategy to design high bioavailable controlled-release nimodipine tablets: the push-pull osmotic pump in combination with the micronization/solid dispersion techniques. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24374219/),%,67.0,13464,DB01373,Calcium
,24374219,relative bioavailability,"In comparison with the commercial reference tables, the relative bioavailability of the two formulations was 67.0% and 121.1%, respectively, indicating the solid dispersion technique was more efficient than the micronization technique in terms of solubilization capability and absorption enhancement.",A two-step strategy to design high bioavailable controlled-release nimodipine tablets: the push-pull osmotic pump in combination with the micronization/solid dispersion techniques. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24374219/),%,121.1,13465,DB01373,Calcium
,14628444,T1/2 alpha,"The osthole pharmacokinetics conforms to a two compartment open model after i.v. administration, T1/2 alpha = 5.81 min, T1/2 beta = 42.2 min, K21 = 0.036 0.min-1, K12 = 0.045 0.min-1, K10 = 0.054 0.min-1, AUC = 235 mg.min.L-1, CLs = 0.043 0 L.min-1.kg-1, Vc = 0.780 L.kg-1.",[Pharmacokinetics of osthole in rabbits]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628444/),min,5.81,14225,DB01373,Calcium
,14628444,T1/2 beta,"The osthole pharmacokinetics conforms to a two compartment open model after i.v. administration, T1/2 alpha = 5.81 min, T1/2 beta = 42.2 min, K21 = 0.036 0.min-1, K12 = 0.045 0.min-1, K10 = 0.054 0.min-1, AUC = 235 mg.min.L-1, CLs = 0.043 0 L.min-1.kg-1, Vc = 0.780 L.kg-1.",[Pharmacokinetics of osthole in rabbits]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628444/),min,42.2,14226,DB01373,Calcium
,14628444,K21,"The osthole pharmacokinetics conforms to a two compartment open model after i.v. administration, T1/2 alpha = 5.81 min, T1/2 beta = 42.2 min, K21 = 0.036 0.min-1, K12 = 0.045 0.min-1, K10 = 0.054 0.min-1, AUC = 235 mg.min.L-1, CLs = 0.043 0 L.min-1.kg-1, Vc = 0.780 L.kg-1.",[Pharmacokinetics of osthole in rabbits]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628444/),[0] / [min],0.036,14227,DB01373,Calcium
,14628444,K12,"The osthole pharmacokinetics conforms to a two compartment open model after i.v. administration, T1/2 alpha = 5.81 min, T1/2 beta = 42.2 min, K21 = 0.036 0.min-1, K12 = 0.045 0.min-1, K10 = 0.054 0.min-1, AUC = 235 mg.min.L-1, CLs = 0.043 0 L.min-1.kg-1, Vc = 0.780 L.kg-1.",[Pharmacokinetics of osthole in rabbits]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628444/),[0] / [min],0.045,14228,DB01373,Calcium
,14628444,K10,"The osthole pharmacokinetics conforms to a two compartment open model after i.v. administration, T1/2 alpha = 5.81 min, T1/2 beta = 42.2 min, K21 = 0.036 0.min-1, K12 = 0.045 0.min-1, K10 = 0.054 0.min-1, AUC = 235 mg.min.L-1, CLs = 0.043 0 L.min-1.kg-1, Vc = 0.780 L.kg-1.",[Pharmacokinetics of osthole in rabbits]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628444/),[0] / [min],0.054,14229,DB01373,Calcium
,14628444,AUC,"The osthole pharmacokinetics conforms to a two compartment open model after i.v. administration, T1/2 alpha = 5.81 min, T1/2 beta = 42.2 min, K21 = 0.036 0.min-1, K12 = 0.045 0.min-1, K10 = 0.054 0.min-1, AUC = 235 mg.min.L-1, CLs = 0.043 0 L.min-1.kg-1, Vc = 0.780 L.kg-1.",[Pharmacokinetics of osthole in rabbits]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628444/),[mg·min] / [l],235,14230,DB01373,Calcium
,14628444,CLs,"The osthole pharmacokinetics conforms to a two compartment open model after i.v. administration, T1/2 alpha = 5.81 min, T1/2 beta = 42.2 min, K21 = 0.036 0.min-1, K12 = 0.045 0.min-1, K10 = 0.054 0.min-1, AUC = 235 mg.min.L-1, CLs = 0.043 0 L.min-1.kg-1, Vc = 0.780 L.kg-1.",[Pharmacokinetics of osthole in rabbits]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628444/),[l] / [kg·min],0.043 0,14231,DB01373,Calcium
,14628444,Vc,"The osthole pharmacokinetics conforms to a two compartment open model after i.v. administration, T1/2 alpha = 5.81 min, T1/2 beta = 42.2 min, K21 = 0.036 0.min-1, K12 = 0.045 0.min-1, K10 = 0.054 0.min-1, AUC = 235 mg.min.L-1, CLs = 0.043 0 L.min-1.kg-1, Vc = 0.780 L.kg-1.",[Pharmacokinetics of osthole in rabbits]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628444/),[l] / [kg],0.780,14232,DB01373,Calcium
,15954160,extraction efficiency,"The mean extraction efficiency of DHP-014 was 109.0 +/- 12.9, 97.7 +/- 8.0 and 102.9 +/- 7.5% for DHP-014 concentrations of 10, 50 and 100 nM, respectively (n = 5).",A high-performance liquid chromatographic method for determination of the niguldipine analogue DHP-014. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15954160/),%,109.0,14333,DB01373,Calcium
,15954160,extraction efficiency,"The mean extraction efficiency of DHP-014 was 109.0 +/- 12.9, 97.7 +/- 8.0 and 102.9 +/- 7.5% for DHP-014 concentrations of 10, 50 and 100 nM, respectively (n = 5).",A high-performance liquid chromatographic method for determination of the niguldipine analogue DHP-014. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15954160/),%,97.7,14334,DB01373,Calcium
,15954160,extraction efficiency,"The mean extraction efficiency of DHP-014 was 109.0 +/- 12.9, 97.7 +/- 8.0 and 102.9 +/- 7.5% for DHP-014 concentrations of 10, 50 and 100 nM, respectively (n = 5).",A high-performance liquid chromatographic method for determination of the niguldipine analogue DHP-014. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15954160/),%,102.9,14335,DB01373,Calcium
,15954160,limit of detection,The limit of detection of DHP-014 in rat plasma was 1.0 nM.,A high-performance liquid chromatographic method for determination of the niguldipine analogue DHP-014. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15954160/),nM,1.0,14336,DB01373,Calcium
>,22283588,solubility,"Of various cosurfactants tested, transcutol provided the most significantly increased solubility of bicyclol (>20 mg/ml).",Preparation and evaluation of bicyclol microemulsions for enhanced oral bioavailability. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22283588/),[mg] / [ml],20,14475,DB01373,Calcium
,19694735,time to maximum plasma concentration,PD 0200390 was rapidly absorbed; mean time to maximum plasma concentration was 1.66-3.24 h.,"Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19694735/),h,1.66-3.24,15528,DB01373,Calcium
,19694735,half-life,"Mean half-life in subjects with normal renal function was 5.36 h, and increased with worsening RI.","Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19694735/),h,5.36,15529,DB01373,Calcium
,11981147,C50,The clevidipine C50 value for a 10% or greater decrease in mean arterial pressure was 9.7 microg/l and for a 20% or greater decrease in mean arterial pressure was 26.3 microg/l.,Clevidipine in adult cardiac surgical patients: a dose-finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981147/),μ,9.7,15616,DB01373,Calcium
,11981147,volume of distribution,The pharmacokinetics of clevidipine were best described with a three-compartment model with a volume of distribution of 32.4 l and clearance of 4.3 l/min.,Clevidipine in adult cardiac surgical patients: a dose-finding study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981147/),l,32.4,15617,DB01373,Calcium
,11981147,clearance,The pharmacokinetics of clevidipine were best described with a three-compartment model with a volume of distribution of 32.4 l and clearance of 4.3 l/min.,Clevidipine in adult cardiac surgical patients: a dose-finding study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981147/),[l] / [min],4.3,15618,DB01373,Calcium
,11981147,half-life,The early phase of drug disposition had a half-life of 0.6 min.,Clevidipine in adult cardiac surgical patients: a dose-finding study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981147/),min,0.6,15619,DB01373,Calcium
less,11981147,half-time,The context-sensitive half-time is less than 2 min for up to 12 h of administration.,Clevidipine in adult cardiac surgical patients: a dose-finding study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981147/),min,2,15620,DB01373,Calcium
,16337109,ED50,"In the high-intensity electroshock test, pregabalin potently inhibited tonic extensor seizures in rats (ED50 = 1.8 mg/kg, PO), and low-intensity electroshock seizures in mice.",Activity profile of pregabalin in rodent models of epilepsy and ataxia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16337109/),[mg] / [kg],1.8,16032,DB01373,Calcium
,16337109,ED50,"It prevented tonic extensor seizures in the DBA/2 audiogenic mouse model (ED50 = 2.7 mg/kg, PO).",Activity profile of pregabalin in rodent models of epilepsy and ataxia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16337109/),[mg] / [kg],2.7,16033,DB01373,Calcium
,16337109,ED50 1,"At higher dosages (ED50 1= 31 mg/kg, PO), pregabalin prevented clonic seizures from pentylenetetrazole in mice.",Activity profile of pregabalin in rodent models of epilepsy and ataxia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16337109/),[mg] / [kg],31,16034,DB01373,Calcium
,21712498,AUC(0-24 h),The geometric mean AUC(0-24 h) of rosuvastatin increased from 109 to 161 ng·h/mL (P < .005) and C(max) increased 6.7 to 16.3 ng/mL (P < .001) when coadministered with darunavir/ritonavir.,Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21712498/),[h·ng] / [ml],109 to 161,16124,DB01373,Calcium
,21712498,C(max),The geometric mean AUC(0-24 h) of rosuvastatin increased from 109 to 161 ng·h/mL (P < .005) and C(max) increased 6.7 to 16.3 ng/mL (P < .001) when coadministered with darunavir/ritonavir.,Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21712498/),[ng] / [ml],6.7 to 16.3,16125,DB01373,Calcium
,21549539,flow rate,The flow rate was 0.4mL/min and the total run time was 6min.,Determination of chamaechromone in rat plasma by liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21549539/),[ml] / [min],0.4,16760,DB01373,Calcium
,21549539,total run time,The flow rate was 0.4mL/min and the total run time was 6min.,Determination of chamaechromone in rat plasma by liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21549539/),min,6,16761,DB01373,Calcium
,21549539,m/z,"The MS/MS ion transitions monitored were m/z 543.3→198.9 and 481.9→258.3 for chamaechromone and rosuvastatin, respectively.",Determination of chamaechromone in rat plasma by liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21549539/),,543.3,16762,DB01373,Calcium
,21549539,m/z,"The MS/MS ion transitions monitored were m/z 543.3→198.9 and 481.9→258.3 for chamaechromone and rosuvastatin, respectively.",Determination of chamaechromone in rat plasma by liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21549539/),,198.9,16763,DB01373,Calcium
,21549539,m/z,"The MS/MS ion transitions monitored were m/z 543.3→198.9 and 481.9→258.3 for chamaechromone and rosuvastatin, respectively.",Determination of chamaechromone in rat plasma by liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21549539/),,481.9,16764,DB01373,Calcium
,21549539,maximum mean concentration in plasma (C(max),"The maximum mean concentration in plasma (C(max), 795.9±14.6ng/L) was achieved at 11.3±0.8h (T(max)) and the area under curve (AUC(0-60)) was 6976.7±1026.9ngh/L.",Determination of chamaechromone in rat plasma by liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21549539/),[ng] / [l],795.9,16765,DB01373,Calcium
,21549539,T(max),"The maximum mean concentration in plasma (C(max), 795.9±14.6ng/L) was achieved at 11.3±0.8h (T(max)) and the area under curve (AUC(0-60)) was 6976.7±1026.9ngh/L.",Determination of chamaechromone in rat plasma by liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21549539/),h,11.3,16766,DB01373,Calcium
,21549539,area under curve (AUC(0-60)),"The maximum mean concentration in plasma (C(max), 795.9±14.6ng/L) was achieved at 11.3±0.8h (T(max)) and the area under curve (AUC(0-60)) was 6976.7±1026.9ngh/L.",Determination of chamaechromone in rat plasma by liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21549539/),[ngh] / [l],6976.7,16767,DB01373,Calcium
,21549539,C(max),"After single intravenously administration of chamaechromone, the essential pharmacokinetic parameters C(max), AUC(0-48) were 4300.7±113.6ng/L and 3672.1±225.4ngh/L, respectively.",Determination of chamaechromone in rat plasma by liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21549539/),[ng] / [l],4300.7,16768,DB01373,Calcium
,21549539,AUC(0-48),"After single intravenously administration of chamaechromone, the essential pharmacokinetic parameters C(max), AUC(0-48) were 4300.7±113.6ng/L and 3672.1±225.4ngh/L, respectively.",Determination of chamaechromone in rat plasma by liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21549539/),[ngh] / [l],3672.1,16769,DB01373,Calcium
,21549539,absolute bioavailability,The result showed that the compound was poorly absorbed with an absolute bioavailability being approximately 8.9%.,Determination of chamaechromone in rat plasma by liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21549539/),%,8.9,16770,DB01373,Calcium
,15066224,Oral systemic bioavailability,"Oral systemic bioavailability of NM in rats was 1.17 %, nasal dosing improved bioavailibility to 67.4 %.",Distribution of nimodipine in brain following intranasal administration in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15066224/),%,1.17,18870,DB01373,Calcium
,15066224,bioavailibility,"Oral systemic bioavailability of NM in rats was 1.17 %, nasal dosing improved bioavailibility to 67.4 %.",Distribution of nimodipine in brain following intranasal administration in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15066224/),%,67.4,18871,DB01373,Calcium
,29701749,total runtime,Polarity switch (negative-positive-negative ionization mode) was performed in a total runtime of 5.0 min.,"Simultaneous determination of rosuvastatin, naringin and naringenin in rat plasma by RRLC-MS/MS and its application to a pharmacokinetic drug interaction study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29701749/),min,5.0,18963,DB01373,Calcium
,30613141,relative bioavailability,"Remarkable improvements in Cmax and AUC0-∞ from NMP-NLC were obtained from pharmacokinetic experiments, and the relative bioavailability of NMP-loaded nanostructured lipid systems was 160.96% relative to NMP suspensions.",Preparation and characterization of nimodipine-loaded nanostructured lipid systems for enhanced solubility and bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30613141/),%,160.96,19099,DB01373,Calcium
,16013069,AUC,"With naringin, the AUC of verapamil was significantly greater (28.4 versus 18.4 microg min/ml).","Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013069/),[min·μg] / [ml],28.4,19260,DB01373,Calcium
,16013069,AUC,"With naringin, the AUC of verapamil was significantly greater (28.4 versus 18.4 microg min/ml).","Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013069/),[min·μg] / [ml],18.4,19261,DB01373,Calcium
,16013069,AUC(verapamil)/AUC(,"Although, the AUC values of norverapamil were not significantly different between groups without and with naringin, the AUC(verapamil)/AUC(norverapamil) ratio was considerably greater (1.49 versus 1.11) with naringin.","Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013069/),,1.49,19262,DB01373,Calcium
,16013069,AUC(verapamil)/AUC(,"Although, the AUC values of norverapamil were not significantly different between groups without and with naringin, the AUC(verapamil)/AUC(norverapamil) ratio was considerably greater (1.49 versus 1.11) with naringin.","Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013069/),,1.11,19263,DB01373,Calcium
,29683790,progression-free survival,"In cohort 2 (n = 15), median progression-free survival was 15 months and median overall survival was not reached (median follow-up, 28 months; 2-year overall survival, 62%).",Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29683790/),month,15,19457,DB01373,Calcium
,24672114,relative bioavailabilities,"The mean (SD) relative bioavailabilities, as represented by AUC0-∞, of amlodipine and benazeprilat for tablets versus capsules were 1.060 (0.170) versus 0.949 (0.197), respectively.","Bioavailability study of fixed-dose tablet versus capsule formulation of amlodipine plus benazepril: A randomized, single-dose, two-sequence, two-period, open-label, crossover study in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24672114/),,1.060,19576,DB01373,Calcium
,24672114,relative bioavailabilities,"The mean (SD) relative bioavailabilities, as represented by AUC0-∞, of amlodipine and benazeprilat for tablets versus capsules were 1.060 (0.170) versus 0.949 (0.197), respectively.","Bioavailability study of fixed-dose tablet versus capsule formulation of amlodipine plus benazepril: A randomized, single-dose, two-sequence, two-period, open-label, crossover study in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24672114/),,0.949,19577,DB01373,Calcium
,29933364,terminal half-life,"The mean terminal half-life of denosumab 60 mg and 120 mg was 15 days and 26 days, respectively.","Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose denosumab in healthy Chinese volunteers: A randomized, single-blind, placebo-controlled study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29933364/),d,15,19611,DB01373,Calcium
,29933364,terminal half-life,"The mean terminal half-life of denosumab 60 mg and 120 mg was 15 days and 26 days, respectively.","Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose denosumab in healthy Chinese volunteers: A randomized, single-blind, placebo-controlled study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29933364/),d,26,19612,DB01373,Calcium
,23392128,AUC glucose level,"Compared with a healthy normal control group, GS patients showed a higher AUC glucose level [16.1 (IQR 12.5-25.4 mEq · h/l) vs. 13.0 (IQR 11.9-13.7 mEq · h/l); p < 0.05] and AUC insulin level [81.0 (IQR 58.9-138 µU · h/ml) vs. 46.4 (IQR 35.6-63.3 µU · h/ml); p < 0.01].",Abnormal glucose metabolism and insulin sensitivity in Chinese patients with Gitelman syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23392128/),[h·meq] / [l],16.1,19717,DB01373,Calcium
,23392128,AUC glucose level,"Compared with a healthy normal control group, GS patients showed a higher AUC glucose level [16.1 (IQR 12.5-25.4 mEq · h/l) vs. 13.0 (IQR 11.9-13.7 mEq · h/l); p < 0.05] and AUC insulin level [81.0 (IQR 58.9-138 µU · h/ml) vs. 46.4 (IQR 35.6-63.3 µU · h/ml); p < 0.01].",Abnormal glucose metabolism and insulin sensitivity in Chinese patients with Gitelman syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23392128/),[h·meq] / [l],13.0,19718,DB01373,Calcium
,23392128,AUC insulin level,"Compared with a healthy normal control group, GS patients showed a higher AUC glucose level [16.1 (IQR 12.5-25.4 mEq · h/l) vs. 13.0 (IQR 11.9-13.7 mEq · h/l); p < 0.05] and AUC insulin level [81.0 (IQR 58.9-138 µU · h/ml) vs. 46.4 (IQR 35.6-63.3 µU · h/ml); p < 0.01].",Abnormal glucose metabolism and insulin sensitivity in Chinese patients with Gitelman syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23392128/),[h·µu] / [ml],81.0,19719,DB01373,Calcium
,23392128,AUC insulin level,"Compared with a healthy normal control group, GS patients showed a higher AUC glucose level [16.1 (IQR 12.5-25.4 mEq · h/l) vs. 13.0 (IQR 11.9-13.7 mEq · h/l); p < 0.05] and AUC insulin level [81.0 (IQR 58.9-138 µU · h/ml) vs. 46.4 (IQR 35.6-63.3 µU · h/ml); p < 0.01].",Abnormal glucose metabolism and insulin sensitivity in Chinese patients with Gitelman syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23392128/),[h·µu] / [ml],46.4,19720,DB01373,Calcium
,16869811,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve was significantly lower in subjects with 2677TT/3435TT (140.8 +/- 35.6 ng h(-1) ml(-1)) and 2677GT/3435CT (149.8 +/- 40.1 ng h(-1) ml(-1)) than in those with 2677GG/3435CC (208.6 +/- 39.2 ng h(-1) ml(-1)) [95% confidence interval (CI) on the difference, 2677GG/3435CC vs. 2677GT/3435CT 12.0, 105.6, P < 0.01; 2677GG/3435CC vs. 2677TT/3435TT 19.6, 116.0, P < 0.01; 2677GT/3435CT vs. 2677TT/3435TT - 39.2, 57.2, P > 0.05].",Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16869811/),[ng] / [h·ml],140.8,19872,DB01373,Calcium
,16869811,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve was significantly lower in subjects with 2677TT/3435TT (140.8 +/- 35.6 ng h(-1) ml(-1)) and 2677GT/3435CT (149.8 +/- 40.1 ng h(-1) ml(-1)) than in those with 2677GG/3435CC (208.6 +/- 39.2 ng h(-1) ml(-1)) [95% confidence interval (CI) on the difference, 2677GG/3435CC vs. 2677GT/3435CT 12.0, 105.6, P < 0.01; 2677GG/3435CC vs. 2677TT/3435TT 19.6, 116.0, P < 0.01; 2677GT/3435CT vs. 2677TT/3435TT - 39.2, 57.2, P > 0.05].",Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16869811/),[ng] / [h·ml],149.8,19873,DB01373,Calcium
,16869811,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve was significantly lower in subjects with 2677TT/3435TT (140.8 +/- 35.6 ng h(-1) ml(-1)) and 2677GT/3435CT (149.8 +/- 40.1 ng h(-1) ml(-1)) than in those with 2677GG/3435CC (208.6 +/- 39.2 ng h(-1) ml(-1)) [95% confidence interval (CI) on the difference, 2677GG/3435CC vs. 2677GT/3435CT 12.0, 105.6, P < 0.01; 2677GG/3435CC vs. 2677TT/3435TT 19.6, 116.0, P < 0.01; 2677GT/3435CT vs. 2677TT/3435TT - 39.2, 57.2, P > 0.05].",Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16869811/),[ng] / [h·ml],208.6,19874,DB01373,Calcium
,16869811,peak plasma concentrations,"The peak plasma concentrations were highest in subjects with 2677GG/3435CC (3.8 +/- 0.5 ng ml(-1)), lower in subjects with 2677GT/3435CT (3.2 +/- 0.5 ng ml(-1)) and 2677TT/3435TT (2.7 +/- 0.5 ng ml(-1)) in rank and showed a significant difference between those with 2677GG/3435CC and with 2677TT/3435TT (95% CI on the difference 0.4, 2.0, P < 0.01).",Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16869811/),[ng] / [ml],3.8,19875,DB01373,Calcium
,16869811,peak plasma concentrations,"The peak plasma concentrations were highest in subjects with 2677GG/3435CC (3.8 +/- 0.5 ng ml(-1)), lower in subjects with 2677GT/3435CT (3.2 +/- 0.5 ng ml(-1)) and 2677TT/3435TT (2.7 +/- 0.5 ng ml(-1)) in rank and showed a significant difference between those with 2677GG/3435CC and with 2677TT/3435TT (95% CI on the difference 0.4, 2.0, P < 0.01).",Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16869811/),[ng] / [ml],3.2,19876,DB01373,Calcium
,16869811,peak plasma concentrations,"The peak plasma concentrations were highest in subjects with 2677GG/3435CC (3.8 +/- 0.5 ng ml(-1)), lower in subjects with 2677GT/3435CT (3.2 +/- 0.5 ng ml(-1)) and 2677TT/3435TT (2.7 +/- 0.5 ng ml(-1)) in rank and showed a significant difference between those with 2677GG/3435CC and with 2677TT/3435TT (95% CI on the difference 0.4, 2.0, P < 0.01).",Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16869811/),[ng] / [ml],2.7,19877,DB01373,Calcium
,16869811,oral clearance,"However, the oral clearance was higher in subjects with 2677TT/3435TT (37.7 +/- 10.2 l h(-1)) than in those with 2677GT/3435CT (35.7 +/- 9.9 l h(-1)) and with 2677GG/3435CC (24.8 +/- 5.4 l h(-1)) and exhibited a significant difference between ABCB1 genotype groups (95% CI on the difference, 2677GG/3435CC vs. 2677GT/3435CT - 21.5, - 0.3, P < 0.05; 2677GG/3435CC vs. 2677TT/3435TT - 23.8, - 2.0, P < 0.05).",Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16869811/),[l] / [h],37.7,19878,DB01373,Calcium
,16869811,oral clearance,"However, the oral clearance was higher in subjects with 2677TT/3435TT (37.7 +/- 10.2 l h(-1)) than in those with 2677GT/3435CT (35.7 +/- 9.9 l h(-1)) and with 2677GG/3435CC (24.8 +/- 5.4 l h(-1)) and exhibited a significant difference between ABCB1 genotype groups (95% CI on the difference, 2677GG/3435CC vs. 2677GT/3435CT - 21.5, - 0.3, P < 0.05; 2677GG/3435CC vs. 2677TT/3435TT - 23.8, - 2.0, P < 0.05).",Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16869811/),[l] / [h],35.7,19879,DB01373,Calcium
,16869811,oral clearance,"However, the oral clearance was higher in subjects with 2677TT/3435TT (37.7 +/- 10.2 l h(-1)) than in those with 2677GT/3435CT (35.7 +/- 9.9 l h(-1)) and with 2677GG/3435CC (24.8 +/- 5.4 l h(-1)) and exhibited a significant difference between ABCB1 genotype groups (95% CI on the difference, 2677GG/3435CC vs. 2677GT/3435CT - 21.5, - 0.3, P < 0.05; 2677GG/3435CC vs. 2677TT/3435TT - 23.8, - 2.0, P < 0.05).",Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16869811/),[l] / [h],24.8,19880,DB01373,Calcium
,23700791,AUC(o-inf),"However, the systemic exposure of the pharmacologyically active metabolites, desacetyl diltiazem, was 2-fold higher in CYP2D6 10/10 genotype carriers than in 1/10 or 1/1 ones (AUC(o-inf) of CYP2D6 1/1, 1/10 and 10/10 are 398.2 +/- 162.9, 371,0 69.2 and 726.2 +/- 468.1 respectively, p <0.05).",Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23700791/),,398.2,20085,DB01373,Calcium
,23700791,AUC(o-inf),"However, the systemic exposure of the pharmacologyically active metabolites, desacetyl diltiazem, was 2-fold higher in CYP2D6 10/10 genotype carriers than in 1/10 or 1/1 ones (AUC(o-inf) of CYP2D6 1/1, 1/10 and 10/10 are 398.2 +/- 162.9, 371,0 69.2 and 726.2 +/- 468.1 respectively, p <0.05).",Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23700791/),,371,20086,DB01373,Calcium
,23700791,AUC(o-inf),"However, the systemic exposure of the pharmacologyically active metabolites, desacetyl diltiazem, was 2-fold higher in CYP2D6 10/10 genotype carriers than in 1/10 or 1/1 ones (AUC(o-inf) of CYP2D6 1/1, 1/10 and 10/10 are 398.2 +/- 162.9, 371,0 69.2 and 726.2 +/- 468.1 respectively, p <0.05).",Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23700791/),,0,20087,DB01373,Calcium
,23700791,AUC(o-inf),"However, the systemic exposure of the pharmacologyically active metabolites, desacetyl diltiazem, was 2-fold higher in CYP2D6 10/10 genotype carriers than in 1/10 or 1/1 ones (AUC(o-inf) of CYP2D6 1/1, 1/10 and 10/10 are 398.2 +/- 162.9, 371,0 69.2 and 726.2 +/- 468.1 respectively, p <0.05).",Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23700791/),,69.2,20088,DB01373,Calcium
,23700791,AUC(o-inf),"However, the systemic exposure of the pharmacologyically active metabolites, desacetyl diltiazem, was 2-fold higher in CYP2D6 10/10 genotype carriers than in 1/10 or 1/1 ones (AUC(o-inf) of CYP2D6 1/1, 1/10 and 10/10 are 398.2 +/- 162.9, 371,0 69.2 and 726.2 +/- 468.1 respectively, p <0.05).",Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23700791/),,726.2,20089,DB01373,Calcium
,29692602,steady-state ratios,"In the case of free and total ezetimibe, the steady-state ratios of AUCτ,ss and concentration at steady-state were 1.131 (1.051-1.218) and 1.182 (1.038-1.346), and 1.055 (0.969-1.148) and 0.996 (0.873-1.135), respectively.","Pharmacokinetic interactions and tolerability of rosuvastatin and ezetimibe: an open-label, randomized, multiple-dose, crossover study in healthy male volunteers. ",Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29692602/),,1,20157,DB01373,Calcium
greater,12907265,Recovery,Recovery for nifedipine was greater than 93.9% and for internal standard nitrendipine was 96.1%.,Determination of nifedipine in human plasma by solid-phase extraction and high-performance liquid chromatography: validation and application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12907265/),%,93.9,20191,DB01373,Calcium
,12907265,Recovery,Recovery for nifedipine was greater than 93.9% and for internal standard nitrendipine was 96.1%.,Determination of nifedipine in human plasma by solid-phase extraction and high-performance liquid chromatography: validation and application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12907265/),%,96.1,20192,DB01373,Calcium
,30756425,apparent clearance,Cinacalcet PK parameters were described by a two-compartment linear model with delayed first-order absorption-elimination (apparent clearance = 287.74 L h-1 ).,Bridging adults and paediatrics with secondary hyperparathyroidism receiving haemodialysis: a pharmacokinetic-pharmacodynamic analysis of cinacalcet. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30756425/),[l] / [h],287.74,20503,DB01373,Calcium
,34371742,loading capacity (LC),"The loading capacity (LC) and encapsulation efficiency (EE) percentages for MTF-loaded LCS and MTF-loaded DPP microcapsules were 14.9% ± 0.7, 29.8 ± 0.8, and 15.2% ± 0.7, 30.3 ± 1.0, respectively.",Sustained In Vitro and In Vivo Delivery of Metformin from Plant Pollen-Derived Composite Microcapsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34371742/),%,14.9,21067,DB01373,Calcium
,34371742,encapsulation efficiency (EE),"The loading capacity (LC) and encapsulation efficiency (EE) percentages for MTF-loaded LCS and MTF-loaded DPP microcapsules were 14.9% ± 0.7, 29.8 ± 0.8, and 15.2% ± 0.7, 30.3 ± 1.0, respectively.",Sustained In Vitro and In Vivo Delivery of Metformin from Plant Pollen-Derived Composite Microcapsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34371742/),%,15.2,21068,DB01373,Calcium
,34371742,encapsulation efficiency (EE),"The loading capacity (LC) and encapsulation efficiency (EE) percentages for MTF-loaded LCS and MTF-loaded DPP microcapsules were 14.9% ± 0.7, 29.8 ± 0.8, and 15.2% ± 0.7, 30.3 ± 1.0, respectively.",Sustained In Vitro and In Vivo Delivery of Metformin from Plant Pollen-Derived Composite Microcapsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34371742/),,30.3,21069,DB01373,Calcium
,25557368,Cmax,"The Cmax, Tmax and relative bioavailability for aceclofenac cocrystal and aceclofenac SDDS were 2.06±0.42 μg/ml, 1 h, 159.72±10.84 and 2.01 μg/ml, 1 h, 352.76±12.91, respectively.",Chitosan cocrystals embedded alginate beads for enhancing the solubility and bioavailability of aceclofenac. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25557368/),[μg] / [ml],2.06,21178,DB01373,Calcium
,25557368,Tmax,"The Cmax, Tmax and relative bioavailability for aceclofenac cocrystal and aceclofenac SDDS were 2.06±0.42 μg/ml, 1 h, 159.72±10.84 and 2.01 μg/ml, 1 h, 352.76±12.91, respectively.",Chitosan cocrystals embedded alginate beads for enhancing the solubility and bioavailability of aceclofenac. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25557368/),,1,21179,DB01373,Calcium
,25557368,Tmax,"The Cmax, Tmax and relative bioavailability for aceclofenac cocrystal and aceclofenac SDDS were 2.06±0.42 μg/ml, 1 h, 159.72±10.84 and 2.01 μg/ml, 1 h, 352.76±12.91, respectively.",Chitosan cocrystals embedded alginate beads for enhancing the solubility and bioavailability of aceclofenac. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25557368/),,159.72,21180,DB01373,Calcium
,25557368,Tmax,"The Cmax, Tmax and relative bioavailability for aceclofenac cocrystal and aceclofenac SDDS were 2.06±0.42 μg/ml, 1 h, 159.72±10.84 and 2.01 μg/ml, 1 h, 352.76±12.91, respectively.",Chitosan cocrystals embedded alginate beads for enhancing the solubility and bioavailability of aceclofenac. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25557368/),[μg] / [ml],2.01,21181,DB01373,Calcium
,25557368,Tmax,"The Cmax, Tmax and relative bioavailability for aceclofenac cocrystal and aceclofenac SDDS were 2.06±0.42 μg/ml, 1 h, 159.72±10.84 and 2.01 μg/ml, 1 h, 352.76±12.91, respectively.",Chitosan cocrystals embedded alginate beads for enhancing the solubility and bioavailability of aceclofenac. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25557368/),,352.76,21182,DB01373,Calcium
,25557368,relative bioavailability,"The Cmax, Tmax and relative bioavailability for aceclofenac cocrystal and aceclofenac SDDS were 2.06±0.42 μg/ml, 1 h, 159.72±10.84 and 2.01 μg/ml, 1 h, 352.76±12.91, respectively.",Chitosan cocrystals embedded alginate beads for enhancing the solubility and bioavailability of aceclofenac. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25557368/),,352.76,21183,DB01373,Calcium
<,33493600,oral bioavailability,"Felodipine is a calcium channel blocker, which shows low oral bioavailability (<15%) owing to poor water solubility and high first pass metabolism.","Oral bioavailability improvement of felodipine using tailored microemulsion: Surface science, ex vivo and in vivo studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33493600/),%,15,21590,DB01373,Calcium
,33493600,relative bioavailability,"The in vivo pharmacokinetic parameters in the rat model confirmed the improvement in oral bioavailability with microemulsion (relative bioavailability = 21.9) in comparison to the felodipine suspension, due to high surface area of oil droplets and its lymphatic uptake via transcellular route.","Oral bioavailability improvement of felodipine using tailored microemulsion: Surface science, ex vivo and in vivo studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33493600/),,21.9,21591,DB01373,Calcium
,16838266,flow gradient,"The chromatographic run time was less than 20 min using flow gradient (0.0-1.60 mL/min) with a mobile phase consisting of 0.01 M ammonium acetate:acetonitrile:methanol (50:40:10, v/v/v) and UV detection at 275 nm.",Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16838266/),[ml] / [min],0.0-1.60,22411,DB01373,Calcium
,16838266,Nominal retention times,"Nominal retention times of RST, GFZ and IS were 6.7, 13.9 and 16.4 min, respectively.",Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16838266/),min,6.7,22412,DB01373,Calcium
,16838266,Nominal retention times,"Nominal retention times of RST, GFZ and IS were 6.7, 13.9 and 16.4 min, respectively.",Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16838266/),min,13.9,22413,DB01373,Calcium
,16838266,Nominal retention times,"Nominal retention times of RST, GFZ and IS were 6.7, 13.9 and 16.4 min, respectively.",Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16838266/),min,16.4,22414,DB01373,Calcium
greater,16838266,Absolute recovery,Absolute recovery of both analytes and IS was greater than 90%.,Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16838266/),%,90,22415,DB01373,Calcium
,17568401,area under the concentration-time curve for 0 to infinity (AUC(0-infinity)),"The area under the concentration-time curve for 0 to infinity (AUC(0-infinity)) of rosuvastatin for group 1 (*1a/*1a, *1a/*1b, *1b/*1b), group 2 (*1a/*15, *1b/*15), and group 3 (*15/*15) were 111+/-49.3, 126+/-45.2, and 191+/-31.0 ng h/ml, respectively, with significant differences among the three groups (P=0.0429) and between *15/*15 and the other groups (P=0.0181).",Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17568401/),[h·ng] / [ml],111,22860,DB01373,Calcium
,17568401,area under the concentration-time curve for 0 to infinity (AUC(0-infinity)),"The area under the concentration-time curve for 0 to infinity (AUC(0-infinity)) of rosuvastatin for group 1 (*1a/*1a, *1a/*1b, *1b/*1b), group 2 (*1a/*15, *1b/*15), and group 3 (*15/*15) were 111+/-49.3, 126+/-45.2, and 191+/-31.0 ng h/ml, respectively, with significant differences among the three groups (P=0.0429) and between *15/*15 and the other groups (P=0.0181).",Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17568401/),[h·ng] / [ml],126,22861,DB01373,Calcium
,17568401,area under the concentration-time curve for 0 to infinity (AUC(0-infinity)),"The area under the concentration-time curve for 0 to infinity (AUC(0-infinity)) of rosuvastatin for group 1 (*1a/*1a, *1a/*1b, *1b/*1b), group 2 (*1a/*15, *1b/*15), and group 3 (*15/*15) were 111+/-49.3, 126+/-45.2, and 191+/-31.0 ng h/ml, respectively, with significant differences among the three groups (P=0.0429) and between *15/*15 and the other groups (P=0.0181).",Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17568401/),[h·ng] / [ml],191,22862,DB01373,Calcium
,11851646,AUC,"The treatment with rifampicin reduced the mean (+/- s.d.) AUC of nilvadipine from 17.4 +/- 8.4 to 0.6 +/- 0.4 microg l-1 h (mean difference -16.8 microg l-1 h, 95% CI -9.4, 24.2 microg l-1 h).",The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11851646/),[h·μg] / [l],17.4,23022,DB01373,Calcium
,11851646,AUC,"The treatment with rifampicin reduced the mean (+/- s.d.) AUC of nilvadipine from 17.4 +/- 8.4 to 0.6 +/- 0.4 microg l-1 h (mean difference -16.8 microg l-1 h, 95% CI -9.4, 24.2 microg l-1 h).",The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11851646/),[h·μg] / [l],0.6,23023,DB01373,Calcium
,21124302,half-life,There was a single exponential decay with a half-life of 33 min.,Treatment with pyrophosphate inhibits uremic vascular calcification. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21124302/),min,33,23024,DB01373,Calcium
,17080256,survival,"The median survival was 10.3 months (95% confidence interval (CI), 8.5-12.8) compared to 12.1 months (95% CI, 10.3-13.3) in the NABTT reference group (p = 0.97).",Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080256/),month,10.3,23264,DB01373,Calcium
,17080256,survival,"The median survival was 10.3 months (95% confidence interval (CI), 8.5-12.8) compared to 12.1 months (95% CI, 10.3-13.3) in the NABTT reference group (p = 0.97).",Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080256/),month,12.1,23265,DB01373,Calcium
,17080256,plasma concentration,The mean CAI plasma concentration for patients taking enzyme inducing antiepileptic drugs (EIAED) was 1.35 +/-1.22 compared to 4.06 +/- 1.50 (p < 0.001) for subjects not taking these agents.,Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080256/),,1.35,23266,DB01373,Calcium
,17080256,plasma concentration,The mean CAI plasma concentration for patients taking enzyme inducing antiepileptic drugs (EIAED) was 1.35 +/-1.22 compared to 4.06 +/- 1.50 (p < 0.001) for subjects not taking these agents.,Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080256/),,4.06,23267,DB01373,Calcium
,16941544,m,"Following a liquid-liquid extraction, the analytes were separated using an isocratic mobile phase on a reversed-phase column and analyzed by mass spectrometry in the multiple reaction monitoring mode using the respective [M-H]- ions, m/z 387.0 --> 164.0 for AR, m/z 389.1 --> 208.1 for AR-M and m/z 359.0 --> 121.8 for the internal standard.",Determination of aranidipine and its active metabolite in human plasma by liquid chromatography/negative electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16941544/),,387.0,23660,DB01373,Calcium
,16941544,m/z,"Following a liquid-liquid extraction, the analytes were separated using an isocratic mobile phase on a reversed-phase column and analyzed by mass spectrometry in the multiple reaction monitoring mode using the respective [M-H]- ions, m/z 387.0 --> 164.0 for AR, m/z 389.1 --> 208.1 for AR-M and m/z 359.0 --> 121.8 for the internal standard.",Determination of aranidipine and its active metabolite in human plasma by liquid chromatography/negative electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16941544/),,389.1,23661,DB01373,Calcium
,16941544,m/z,"Following a liquid-liquid extraction, the analytes were separated using an isocratic mobile phase on a reversed-phase column and analyzed by mass spectrometry in the multiple reaction monitoring mode using the respective [M-H]- ions, m/z 387.0 --> 164.0 for AR, m/z 389.1 --> 208.1 for AR-M and m/z 359.0 --> 121.8 for the internal standard.",Determination of aranidipine and its active metabolite in human plasma by liquid chromatography/negative electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16941544/),,208.1,23662,DB01373,Calcium
,16941544,m/z,"Following a liquid-liquid extraction, the analytes were separated using an isocratic mobile phase on a reversed-phase column and analyzed by mass spectrometry in the multiple reaction monitoring mode using the respective [M-H]- ions, m/z 387.0 --> 164.0 for AR, m/z 389.1 --> 208.1 for AR-M and m/z 359.0 --> 121.8 for the internal standard.",Determination of aranidipine and its active metabolite in human plasma by liquid chromatography/negative electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16941544/),,359.0,23663,DB01373,Calcium
,16941544,m/z,"Following a liquid-liquid extraction, the analytes were separated using an isocratic mobile phase on a reversed-phase column and analyzed by mass spectrometry in the multiple reaction monitoring mode using the respective [M-H]- ions, m/z 387.0 --> 164.0 for AR, m/z 389.1 --> 208.1 for AR-M and m/z 359.0 --> 121.8 for the internal standard.",Determination of aranidipine and its active metabolite in human plasma by liquid chromatography/negative electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16941544/),,121.8,23664,DB01373,Calcium
,16941544,linear dynamic,The assay exhibited a linear dynamic range of 0.02-10 ng x mL(-1) for AR and 0.2-100 ng x mL(-1) for AR-M in human plasma.,Determination of aranidipine and its active metabolite in human plasma by liquid chromatography/negative electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16941544/),[ng] / [ml],0.02-10,23665,DB01373,Calcium
,16941544,linear dynamic,The assay exhibited a linear dynamic range of 0.02-10 ng x mL(-1) for AR and 0.2-100 ng x mL(-1) for AR-M in human plasma.,Determination of aranidipine and its active metabolite in human plasma by liquid chromatography/negative electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16941544/),[ng] / [ml],0.2-100,23666,DB01373,Calcium
,16941544,run time,A run time of 2.8 min for each sample exhibited its high-throughout analysis ability.,Determination of aranidipine and its active metabolite in human plasma by liquid chromatography/negative electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16941544/),min,2.8,23667,DB01373,Calcium
,30499176,volume of distribution at steady state,"The volume of distribution at steady state, systemic clearance, and terminal half-life was 0.194 ± 0.019 L/kg, 23.9 ± 4.48 mL/h/kg, and 10.9 ± 5.32 hours, respectively.","Phenylbutazone blood and urine concentrations, pharmacokinetics, and effects on biomarkers of inflammation in horses following intravenous and oral administration of clinical doses. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30499176/),[l] / [kg],0.194,24007,DB01373,Calcium
,30499176,systemic clearance,"The volume of distribution at steady state, systemic clearance, and terminal half-life was 0.194 ± 0.019 L/kg, 23.9 ± 4.48 mL/h/kg, and 10.9 ± 5.32 hours, respectively.","Phenylbutazone blood and urine concentrations, pharmacokinetics, and effects on biomarkers of inflammation in horses following intravenous and oral administration of clinical doses. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30499176/),[ml] / [h·kg],23.9,24008,DB01373,Calcium
,30499176,terminal half-life,"The volume of distribution at steady state, systemic clearance, and terminal half-life was 0.194 ± 0.019 L/kg, 23.9 ± 4.48 mL/h/kg, and 10.9 ± 5.32 hours, respectively.","Phenylbutazone blood and urine concentrations, pharmacokinetics, and effects on biomarkers of inflammation in horses following intravenous and oral administration of clinical doses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30499176/),h,10.9,24009,DB01373,Calcium
,30499176,terminal half-life,The terminal half-life following oral administration was 13.4 ± 3.01 (paste) and 15.1 ± 3.96 hours (tablets).,"Phenylbutazone blood and urine concentrations, pharmacokinetics, and effects on biomarkers of inflammation in horses following intravenous and oral administration of clinical doses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30499176/),h,13.4,24010,DB01373,Calcium
,30499176,terminal half-life,The terminal half-life following oral administration was 13.4 ± 3.01 (paste) and 15.1 ± 3.96 hours (tablets).,"Phenylbutazone blood and urine concentrations, pharmacokinetics, and effects on biomarkers of inflammation in horses following intravenous and oral administration of clinical doses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30499176/),h,15.1,24011,DB01373,Calcium
,33319618,PDI,"Particle size, PDI, zeta potential and LE% of optimized formulations of CND-PCL-NPs were 220.3 ± 2.6 nm, 0.25 ± 0.1, -19.5 ± 0.9 mV, and 46.4 ± 1.8%, respectively.","Cilnidipine loaded poly (ε-caprolactone) nanoparticles for enhanced oral delivery: optimization using DoE, physical characterization, pharmacokinetic, and pharmacodynamic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33319618/),mv,0.25,24311,DB01373,Calcium
,33319618,zeta potential,"Particle size, PDI, zeta potential and LE% of optimized formulations of CND-PCL-NPs were 220.3 ± 2.6 nm, 0.25 ± 0.1, -19.5 ± 0.9 mV, and 46.4 ± 1.8%, respectively.","Cilnidipine loaded poly (ε-caprolactone) nanoparticles for enhanced oral delivery: optimization using DoE, physical characterization, pharmacokinetic, and pharmacodynamic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33319618/),mv,0.25,24312,DB01373,Calcium
,33319618,LE%,"Particle size, PDI, zeta potential and LE% of optimized formulations of CND-PCL-NPs were 220.3 ± 2.6 nm, 0.25 ± 0.1, -19.5 ± 0.9 mV, and 46.4 ± 1.8%, respectively.","Cilnidipine loaded poly (ε-caprolactone) nanoparticles for enhanced oral delivery: optimization using DoE, physical characterization, pharmacokinetic, and pharmacodynamic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33319618/),mv,-,24313,DB01373,Calcium
,33319618,LE%,"Particle size, PDI, zeta potential and LE% of optimized formulations of CND-PCL-NPs were 220.3 ± 2.6 nm, 0.25 ± 0.1, -19.5 ± 0.9 mV, and 46.4 ± 1.8%, respectively.","Cilnidipine loaded poly (ε-caprolactone) nanoparticles for enhanced oral delivery: optimization using DoE, physical characterization, pharmacokinetic, and pharmacodynamic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33319618/),mv,19.5,24314,DB01373,Calcium
,33319618,LE%,"Particle size, PDI, zeta potential and LE% of optimized formulations of CND-PCL-NPs were 220.3 ± 2.6 nm, 0.25 ± 0.1, -19.5 ± 0.9 mV, and 46.4 ± 1.8%, respectively.","Cilnidipine loaded poly (ε-caprolactone) nanoparticles for enhanced oral delivery: optimization using DoE, physical characterization, pharmacokinetic, and pharmacodynamic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33319618/),%,46.4,24315,DB01373,Calcium
,33319618,Fabs,Oral pharmacokinetic studies revealed that Fabs of CND-PCL-NPs (0.55) were significantly higher than the CND suspension (0.26).,"Cilnidipine loaded poly (ε-caprolactone) nanoparticles for enhanced oral delivery: optimization using DoE, physical characterization, pharmacokinetic, and pharmacodynamic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33319618/),,0.55,24316,DB01373,Calcium
,33319618,Fabs,Oral pharmacokinetic studies revealed that Fabs of CND-PCL-NPs (0.55) were significantly higher than the CND suspension (0.26).,"Cilnidipine loaded poly (ε-caprolactone) nanoparticles for enhanced oral delivery: optimization using DoE, physical characterization, pharmacokinetic, and pharmacodynamic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33319618/),,0.26,24317,DB01373,Calcium
,19954720,plasma concentration peaked (Cmax),"Rosuvastatin plasma concentration peaked (Cmax) at 3.68 +/- 2.3 ng/ml (geometric mean), 4.5 hours (median; range 2 - 6 hours) after oral dosing.",Pharmacokinetics of rosuvastatin in patients with end-stage kidney disease undergoing peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19954720/),[ng] / [ml],3.68,24537,DB01373,Calcium
,19954720,area under the plasma concentration-time from 0 to 48 hours (AUC0-48),The area under the plasma concentration-time from 0 to 48 hours (AUC0-48) was 32.6 +/- 1.6 ng/ml/h.,Pharmacokinetics of rosuvastatin in patients with end-stage kidney disease undergoing peritoneal dialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19954720/),[ng] / [h·ml],32.6,24538,DB01373,Calcium
,17328582,elimination half-life (t(1/2)),"Levosimendan, the parent drug, was eliminated rapidly from the plasma after discontinuation of its infusion, with an elimination half-life (t(1/2)) [mean +/- standard error of mean] of 1.5 +/- 0.09 hours in ESRD patients undergoing haemodialysis, 1.0 +/- 0.2 hours in patients with severe CRF and 0.91 +/- 0.03 hours in healthy subjects.",Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17328582/),h,1.5,24861,DB01373,Calcium
,17328582,elimination half-life (t(1/2)),"Levosimendan, the parent drug, was eliminated rapidly from the plasma after discontinuation of its infusion, with an elimination half-life (t(1/2)) [mean +/- standard error of mean] of 1.5 +/- 0.09 hours in ESRD patients undergoing haemodialysis, 1.0 +/- 0.2 hours in patients with severe CRF and 0.91 +/- 0.03 hours in healthy subjects.",Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17328582/),h,1.0,24862,DB01373,Calcium
,17328582,elimination half-life (t(1/2)),"Levosimendan, the parent drug, was eliminated rapidly from the plasma after discontinuation of its infusion, with an elimination half-life (t(1/2)) [mean +/- standard error of mean] of 1.5 +/- 0.09 hours in ESRD patients undergoing haemodialysis, 1.0 +/- 0.2 hours in patients with severe CRF and 0.91 +/- 0.03 hours in healthy subjects.",Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17328582/),h,0.91,24863,DB01373,Calcium
,17328582,t(1/2),"The t(1/2) of OR-1855 and OR-1896 were 94.0 +/- 20.4 hours and 96.5 +/- 19.5 hours, respectively, in ESRD patients undergoing haemodialysis compared with 60.8 +/- 5.2 and 61.6 +/- 5.2 hours, respectively, in healthy subjects (p = not significant).",Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17328582/),h,94.0,24864,DB01373,Calcium
,17328582,t(1/2),"The t(1/2) of OR-1855 and OR-1896 were 94.0 +/- 20.4 hours and 96.5 +/- 19.5 hours, respectively, in ESRD patients undergoing haemodialysis compared with 60.8 +/- 5.2 and 61.6 +/- 5.2 hours, respectively, in healthy subjects (p = not significant).",Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17328582/),h,96.5,24865,DB01373,Calcium
,17328582,t(1/2),"The t(1/2) of OR-1855 and OR-1896 were 94.0 +/- 20.4 hours and 96.5 +/- 19.5 hours, respectively, in ESRD patients undergoing haemodialysis compared with 60.8 +/- 5.2 and 61.6 +/- 5.2 hours, respectively, in healthy subjects (p = not significant).",Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17328582/),h,60.8,24866,DB01373,Calcium
,17328582,t(1/2),"The t(1/2) of OR-1855 and OR-1896 were 94.0 +/- 20.4 hours and 96.5 +/- 19.5 hours, respectively, in ESRD patients undergoing haemodialysis compared with 60.8 +/- 5.2 and 61.6 +/- 5.2 hours, respectively, in healthy subjects (p = not significant).",Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17328582/),h,61.6,24867,DB01373,Calcium
,17328582,t(1/2),"The t(1/2) of OR-1855 was significantly longer (85.0 +/- 13.6 hours) in patients with severe CRF than in healthy subjects (60.8 +/- 5.2 hours, p < 0.05).",Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17328582/),h,85.0,24868,DB01373,Calcium
,17328582,t(1/2),"The t(1/2) of OR-1855 was significantly longer (85.0 +/- 13.6 hours) in patients with severe CRF than in healthy subjects (60.8 +/- 5.2 hours, p < 0.05).",Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17328582/),h,60.8,24869,DB01373,Calcium
,17328582,unbound fraction (f(u)),"The mean unbound fraction (f(u)) of levosimendan in plasma was approximately 2% in each study group, whereas the f(u) of the metabolites was considerably higher (63-70%).",Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17328582/),%,2,24870,DB01373,Calcium
,17328582,f(u),"The mean unbound fraction (f(u)) of levosimendan in plasma was approximately 2% in each study group, whereas the f(u) of the metabolites was considerably higher (63-70%).",Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17328582/),%,63-70,24871,DB01373,Calcium
,17328582,clearance,"In contrast to levosimendan, the metabolites were dialysable, with dialysis clearance of approximately 100 mL/minute.",Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17328582/),[ml] / [min],100,24872,DB01373,Calcium
,34375028,Peak plasma-Pt concentration,"Peak plasma-Pt concentration was 225.78 ng/ml at 12 h, and decreased over time, but Pt was still detectable on d28.",Pharmacokinetic and safety assessment of carboplatin-impregnated calcium sulfate hemihydrate beads in eight rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34375028/),[ng] / [ml],225.78,25388,DB01373,Calcium
,34375028,elimination half-life,The elimination half-life was 5.03 ± 1.13 days.,Pharmacokinetic and safety assessment of carboplatin-impregnated calcium sulfate hemihydrate beads in eight rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34375028/),d,5.03,25389,DB01373,Calcium
,20660125,IC(50),"CCX282-B inhibited CCR9-mediated Ca(2+) mobilization and chemotaxis on Molt-4 cells with IC(50) values of 5.4 and 3.4 nM, respectively.","Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20660125/),nM,5.4,26124,DB01373,Calcium
,20660125,IC(50),"CCX282-B inhibited CCR9-mediated Ca(2+) mobilization and chemotaxis on Molt-4 cells with IC(50) values of 5.4 and 3.4 nM, respectively.","Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20660125/),nM,3.4,26125,DB01373,Calcium
,20660125,IC(50),"In the presence of 100% human serum, CCX282-B inhibited CCR9-mediated chemotaxis with an IC(50) of 33 nM, and the addition of α1-acid glycoprotein did not affect its potency.","Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20660125/),nM,33,26126,DB01373,Calcium
,20660125,IC(50),CCX282-B inhibited chemotaxis of primary CCR9-expressing cells to CCL25 with an IC(50) of 6.8 nM.,"Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20660125/),nM,6.8,26127,DB01373,Calcium
,20660125,IC(50),"CCX282-B was an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC(50) values of 2.8 and 2.6 nM, respectively.","Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20660125/),nM,2.8,26128,DB01373,Calcium
,20660125,IC(50),"CCX282-B was an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC(50) values of 2.8 and 2.6 nM, respectively.","Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20660125/),nM,2.6,26129,DB01373,Calcium
,12942850,elimination half-life,"It is mainly eliminated in the faeces, with an elimination half-life in humans of between 13 and 21 hours.","[Pharmacologic characteristics of rosuvastatin, a new HMG-CoA reductase inhibitor]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942850/),h,13 and 21,26698,DB01373,Calcium
more,26592698,gastric residence,In vitro wash off and buoyancy test in gastric media revealed that the beads containing CaCO3 has gastric residence of more than 12 h.,Tapioca starch blended alginate mucoadhesive-floating beads for intragastric delivery of Metoprolol Tartrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26592698/),,12,27155,DB01373,Calcium
,26592698,relative oral bioavailability,"Pharmacokinetic study performed in rabbit model showed that the relative oral bioavailability of MT after administration of oral solution, sustain release and optimized formulation was 51%, 67% and 87%, respectively.",Tapioca starch blended alginate mucoadhesive-floating beads for intragastric delivery of Metoprolol Tartrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26592698/),%,51,27156,DB01373,Calcium
,26592698,relative oral bioavailability,"Pharmacokinetic study performed in rabbit model showed that the relative oral bioavailability of MT after administration of oral solution, sustain release and optimized formulation was 51%, 67% and 87%, respectively.",Tapioca starch blended alginate mucoadhesive-floating beads for intragastric delivery of Metoprolol Tartrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26592698/),%,67,27157,DB01373,Calcium
,26592698,relative oral bioavailability,"Pharmacokinetic study performed in rabbit model showed that the relative oral bioavailability of MT after administration of oral solution, sustain release and optimized formulation was 51%, 67% and 87%, respectively.",Tapioca starch blended alginate mucoadhesive-floating beads for intragastric delivery of Metoprolol Tartrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26592698/),%,87,27158,DB01373,Calcium
,15373936,tlag,"The tlag was 240 min [range 60-603 min; 95% confidence interval (CI) 139, 471] shorter when the tablet was taken after an overnight fast (90 min; range 60-120 min; 95% CI 66, 107) than when taken with breakfast (300 min; range 180-723 min; 95% CI 0, 1002).",Pharmacokinetics of oral fumarates in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15373936/),min,240,27492,DB01373,Calcium
,15373936,tmax,"The tmax was 241 min (range 60-1189 min, 95% CI 53, 781) shorter when the tablet was taken after an overnight fast (182 min; range 120-240 min; 95% CI 146, 211) than when taken with breakfast (361 min; range 240-1429 min; 95% CI 0, 1062).",Pharmacokinetics of oral fumarates in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15373936/),min,241,27493,DB01373,Calcium
,15373936,tmax,"The tmax was 241 min (range 60-1189 min, 95% CI 53, 781) shorter when the tablet was taken after an overnight fast (182 min; range 120-240 min; 95% CI 146, 211) than when taken with breakfast (361 min; range 240-1429 min; 95% CI 0, 1062).",Pharmacokinetics of oral fumarates in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15373936/),min,182,27494,DB01373,Calcium
,15373936,tmax,"The tmax was 241 min (range 60-1189 min, 95% CI 53, 781) shorter when the tablet was taken after an overnight fast (182 min; range 120-240 min; 95% CI 146, 211) than when taken with breakfast (361 min; range 240-1429 min; 95% CI 0, 1062).",Pharmacokinetics of oral fumarates in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15373936/),min,361,27495,DB01373,Calcium
,15373936,Cmax,"The mean Cmax for monomethylfumarate in the blood of fasting subjects was to 0.84 mg l(-1) (range 0.37-1.29 mg l(-1); 95% CI 0.52, 1.07) and did not differ from that in fed subjects (0.48 mg l(-1); range 0-1.22 mg l(-1); 95% CI 0, 5.55).",Pharmacokinetics of oral fumarates in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15373936/),[mg] / [l],0.84,27496,DB01373,Calcium
,15373936,Cmax,"The mean Cmax for monomethylfumarate in the blood of fasting subjects was to 0.84 mg l(-1) (range 0.37-1.29 mg l(-1); 95% CI 0.52, 1.07) and did not differ from that in fed subjects (0.48 mg l(-1); range 0-1.22 mg l(-1); 95% CI 0, 5.55).",Pharmacokinetics of oral fumarates in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15373936/),[mg] / [l],0.48,27497,DB01373,Calcium
,17706903,Maximum insulin concentration in blood,Maximum insulin concentration in blood was 11.3+/-6.2ng/ml and was reached 6h after administration.,Design and in vivo evaluation of a patch delivery system for insulin based on thiolated polymers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17706903/),[ng] / [ml],11.3,27523,DB01373,Calcium
,17706903,relative bioavailability,The relative bioavailability of orally administered patch system versus subcutaneous injection was 2.2%.,Design and in vivo evaluation of a patch delivery system for insulin based on thiolated polymers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17706903/),%,2.2,27524,DB01373,Calcium
,21189658,50% inhibition concentration,Lovastatin inhibited CYP3A4 enzyme activity with a 50% inhibition concentration of 6.06 µM.,"Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21189658/),μM,6.06,27930,DB01373,Calcium
,21189658,absolute bioavailability,"Consequently, the absolute bioavailability values of diltiazem in the presence of lovastatin (11.1% at 1.0 mg/kg) were significantly higher (P < 0.05) than that of the control group (7.6%).","Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21189658/),%,11.1,27931,DB01373,Calcium
,21189658,absolute bioavailability,"Consequently, the absolute bioavailability values of diltiazem in the presence of lovastatin (11.1% at 1.0 mg/kg) were significantly higher (P < 0.05) than that of the control group (7.6%).","Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21189658/),%,7.6,27932,DB01373,Calcium
,31233749,pD2,"In the present study, we report that neolignan1 (Diethyl-4,4'-dihydroxy-8,3'-neolign-7,7'-dien-9,9'-dionate) relaxes the superior mesenteric artery in a concentration dependent manner (pD2 value 5.392 ± 0.04; n = 8 for endothelium intact and 5.204 ± 0.03; n = 8 for endothelium denuded mesenteric rings, respectively).","Antihypertensive activity of diethyl-4,4'-dihydroxy-8,3'-neolign-7,7'-dien-9,9'-dionate: A continuation study in L-NAME treated wistar rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31233749/),,5.392,28063,DB01373,Calcium
,31233749,pD2,"In the present study, we report that neolignan1 (Diethyl-4,4'-dihydroxy-8,3'-neolign-7,7'-dien-9,9'-dionate) relaxes the superior mesenteric artery in a concentration dependent manner (pD2 value 5.392 ± 0.04; n = 8 for endothelium intact and 5.204 ± 0.03; n = 8 for endothelium denuded mesenteric rings, respectively).","Antihypertensive activity of diethyl-4,4'-dihydroxy-8,3'-neolign-7,7'-dien-9,9'-dionate: A continuation study in L-NAME treated wistar rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31233749/),,5.204,28064,DB01373,Calcium
,30168004,time to maximum plasma concentration,"After a single dose of evocalcet 1-20 mg, the time to maximum plasma concentration was attained in 1.5-2 h (median), and the elimination half-life was 12.98-19.77 h (mean).","Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30168004/),h,1.5-2,28578,DB01373,Calcium
,30168004,elimination half-life,"After a single dose of evocalcet 1-20 mg, the time to maximum plasma concentration was attained in 1.5-2 h (median), and the elimination half-life was 12.98-19.77 h (mean).","Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30168004/),h,12.98-19.77,28579,DB01373,Calcium
,28905271,half-life,"After the first and final dose, the half-life of DP001 was similar (55.8 ± 13.0 and 50.8 ± 8.2 h, respectively).","Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905271/),h,55.8,28814,DB01373,Calcium
,28905271,half-life,"After the first and final dose, the half-life of DP001 was similar (55.8 ± 13.0 and 50.8 ± 8.2 h, respectively).","Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905271/),h,50.8,28815,DB01373,Calcium
,28905271,time to maximum plasma concentration,"At 4 weeks, the time to maximum plasma concentration was 4.0 ± 0.8 h, with a concentration maximum of 3.4 ± 0.3 pg/mL.","Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905271/),h,4.0,28816,DB01373,Calcium
,28905271,concentration maximum,"At 4 weeks, the time to maximum plasma concentration was 4.0 ± 0.8 h, with a concentration maximum of 3.4 ± 0.3 pg/mL.","Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905271/),[pg] / [ml],3.4,28817,DB01373,Calcium
,28905271,area under the curve (0 to infinity),"The area under the curve (0 to infinity) after the final dose was 204.3 ± 23.9 pg h/mL, and apparent volume of distribution was 2.03 ± 0.22 L/kg.","Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905271/),[h·pg] / [ml],204.3,28818,DB01373,Calcium
,28905271,apparent volume of distribution,"The area under the curve (0 to infinity) after the final dose was 204.3 ± 23.9 pg h/mL, and apparent volume of distribution was 2.03 ± 0.22 L/kg.","Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905271/),[l] / [kg],2.03,28819,DB01373,Calcium
,25750535,peak plasma concentration,"In Chinese healthy volunteers, a single-dose oral administration of azelnidipine 8-16 mg had a peak plasma concentration of 1.66-23.06 ng/mL and time to peak plasma concentration was 2.6-4.0 hours and the area under the plasma concentration versus time curve from time 0 hour to 96 hours was 17.9-429 ng/mL·h and elimination half-life was 16.0-28.0 hours.",Clinical use of azelnidipine in the treatment of hypertension in Chinese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25750535/),[ng] / [ml],1.66-23.06,29970,DB01373,Calcium
,25750535,time to peak plasma concentration,"In Chinese healthy volunteers, a single-dose oral administration of azelnidipine 8-16 mg had a peak plasma concentration of 1.66-23.06 ng/mL and time to peak plasma concentration was 2.6-4.0 hours and the area under the plasma concentration versus time curve from time 0 hour to 96 hours was 17.9-429 ng/mL·h and elimination half-life was 16.0-28.0 hours.",Clinical use of azelnidipine in the treatment of hypertension in Chinese patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25750535/),h,2.6-4.0,29971,DB01373,Calcium
,25750535,area under the plasma concentration versus time curve from time 0 hour to 96 hours,"In Chinese healthy volunteers, a single-dose oral administration of azelnidipine 8-16 mg had a peak plasma concentration of 1.66-23.06 ng/mL and time to peak plasma concentration was 2.6-4.0 hours and the area under the plasma concentration versus time curve from time 0 hour to 96 hours was 17.9-429 ng/mL·h and elimination half-life was 16.0-28.0 hours.",Clinical use of azelnidipine in the treatment of hypertension in Chinese patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25750535/),[ng] / [h·ml],17.9-429,29972,DB01373,Calcium
,25750535,elimination half-life,"In Chinese healthy volunteers, a single-dose oral administration of azelnidipine 8-16 mg had a peak plasma concentration of 1.66-23.06 ng/mL and time to peak plasma concentration was 2.6-4.0 hours and the area under the plasma concentration versus time curve from time 0 hour to 96 hours was 17.9-429 ng/mL·h and elimination half-life was 16.0-28.0 hours.",Clinical use of azelnidipine in the treatment of hypertension in Chinese patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25750535/),h,16.0-28.0,29973,DB01373,Calcium
,30349192,specific surface area,"VRC-S showed a positively skewed unimodal size distribution with a specific surface area of 2.02 m2/g, single endothermic peak of 225.2°C in differential scanning calorimetry, crystalline internal structure in powder X-ray diffraction, aqueous solubility of 244.7 mg/mL, and hygroscopicity of 0.256 mg/g.",Immediate release tablet formulation of varenicline salicylate and comparative pharmacokinetic study in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30349192/),[m2] / [g],2.02,32466,DB01373,Calcium
,30349192,solubility,"VRC-S showed a positively skewed unimodal size distribution with a specific surface area of 2.02 m2/g, single endothermic peak of 225.2°C in differential scanning calorimetry, crystalline internal structure in powder X-ray diffraction, aqueous solubility of 244.7 mg/mL, and hygroscopicity of 0.256 mg/g.",Immediate release tablet formulation of varenicline salicylate and comparative pharmacokinetic study in human volunteers. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30349192/),[mg] / [ml],244.7,32467,DB01373,Calcium
,30349192,f 2,"The dissolution of VRC was pH independent, revealing f 2 values of 76.49 and 68.38 at pH 1.2 and pH 6.8, respectively.",Immediate release tablet formulation of varenicline salicylate and comparative pharmacokinetic study in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30349192/),,76.49,32468,DB01373,Calcium
,30349192,f 2,"The dissolution of VRC was pH independent, revealing f 2 values of 76.49 and 68.38 at pH 1.2 and pH 6.8, respectively.",Immediate release tablet formulation of varenicline salicylate and comparative pharmacokinetic study in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30349192/),,68.38,32469,DB01373,Calcium
,16759888,bioavailability,"The bioavailability of 1,25(OH)(2)D(3) administered IVAG at 1.0microg/kg BW was approximately 93%.","Dose response to vaginal administration of 1,25-dihydroxyvitamin D3 to cows. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16759888/),%,93,32669,DB01373,Calcium
,18018771,C(min),"Median (interquartile range) rosuvastatin C(min) for 10 mg, 20 mg and 40 mg once daily were 0.97 (0.70-1.5), 2.5 (1.3-3.3) and 5.5 (3.3-8.8) ng/ml, respectively.",Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18018771/),[ng] / [ml],0.97,32826,DB01373,Calcium
,18018771,C(min),"Median (interquartile range) rosuvastatin C(min) for 10 mg, 20 mg and 40 mg once daily were 0.97 (0.70-1.5), 2.5 (1.3-3.3) and 5.5 (3.3-8.8) ng/ml, respectively.",Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18018771/),[ng] / [ml],2.5,32827,DB01373,Calcium
,18018771,C(min),"Median (interquartile range) rosuvastatin C(min) for 10 mg, 20 mg and 40 mg once daily were 0.97 (0.70-1.5), 2.5 (1.3-3.3) and 5.5 (3.3-8.8) ng/ml, respectively.",Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18018771/),[ng] / [ml],5.5,32828,DB01373,Calcium
,11863282,total run time,The total run time was 21 min.,Determination of alendronate in human urine as 9-fluorenylmethyl derivative by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11863282/),min,21,32868,DB01373,Calcium
,29162214,C<sub>max</sub>,"The mean C<sub>max</sub> and AUC<sub>0-t</sub> values of rosuvastatin were 12.5 ng/mL and 115.6 ng×h/mL for the FDC, and 12.2 ng/mL and 115.1 ng×h/mL for the single agents concomitantly administered, respectively.",Pharmacokinetics and bioequivalence of a rosuvastatin/ezetimibe fixed-dose combination tablet versus single agents in healthy male subjects . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29162214/),[ng] / [ml],12.5,33125,DB01373,Calcium
,29162214,C<sub>max</sub>,"The mean C<sub>max</sub> and AUC<sub>0-t</sub> values of rosuvastatin were 12.5 ng/mL and 115.6 ng×h/mL for the FDC, and 12.2 ng/mL and 115.1 ng×h/mL for the single agents concomitantly administered, respectively.",Pharmacokinetics and bioequivalence of a rosuvastatin/ezetimibe fixed-dose combination tablet versus single agents in healthy male subjects . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29162214/),[ng] / [ml],12.2,33126,DB01373,Calcium
,29162214,AUC<sub>0-t</sub>,"The mean C<sub>max</sub> and AUC<sub>0-t</sub> values of rosuvastatin were 12.5 ng/mL and 115.6 ng×h/mL for the FDC, and 12.2 ng/mL and 115.1 ng×h/mL for the single agents concomitantly administered, respectively.",Pharmacokinetics and bioequivalence of a rosuvastatin/ezetimibe fixed-dose combination tablet versus single agents in healthy male subjects . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29162214/),[h·ng] / [ml],115.6,33127,DB01373,Calcium
,29162214,AUC<sub>0-t</sub>,"The mean C<sub>max</sub> and AUC<sub>0-t</sub> values of rosuvastatin were 12.5 ng/mL and 115.6 ng×h/mL for the FDC, and 12.2 ng/mL and 115.1 ng×h/mL for the single agents concomitantly administered, respectively.",Pharmacokinetics and bioequivalence of a rosuvastatin/ezetimibe fixed-dose combination tablet versus single agents in healthy male subjects . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29162214/),[h·ng] / [ml],115.1,33128,DB01373,Calcium
,29162214,C<sub>max</sub>,"The mean C<sub>max</sub> and AUC<sub>0-t</sub> values of ezetimibe were 4.7 ng/mL and 67.3 ng×h/mL for the FDC, and 4.5 ng/mL and 68.2 ng×h/mL for the single agents concomitantly administered, respectively.",Pharmacokinetics and bioequivalence of a rosuvastatin/ezetimibe fixed-dose combination tablet versus single agents in healthy male subjects . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29162214/),[ng] / [ml],4.7,33129,DB01373,Calcium
,29162214,C<sub>max</sub>,"The mean C<sub>max</sub> and AUC<sub>0-t</sub> values of ezetimibe were 4.7 ng/mL and 67.3 ng×h/mL for the FDC, and 4.5 ng/mL and 68.2 ng×h/mL for the single agents concomitantly administered, respectively.",Pharmacokinetics and bioequivalence of a rosuvastatin/ezetimibe fixed-dose combination tablet versus single agents in healthy male subjects . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29162214/),[ng] / [ml],4.5,33130,DB01373,Calcium
,29162214,AUC<sub>0-t</sub>,"The mean C<sub>max</sub> and AUC<sub>0-t</sub> values of ezetimibe were 4.7 ng/mL and 67.3 ng×h/mL for the FDC, and 4.5 ng/mL and 68.2 ng×h/mL for the single agents concomitantly administered, respectively.",Pharmacokinetics and bioequivalence of a rosuvastatin/ezetimibe fixed-dose combination tablet versus single agents in healthy male subjects . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29162214/),[h·ng] / [ml],67.3,33131,DB01373,Calcium
,29162214,AUC<sub>0-t</sub>,"The mean C<sub>max</sub> and AUC<sub>0-t</sub> values of ezetimibe were 4.7 ng/mL and 67.3 ng×h/mL for the FDC, and 4.5 ng/mL and 68.2 ng×h/mL for the single agents concomitantly administered, respectively.",Pharmacokinetics and bioequivalence of a rosuvastatin/ezetimibe fixed-dose combination tablet versus single agents in healthy male subjects . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29162214/),[h·ng] / [ml],68.2,33132,DB01373,Calcium
,17479539,bioavailability,"The bioavailability of the new peroral retard formulation was (20.00 +/- 4.30)% and was in reasonable agreement with that determined for the already registered verapamil retard formulation, i.e. (19.46 +/- 4.02)%, thereby indicating bioequivalence.",Validation of the hepatic blood flow rate model for verapamil first-pass metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17479539/),%,20.00,33165,DB01373,Calcium
,17479539,bioavailability,"The bioavailability of the new peroral retard formulation was (20.00 +/- 4.30)% and was in reasonable agreement with that determined for the already registered verapamil retard formulation, i.e. (19.46 +/- 4.02)%, thereby indicating bioequivalence.",Validation of the hepatic blood flow rate model for verapamil first-pass metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17479539/),%,19.46,33166,DB01373,Calcium
,27810472,oral bioavailability,RC is anti-hyperlipidemic drug with low oral bioavailability (20%) due to first-pass metabolism.,Improved anti-hyperlipidemic activity of Rosuvastatin Calcium via lipid nanoparticles: Pharmacokinetic and pharmacodynamic evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27810472/),%,20,33367,DB01373,Calcium
,21134325,times to peak plasma,"In both the studies, the times to peak plasma HMB were 128 (sem 11), 38 (sem 4) and 38 (sem 1) min (P < 0·0001) for CaHMB, FASW and FASL, respectively.",Free acid gel form of β-hydroxy-β-methylbutyrate (HMB) improves HMB clearance from plasma in human subjects compared with the calcium HMB salt. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21134325/),min,128,33878,DB01373,Calcium
,21134325,times to peak plasma,"In both the studies, the times to peak plasma HMB were 128 (sem 11), 38 (sem 4) and 38 (sem 1) min (P < 0·0001) for CaHMB, FASW and FASL, respectively.",Free acid gel form of β-hydroxy-β-methylbutyrate (HMB) improves HMB clearance from plasma in human subjects compared with the calcium HMB salt. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21134325/),min,38,33879,DB01373,Calcium
,21134325,times to peak plasma,"In both the studies, the times to peak plasma HMB were 128 (sem 11), 38 (sem 4) and 38 (sem 1) min (P < 0·0001) for CaHMB, FASW and FASL, respectively.",Free acid gel form of β-hydroxy-β-methylbutyrate (HMB) improves HMB clearance from plasma in human subjects compared with the calcium HMB salt. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21134325/),min,38,33880,DB01373,Calcium
,21134325,peak concentrations,"The peak concentrations were 131 (sem 6), 249 (sem 14) and 239 (sem 14) μmol/l (P < 0·0001) for CaHMB, FASW and FASL, respectively.",Free acid gel form of β-hydroxy-β-methylbutyrate (HMB) improves HMB clearance from plasma in human subjects compared with the calcium HMB salt. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21134325/),[μM] / [l],131,33881,DB01373,Calcium
,21134325,peak concentrations,"The peak concentrations were 131 (sem 6), 249 (sem 14) and 239 (sem 14) μmol/l (P < 0·0001) for CaHMB, FASW and FASL, respectively.",Free acid gel form of β-hydroxy-β-methylbutyrate (HMB) improves HMB clearance from plasma in human subjects compared with the calcium HMB salt. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21134325/),[μM] / [l],249,33882,DB01373,Calcium
,21134325,peak concentrations,"The peak concentrations were 131 (sem 6), 249 (sem 14) and 239 (sem 14) μmol/l (P < 0·0001) for CaHMB, FASW and FASL, respectively.",Free acid gel form of β-hydroxy-β-methylbutyrate (HMB) improves HMB clearance from plasma in human subjects compared with the calcium HMB salt. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21134325/),[μM] / [l],239,33883,DB01373,Calcium
,21134325,Half-lives,"Half-lives were 3·17 (sem 0·22), 2·50 (sem 0·13) and 2·51 (sem 0·14) h for CaHMB, FASW and FASL, respectively (P < 0·004).",Free acid gel form of β-hydroxy-β-methylbutyrate (HMB) improves HMB clearance from plasma in human subjects compared with the calcium HMB salt. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21134325/),h,3·17,33884,DB01373,Calcium
,21134325,Half-lives,"Half-lives were 3·17 (sem 0·22), 2·50 (sem 0·13) and 2·51 (sem 0·14) h for CaHMB, FASW and FASL, respectively (P < 0·004).",Free acid gel form of β-hydroxy-β-methylbutyrate (HMB) improves HMB clearance from plasma in human subjects compared with the calcium HMB salt. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21134325/),h,2·50,33885,DB01373,Calcium
,21134325,Half-lives,"Half-lives were 3·17 (sem 0·22), 2·50 (sem 0·13) and 2·51 (sem 0·14) h for CaHMB, FASW and FASL, respectively (P < 0·004).",Free acid gel form of β-hydroxy-β-methylbutyrate (HMB) improves HMB clearance from plasma in human subjects compared with the calcium HMB salt. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21134325/),h,2·51,33886,DB01373,Calcium
,20649573,IC(50),"In vitro, AM966 inhibited LPA-stimulated intracellular calcium release (IC(50)= 17 nM) from Chinese hamster ovary cells stably expressing human LPA(1) receptors and inhibited LPA-induced chemotaxis (IC(50)= 181 nM) of human IMR-90 lung fibroblasts expressing LPA(1) receptors.","A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20649573/),nM,17,34167,DB01373,Calcium
,20649573,IC(50),"In vitro, AM966 inhibited LPA-stimulated intracellular calcium release (IC(50)= 17 nM) from Chinese hamster ovary cells stably expressing human LPA(1) receptors and inhibited LPA-induced chemotaxis (IC(50)= 181 nM) of human IMR-90 lung fibroblasts expressing LPA(1) receptors.","A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20649573/),nM,181,34168,DB01373,Calcium
,16176019,absolute p,The relative pharmacological bioavailability of the intracolonically administered Lys18-PEG(2K)-sCT was 2.1-fold higher than sCT and the absolute pharmacological bioavailability was 73.59% of i.v.-injected sCT in an 8-hr period.,Oral delivery of mono-PEGylated sCT (Lys18) in rats: regional difference in stability and hypocalcemic effect. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16176019/),%,73.59,35153,DB01373,Calcium
,32122739,IC50,"Among these analogues, 3d exhibited excellent PAR-1 inhibitory activity (IC50 = 0.18 μM) and the lower ability to cross the blood-brain barrier compared with vorapaxar (IC50 = 0.25 μM).",Design and synthesis of potent PAR-1 antagonists based on vorapaxar. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32122739/),μM,0.18,35452,DB01373,Calcium
,32122739,IC50,"Among these analogues, 3d exhibited excellent PAR-1 inhibitory activity (IC50 = 0.18 μM) and the lower ability to cross the blood-brain barrier compared with vorapaxar (IC50 = 0.25 μM).",Design and synthesis of potent PAR-1 antagonists based on vorapaxar. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32122739/),μM,0.25,35453,DB01373,Calcium
,27557342,Cmax,"After adjusting for the 421C>A and 521T>C variants, the Cmax in subjects with NR1I2 63396TT wild type were about 2-fold of those of NR1I2 mutant type (63396CC and CT) (10.7 vs. 20.4 ng/mL, P = 0.023), whereas no significant differences were observed for other parameters.","Effects of Polymorphisms in NR1H4, NR1I2, SLCO1B1, and ABCG2 on the Pharmacokinetics of Rosuvastatin in Healthy Chinese Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27557342/),[ng] / [ml],10.7,35849,DB01373,Calcium
,27557342,Cmax,"After adjusting for the 421C>A and 521T>C variants, the Cmax in subjects with NR1I2 63396TT wild type were about 2-fold of those of NR1I2 mutant type (63396CC and CT) (10.7 vs. 20.4 ng/mL, P = 0.023), whereas no significant differences were observed for other parameters.","Effects of Polymorphisms in NR1H4, NR1I2, SLCO1B1, and ABCG2 on the Pharmacokinetics of Rosuvastatin in Healthy Chinese Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27557342/),[ng] / [ml],20.4,35850,DB01373,Calcium
,12583003,extraction efficiency,"The mean (+/-SD) extraction efficiency of NC was 77.56 +/- 5.4, 84.23 +/- 4.32 and 83.94 +/- 3.87% for drug concentrations of 5, 25 and 100 ng/mL, respectively.",A simple method for nicardipine hydrochloride quantification in plasma using solid-phase extraction and reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12583003/),%,77.56,36212,DB01373,Calcium
,12583003,extraction efficiency,"The mean (+/-SD) extraction efficiency of NC was 77.56 +/- 5.4, 84.23 +/- 4.32 and 83.94 +/- 3.87% for drug concentrations of 5, 25 and 100 ng/mL, respectively.",A simple method for nicardipine hydrochloride quantification in plasma using solid-phase extraction and reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12583003/),%,84.23,36213,DB01373,Calcium
,12583003,extraction efficiency,"The mean (+/-SD) extraction efficiency of NC was 77.56 +/- 5.4, 84.23 +/- 4.32 and 83.94 +/- 3.87% for drug concentrations of 5, 25 and 100 ng/mL, respectively.",A simple method for nicardipine hydrochloride quantification in plasma using solid-phase extraction and reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12583003/),%,83.94,36214,DB01373,Calcium
,12583003,half-life (t(1/2),The results inferred that NC is rapidly absorbed in rabbits and has a short half-life (t(1/2) = 1.34 h).,A simple method for nicardipine hydrochloride quantification in plasma using solid-phase extraction and reversed-phase high-performance liquid chromatography. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12583003/),h,1.34,36215,DB01373,Calcium
,27572343,net efflux ratio,"In MDCK-pAbcb1 cells, enrofloxacin was transported by P-gp with net efflux ratio of 2.48 and the efflux function was blocked by P-gp inhibitor verapamil.","Abcb1 in Pigs: Molecular cloning, tissues distribution, functional analysis, and its effect on pharmacokinetics of enrofloxacin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27572343/),,2.48,36285,DB01373,Calcium
,16048963,90% effective concentration,TAK-220 inhibited the replication of six CCR5-using (R5) HIV-1 clinical isolates in peripheral blood mononuclear cells (PBMCs) with a mean 90% effective concentration of 13 nM.,"Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16048963/),nM,13,37706,DB01373,Calcium
,16048963,oral bioavailabilities,"At a dose of 5 mg/kg of body weight, TAK-220 showed oral bioavailabilities of 9.5 and 28.9% in rats and monkeys, respectively.","Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16048963/),%,9.5,37707,DB01373,Calcium
,16048963,oral bioavailabilities,"At a dose of 5 mg/kg of body weight, TAK-220 showed oral bioavailabilities of 9.5 and 28.9% in rats and monkeys, respectively.","Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16048963/),%,28.9,37708,DB01373,Calcium
,26165421,half-life,CNZ is characterized by short half-life (3-6 h).,Utilization of ionotropic gelation technique for bioavailability enhancement of cinnarizine: in-vitro optimization and in-vivo performance in human. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26165421/),h,3-6,37723,DB01373,Calcium
,30076448,Ki,"ASP7657 exhibited high affinity for rat and human EP4 receptors, with Ki values of 6.02 nM and 2.21 nM, respectively.","Pharmacological properties of ASP7657, a novel, potent, and selective prostaglandin EP4 receptor antagonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076448/),nM,6.02,38032,DB01373,Calcium
,30076448,Ki,"ASP7657 exhibited high affinity for rat and human EP4 receptors, with Ki values of 6.02 nM and 2.21 nM, respectively.","Pharmacological properties of ASP7657, a novel, potent, and selective prostaglandin EP4 receptor antagonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076448/),nM,2.21,38033,DB01373,Calcium
,30076448,IC50,"In addition, ASP7657 potently inhibited the PGE2-induced cyclic adenosine monophosphate (cAMP) increase in Chinese hamster ovary (CHO) cells expressing rat EP4 receptors and human lymphoblastoid T (Jurkat) cells, with IC50 values of 0.86 nM and 0.29 nM, respectively.","Pharmacological properties of ASP7657, a novel, potent, and selective prostaglandin EP4 receptor antagonist. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076448/),nM,0.86,38034,DB01373,Calcium
,30076448,IC50,"In addition, ASP7657 potently inhibited the PGE2-induced cyclic adenosine monophosphate (cAMP) increase in Chinese hamster ovary (CHO) cells expressing rat EP4 receptors and human lymphoblastoid T (Jurkat) cells, with IC50 values of 0.86 nM and 0.29 nM, respectively.","Pharmacological properties of ASP7657, a novel, potent, and selective prostaglandin EP4 receptor antagonist. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076448/),nM,0.29,38035,DB01373,Calcium
,17039785,lag time of release,In vitro the lag time of release profile of VH from VH-COERP was 5 h and then VH was extended release from VH-COERP in the following time.,[Preparation of verapamil hydrochloride controlled-onset extended-release pellets and its pharmacokinetics in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17039785/),h,5,38265,DB01373,Calcium
,17039785,lag time,"Compared with the VH-DRP, VH-COERP in vivo has an obviously lag time (4 h) , Tmax was also delayed (8 h) and the relative bioavailability was (94.56 +/- 7.64)%.",[Preparation of verapamil hydrochloride controlled-onset extended-release pellets and its pharmacokinetics in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17039785/),h,4,38266,DB01373,Calcium
,17039785,Tmax,"Compared with the VH-DRP, VH-COERP in vivo has an obviously lag time (4 h) , Tmax was also delayed (8 h) and the relative bioavailability was (94.56 +/- 7.64)%.",[Preparation of verapamil hydrochloride controlled-onset extended-release pellets and its pharmacokinetics in dogs]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17039785/),h,8,38267,DB01373,Calcium
,17039785,relative bioavailability,"Compared with the VH-DRP, VH-COERP in vivo has an obviously lag time (4 h) , Tmax was also delayed (8 h) and the relative bioavailability was (94.56 +/- 7.64)%.",[Preparation of verapamil hydrochloride controlled-onset extended-release pellets and its pharmacokinetics in dogs]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17039785/),%,94.56,38268,DB01373,Calcium
,21142292,influx rate constant [K(1)],"Most pharmacokinetic parameters of (R)- and (S)-verapamil as well as parameters describing exchange of radioactivity between plasma and brain (influx rate constant [K(1)] = 0.030 ± 0.003 and 0.031 ± 0.005 mL/mL/min and efflux rate constant [k(2)] = 0.099 ± 0.006 and 0.095 ± 0.008 min-1 for period 1 and 2, respectively) were not statistically different between the two periods although there was a trend for nonlinear pharmacokinetics for the (R)-enantiomer.",A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21142292/),[ml] / [min·ml],0.030,38695,DB01373,Calcium
,21142292,influx rate constant [K(1)],"Most pharmacokinetic parameters of (R)- and (S)-verapamil as well as parameters describing exchange of radioactivity between plasma and brain (influx rate constant [K(1)] = 0.030 ± 0.003 and 0.031 ± 0.005 mL/mL/min and efflux rate constant [k(2)] = 0.099 ± 0.006 and 0.095 ± 0.008 min-1 for period 1 and 2, respectively) were not statistically different between the two periods although there was a trend for nonlinear pharmacokinetics for the (R)-enantiomer.",A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21142292/),[ml] / [min·ml],0.031,38696,DB01373,Calcium
,21142292,efflux rate constant [k(2)],"Most pharmacokinetic parameters of (R)- and (S)-verapamil as well as parameters describing exchange of radioactivity between plasma and brain (influx rate constant [K(1)] = 0.030 ± 0.003 and 0.031 ± 0.005 mL/mL/min and efflux rate constant [k(2)] = 0.099 ± 0.006 and 0.095 ± 0.008 min-1 for period 1 and 2, respectively) were not statistically different between the two periods although there was a trend for nonlinear pharmacokinetics for the (R)-enantiomer.",A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21142292/),1/[min],0.099,38697,DB01373,Calcium
,21142292,efflux rate constant [k(2)],"Most pharmacokinetic parameters of (R)- and (S)-verapamil as well as parameters describing exchange of radioactivity between plasma and brain (influx rate constant [K(1)] = 0.030 ± 0.003 and 0.031 ± 0.005 mL/mL/min and efflux rate constant [k(2)] = 0.099 ± 0.006 and 0.095 ± 0.008 min-1 for period 1 and 2, respectively) were not statistically different between the two periods although there was a trend for nonlinear pharmacokinetics for the (R)-enantiomer.",A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21142292/),1/[min],0.095,38698,DB01373,Calcium
,30402291,Peak concentrations (Cmax),"Peak concentrations (Cmax) of 21.799 ± 1.993 ng/ml and 20.844 ± 2.661 ng/ml were achieved after 6 ± 0.23 h and 6 ± 0.35 h (Tmax), respectively, for capsules A and B.",Potential of Cocoa Pod Husk Pectin-Based Modified Release Capsules as a Carrier for Chronodelivery of Hydrocortisone in Sprague-Dawley Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30402291/),[ng] / [ml],21.799,38738,DB01373,Calcium
,30402291,Peak concentrations (Cmax),"Peak concentrations (Cmax) of 21.799 ± 1.993 ng/ml and 20.844 ± 2.661 ng/ml were achieved after 6 ± 0.23 h and 6 ± 0.35 h (Tmax), respectively, for capsules A and B.",Potential of Cocoa Pod Husk Pectin-Based Modified Release Capsules as a Carrier for Chronodelivery of Hydrocortisone in Sprague-Dawley Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30402291/),[ng] / [ml],20.844,38739,DB01373,Calcium
,30402291,Tmax,"Peak concentrations (Cmax) of 21.799 ± 1.993 ng/ml and 20.844 ± 2.661 ng/ml were achieved after 6 ± 0.23 h and 6 ± 0.35 h (Tmax), respectively, for capsules A and B.",Potential of Cocoa Pod Husk Pectin-Based Modified Release Capsules as a Carrier for Chronodelivery of Hydrocortisone in Sprague-Dawley Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30402291/),h,6,38740,DB01373,Calcium
,30402291,Tmax,"Peak concentrations (Cmax) of 21.799 ± 1.993 ng/ml and 20.844 ± 2.661 ng/ml were achieved after 6 ± 0.23 h and 6 ± 0.35 h (Tmax), respectively, for capsules A and B.",Potential of Cocoa Pod Husk Pectin-Based Modified Release Capsules as a Carrier for Chronodelivery of Hydrocortisone in Sprague-Dawley Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30402291/),h,6,38741,DB01373,Calcium
,30402291,peak concentration,The immediate release formulation had a peak concentration of 15.322 ± 0.313 ng/ml within 1 ± 0.2 h.,Potential of Cocoa Pod Husk Pectin-Based Modified Release Capsules as a Carrier for Chronodelivery of Hydrocortisone in Sprague-Dawley Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30402291/),[ng] / [ml],15.322,38742,DB01373,Calcium
,30402291,relative bioavailability,"The relative bioavailability of the CPH pectin-based capsules A and B was 213% and 274%, respectively.",Potential of Cocoa Pod Husk Pectin-Based Modified Release Capsules as a Carrier for Chronodelivery of Hydrocortisone in Sprague-Dawley Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30402291/),%,213,38743,DB01373,Calcium
,30402291,relative bioavailability,"The relative bioavailability of the CPH pectin-based capsules A and B was 213% and 274%, respectively.",Potential of Cocoa Pod Husk Pectin-Based Modified Release Capsules as a Carrier for Chronodelivery of Hydrocortisone in Sprague-Dawley Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30402291/),%,274,38744,DB01373,Calcium
,15637285,IC(50),"It possesses potent antagonist activity at the human CaR with IC(50) values of 64 nm and 230 nm in inhibiting intracellular Ca(2+) flux and inositol phosphate generation in vitro, respectively.",A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15637285/),nm,64,39561,DB01373,Calcium
,15637285,IC(50),"It possesses potent antagonist activity at the human CaR with IC(50) values of 64 nm and 230 nm in inhibiting intracellular Ca(2+) flux and inositol phosphate generation in vitro, respectively.",A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15637285/),nm,230,39562,DB01373,Calcium
,15637285,half-life,The pharmacokinetic profile of compound 1 after oral administration revealed that maximal plasma levels of compound were reached within 1 h and the half-life of the compound to be approximately 2 h in rats.,A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15637285/),h,2,39563,DB01373,Calcium
,24235081,terminal elimination of half-life,Velcalcetide plasma exposure increased in a dose-related manner and the terminal elimination of half-life was comparable across the dose range evaluated and ranged from 18.4 to 20.0 h.,"Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24235081/),h,18.4 to 20.0,39957,DB01373,Calcium
,29589994,Mage,Ten subjects (Mage ± SD = 33.7 ± 10.2 years; 60% male) completed the study.,Concurrent Milk Ingestion Decreases Absorption of Levothyroxine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29589994/),,33.7,40286,DB01373,Calcium
,29589994,area under the curve (AUC),The area under the curve (AUC) of TT4 concentrations was significantly lower when levothyroxine was ingested along with 12 oz (355 mL) of 2% cow's milk (M ± SD = 67.3 ± 12.1) compared to that with levothyroxine alone (73.5 ± 17.0; p = 0.02).,Concurrent Milk Ingestion Decreases Absorption of Levothyroxine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29589994/),,67.3,40287,DB01373,Calcium
,29589994,area under the curve (AUC),The area under the curve (AUC) of TT4 concentrations was significantly lower when levothyroxine was ingested along with 12 oz (355 mL) of 2% cow's milk (M ± SD = 67.3 ± 12.1) compared to that with levothyroxine alone (73.5 ± 17.0; p = 0.02).,Concurrent Milk Ingestion Decreases Absorption of Levothyroxine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29589994/),,73.5,40288,DB01373,Calcium
,29589994,peak serum TT4 concentrations,"Also, peak serum TT4 concentrations were significantly lower when cow's milk was co-administered with levothyroxine (M ± SD = 14.1 ± 0.8 μg/dL) than with levothyroxine alone (13.0 ± 0.9 μg/dL; p = 0.04).",Concurrent Milk Ingestion Decreases Absorption of Levothyroxine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29589994/),[μg] / [dl],14.1,40289,DB01373,Calcium
,29589994,peak serum TT4 concentrations,"Also, peak serum TT4 concentrations were significantly lower when cow's milk was co-administered with levothyroxine (M ± SD = 14.1 ± 0.8 μg/dL) than with levothyroxine alone (13.0 ± 0.9 μg/dL; p = 0.04).",Concurrent Milk Ingestion Decreases Absorption of Levothyroxine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29589994/),[μg] / [dl],13.0,40290,DB01373,Calcium
,11996900,Oral bioavailability,Oral bioavailability of M6G was 2.1%; 13% of oral M6G was deglucuronidated to morphine.,Verapamil decreases glucuronidase activity in the gut. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996900/),%,2.1,40433,DB01373,Calcium
,11996900,Oral bioavailability,Oral bioavailability of M6G was 2.1%; 13% of oral M6G was deglucuronidated to morphine.,Verapamil decreases glucuronidase activity in the gut. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996900/),%,13,40434,DB01373,Calcium
,11996900,IC(50),"In vitro experiments provided evidence that verapamil inhibits beta-glucuronidase from E. coli with an IC(50) of 30 microM, whereas no inhibition of the rat beta-glucuronidase from small intestine was seen.",Verapamil decreases glucuronidase activity in the gut. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996900/),μM,30,40435,DB01373,Calcium
,21477267,T(max),The median for digoxin T(max) was 0.75 h before and after vitamin D3 ingestion.,Effect of vitamin D3 supplementation on the pharmacokinetics of digoxin--a pilot study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21477267/),h,0.75,41061,DB01373,Calcium
,12672710,AUC(9),"AUC(9) (+/- SEM), was 3.63 mg hr/dL +/- 0.234 in participants pretreated with 25OHD and 2.20 +/- 0.240 in those not pretreated (P < 0.001).",Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12672710/),[h·mg] / [dl],3.63,41068,DB01373,Calcium
,12672710,AUC(9),"AUC(9) (+/- SEM), was 3.63 mg hr/dL +/- 0.234 in participants pretreated with 25OHD and 2.20 +/- 0.240 in those not pretreated (P < 0.001).",Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12672710/),[h·mg] / [dl],2.20,41069,DB01373,Calcium
,20238375,absolute bioavailability (F %),"The absolute bioavailability (F %) of talinolol in the rats pretreated with morin was significantly higher (89.09-98.29%, p<0.01) than the control (52.14%).",Pre-clinical evidence of enhanced oral bioavailability of the P-glycoprotein substrate talinolol in combination with morin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20238375/),%,89.09-98.29,41163,DB01373,Calcium
,20238375,absolute bioavailability (F %),"The absolute bioavailability (F %) of talinolol in the rats pretreated with morin was significantly higher (89.09-98.29%, p<0.01) than the control (52.14%).",Pre-clinical evidence of enhanced oral bioavailability of the P-glycoprotein substrate talinolol in combination with morin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20238375/),%,52.14,41164,DB01373,Calcium
,23395659,IC50 ratio,"Compound 6m and 6q showed high selectivity over hERG channel (IC50 ratio of hERG/α1G6m=8.5, 6q=18.38) and they were subjected to measure pharmacokinetics profiles.",Synthesis and biological evaluation of 1-(2-hydroxy-3-phenyloxypropyl)piperazine derivatives as T-type calcium channel blockers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395659/),,8.5,41875,DB01373,Calcium
,23395659,IC50 ratio,"Compound 6m and 6q showed high selectivity over hERG channel (IC50 ratio of hERG/α1G6m=8.5, 6q=18.38) and they were subjected to measure pharmacokinetics profiles.",Synthesis and biological evaluation of 1-(2-hydroxy-3-phenyloxypropyl)piperazine derivatives as T-type calcium channel blockers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395659/),,18.38,41876,DB01373,Calcium
,18534803,flow rate,"The analysis was carried out on an Acquity UPLC BEH C18 column (50 mm x 2.1 mm, 1.7 microm) with flow rate of 0.28 ml/min.",Ultra-performance liquid chromatography-tandem mass spectrometry for the determination of lacidipine in human plasma and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18534803/),[ml] / [min],0.28,42069,DB01373,Calcium
>,26429767,specific activity,"(R)- and (S)-[(11)C]EMP yields were ~30%, with specific activity>74 GBq/μmol and radiochemical purity>99%.",(R)-[¹¹C]Emopamil as a novel tracer for imaging enhanced P-glycoprotein function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26429767/),[gbq] / [μM],74,42704,DB01373,Calcium
,14667956,absolute oral bioavailability,"The absolute oral bioavailability of rosuvastatin was estimated to be 20.1%,and the hepatic extraction ratio was estimated to be 0.63.",Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14667956/),%,20.1,42962,DB01373,Calcium
,14667956,hepatic extraction ratio,"The absolute oral bioavailability of rosuvastatin was estimated to be 20.1%,and the hepatic extraction ratio was estimated to be 0.63.",Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14667956/),,0.63,42963,DB01373,Calcium
,14667956,volume of distribution at steady state,The mean volume of distribution at steady state was 134 L.,Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14667956/),l,134,42964,DB01373,Calcium
,14667956,total plasma clearance,Renal clearance accounted for approximately 28% of total plasma clearance (48.9 L/h).,Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14667956/),[l] / [h],48.9,42965,DB01373,Calcium
,14667956,absolute oral bioavailability,"The absolute oral bioavailability of rosuvastatin in these 10 healthy volunteers was approximately 20%, and absorption was estimated to be 50%.",Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14667956/),%,20,42966,DB01373,Calcium
,14667956,absorption,"The absolute oral bioavailability of rosuvastatin in these 10 healthy volunteers was approximately 20%, and absorption was estimated to be 50%.",Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14667956/),%,50,42967,DB01373,Calcium
,15922817,compliance rates,"Compliance rates were similar between groups, with mean (SD) compliance rates of 97.4% (2.8%) and 97.1% (3.6%) in the amlodipine maleate and amlodipine besylate groups, respectively.","Results of a multicenter, 8-week, parallel-group, randomized,double-blind, double-dummy, Phase III clinical trial to evaluate the efficacy and tolerability of amlodipine maleate versus amlodipine besylate in Korean patients with mild to moderate hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15922817/),%,97.4,43817,DB01373,Calcium
,15922817,compliance rates,"Compliance rates were similar between groups, with mean (SD) compliance rates of 97.4% (2.8%) and 97.1% (3.6%) in the amlodipine maleate and amlodipine besylate groups, respectively.","Results of a multicenter, 8-week, parallel-group, randomized,double-blind, double-dummy, Phase III clinical trial to evaluate the efficacy and tolerability of amlodipine maleate versus amlodipine besylate in Korean patients with mild to moderate hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15922817/),%,97.1,43818,DB01373,Calcium
,20166442,peak plasma concentration,"Single dose administration of the rosuvastatinon was characterized by a rapid absorption (2.045 +/- 0.891 h, 2.273 +/- 1.009 h and 1.667 +/- 0.651 h) and a marked peak plasma concentration (9.938 +/- 4.438, 28.09 +/- 12.075 and 43.092 +/- 22.09 ng/ml) for the three different doses (5 mg, 10 mg and 20 mg) of rosuvastatin.",Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166442/),[ng] / [ml],9.938,44400,DB01373,Calcium
,20166442,peak plasma concentration,"Single dose administration of the rosuvastatinon was characterized by a rapid absorption (2.045 +/- 0.891 h, 2.273 +/- 1.009 h and 1.667 +/- 0.651 h) and a marked peak plasma concentration (9.938 +/- 4.438, 28.09 +/- 12.075 and 43.092 +/- 22.09 ng/ml) for the three different doses (5 mg, 10 mg and 20 mg) of rosuvastatin.",Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166442/),[ng] / [ml],28.09,44401,DB01373,Calcium
,20166442,peak plasma concentration,"Single dose administration of the rosuvastatinon was characterized by a rapid absorption (2.045 +/- 0.891 h, 2.273 +/- 1.009 h and 1.667 +/- 0.651 h) and a marked peak plasma concentration (9.938 +/- 4.438, 28.09 +/- 12.075 and 43.092 +/- 22.09 ng/ml) for the three different doses (5 mg, 10 mg and 20 mg) of rosuvastatin.",Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166442/),[ng] / [ml],43.092,44402,DB01373,Calcium
,20166442,apparent elimination half-life,"The apparent elimination half-life amounted to 7.914 +/- 3.813 h, 8.445 +/- 4.994 h and 15.401 +/- 5.429 h following administration, respectively.",Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166442/),h,7.914,44403,DB01373,Calcium
,20166442,apparent elimination half-life,"The apparent elimination half-life amounted to 7.914 +/- 3.813 h, 8.445 +/- 4.994 h and 15.401 +/- 5.429 h following administration, respectively.",Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166442/),h,8.445,44404,DB01373,Calcium
,20166442,apparent elimination half-life,"The apparent elimination half-life amounted to 7.914 +/- 3.813 h, 8.445 +/- 4.994 h and 15.401 +/- 5.429 h following administration, respectively.",Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166442/),h,15.401,44405,DB01373,Calcium
,20166442,peak plasma concentration,"A rapid absorption (3 +/- 1.365 h, 3.042 +/- 1.054 h and 2.375 +/- 0.829 h) and a marked peak plasma concentration (9.288 +/- 5.314, 18.808 +/- 6.687 and 49.808 +/- 23.516 ng/ml) for the three different doses (5 mg, 10 mg and 20 mg) of rosuvastatin were observed.",Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166442/),[ng] / [ml],9.288,44406,DB01373,Calcium
,20166442,peak plasma concentration,"A rapid absorption (3 +/- 1.365 h, 3.042 +/- 1.054 h and 2.375 +/- 0.829 h) and a marked peak plasma concentration (9.288 +/- 5.314, 18.808 +/- 6.687 and 49.808 +/- 23.516 ng/ml) for the three different doses (5 mg, 10 mg and 20 mg) of rosuvastatin were observed.",Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166442/),[ng] / [ml],18.808,44407,DB01373,Calcium
,20166442,peak plasma concentration,"A rapid absorption (3 +/- 1.365 h, 3.042 +/- 1.054 h and 2.375 +/- 0.829 h) and a marked peak plasma concentration (9.288 +/- 5.314, 18.808 +/- 6.687 and 49.808 +/- 23.516 ng/ml) for the three different doses (5 mg, 10 mg and 20 mg) of rosuvastatin were observed.",Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166442/),[ng] / [ml],49.808,44408,DB01373,Calcium
,20166442,apparent elimination half-life,"The apparent elimination half-life amounted to 13.181 +/- 5.492 h, 8.035 +/- 3.331 h and 15.509 +/- 6.43 h following administration, respectively.",Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166442/),h,13.181,44409,DB01373,Calcium
,20166442,apparent elimination half-life,"The apparent elimination half-life amounted to 13.181 +/- 5.492 h, 8.035 +/- 3.331 h and 15.509 +/- 6.43 h following administration, respectively.",Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166442/),h,8.035,44410,DB01373,Calcium
,20166442,apparent elimination half-life,"The apparent elimination half-life amounted to 13.181 +/- 5.492 h, 8.035 +/- 3.331 h and 15.509 +/- 6.43 h following administration, respectively.",Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166442/),h,15.509,44411,DB01373,Calcium
,17339138,ch,The method had a chromatographic running time of approximately 2.5 min and linear calibration curves over the concentrations of 0.5-100 ng/mL for NIF and DNIF.,Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical herb-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339138/),min,2.5,44539,DB01373,Calcium
,17339138,running time,The method had a chromatographic running time of approximately 2.5 min and linear calibration curves over the concentrations of 0.5-100 ng/mL for NIF and DNIF.,Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical herb-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339138/),min,2.5,44540,DB01373,Calcium
,17339138,recoveries,The recoveries of the one-step liquid extraction method were 81.3-89.1% for NIF and 71.6-80.4% for DNIF.,Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical herb-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339138/),%,81.3-89.1,44541,DB01373,Calcium
,17339138,recoveries,The recoveries of the one-step liquid extraction method were 81.3-89.1% for NIF and 71.6-80.4% for DNIF.,Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical herb-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339138/),%,71.6-80.4,44542,DB01373,Calcium
,17339138,running time,These results indicated that the developed LC/MS/MS method was efficient with a significantly shorter running time (2.5 min) for NIF and DNIF compared to those methods previously reported in the literature.,Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical herb-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339138/),min,2.5,44543,DB01373,Calcium
,31950646,half-life,"After absorption, pyrimethamine was eliminated, with a mean half-life of 122.8 hours in Japanese subjects and 99.5 hours in European subjects.","Evaluation of the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Pyrimethamine in Healthy Male Subjects of Japanese and European Ancestry. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31950646/),h,122.8,45851,DB01373,Calcium
,31950646,half-life,"After absorption, pyrimethamine was eliminated, with a mean half-life of 122.8 hours in Japanese subjects and 99.5 hours in European subjects.","Evaluation of the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Pyrimethamine in Healthy Male Subjects of Japanese and European Ancestry. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31950646/),h,99.5,45852,DB01373,Calcium
,31950646,Cmax,The mean Cmax and AUC0-t were 433.8 ng/mL and 59.63 µg·h/mL in Japanese subjects and 372.7 ng/mL and 42.83 µg·h/mL in European subjects.,"Evaluation of the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Pyrimethamine in Healthy Male Subjects of Japanese and European Ancestry. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31950646/),[ng] / [ml],433.8,45853,DB01373,Calcium
,31950646,Cmax,The mean Cmax and AUC0-t were 433.8 ng/mL and 59.63 µg·h/mL in Japanese subjects and 372.7 ng/mL and 42.83 µg·h/mL in European subjects.,"Evaluation of the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Pyrimethamine in Healthy Male Subjects of Japanese and European Ancestry. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31950646/),[ng] / [ml],372.7,45854,DB01373,Calcium
,31950646,AUC0-t,The mean Cmax and AUC0-t were 433.8 ng/mL and 59.63 µg·h/mL in Japanese subjects and 372.7 ng/mL and 42.83 µg·h/mL in European subjects.,"Evaluation of the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Pyrimethamine in Healthy Male Subjects of Japanese and European Ancestry. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31950646/),[h·μg] / [ml],59.63,45855,DB01373,Calcium
,31950646,AUC0-t,The mean Cmax and AUC0-t were 433.8 ng/mL and 59.63 µg·h/mL in Japanese subjects and 372.7 ng/mL and 42.83 µg·h/mL in European subjects.,"Evaluation of the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Pyrimethamine in Healthy Male Subjects of Japanese and European Ancestry. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31950646/),[h·μg] / [ml],42.83,45856,DB01373,Calcium
,20921291,area under the curve over 48 h (AUC(0-48)),"Co-administration of lanthanum carbonate with calcitriol had no significant effect on area under the curve over 48 h (AUC(0-48)) for serum exogenous calcitriol [least-squares (LS) mean, calcitriol with lanthanum carbonate vs calcitriol alone: 429 pg h/mL vs 318 pg h/mL, respectively; P = 0.171].",The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921291/),[h·pg] / [ml],429,46285,DB01373,Calcium
,20921291,area under the curve over 48 h (AUC(0-48)),"Co-administration of lanthanum carbonate with calcitriol had no significant effect on area under the curve over 48 h (AUC(0-48)) for serum exogenous calcitriol [least-squares (LS) mean, calcitriol with lanthanum carbonate vs calcitriol alone: 429 pg h/mL vs 318 pg h/mL, respectively; P = 0.171].",The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921291/),[h·pg] / [ml],318,46286,DB01373,Calcium
,20921291,AUC(0-48),"In contrast, co-administration with sevelamer was associated with a significant reduction in bioavailability parameters for calcitriol (calcitriol with sevelamer carbonate vs calcitriol alone, LS mean AUC(0-48): 137 pg h/mL vs 318 pg h/mL, respectively; P = 0.024; LS mean C(max): 40.1 pg/mL vs 49.7 pg/mL, respectively; P < 0.001).",The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921291/),[h·pg] / [ml],137,46287,DB01373,Calcium
,20921291,AUC(0-48),"In contrast, co-administration with sevelamer was associated with a significant reduction in bioavailability parameters for calcitriol (calcitriol with sevelamer carbonate vs calcitriol alone, LS mean AUC(0-48): 137 pg h/mL vs 318 pg h/mL, respectively; P = 0.024; LS mean C(max): 40.1 pg/mL vs 49.7 pg/mL, respectively; P < 0.001).",The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921291/),[h·pg] / [ml],318,46288,DB01373,Calcium
,20921291,C(max),"In contrast, co-administration with sevelamer was associated with a significant reduction in bioavailability parameters for calcitriol (calcitriol with sevelamer carbonate vs calcitriol alone, LS mean AUC(0-48): 137 pg h/mL vs 318 pg h/mL, respectively; P = 0.024; LS mean C(max): 40.1 pg/mL vs 49.7 pg/mL, respectively; P < 0.001).",The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921291/),[pg] / [ml],40.1,46289,DB01373,Calcium
,20921291,C(max),"In contrast, co-administration with sevelamer was associated with a significant reduction in bioavailability parameters for calcitriol (calcitriol with sevelamer carbonate vs calcitriol alone, LS mean AUC(0-48): 137 pg h/mL vs 318 pg h/mL, respectively; P = 0.024; LS mean C(max): 40.1 pg/mL vs 49.7 pg/mL, respectively; P < 0.001).",The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921291/),[pg] / [ml],49.7,46290,DB01373,Calcium
,15175561,peak concentration,"Following capsule administration, there was a rapid rise in plasma concentration of drug achieving a peak concentration of 196(35) ng/mL (mean and coefficient of variation) within 0.7 (105) hours and an AUC(infinity) of 973(39) ng.hr/mL.",Formulation dependent pharmacokinetics--does the dosage form matter for nifedipine? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15175561/),[ng] / [ml],196,46540,DB01373,Calcium
,15175561,AUC(infinity),"Following capsule administration, there was a rapid rise in plasma concentration of drug achieving a peak concentration of 196(35) ng/mL (mean and coefficient of variation) within 0.7 (105) hours and an AUC(infinity) of 973(39) ng.hr/mL.",Formulation dependent pharmacokinetics--does the dosage form matter for nifedipine? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15175561/),[h·ng] / [ml],973,46541,DB01373,Calcium
,15175561,Cmax,After nifedipine PA there was also a rapid rise in plasma concentration of drug achieving a Cmax of 85.5 (36) ng/mL with a tmax of 1.7(58) hours and an AUC(infinity) of 879(46) ng.hr/mL.,Formulation dependent pharmacokinetics--does the dosage form matter for nifedipine? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15175561/),[ng] / [ml],85.5,46542,DB01373,Calcium
,15175561,tmax,After nifedipine PA there was also a rapid rise in plasma concentration of drug achieving a Cmax of 85.5 (36) ng/mL with a tmax of 1.7(58) hours and an AUC(infinity) of 879(46) ng.hr/mL.,Formulation dependent pharmacokinetics--does the dosage form matter for nifedipine? ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15175561/),h,1.7,46543,DB01373,Calcium
,15175561,AUC(infinity),After nifedipine PA there was also a rapid rise in plasma concentration of drug achieving a Cmax of 85.5 (36) ng/mL with a tmax of 1.7(58) hours and an AUC(infinity) of 879(46) ng.hr/mL.,Formulation dependent pharmacokinetics--does the dosage form matter for nifedipine? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15175561/),[h·ng] / [ml],879,46544,DB01373,Calcium
,15175561,Cmax,"For the nifedipine GITS formulation, there was a lag in the plasma concentration time profile for approximately 2 to 3 hours, then it rose gradually achieving a Cmax of of 686(54) 30.5(63) ng/mL with a tmax of 15.0(50) hours and an AUC(infinity) ng.hr/mL.",Formulation dependent pharmacokinetics--does the dosage form matter for nifedipine? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15175561/),[ng] / [ml],686,46545,DB01373,Calcium
,15175561,Cmax,"For the nifedipine GITS formulation, there was a lag in the plasma concentration time profile for approximately 2 to 3 hours, then it rose gradually achieving a Cmax of of 686(54) 30.5(63) ng/mL with a tmax of 15.0(50) hours and an AUC(infinity) ng.hr/mL.",Formulation dependent pharmacokinetics--does the dosage form matter for nifedipine? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15175561/),[ng] / [ml],30.5,46546,DB01373,Calcium
,15175561,tmax,"For the nifedipine GITS formulation, there was a lag in the plasma concentration time profile for approximately 2 to 3 hours, then it rose gradually achieving a Cmax of of 686(54) 30.5(63) ng/mL with a tmax of 15.0(50) hours and an AUC(infinity) ng.hr/mL.",Formulation dependent pharmacokinetics--does the dosage form matter for nifedipine? ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15175561/),h,15.0,46547,DB01373,Calcium
,12483453,C(max),"The following differences were observed between the (+)-N and (-)-N enantiomers, respectively, in the patients presenting with DM (means and ranges): C(max) 3.9 (1.7-6.1) ng ml(-1) versus 0.7 (0.4-1.0) ng ml(-1), AUC(0-24) 51.5 (29.0-74.0) ng ml(-1) h versus 9.4 (5.9-12.8) ng ml(-1) h, and Cl/f 3.6 (1.9-5.4) l h(-1) kg(-1) versus 18.7 (11.7-25.7) l h(-1) kg(-1).",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[ng] / [ml],3.9,47136,DB01373,Calcium
,12483453,C(max),"The following differences were observed between the (+)-N and (-)-N enantiomers, respectively, in the patients presenting with DM (means and ranges): C(max) 3.9 (1.7-6.1) ng ml(-1) versus 0.7 (0.4-1.0) ng ml(-1), AUC(0-24) 51.5 (29.0-74.0) ng ml(-1) h versus 9.4 (5.9-12.8) ng ml(-1) h, and Cl/f 3.6 (1.9-5.4) l h(-1) kg(-1) versus 18.7 (11.7-25.7) l h(-1) kg(-1).",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[ng] / [ml],0.7,47137,DB01373,Calcium
,12483453,AUC(0-24),"The following differences were observed between the (+)-N and (-)-N enantiomers, respectively, in the patients presenting with DM (means and ranges): C(max) 3.9 (1.7-6.1) ng ml(-1) versus 0.7 (0.4-1.0) ng ml(-1), AUC(0-24) 51.5 (29.0-74.0) ng ml(-1) h versus 9.4 (5.9-12.8) ng ml(-1) h, and Cl/f 3.6 (1.9-5.4) l h(-1) kg(-1) versus 18.7 (11.7-25.7) l h(-1) kg(-1).",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[h·ng] / [ml],51.5,47138,DB01373,Calcium
,12483453,AUC(0-24),"The following differences were observed between the (+)-N and (-)-N enantiomers, respectively, in the patients presenting with DM (means and ranges): C(max) 3.9 (1.7-6.1) ng ml(-1) versus 0.7 (0.4-1.0) ng ml(-1), AUC(0-24) 51.5 (29.0-74.0) ng ml(-1) h versus 9.4 (5.9-12.8) ng ml(-1) h, and Cl/f 3.6 (1.9-5.4) l h(-1) kg(-1) versus 18.7 (11.7-25.7) l h(-1) kg(-1).",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[h·ng] / [ml],9.4,47139,DB01373,Calcium
,12483453,Cl/f,"The following differences were observed between the (+)-N and (-)-N enantiomers, respectively, in the patients presenting with DM (means and ranges): C(max) 3.9 (1.7-6.1) ng ml(-1) versus 0.7 (0.4-1.0) ng ml(-1), AUC(0-24) 51.5 (29.0-74.0) ng ml(-1) h versus 9.4 (5.9-12.8) ng ml(-1) h, and Cl/f 3.6 (1.9-5.4) l h(-1) kg(-1) versus 18.7 (11.7-25.7) l h(-1) kg(-1).",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[l] / [h·kg],3.6,47140,DB01373,Calcium
,12483453,Cl/f,"The following differences were observed between the (+)-N and (-)-N enantiomers, respectively, in the patients presenting with DM (means and ranges): C(max) 3.9 (1.7-6.1) ng ml(-1) versus 0.7 (0.4-1.0) ng ml(-1), AUC(0-24) 51.5 (29.0-74.0) ng ml(-1) h versus 9.4 (5.9-12.8) ng ml(-1) h, and Cl/f 3.6 (1.9-5.4) l h(-1) kg(-1) versus 18.7 (11.7-25.7) l h(-1) kg(-1).",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[l] / [h·kg],18.7,47141,DB01373,Calcium
,12483453,Cl/f,The Cl/f value of (+)-N was lower (Mann-Whitney test) in patients with DM: 6.0 (4.3-7.5) l h(-1) kg(-1) versus 3.6 (1.9-5.4) l h(-1) kg(-1).,Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[l] / [h·kg],6.0,47142,DB01373,Calcium
,12483453,Cl/f,The Cl/f value of (+)-N was lower (Mann-Whitney test) in patients with DM: 6.0 (4.3-7.5) l h(-1) kg(-1) versus 3.6 (1.9-5.4) l h(-1) kg(-1).,Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[l] / [h·kg],3.6,47143,DB01373,Calcium
,12483453,Cl/f,"The same observation was made for the (-)-N, with Cl/f reaching 38.8 (26.8-51.0) l h(-1) kg(-1) and 18.7 (11.7-25.7) l h(-1) kg(-1) for the non-diabetic and DM groups, respectively.",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[l] / [h·kg],38.8,47144,DB01373,Calcium
,12483453,Cl/f,"The same observation was made for the (-)-N, with Cl/f reaching 38.8 (26.8-51.0) l h(-1) kg(-1) and 18.7 (11.7-25.7) l h(-1) kg(-1) for the non-diabetic and DM groups, respectively.",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[l] / [h·kg],18.7,47145,DB01373,Calcium
,12483453,plasma concentrations,The data also demonstrated that the plasma concentrations of noradrenaline 30 min after N administration were lower (P < 0.05) in diabetic (mean 2.86 pmol ml(-1)) than in non-diabetic patients (4.80 pmol ml(-1)).,Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),pm,2.86,47146,DB01373,Calcium
,12483453,plasma concentrations,The data also demonstrated that the plasma concentrations of noradrenaline 30 min after N administration were lower (P < 0.05) in diabetic (mean 2.86 pmol ml(-1)) than in non-diabetic patients (4.80 pmol ml(-1)).,Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[pM] / [ml],4.80,47147,DB01373,Calcium
,15618755,MRT,The pharmacokinetics of sCT described by a conventional two-compartment model showed the extremely rapid elimination of sCT from plasma (MRT; 6.86 min).,Estimation of bioavailability of salmon calcitonin from the hypocalcemic effect in rats (I): pharmacokinetic-pharmacodynamic modeling based on the endogenous Ca regulatory system. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618755/),min,6.86,47305,DB01373,Calcium
,26360834,Tmax,"Main pharmacokinetic parameters of test and reference formulations were as follows: multiple dosing, Tmax 9.94±6.59 and 9.47±5.47h, Cmax 435.74±348.10 and 346.54±155.66ng·mL(-1), AUC0-t 8600.52±5264.77 and 9315.10±6820.03ng·mL(-1)·h, AUC0-∞ 8845.38±5838.18 and 9669.24±7326.53ng·mL(-1)·h, t1/2 10.06±8.83 and 9.87±10.35h; single dosing under fasting conditions, Tmax 7.29±4.87 and 6.57±1.85h, Cmax 247.85±110.05 and 244.64±132.43ng·mL(-1), AUC0-t 3385.41±1418.92 and 3496.24±1767.29ng·mL(-1)·h, AUC0-∞ 3781.53±1556.96 and 3829.56±1981.25ng·mL(-1)·h, t1/2 13.07±17.24 and 10.26±7.78h; single dosing under fed conditions, Tmax 17.72±9.42 and 19.50±9.84h, Cmax 183.90±74.52 and 168.14±60.67ng·mL(-1), AUC0-t 3181.71±1368.24 and 3575.11±1416.39ng·mL(-1)·h, AUC0-∞3442.39±2002.53 and 3624.44±1418.12ng·mL(-1)·h, t1/2 8.76±12.28 and 6.67±4.84h, respectively.",Pharmacokinetics and bioequivalence evaluation of acamprosate calcium tablets in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26360834/),h,9.94,47318,DB01373,Calcium
,26360834,Tmax,"Main pharmacokinetic parameters of test and reference formulations were as follows: multiple dosing, Tmax 9.94±6.59 and 9.47±5.47h, Cmax 435.74±348.10 and 346.54±155.66ng·mL(-1), AUC0-t 8600.52±5264.77 and 9315.10±6820.03ng·mL(-1)·h, AUC0-∞ 8845.38±5838.18 and 9669.24±7326.53ng·mL(-1)·h, t1/2 10.06±8.83 and 9.87±10.35h; single dosing under fasting conditions, Tmax 7.29±4.87 and 6.57±1.85h, Cmax 247.85±110.05 and 244.64±132.43ng·mL(-1), AUC0-t 3385.41±1418.92 and 3496.24±1767.29ng·mL(-1)·h, AUC0-∞ 3781.53±1556.96 and 3829.56±1981.25ng·mL(-1)·h, t1/2 13.07±17.24 and 10.26±7.78h; single dosing under fed conditions, Tmax 17.72±9.42 and 19.50±9.84h, Cmax 183.90±74.52 and 168.14±60.67ng·mL(-1), AUC0-t 3181.71±1368.24 and 3575.11±1416.39ng·mL(-1)·h, AUC0-∞3442.39±2002.53 and 3624.44±1418.12ng·mL(-1)·h, t1/2 8.76±12.28 and 6.67±4.84h, respectively.",Pharmacokinetics and bioequivalence evaluation of acamprosate calcium tablets in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26360834/),h,9.47,47319,DB01373,Calcium
,26360834,Cmax,"Main pharmacokinetic parameters of test and reference formulations were as follows: multiple dosing, Tmax 9.94±6.59 and 9.47±5.47h, Cmax 435.74±348.10 and 346.54±155.66ng·mL(-1), AUC0-t 8600.52±5264.77 and 9315.10±6820.03ng·mL(-1)·h, AUC0-∞ 8845.38±5838.18 and 9669.24±7326.53ng·mL(-1)·h, t1/2 10.06±8.83 and 9.87±10.35h; single dosing under fasting conditions, Tmax 7.29±4.87 and 6.57±1.85h, Cmax 247.85±110.05 and 244.64±132.43ng·mL(-1), AUC0-t 3385.41±1418.92 and 3496.24±1767.29ng·mL(-1)·h, AUC0-∞ 3781.53±1556.96 and 3829.56±1981.25ng·mL(-1)·h, t1/2 13.07±17.24 and 10.26±7.78h; single dosing under fed conditions, Tmax 17.72±9.42 and 19.50±9.84h, Cmax 183.90±74.52 and 168.14±60.67ng·mL(-1), AUC0-t 3181.71±1368.24 and 3575.11±1416.39ng·mL(-1)·h, AUC0-∞3442.39±2002.53 and 3624.44±1418.12ng·mL(-1)·h, t1/2 8.76±12.28 and 6.67±4.84h, respectively.",Pharmacokinetics and bioequivalence evaluation of acamprosate calcium tablets in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26360834/),[ng] / [ml],435.74,47320,DB01373,Calcium
,26360834,Cmax,"Main pharmacokinetic parameters of test and reference formulations were as follows: multiple dosing, Tmax 9.94±6.59 and 9.47±5.47h, Cmax 435.74±348.10 and 346.54±155.66ng·mL(-1), AUC0-t 8600.52±5264.77 and 9315.10±6820.03ng·mL(-1)·h, AUC0-∞ 8845.38±5838.18 and 9669.24±7326.53ng·mL(-1)·h, t1/2 10.06±8.83 and 9.87±10.35h; single dosing under fasting conditions, Tmax 7.29±4.87 and 6.57±1.85h, Cmax 247.85±110.05 and 244.64±132.43ng·mL(-1), AUC0-t 3385.41±1418.92 and 3496.24±1767.29ng·mL(-1)·h, AUC0-∞ 3781.53±1556.96 and 3829.56±1981.25ng·mL(-1)·h, t1/2 13.07±17.24 and 10.26±7.78h; single dosing under fed conditions, Tmax 17.72±9.42 and 19.50±9.84h, Cmax 183.90±74.52 and 168.14±60.67ng·mL(-1), AUC0-t 3181.71±1368.24 and 3575.11±1416.39ng·mL(-1)·h, AUC0-∞3442.39±2002.53 and 3624.44±1418.12ng·mL(-1)·h, t1/2 8.76±12.28 and 6.67±4.84h, respectively.",Pharmacokinetics and bioequivalence evaluation of acamprosate calcium tablets in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26360834/),[ng] / [ml],346.54,47321,DB01373,Calcium
,26360834,AUC0-t,"Main pharmacokinetic parameters of test and reference formulations were as follows: multiple dosing, Tmax 9.94±6.59 and 9.47±5.47h, Cmax 435.74±348.10 and 346.54±155.66ng·mL(-1), AUC0-t 8600.52±5264.77 and 9315.10±6820.03ng·mL(-1)·h, AUC0-∞ 8845.38±5838.18 and 9669.24±7326.53ng·mL(-1)·h, t1/2 10.06±8.83 and 9.87±10.35h; single dosing under fasting conditions, Tmax 7.29±4.87 and 6.57±1.85h, Cmax 247.85±110.05 and 244.64±132.43ng·mL(-1), AUC0-t 3385.41±1418.92 and 3496.24±1767.29ng·mL(-1)·h, AUC0-∞ 3781.53±1556.96 and 3829.56±1981.25ng·mL(-1)·h, t1/2 13.07±17.24 and 10.26±7.78h; single dosing under fed conditions, Tmax 17.72±9.42 and 19.50±9.84h, Cmax 183.90±74.52 and 168.14±60.67ng·mL(-1), AUC0-t 3181.71±1368.24 and 3575.11±1416.39ng·mL(-1)·h, AUC0-∞3442.39±2002.53 and 3624.44±1418.12ng·mL(-1)·h, t1/2 8.76±12.28 and 6.67±4.84h, respectively.",Pharmacokinetics and bioequivalence evaluation of acamprosate calcium tablets in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26360834/),[h·ng] / [ml],8600.52,47322,DB01373,Calcium
,26360834,AUC0-t,"Main pharmacokinetic parameters of test and reference formulations were as follows: multiple dosing, Tmax 9.94±6.59 and 9.47±5.47h, Cmax 435.74±348.10 and 346.54±155.66ng·mL(-1), AUC0-t 8600.52±5264.77 and 9315.10±6820.03ng·mL(-1)·h, AUC0-∞ 8845.38±5838.18 and 9669.24±7326.53ng·mL(-1)·h, t1/2 10.06±8.83 and 9.87±10.35h; single dosing under fasting conditions, Tmax 7.29±4.87 and 6.57±1.85h, Cmax 247.85±110.05 and 244.64±132.43ng·mL(-1), AUC0-t 3385.41±1418.92 and 3496.24±1767.29ng·mL(-1)·h, AUC0-∞ 3781.53±1556.96 and 3829.56±1981.25ng·mL(-1)·h, t1/2 13.07±17.24 and 10.26±7.78h; single dosing under fed conditions, Tmax 17.72±9.42 and 19.50±9.84h, Cmax 183.90±74.52 and 168.14±60.67ng·mL(-1), AUC0-t 3181.71±1368.24 and 3575.11±1416.39ng·mL(-1)·h, AUC0-∞3442.39±2002.53 and 3624.44±1418.12ng·mL(-1)·h, t1/2 8.76±12.28 and 6.67±4.84h, respectively.",Pharmacokinetics and bioequivalence evaluation of acamprosate calcium tablets in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26360834/),[h·ng] / [ml],9315.10,47323,DB01373,Calcium
,26360834,AUC0-∞,"Main pharmacokinetic parameters of test and reference formulations were as follows: multiple dosing, Tmax 9.94±6.59 and 9.47±5.47h, Cmax 435.74±348.10 and 346.54±155.66ng·mL(-1), AUC0-t 8600.52±5264.77 and 9315.10±6820.03ng·mL(-1)·h, AUC0-∞ 8845.38±5838.18 and 9669.24±7326.53ng·mL(-1)·h, t1/2 10.06±8.83 and 9.87±10.35h; single dosing under fasting conditions, Tmax 7.29±4.87 and 6.57±1.85h, Cmax 247.85±110.05 and 244.64±132.43ng·mL(-1), AUC0-t 3385.41±1418.92 and 3496.24±1767.29ng·mL(-1)·h, AUC0-∞ 3781.53±1556.96 and 3829.56±1981.25ng·mL(-1)·h, t1/2 13.07±17.24 and 10.26±7.78h; single dosing under fed conditions, Tmax 17.72±9.42 and 19.50±9.84h, Cmax 183.90±74.52 and 168.14±60.67ng·mL(-1), AUC0-t 3181.71±1368.24 and 3575.11±1416.39ng·mL(-1)·h, AUC0-∞3442.39±2002.53 and 3624.44±1418.12ng·mL(-1)·h, t1/2 8.76±12.28 and 6.67±4.84h, respectively.",Pharmacokinetics and bioequivalence evaluation of acamprosate calcium tablets in healthy Chinese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26360834/),[h·ng] / [ml],8845.38,47324,DB01373,Calcium
,26360834,AUC0-∞,"Main pharmacokinetic parameters of test and reference formulations were as follows: multiple dosing, Tmax 9.94±6.59 and 9.47±5.47h, Cmax 435.74±348.10 and 346.54±155.66ng·mL(-1), AUC0-t 8600.52±5264.77 and 9315.10±6820.03ng·mL(-1)·h, AUC0-∞ 8845.38±5838.18 and 9669.24±7326.53ng·mL(-1)·h, t1/2 10.06±8.83 and 9.87±10.35h; single dosing under fasting conditions, Tmax 7.29±4.87 and 6.57±1.85h, Cmax 247.85±110.05 and 244.64±132.43ng·mL(-1), AUC0-t 3385.41±1418.92 and 3496.24±1767.29ng·mL(-1)·h, AUC0-∞ 3781.53±1556.96 and 3829.56±1981.25ng·mL(-1)·h, t1/2 13.07±17.24 and 10.26±7.78h; single dosing under fed conditions, Tmax 17.72±9.42 and 19.50±9.84h, Cmax 183.90±74.52 and 168.14±60.67ng·mL(-1), AUC0-t 3181.71±1368.24 and 3575.11±1416.39ng·mL(-1)·h, AUC0-∞3442.39±2002.53 and 3624.44±1418.12ng·mL(-1)·h, t1/2 8.76±12.28 and 6.67±4.84h, respectively.",Pharmacokinetics and bioequivalence evaluation of acamprosate calcium tablets in healthy Chinese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26360834/),[h·ng] / [ml],9669.24,47325,DB01373,Calcium
,26360834,t1/2,"Main pharmacokinetic parameters of test and reference formulations were as follows: multiple dosing, Tmax 9.94±6.59 and 9.47±5.47h, Cmax 435.74±348.10 and 346.54±155.66ng·mL(-1), AUC0-t 8600.52±5264.77 and 9315.10±6820.03ng·mL(-1)·h, AUC0-∞ 8845.38±5838.18 and 9669.24±7326.53ng·mL(-1)·h, t1/2 10.06±8.83 and 9.87±10.35h; single dosing under fasting conditions, Tmax 7.29±4.87 and 6.57±1.85h, Cmax 247.85±110.05 and 244.64±132.43ng·mL(-1), AUC0-t 3385.41±1418.92 and 3496.24±1767.29ng·mL(-1)·h, AUC0-∞ 3781.53±1556.96 and 3829.56±1981.25ng·mL(-1)·h, t1/2 13.07±17.24 and 10.26±7.78h; single dosing under fed conditions, Tmax 17.72±9.42 and 19.50±9.84h, Cmax 183.90±74.52 and 168.14±60.67ng·mL(-1), AUC0-t 3181.71±1368.24 and 3575.11±1416.39ng·mL(-1)·h, AUC0-∞3442.39±2002.53 and 3624.44±1418.12ng·mL(-1)·h, t1/2 8.76±12.28 and 6.67±4.84h, respectively.",Pharmacokinetics and bioequivalence evaluation of acamprosate calcium tablets in healthy Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26360834/),h,10.06,47326,DB01373,Calcium
,26360834,t1/2,"Main pharmacokinetic parameters of test and reference formulations were as follows: multiple dosing, Tmax 9.94±6.59 and 9.47±5.47h, Cmax 435.74±348.10 and 346.54±155.66ng·mL(-1), AUC0-t 8600.52±5264.77 and 9315.10±6820.03ng·mL(-1)·h, AUC0-∞ 8845.38±5838.18 and 9669.24±7326.53ng·mL(-1)·h, t1/2 10.06±8.83 and 9.87±10.35h; single dosing under fasting conditions, Tmax 7.29±4.87 and 6.57±1.85h, Cmax 247.85±110.05 and 244.64±132.43ng·mL(-1), AUC0-t 3385.41±1418.92 and 3496.24±1767.29ng·mL(-1)·h, AUC0-∞ 3781.53±1556.96 and 3829.56±1981.25ng·mL(-1)·h, t1/2 13.07±17.24 and 10.26±7.78h; single dosing under fed conditions, Tmax 17.72±9.42 and 19.50±9.84h, Cmax 183.90±74.52 and 168.14±60.67ng·mL(-1), AUC0-t 3181.71±1368.24 and 3575.11±1416.39ng·mL(-1)·h, AUC0-∞3442.39±2002.53 and 3624.44±1418.12ng·mL(-1)·h, t1/2 8.76±12.28 and 6.67±4.84h, respectively.",Pharmacokinetics and bioequivalence evaluation of acamprosate calcium tablets in healthy Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26360834/),h,9.87,47327,DB01373,Calcium
,26360834,Tmax,"Main pharmacokinetic parameters of test and reference formulations were as follows: multiple dosing, Tmax 9.94±6.59 and 9.47±5.47h, Cmax 435.74±348.10 and 346.54±155.66ng·mL(-1), AUC0-t 8600.52±5264.77 and 9315.10±6820.03ng·mL(-1)·h, AUC0-∞ 8845.38±5838.18 and 9669.24±7326.53ng·mL(-1)·h, t1/2 10.06±8.83 and 9.87±10.35h; single dosing under fasting conditions, Tmax 7.29±4.87 and 6.57±1.85h, Cmax 247.85±110.05 and 244.64±132.43ng·mL(-1), AUC0-t 3385.41±1418.92 and 3496.24±1767.29ng·mL(-1)·h, AUC0-∞ 3781.53±1556.96 and 3829.56±1981.25ng·mL(-1)·h, t1/2 13.07±17.24 and 10.26±7.78h; single dosing under fed conditions, Tmax 17.72±9.42 and 19.50±9.84h, Cmax 183.90±74.52 and 168.14±60.67ng·mL(-1), AUC0-t 3181.71±1368.24 and 3575.11±1416.39ng·mL(-1)·h, AUC0-∞3442.39±2002.53 and 3624.44±1418.12ng·mL(-1)·h, t1/2 8.76±12.28 and 6.67±4.84h, respectively.",Pharmacokinetics and bioequivalence evaluation of acamprosate calcium tablets in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26360834/),h,7.29,47328,DB01373,Calcium
,26360834,Tmax,"Main pharmacokinetic parameters of test and reference formulations were as follows: multiple dosing, Tmax 9.94±6.59 and 9.47±5.47h, Cmax 435.74±348.10 and 346.54±155.66ng·mL(-1), AUC0-t 8600.52±5264.77 and 9315.10±6820.03ng·mL(-1)·h, AUC0-∞ 8845.38±5838.18 and 9669.24±7326.53ng·mL(-1)·h, t1/2 10.06±8.83 and 9.87±10.35h; single dosing under fasting conditions, Tmax 7.29±4.87 and 6.57±1.85h, Cmax 247.85±110.05 and 244.64±132.43ng·mL(-1), AUC0-t 3385.41±1418.92 and 3496.24±1767.29ng·mL(-1)·h, AUC0-∞ 3781.53±1556.96 and 3829.56±1981.25ng·mL(-1)·h, t1/2 13.07±17.24 and 10.26±7.78h; single dosing under fed conditions, Tmax 17.72±9.42 and 19.50±9.84h, Cmax 183.90±74.52 and 168.14±60.67ng·mL(-1), AUC0-t 3181.71±1368.24 and 3575.11±1416.39ng·mL(-1)·h, AUC0-∞3442.39±2002.53 and 3624.44±1418.12ng·mL(-1)·h, t1/2 8.76±12.28 and 6.67±4.84h, respectively.",Pharmacokinetics and bioequivalence evaluation of acamprosate calcium tablets in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26360834/),h,6.57,47329,DB01373,Calcium
,26360834,Cmax,"Main pharmacokinetic parameters of test and reference formulations were as follows: multiple dosing, Tmax 9.94±6.59 and 9.47±5.47h, Cmax 435.74±348.10 and 346.54±155.66ng·mL(-1), AUC0-t 8600.52±5264.77 and 9315.10±6820.03ng·mL(-1)·h, AUC0-∞ 8845.38±5838.18 and 9669.24±7326.53ng·mL(-1)·h, t1/2 10.06±8.83 and 9.87±10.35h; single dosing under fasting conditions, Tmax 7.29±4.87 and 6.57±1.85h, Cmax 247.85±110.05 and 244.64±132.43ng·mL(-1), AUC0-t 3385.41±1418.92 and 3496.24±1767.29ng·mL(-1)·h, AUC0-∞ 3781.53±1556.96 and 3829.56±1981.25ng·mL(-1)·h, t1/2 13.07±17.24 and 10.26±7.78h; single dosing under fed conditions, Tmax 17.72±9.42 and 19.50±9.84h, Cmax 183.90±74.52 and 168.14±60.67ng·mL(-1), AUC0-t 3181.71±1368.24 and 3575.11±1416.39ng·mL(-1)·h, AUC0-∞3442.39±2002.53 and 3624.44±1418.12ng·mL(-1)·h, t1/2 8.76±12.28 and 6.67±4.84h, respectively.",Pharmacokinetics and bioequivalence evaluation of acamprosate calcium tablets in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26360834/),[ng] / [ml],247.85,47330,DB01373,Calcium
,26360834,Cmax,"Main pharmacokinetic parameters of test and reference formulations were as follows: multiple dosing, Tmax 9.94±6.59 and 9.47±5.47h, Cmax 435.74±348.10 and 346.54±155.66ng·mL(-1), AUC0-t 8600.52±5264.77 and 9315.10±6820.03ng·mL(-1)·h, AUC0-∞ 8845.38±5838.18 and 9669.24±7326.53ng·mL(-1)·h, t1/2 10.06±8.83 and 9.87±10.35h; single dosing under fasting conditions, Tmax 7.29±4.87 and 6.57±1.85h, Cmax 247.85±110.05 and 244.64±132.43ng·mL(-1), AUC0-t 3385.41±1418.92 and 3496.24±1767.29ng·mL(-1)·h, AUC0-∞ 3781.53±1556.96 and 3829.56±1981.25ng·mL(-1)·h, t1/2 13.07±17.24 and 10.26±7.78h; single dosing under fed conditions, Tmax 17.72±9.42 and 19.50±9.84h, Cmax 183.90±74.52 and 168.14±60.67ng·mL(-1), AUC0-t 3181.71±1368.24 and 3575.11±1416.39ng·mL(-1)·h, AUC0-∞3442.39±2002.53 and 3624.44±1418.12ng·mL(-1)·h, t1/2 8.76±12.28 and 6.67±4.84h, respectively.",Pharmacokinetics and bioequivalence evaluation of acamprosate calcium tablets in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26360834/),[ng] / [ml],244.64,47331,DB01373,Calcium
,26360834,AUC0-t,"Main pharmacokinetic parameters of test and reference formulations were as follows: multiple dosing, Tmax 9.94±6.59 and 9.47±5.47h, Cmax 435.74±348.10 and 346.54±155.66ng·mL(-1), AUC0-t 8600.52±5264.77 and 9315.10±6820.03ng·mL(-1)·h, AUC0-∞ 8845.38±5838.18 and 9669.24±7326.53ng·mL(-1)·h, t1/2 10.06±8.83 and 9.87±10.35h; single dosing under fasting conditions, Tmax 7.29±4.87 and 6.57±1.85h, Cmax 247.85±110.05 and 244.64±132.43ng·mL(-1), AUC0-t 3385.41±1418.92 and 3496.24±1767.29ng·mL(-1)·h, AUC0-∞ 3781.53±1556.96 and 3829.56±1981.25ng·mL(-1)·h, t1/2 13.07±17.24 and 10.26±7.78h; single dosing under fed conditions, Tmax 17.72±9.42 and 19.50±9.84h, Cmax 183.90±74.52 and 168.14±60.67ng·mL(-1), AUC0-t 3181.71±1368.24 and 3575.11±1416.39ng·mL(-1)·h, AUC0-∞3442.39±2002.53 and 3624.44±1418.12ng·mL(-1)·h, t1/2 8.76±12.28 and 6.67±4.84h, respectively.",Pharmacokinetics and bioequivalence evaluation of acamprosate calcium tablets in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26360834/),ml(-·ng,3385.41,47332,DB01373,Calcium
,26360834,AUC0-t,"Main pharmacokinetic parameters of test and reference formulations were as follows: multiple dosing, Tmax 9.94±6.59 and 9.47±5.47h, Cmax 435.74±348.10 and 346.54±155.66ng·mL(-1), AUC0-t 8600.52±5264.77 and 9315.10±6820.03ng·mL(-1)·h, AUC0-∞ 8845.38±5838.18 and 9669.24±7326.53ng·mL(-1)·h, t1/2 10.06±8.83 and 9.87±10.35h; single dosing under fasting conditions, Tmax 7.29±4.87 and 6.57±1.85h, Cmax 247.85±110.05 and 244.64±132.43ng·mL(-1), AUC0-t 3385.41±1418.92 and 3496.24±1767.29ng·mL(-1)·h, AUC0-∞ 3781.53±1556.96 and 3829.56±1981.25ng·mL(-1)·h, t1/2 13.07±17.24 and 10.26±7.78h; single dosing under fed conditions, Tmax 17.72±9.42 and 19.50±9.84h, Cmax 183.90±74.52 and 168.14±60.67ng·mL(-1), AUC0-t 3181.71±1368.24 and 3575.11±1416.39ng·mL(-1)·h, AUC0-∞3442.39±2002.53 and 3624.44±1418.12ng·mL(-1)·h, t1/2 8.76±12.28 and 6.67±4.84h, respectively.",Pharmacokinetics and bioequivalence evaluation of acamprosate calcium tablets in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26360834/),ml(-·ng,3496.24,47333,DB01373,Calcium
,32034814,maximum plasma concentration (Cmax ),"In fasting subjects, the maximum plasma concentration (Cmax ) was 3.881 ± 0.982 ng/mL at 6 hours (median) of sponsor T, and 4.042 ± 1.147 ng/mL at 6 hours (median) of sponsor R.",Evaluation of pharmacokinetics and safety with bioequivalence of Amlodipine in healthy Chinese volunteers: Bioequivalence Study Findings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32034814/),[ng] / [ml],3.881,47709,DB01373,Calcium
,32034814,maximum plasma concentration (Cmax ),"In fasting subjects, the maximum plasma concentration (Cmax ) was 3.881 ± 0.982 ng/mL at 6 hours (median) of sponsor T, and 4.042 ± 1.147 ng/mL at 6 hours (median) of sponsor R.",Evaluation of pharmacokinetics and safety with bioequivalence of Amlodipine in healthy Chinese volunteers: Bioequivalence Study Findings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32034814/),[ng] / [ml],4.042,47710,DB01373,Calcium
,32034814,Cmax,"In fed subjects, Cmax was 3.312 ± 0.789 ng/mL at 6 hours (median) of sponsor T, and 3.392 ± 0.902 ng/mL at 5 hours (median) of sponsor R.",Evaluation of pharmacokinetics and safety with bioequivalence of Amlodipine in healthy Chinese volunteers: Bioequivalence Study Findings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32034814/),[ng] / [ml],3.312,47711,DB01373,Calcium
,32034814,Cmax,"In fed subjects, Cmax was 3.312 ± 0.789 ng/mL at 6 hours (median) of sponsor T, and 3.392 ± 0.902 ng/mL at 5 hours (median) of sponsor R.",Evaluation of pharmacokinetics and safety with bioequivalence of Amlodipine in healthy Chinese volunteers: Bioequivalence Study Findings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32034814/),[ng] / [ml],3.392,47712,DB01373,Calcium
,21455679,concentration peak in blood,The mean gentamicin concentration peak in blood was 4.2 μg/ml and the mean local concentration in synovial fluids during the first 8 h was 305 μg/ml.,A new concept of gentamicin loaded HAP/TCP bone substitute for prophylactic action: in vivo pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21455679/),[μg] / [ml],4.2,47941,DB01373,Calcium
,21455679,local concentration,The mean gentamicin concentration peak in blood was 4.2 μg/ml and the mean local concentration in synovial fluids during the first 8 h was 305 μg/ml.,A new concept of gentamicin loaded HAP/TCP bone substitute for prophylactic action: in vivo pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21455679/),[μg] / [ml],305,47942,DB01373,Calcium
,22241592,max,"Mean concentrations for nimodipine were 46.9 ng/ml (SD: 6.4; min. 4.1 and max. 92.7 ng/ml) in intraoperative serum, 73.2 ng/ml (SD: 16.7; min. 6.6 and max.",Prophylactic intravenous nimodipine treatment in skull base surgery: pharmacokinetic aspects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22241592/),[ng] / [ml],73.2,48086,DB01373,Calcium
,12579861,flow-rate,"The mobile phase consisted of acetonitrile-water-formic acid (75:35:1), at a flow-rate of 0.4 mL.min-1.",[Determination of amlodipine in human plasma by liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579861/),[ml] / [min],0.4,48172,DB01373,Calcium
,24958817,EC50,"We identified SKA-111 (5-methylnaphtho[1,2-d]thiazol-2-amine), which displays 123-fold selectivity for KCa3.1 (EC50 111 ± 27 nM) over KCa2.3 (EC50 13.7 ± 6.9 μM), and SKA-121 (5-methylnaphtho[2,1-d]oxazol-2-amine), which displays 41-fold selectivity for KCa3.1 (EC50 109 nM ± 14 nM) over KCa2.3 (EC50 4.4 ± 1.6 μM).",New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24958817/),nM,111,48562,DB01373,Calcium
,24958817,EC50,"We identified SKA-111 (5-methylnaphtho[1,2-d]thiazol-2-amine), which displays 123-fold selectivity for KCa3.1 (EC50 111 ± 27 nM) over KCa2.3 (EC50 13.7 ± 6.9 μM), and SKA-121 (5-methylnaphtho[2,1-d]oxazol-2-amine), which displays 41-fold selectivity for KCa3.1 (EC50 109 nM ± 14 nM) over KCa2.3 (EC50 4.4 ± 1.6 μM).",New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24958817/),μM,13.7,48563,DB01373,Calcium
,24958817,EC50,"We identified SKA-111 (5-methylnaphtho[1,2-d]thiazol-2-amine), which displays 123-fold selectivity for KCa3.1 (EC50 111 ± 27 nM) over KCa2.3 (EC50 13.7 ± 6.9 μM), and SKA-121 (5-methylnaphtho[2,1-d]oxazol-2-amine), which displays 41-fold selectivity for KCa3.1 (EC50 109 nM ± 14 nM) over KCa2.3 (EC50 4.4 ± 1.6 μM).",New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24958817/),nM,109,48564,DB01373,Calcium
,24958817,EC50,"We identified SKA-111 (5-methylnaphtho[1,2-d]thiazol-2-amine), which displays 123-fold selectivity for KCa3.1 (EC50 111 ± 27 nM) over KCa2.3 (EC50 13.7 ± 6.9 μM), and SKA-121 (5-methylnaphtho[2,1-d]oxazol-2-amine), which displays 41-fold selectivity for KCa3.1 (EC50 109 nM ± 14 nM) over KCa2.3 (EC50 4.4 ± 1.6 μM).",New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24958817/),μM,4.4,48565,DB01373,Calcium
,20060457,flux,"The gel of optimized formulation (ME-OPT) showed a flux of 43.7microgcm(-2)h(-1), which could meet the target flux (12.16microgcm(-2)h(-1)).","Enhanced bioavailability of lacidipine via microemulsion based transdermal gels: formulation optimization, ex vivo and in vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20060457/),1/[(μgcm)^2],43.7,48579,DB01373,Calcium
,20060457,flux,"The gel of optimized formulation (ME-OPT) showed a flux of 43.7microgcm(-2)h(-1), which could meet the target flux (12.16microgcm(-2)h(-1)).","Enhanced bioavailability of lacidipine via microemulsion based transdermal gels: formulation optimization, ex vivo and in vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20060457/),1/[(μgcm)^2],12.16,48580,DB01373,Calcium
,28385543,AUC0-48,"For single rosuvastatin doses, AUC0-48 were 92.5 (±36.2) and 83.5 (±32.2) ng/mL × h and Cmax were 10.0 (±4.1) and 7.6 (±3.0) ng/mL for Asians and Whites, respectively.",Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28385543/),[ng] / [h·ml],92.5,48581,DB01373,Calcium
,28385543,AUC0-48,"For single rosuvastatin doses, AUC0-48 were 92.5 (±36.2) and 83.5 (±32.2) ng/mL × h and Cmax were 10.0 (±4.1) and 7.6 (±3.0) ng/mL for Asians and Whites, respectively.",Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28385543/),[ng] / [h·ml],83.5,48582,DB01373,Calcium
,28385543,Cmax,"For single rosuvastatin doses, AUC0-48 were 92.5 (±36.2) and 83.5 (±32.2) ng/mL × h and Cmax were 10.0 (±4.1) and 7.6 (±3.0) ng/mL for Asians and Whites, respectively.",Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28385543/),[ng] / [ml],10.0,48583,DB01373,Calcium
,28385543,Cmax,"For single rosuvastatin doses, AUC0-48 were 92.5 (±36.2) and 83.5 (±32.2) ng/mL × h and Cmax were 10.0 (±4.1) and 7.6 (±3.0) ng/mL for Asians and Whites, respectively.",Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28385543/),[ng] / [ml],7.6,48584,DB01373,Calcium
,27487342,tmax,PTH was absorbed rapidly from the subcutaneous tissue with a median tmax of 30 minutes for 20 and 40 µg of PTH-1-37.,Pharmacokinetic and Pharmacodynamic Characteristics of Subcutaneously Applied PTH-1-37. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27487342/),min,30,48608,DB01373,Calcium
,27487342,tmax,tmax was 45 minutes for 20 µg PTH-1-34.,Pharmacokinetic and Pharmacodynamic Characteristics of Subcutaneously Applied PTH-1-37. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27487342/),min,45,48609,DB01373,Calcium
,27487342,Elimination half-lives,"Elimination half-lives were estimated as 76 ± 34 min and 70 ± 13 min for 20 µg and 40 µg PTH-1-37 (mean ± SD), and 78 ± 34 for 20 µg PTH-1-34.",Pharmacokinetic and Pharmacodynamic Characteristics of Subcutaneously Applied PTH-1-37. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27487342/),min,76,48610,DB01373,Calcium
,27487342,Elimination half-lives,"Elimination half-lives were estimated as 76 ± 34 min and 70 ± 13 min for 20 µg and 40 µg PTH-1-37 (mean ± SD), and 78 ± 34 for 20 µg PTH-1-34.",Pharmacokinetic and Pharmacodynamic Characteristics of Subcutaneously Applied PTH-1-37. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27487342/),min,70,48611,DB01373,Calcium
,27487342,Elimination half-lives,"Elimination half-lives were estimated as 76 ± 34 min and 70 ± 13 min for 20 µg and 40 µg PTH-1-37 (mean ± SD), and 78 ± 34 for 20 µg PTH-1-34.",Pharmacokinetic and Pharmacodynamic Characteristics of Subcutaneously Applied PTH-1-37. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27487342/),,78,48612,DB01373,Calcium
,21341682,IC(50),"Optimization of early leads for potency and pharmacokinetic parameters resulted in the identification of 17, a potent inhibitor of chemotaxis (IC(50) = 80 nM) with excellent oral bioavailability in rats (F = 60%).","Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21341682/),nM,80,48732,DB01373,Calcium
,21341682,oral bioavailability,"Optimization of early leads for potency and pharmacokinetic parameters resulted in the identification of 17, a potent inhibitor of chemotaxis (IC(50) = 80 nM) with excellent oral bioavailability in rats (F = 60%).","Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21341682/),%,60,48733,DB01373,Calcium
,21341682,F,"Optimization of early leads for potency and pharmacokinetic parameters resulted in the identification of 17, a potent inhibitor of chemotaxis (IC(50) = 80 nM) with excellent oral bioavailability in rats (F = 60%).","Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21341682/),%,60,48734,DB01373,Calcium
,16681041,absolute bioavailability (A.B%),"The absolute bioavailability (A.B%) of nimodipine in the rabbits pretreated with morin was significantly (p < 0.05 at 10 mg/kg, p < 0.01 at 20 mg/kg) higher (54.1-65.0%) than the control (36.7%).","Enhanced nimodipine bioavailability after oral administration of nimodipine with morin, a flavonoid, in rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16681041/),%,54.1-65.0,48741,DB01373,Calcium
,16681041,absolute bioavailability (A.B%),"The absolute bioavailability (A.B%) of nimodipine in the rabbits pretreated with morin was significantly (p < 0.05 at 10 mg/kg, p < 0.01 at 20 mg/kg) higher (54.1-65.0%) than the control (36.7%).","Enhanced nimodipine bioavailability after oral administration of nimodipine with morin, a flavonoid, in rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16681041/),%,36.7,48742,DB01373,Calcium
,22472448,V/V,"VAL, AML and HCT were resolved using a Gemini C18 column and mobile phase gradient starting from 20 % acetonitrile and 80 % 10 mmol L(-1) ammonium formate (V/V, pH 3.5 ± 0.2, by formic acid) to 70 % acetonitrile and 30 % 10 mmol L(-1) ammonium formate, over 20 minutes, with a flow rate of 1 mL min(-1).","Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22472448/),,3.5,48975,DB01373,Calcium
,22472448,flow rate,"VAL, AML and HCT were resolved using a Gemini C18 column and mobile phase gradient starting from 20 % acetonitrile and 80 % 10 mmol L(-1) ammonium formate (V/V, pH 3.5 ± 0.2, by formic acid) to 70 % acetonitrile and 30 % 10 mmol L(-1) ammonium formate, over 20 minutes, with a flow rate of 1 mL min(-1).","Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22472448/),[ml] / [min],1,48976,DB01373,Calcium
,22472448,extraction recoveries,"Mean extraction recoveries of three QCs for the triple drug combination were 76.5 (VAL), 72.0 (AML) and 73.0 (HCT) % for human plasma.","Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22472448/),%,76.5,48977,DB01373,Calcium
,22472448,extraction recoveries,"Mean extraction recoveries of three QCs for the triple drug combination were 76.5 (VAL), 72.0 (AML) and 73.0 (HCT) % for human plasma.","Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22472448/),%,72.0,48978,DB01373,Calcium
,22472448,extraction recoveries,"Mean extraction recoveries of three QCs for the triple drug combination were 76.5 (VAL), 72.0 (AML) and 73.0 (HCT) % for human plasma.","Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22472448/),%,73.0,48979,DB01373,Calcium
,14586212,C(max),"Pharmacokinetics at dose levels 14 (40 mug/m(2)/day) (1 patient) and 15 (45 mug/m(2)/day) (2 patients) demonstrated an average C(max) of 30.4 +/- 7.8 pg/ml (0.07 nM) and 104 +/- 38.2 pg/ml (0.25 nM), and AUCs of 222.5 +/- 225.2 pg.h/ml and 855 +/- 536 pg h/ml, respectively.","Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586212/),[pg] / [ml],30.4,50094,DB01373,Calcium
,14586212,C(max),"Pharmacokinetics at dose levels 14 (40 mug/m(2)/day) (1 patient) and 15 (45 mug/m(2)/day) (2 patients) demonstrated an average C(max) of 30.4 +/- 7.8 pg/ml (0.07 nM) and 104 +/- 38.2 pg/ml (0.25 nM), and AUCs of 222.5 +/- 225.2 pg.h/ml and 855 +/- 536 pg h/ml, respectively.","Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586212/),nM,0.07,50095,DB01373,Calcium
,14586212,C(max),"Pharmacokinetics at dose levels 14 (40 mug/m(2)/day) (1 patient) and 15 (45 mug/m(2)/day) (2 patients) demonstrated an average C(max) of 30.4 +/- 7.8 pg/ml (0.07 nM) and 104 +/- 38.2 pg/ml (0.25 nM), and AUCs of 222.5 +/- 225.2 pg.h/ml and 855 +/- 536 pg h/ml, respectively.","Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586212/),[pg] / [ml],104,50096,DB01373,Calcium
,14586212,C(max),"Pharmacokinetics at dose levels 14 (40 mug/m(2)/day) (1 patient) and 15 (45 mug/m(2)/day) (2 patients) demonstrated an average C(max) of 30.4 +/- 7.8 pg/ml (0.07 nM) and 104 +/- 38.2 pg/ml (0.25 nM), and AUCs of 222.5 +/- 225.2 pg.h/ml and 855 +/- 536 pg h/ml, respectively.","Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586212/),nM,0.25,50097,DB01373,Calcium
,14586212,AUCs,"Pharmacokinetics at dose levels 14 (40 mug/m(2)/day) (1 patient) and 15 (45 mug/m(2)/day) (2 patients) demonstrated an average C(max) of 30.4 +/- 7.8 pg/ml (0.07 nM) and 104 +/- 38.2 pg/ml (0.25 nM), and AUCs of 222.5 +/- 225.2 pg.h/ml and 855 +/- 536 pg h/ml, respectively.","Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586212/),[h·pg] / [ml],222.5,50098,DB01373,Calcium
,14586212,AUCs,"Pharmacokinetics at dose levels 14 (40 mug/m(2)/day) (1 patient) and 15 (45 mug/m(2)/day) (2 patients) demonstrated an average C(max) of 30.4 +/- 7.8 pg/ml (0.07 nM) and 104 +/- 38.2 pg/ml (0.25 nM), and AUCs of 222.5 +/- 225.2 pg.h/ml and 855 +/- 536 pg h/ml, respectively.","Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586212/),[h·pg] / [ml],855,50099,DB01373,Calcium
,15525456,half-lives,"The in-vitro half-lives of mebudipine (22 +/- 7.1 min) and dibudipine (40 +/- 9.8 min) were significantly longer than that of nifedipine (5.5 +/- 1.1 min), which was investigated in parallel in this study.",Metabolism of the dihydropyridine calcium channel blockers mebudipine and dibudipine by isolated rat hepatocytes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15525456/),min,22,50262,DB01373,Calcium
,15525456,half-lives,"The in-vitro half-lives of mebudipine (22 +/- 7.1 min) and dibudipine (40 +/- 9.8 min) were significantly longer than that of nifedipine (5.5 +/- 1.1 min), which was investigated in parallel in this study.",Metabolism of the dihydropyridine calcium channel blockers mebudipine and dibudipine by isolated rat hepatocytes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15525456/),min,40,50263,DB01373,Calcium
,15525456,half-lives,"The in-vitro half-lives of mebudipine (22 +/- 7.1 min) and dibudipine (40 +/- 9.8 min) were significantly longer than that of nifedipine (5.5 +/- 1.1 min), which was investigated in parallel in this study.",Metabolism of the dihydropyridine calcium channel blockers mebudipine and dibudipine by isolated rat hepatocytes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15525456/),min,5.5,50264,DB01373,Calcium
,16080714,maximum whole blood concentration (C(max)),"Among these tests, CsA-loaded AOBs stabilized by the recombinant caleosin exhibited better bioavailability than the commercial formulation and possessed the highest maximum whole blood concentration (C(max)), 1247.4 +/- 106.8 ng/mL, in the experimental animals 4.3 +/- 0.7 h (t(max)) after oral administration.",Elevating bioavailability of cyclosporine a via encapsulation in artificial oil bodies stabilized by caleosin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080714/),[ng] / [ml],1247.4,50489,DB01373,Calcium
,16080714,t(max),"Among these tests, CsA-loaded AOBs stabilized by the recombinant caleosin exhibited better bioavailability than the commercial formulation and possessed the highest maximum whole blood concentration (C(max)), 1247.4 +/- 106.8 ng/mL, in the experimental animals 4.3 +/- 0.7 h (t(max)) after oral administration.",Elevating bioavailability of cyclosporine a via encapsulation in artificial oil bodies stabilized by caleosin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080714/),h,4.3,50490,DB01373,Calcium
,17910813,bioavailability,Co-administration with carvedilol increased ciclosporin bioavailability from 33% to 70%.,Carvedilol increases ciclosporin bioavailability by inhibiting P-glycoprotein-mediated transport. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17910813/),%,33,50838,DB01373,Calcium
,17910813,bioavailability,Co-administration with carvedilol increased ciclosporin bioavailability from 33% to 70%.,Carvedilol increases ciclosporin bioavailability by inhibiting P-glycoprotein-mediated transport. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17910813/),%,70,50839,DB01373,Calcium
,28332096,peak plasma concentration,"In the stage 3/4 CKD study, mean peak plasma concentration and area under the time curve from zero to infinity were 0.13 ng/mL and 2.87 ng•h/((or ng×h/))mL, respectively, for 12 children who received 3 μg paricalcitol.",Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28332096/),[ng] / [ml],0.13,51360,DB01373,Calcium
,28332096,area under the time curve from zero to infinity,"In the stage 3/4 CKD study, mean peak plasma concentration and area under the time curve from zero to infinity were 0.13 ng/mL and 2.87 ng•h/((or ng×h/))mL, respectively, for 12 children who received 3 μg paricalcitol.",Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28332096/),[h·ng] / [))ml·h·ng·or],2.87,51361,DB01373,Calcium
,11697758,peak plasma concentration,"In steady-state conditions during combination treatment, a modest increase in mean (+/- SD) peak plasma concentration of dofetilide from 2.40 +/- 0.42 to 3.43 +/- 0.71 ng x ml(-1) (43% increase, p < 0.1) was noted.","Transient kinetic and dynamic interactions between verapamil and dofetilide, a class III antiarrhythmic. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11697758/),[ng] / [ml],2.40,52043,DB01373,Calcium
,11697758,peak plasma concentration,"In steady-state conditions during combination treatment, a modest increase in mean (+/- SD) peak plasma concentration of dofetilide from 2.40 +/- 0.42 to 3.43 +/- 0.71 ng x ml(-1) (43% increase, p < 0.1) was noted.","Transient kinetic and dynamic interactions between verapamil and dofetilide, a class III antiarrhythmic. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11697758/),[ng] / [ml],3.43,52044,DB01373,Calcium
,11697758,AUC,"During the combination period, for the first 4 hours, mean AUC values for D increased from 7.4 +/- 1.0 (D alone) to 9.2 +/- 1.4 ng x h x ml(-1) (26% increase, p <0.1).","Transient kinetic and dynamic interactions between verapamil and dofetilide, a class III antiarrhythmic. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11697758/),[h·ng] / [ml],7.4,52045,DB01373,Calcium
,11697758,AUC,"During the combination period, for the first 4 hours, mean AUC values for D increased from 7.4 +/- 1.0 (D alone) to 9.2 +/- 1.4 ng x h x ml(-1) (26% increase, p <0.1).","Transient kinetic and dynamic interactions between verapamil and dofetilide, a class III antiarrhythmic. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11697758/),[h·ng] / [ml],9.2,52046,DB01373,Calcium
,11697758,maximal,"The maximal mean increase in QT, over steady-state baseline values was 20 msec for D alone versus 26 msec during combination therapy.","Transient kinetic and dynamic interactions between verapamil and dofetilide, a class III antiarrhythmic. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11697758/),,20,52047,DB01373,Calcium
,31746448,Cmax,"Following a single oral administration, SR formulation had a lower Cmax, compared to IR formulation (54.46±17.75 , 107.45±29.85 ng/mL, respectively), and Tmax was significantly longer (2.97 vs. 1.13 h) for the SR and IR formulation, respectively.","Pharmacokinetic and Tolerability Comparison of Sustained and Immediate Release Oral Formulations of Nifedipine Tablet Formulations: A Single-Dose, Randomized, Open-Label, Two-Period, Two-Way Crossover Study in Healthy, Fasting Egyptian Male Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31746448/),[ng] / [ml],54.46,52568,DB01373,Calcium
,31746448,Cmax,"Following a single oral administration, SR formulation had a lower Cmax, compared to IR formulation (54.46±17.75 , 107.45±29.85 ng/mL, respectively), and Tmax was significantly longer (2.97 vs. 1.13 h) for the SR and IR formulation, respectively.","Pharmacokinetic and Tolerability Comparison of Sustained and Immediate Release Oral Formulations of Nifedipine Tablet Formulations: A Single-Dose, Randomized, Open-Label, Two-Period, Two-Way Crossover Study in Healthy, Fasting Egyptian Male Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31746448/),[ng] / [ml],107.45,52569,DB01373,Calcium
,31746448,Tmax,"Following a single oral administration, SR formulation had a lower Cmax, compared to IR formulation (54.46±17.75 , 107.45±29.85 ng/mL, respectively), and Tmax was significantly longer (2.97 vs. 1.13 h) for the SR and IR formulation, respectively.","Pharmacokinetic and Tolerability Comparison of Sustained and Immediate Release Oral Formulations of Nifedipine Tablet Formulations: A Single-Dose, Randomized, Open-Label, Two-Period, Two-Way Crossover Study in Healthy, Fasting Egyptian Male Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31746448/),h,2.97,52570,DB01373,Calcium
,31746448,Tmax,"Following a single oral administration, SR formulation had a lower Cmax, compared to IR formulation (54.46±17.75 , 107.45±29.85 ng/mL, respectively), and Tmax was significantly longer (2.97 vs. 1.13 h) for the SR and IR formulation, respectively.","Pharmacokinetic and Tolerability Comparison of Sustained and Immediate Release Oral Formulations of Nifedipine Tablet Formulations: A Single-Dose, Randomized, Open-Label, Two-Period, Two-Way Crossover Study in Healthy, Fasting Egyptian Male Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31746448/),h,1.13,52571,DB01373,Calcium
,31746448,AUC0-last,"There was no significant difference between the SR and the IR formulations for AUC0-last and AUC0-∞ (326.7±98.28 vs. 309.27±105.53 ng·h·mL-1 and 380.9 ± 105.24 vs. 334.36±108.1 ng·h·mL-1, respectively).","Pharmacokinetic and Tolerability Comparison of Sustained and Immediate Release Oral Formulations of Nifedipine Tablet Formulations: A Single-Dose, Randomized, Open-Label, Two-Period, Two-Way Crossover Study in Healthy, Fasting Egyptian Male Volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31746448/),[h·ng] / [ml],326.7,52572,DB01373,Calcium
,31746448,AUC0-last,"There was no significant difference between the SR and the IR formulations for AUC0-last and AUC0-∞ (326.7±98.28 vs. 309.27±105.53 ng·h·mL-1 and 380.9 ± 105.24 vs. 334.36±108.1 ng·h·mL-1, respectively).","Pharmacokinetic and Tolerability Comparison of Sustained and Immediate Release Oral Formulations of Nifedipine Tablet Formulations: A Single-Dose, Randomized, Open-Label, Two-Period, Two-Way Crossover Study in Healthy, Fasting Egyptian Male Volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31746448/),[h·ng] / [ml],309.27,52573,DB01373,Calcium
,31746448,AUC0-∞,"There was no significant difference between the SR and the IR formulations for AUC0-last and AUC0-∞ (326.7±98.28 vs. 309.27±105.53 ng·h·mL-1 and 380.9 ± 105.24 vs. 334.36±108.1 ng·h·mL-1, respectively).","Pharmacokinetic and Tolerability Comparison of Sustained and Immediate Release Oral Formulations of Nifedipine Tablet Formulations: A Single-Dose, Randomized, Open-Label, Two-Period, Two-Way Crossover Study in Healthy, Fasting Egyptian Male Volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31746448/),[h·ng] / [ml],380.9,52574,DB01373,Calcium
,31746448,AUC0-∞,"There was no significant difference between the SR and the IR formulations for AUC0-last and AUC0-∞ (326.7±98.28 vs. 309.27±105.53 ng·h·mL-1 and 380.9 ± 105.24 vs. 334.36±108.1 ng·h·mL-1, respectively).","Pharmacokinetic and Tolerability Comparison of Sustained and Immediate Release Oral Formulations of Nifedipine Tablet Formulations: A Single-Dose, Randomized, Open-Label, Two-Period, Two-Way Crossover Study in Healthy, Fasting Egyptian Male Volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31746448/),[h·ng] / [ml],334.36,52575,DB01373,Calcium
,15282762,run time,The chromatographic run time was 1.5 min and the weighted (1/x(2)) calibration curves were linear over the range 0.1-25 ng ml(-1).,"Simple, sensitive and rapid liquid chromatographic/electrospray ionization tandem mass spectrometric method for the quantification of lacidipine in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282762/),min,1.5,52957,DB01373,Calcium
,15282762,limit of detection,"The limit of detection and lower limit of quantification in human plasma were 50 and 100 pg ml(-1), respectively.","Simple, sensitive and rapid liquid chromatographic/electrospray ionization tandem mass spectrometric method for the quantification of lacidipine in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282762/),[pg] / [ml],50,52958,DB01373,Calcium
,15282762,limit of detection,"The limit of detection and lower limit of quantification in human plasma were 50 and 100 pg ml(-1), respectively.","Simple, sensitive and rapid liquid chromatographic/electrospray ionization tandem mass spectrometric method for the quantification of lacidipine in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282762/),[pg] / [ml],100,52959,DB01373,Calcium
,15282762,absolute recoveries,"The average absolute recoveries of lacidipine and amlodipine (IS) from spiked plasma samples were 51.1 +/- 1.3 and 50.3 +/- 4.9%, respectively.","Simple, sensitive and rapid liquid chromatographic/electrospray ionization tandem mass spectrometric method for the quantification of lacidipine in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282762/),%,51.1,52960,DB01373,Calcium
,15282762,absolute recoveries,"The average absolute recoveries of lacidipine and amlodipine (IS) from spiked plasma samples were 51.1 +/- 1.3 and 50.3 +/- 4.9%, respectively.","Simple, sensitive and rapid liquid chromatographic/electrospray ionization tandem mass spectrometric method for the quantification of lacidipine in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282762/),%,50.3,52961,DB01373,Calcium
,11808823,heart rate increase,"After the recommended infusion period of 24 hours, the mean heart rate increase was only 2 and 6 beats/min in the lower and higher levosimendan dose groups, respectively.","Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808823/),[beats] / [min],2,53486,DB01373,Calcium
,11808823,heart rate increase,"After the recommended infusion period of 24 hours, the mean heart rate increase was only 2 and 6 beats/min in the lower and higher levosimendan dose groups, respectively.","Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808823/),[beats] / [min],6,53487,DB01373,Calcium
,11808823,elimination half-life,The elimination half-life of levosimendan was approximately 1 hour and of the metabolites 70 to 80 hours.,"Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808823/),h,1,53488,DB01373,Calcium
,11808823,elimination half-life,The elimination half-life of levosimendan was approximately 1 hour and of the metabolites 70 to 80 hours.,"Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808823/),h,70 to 80,53489,DB01373,Calcium
,17988844,n,Obvious increase in overall release rate was observed at sodium chloride level of 0.9% with an n value of 1.20 and a T0.1 of 3.4h.,"Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17988844/),,1.20,53549,DB01373,Calcium
,17988844,T0.1,Obvious increase in overall release rate was observed at sodium chloride level of 0.9% with an n value of 1.20 and a T0.1 of 3.4h.,"Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17988844/),h,3.4,53550,DB01373,Calcium
,17988844,Tmax/Cmax,"Pharmacokinetic study in dogs gave Tmax/Cmax of 4h/604 ng/ml and 3h/1662 ng/ml for HPMC/pectin/calcium and HPMC/pectin tablet, respectively.","Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17988844/),-1·h,4,53551,DB01373,Calcium
,17988844,Tmax/Cmax,"Pharmacokinetic study in dogs gave Tmax/Cmax of 4h/604 ng/ml and 3h/1662 ng/ml for HPMC/pectin/calcium and HPMC/pectin tablet, respectively.","Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17988844/),[ng] / [ml],604,53552,DB01373,Calcium
,17988844,Tmax/Cmax,"Pharmacokinetic study in dogs gave Tmax/Cmax of 4h/604 ng/ml and 3h/1662 ng/ml for HPMC/pectin/calcium and HPMC/pectin tablet, respectively.","Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17988844/),-1·h,3,53553,DB01373,Calcium
,17988844,Tmax/Cmax,"Pharmacokinetic study in dogs gave Tmax/Cmax of 4h/604 ng/ml and 3h/1662 ng/ml for HPMC/pectin/calcium and HPMC/pectin tablet, respectively.","Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17988844/),[ng] / [ml],1662,53554,DB01373,Calcium
,17988844,MRT,"The plasma indomethacin level of the calcium-containing tablet was maintained at a much lower level for 3h with a MRT of 7.13 h, longer than 3.97 and 5.61 h for indomethacin crude drug and HPMC/pectin tablet, confirming delayed absorption.","Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17988844/),h,7.13,53555,DB01373,Calcium
,17988844,MRT,"The plasma indomethacin level of the calcium-containing tablet was maintained at a much lower level for 3h with a MRT of 7.13 h, longer than 3.97 and 5.61 h for indomethacin crude drug and HPMC/pectin tablet, confirming delayed absorption.","Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17988844/),h,longer,53556,DB01373,Calcium
,17988844,MRT,"The plasma indomethacin level of the calcium-containing tablet was maintained at a much lower level for 3h with a MRT of 7.13 h, longer than 3.97 and 5.61 h for indomethacin crude drug and HPMC/pectin tablet, confirming delayed absorption.","Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17988844/),h,3.97,53557,DB01373,Calcium
,17988844,MRT,"The plasma indomethacin level of the calcium-containing tablet was maintained at a much lower level for 3h with a MRT of 7.13 h, longer than 3.97 and 5.61 h for indomethacin crude drug and HPMC/pectin tablet, confirming delayed absorption.","Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17988844/),h,5.61,53558,DB01373,Calcium
,22531846,T(max),"In the in vivo study, the C(max) of nitrendipine remained the same, however, the T(max) delayed from 0.75 h to 1.5 h with the chitosan modified nanocrystals.",A novel surface modified nitrendipine nanocrystals with enhancement of bioavailability and stability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22531846/),h,0.75,53782,DB01373,Calcium
,22531846,T(max),"In the in vivo study, the C(max) of nitrendipine remained the same, however, the T(max) delayed from 0.75 h to 1.5 h with the chitosan modified nanocrystals.",A novel surface modified nitrendipine nanocrystals with enhancement of bioavailability and stability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22531846/),h,1.5,53783,DB01373,Calcium
,15963088,half-life,On day 1 following administration of 1 mg kg(-1) the mean half-life of DP-b99 in young volunteers was 3.47 +/- 0.90 h and in the elderly was 2.11 +/- 0.09 h.,Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15963088/),h,3.47,54468,DB01373,Calcium
,15963088,half-life,On day 1 following administration of 1 mg kg(-1) the mean half-life of DP-b99 in young volunteers was 3.47 +/- 0.90 h and in the elderly was 2.11 +/- 0.09 h.,Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15963088/),h,2.11,54469,DB01373,Calcium
,15963088,half-life,"On day 4 following the same administration of DP-b99 the mean half-life was 4.36 +/- 1.49 and 2.10 +/- 1.14 h in the young and elderly, respectively.",Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15963088/),h,4.36,54470,DB01373,Calcium
,15963088,half-life,"On day 4 following the same administration of DP-b99 the mean half-life was 4.36 +/- 1.49 and 2.10 +/- 1.14 h in the young and elderly, respectively.",Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15963088/),h,2.10,54471,DB01373,Calcium
,30327682,flow rate,Ammonium acetate aqueous solution (1 mmol/L) and acetonitrile were used as the mobile phase and the flow rate was 0.3 mL/min.,Simultaneous Determination of Columbianadin and Its Metabolite Columbianetin in Rat Plasma by LC-MS/MS: Application to Pharmacokinetics of Columbianadin after Oral Administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327682/),[ml] / [min],0.3,55213,DB01373,Calcium
,24412691,flow rate,"Plasma samples were separated by HPLC on an Agela Venusil XBP Phenyl column (100 mm × 2.1 mm, 5 μm) using a mobile phase consisting of methanol-2mM ammonium acetate-formic acid (70:30:0.1, v/v/v) and the flow rate was set at 0.35 mL/min.",Determination of lomerizine in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24412691/),[ml] / [min],0.35,55295,DB01373,Calcium
,24412691,total run time,The total run time was 4.0 min and the elution of lomerizine was at 1.9 min.,Determination of lomerizine in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24412691/),min,4.0,55296,DB01373,Calcium
,24412691,elution,The total run time was 4.0 min and the elution of lomerizine was at 1.9 min.,Determination of lomerizine in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24412691/),min,1.9,55297,DB01373,Calcium
,22396916,maximum drug dissolution rate,"The best formulation, AT4, consisting of Ethyl cellulose, DSS and Poly Ox®, had a maximum drug dissolution rate of 97.86 %, as compared to Storvas 80 mg (Ranbaxy Ltd, as a reference) which had a rate of only 54% during a period of 12 h in acidic media.",Enhanced Bioavailability and Dissolution of Atorvastatin Calcium from Floating Microcapsules using Minimum Additives. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22396916/),%,97.86,55846,DB01373,Calcium
,22396916,rate,"The best formulation, AT4, consisting of Ethyl cellulose, DSS and Poly Ox®, had a maximum drug dissolution rate of 97.86 %, as compared to Storvas 80 mg (Ranbaxy Ltd, as a reference) which had a rate of only 54% during a period of 12 h in acidic media.",Enhanced Bioavailability and Dissolution of Atorvastatin Calcium from Floating Microcapsules using Minimum Additives. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22396916/),,54,55847,DB01373,Calcium
,24802860,t½,"After administration of rhPTH(1-84) 50 µg (n = 6) and 100 µg (n = 7), the approximate t½ was 2.5 to 3 hours.","Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24802860/),h,2.5 to 3,56560,DB01373,Calcium
,12131552,steady state level,"In nonischemic hearts, clevidipine reached a steady state level in the coronary venous blood of about 30 nM during the infusion.",Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131552/),nM,30,56705,DB01373,Calcium
,12131552,blood clearance,"The mean blood clearance of clevidipine was calculated to be 0.17 l/min per kilogram, and the estimated half-life was 0.5 minute.",Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131552/),[l] / [kg·min],0.17,56706,DB01373,Calcium
,12131552,half-life,"The mean blood clearance of clevidipine was calculated to be 0.17 l/min per kilogram, and the estimated half-life was 0.5 minute.",Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131552/),min,0.5,56707,DB01373,Calcium
,12131552,half-life,"The in vitro half-life in pig blood was 13 minutes, and the corresponding half-life in plasma was 111 minutes.",Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131552/),min,13,56708,DB01373,Calcium
,12131552,half-life,"The in vitro half-life in pig blood was 13 minutes, and the corresponding half-life in plasma was 111 minutes.",Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131552/),min,111,56709,DB01373,Calcium
,17973928,oral bioavailability,The oral bioavailability of verapamil was 32.9% in normal rats and 34.4% in rats with liver fibrosis.,Effects of liver fibrosis on verapamil pharmacokinetics in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973928/),%,32.9,58066,DB01373,Calcium
,17973928,oral bioavailability,The oral bioavailability of verapamil was 32.9% in normal rats and 34.4% in rats with liver fibrosis.,Effects of liver fibrosis on verapamil pharmacokinetics in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973928/),%,34.4,58067,DB01373,Calcium
,27008238,concentration peak (Cmax,"Quatrefolic® administration produced a plasmatic (6S)5-MTHF concentration peak (Cmax: 879.6±330.3 ng/mL) 1.8 times higher than (6S)5-MTHF Ca salt (486.8±184.1 ng/mL), and 3.1 times higher than folic acid supplementation (281.5±135.7 ng/mL), while tmax values were similar for the three folate forms.",Enhanced oral bioavailability of a novel folate salt: comparison with folic acid and a calcium folate salt in a pharmacokinetic study in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27008238/),[ng] / [ml],879.6,58814,DB01373,Calcium
,27008238,concentration peak (Cmax,"Quatrefolic® administration produced a plasmatic (6S)5-MTHF concentration peak (Cmax: 879.6±330.3 ng/mL) 1.8 times higher than (6S)5-MTHF Ca salt (486.8±184.1 ng/mL), and 3.1 times higher than folic acid supplementation (281.5±135.7 ng/mL), while tmax values were similar for the three folate forms.",Enhanced oral bioavailability of a novel folate salt: comparison with folic acid and a calcium folate salt in a pharmacokinetic study in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27008238/),[ng] / [ml],486.8,58815,DB01373,Calcium
,27008238,concentration peak (Cmax,"Quatrefolic® administration produced a plasmatic (6S)5-MTHF concentration peak (Cmax: 879.6±330.3 ng/mL) 1.8 times higher than (6S)5-MTHF Ca salt (486.8±184.1 ng/mL), and 3.1 times higher than folic acid supplementation (281.5±135.7 ng/mL), while tmax values were similar for the three folate forms.",Enhanced oral bioavailability of a novel folate salt: comparison with folic acid and a calcium folate salt in a pharmacokinetic study in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27008238/),[ng] / [ml],281.5,58816,DB01373,Calcium
,27008238,AUC8h,Quatrefolic® supplementation showed AUC8h (1123.9 ng/mL ∙ h) 9.7 times higher than folic acid (114.7 ng/mL ∙ h) and 1.12 times higher than (6S)5-MTHF Ca salt (997.6 ng/mL ∙ h).,Enhanced oral bioavailability of a novel folate salt: comparison with folic acid and a calcium folate salt in a pharmacokinetic study in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27008238/),[ng] / [h·ml·∙],1123.9,58817,DB01373,Calcium
,27008238,AUC8h,Quatrefolic® supplementation showed AUC8h (1123.9 ng/mL ∙ h) 9.7 times higher than folic acid (114.7 ng/mL ∙ h) and 1.12 times higher than (6S)5-MTHF Ca salt (997.6 ng/mL ∙ h).,Enhanced oral bioavailability of a novel folate salt: comparison with folic acid and a calcium folate salt in a pharmacokinetic study in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27008238/),[ng] / [h·ml·∙],114.7,58818,DB01373,Calcium
,27008238,AUC8h,Quatrefolic® supplementation showed AUC8h (1123.9 ng/mL ∙ h) 9.7 times higher than folic acid (114.7 ng/mL ∙ h) and 1.12 times higher than (6S)5-MTHF Ca salt (997.6 ng/mL ∙ h).,Enhanced oral bioavailability of a novel folate salt: comparison with folic acid and a calcium folate salt in a pharmacokinetic study in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27008238/),[ng] / [h·ml·∙],997.6,58819,DB01373,Calcium
,12162502,absolute bioavailability,"SCT was reliably absorbed from the oral formulation, with an absolute bioavailability of 0.5-1.4%, depending on the dose.",Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162502/),%,0.5-1.4,59579,DB01373,Calcium
,11958560,bioavailability (F),"Following oral administration, the bioavailability (F) of I (17%) was much higher than that of II (1%).","Differences in the absorption, metabolism and biliary excretion of a diastereomeric pair of alphavbeta3-antagonists in rat: limited role of P-glycoprotein. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11958560/),%,17,59734,DB01373,Calcium
,11958560,bioavailability (F),"Following oral administration, the bioavailability (F) of I (17%) was much higher than that of II (1%).","Differences in the absorption, metabolism and biliary excretion of a diastereomeric pair of alphavbeta3-antagonists in rat: limited role of P-glycoprotein. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11958560/),%,1,59735,DB01373,Calcium
,28481663,zeta potential,"Optimised ATC-SNEDDS resulted in droplets size of 5.66 nm, zeta potential of -19.52 mV, t90 of 5.43 min and completely released ATC within 30 min irrespective of pH of the medium.",Development and optimisation of atorvastatin calcium loaded self-nanoemulsifying drug delivery system (SNEDDS) for enhancing oral bioavailability: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28481663/),mv,19.52,59944,DB01373,Calcium
,28481663,t90,"Optimised ATC-SNEDDS resulted in droplets size of 5.66 nm, zeta potential of -19.52 mV, t90 of 5.43 min and completely released ATC within 30 min irrespective of pH of the medium.",Development and optimisation of atorvastatin calcium loaded self-nanoemulsifying drug delivery system (SNEDDS) for enhancing oral bioavailability: in vitro and in vivo evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28481663/),min,5.43,59945,DB01373,Calcium
,26584914,relative bioavailability,"The pharmacokinetic results showed that the relative bioavailability was 397 % in comparison with Nimotop(®), suggesting that NCs are an efficient strategy for improving the oral bioavailability of poorly water-soluble drugs.",Formulation of nimodipine nanocrystals for oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26584914/),%,397,60691,DB01373,Calcium
,29260378,Solubility,"Solubility of RSV in Perilla frutescens oil and Cremophor EL was 25.0 ± 3.0 and 60.0 ± 5.0 mg/mL, respectively.",ω-3 Fatty Acid Synergized Novel Nanoemulsifying System for Rosuvastatin Delivery: In Vitro and In Vivo Evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29260378/),[mg] / [ml],25.0,60795,DB01373,Calcium
,29260378,Solubility,"Solubility of RSV in Perilla frutescens oil and Cremophor EL was 25.0 ± 3.0 and 60.0 ± 5.0 mg/mL, respectively.",ω-3 Fatty Acid Synergized Novel Nanoemulsifying System for Rosuvastatin Delivery: In Vitro and In Vivo Evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29260378/),[mg] / [ml],60.0,60796,DB01373,Calcium
,29260378,viscosity,"Optimized SNES formulation demonstrated particle size of 17.90 nm, dissolution 98.80%, cloud point 45°C, emulsification time 2 min, and viscosity 241.41 ± 5.52 cP.",ω-3 Fatty Acid Synergized Novel Nanoemulsifying System for Rosuvastatin Delivery: In Vitro and In Vivo Evaluation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29260378/),cp,241.41,60797,DB01373,Calcium
,29260378,C max,"Pharmacokinetic study of SNES revealed significantly higher C max (60.13 ± 25.43 ng/mL) and AUC0-∞ (6195 ± 42.38 ng h/mL) vis-à-vis marketed tablet (284.80 ± 13.44 ng/mL, 3131.72 ± 51.93 ng h/mL, respectively).",ω-3 Fatty Acid Synergized Novel Nanoemulsifying System for Rosuvastatin Delivery: In Vitro and In Vivo Evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29260378/),[ng] / [ml],60.13,60798,DB01373,Calcium
,29260378,AUC0-∞,"Pharmacokinetic study of SNES revealed significantly higher C max (60.13 ± 25.43 ng/mL) and AUC0-∞ (6195 ± 42.38 ng h/mL) vis-à-vis marketed tablet (284.80 ± 13.44 ng/mL, 3131.72 ± 51.93 ng h/mL, respectively).",ω-3 Fatty Acid Synergized Novel Nanoemulsifying System for Rosuvastatin Delivery: In Vitro and In Vivo Evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29260378/),[h·ng] / [ml],6195,60799,DB01373,Calcium
,29260378,AUC0-∞,"Pharmacokinetic study of SNES revealed significantly higher C max (60.13 ± 25.43 ng/mL) and AUC0-∞ (6195 ± 42.38 ng h/mL) vis-à-vis marketed tablet (284.80 ± 13.44 ng/mL, 3131.72 ± 51.93 ng h/mL, respectively).",ω-3 Fatty Acid Synergized Novel Nanoemulsifying System for Rosuvastatin Delivery: In Vitro and In Vivo Evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29260378/),[ng] / [ml],284.80,60800,DB01373,Calcium
,29260378,AUC0-∞,"Pharmacokinetic study of SNES revealed significantly higher C max (60.13 ± 25.43 ng/mL) and AUC0-∞ (6195 ± 42.38 ng h/mL) vis-à-vis marketed tablet (284.80 ± 13.44 ng/mL, 3131.72 ± 51.93 ng h/mL, respectively).",ω-3 Fatty Acid Synergized Novel Nanoemulsifying System for Rosuvastatin Delivery: In Vitro and In Vivo Evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29260378/),[h·ng] / [ml],3131.72,60801,DB01373,Calcium
,27186137,mean residence time (MRTab),"The mean residence time (MRTab) of calcium from calcium ascorbate (32.2 minutes) in the intestinal tract was much longer than that from calcium L-lactate (9.5 minutes), calcium acetate (15.0 minutes) and calcium chloride (13.6 minutes).",Effect of anions or foods on absolute bioavailability of calcium from calcium salts in mice by pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27186137/),min,32.2,60896,DB01373,Calcium
,27186137,mean residence time (MRTab),"The mean residence time (MRTab) of calcium from calcium ascorbate (32.2 minutes) in the intestinal tract was much longer than that from calcium L-lactate (9.5 minutes), calcium acetate (15.0 minutes) and calcium chloride (13.6 minutes).",Effect of anions or foods on absolute bioavailability of calcium from calcium salts in mice by pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27186137/),min,9.5,60897,DB01373,Calcium
,27186137,mean residence time (MRTab),"The mean residence time (MRTab) of calcium from calcium ascorbate (32.2 minutes) in the intestinal tract was much longer than that from calcium L-lactate (9.5 minutes), calcium acetate (15.0 minutes) and calcium chloride (13.6 minutes).",Effect of anions or foods on absolute bioavailability of calcium from calcium salts in mice by pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27186137/),min,15.0,60898,DB01373,Calcium
,27186137,mean residence time (MRTab),"The mean residence time (MRTab) of calcium from calcium ascorbate (32.2 minutes) in the intestinal tract was much longer than that from calcium L-lactate (9.5 minutes), calcium acetate (15.0 minutes) and calcium chloride (13.6 minutes).",Effect of anions or foods on absolute bioavailability of calcium from calcium salts in mice by pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27186137/),min,13.6,60899,DB01373,Calcium
,27186137,MRTab,"Furthermore, the foods di-D-fructo-furanose-1,2':2,3'-dianhydride, sudachi (Citrus sudachi) juice, and moromi-su (a Japanese vinegar) increased the absolute bioavailability of calcium from calcium chloride by 2.46-fold, 2.86-fold, and 1.23-fold, respectively, and prolonged MRTab by 48.5 minutes, 43.1 minutes, and 44.9 minutes, respectively.",Effect of anions or foods on absolute bioavailability of calcium from calcium salts in mice by pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27186137/),min,43.1,60900,DB01373,Calcium
,27186137,MRTab,"Furthermore, the foods di-D-fructo-furanose-1,2':2,3'-dianhydride, sudachi (Citrus sudachi) juice, and moromi-su (a Japanese vinegar) increased the absolute bioavailability of calcium from calcium chloride by 2.46-fold, 2.86-fold, and 1.23-fold, respectively, and prolonged MRTab by 48.5 minutes, 43.1 minutes, and 44.9 minutes, respectively.",Effect of anions or foods on absolute bioavailability of calcium from calcium salts in mice by pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27186137/),min,44.9,60901,DB01373,Calcium
,30130726,flow rate,"Separation of AC and rosuvastatin calcium (internal standard, IS) were achieved on a Dikma Leapsil C18 reversed phase column (100 × 2.1 mm, 2.7 μm) with gradient elution using 0.2% (v/v) formic acid in water and acetonitrile as mobile phases, at the flow rate of 0.3 mL/min.",UHPLC-MS/MS method for determination of atorvastatin calcium in human plasma: Application to a pharmacokinetic study based on healthy volunteers with specific genotype. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30130726/),[ml] / [min],0.3,60920,DB01373,Calcium
,17192769,Dose/trough concentration ratios,Dose/trough concentration ratios were 0.67+/-0.3 and 1.36+/-0.73 x 10(3) l (P<0.00001) for tacrolimus and 0.42+/-0.17 and 0.84+/-0.46 x 10(3) l (P=0.18) for sirolimus in CYP3A5 non-expressors and expressors.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),l,0.67,60927,DB01373,Calcium
,17192769,Dose/trough concentration ratios,Dose/trough concentration ratios were 0.67+/-0.3 and 1.36+/-0.73 x 10(3) l (P<0.00001) for tacrolimus and 0.42+/-0.17 and 0.84+/-0.46 x 10(3) l (P=0.18) for sirolimus in CYP3A5 non-expressors and expressors.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),l,1.36,60928,DB01373,Calcium
,17192769,Dose/trough concentration ratios,Dose/trough concentration ratios were 0.67+/-0.3 and 1.36+/-0.73 x 10(3) l (P<0.00001) for tacrolimus and 0.42+/-0.17 and 0.84+/-0.46 x 10(3) l (P=0.18) for sirolimus in CYP3A5 non-expressors and expressors.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),10,0.42,60929,DB01373,Calcium
,17192769,Dose/trough concentration ratios,Dose/trough concentration ratios were 0.67+/-0.3 and 1.36+/-0.73 x 10(3) l (P<0.00001) for tacrolimus and 0.42+/-0.17 and 0.84+/-0.46 x 10(3) l (P=0.18) for sirolimus in CYP3A5 non-expressors and expressors.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),l,0.84,60930,DB01373,Calcium
,17192769,area under curve (AUC)(0-12),The unadjusted tacrolimus area under curve (AUC)(0-12) was 106.8+/-17.5 ng/ml x h compared with 133.3+/-42.2 ng/ml x h (P=0.37) without affecting serum creatinine.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),[ng] / [h·ml],106.8,60931,DB01373,Calcium
,17192769,area under curve (AUC)(0-12),The unadjusted tacrolimus area under curve (AUC)(0-12) was 106.8+/-17.5 ng/ml x h compared with 133.3+/-42.2 ng/ml x h (P=0.37) without affecting serum creatinine.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),[ng] / [h·ml],133.3,60932,DB01373,Calcium
,34031791,% DE30,The formulation F8 showed high dissolution performance (% DE30 value of 80.65 ± 3.05) among the other formulations.,Formulation of Gelucire®-Based Solid Dispersions of Atorvastatin Calcium: In Vitro Dissolution and In Vivo Bioavailability Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34031791/),,80.65,61857,DB01373,Calcium
,34031791,Cmax,Optimized Gelucire®48/16-based SDs formulation suggested improved oral absorption of atorvastatin as evidenced with improved pharmacokinetic parameters (Cmax 2864.33 ± 573.86 ng/ml; AUC0-t 5594.95 ± 623.3 ng/h ml) as compared to ATV suspension (Cmax 317.82 ± 63.56 ng/ml; AUC0-t 573.94 ± 398.9 ng/h ml) and marketed tablets (Cmax 852.72 ± 42.63 ng/ml; 4837.4 ± 174.7 ng/h ml).,Formulation of Gelucire®-Based Solid Dispersions of Atorvastatin Calcium: In Vitro Dissolution and In Vivo Bioavailability Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34031791/),[ng] / [ml],2864.33,61858,DB01373,Calcium
,34031791,AUC0-t,Optimized Gelucire®48/16-based SDs formulation suggested improved oral absorption of atorvastatin as evidenced with improved pharmacokinetic parameters (Cmax 2864.33 ± 573.86 ng/ml; AUC0-t 5594.95 ± 623.3 ng/h ml) as compared to ATV suspension (Cmax 317.82 ± 63.56 ng/ml; AUC0-t 573.94 ± 398.9 ng/h ml) and marketed tablets (Cmax 852.72 ± 42.63 ng/ml; 4837.4 ± 174.7 ng/h ml).,Formulation of Gelucire®-Based Solid Dispersions of Atorvastatin Calcium: In Vitro Dissolution and In Vivo Bioavailability Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34031791/),[ng] / [h·ml],5594.95,61859,DB01373,Calcium
,34031791,Cmax,Optimized Gelucire®48/16-based SDs formulation suggested improved oral absorption of atorvastatin as evidenced with improved pharmacokinetic parameters (Cmax 2864.33 ± 573.86 ng/ml; AUC0-t 5594.95 ± 623.3 ng/h ml) as compared to ATV suspension (Cmax 317.82 ± 63.56 ng/ml; AUC0-t 573.94 ± 398.9 ng/h ml) and marketed tablets (Cmax 852.72 ± 42.63 ng/ml; 4837.4 ± 174.7 ng/h ml).,Formulation of Gelucire®-Based Solid Dispersions of Atorvastatin Calcium: In Vitro Dissolution and In Vivo Bioavailability Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34031791/),[ng] / [ml],317.82,61860,DB01373,Calcium
,34031791,AUC0-t,Optimized Gelucire®48/16-based SDs formulation suggested improved oral absorption of atorvastatin as evidenced with improved pharmacokinetic parameters (Cmax 2864.33 ± 573.86 ng/ml; AUC0-t 5594.95 ± 623.3 ng/h ml) as compared to ATV suspension (Cmax 317.82 ± 63.56 ng/ml; AUC0-t 573.94 ± 398.9 ng/h ml) and marketed tablets (Cmax 852.72 ± 42.63 ng/ml; 4837.4 ± 174.7 ng/h ml).,Formulation of Gelucire®-Based Solid Dispersions of Atorvastatin Calcium: In Vitro Dissolution and In Vivo Bioavailability Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34031791/),[ng] / [h·ml],573.94,61861,DB01373,Calcium
,34031791,Cmax,Optimized Gelucire®48/16-based SDs formulation suggested improved oral absorption of atorvastatin as evidenced with improved pharmacokinetic parameters (Cmax 2864.33 ± 573.86 ng/ml; AUC0-t 5594.95 ± 623.3 ng/h ml) as compared to ATV suspension (Cmax 317.82 ± 63.56 ng/ml; AUC0-t 573.94 ± 398.9 ng/h ml) and marketed tablets (Cmax 852.72 ± 42.63 ng/ml; 4837.4 ± 174.7 ng/h ml).,Formulation of Gelucire®-Based Solid Dispersions of Atorvastatin Calcium: In Vitro Dissolution and In Vivo Bioavailability Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34031791/),[ng] / [ml],852.72,61862,DB01373,Calcium
,34031791,Cmax,Optimized Gelucire®48/16-based SDs formulation suggested improved oral absorption of atorvastatin as evidenced with improved pharmacokinetic parameters (Cmax 2864.33 ± 573.86 ng/ml; AUC0-t 5594.95 ± 623.3 ng/h ml) as compared to ATV suspension (Cmax 317.82 ± 63.56 ng/ml; AUC0-t 573.94 ± 398.9 ng/h ml) and marketed tablets (Cmax 852.72 ± 42.63 ng/ml; 4837.4 ± 174.7 ng/h ml).,Formulation of Gelucire®-Based Solid Dispersions of Atorvastatin Calcium: In Vitro Dissolution and In Vivo Bioavailability Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34031791/),[ng] / [h·ml],4837.4,61863,DB01373,Calcium
,11801543,MTD,The final MTD was 150 mg/m(2).,"Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801543/),[mg] / [m(2],150,62046,DB01373,Calcium
> or =,11801543,C(ss),Patients with C(ss) of > or = 4.0 mg/liter were more likely to have neurotoxicity.,"Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801543/),[mg] / [l],4.0,62047,DB01373,Calcium
,16207605,relative bioavailabilities,"The relative bioavailabilities of test formulations were intensively improved compared with the domestic nitrendipine tablets, while the ratio is in a range of 80-120% in comparison with Baypress nitrendipine tablets.",In vivo evaluation of two novel controlled-release nitrendipine formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207605/),%,80-120,62464,DB01373,Calcium
,16207605,ratio,"The relative bioavailabilities of test formulations were intensively improved compared with the domestic nitrendipine tablets, while the ratio is in a range of 80-120% in comparison with Baypress nitrendipine tablets.",In vivo evaluation of two novel controlled-release nitrendipine formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207605/),%,80-120,62465,DB01373,Calcium
up to,33035605,Tmax,"In addition, pharmacokinetics studies in SD rats showed that the Tmax (up to 1.79 ± 0.24 h) and AUC0-12 (46.37 ± 2.71 μg/mL·h) of ACC/SA in situ hydrogels treated group were significantly higher (p < 0.05) than that of free drug solution.",Intragastric amorphous calcium carbonate consumption triggered generation of in situ hydrogel piece for sustained drug release. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33035605/),h,1.79,62850,DB01373,Calcium
,33035605,AUC0-12,"In addition, pharmacokinetics studies in SD rats showed that the Tmax (up to 1.79 ± 0.24 h) and AUC0-12 (46.37 ± 2.71 μg/mL·h) of ACC/SA in situ hydrogels treated group were significantly higher (p < 0.05) than that of free drug solution.",Intragastric amorphous calcium carbonate consumption triggered generation of in situ hydrogel piece for sustained drug release. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33035605/),[μg] / [h·ml],46.37,62851,DB01373,Calcium
,12031392,area under the concentration versus time curve,The mean total calcitriol exposure (area under the concentration versus time curve) in the prostate was 297.6 (+/-159) pg/hr/mL (intact) and 272.7 (+/-123.6) pg/hr/mL (castrated).,"Evaluation of intraprostatic metabolism of 1,25-dihydroxyvitamin D(3) (calcitriol) using a microdialysis technique. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12031392/),[pg] / [h·ml],297.6,62885,DB01373,Calcium
,12031392,area under the concentration versus time curve,The mean total calcitriol exposure (area under the concentration versus time curve) in the prostate was 297.6 (+/-159) pg/hr/mL (intact) and 272.7 (+/-123.6) pg/hr/mL (castrated).,"Evaluation of intraprostatic metabolism of 1,25-dihydroxyvitamin D(3) (calcitriol) using a microdialysis technique. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12031392/),[pg] / [h·ml],272.7,62886,DB01373,Calcium
,18674408,apparent oral clearance (CL/F),"For example, apparent oral clearance (CL/F) was estimated to be 257 L/h.","Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18674408/),[l] / [h],257,63182,DB01373,Calcium
,26373270,plasma clearance rate,"HMB-FA administered in capsules was more efficient than Ca-HMB capsule at HMB delivery with a 37 % increase in plasma clearance rate (74·8 (sem 4·0) v. 54·5 (sem 3·2) ml/min, P<0·0001) and a 76 % increase in peak plasma HMB concentration (270·2 (sem 17·8) v. 153·9 (sem 17·9) μmol/l, P<0·006), which was reached in one-third the time (P<0·009).",Comparison of availability and plasma clearance rates of β-hydroxy-β-methylbutyrate delivery in the free acid and calcium salt forms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26373270/),[ml] / [min],74·8,63595,DB01373,Calcium
,26373270,plasma clearance rate,"HMB-FA administered in capsules was more efficient than Ca-HMB capsule at HMB delivery with a 37 % increase in plasma clearance rate (74·8 (sem 4·0) v. 54·5 (sem 3·2) ml/min, P<0·0001) and a 76 % increase in peak plasma HMB concentration (270·2 (sem 17·8) v. 153·9 (sem 17·9) μmol/l, P<0·006), which was reached in one-third the time (P<0·009).",Comparison of availability and plasma clearance rates of β-hydroxy-β-methylbutyrate delivery in the free acid and calcium salt forms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26373270/),[ml] / [min],54·5,63596,DB01373,Calcium
,26373270,peak plasma HMB concentration,"HMB-FA administered in capsules was more efficient than Ca-HMB capsule at HMB delivery with a 37 % increase in plasma clearance rate (74·8 (sem 4·0) v. 54·5 (sem 3·2) ml/min, P<0·0001) and a 76 % increase in peak plasma HMB concentration (270·2 (sem 17·8) v. 153·9 (sem 17·9) μmol/l, P<0·006), which was reached in one-third the time (P<0·009).",Comparison of availability and plasma clearance rates of β-hydroxy-β-methylbutyrate delivery in the free acid and calcium salt forms. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26373270/),[μM] / [l],270·2,63597,DB01373,Calcium
,26373270,peak plasma HMB concentration,"HMB-FA administered in capsules was more efficient than Ca-HMB capsule at HMB delivery with a 37 % increase in plasma clearance rate (74·8 (sem 4·0) v. 54·5 (sem 3·2) ml/min, P<0·0001) and a 76 % increase in peak plasma HMB concentration (270·2 (sem 17·8) v. 153·9 (sem 17·9) μmol/l, P<0·006), which was reached in one-third the time (P<0·009).",Comparison of availability and plasma clearance rates of β-hydroxy-β-methylbutyrate delivery in the free acid and calcium salt forms. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26373270/),[μM] / [l],153·9,63598,DB01373,Calcium
,34396892,IC50,"Phloretin markedly decreased OATP2B1-mediated rosuvastatin uptake, with an IC50 value of 3.6 μM.",In vitro and in vivo evaluation of organic anion-transporting polypeptide 2B1-mediated pharmacokinetic interactions by apple polyphenols. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34396892/),μM,3.6,63706,DB01373,Calcium
,12134944,bioavailability,The application of microparticles in powder form compared to an equivalent suspension improved the intrajejunal bioavailability of the oligonucleotide (25% and 10% respectively) in rats.,Alginate/poly-L-lysine microparticles for the intestinal delivery of antisense oligonucleotides. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12134944/),%,25,64782,DB01373,Calcium
,12134944,bioavailability,The application of microparticles in powder form compared to an equivalent suspension improved the intrajejunal bioavailability of the oligonucleotide (25% and 10% respectively) in rats.,Alginate/poly-L-lysine microparticles for the intestinal delivery of antisense oligonucleotides. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12134944/),%,10,64783,DB01373,Calcium
,12134944,bioavailability,"On the contrary, the intrajejunal administration to dogs resulted in poor oligonucleotide bioavailability (0.42%).",Alginate/poly-L-lysine microparticles for the intestinal delivery of antisense oligonucleotides. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12134944/),%,0.42,64784,DB01373,Calcium
,34051480,m,"The protonated precursor ion [M+H]+ and major fragment ion were confirmed at m/z 588.2 and 180.1, respectively.",A sensitive analytical method for the determination of SG-SP1 in rat plasma by HPLC-MS/MS and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34051480/),,588.2,65209,DB01373,Calcium
,34051480,m,"The protonated precursor ion [M+H]+ and major fragment ion were confirmed at m/z 588.2 and 180.1, respectively.",A sensitive analytical method for the determination of SG-SP1 in rat plasma by HPLC-MS/MS and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34051480/),,180.1,65210,DB01373,Calcium
,34051480,terminal half-life,SG-SP1 decayed in a biphasic pattern with terminal half-life of 5.1 h and clearance of about 3.2 L/h/kg.,A sensitive analytical method for the determination of SG-SP1 in rat plasma by HPLC-MS/MS and its application to a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34051480/),h,5.1,65211,DB01373,Calcium
,34051480,clearance,SG-SP1 decayed in a biphasic pattern with terminal half-life of 5.1 h and clearance of about 3.2 L/h/kg.,A sensitive analytical method for the determination of SG-SP1 in rat plasma by HPLC-MS/MS and its application to a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34051480/),[l] / [h·kg],3.2,65212,DB01373,Calcium
,34051480,absolute oral bioavailability,"Double peaks were observed following oral administration, and the absolute oral bioavailability was ∼1 %.",A sensitive analytical method for the determination of SG-SP1 in rat plasma by HPLC-MS/MS and its application to a pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34051480/),%,∼1,65213,DB01373,Calcium
,17024486,steady state concentrations,Pamidronate levels reached steady state concentrations of 0.9-1.5 microg/ml within 30 min and the clearance of the drug (mean+/-SE) from blood was 180.0+/-64.2 ml/kg/h with an elimination half-life of less than 1 h.,Pamidronate distribution in pediatric renal and rheumatologic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17024486/),[μg] / [ml],0.9-1.5,65258,DB01373,Calcium
,17024486,clearance of,Pamidronate levels reached steady state concentrations of 0.9-1.5 microg/ml within 30 min and the clearance of the drug (mean+/-SE) from blood was 180.0+/-64.2 ml/kg/h with an elimination half-life of less than 1 h.,Pamidronate distribution in pediatric renal and rheumatologic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17024486/),[ml] / [h·kg],180.0,65259,DB01373,Calcium
less,17024486,elimination half-life,Pamidronate levels reached steady state concentrations of 0.9-1.5 microg/ml within 30 min and the clearance of the drug (mean+/-SE) from blood was 180.0+/-64.2 ml/kg/h with an elimination half-life of less than 1 h.,Pamidronate distribution in pediatric renal and rheumatologic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17024486/),h,1,65260,DB01373,Calcium
,17024486,urinary excretion,"The mean urinary excretion of 31.5+/-2.2% of the administered dose indicated that about 68% of the drug was incorporated into bone, confirming the uptake of pamidronate into bone was similar in pediatric patients compared to that previously reported for adults.",Pamidronate distribution in pediatric renal and rheumatologic patients. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17024486/),%,31.5,65261,DB01373,Calcium
,20171424,AUC(0-last),The mean (SD) AUC(0-last) was 129.7 (62.8) ng . h/mL after dosing with S-amlodipine and 129.0 (59.6) ng . h/mL after dosing with amlodipine racemate.,"Pharmacodynamic (hemodynamic) and pharmacokinetic comparisons of S-amlodipine gentisate and racemate amlodipine besylate in healthy Korean male volunteers: two double-blind, randomized, two-period, two-treatment, two-sequence, double-dummy, single-dose crossover studies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171424/),[h·ng] / [ml],129.7,65497,DB01373,Calcium
,20171424,AUC(0-last),The mean (SD) AUC(0-last) was 129.7 (62.8) ng . h/mL after dosing with S-amlodipine and 129.0 (59.6) ng . h/mL after dosing with amlodipine racemate.,"Pharmacodynamic (hemodynamic) and pharmacokinetic comparisons of S-amlodipine gentisate and racemate amlodipine besylate in healthy Korean male volunteers: two double-blind, randomized, two-period, two-treatment, two-sequence, double-dummy, single-dose crossover studies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171424/),[h·ng] / [ml],129.0,65498,DB01373,Calcium
<,21667092,Ca/Cr clearance ratio,"In the group of patients with Ca/Cr clearance ratio <0.01, seven patients had hypercalcemia, and four patients had hypercalcemia and elevated iPTH.",Impaired regulation of calcium excretion in kidney transplant recipients. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21667092/),,0.01,66451,DB01373,Calcium
,32212275,half-life,"Free PTH demonstrated an effective half-life of approximately 60 hours and a dose-dependent, sustained exposure with an infusion-like profile within the calculated physiologic range for active PTH at steady-state.",A Randomized Double-Blind Placebo-Controlled First-In-Human Phase 1 Trial of TransCon PTH in Healthy Adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32212275/),h,60,66621,DB01373,Calcium
,18236139,K (i),"Silymarin inhibited both OATP1B1- and BCRP-mediated rosuvastatin transport in vitro (K (i) 0.93 microM and 97 microM, respectively).",Effect of silymarin supplement on the pharmacokinetics of rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18236139/),μM,0.93,67534,DB01373,Calcium
,18236139,K (i),"Silymarin inhibited both OATP1B1- and BCRP-mediated rosuvastatin transport in vitro (K (i) 0.93 microM and 97 microM, respectively).",Effect of silymarin supplement on the pharmacokinetics of rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18236139/),μM,97,67535,DB01373,Calcium
,24885631,half-life,"25(OH)D2 half-life [mean (SD)] [13.9 (2.6) d] was shorter than 25(OH)D3 half-life [15.1 (3.1) d; P = .001] for countries combined, and in Gambians [12.8 (2.3) d vs 14.7 (3.5) d; P < .001], but not in the United Kingdom [15.1 (2.4) d vs 15.6 (2.5) d; P = .3].",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,13.9,68088,DB01373,Calcium
,24885631,half-life,"25(OH)D2 half-life [mean (SD)] [13.9 (2.6) d] was shorter than 25(OH)D3 half-life [15.1 (3.1) d; P = .001] for countries combined, and in Gambians [12.8 (2.3) d vs 14.7 (3.5) d; P < .001], but not in the United Kingdom [15.1 (2.4) d vs 15.6 (2.5) d; P = .3].",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,15.1,68089,DB01373,Calcium
,24885631,half-life,"25(OH)D2 half-life [mean (SD)] [13.9 (2.6) d] was shorter than 25(OH)D3 half-life [15.1 (3.1) d; P = .001] for countries combined, and in Gambians [12.8 (2.3) d vs 14.7 (3.5) d; P < .001], but not in the United Kingdom [15.1 (2.4) d vs 15.6 (2.5) d; P = .3].",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,12.8,68090,DB01373,Calcium
,24885631,half-life,"25(OH)D2 half-life [mean (SD)] [13.9 (2.6) d] was shorter than 25(OH)D3 half-life [15.1 (3.1) d; P = .001] for countries combined, and in Gambians [12.8 (2.3) d vs 14.7 (3.5) d; P < .001], but not in the United Kingdom [15.1 (2.4) d vs 15.6 (2.5) d; P = .3].",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,14.7,68091,DB01373,Calcium
,24885631,half-life,"25(OH)D2 half-life [mean (SD)] [13.9 (2.6) d] was shorter than 25(OH)D3 half-life [15.1 (3.1) d; P = .001] for countries combined, and in Gambians [12.8 (2.3) d vs 14.7 (3.5) d; P < .001], but not in the United Kingdom [15.1 (2.4) d vs 15.6 (2.5) d; P = .3].",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,15.1,68092,DB01373,Calcium
,24885631,half-life,"25(OH)D2 half-life [mean (SD)] [13.9 (2.6) d] was shorter than 25(OH)D3 half-life [15.1 (3.1) d; P = .001] for countries combined, and in Gambians [12.8 (2.3) d vs 14.7 (3.5) d; P < .001], but not in the United Kingdom [15.1 (2.4) d vs 15.6 (2.5) d; P = .3].",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,15.6,68093,DB01373,Calcium
,24885631,half-life,"Half-lives were positively associated with plasma DBP concentration for countries combined [25(OH)D2 half-life: regression coefficient (SE) 0.03 (0.01) d per 1 mg/L DBP, P = .03; 25(OH)D3 half-life: 0.04 (0.02) d, P = .02] and in Gambians [25(OH)D2 half-life: 0.04 (0.01) d; P = .02; 25(OH)D3 half-life: 0.06 (0.02) d, P = .01] but not in UK participants.",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,0.03,68094,DB01373,Calcium
,24885631,half-life,"Half-lives were positively associated with plasma DBP concentration for countries combined [25(OH)D2 half-life: regression coefficient (SE) 0.03 (0.01) d per 1 mg/L DBP, P = .03; 25(OH)D3 half-life: 0.04 (0.02) d, P = .02] and in Gambians [25(OH)D2 half-life: 0.04 (0.01) d; P = .02; 25(OH)D3 half-life: 0.06 (0.02) d, P = .01] but not in UK participants.",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,0.04,68095,DB01373,Calcium
,24885631,half-life,"Half-lives were positively associated with plasma DBP concentration for countries combined [25(OH)D2 half-life: regression coefficient (SE) 0.03 (0.01) d per 1 mg/L DBP, P = .03; 25(OH)D3 half-life: 0.04 (0.02) d, P = .02] and in Gambians [25(OH)D2 half-life: 0.04 (0.01) d; P = .02; 25(OH)D3 half-life: 0.06 (0.02) d, P = .01] but not in UK participants.",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,0.04,68096,DB01373,Calcium
,24885631,half-life,"Half-lives were positively associated with plasma DBP concentration for countries combined [25(OH)D2 half-life: regression coefficient (SE) 0.03 (0.01) d per 1 mg/L DBP, P = .03; 25(OH)D3 half-life: 0.04 (0.02) d, P = .02] and in Gambians [25(OH)D2 half-life: 0.04 (0.01) d; P = .02; 25(OH)D3 half-life: 0.06 (0.02) d, P = .01] but not in UK participants.",25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24885631/),d,0.06,68097,DB01373,Calcium
,29452493,zeta potential,The prepared AC-NS showed particles size ranged from 408.7 ± 12.9 to 423 ± 15.9 nm while zeta potential values varied from -21.7 ± 0.90 to -22.7 ± 0.85 mV.,In vitro and in vivo evaluation of cyclodextrin-based nanosponges for enhancing oral bioavailability of atorvastatin calcium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29452493/),mv,-,68303,DB01373,Calcium
,29452493,zeta potential,The prepared AC-NS showed particles size ranged from 408.7 ± 12.9 to 423 ± 15.9 nm while zeta potential values varied from -21.7 ± 0.90 to -22.7 ± 0.85 mV.,In vitro and in vivo evaluation of cyclodextrin-based nanosponges for enhancing oral bioavailability of atorvastatin calcium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29452493/),mv,21.7,68304,DB01373,Calcium
,29452493,zeta potential,The prepared AC-NS showed particles size ranged from 408.7 ± 12.9 to 423 ± 15.9 nm while zeta potential values varied from -21.7 ± 0.90 to -22.7 ± 0.85 mV.,In vitro and in vivo evaluation of cyclodextrin-based nanosponges for enhancing oral bioavailability of atorvastatin calcium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29452493/),mv,22.7,68305,DB01373,Calcium
,29452493,loading capacity,The loading capacity varied from 17.9 ± 1.21 to 34.1 ± 1.16%.,In vitro and in vivo evaluation of cyclodextrin-based nanosponges for enhancing oral bioavailability of atorvastatin calcium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29452493/),%,17.9,68306,DB01373,Calcium
,29452493,loading capacity,The loading capacity varied from 17.9 ± 1.21 to 34.1 ± 1.16%.,In vitro and in vivo evaluation of cyclodextrin-based nanosponges for enhancing oral bioavailability of atorvastatin calcium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29452493/),%,34.1,68307,DB01373,Calcium
,24471938,lag time,The lag time varied between 3 h and 7 h depending on the amount of calcium chloride and the coating weight.,An in situ crosslinked compression coat comprised of pectin and calcium chloride for colon-specific delivery of indomethacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24471938/),h,3,68935,DB01373,Calcium
,24471938,lag time,The lag time varied between 3 h and 7 h depending on the amount of calcium chloride and the coating weight.,An in situ crosslinked compression coat comprised of pectin and calcium chloride for colon-specific delivery of indomethacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24471938/),h,7,68936,DB01373,Calcium
,12355579,Cl(r),"The mean Cl(r) values were, respectively, 4.60+/-0.42, 4.28+/-0.52 and 4.08+/-0.67 ml/min, practically equivalent to the Cl(t) values (4.78+/-0.38, 4.51+/-0.36 and 4.21+/-0.56 ml/min), confirming that the drug is mainly eliminated via renal excretion.",Disposition of acamprosate in the rat: influence of probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12355579/),[ml] / [min],4.60,69848,DB01373,Calcium
,12355579,Cl(r),"The mean Cl(r) values were, respectively, 4.60+/-0.42, 4.28+/-0.52 and 4.08+/-0.67 ml/min, practically equivalent to the Cl(t) values (4.78+/-0.38, 4.51+/-0.36 and 4.21+/-0.56 ml/min), confirming that the drug is mainly eliminated via renal excretion.",Disposition of acamprosate in the rat: influence of probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12355579/),[ml] / [min],4.28,69849,DB01373,Calcium
,12355579,Cl(r),"The mean Cl(r) values were, respectively, 4.60+/-0.42, 4.28+/-0.52 and 4.08+/-0.67 ml/min, practically equivalent to the Cl(t) values (4.78+/-0.38, 4.51+/-0.36 and 4.21+/-0.56 ml/min), confirming that the drug is mainly eliminated via renal excretion.",Disposition of acamprosate in the rat: influence of probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12355579/),[ml] / [min],4.08,69850,DB01373,Calcium
,12355579,Cl(t),"The mean Cl(r) values were, respectively, 4.60+/-0.42, 4.28+/-0.52 and 4.08+/-0.67 ml/min, practically equivalent to the Cl(t) values (4.78+/-0.38, 4.51+/-0.36 and 4.21+/-0.56 ml/min), confirming that the drug is mainly eliminated via renal excretion.",Disposition of acamprosate in the rat: influence of probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12355579/),[ml] / [min],4.78,69851,DB01373,Calcium
,12355579,Cl(t),"The mean Cl(r) values were, respectively, 4.60+/-0.42, 4.28+/-0.52 and 4.08+/-0.67 ml/min, practically equivalent to the Cl(t) values (4.78+/-0.38, 4.51+/-0.36 and 4.21+/-0.56 ml/min), confirming that the drug is mainly eliminated via renal excretion.",Disposition of acamprosate in the rat: influence of probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12355579/),[ml] / [min],4.51,69852,DB01373,Calcium
,12355579,Cl(t),"The mean Cl(r) values were, respectively, 4.60+/-0.42, 4.28+/-0.52 and 4.08+/-0.67 ml/min, practically equivalent to the Cl(t) values (4.78+/-0.38, 4.51+/-0.36 and 4.21+/-0.56 ml/min), confirming that the drug is mainly eliminated via renal excretion.",Disposition of acamprosate in the rat: influence of probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12355579/),[ml] / [min],4.21,69853,DB01373,Calcium
,12355579,total clearance,Probenecid provoked a statistically significant dose-dependent reduction in the total clearance of acamprosate (from 5.8+/-0.7 ml/min in the control group to 2.6+/-0.1 ml/min in the animals treated with 66 mg/kg of probenecid) demonstrating the existence of a tubular secretion process on the renal excretion of acamprosate in the rat.,Disposition of acamprosate in the rat: influence of probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12355579/),[ml] / [min],5.8,69854,DB01373,Calcium
,12355579,total clearance,Probenecid provoked a statistically significant dose-dependent reduction in the total clearance of acamprosate (from 5.8+/-0.7 ml/min in the control group to 2.6+/-0.1 ml/min in the animals treated with 66 mg/kg of probenecid) demonstrating the existence of a tubular secretion process on the renal excretion of acamprosate in the rat.,Disposition of acamprosate in the rat: influence of probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12355579/),[ml] / [min],2.6,69855,DB01373,Calcium
,16400620,pKa,"More unionized fractions of amlodipine could exist in less acidic conditions of gastrointestinal fluids, since amlodipine is a weak basic drug with pKa of 8.7.",Pharmacokinetics of oral amlodipine orotate in vagotomized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16400620/),,8.7,71959,DB01373,Calcium
,16400620,"total area under the plasma concentration-time curve from time zero to the last measured time, 48 h","For example, in vagotomized dogs, the total area under the plasma concentration-time curve from time zero to the last measured time, 48 h, in plasma (AUC(0-48 h)) was significantly greater (725 versus 348 ng h/ml) and Tmax was significantly shorter (1.50 versus 5.00 h) than those in dogs without vagotomy.",Pharmacokinetics of oral amlodipine orotate in vagotomized dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16400620/),[h·ng] / [ml],725,71960,DB01373,Calcium
,16400620,"total area under the plasma concentration-time curve from time zero to the last measured time, 48 h","For example, in vagotomized dogs, the total area under the plasma concentration-time curve from time zero to the last measured time, 48 h, in plasma (AUC(0-48 h)) was significantly greater (725 versus 348 ng h/ml) and Tmax was significantly shorter (1.50 versus 5.00 h) than those in dogs without vagotomy.",Pharmacokinetics of oral amlodipine orotate in vagotomized dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16400620/),[h·ng] / [ml],348,71961,DB01373,Calcium
,16400620,Tmax,"For example, in vagotomized dogs, the total area under the plasma concentration-time curve from time zero to the last measured time, 48 h, in plasma (AUC(0-48 h)) was significantly greater (725 versus 348 ng h/ml) and Tmax was significantly shorter (1.50 versus 5.00 h) than those in dogs without vagotomy.",Pharmacokinetics of oral amlodipine orotate in vagotomized dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16400620/),h,1.50,71962,DB01373,Calcium
,16400620,Tmax,"For example, in vagotomized dogs, the total area under the plasma concentration-time curve from time zero to the last measured time, 48 h, in plasma (AUC(0-48 h)) was significantly greater (725 versus 348 ng h/ml) and Tmax was significantly shorter (1.50 versus 5.00 h) than those in dogs without vagotomy.",Pharmacokinetics of oral amlodipine orotate in vagotomized dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16400620/),h,5.00,71963,DB01373,Calcium
,15652200,C(max),"After small intestinal administration of LPZ, 5.0 mg/kg, solution with HCO-60 showed the highest plasma LPZ concentration versus time curve of which C(max) and AUC was 0.46+/-0.01 microg/mL and 0.73+/-0.03 microgh/mL.",Effect of adsorbents on the absorption of lansoprazole with surfactant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15652200/),[μg] / [ml],0.46,72253,DB01373,Calcium
,15652200,AUC,"After small intestinal administration of LPZ, 5.0 mg/kg, solution with HCO-60 showed the highest plasma LPZ concentration versus time curve of which C(max) and AUC was 0.46+/-0.01 microg/mL and 0.73+/-0.03 microgh/mL.",Effect of adsorbents on the absorption of lansoprazole with surfactant. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15652200/),[μgh] / [ml],0.73,72254,DB01373,Calcium
,15652200,BA,"By comparing to that after i.v. injection of LPZ solution, 2.0 mg/kg, the BA of LPZ from HCO-60 solution was 39.0%, which was about seven times higher than that of LPZ powder.",Effect of adsorbents on the absorption of lansoprazole with surfactant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15652200/),%,39.0,72255,DB01373,Calcium
,15652200,T50%,"Sylysia 320, Neusilin S2 and Neusilin NS2 showed the T50% of about 1h.",Effect of adsorbents on the absorption of lansoprazole with surfactant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15652200/),h,1,72256,DB01373,Calcium
,15652200,AUC,The AUC of Sylysia 550 system was 2.16+/-0.26 microgh/mL and was greater than enteric tablet and the BA of 71.7% was obtained.,Effect of adsorbents on the absorption of lansoprazole with surfactant. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15652200/),[μgh] / [ml],2.16,72257,DB01373,Calcium
,16177199,Fractional Ca absorption,"Fractional Ca absorption in CCSM (0.211 +/- 0.057) did not differ from that of cow's milk (0.217 +/- 0.040), but both were higher (P < 0.05) than that of TCPSM (0.181 +/- 0.039).",Calcium bioavailability of calcium carbonate fortified soymilk is equivalent to cow's milk in young women. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16177199/),,0.211,72399,DB01373,Calcium
,16177199,Fractional Ca absorption,"Fractional Ca absorption in CCSM (0.211 +/- 0.057) did not differ from that of cow's milk (0.217 +/- 0.040), but both were higher (P < 0.05) than that of TCPSM (0.181 +/- 0.039).",Calcium bioavailability of calcium carbonate fortified soymilk is equivalent to cow's milk in young women. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16177199/),,0.217,72400,DB01373,Calcium
,16177199,Fractional Ca absorption,"Fractional Ca absorption in CCSM (0.211 +/- 0.057) did not differ from that of cow's milk (0.217 +/- 0.040), but both were higher (P < 0.05) than that of TCPSM (0.181 +/- 0.039).",Calcium bioavailability of calcium carbonate fortified soymilk is equivalent to cow's milk in young women. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16177199/),,0.181,72401,DB01373,Calcium
,14593085,EC(50),Cinacalcet HCl (EC(50) = 51 nM) in the presence of 0.5 mM extracellular Ca(2+) elicited increases in [Ca(2+)](i) in a dose- and calcium-dependent manner.,Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14593085/),nM,51,72697,DB01373,Calcium
,14593085,IC(50),"Similarly, in the presence of 0.5 mM extracellular Ca(2+), cinacalcet HCl (IC(50) = 28 nM) produced a concentration-dependent decrease in PTH secretion from cultured bovine parathyroid cells.",Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14593085/),nM,28,72698,DB01373,Calcium
,14593085,EC(50),"Using rat medullary thyroid carcinoma 6-23 cells expressing the CaR, cinacalcet HCl (EC(50) = 34 nM) produced a concentration-dependent increase in calcitonin secretion.",Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14593085/),nM,34,72699,DB01373,Calcium
,31060428,Cmax,"The results indicated that Cmax (16.25 ± 2.65 vs. 22.79 ± 2.35 ng/ml), AUC(0-t) (222.87 ± 59.95 vs. 468.32 ± 69.87 n gh/ml), and t1/2 (10.60 ± 1.05 vs. 14.15 ± 1.59 h) decreased significantly when DST and ALDP were co-administered, which suggested that DST might influence the pharmacokinetic behaviour of ALDP when they are co-administered.",Effects of Danshen tablets on pharmacokinetics of amlodipine in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31060428/),[ng] / [ml],16.25,73205,DB01373,Calcium
,31060428,Cmax,"The results indicated that Cmax (16.25 ± 2.65 vs. 22.79 ± 2.35 ng/ml), AUC(0-t) (222.87 ± 59.95 vs. 468.32 ± 69.87 n gh/ml), and t1/2 (10.60 ± 1.05 vs. 14.15 ± 1.59 h) decreased significantly when DST and ALDP were co-administered, which suggested that DST might influence the pharmacokinetic behaviour of ALDP when they are co-administered.",Effects of Danshen tablets on pharmacokinetics of amlodipine in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31060428/),[ng] / [ml],22.79,73206,DB01373,Calcium
,31060428,AUC(0-t),"The results indicated that Cmax (16.25 ± 2.65 vs. 22.79 ± 2.35 ng/ml), AUC(0-t) (222.87 ± 59.95 vs. 468.32 ± 69.87 n gh/ml), and t1/2 (10.60 ± 1.05 vs. 14.15 ± 1.59 h) decreased significantly when DST and ALDP were co-administered, which suggested that DST might influence the pharmacokinetic behaviour of ALDP when they are co-administered.",Effects of Danshen tablets on pharmacokinetics of amlodipine in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31060428/),[gh·n] / [ml],222.87,73207,DB01373,Calcium
,31060428,AUC(0-t),"The results indicated that Cmax (16.25 ± 2.65 vs. 22.79 ± 2.35 ng/ml), AUC(0-t) (222.87 ± 59.95 vs. 468.32 ± 69.87 n gh/ml), and t1/2 (10.60 ± 1.05 vs. 14.15 ± 1.59 h) decreased significantly when DST and ALDP were co-administered, which suggested that DST might influence the pharmacokinetic behaviour of ALDP when they are co-administered.",Effects of Danshen tablets on pharmacokinetics of amlodipine in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31060428/),[gh·n] / [ml],468.32,73208,DB01373,Calcium
,31060428,t1/2,"The results indicated that Cmax (16.25 ± 2.65 vs. 22.79 ± 2.35 ng/ml), AUC(0-t) (222.87 ± 59.95 vs. 468.32 ± 69.87 n gh/ml), and t1/2 (10.60 ± 1.05 vs. 14.15 ± 1.59 h) decreased significantly when DST and ALDP were co-administered, which suggested that DST might influence the pharmacokinetic behaviour of ALDP when they are co-administered.",Effects of Danshen tablets on pharmacokinetics of amlodipine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31060428/),h,10.60,73209,DB01373,Calcium
,31060428,t1/2,"The results indicated that Cmax (16.25 ± 2.65 vs. 22.79 ± 2.35 ng/ml), AUC(0-t) (222.87 ± 59.95 vs. 468.32 ± 69.87 n gh/ml), and t1/2 (10.60 ± 1.05 vs. 14.15 ± 1.59 h) decreased significantly when DST and ALDP were co-administered, which suggested that DST might influence the pharmacokinetic behaviour of ALDP when they are co-administered.",Effects of Danshen tablets on pharmacokinetics of amlodipine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31060428/),h,14.15,73210,DB01373,Calcium
,31060428,metabolic stability,The metabolic stability of ALDP was also decreased (23.6 ± 4.7 vs. 38.9 ± 5.2) with the pretreatment of DST.,Effects of Danshen tablets on pharmacokinetics of amlodipine in rats. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31060428/),,23.6,73211,DB01373,Calcium
,31060428,metabolic stability,The metabolic stability of ALDP was also decreased (23.6 ± 4.7 vs. 38.9 ± 5.2) with the pretreatment of DST.,Effects of Danshen tablets on pharmacokinetics of amlodipine in rats. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31060428/),,38.9,73212,DB01373,Calcium
,27564321,T100%,Hydrophobic carriers as microcrystalline cellulose 102 (MCC) showed superior physical characters and higher dissolution rate over hydrophilic carriers as maltodextrin with respective T100% 30 min and 45 min.,Solid super saturated self-nanoemulsifying drug delivery system (sat-SNEDDS) as a promising alternative to conventional SNEDDS for improvement rosuvastatin calcium oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27564321/),min,30,73371,DB01373,Calcium
,27564321,T100%,Hydrophobic carriers as microcrystalline cellulose 102 (MCC) showed superior physical characters and higher dissolution rate over hydrophilic carriers as maltodextrin with respective T100% 30 min and 45 min.,Solid super saturated self-nanoemulsifying drug delivery system (sat-SNEDDS) as a promising alternative to conventional SNEDDS for improvement rosuvastatin calcium oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27564321/),min,45,73372,DB01373,Calcium
,27317801,plasma concentrations,"Average plasma concentrations of CP-I and CP-III prior to drug administration were 0.91 ± 0.21 and 0.15 ± 0.04 nM, respectively, with minimum fluctuation over the three periods.",Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27317801/),nM,0.91,73998,DB01373,Calcium
,27317801,plasma concentrations,"Average plasma concentrations of CP-I and CP-III prior to drug administration were 0.91 ± 0.21 and 0.15 ± 0.04 nM, respectively, with minimum fluctuation over the three periods.",Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27317801/),nM,0.15,73999,DB01373,Calcium
,12018438,Liquid passage from,Liquid passage from the rumen was similar among the four analog treatments (0.136 +/- 0.012/h; mean +/- SEM).,Rumen degradation and availability of various amounts of liquid methionine hydroxy analog in lactating dairy cows. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12018438/),1/[h],0.136,74452,DB01373,Calcium
,12018438,Ruminal escape,"Ruminal escape of HMB as a percentage of the dose (100% x k(p)/k(rHMB)) did not differ between cows receiving 25, 50, and 51.2 g of the methionine analogs (42.5, 41.0, and 34.9 +/- 9.0%, respectively) and averaged 39.5%.",Rumen degradation and availability of various amounts of liquid methionine hydroxy analog in lactating dairy cows. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12018438/),%,42.5,74453,DB01373,Calcium
,12018438,Ruminal escape,"Ruminal escape of HMB as a percentage of the dose (100% x k(p)/k(rHMB)) did not differ between cows receiving 25, 50, and 51.2 g of the methionine analogs (42.5, 41.0, and 34.9 +/- 9.0%, respectively) and averaged 39.5%.",Rumen degradation and availability of various amounts of liquid methionine hydroxy analog in lactating dairy cows. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12018438/),%,41.0,74454,DB01373,Calcium
,12018438,Ruminal escape,"Ruminal escape of HMB as a percentage of the dose (100% x k(p)/k(rHMB)) did not differ between cows receiving 25, 50, and 51.2 g of the methionine analogs (42.5, 41.0, and 34.9 +/- 9.0%, respectively) and averaged 39.5%.",Rumen degradation and availability of various amounts of liquid methionine hydroxy analog in lactating dairy cows. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12018438/),%,34.9,74455,DB01373,Calcium
,12018438,Ruminal escape,"Ruminal escape of HMB as a percentage of the dose (100% x k(p)/k(rHMB)) did not differ between cows receiving 25, 50, and 51.2 g of the methionine analogs (42.5, 41.0, and 34.9 +/- 9.0%, respectively) and averaged 39.5%.",Rumen degradation and availability of various amounts of liquid methionine hydroxy analog in lactating dairy cows. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12018438/),%,39.5,74456,DB01373,Calcium
,12018438,Omasal absorption,Omasal absorption of HMB was variable ranging from 12.3 to 26.3% and averaged 17.6%.,Rumen degradation and availability of various amounts of liquid methionine hydroxy analog in lactating dairy cows. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12018438/),%,12.3 to 26.3,74457,DB01373,Calcium
,12018438,Omasal absorption,Omasal absorption of HMB was variable ranging from 12.3 to 26.3% and averaged 17.6%.,Rumen degradation and availability of various amounts of liquid methionine hydroxy analog in lactating dairy cows. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12018438/),%,17.6,74458,DB01373,Calcium
,33486718,apparent clearance,"A two-compartment model with first-order absorption adequately described roxadustat pharmacokinetics, with parameter estimates (relative standard error) for apparent clearance of 1.1 (0.0223) L/h in NDD subjects, and apparent central and peripheral volumes of distribution of 14.9 (0.0278) L and 9.5 (0.0872) L, respectively.",Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis- and Non-Dialysis-Dependent Patients with Chronic Kidney Disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33486718/),[l] / [h],1.1,74526,DB01373,Calcium
,33486718,apparent central,"A two-compartment model with first-order absorption adequately described roxadustat pharmacokinetics, with parameter estimates (relative standard error) for apparent clearance of 1.1 (0.0223) L/h in NDD subjects, and apparent central and peripheral volumes of distribution of 14.9 (0.0278) L and 9.5 (0.0872) L, respectively.",Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis- and Non-Dialysis-Dependent Patients with Chronic Kidney Disease. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33486718/),l,14.9,74527,DB01373,Calcium
,33486718,peripheral volumes of distribution,"A two-compartment model with first-order absorption adequately described roxadustat pharmacokinetics, with parameter estimates (relative standard error) for apparent clearance of 1.1 (0.0223) L/h in NDD subjects, and apparent central and peripheral volumes of distribution of 14.9 (0.0278) L and 9.5 (0.0872) L, respectively.",Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis- and Non-Dialysis-Dependent Patients with Chronic Kidney Disease. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33486718/),l,9.5,74528,DB01373,Calcium
,29606543,recovery,"Mean recovery of [14C] radioactivity in urine and feces was 30.08% and 49.31%, respectively, and mean total recovery of [14C] radioactivity was 79.39%.","A phase I, open-label, single-dose micro tracer mass balance study of 14C-labeled ASP7991 in healthy Japanese male subjects using accelerator mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29606543/),%,30.08,74860,DB01373,Calcium
,29606543,recovery,"Mean recovery of [14C] radioactivity in urine and feces was 30.08% and 49.31%, respectively, and mean total recovery of [14C] radioactivity was 79.39%.","A phase I, open-label, single-dose micro tracer mass balance study of 14C-labeled ASP7991 in healthy Japanese male subjects using accelerator mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29606543/),%,49.31,74861,DB01373,Calcium
,29606543,total recovery of,"Mean recovery of [14C] radioactivity in urine and feces was 30.08% and 49.31%, respectively, and mean total recovery of [14C] radioactivity was 79.39%.","A phase I, open-label, single-dose micro tracer mass balance study of 14C-labeled ASP7991 in healthy Japanese male subjects using accelerator mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29606543/),%,79.39,74862,DB01373,Calcium
,29643253,uptake Km,"In vitro studies using plated cynomolgus monkey hepatocytes showed active uptake Km values of 2.0 and 3.9 µM for OATP1B probe substrates, pitavastatin and rosuvastatin, respectively.",In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29643253/),μM,2.0,74942,DB01373,Calcium
,29643253,uptake Km,"In vitro studies using plated cynomolgus monkey hepatocytes showed active uptake Km values of 2.0 and 3.9 µM for OATP1B probe substrates, pitavastatin and rosuvastatin, respectively.",In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29643253/),μM,3.9,74943,DB01373,Calcium
,29643253,IC50,"Rifampicin inhibited pitavastatin and rosuvastatin active uptake in monkey hepatocytes with IC50 values of 3.0 and 0.54 µM, respectively, following preincubation with the inhibitor.",In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29643253/),μM,3.0,74944,DB01373,Calcium
,29643253,IC50,"Rifampicin inhibited pitavastatin and rosuvastatin active uptake in monkey hepatocytes with IC50 values of 3.0 and 0.54 µM, respectively, following preincubation with the inhibitor.",In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29643253/),μM,0.54,74945,DB01373,Calcium
,29643253,IC50,Use of in vitro IC50 obtained following 1 hour preincubation with rifampicin (0.54 µM) predicted correctly the change in mean i.v. clearance and oral exposure of statins as a function of mean unbound maximum plasma concentration of rifampicin.,In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29643253/),μM,0.54,74946,DB01373,Calcium
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,47.0,75129,DB01373,Calcium
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,5.2,75130,DB01373,Calcium
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,15.0,75131,DB01373,Calcium
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,3.3,75132,DB01373,Calcium
,11752131,K(i),SB 235375 inhibited (125)I-[MePhe(7)]-neurokinin B (NKB) binding to membranes of Chinese hamster ovary (CHO) cells expressing the hNK-3R (CHO-hNK-3R) with a K(i) = 2.2 nM and antagonized competitively NKB-induced Ca(2+) mobilization in human embryonic kidney (HEK) 293 cells expressing the hNK-3R (HEK 293-hNK-3R) with a K(b) = 12 nM.,"Nonpeptide tachykinin receptor antagonists. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigs. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752131/),nM,2.2,76376,DB01373,Calcium
,11752131,K(b),SB 235375 inhibited (125)I-[MePhe(7)]-neurokinin B (NKB) binding to membranes of Chinese hamster ovary (CHO) cells expressing the hNK-3R (CHO-hNK-3R) with a K(i) = 2.2 nM and antagonized competitively NKB-induced Ca(2+) mobilization in human embryonic kidney (HEK) 293 cells expressing the hNK-3R (HEK 293-hNK-3R) with a K(b) = 12 nM.,"Nonpeptide tachykinin receptor antagonists. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigs. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752131/),nM,12,76377,DB01373,Calcium
>,11752131,K(i),"SB 235375 was selective for the hNK-3R compared with hNK-1 (K(i) > 100,000 nM) and hNK-2 receptors (K(i) = 209 nM), and was without effect, at 1 microM, in 68 other receptor, enzyme, and ion channel assays.","Nonpeptide tachykinin receptor antagonists. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigs. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752131/),nM,"100,000",76378,DB01373,Calcium
,11752131,K(i),"SB 235375 was selective for the hNK-3R compared with hNK-1 (K(i) > 100,000 nM) and hNK-2 receptors (K(i) = 209 nM), and was without effect, at 1 microM, in 68 other receptor, enzyme, and ion channel assays.","Nonpeptide tachykinin receptor antagonists. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigs. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752131/),nM,209,76379,DB01373,Calcium
,11752131,ED(50),Intravenous SB 235375 produced a dose-related inhibition of miosis induced by i.v. senktide in the rabbit (ED(50) of 0.56 mg/kg).,"Nonpeptide tachykinin receptor antagonists. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752131/),[mg] / [kg],0.56,76380,DB01373,Calcium
,18443034,area under the curve (AUC)(0-72),Intake of UDCA led to a significant increase in rosuvastatin area under the curve (AUC)(0-72) from 128.5 ng/ml.h to 182.1 ng/ml.h(P = 0.008) compared with the control group.,Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18443034/),[ng] / [h·ml],128.5,76593,DB01373,Calcium
,18443034,area under the curve (AUC)(0-72),Intake of UDCA led to a significant increase in rosuvastatin area under the curve (AUC)(0-72) from 128.5 ng/ml.h to 182.1 ng/ml.h(P = 0.008) compared with the control group.,Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18443034/),[ng] / [h·ml],182.1,76594,DB01373,Calcium
,18443034,oral clearance,The oral clearance decreased from 155.2 l/h with placebo to 109.8 l/h with UDCA.,Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18443034/),[l] / [h],155.2,76595,DB01373,Calcium
,18443034,oral clearance,The oral clearance decreased from 155.2 l/h with placebo to 109.8 l/h with UDCA.,Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18443034/),[l] / [h],109.8,76596,DB01373,Calcium
,33811848,drug release,"The drug release was found to be 25.8 ± 2.5 and 89.96 ± 2.8 % in five mins, respectively from MTPS and RC-NP formulations.",Attenuation of lipid levels in triton induced hyperlipidemia rats through rosuvastatin calcium nanoparticles: Pharmacokinetic and pharmacodynamic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33811848/),%,25.8,77200,DB01373,Calcium
,33811848,drug release,"The drug release was found to be 25.8 ± 2.5 and 89.96 ± 2.8 % in five mins, respectively from MTPS and RC-NP formulations.",Attenuation of lipid levels in triton induced hyperlipidemia rats through rosuvastatin calcium nanoparticles: Pharmacokinetic and pharmacodynamic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33811848/),%,89.96,77201,DB01373,Calcium
,33811848,Peff,"The Peff of MTPS and NP of RC was 1.8 ± 0.2 × 10-5 and 2.7 ± 0.3 × 10-5 cm/s, respectively.",Attenuation of lipid levels in triton induced hyperlipidemia rats through rosuvastatin calcium nanoparticles: Pharmacokinetic and pharmacodynamic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33811848/),[cm] / [s],1.8,77202,DB01373,Calcium
,33811848,Peff,"The Peff of MTPS and NP of RC was 1.8 ± 0.2 × 10-5 and 2.7 ± 0.3 × 10-5 cm/s, respectively.",Attenuation of lipid levels in triton induced hyperlipidemia rats through rosuvastatin calcium nanoparticles: Pharmacokinetic and pharmacodynamic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33811848/),[cm] / [s],2.7,77203,DB01373,Calcium
,12161113,IC(50),L-Cysteine derivative 9 was found to be a potent and selective N-type calcium channel blocker with IC(50) of 0.33 microM in calcium influx assay using IMR-32 cells and was 15-fold selective for N-type calcium channels over L-type channels.,"L-Cysteine based N-type calcium channel blockers: structure-activity relationships of the C-terminal lipophilic moiety, and oral analgesic efficacy in rat pain models. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12161113/),μM,0.33,77266,DB01373,Calcium
,31299174,half-maximal inhibitory concentration,"We previously identified the acylaminocycloalkylthiophene class of TMEM16A inhibitors, which, following medicinal chemistry, gave analog 2-bromodifluoroacetylamino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid o-tolylamide (TMinh-23) with 30 nM half-maximal inhibitory concentration.",Slowed gastric emptying and improved oral glucose tolerance produced by a nanomolar-potency inhibitor of calcium-activated chloride channel TMEM16A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31299174/),nM,30,77503,DB01373,Calcium
,29782035,recovery,The recovery for both the analytes and their deuterated internal standards (ISs) ranged from 95.7 to 99.8%.,Simultaneous quantitation of rosuvastatin and ezetimibe in human plasma by LC-MS/MS: Pharmacokinetic study of fixed-dose formulation and separate tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29782035/),%,95.7 to 99.8,77859,DB01373,Calcium
,29782035,resolution factor,The analytes were well resolved with a resolution factor of 3.8.,Simultaneous quantitation of rosuvastatin and ezetimibe in human plasma by LC-MS/MS: Pharmacokinetic study of fixed-dose formulation and separate tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29782035/),,3.8,77860,DB01373,Calcium
,12392584,bioavailability,"The bioavailability (90% confidence intervals) of Ro 64-0802 following administration of oseltamivir together with Maalox suspension vs administration of oseltamivir alone, was 90% (83.6, 96.9%) for C(max) and 94.1% (91.4, 96.9%) for AUC(0, infinity); similarly, for Titralac tablets, the equivalent values were 95.1% (88.3, 102%) for C(max) and 94.7% (91.9, 97.5%) for AUC(0, infinity).",Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392584/),%,90,78477,DB01373,Calcium
,12392584,bioavailability,"The bioavailability (90% confidence intervals) of Ro 64-0802 following administration of oseltamivir together with Maalox suspension vs administration of oseltamivir alone, was 90% (83.6, 96.9%) for C(max) and 94.1% (91.4, 96.9%) for AUC(0, infinity); similarly, for Titralac tablets, the equivalent values were 95.1% (88.3, 102%) for C(max) and 94.7% (91.9, 97.5%) for AUC(0, infinity).",Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392584/),%,94.1,78478,DB01373,Calcium
,12392584,bioavailability,"The bioavailability (90% confidence intervals) of Ro 64-0802 following administration of oseltamivir together with Maalox suspension vs administration of oseltamivir alone, was 90% (83.6, 96.9%) for C(max) and 94.1% (91.4, 96.9%) for AUC(0, infinity); similarly, for Titralac tablets, the equivalent values were 95.1% (88.3, 102%) for C(max) and 94.7% (91.9, 97.5%) for AUC(0, infinity).",Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392584/),%,95.1,78479,DB01373,Calcium
,12392584,bioavailability,"The bioavailability (90% confidence intervals) of Ro 64-0802 following administration of oseltamivir together with Maalox suspension vs administration of oseltamivir alone, was 90% (83.6, 96.9%) for C(max) and 94.1% (91.4, 96.9%) for AUC(0, infinity); similarly, for Titralac tablets, the equivalent values were 95.1% (88.3, 102%) for C(max) and 94.7% (91.9, 97.5%) for AUC(0, infinity).",Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392584/),%,94.7,78480,DB01373,Calcium
,17495416,maximum concentration,The maximum concentration of nifedipine in plasma after administration into the intestinal loop (0.8 mg/kg) was significantly higher in L. casei-treated rats (3.26 microg/mL) than in those untreated rats (2.33 microg/mL) by 40%.,Effect of Lactobacillus casei on the absorption of nifedipine from rat small intestine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17495416/),[μg] / [ml],3.26,78787,DB01373,Calcium
,17495416,maximum concentration,The maximum concentration of nifedipine in plasma after administration into the intestinal loop (0.8 mg/kg) was significantly higher in L. casei-treated rats (3.26 microg/mL) than in those untreated rats (2.33 microg/mL) by 40%.,Effect of Lactobacillus casei on the absorption of nifedipine from rat small intestine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17495416/),[μg] / [ml],2.33,78788,DB01373,Calcium
,21950148,"t(max,ss","The mean +/- SD t(max,ss,) CG(max,ss) and AUG(tau) of dose normalized to 10 mg felodipine was 3.32 +/- 1.33 h, 13.12 +/- 5.34 nmol/L and 136.33 +/- 63.18 nmol x h/L, respectively.",Pharmacokinetics of felodipine extended-release tablets in healthy Taiwanese subjects: a retrospective review. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950148/),h,3.32,78861,DB01373,Calcium
,21950148,"CG(max,ss)","The mean +/- SD t(max,ss,) CG(max,ss) and AUG(tau) of dose normalized to 10 mg felodipine was 3.32 +/- 1.33 h, 13.12 +/- 5.34 nmol/L and 136.33 +/- 63.18 nmol x h/L, respectively.",Pharmacokinetics of felodipine extended-release tablets in healthy Taiwanese subjects: a retrospective review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950148/),[nM] / [l],13.12,78862,DB01373,Calcium
,21950148,AUG(tau),"The mean +/- SD t(max,ss,) CG(max,ss) and AUG(tau) of dose normalized to 10 mg felodipine was 3.32 +/- 1.33 h, 13.12 +/- 5.34 nmol/L and 136.33 +/- 63.18 nmol x h/L, respectively.",Pharmacokinetics of felodipine extended-release tablets in healthy Taiwanese subjects: a retrospective review. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950148/),[h·nM] / [l],136.33,78863,DB01373,Calcium
,25740267,IC(50),Pradigastat inhibited BCRP-mediated efflux activity in a dose-dependent fashion in a BCRP over-expressing human ovarian cancer cell line with an IC(50) value of 5 μM.,"Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740267/),μM,5,79057,DB01373,Calcium
,25740267,IC(50),"Similarly, pradigastat inhibited OATP1B1, OATP1B3 (estradiol 17β glucuronide transport), and OAT3 (estrone 3 sulfate transport) activity in a concentrationdependent manner with estimated IC(50) values of 1.66 ± 0.95 μM, 3.34 ± 0.64 μM, and 0.973 ± 0.11 μM, respectively.","Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740267/),μM,1.66,79058,DB01373,Calcium
,25740267,IC(50),"Similarly, pradigastat inhibited OATP1B1, OATP1B3 (estradiol 17β glucuronide transport), and OAT3 (estrone 3 sulfate transport) activity in a concentrationdependent manner with estimated IC(50) values of 1.66 ± 0.95 μM, 3.34 ± 0.64 μM, and 0.973 ± 0.11 μM, respectively.","Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740267/),μM,3.34,79059,DB01373,Calcium
,25740267,IC(50),"Similarly, pradigastat inhibited OATP1B1, OATP1B3 (estradiol 17β glucuronide transport), and OAT3 (estrone 3 sulfate transport) activity in a concentrationdependent manner with estimated IC(50) values of 1.66 ± 0.95 μM, 3.34 ± 0.64 μM, and 0.973 ± 0.11 μM, respectively.","Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740267/),μM,0.973,79060,DB01373,Calcium
,25740267,"AUC(τ, ss)","In the presence of steady state pradigastat concentrations, AUC(τ, ss) of rosuvastatin was unchanged and its Cmax,ss decreased by 14% (5.30 and 4.61 ng/mL when administered alone and coadministered with pradigastat, respectively).","Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740267/),[ng] / [ml],5.30,79061,DB01373,Calcium
,25740267,"AUC(τ, ss)","In the presence of steady state pradigastat concentrations, AUC(τ, ss) of rosuvastatin was unchanged and its Cmax,ss decreased by 14% (5.30 and 4.61 ng/mL when administered alone and coadministered with pradigastat, respectively).","Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740267/),[ng] / [ml],4.61,79062,DB01373,Calcium
,16397912,linear dynamic,"The assay exhibited a linear dynamic range of 50-10,000 pg/mL for amlodipine in human plasma.",Sensitive and rapid liquid chromatography/tandem mass spectrometry assay for the quantification of amlodipine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16397912/),[pg] / [ml],"50-10,000",79752,DB01373,Calcium
,16397912,absolute recoveries,"The average absolute recoveries of amlodipine and the IS from spiked plasma samples were 74.7 +/- 4.6 and 72.1 +/- 2.0%, respectively.",Sensitive and rapid liquid chromatography/tandem mass spectrometry assay for the quantification of amlodipine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16397912/),%,74.7,79753,DB01373,Calcium
,16397912,absolute recoveries,"The average absolute recoveries of amlodipine and the IS from spiked plasma samples were 74.7 +/- 4.6 and 72.1 +/- 2.0%, respectively.",Sensitive and rapid liquid chromatography/tandem mass spectrometry assay for the quantification of amlodipine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16397912/),%,72.1,79754,DB01373,Calcium
,16397912,run time,A run time of 1.5 min for each sample made it possible to analyze more than 400 human plasma samples per day.,Sensitive and rapid liquid chromatography/tandem mass spectrometry assay for the quantification of amlodipine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16397912/),min,1.5,79755,DB01373,Calcium
,16397912,observed maximum plasma concentration (Cmax),"The observed maximum plasma concentration (Cmax) of amlodipine (2.5 mg oral dose) was 1425 pg/mL, time to observed maximum plasma concentration (Tmax) was 8.1 h and elimination half-life (T(1/2)) was 50.1 h.",Sensitive and rapid liquid chromatography/tandem mass spectrometry assay for the quantification of amlodipine in human plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16397912/),[pg] / [ml],1425,79756,DB01373,Calcium
,16397912,time to observed maximum plasma concentration (Tmax),"The observed maximum plasma concentration (Cmax) of amlodipine (2.5 mg oral dose) was 1425 pg/mL, time to observed maximum plasma concentration (Tmax) was 8.1 h and elimination half-life (T(1/2)) was 50.1 h.",Sensitive and rapid liquid chromatography/tandem mass spectrometry assay for the quantification of amlodipine in human plasma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16397912/),h,8.1,79757,DB01373,Calcium
,16397912,elimination half-life (T(1/2)),"The observed maximum plasma concentration (Cmax) of amlodipine (2.5 mg oral dose) was 1425 pg/mL, time to observed maximum plasma concentration (Tmax) was 8.1 h and elimination half-life (T(1/2)) was 50.1 h.",Sensitive and rapid liquid chromatography/tandem mass spectrometry assay for the quantification of amlodipine in human plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16397912/),h,50.1,79758,DB01373,Calcium
,15907592,absolute bioavailability (AB%),"The absolute bioavailability (AB%) of diltiazem in the rabbits pretreated with quercetin was significantly (p<0.05 at 2 mg/kg, p<0.01 at 10 and 20 mg/kg) higher (9.10-12.81%) than the control (4.64%).",Enhanced diltiazem bioavailability after oral administration of diltiazem with quercetin to rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907592/),%,9.10-12.81,79839,DB01373,Calcium
,15907592,absolute bioavailability (AB%),"The absolute bioavailability (AB%) of diltiazem in the rabbits pretreated with quercetin was significantly (p<0.05 at 2 mg/kg, p<0.01 at 10 and 20 mg/kg) higher (9.10-12.81%) than the control (4.64%).",Enhanced diltiazem bioavailability after oral administration of diltiazem with quercetin to rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907592/),%,4.64,79840,DB01373,Calcium
below,14998422,Trough plasma perhexiline concentrations,Trough plasma perhexiline concentrations from two patients were below the limit of quantification of the assay (0.05 mg l-1) and thus were excluded from the analysis.,Concentration-time profile for perhexiline and hydroxyperhexiline in patients at steady state. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998422/),[mg] / [l],0.05,81545,DB01373,Calcium
,20590629,pIC(50),"The pIC(50) estimates for these receptors ranged from 7.3 to 8.5, while concentrations 300-fold higher had little or no effect on other P2X channels or on an assortment of receptors, enzymes and transporter proteins.","AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590629/),,7.3 to 8.5,81834,DB01373,Calcium
,20590629,oral bioavailability (%F,"Favourable pharmacokinetic parameters were observed in rat, with good oral bioavailability (%F = 32.9), reasonable half-life (t(1/2) = 1.63 h) and plasma-free fraction (98.2% protein bound).","AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590629/),,32.9,81835,DB01373,Calcium
,20590629,half-life (t(1/2),"Favourable pharmacokinetic parameters were observed in rat, with good oral bioavailability (%F = 32.9), reasonable half-life (t(1/2) = 1.63 h) and plasma-free fraction (98.2% protein bound).","AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590629/),h,1.63,81836,DB01373,Calcium
,15876422,half-life,Mono(diethylphosphoryl) obidoxime (DEP-obidoxime) was isolated for the first time showing remarkable stability under physiological conditions (half-life 13.5min; pH 7.1; 37 degrees C).,"Formation and disposition of diethylphosphoryl-obidoxime, a potent anticholinesterase that is hydrolyzed by human paraoxonase (PON1). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15876422/),min,13.5,81851,DB01373,Calcium
,15876422,half-life,"The half-life was considerably extended to 20h at 0 degrees C, which facilitated the preparation and allowed isolation by HPLC.","Formation and disposition of diethylphosphoryl-obidoxime, a potent anticholinesterase that is hydrolyzed by human paraoxonase (PON1). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15876422/),h,20,81852,DB01373,Calcium
,15876422,second-order rate constant,DEP-Obidoxime was an extremely potent inhibitor of human acetylcholinesterase approaching a second-order rate constant of 10(9)M(-1)min(-1) (pH 7.4; 37 degrees C).,"Formation and disposition of diethylphosphoryl-obidoxime, a potent anticholinesterase that is hydrolyzed by human paraoxonase (PON1). ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15876422/),1/[M],10(9),81853,DB01373,Calcium
>,19229957,m/z,VER and NOR enantiomers in rat plasma was analyzed by LC-MS/MS (m/z = 441.3 > 165.5 for the NOR and m/z 455.3 > 165.5 for the VER enantiomers) using a Chiralpak AD column.,Influence of N-hexane inhalation on the enantioselective pharmacokinetics and metabolism of verapamil in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19229957/),,441.3,82289,DB01373,Calcium
>,19229957,m/z,VER and NOR enantiomers in rat plasma was analyzed by LC-MS/MS (m/z = 441.3 > 165.5 for the NOR and m/z 455.3 > 165.5 for the VER enantiomers) using a Chiralpak AD column.,Influence of N-hexane inhalation on the enantioselective pharmacokinetics and metabolism of verapamil in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19229957/),,165.5,82290,DB01373,Calcium
>,19229957,m/z,VER and NOR enantiomers in rat plasma was analyzed by LC-MS/MS (m/z = 441.3 > 165.5 for the NOR and m/z 455.3 > 165.5 for the VER enantiomers) using a Chiralpak AD column.,Influence of N-hexane inhalation on the enantioselective pharmacokinetics and metabolism of verapamil in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19229957/),,455.3,82291,DB01373,Calcium
>,19229957,m/z,VER and NOR enantiomers in rat plasma was analyzed by LC-MS/MS (m/z = 441.3 > 165.5 for the NOR and m/z 455.3 > 165.5 for the VER enantiomers) using a Chiralpak AD column.,Influence of N-hexane inhalation on the enantioselective pharmacokinetics and metabolism of verapamil in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19229957/),,165.5,82292,DB01373,Calcium
,19229957,AUC(0-infinity),"The pharmacokinetics of VER was enantioselective in control rats, with higher plasma proportions of the (-)-(S)-VER eutomer (AUC(0-infinity) = 250.8 vs. 120.4 ng/ml/h; P < or = 0.05, Wilcoxon test).",Influence of N-hexane inhalation on the enantioselective pharmacokinetics and metabolism of verapamil in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19229957/),[ng] / [h·ml],250.8,82293,DB01373,Calcium
,19229957,AUC(0-infinity),"The pharmacokinetics of VER was enantioselective in control rats, with higher plasma proportions of the (-)-(S)-VER eutomer (AUC(0-infinity) = 250.8 vs. 120.4 ng/ml/h; P < or = 0.05, Wilcoxon test).",Influence of N-hexane inhalation on the enantioselective pharmacokinetics and metabolism of verapamil in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19229957/),[ng] / [h·ml],120.4,82294,DB01373,Calcium
,19229957,AUC(0-infinity) ratio,"The (S)-NOR metabolite was also found to accumulate in plasma of control animals, with an S/R AUC(0-infinity) ratio of 1.5.",Influence of N-hexane inhalation on the enantioselective pharmacokinetics and metabolism of verapamil in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19229957/),,1.5,82295,DB01373,Calcium
,18520949,time to reach Cmax,"Compared to baseline, the area under the plasma concentration-time curve (AUC 0-24h) and maximum plasma concentration (Cmax) of RSV increased by 213% and 600%, respectively, and the time to reach Cmax was shorter (1.75 h vs. 2.91 h) when given with ATV/RTV (P < 0.05).",Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520949/),h,1.75,82303,DB01373,Calcium
,18520949,time to reach Cmax,"Compared to baseline, the area under the plasma concentration-time curve (AUC 0-24h) and maximum plasma concentration (Cmax) of RSV increased by 213% and 600%, respectively, and the time to reach Cmax was shorter (1.75 h vs. 2.91 h) when given with ATV/RTV (P < 0.05).",Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520949/),h,2.91,82304,DB01373,Calcium
,12426519,peak concentration (C(max)),"The pharmacokinetic parameters of nimodipine after intravenous administration were as follows: peak concentration (C(max)), 319.6 +/- 38.9 ng/mL at the first sampling time; area under the curve (AUC), 239 +/- 25 ng.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),[ng] / [ml],319.6,82575,DB01373,Calcium
,12426519,area under the curve (AUC),"The pharmacokinetic parameters of nimodipine after intravenous administration were as follows: peak concentration (C(max)), 319.6 +/- 38.9 ng/mL at the first sampling time; area under the curve (AUC), 239 +/- 25 ng.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),ng,239,82576,DB01373,Calcium
,12426519,terminal half-life,"h/mL; and terminal half-life, 3.12 +/- 0.97 hours.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),h,3.12,82577,DB01373,Calcium
,12426519,C(max),"After oral administration, the drug kinetics was linear in the administered dose range and the pharmacokinetic parameters were as follows: C(max)(30 mg), 46.1 +/- 5.8 ng/mL; C(max)(60 mg), 81.7 +/- 14.6 ng/mL; C(max)(90 mg), 131.6 +/- 16.3 ng/mL; AUC(30 mg), 119 +/- 25 ng. h/mL; AUC(60 mg), 256 +/- 48 ng. h/mL; and AUC(90 mg), 389 +/- 54 ng.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),[ng] / [ml],46.1,82578,DB01373,Calcium
,12426519,C(max),"After oral administration, the drug kinetics was linear in the administered dose range and the pharmacokinetic parameters were as follows: C(max)(30 mg), 46.1 +/- 5.8 ng/mL; C(max)(60 mg), 81.7 +/- 14.6 ng/mL; C(max)(90 mg), 131.6 +/- 16.3 ng/mL; AUC(30 mg), 119 +/- 25 ng. h/mL; AUC(60 mg), 256 +/- 48 ng. h/mL; and AUC(90 mg), 389 +/- 54 ng.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),[ng] / [ml],81.7,82579,DB01373,Calcium
,12426519,C(max),"After oral administration, the drug kinetics was linear in the administered dose range and the pharmacokinetic parameters were as follows: C(max)(30 mg), 46.1 +/- 5.8 ng/mL; C(max)(60 mg), 81.7 +/- 14.6 ng/mL; C(max)(90 mg), 131.6 +/- 16.3 ng/mL; AUC(30 mg), 119 +/- 25 ng. h/mL; AUC(60 mg), 256 +/- 48 ng. h/mL; and AUC(90 mg), 389 +/- 54 ng.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),[ng] / [ml],131.6,82580,DB01373,Calcium
,12426519,AUC,"After oral administration, the drug kinetics was linear in the administered dose range and the pharmacokinetic parameters were as follows: C(max)(30 mg), 46.1 +/- 5.8 ng/mL; C(max)(60 mg), 81.7 +/- 14.6 ng/mL; C(max)(90 mg), 131.6 +/- 16.3 ng/mL; AUC(30 mg), 119 +/- 25 ng. h/mL; AUC(60 mg), 256 +/- 48 ng. h/mL; and AUC(90 mg), 389 +/- 54 ng.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),[h·ng] / [ml],119,82581,DB01373,Calcium
,12426519,AUC,"After oral administration, the drug kinetics was linear in the administered dose range and the pharmacokinetic parameters were as follows: C(max)(30 mg), 46.1 +/- 5.8 ng/mL; C(max)(60 mg), 81.7 +/- 14.6 ng/mL; C(max)(90 mg), 131.6 +/- 16.3 ng/mL; AUC(30 mg), 119 +/- 25 ng. h/mL; AUC(60 mg), 256 +/- 48 ng. h/mL; and AUC(90 mg), 389 +/- 54 ng.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),[h·ng] / [ml],256,82582,DB01373,Calcium
,12426519,AUC,"After oral administration, the drug kinetics was linear in the administered dose range and the pharmacokinetic parameters were as follows: C(max)(30 mg), 46.1 +/- 5.8 ng/mL; C(max)(60 mg), 81.7 +/- 14.6 ng/mL; C(max)(90 mg), 131.6 +/- 16.3 ng/mL; AUC(30 mg), 119 +/- 25 ng. h/mL; AUC(60 mg), 256 +/- 48 ng. h/mL; and AUC(90 mg), 389 +/- 54 ng.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),ng,389,82583,DB01373,Calcium
,12426519,bioavailability,"The half-life was similar to the values observed after intravenous administration, whereas the bioavailability ranged between 2% and 5.9%.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),%,2,82584,DB01373,Calcium
,12426519,bioavailability,"The half-life was similar to the values observed after intravenous administration, whereas the bioavailability ranged between 2% and 5.9%.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),%,5.9,82585,DB01373,Calcium
,19641202,parasite clearance times,"The overall median parasite clearance times were 84 hours (interquartile range, 60 to 96) in Pailin and 48 hours (interquartile range, 36 to 66) in Wang Pha (P<0.001).",Artemisinin resistance in Plasmodium falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19641202/),h,84,82896,DB01373,Calcium
,19641202,parasite clearance times,"The overall median parasite clearance times were 84 hours (interquartile range, 60 to 96) in Pailin and 48 hours (interquartile range, 36 to 66) in Wang Pha (P<0.001).",Artemisinin resistance in Plasmodium falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19641202/),h,48,82897,DB01373,Calcium
,28624574,t1/2,"Mean rosuvastatin (standard deviation) t1/2 was similar when rosuvastatin was used concomitantly with ESL and when it was used alone (26.5 [16.3]h, and 22.4 [9.5]h, respectively).",Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28624574/),h,26.5,83834,DB01373,Calcium
,28624574,t1/2,"Mean rosuvastatin (standard deviation) t1/2 was similar when rosuvastatin was used concomitantly with ESL and when it was used alone (26.5 [16.3]h, and 22.4 [9.5]h, respectively).",Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28624574/),h,22.4,83835,DB01373,Calcium
,26006182,elimination half-life,Amlodipine elimination half-life during the first MARS™ session was calculated at 7.6 h.,Mixed amlodipine/valsartan overdose treated by the molecular adsorbent recirculating system (MARS™). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26006182/),h,7.6,84289,DB01373,Calcium
,12565199,clearance rate,Toxicokinetics parameters showed verapamil could increase clearance rate from 20.8+/-1.51 to 44.3+/-7.0 ml kg(-1)s(-1) and reduce AUC of P(-)soman from 2.08+/-0.151 to 0.996+/-0.172 mg s l(-1).,Effects of pretreatment with verapamil on the toxicokinetics of soman in rabbits and distribution in mouse brain and diaphragm. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12565199/),[ml] / [kg],20.8,84472,DB01373,Calcium
,12565199,clearance rate,Toxicokinetics parameters showed verapamil could increase clearance rate from 20.8+/-1.51 to 44.3+/-7.0 ml kg(-1)s(-1) and reduce AUC of P(-)soman from 2.08+/-0.151 to 0.996+/-0.172 mg s l(-1).,Effects of pretreatment with verapamil on the toxicokinetics of soman in rabbits and distribution in mouse brain and diaphragm. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12565199/),[ml] / [kg],44.3,84473,DB01373,Calcium
,12565199,AUC,Toxicokinetics parameters showed verapamil could increase clearance rate from 20.8+/-1.51 to 44.3+/-7.0 ml kg(-1)s(-1) and reduce AUC of P(-)soman from 2.08+/-0.151 to 0.996+/-0.172 mg s l(-1).,Effects of pretreatment with verapamil on the toxicokinetics of soman in rabbits and distribution in mouse brain and diaphragm. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12565199/),[mg·s] / [l],2.08,84474,DB01373,Calcium
,12565199,AUC,Toxicokinetics parameters showed verapamil could increase clearance rate from 20.8+/-1.51 to 44.3+/-7.0 ml kg(-1)s(-1) and reduce AUC of P(-)soman from 2.08+/-0.151 to 0.996+/-0.172 mg s l(-1).,Effects of pretreatment with verapamil on the toxicokinetics of soman in rabbits and distribution in mouse brain and diaphragm. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12565199/),[mg·s] / [l],0.996,84475,DB01373,Calcium
,19819100,T(max),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),min,2.0,84534,DB01373,Calcium
,19819100,T(max),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),min,2.5,84535,DB01373,Calcium
,19819100,C(max),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[μg] / [ml],0.084,84536,DB01373,Calcium
,19819100,C(max),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[μg] / [ml],0.076,84537,DB01373,Calcium
,19819100,T(1/2),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),min,84.0,84538,DB01373,Calcium
,19819100,T(1/2),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),min,91.4,84539,DB01373,Calcium
,19819100,AUC(0-t),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],4.183,84540,DB01373,Calcium
,19819100,AUC(0-t),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],3.467,84541,DB01373,Calcium
,19819100,AUC(infinity),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),,5.915,84542,DB01373,Calcium
,19819100,AUMC(0-t),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],224.073,84543,DB01373,Calcium
,19819100,AUMC(0-t),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],173.063,84544,DB01373,Calcium
,19819100,AUMC(infinity),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],776.871,84545,DB01373,Calcium
,19819100,AUMC(infinity),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],575.038,84546,DB01373,Calcium
,19819100,MRT(0-t),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],53.608,84547,DB01373,Calcium
,19819100,MRT(0-t),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],49.538,84548,DB01373,Calcium
,19819100,MRT(infinity),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],118.194,84549,DB01373,Calcium
,19819100,MRT(infinity),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],115.246,84550,DB01373,Calcium
,19819100,CL(tot),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[l] / [h],0.0375,84551,DB01373,Calcium
,19819100,CL(tot),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[l] / [h],0.0433,84552,DB01373,Calcium
,19819100,Vd(ss),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),l,3.999,84553,DB01373,Calcium
,19819100,Vd(ss),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),l,4.641,84554,DB01373,Calcium
,22289659,Cmax,"Mean+/-SD hPTH134 Cmax values were, respectively, 74+/-59, 138+/-101, 717+/-496, and 1624+/-1579 pg/mL for 1, 2.5, 5, and 10 mg doses of this peptide administered with 200 mg 5-CNAC; while mean+/-SD AUC (0-last) values were, respectively, 30+/-40, 62+/-69, 320+/-269, and 627+/-633 h*pg/mL.",The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289659/),[pg] / [ml],74,84959,DB01373,Calcium
,22289659,Cmax,"Mean+/-SD hPTH134 Cmax values were, respectively, 74+/-59, 138+/-101, 717+/-496, and 1624+/-1579 pg/mL for 1, 2.5, 5, and 10 mg doses of this peptide administered with 200 mg 5-CNAC; while mean+/-SD AUC (0-last) values were, respectively, 30+/-40, 62+/-69, 320+/-269, and 627+/-633 h*pg/mL.",The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289659/),[pg] / [ml],138,84960,DB01373,Calcium
,22289659,Cmax,"Mean+/-SD hPTH134 Cmax values were, respectively, 74+/-59, 138+/-101, 717+/-496, and 1624+/-1579 pg/mL for 1, 2.5, 5, and 10 mg doses of this peptide administered with 200 mg 5-CNAC; while mean+/-SD AUC (0-last) values were, respectively, 30+/-40, 62+/-69, 320+/-269, and 627+/-633 h*pg/mL.",The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289659/),[pg] / [ml],717,84961,DB01373,Calcium
,22289659,Cmax,"Mean+/-SD hPTH134 Cmax values were, respectively, 74+/-59, 138+/-101, 717+/-496, and 1624+/-1579 pg/mL for 1, 2.5, 5, and 10 mg doses of this peptide administered with 200 mg 5-CNAC; while mean+/-SD AUC (0-last) values were, respectively, 30+/-40, 62+/-69, 320+/-269, and 627+/-633 h*pg/mL.",The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289659/),[pg] / [ml],1624,84962,DB01373,Calcium
,22289659,AUC (0-last),"Mean+/-SD hPTH134 Cmax values were, respectively, 74+/-59, 138+/-101, 717+/-496, and 1624+/-1579 pg/mL for 1, 2.5, 5, and 10 mg doses of this peptide administered with 200 mg 5-CNAC; while mean+/-SD AUC (0-last) values were, respectively, 30+/-40, 62+/-69, 320+/-269, and 627+/-633 h*pg/mL.",The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289659/),[h·pg] / [ml],30,84963,DB01373,Calcium
,22289659,AUC (0-last),"Mean+/-SD hPTH134 Cmax values were, respectively, 74+/-59, 138+/-101, 717+/-496, and 1624+/-1579 pg/mL for 1, 2.5, 5, and 10 mg doses of this peptide administered with 200 mg 5-CNAC; while mean+/-SD AUC (0-last) values were, respectively, 30+/-40, 62+/-69, 320+/-269, and 627+/-633 h*pg/mL.",The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289659/),[h·pg] / [ml],62,84964,DB01373,Calcium
,22289659,AUC (0-last),"Mean+/-SD hPTH134 Cmax values were, respectively, 74+/-59, 138+/-101, 717+/-496, and 1624+/-1579 pg/mL for 1, 2.5, 5, and 10 mg doses of this peptide administered with 200 mg 5-CNAC; while mean+/-SD AUC (0-last) values were, respectively, 30+/-40, 62+/-69, 320+/-269, and 627+/-633 h*pg/mL.",The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289659/),[h·pg] / [ml],320,84965,DB01373,Calcium
,22289659,AUC (0-last),"Mean+/-SD hPTH134 Cmax values were, respectively, 74+/-59, 138+/-101, 717+/-496, and 1624+/-1579 pg/mL for 1, 2.5, 5, and 10 mg doses of this peptide administered with 200 mg 5-CNAC; while mean+/-SD AUC (0-last) values were, respectively, 30+/-40, 62+/-69, 320+/-269, and 627+/-633 h*pg/mL.",The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289659/),[h·pg] / [ml],627,84966,DB01373,Calcium
,22289659,Cmax,The corresponding estimates for teriparatide 20 μg sc were 149+/-35 for Cmax and 236+/-58 for AUC (0-last) Ionized calcium remained within normal limits in all treatment groups except for 3 isolated events.,The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289659/),,149,84967,DB01373,Calcium
,22289659,Cmax,The corresponding estimates for teriparatide 20 μg sc were 149+/-35 for Cmax and 236+/-58 for AUC (0-last) Ionized calcium remained within normal limits in all treatment groups except for 3 isolated events.,The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289659/),,35,84968,DB01373,Calcium
,22289659,AUC (0-last),The corresponding estimates for teriparatide 20 μg sc were 149+/-35 for Cmax and 236+/-58 for AUC (0-last) Ionized calcium remained within normal limits in all treatment groups except for 3 isolated events.,The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289659/),,236,84969,DB01373,Calcium
,29316656,IC50,"The peptide effectively inhibited (IC50 ~ 19 nM) calcium response of muscle nAChR evoked by 30 μM (EC100) acetylcholine but was less potent (IC50 ~ 3 μM) at α7 nAChR activated by 10 μM (EC50) acetylcholine and had a low affinity to α4β2 and α3-containing nAChR, as well as to GABAA or 5HT₃ receptors.","Azemiopsin, a Selective Peptide Antagonist of Muscle Nicotinic Acetylcholine Receptor: Preclinical Evaluation as a Local Muscle Relaxant. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29316656/),nM,19,85443,DB01373,Calcium
,29316656,IC50,"The peptide effectively inhibited (IC50 ~ 19 nM) calcium response of muscle nAChR evoked by 30 μM (EC100) acetylcholine but was less potent (IC50 ~ 3 μM) at α7 nAChR activated by 10 μM (EC50) acetylcholine and had a low affinity to α4β2 and α3-containing nAChR, as well as to GABAA or 5HT₃ receptors.","Azemiopsin, a Selective Peptide Antagonist of Muscle Nicotinic Acetylcholine Receptor: Preclinical Evaluation as a Local Muscle Relaxant. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29316656/),μM,3,85444,DB01373,Calcium
,29316656,elimination half-life,The maximal muscle relaxant effect of Az was achieved in 10 min after the administration and elimination half-life of Az in mice was calculated as 20-40 min.,"Azemiopsin, a Selective Peptide Antagonist of Muscle Nicotinic Acetylcholine Receptor: Preclinical Evaluation as a Local Muscle Relaxant. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29316656/),min,20-40,85445,DB01373,Calcium
,29316656,LD50,"The highest acute toxicity (LD50 510 μg/kg) was observed at intravenous injection of Az, at intramuscular or intraperitoneal administration it was less toxic.","Azemiopsin, a Selective Peptide Antagonist of Muscle Nicotinic Acetylcholine Receptor: Preclinical Evaluation as a Local Muscle Relaxant. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29316656/),[μg] / [kg],510,85446,DB01373,Calcium
,16753830,availability (PA)%,"A marked decrease in plasma calcium levels was observed following the oral administration of chitosan capsules containing ECT, S-nitroso-N-acetyl-dl-penicillamine (SNAP), sodium glycocholate, bacitracin and aprotinin (pharmacological availability (PA)% = 6.344%), as compared with capsules containing only ECT (PA% = 0.551%) or capsules containing ECT with SNAP only (PA% = 1.651%).","Colon-specific delivery and enhanced colonic absorption of [Asu(1,7)]-eel calcitonin using chitosan capsules containing various additives in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16753830/),%,6.344,85581,DB01373,Calcium
,16753830,PA%,"A marked decrease in plasma calcium levels was observed following the oral administration of chitosan capsules containing ECT, S-nitroso-N-acetyl-dl-penicillamine (SNAP), sodium glycocholate, bacitracin and aprotinin (pharmacological availability (PA)% = 6.344%), as compared with capsules containing only ECT (PA% = 0.551%) or capsules containing ECT with SNAP only (PA% = 1.651%).","Colon-specific delivery and enhanced colonic absorption of [Asu(1,7)]-eel calcitonin using chitosan capsules containing various additives in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16753830/),%,0.551,85582,DB01373,Calcium
,16753830,PA%,"A marked decrease in plasma calcium levels was observed following the oral administration of chitosan capsules containing ECT, S-nitroso-N-acetyl-dl-penicillamine (SNAP), sodium glycocholate, bacitracin and aprotinin (pharmacological availability (PA)% = 6.344%), as compared with capsules containing only ECT (PA% = 0.551%) or capsules containing ECT with SNAP only (PA% = 1.651%).","Colon-specific delivery and enhanced colonic absorption of [Asu(1,7)]-eel calcitonin using chitosan capsules containing various additives in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16753830/),%,1.651,85583,DB01373,Calcium
,11707062,V1,"Final pharmacokinetic parameters were: CL (L/h) = (0.036 x TBW + 0.112 x CL(CR)) x 0.77SPI x 0.784CCB, V1 = 1.83 L/kg, V2 = 22.6 L/kg and Q = 0.629 L/h/kg, where CL is total body clearance, V1 and V2 are the apparent volumes of distribution in the central and peripheral compartments, Q is intercompartmental clearance, TBW is total bodyweight (in kg), CL(CR) is creatinine clearance (in ml/min), SPI = 1 for concomitant administration of spironolactone (and zero otherwise) and CCB = 1 for concomitant administration of calcium antagonists (and zero otherwise).",Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707062/),[l] / [kg],1.83,85950,DB01373,Calcium
,11707062,V2,"Final pharmacokinetic parameters were: CL (L/h) = (0.036 x TBW + 0.112 x CL(CR)) x 0.77SPI x 0.784CCB, V1 = 1.83 L/kg, V2 = 22.6 L/kg and Q = 0.629 L/h/kg, where CL is total body clearance, V1 and V2 are the apparent volumes of distribution in the central and peripheral compartments, Q is intercompartmental clearance, TBW is total bodyweight (in kg), CL(CR) is creatinine clearance (in ml/min), SPI = 1 for concomitant administration of spironolactone (and zero otherwise) and CCB = 1 for concomitant administration of calcium antagonists (and zero otherwise).",Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707062/),[l] / [kg],22.6,85951,DB01373,Calcium
,11707062,Q,"Final pharmacokinetic parameters were: CL (L/h) = (0.036 x TBW + 0.112 x CL(CR)) x 0.77SPI x 0.784CCB, V1 = 1.83 L/kg, V2 = 22.6 L/kg and Q = 0.629 L/h/kg, where CL is total body clearance, V1 and V2 are the apparent volumes of distribution in the central and peripheral compartments, Q is intercompartmental clearance, TBW is total bodyweight (in kg), CL(CR) is creatinine clearance (in ml/min), SPI = 1 for concomitant administration of spironolactone (and zero otherwise) and CCB = 1 for concomitant administration of calcium antagonists (and zero otherwise).",Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707062/),[l] / [h·kg],0.629,85952,DB01373,Calcium
,18787794,ch,The method has a chromatographic run time of 1.25 min and a linear calibration curve over the range 200-10000 ng/mL (r(2)>0.9994).,Analysis of acamprosate in beagle dog plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18787794/),min,1.25,86273,DB01373,Calcium
,33255787,AUC0-8 h,We found that the AUC0-8 h of plasma (6S)-5-Methyl-THF (mean (SD) = 126.0 (33.6) vs. 56.0 (25.3) nmol/L*h) and Cmax (36.8 (10.8) vs. 11.1 (4.1) nmol/L) were higher after administration of (6S)-5-Methyl-THF-Na than after the administration of folic acid (p < 0.001 for both).,Pharmacokinetics of Sodium and Calcium Salts of (6S)-5-Methyltetrahydrofolic Acid Compared to Folic Acid and Indirect Comparison of the Two Salts. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33255787/),[nM] / [h·l],126.0,87958,DB01373,Calcium
,33255787,AUC0-8 h,We found that the AUC0-8 h of plasma (6S)-5-Methyl-THF (mean (SD) = 126.0 (33.6) vs. 56.0 (25.3) nmol/L*h) and Cmax (36.8 (10.8) vs. 11.1 (4.1) nmol/L) were higher after administration of (6S)-5-Methyl-THF-Na than after the administration of folic acid (p < 0.001 for both).,Pharmacokinetics of Sodium and Calcium Salts of (6S)-5-Methyltetrahydrofolic Acid Compared to Folic Acid and Indirect Comparison of the Two Salts. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33255787/),[nM] / [h·l],56.0,87959,DB01373,Calcium
,33255787,Cmax,We found that the AUC0-8 h of plasma (6S)-5-Methyl-THF (mean (SD) = 126.0 (33.6) vs. 56.0 (25.3) nmol/L*h) and Cmax (36.8 (10.8) vs. 11.1 (4.1) nmol/L) were higher after administration of (6S)-5-Methyl-THF-Na than after the administration of folic acid (p < 0.001 for both).,Pharmacokinetics of Sodium and Calcium Salts of (6S)-5-Methyltetrahydrofolic Acid Compared to Folic Acid and Indirect Comparison of the Two Salts. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33255787/),[nM] / [l],36.8,87960,DB01373,Calcium
,33255787,Cmax,We found that the AUC0-8 h of plasma (6S)-5-Methyl-THF (mean (SD) = 126.0 (33.6) vs. 56.0 (25.3) nmol/L*h) and Cmax (36.8 (10.8) vs. 11.1 (4.1) nmol/L) were higher after administration of (6S)-5-Methyl-THF-Na than after the administration of folic acid (p < 0.001 for both).,Pharmacokinetics of Sodium and Calcium Salts of (6S)-5-Methyltetrahydrofolic Acid Compared to Folic Acid and Indirect Comparison of the Two Salts. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33255787/),[nM] / [l],11.1,87961,DB01373,Calcium
,21896243,peak plasma concentration,The peak plasma concentration of 25(OH)D2 was 9·6 (sd 0·9) nmol/l at 4·4 (sd 1·8) h.,Plasma appearance and disappearance of an oral dose of 25-hydroxyvitamin D2 in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21896243/),[nM] / [l],9·6,88147,DB01373,Calcium
,21896243,terminal half-life,The terminal half-life of plasma 25(OH)D2 was 13·4 (sd 2·7) d.,Plasma appearance and disappearance of an oral dose of 25-hydroxyvitamin D2 in healthy adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21896243/),d,13·4,88148,DB01373,Calcium
,26195909,C max,"The C max, i.e. C max after administration of calcium sandoz-250 was 0.793 mg/ml at 90 min (T max).",Bioavailability study of calcium sandoz-250 by atomic absorption spectroscopy in albino rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195909/),[mg] / [ml],0.793,88203,DB01373,Calcium
,26195909,T max,"The C max, i.e. C max after administration of calcium sandoz-250 was 0.793 mg/ml at 90 min (T max).",Bioavailability study of calcium sandoz-250 by atomic absorption spectroscopy in albino rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195909/),min,90,88204,DB01373,Calcium
,18540536,Cmax,"NBATs exhibited a Cmax 74.6 ng/mL, Tmax 3.5 h, t(1/2) 4.36 h.",Novel buccal adhesive tablets using Aloe vera L and Sinapis alba--a promising option for improved bioavailability of diltiazem hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18540536/),[ng] / [ml],74.6,88227,DB01373,Calcium
,18540536,Tmax,"NBATs exhibited a Cmax 74.6 ng/mL, Tmax 3.5 h, t(1/2) 4.36 h.",Novel buccal adhesive tablets using Aloe vera L and Sinapis alba--a promising option for improved bioavailability of diltiazem hydrochloride. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18540536/),h,3.5,88228,DB01373,Calcium
,18540536,t(1/2),"NBATs exhibited a Cmax 74.6 ng/mL, Tmax 3.5 h, t(1/2) 4.36 h.",Novel buccal adhesive tablets using Aloe vera L and Sinapis alba--a promising option for improved bioavailability of diltiazem hydrochloride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18540536/),h,4.36,88229,DB01373,Calcium
,18540536,bioavailability,The NBATs prevented salivary scavenging effect and exhibited 82.1% bioavailability.,Novel buccal adhesive tablets using Aloe vera L and Sinapis alba--a promising option for improved bioavailability of diltiazem hydrochloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18540536/),%,82.1,88230,DB01373,Calcium
,19041284,retention times,The retention times of isradipine (0.81 min) and IS (0.65 min) suggested the potential for high throughput of the proposed method.,Quantification of isradipine in human plasma using LC-MS/MS for pharmacokinetic and bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19041284/),min,0.81,88570,DB01373,Calcium
,19041284,retention times,The retention times of isradipine (0.81 min) and IS (0.65 min) suggested the potential for high throughput of the proposed method.,Quantification of isradipine in human plasma using LC-MS/MS for pharmacokinetic and bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19041284/),min,0.65,88571,DB01373,Calcium
,12403271,relative bioavailability,"The relative bioavailability of calcium from the control (100%), TSPF+SF (30%), NTSPF+SF (23%), TSPF (57%) and NTSPF (46%) indicated that sweetpotatoes could be the better source of calcium, however, supplementation with soy flour might reduce the bioavailability of calcium.",Bioavailability of calcium from sweetpotato and soy flour supplemented diets in hamsters. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403271/),%,100,88589,DB01373,Calcium
,12403271,relative bioavailability,"The relative bioavailability of calcium from the control (100%), TSPF+SF (30%), NTSPF+SF (23%), TSPF (57%) and NTSPF (46%) indicated that sweetpotatoes could be the better source of calcium, however, supplementation with soy flour might reduce the bioavailability of calcium.",Bioavailability of calcium from sweetpotato and soy flour supplemented diets in hamsters. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403271/),%,30,88590,DB01373,Calcium
,12403271,relative bioavailability,"The relative bioavailability of calcium from the control (100%), TSPF+SF (30%), NTSPF+SF (23%), TSPF (57%) and NTSPF (46%) indicated that sweetpotatoes could be the better source of calcium, however, supplementation with soy flour might reduce the bioavailability of calcium.",Bioavailability of calcium from sweetpotato and soy flour supplemented diets in hamsters. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403271/),%,23,88591,DB01373,Calcium
,12403271,relative bioavailability,"The relative bioavailability of calcium from the control (100%), TSPF+SF (30%), NTSPF+SF (23%), TSPF (57%) and NTSPF (46%) indicated that sweetpotatoes could be the better source of calcium, however, supplementation with soy flour might reduce the bioavailability of calcium.",Bioavailability of calcium from sweetpotato and soy flour supplemented diets in hamsters. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403271/),%,57,88592,DB01373,Calcium
,12403271,relative bioavailability,"The relative bioavailability of calcium from the control (100%), TSPF+SF (30%), NTSPF+SF (23%), TSPF (57%) and NTSPF (46%) indicated that sweetpotatoes could be the better source of calcium, however, supplementation with soy flour might reduce the bioavailability of calcium.",Bioavailability of calcium from sweetpotato and soy flour supplemented diets in hamsters. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403271/),%,46,88593,DB01373,Calcium
,30080272,volume of distribution at steady state,"The volume of distribution at steady state, systemic clearance and elimination half-life was 5.90 ± 0.200 L/kg, 30.7 ± 0.166 mL/min/kg and 4.84 ± 0.83 h respectively.",Pharmacokinetics of intravenous flumetasone and effects on plasma hydrocortisone concentrations and inflammatory mediators in the horse. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30080272/),[l] / [kg],5.90,89618,DB01373,Calcium
,30080272,systemic clearance,"The volume of distribution at steady state, systemic clearance and elimination half-life was 5.90 ± 0.200 L/kg, 30.7 ± 0.166 mL/min/kg and 4.84 ± 0.83 h respectively.",Pharmacokinetics of intravenous flumetasone and effects on plasma hydrocortisone concentrations and inflammatory mediators in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30080272/),[ml] / [kg·min],30.7,89619,DB01373,Calcium
,30080272,elimination half-life,"The volume of distribution at steady state, systemic clearance and elimination half-life was 5.90 ± 0.200 L/kg, 30.7 ± 0.166 mL/min/kg and 4.84 ± 0.83 h respectively.",Pharmacokinetics of intravenous flumetasone and effects on plasma hydrocortisone concentrations and inflammatory mediators in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30080272/),h,4.84,89620,DB01373,Calcium
,30080272,Kin,"For cortisol, Kin , Kout and the t1/2out were 30.3 ± 1.56 ng/mL × h, 0.331 ± 0.02 1/h and 2.1 h respectively.",Pharmacokinetics of intravenous flumetasone and effects on plasma hydrocortisone concentrations and inflammatory mediators in the horse. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30080272/),[ng] / [h·ml],30.3,89621,DB01373,Calcium
,30080272,Kout,"For cortisol, Kin , Kout and the t1/2out were 30.3 ± 1.56 ng/mL × h, 0.331 ± 0.02 1/h and 2.1 h respectively.",Pharmacokinetics of intravenous flumetasone and effects on plasma hydrocortisone concentrations and inflammatory mediators in the horse. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30080272/),[1] / [h],0.331,89622,DB01373,Calcium
,30080272,t1/2out,"For cortisol, Kin , Kout and the t1/2out were 30.3 ± 1.56 ng/mL × h, 0.331 ± 0.02 1/h and 2.1 h respectively.",Pharmacokinetics of intravenous flumetasone and effects on plasma hydrocortisone concentrations and inflammatory mediators in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30080272/),h,2.1,89623,DB01373,Calcium
,21849627,brain/plasma ratio,CTEP penetrates the brain with a brain/plasma ratio of 2.6 and displaces the tracer [(3)H]3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone-O-methyl-oxime (ABP688) in vivo in mice from brain regions expressing mGlu5 with an average ED(50) equivalent to a drug concentration of 77.5 ng/g in brain tissue.,"CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21849627/),,2.6,89632,DB01373,Calcium
,21849627,minimal effective doses,"This novel mGlu5 inhibitor is active in the stress-induced hyperthermia procedure in mice and the Vogel conflict drinking test in rats with minimal effective doses of 0.1 and 0.3 mg/kg, respectively, reflecting a 30- to 100-fold higher in vivo potency compared with 2-methyl-6-(phenylethynyl)pyridine (MPEP) and fenobam.","CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21849627/),[mg] / [kg],0.1,89633,DB01373,Calcium
,21849627,minimal effective doses,"This novel mGlu5 inhibitor is active in the stress-induced hyperthermia procedure in mice and the Vogel conflict drinking test in rats with minimal effective doses of 0.1 and 0.3 mg/kg, respectively, reflecting a 30- to 100-fold higher in vivo potency compared with 2-methyl-6-(phenylethynyl)pyridine (MPEP) and fenobam.","CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21849627/),[mg] / [kg],0.3,89634,DB01373,Calcium
,21849627,half-life,CTEP is the first reported mGlu5 inhibitor with both long half-life of approximately 18 h and high oral bioavailability allowing chronic treatment with continuous receptor blockade with one dose every 48 h in adult and newborn animals.,"CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21849627/),h,18,89635,DB01373,Calcium
,12534926,urinary oxalate excretion,"Cumulative urinary oxalate excretion during 5 h was 1.69 +/- 0.10 mg (mean +/- SD; 17%), 1.43 +/- 0.13 mg (13%), and 0.22 +/- 0.03 mg (2%) after the administration of oxalic acid, disodium oxalate, and calcium oxalate, respectively.",Urinary oxalic acid excretion differs after oral loading of rats with various oxalate salts. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534926/),mg,1.69,90253,DB01373,Calcium
,12534926,urinary oxalate excretion,"Cumulative urinary oxalate excretion during 5 h was 1.69 +/- 0.10 mg (mean +/- SD; 17%), 1.43 +/- 0.13 mg (13%), and 0.22 +/- 0.03 mg (2%) after the administration of oxalic acid, disodium oxalate, and calcium oxalate, respectively.",Urinary oxalic acid excretion differs after oral loading of rats with various oxalate salts. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534926/),mg,1.43,90254,DB01373,Calcium
,12534926,urinary oxalate excretion,"Cumulative urinary oxalate excretion during 5 h was 1.69 +/- 0.10 mg (mean +/- SD; 17%), 1.43 +/- 0.13 mg (13%), and 0.22 +/- 0.03 mg (2%) after the administration of oxalic acid, disodium oxalate, and calcium oxalate, respectively.",Urinary oxalic acid excretion differs after oral loading of rats with various oxalate salts. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534926/),mg,0.22,90255,DB01373,Calcium
,14658727,urine volume,"There was not a statistically significant difference in urine volume over 24 hours between methods; however, urine volume was significantly greater after CRI compared with IA during the first 8 hours ([median 25th percentile, 75th percentile]: 9.6 L [8.9, 14.4] for CRI versus 5.9 L [5.3, 6.0] for IA).",Furosemide continuous rate infusion in the horse: evaluation of enhanced efficacy and reduced side effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14658727/),l,9.6,90550,DB01373,Calcium
,14658727,urine volume,"There was not a statistically significant difference in urine volume over 24 hours between methods; however, urine volume was significantly greater after CRI compared with IA during the first 8 hours ([median 25th percentile, 75th percentile]: 9.6 L [8.9, 14.4] for CRI versus 5.9 L [5.3, 6.0] for IA).",Furosemide continuous rate infusion in the horse: evaluation of enhanced efficacy and reduced side effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14658727/),l,5.9,90551,DB01373,Calcium
,14658727,Cl excretion,"Potassium, Ca, and Cl excretion was greater during CRI than IA (1,133 mmol [1.110, 1,229] versus 764 mmol [709, 904], 102.7 mmol [96.0, 117.2] versus 73.3 mmol [65.0, 73.5], and 1,776 mmol [1,657, 2.378] versus 1,596 mmol [1,457, 1,767], respectively).",Furosemide continuous rate infusion in the horse: evaluation of enhanced efficacy and reduced side effects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14658727/),mM,73.3,90552,DB01373,Calcium
,14658727,Cl excretion,"Potassium, Ca, and Cl excretion was greater during CRI than IA (1,133 mmol [1.110, 1,229] versus 764 mmol [709, 904], 102.7 mmol [96.0, 117.2] versus 73.3 mmol [65.0, 73.5], and 1,776 mmol [1,657, 2.378] versus 1,596 mmol [1,457, 1,767], respectively).",Furosemide continuous rate infusion in the horse: evaluation of enhanced efficacy and reduced side effects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14658727/),mM,"1,776",90553,DB01373,Calcium
,14658727,Cl excretion,"Potassium, Ca, and Cl excretion was greater during CRI than IA (1,133 mmol [1.110, 1,229] versus 764 mmol [709, 904], 102.7 mmol [96.0, 117.2] versus 73.3 mmol [65.0, 73.5], and 1,776 mmol [1,657, 2.378] versus 1,596 mmol [1,457, 1,767], respectively).",Furosemide continuous rate infusion in the horse: evaluation of enhanced efficacy and reduced side effects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14658727/),mM,"1,596",90554,DB01373,Calcium
,14658727,Elimination half-lives,"Elimination half-lives of furosemide were 1.35 and 0.47 hours for CRI and IA, respectively.",Furosemide continuous rate infusion in the horse: evaluation of enhanced efficacy and reduced side effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14658727/),h,1.35,90555,DB01373,Calcium
,14658727,Elimination half-lives,"Elimination half-lives of furosemide were 1.35 and 0.47 hours for CRI and IA, respectively.",Furosemide continuous rate infusion in the horse: evaluation of enhanced efficacy and reduced side effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14658727/),h,0.47,90556,DB01373,Calcium
,14658727,area under the excretion rate curve,"The area under the excretion rate curve was 1,285.7 and 184.2 mL x mg/mL for CRI and IA, respectively.",Furosemide continuous rate infusion in the horse: evaluation of enhanced efficacy and reduced side effects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14658727/),[mg·ml] / [ml],"1,285.7",90557,DB01373,Calcium
,14658727,area under the excretion rate curve,"The area under the excretion rate curve was 1,285.7 and 184.2 mL x mg/mL for CRI and IA, respectively.",Furosemide continuous rate infusion in the horse: evaluation of enhanced efficacy and reduced side effects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14658727/),[mg·ml] / [ml],184.2,90558,DB01373,Calcium
not exceeding,29985967,bioavailability,Rosuvastatin calcium (ROSCa) is a poorly soluble drug with bioavailability not exceeding 20%.,Rosuvastatin calcium nanoparticles: Improving bioavailability by formulation and stabilization codesign. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29985967/),%,20,90559,DB01373,Calcium
,29985967,zeta potential,The particle size of the leading formula was 461.8 ± 16.68 nm with zeta potential of -31.8 ± 7.22 mV compared to untreated drug that has a particle size of 618μm.,Rosuvastatin calcium nanoparticles: Improving bioavailability by formulation and stabilization codesign. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29985967/),mv,-,90560,DB01373,Calcium
,29985967,zeta potential,The particle size of the leading formula was 461.8 ± 16.68 nm with zeta potential of -31.8 ± 7.22 mV compared to untreated drug that has a particle size of 618μm.,Rosuvastatin calcium nanoparticles: Improving bioavailability by formulation and stabilization codesign. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29985967/),mv,31.8,90561,DB01373,Calcium
,29985967,Cmax,The in-vivo study of ROSCa from the leading nanoparticle formula showed a significant enhancement in the Cmax after 2 h (82.35 ng/ml) compared to 9.2 ng/ml for untreated drug.,Rosuvastatin calcium nanoparticles: Improving bioavailability by formulation and stabilization codesign. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29985967/),[ng] / [ml],82.35,90562,DB01373,Calcium
,29985967,Cmax,The in-vivo study of ROSCa from the leading nanoparticle formula showed a significant enhancement in the Cmax after 2 h (82.35 ng/ml) compared to 9.2 ng/ml for untreated drug.,Rosuvastatin calcium nanoparticles: Improving bioavailability by formulation and stabilization codesign. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29985967/),[ng] / [ml],9.2,90563,DB01373,Calcium
,22263871,heart rate,He was found to be bradycardic with a heart rate of 42/min.,"Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22263871/),1/[min],42,90698,DB01373,Calcium
,22263871,trough,"The tacrolimus trough was elevated at 14 ng/mL, which decreased after stopping ranolazine, reaching 7 ng/mL after 3 days, while continuing the same dose of tacrolimus.","Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22263871/),[ng] / [ml],14,90699,DB01373,Calcium
,22263871,trough,"The tacrolimus trough was elevated at 14 ng/mL, which decreased after stopping ranolazine, reaching 7 ng/mL after 3 days, while continuing the same dose of tacrolimus.","Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22263871/),[ng] / [ml],7,90700,DB01373,Calcium
,15361277,area under the concentration-time curve (AUC),The values of the area under the concentration-time curve (AUC) were not significantly different between LI (79.1 +/- 36.0 micro M*h) and HICA (91.4 +/- 50.4 micro M*h) (P =.37).,Iron bioavailability in prenatal multivitamin supplements with separated and combined iron and calcium. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15361277/),h·μM,79.1,91594,DB01373,Calcium
,15361277,area under the concentration-time curve (AUC),The values of the area under the concentration-time curve (AUC) were not significantly different between LI (79.1 +/- 36.0 micro M*h) and HICA (91.4 +/- 50.4 micro M*h) (P =.37).,Iron bioavailability in prenatal multivitamin supplements with separated and combined iron and calcium. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15361277/),h·μM,91.4,91595,DB01373,Calcium
,15361277,AUC,"After standardizing the AUC for dose, the relative absorption over the 8-hour time period was significantly higher for LI (2.3 +/-.0 micro M*h/mg) than for HICA (1.5 +/- 0.8 micro M*h/mg) (P =.021).",Iron bioavailability in prenatal multivitamin supplements with separated and combined iron and calcium. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15361277/),[h·μM] / [mg],2.3,91596,DB01373,Calcium
,15361277,relative absorption,"After standardizing the AUC for dose, the relative absorption over the 8-hour time period was significantly higher for LI (2.3 +/-.0 micro M*h/mg) than for HICA (1.5 +/- 0.8 micro M*h/mg) (P =.021).",Iron bioavailability in prenatal multivitamin supplements with separated and combined iron and calcium. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15361277/),[h·μM] / [mg],2.3,91597,DB01373,Calcium
,15361277,relative absorption,"After standardizing the AUC for dose, the relative absorption over the 8-hour time period was significantly higher for LI (2.3 +/-.0 micro M*h/mg) than for HICA (1.5 +/- 0.8 micro M*h/mg) (P =.021).",Iron bioavailability in prenatal multivitamin supplements with separated and combined iron and calcium. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15361277/),[h·μM] / [mg],1.5,91598,DB01373,Calcium
,19740397,AUC(last),"AUC(last) was significantly lower among individuals with the 2677TT/3435TT (159.5 +/- 79.0 ng ml(-1) h) and 2677GT/3435CT (189.3 +/- 73.1 ng ml(-1) h) genotypes than those with the 2677GG/3435CC genotype (303.1 +/- 83.7 ng ml(-1) h) (P= 0.004 and P= 0.008, respectively).",Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740397/),[h·ng] / [ml],159.5,91829,DB01373,Calcium
,19740397,AUC(last),"AUC(last) was significantly lower among individuals with the 2677TT/3435TT (159.5 +/- 79.0 ng ml(-1) h) and 2677GT/3435CT (189.3 +/- 73.1 ng ml(-1) h) genotypes than those with the 2677GG/3435CC genotype (303.1 +/- 83.7 ng ml(-1) h) (P= 0.004 and P= 0.008, respectively).",Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740397/),[h·ng] / [ml],189.3,91830,DB01373,Calcium
,19740397,AUC(last),"AUC(last) was significantly lower among individuals with the 2677TT/3435TT (159.5 +/- 79.0 ng ml(-1) h) and 2677GT/3435CT (189.3 +/- 73.1 ng ml(-1) h) genotypes than those with the 2677GG/3435CC genotype (303.1 +/- 83.7 ng ml(-1) h) (P= 0.004 and P= 0.008, respectively).",Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740397/),[h·ng] / [ml],303.1,91831,DB01373,Calcium
,19740397,CL/F,"However, the CL/F value was higher among subjects with the 2677TT/3435TT (523.0 +/- 173.7 l h(-1)) genotype than those with the 2677GT/3435CT (452.2 +/- 188.6 l h(-1)) or 2677GG/3435CC (265.4 +/- 72.8 l h(-1)) genotypes.",Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740397/),[l] / [h],523.0,91832,DB01373,Calcium
,19740397,CL/F,"However, the CL/F value was higher among subjects with the 2677TT/3435TT (523.0 +/- 173.7 l h(-1)) genotype than those with the 2677GT/3435CT (452.2 +/- 188.6 l h(-1)) or 2677GG/3435CC (265.4 +/- 72.8 l h(-1)) genotypes.",Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740397/),[l] / [h],452.2,91833,DB01373,Calcium
,19740397,CL/F,"However, the CL/F value was higher among subjects with the 2677TT/3435TT (523.0 +/- 173.7 l h(-1)) genotype than those with the 2677GT/3435CT (452.2 +/- 188.6 l h(-1)) or 2677GG/3435CC (265.4 +/- 72.8 l h(-1)) genotypes.",Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740397/),[l] / [h],265.4,91834,DB01373,Calcium
,19740397,C(max),"In addition, the C(max) tended to be higher among subjects with the 2677GG/3435CC genotype than those with the 2677GT/3435CT or 2677TT/3435TT genotypes (42.2 +/- 3.9 vs 32.2 +/- 16.2 vs 38.1 +/- 13.7 ng ml(-1)).",Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740397/),[ng] / [ml],42.2,91835,DB01373,Calcium
,19740397,C(max),"In addition, the C(max) tended to be higher among subjects with the 2677GG/3435CC genotype than those with the 2677GT/3435CT or 2677TT/3435TT genotypes (42.2 +/- 3.9 vs 32.2 +/- 16.2 vs 38.1 +/- 13.7 ng ml(-1)).",Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740397/),[ng] / [ml],32.2,91836,DB01373,Calcium
,19740397,C(max),"In addition, the C(max) tended to be higher among subjects with the 2677GG/3435CC genotype than those with the 2677GT/3435CT or 2677TT/3435TT genotypes (42.2 +/- 3.9 vs 32.2 +/- 16.2 vs 38.1 +/- 13.7 ng ml(-1)).",Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740397/),[ng] / [ml],38.1,91837,DB01373,Calcium
,28296193,Inhibition constant (Ki ),"The predicted effects of rifampin and cyclosporine (6.58-fold and 5.07-fold increase in rosuvastatin area under the curve (AUC), respectively) were mediated primarily via inhibition of hepatic organic anion-transporting polypeptide (OATP)1B1 (Inhibition constant (Ki ) ∼1.1 and 0.014 µM, respectively) and OATP1B3 (Ki ∼0.3 and 0.007 µM, respectively), with cyclosporine also inhibiting intestinal breast cancer resistance protein (BCRP; Ki ∼0.07 µM).",Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28296193/),μM,∼1.1,92275,DB01373,Calcium
,28296193,Inhibition constant (Ki ),"The predicted effects of rifampin and cyclosporine (6.58-fold and 5.07-fold increase in rosuvastatin area under the curve (AUC), respectively) were mediated primarily via inhibition of hepatic organic anion-transporting polypeptide (OATP)1B1 (Inhibition constant (Ki ) ∼1.1 and 0.014 µM, respectively) and OATP1B3 (Ki ∼0.3 and 0.007 µM, respectively), with cyclosporine also inhibiting intestinal breast cancer resistance protein (BCRP; Ki ∼0.07 µM).",Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28296193/),μM,0.014,92276,DB01373,Calcium
,28296193,Ki,"The predicted effects of rifampin and cyclosporine (6.58-fold and 5.07-fold increase in rosuvastatin area under the curve (AUC), respectively) were mediated primarily via inhibition of hepatic organic anion-transporting polypeptide (OATP)1B1 (Inhibition constant (Ki ) ∼1.1 and 0.014 µM, respectively) and OATP1B3 (Ki ∼0.3 and 0.007 µM, respectively), with cyclosporine also inhibiting intestinal breast cancer resistance protein (BCRP; Ki ∼0.07 µM).",Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28296193/),μM,∼0.3,92277,DB01373,Calcium
,28296193,Ki,"The predicted effects of rifampin and cyclosporine (6.58-fold and 5.07-fold increase in rosuvastatin area under the curve (AUC), respectively) were mediated primarily via inhibition of hepatic organic anion-transporting polypeptide (OATP)1B1 (Inhibition constant (Ki ) ∼1.1 and 0.014 µM, respectively) and OATP1B3 (Ki ∼0.3 and 0.007 µM, respectively), with cyclosporine also inhibiting intestinal breast cancer resistance protein (BCRP; Ki ∼0.07 µM).",Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28296193/),μM,0.007,92278,DB01373,Calcium
,29161913,particle size,"The particle size and % drug entrapment of the optimized batch was 494.37 ± 1.4 µm and 81.39 ± 2.9%, respectively, closer to the value predicted by Minitab 17 software.",Development and optimization of locust bean gum and sodium alginate interpenetrating polymeric network of capecitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29161913/),µm,494.37,92951,DB01373,Calcium
,29161913,% drug entrapment,"The particle size and % drug entrapment of the optimized batch was 494.37 ± 1.4 µm and 81.39 ± 2.9%, respectively, closer to the value predicted by Minitab 17 software.",Development and optimization of locust bean gum and sodium alginate interpenetrating polymeric network of capecitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29161913/),%,81.39,92952,DB01373,Calcium
,15692829,half-life,"Acute hypoxia did not alter the pharmacokinetics of theophylline [half-life+/-SD: 9.29+/-1.77 versus 9.39+/-1.40 (hypoxia)], 1,3-dimethyluric acid (12.9+/-4.72 versus 15.1+/-8.59), verapamil (2.00+/-0.98 versus 1.79+/-0.58), or norverapamil (7.98+/-2.94 versus 9.91+/-6.40).","Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692829/),,9.29,93165,DB01373,Calcium
,15692829,half-life,"Acute hypoxia did not alter the pharmacokinetics of theophylline [half-life+/-SD: 9.29+/-1.77 versus 9.39+/-1.40 (hypoxia)], 1,3-dimethyluric acid (12.9+/-4.72 versus 15.1+/-8.59), verapamil (2.00+/-0.98 versus 1.79+/-0.58), or norverapamil (7.98+/-2.94 versus 9.91+/-6.40).","Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692829/),,9.39,93166,DB01373,Calcium
,15692829,half-life,"Acute hypoxia did not alter the pharmacokinetics of theophylline [half-life+/-SD: 9.29+/-1.77 versus 9.39+/-1.40 (hypoxia)], 1,3-dimethyluric acid (12.9+/-4.72 versus 15.1+/-8.59), verapamil (2.00+/-0.98 versus 1.79+/-0.58), or norverapamil (7.98+/-2.94 versus 9.91+/-6.40).","Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692829/),,12.9,93167,DB01373,Calcium
,15692829,half-life,"Acute hypoxia did not alter the pharmacokinetics of theophylline [half-life+/-SD: 9.29+/-1.77 versus 9.39+/-1.40 (hypoxia)], 1,3-dimethyluric acid (12.9+/-4.72 versus 15.1+/-8.59), verapamil (2.00+/-0.98 versus 1.79+/-0.58), or norverapamil (7.98+/-2.94 versus 9.91+/-6.40).","Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692829/),,15.1,93168,DB01373,Calcium
,15692829,half-life,"Acute hypoxia did not alter the pharmacokinetics of theophylline [half-life+/-SD: 9.29+/-1.77 versus 9.39+/-1.40 (hypoxia)], 1,3-dimethyluric acid (12.9+/-4.72 versus 15.1+/-8.59), verapamil (2.00+/-0.98 versus 1.79+/-0.58), or norverapamil (7.98+/-2.94 versus 9.91+/-6.40).","Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692829/),,2.00,93169,DB01373,Calcium
,15692829,half-life,"Acute hypoxia did not alter the pharmacokinetics of theophylline [half-life+/-SD: 9.29+/-1.77 versus 9.39+/-1.40 (hypoxia)], 1,3-dimethyluric acid (12.9+/-4.72 versus 15.1+/-8.59), verapamil (2.00+/-0.98 versus 1.79+/-0.58), or norverapamil (7.98+/-2.94 versus 9.91+/-6.40).","Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692829/),,1.79,93170,DB01373,Calcium
,15692829,half-life,"Acute hypoxia did not alter the pharmacokinetics of theophylline [half-life+/-SD: 9.29+/-1.77 versus 9.39+/-1.40 (hypoxia)], 1,3-dimethyluric acid (12.9+/-4.72 versus 15.1+/-8.59), verapamil (2.00+/-0.98 versus 1.79+/-0.58), or norverapamil (7.98+/-2.94 versus 9.91+/-6.40).","Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692829/),,7.98,93171,DB01373,Calcium
,15692829,half-life,"Acute hypoxia did not alter the pharmacokinetics of theophylline [half-life+/-SD: 9.29+/-1.77 versus 9.39+/-1.40 (hypoxia)], 1,3-dimethyluric acid (12.9+/-4.72 versus 15.1+/-8.59), verapamil (2.00+/-0.98 versus 1.79+/-0.58), or norverapamil (7.98+/-2.94 versus 9.91+/-6.40).","Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692829/),,9.91,93172,DB01373,Calcium
,17953788,maximum concentration,"Concerning AA, only CIT, ornithine (ORN) and arginine (ARG) plasma concentrations were affected (maximum concentration 146 (sem 8) to 303 (sem 11) micromol/l (ARG) and 81 (sem 4) to 179 (sem 10) micromol/l (ORN); time to reach maximum concentration 1.17 (sem 0.26) to 2.29 (sem 0.20) h (ARG) and 1.38 (sem 0.25) to 1.79 (sem 0.11) h (ORN) according to CIT dose).",Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17953788/),[μM] / [l],146,93834,DB01373,Calcium
,17953788,maximum concentration,"Concerning AA, only CIT, ornithine (ORN) and arginine (ARG) plasma concentrations were affected (maximum concentration 146 (sem 8) to 303 (sem 11) micromol/l (ARG) and 81 (sem 4) to 179 (sem 10) micromol/l (ORN); time to reach maximum concentration 1.17 (sem 0.26) to 2.29 (sem 0.20) h (ARG) and 1.38 (sem 0.25) to 1.79 (sem 0.11) h (ORN) according to CIT dose).",Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17953788/),[μM] / [l],303,93835,DB01373,Calcium
,17953788,maximum concentration,"Concerning AA, only CIT, ornithine (ORN) and arginine (ARG) plasma concentrations were affected (maximum concentration 146 (sem 8) to 303 (sem 11) micromol/l (ARG) and 81 (sem 4) to 179 (sem 10) micromol/l (ORN); time to reach maximum concentration 1.17 (sem 0.26) to 2.29 (sem 0.20) h (ARG) and 1.38 (sem 0.25) to 1.79 (sem 0.11) h (ORN) according to CIT dose).",Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17953788/),[μM] / [l],81,93836,DB01373,Calcium
,17953788,maximum concentration,"Concerning AA, only CIT, ornithine (ORN) and arginine (ARG) plasma concentrations were affected (maximum concentration 146 (sem 8) to 303 (sem 11) micromol/l (ARG) and 81 (sem 4) to 179 (sem 10) micromol/l (ORN); time to reach maximum concentration 1.17 (sem 0.26) to 2.29 (sem 0.20) h (ARG) and 1.38 (sem 0.25) to 1.79 (sem 0.11) h (ORN) according to CIT dose).",Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17953788/),[μM] / [l],179,93837,DB01373,Calcium
,17953788,time to reach maximum concentration,"Concerning AA, only CIT, ornithine (ORN) and arginine (ARG) plasma concentrations were affected (maximum concentration 146 (sem 8) to 303 (sem 11) micromol/l (ARG) and 81 (sem 4) to 179 (sem 10) micromol/l (ORN); time to reach maximum concentration 1.17 (sem 0.26) to 2.29 (sem 0.20) h (ARG) and 1.38 (sem 0.25) to 1.79 (sem 0.11) h (ORN) according to CIT dose).",Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17953788/),h,1.17,93838,DB01373,Calcium
,17953788,time to reach maximum concentration,"Concerning AA, only CIT, ornithine (ORN) and arginine (ARG) plasma concentrations were affected (maximum concentration 146 (sem 8) to 303 (sem 11) micromol/l (ARG) and 81 (sem 4) to 179 (sem 10) micromol/l (ORN); time to reach maximum concentration 1.17 (sem 0.26) to 2.29 (sem 0.20) h (ARG) and 1.38 (sem 0.25) to 1.79 (sem 0.11) h (ORN) according to CIT dose).",Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17953788/),h,2.29,93839,DB01373,Calcium
,17953788,time to reach maximum concentration,"Concerning AA, only CIT, ornithine (ORN) and arginine (ARG) plasma concentrations were affected (maximum concentration 146 (sem 8) to 303 (sem 11) micromol/l (ARG) and 81 (sem 4) to 179 (sem 10) micromol/l (ORN); time to reach maximum concentration 1.17 (sem 0.26) to 2.29 (sem 0.20) h (ARG) and 1.38 (sem 0.25) to 1.79 (sem 0.11) h (ORN) according to CIT dose).",Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17953788/),h,1.38,93840,DB01373,Calcium
,17953788,time to reach maximum concentration,"Concerning AA, only CIT, ornithine (ORN) and arginine (ARG) plasma concentrations were affected (maximum concentration 146 (sem 8) to 303 (sem 11) micromol/l (ARG) and 81 (sem 4) to 179 (sem 10) micromol/l (ORN); time to reach maximum concentration 1.17 (sem 0.26) to 2.29 (sem 0.20) h (ARG) and 1.38 (sem 0.25) to 1.79 (sem 0.11) h (ORN) according to CIT dose).",Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17953788/),h,1.79,93841,DB01373,Calcium
<,17953788,urinary excretion,"Even at high doses, urinary excretion of CIT remained low ( < 5 %).",Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic study. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17953788/),%,5,93842,DB01373,Calcium
,23381958,maximum concentration (Cmax),"In the absence of diltiazem, the mean (95 % confidence interval [CI]) maximum concentration (Cmax) and area under the curve from time zero to infinity (AUC∞) were 26.8 (20.1-35.8) ng/mL and 454 (351-587) ng·h/mL, respectively.","Drug-drug interaction study of ACT-178882, a new renin inhibitor, and diltiazem in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23381958/),[ng] / [ml],26.8,94116,DB01373,Calcium
,23381958,area under the curve from time zero to infinity (AUC∞),"In the absence of diltiazem, the mean (95 % confidence interval [CI]) maximum concentration (Cmax) and area under the curve from time zero to infinity (AUC∞) were 26.8 (20.1-35.8) ng/mL and 454 (351-587) ng·h/mL, respectively.","Drug-drug interaction study of ACT-178882, a new renin inhibitor, and diltiazem in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23381958/),[h·ng] / [ml],454,94117,DB01373,Calcium
,23381958,time to Cmax (tmax),"The median time to Cmax (tmax) for ACT-178882 was prolonged from 3.5 to 5.0 h by diltiazem whereas its apparent terminal half-life (t½) was unaffected by diltiazem, 22.9 and 24.2 h for treatments A and B, respectively.","Drug-drug interaction study of ACT-178882, a new renin inhibitor, and diltiazem in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23381958/),h,3.5,94118,DB01373,Calcium
,23381958,time to Cmax (tmax),"The median time to Cmax (tmax) for ACT-178882 was prolonged from 3.5 to 5.0 h by diltiazem whereas its apparent terminal half-life (t½) was unaffected by diltiazem, 22.9 and 24.2 h for treatments A and B, respectively.","Drug-drug interaction study of ACT-178882, a new renin inhibitor, and diltiazem in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23381958/),h,5.0,94119,DB01373,Calcium
,23381958,apparent terminal half-life (t½),"The median time to Cmax (tmax) for ACT-178882 was prolonged from 3.5 to 5.0 h by diltiazem whereas its apparent terminal half-life (t½) was unaffected by diltiazem, 22.9 and 24.2 h for treatments A and B, respectively.","Drug-drug interaction study of ACT-178882, a new renin inhibitor, and diltiazem in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23381958/),h,22.9,94120,DB01373,Calcium
,23381958,apparent terminal half-life (t½),"The median time to Cmax (tmax) for ACT-178882 was prolonged from 3.5 to 5.0 h by diltiazem whereas its apparent terminal half-life (t½) was unaffected by diltiazem, 22.9 and 24.2 h for treatments A and B, respectively.","Drug-drug interaction study of ACT-178882, a new renin inhibitor, and diltiazem in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23381958/),h,24.2,94121,DB01373,Calcium
,17981422,total chromatographic run time,"Transitions 456>166 for VER enantiomers, 441>166 for NOR enantiomers and 330>193 for the internal standard were monitored and the method had a total chromatographic run time of 12 min.",Simultaneous analysis of the enantiomers of verapamil and norverapamil in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17981422/),min,12,94549,DB01373,Calcium
,17981422,AUC ratio (-)/(+),"The concentration of (-)-(S)-VER was three folds higher than (+)-(R)-VER, with an AUC ratio (-)/(+) of 2.66.",Simultaneous analysis of the enantiomers of verapamil and norverapamil in rat plasma by liquid chromatography-tandem mass spectrometry. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17981422/),,2.66,94550,DB01373,Calcium
,17981422,Oral clearance,"Oral clearance values were 12.17 and 28.77 L/h/kg for (-)-(S)-VER and (+)-(R)-VER, respectively.",Simultaneous analysis of the enantiomers of verapamil and norverapamil in rat plasma by liquid chromatography-tandem mass spectrometry. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17981422/),[l] / [h·kg],12.17,94551,DB01373,Calcium
,17981422,Oral clearance,"Oral clearance values were 12.17 and 28.77 L/h/kg for (-)-(S)-VER and (+)-(R)-VER, respectively.",Simultaneous analysis of the enantiomers of verapamil and norverapamil in rat plasma by liquid chromatography-tandem mass spectrometry. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17981422/),[l] / [h·kg],28.77,94552,DB01373,Calcium
,21342321,PTH,The patients who achieved target PTH of 16-32 pmol/L were 82% in the calcitriol and 67% in the alfacalcidol group (P = 0.44).,Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21342321/),[pM] / [l],16-32,94563,DB01373,Calcium
,16389642,flow rate,"Mobile phase consisting of 0.05 m formic acid and acetonitrile (55:45, v/v) was used at a flow rate of 1.0 mL/min for the effective separation of RST and IS.",Determination of rosuvastatin in rat plasma by HPLC: Validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16389642/),[ml] / [min],1.0,94723,DB01373,Calcium
,16389642,Nominal retention times,"Nominal retention times of RST and IS were 8.6 and 12.5 min, respectively.",Determination of rosuvastatin in rat plasma by HPLC: Validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16389642/),min,8.6,94724,DB01373,Calcium
,16389642,Nominal retention times,"Nominal retention times of RST and IS were 8.6 and 12.5 min, respectively.",Determination of rosuvastatin in rat plasma by HPLC: Validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16389642/),min,12.5,94725,DB01373,Calcium
,16389642,Absolute recoveries,"Absolute recoveries of RST and IS were 85-110 and >100%, respectively, from rat plasma.",Determination of rosuvastatin in rat plasma by HPLC: Validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16389642/),%,85-110,94726,DB01373,Calcium
,16389642,Absolute recoveries,"Absolute recoveries of RST and IS were 85-110 and >100%, respectively, from rat plasma.",Determination of rosuvastatin in rat plasma by HPLC: Validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16389642/),%,>,94727,DB01373,Calcium
,16389642,Absolute recoveries,"Absolute recoveries of RST and IS were 85-110 and >100%, respectively, from rat plasma.",Determination of rosuvastatin in rat plasma by HPLC: Validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16389642/),%,100,94728,DB01373,Calcium
,19539409,half-lives,(90)Sr stays long in the freshwater ecosystem; the observed half-lives during the study period were generally around 10 years in water and even longer in fish.,Transfer of 90Sr into fish in Finnish lakes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539409/),years,10,95313,DB01373,Calcium
less,19539409,half-life,"One lake exhibited very different behavior for (90)Sr, with elevated levels in fish and water and very short observed half-life in fish, less than 2 years.",Transfer of 90Sr into fish in Finnish lakes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539409/),years,2,95314,DB01373,Calcium
,24399740,IC50,"Administration of nifedipine resulted in inhibition CYP3A4 activity with an IC50 value of 7.8 μM, and nifedipine significantly inhibited P-gp activity in a concentration-dependent manner.",Effects of nifedipine on the pharmacokinetics of repaglinide in rats: possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24399740/),μM,7.8,95337,DB01373,Calcium
,24399740,absolute bioavailability (AB),Nifedipine also increased the absolute bioavailability (AB) of repaglinide by 50.0% compared to the oral control group (33.6%).,Effects of nifedipine on the pharmacokinetics of repaglinide in rats: possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24399740/),%,33.6,95338,DB01373,Calcium
,21324753,flow rate,"The method showed adequate separation for rosuvastatin and atorvastatin and best resolution was achieved with Brownlee analytical C18 column (150×4.6 mm, 5 μm) using methanol-water (68:32, v/v; pH adjusted to 3.0 with trifluoroacetic acid) as a mobile phase at a flow rate of 1.5 ml/min and wavelength of 241 nm.","Simultaneous determination of rosuvastatin and atorvastatin in human serum using RP-HPLC/UV detection: method development, validation and optimization of various experimental parameters. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21324753/),[ml] / [min],1.5,95580,DB01373,Calcium
,12395979,elimination half-life,The elimination half-life of levosimendan was 1.3 hours and that of the metabolites 75-78 hours.,Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395979/),h,1.3,95871,DB01373,Calcium
,12395979,elimination half-life,The elimination half-life of levosimendan was 1.3 hours and that of the metabolites 75-78 hours.,Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395979/),h,75-78,95872,DB01373,Calcium
,26804640,Cmax,"Mean (SD) Cmax values were 7.68 (4.25), 17 (6.33), and 31.3 (16.42) ng/mL with single doses of 25, 50, and 100 mg of cinacalcet, respectively.","Pharmacokinetic and Pharmacodynamic Properties of Cinacalcet (KRN1493) in Chinese Healthy Volunteers: A Randomized, Open-label, Single Ascending-dose and Multiple-dose, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804640/),[ng] / [ml],7.68,96447,DB01373,Calcium
,26804640,Cmax,"Mean (SD) Cmax values were 7.68 (4.25), 17 (6.33), and 31.3 (16.42) ng/mL with single doses of 25, 50, and 100 mg of cinacalcet, respectively.","Pharmacokinetic and Pharmacodynamic Properties of Cinacalcet (KRN1493) in Chinese Healthy Volunteers: A Randomized, Open-label, Single Ascending-dose and Multiple-dose, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804640/),[ng] / [ml],17,96448,DB01373,Calcium
,26804640,Cmax,"Mean (SD) Cmax values were 7.68 (4.25), 17 (6.33), and 31.3 (16.42) ng/mL with single doses of 25, 50, and 100 mg of cinacalcet, respectively.","Pharmacokinetic and Pharmacodynamic Properties of Cinacalcet (KRN1493) in Chinese Healthy Volunteers: A Randomized, Open-label, Single Ascending-dose and Multiple-dose, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804640/),[ng] / [ml],31.3,96449,DB01373,Calcium
,26804640,AUC0- last,"Mean (SD) AUC0- last values were 58.4 (25.38), 187 (70.7), and 367 (180.03) hr∙ng/mL with single doses of 25, 50, and 100 mg of cinacalcet, respectively.","Pharmacokinetic and Pharmacodynamic Properties of Cinacalcet (KRN1493) in Chinese Healthy Volunteers: A Randomized, Open-label, Single Ascending-dose and Multiple-dose, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804640/),[hr∙ng] / [ml],58.4,96450,DB01373,Calcium
,26804640,AUC0- last,"Mean (SD) AUC0- last values were 58.4 (25.38), 187 (70.7), and 367 (180.03) hr∙ng/mL with single doses of 25, 50, and 100 mg of cinacalcet, respectively.","Pharmacokinetic and Pharmacodynamic Properties of Cinacalcet (KRN1493) in Chinese Healthy Volunteers: A Randomized, Open-label, Single Ascending-dose and Multiple-dose, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804640/),[hr∙ng] / [ml],187,96451,DB01373,Calcium
,26804640,AUC0- last,"Mean (SD) AUC0- last values were 58.4 (25.38), 187 (70.7), and 367 (180.03) hr∙ng/mL with single doses of 25, 50, and 100 mg of cinacalcet, respectively.","Pharmacokinetic and Pharmacodynamic Properties of Cinacalcet (KRN1493) in Chinese Healthy Volunteers: A Randomized, Open-label, Single Ascending-dose and Multiple-dose, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804640/),[hr∙ng] / [ml],367,96452,DB01373,Calcium
,26804640,Cmax,"At steady state, the mean (SD) Cmax and AUC0-last values were 20.6 (9.63) ng/mL and 297 (146.15) ng∙h/mL.","Pharmacokinetic and Pharmacodynamic Properties of Cinacalcet (KRN1493) in Chinese Healthy Volunteers: A Randomized, Open-label, Single Ascending-dose and Multiple-dose, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804640/),[ng] / [ml],20.6,96453,DB01373,Calcium
,26804640,AUC0-last,"At steady state, the mean (SD) Cmax and AUC0-last values were 20.6 (9.63) ng/mL and 297 (146.15) ng∙h/mL.","Pharmacokinetic and Pharmacodynamic Properties of Cinacalcet (KRN1493) in Chinese Healthy Volunteers: A Randomized, Open-label, Single Ascending-dose and Multiple-dose, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804640/),[ng∙h] / [ml],297,96454,DB01373,Calcium
,26804640,accumulation ratios,The accumulation ratios of Cmax and AUC (AUCτ/AUC0-24) were 1.21 and 1.32.,"Pharmacokinetic and Pharmacodynamic Properties of Cinacalcet (KRN1493) in Chinese Healthy Volunteers: A Randomized, Open-label, Single Ascending-dose and Multiple-dose, Parallel-group Study. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804640/),,1.21,96455,DB01373,Calcium
,26804640,accumulation ratios,The accumulation ratios of Cmax and AUC (AUCτ/AUC0-24) were 1.21 and 1.32.,"Pharmacokinetic and Pharmacodynamic Properties of Cinacalcet (KRN1493) in Chinese Healthy Volunteers: A Randomized, Open-label, Single Ascending-dose and Multiple-dose, Parallel-group Study. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804640/),,1.32,96456,DB01373,Calcium
,30830506,relative bioavailability,In vivo pharmacokinetic studies of EVLF in rats demonstrated a 199% relative bioavailability compared to ERL suspension.,Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30830506/),%,199,96575,DB01373,Calcium
,28646274,absorption rate constant (K a),"The absorption rate constant (K a), V/F, and apparent oral clearance (CL/F) of the final population pharmacokinetic (PopPK) model of diltiazem were 1.96/h, 3550 L, and 92.4 L/h, respectively.",Population Pharmacokinetic Modeling of Diltiazem in Chinese Renal Transplant Recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28646274/),1/[h],1.96,96725,DB01373,Calcium
,28646274,V/F,"The absorption rate constant (K a), V/F, and apparent oral clearance (CL/F) of the final population pharmacokinetic (PopPK) model of diltiazem were 1.96/h, 3550 L, and 92.4 L/h, respectively.",Population Pharmacokinetic Modeling of Diltiazem in Chinese Renal Transplant Recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28646274/),l,3550,96726,DB01373,Calcium
,28646274,apparent oral clearance (CL/F),"The absorption rate constant (K a), V/F, and apparent oral clearance (CL/F) of the final population pharmacokinetic (PopPK) model of diltiazem were 1.96/h, 3550 L, and 92.4 L/h, respectively.",Population Pharmacokinetic Modeling of Diltiazem in Chinese Renal Transplant Recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28646274/),[l] / [h],92.4,96727,DB01373,Calcium
,28250348,t1/2,"Cesium-137 (137Cs) (t1/2=30.1 year), a water-soluble radionuclide with a long physical half-life, contaminates aquatic ecosystems and food products.",Complexes of myo-Inositol-Hexakisphosphate (IP6) with Zinc or Lanthanum for the Decorporation of Radiocesium. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28250348/),year,30.1,97115,DB01373,Calcium
,19738417,MTD,"The MTD of the combination of CAI and paclitaxel is 250 mg daily and 200 mg/m(2) q3weeks, respectively.",A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19738417/),mg,250,97276,DB01373,Calcium
,27668695,C<sub>max,"The mean C<sub>max,ss</sub> and AUC<sub>τ,ss</sub> values of fimasartan were 258.03 ± 176.75 ng/mL and 746.52 ± 273.49 ng×h/mL for fimasartan alone, and 289.40 ± 231.44 ng/mL and 848.43 ± 267.45 ng×h/mL for fimasartan and rosuvastatin coadministration, respectively (p-values for C<sub>max,ss</sub> and AUC<sub>τ,ss</sub>, 0. 513 and 0.006, respectively).",Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27668695/),[ng] / [ml],258.03,97782,DB01373,Calcium
,27668695,C<sub>max,"The mean C<sub>max,ss</sub> and AUC<sub>τ,ss</sub> values of fimasartan were 258.03 ± 176.75 ng/mL and 746.52 ± 273.49 ng×h/mL for fimasartan alone, and 289.40 ± 231.44 ng/mL and 848.43 ± 267.45 ng×h/mL for fimasartan and rosuvastatin coadministration, respectively (p-values for C<sub>max,ss</sub> and AUC<sub>τ,ss</sub>, 0. 513 and 0.006, respectively).",Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27668695/),[ng] / [ml],289.40,97783,DB01373,Calcium
,27668695,"AUC<sub>τ,ss</sub>","The mean C<sub>max,ss</sub> and AUC<sub>τ,ss</sub> values of fimasartan were 258.03 ± 176.75 ng/mL and 746.52 ± 273.49 ng×h/mL for fimasartan alone, and 289.40 ± 231.44 ng/mL and 848.43 ± 267.45 ng×h/mL for fimasartan and rosuvastatin coadministration, respectively (p-values for C<sub>max,ss</sub> and AUC<sub>τ,ss</sub>, 0. 513 and 0.006, respectively).",Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27668695/),[h·ng] / [ml],746.52,97784,DB01373,Calcium
,27668695,"AUC<sub>τ,ss</sub>","The mean C<sub>max,ss</sub> and AUC<sub>τ,ss</sub> values of fimasartan were 258.03 ± 176.75 ng/mL and 746.52 ± 273.49 ng×h/mL for fimasartan alone, and 289.40 ± 231.44 ng/mL and 848.43 ± 267.45 ng×h/mL for fimasartan and rosuvastatin coadministration, respectively (p-values for C<sub>max,ss</sub> and AUC<sub>τ,ss</sub>, 0. 513 and 0.006, respectively).",Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27668695/),[h·ng] / [ml],848.43,97785,DB01373,Calcium
,27668695,C<sub>max,"The mean C<sub>max,ss</sub> and AUC<sub>τ,ss</sub> values of rosuvastatin were 9.94 ± 4.48 ng/mL and 85.29 ± 36.25 ng×h/mL for rosuvastatin alone and 11.94 ± 8.47 ng/mL and 77.33 ± 38.71 ng×h/mL for fimasartan and rosuvastatin coadministration, respectively (p-values for C<sub>max,ss</sub> and AUC<sub>τ,ss</sub>, 0.066 and 0.009, respectively).",Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27668695/),[ng] / [ml],9.94,97786,DB01373,Calcium
,27668695,C<sub>max,"The mean C<sub>max,ss</sub> and AUC<sub>τ,ss</sub> values of rosuvastatin were 9.94 ± 4.48 ng/mL and 85.29 ± 36.25 ng×h/mL for rosuvastatin alone and 11.94 ± 8.47 ng/mL and 77.33 ± 38.71 ng×h/mL for fimasartan and rosuvastatin coadministration, respectively (p-values for C<sub>max,ss</sub> and AUC<sub>τ,ss</sub>, 0.066 and 0.009, respectively).",Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27668695/),[ng] / [ml],11.94,97787,DB01373,Calcium
,27668695,"AUC<sub>τ,ss</sub>","The mean C<sub>max,ss</sub> and AUC<sub>τ,ss</sub> values of rosuvastatin were 9.94 ± 4.48 ng/mL and 85.29 ± 36.25 ng×h/mL for rosuvastatin alone and 11.94 ± 8.47 ng/mL and 77.33 ± 38.71 ng×h/mL for fimasartan and rosuvastatin coadministration, respectively (p-values for C<sub>max,ss</sub> and AUC<sub>τ,ss</sub>, 0.066 and 0.009, respectively).",Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27668695/),[h·ng] / [ml],85.29,97788,DB01373,Calcium
,27668695,"AUC<sub>τ,ss</sub>","The mean C<sub>max,ss</sub> and AUC<sub>τ,ss</sub> values of rosuvastatin were 9.94 ± 4.48 ng/mL and 85.29 ± 36.25 ng×h/mL for rosuvastatin alone and 11.94 ± 8.47 ng/mL and 77.33 ± 38.71 ng×h/mL for fimasartan and rosuvastatin coadministration, respectively (p-values for C<sub>max,ss</sub> and AUC<sub>τ,ss</sub>, 0.066 and 0.009, respectively).",Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27668695/),[h·ng] / [ml],77.33,97789,DB01373,Calcium
,32725783,terminal half-life,AP30663 displayed a less than dose proportional increase in peak plasma concentration (Cmax ) and a terminal half-life of around 5 hours.,First Clinical Study with AP30663 - a KCa 2 Channel Inhibitor in Development for Conversion of Atrial Fibrillation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32725783/),h,5,97797,DB01373,Calcium
,15289793,steady,"In transplant recipients taking 10 mg rosuvastatin, geometric mean values and percent coefficient of variation for steady-state AUC(0-24) and Cmax were 284 ng.",Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289793/),ng,28,98031,DB01373,Calcium
,15289793,association constant,"The in vitro results demonstrate that rosuvastatin is a good substrate for OATP-C-mediated hepatic uptake (association constant, 8.5 +/- 1.1 micromol/L) and that cyclosporine is an effective inhibitor of this process (50% inhibition constant, 2.2 +/- 0.4 micromol/L when the rosuvastatin concentration was 5 micromol/L).",Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289793/),[μM] / [l],8.5,98032,DB01373,Calcium
,15289793,50% inhibition constant,"The in vitro results demonstrate that rosuvastatin is a good substrate for OATP-C-mediated hepatic uptake (association constant, 8.5 +/- 1.1 micromol/L) and that cyclosporine is an effective inhibitor of this process (50% inhibition constant, 2.2 +/- 0.4 micromol/L when the rosuvastatin concentration was 5 micromol/L).",Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289793/),[μM] / [l],2.2,98033,DB01373,Calcium
,18522929,bioavailability,"At a dose of 1 mg/kg subcutaneous (sc) bioavailability of atacicept in mice and monkeys was 76 and 92%, with a mean serum t(1/2) of 44 and 179 h, respectively.","Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18522929/),%,76,99009,DB01373,Calcium
,18522929,bioavailability,"At a dose of 1 mg/kg subcutaneous (sc) bioavailability of atacicept in mice and monkeys was 76 and 92%, with a mean serum t(1/2) of 44 and 179 h, respectively.","Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18522929/),%,92,99010,DB01373,Calcium
,18522929,serum t(1/2),"At a dose of 1 mg/kg subcutaneous (sc) bioavailability of atacicept in mice and monkeys was 76 and 92%, with a mean serum t(1/2) of 44 and 179 h, respectively.","Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18522929/),h,44,99011,DB01373,Calcium
,18522929,serum t(1/2),"At a dose of 1 mg/kg subcutaneous (sc) bioavailability of atacicept in mice and monkeys was 76 and 92%, with a mean serum t(1/2) of 44 and 179 h, respectively.","Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18522929/),h,179,99012,DB01373,Calcium
,19298584,Normalized area under the phosphate vs. time curve,Normalized area under the phosphate vs. time curve for Group I was 1120 +/- 190 mg/dL*min and 685 +/- 136 mg/dL*min for Group II (P < 0.001).,Increased serum phosphate levels and calcium fluxes are seen in smaller individuals after a single dose of sodium phosphate colon cleansing solution: a pharmacokinetic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19298584/),[mg] / [dl·min],1120,99392,DB01373,Calcium
,19298584,Normalized area under the phosphate vs. time curve,Normalized area under the phosphate vs. time curve for Group I was 1120 +/- 190 mg/dL*min and 685 +/- 136 mg/dL*min for Group II (P < 0.001).,Increased serum phosphate levels and calcium fluxes are seen in smaller individuals after a single dose of sodium phosphate colon cleansing solution: a pharmacokinetic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19298584/),[mg] / [dl·min],685,99393,DB01373,Calcium
,32428844,serum half-life,"In the multiple ascending dose Phase 1 clinical trial, the serum half-life of about 30 h provides a favorable profile for once daily dosing of IMU-838, with quick dosing to steady state through levels within 5 days and the ability to wash out drug quickly, if required.","Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32428844/),h,30,99520,DB01373,Calcium
,14677272,Cmax,"The Cmax was found to be 51.4 +/- 15.5 and 48.6 +/- 17.9 (ng/ml) for Manidon and B, respectively and the corresponding tmax were 7.0 +/- 1.9 and 6.0 +/- 0, respectively.",Intra-gastric performance and bioavailability study of a new per-oral bioadhesive Verapamil HCl matrix tablet in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14677272/),[ng] / [ml],51.4,99631,DB01373,Calcium
,14677272,Cmax,"The Cmax was found to be 51.4 +/- 15.5 and 48.6 +/- 17.9 (ng/ml) for Manidon and B, respectively and the corresponding tmax were 7.0 +/- 1.9 and 6.0 +/- 0, respectively.",Intra-gastric performance and bioavailability study of a new per-oral bioadhesive Verapamil HCl matrix tablet in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14677272/),[ng] / [ml],48.6,99632,DB01373,Calcium
,14677272,tmax,"The Cmax was found to be 51.4 +/- 15.5 and 48.6 +/- 17.9 (ng/ml) for Manidon and B, respectively and the corresponding tmax were 7.0 +/- 1.9 and 6.0 +/- 0, respectively.",Intra-gastric performance and bioavailability study of a new per-oral bioadhesive Verapamil HCl matrix tablet in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14677272/),,7.0,99633,DB01373,Calcium
,14677272,tmax,"The Cmax was found to be 51.4 +/- 15.5 and 48.6 +/- 17.9 (ng/ml) for Manidon and B, respectively and the corresponding tmax were 7.0 +/- 1.9 and 6.0 +/- 0, respectively.",Intra-gastric performance and bioavailability study of a new per-oral bioadhesive Verapamil HCl matrix tablet in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14677272/),,6.0,99634,DB01373,Calcium
,14677272,AUCO-.,"The AUCO-. for Manidon and B were 949.84 +/- 245.11 and 722.92 +/- 144.42 ng.h/ml, respectively.",Intra-gastric performance and bioavailability study of a new per-oral bioadhesive Verapamil HCl matrix tablet in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14677272/),[h·ng] / [ml],949.84,99635,DB01373,Calcium
,14677272,AUCO-.,"The AUCO-. for Manidon and B were 949.84 +/- 245.11 and 722.92 +/- 144.42 ng.h/ml, respectively.",Intra-gastric performance and bioavailability study of a new per-oral bioadhesive Verapamil HCl matrix tablet in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14677272/),[h·ng] / [ml],722.92,99636,DB01373,Calcium
,17240061,"maximal concentration, C(max)","In pre-treated rats with V, hippocampal PHT concentrations were lower in MP (maximal concentration, C(max): 2.7+/-0.3 microg ml(-1), p<0.05 versus C rats) than in C animals (C(max): 5.3+/-0.9 microg ml(-1)).",Nimodipine restores the altered hippocampal phenytoin pharmacokinetics in a refractory epileptic model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17240061/),[μg] / [ml],2.7,101476,DB01373,Calcium
,17240061,C(max),"In pre-treated rats with V, hippocampal PHT concentrations were lower in MP (maximal concentration, C(max): 2.7+/-0.3 microg ml(-1), p<0.05 versus C rats) than in C animals (C(max): 5.3+/-0.9 microg ml(-1)).",Nimodipine restores the altered hippocampal phenytoin pharmacokinetics in a refractory epileptic model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17240061/),[μg] / [ml],5.3,101477,DB01373,Calcium
,17240061,C(max),"Control rats pre-treated with NIMO showed similar results (C(max): 4.5+/-0.8 microg ml(-1)) than those pre-treated with V. NIMO pre-treatment of MP rats showed higher PHT concentrations (C(max): 6.8+/-1.0 microg ml(-1), p<0.05) when compared with V pre-treated MP group.",Nimodipine restores the altered hippocampal phenytoin pharmacokinetics in a refractory epileptic model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17240061/),[μg] / [ml],4.5,101478,DB01373,Calcium
,17240061,C(max),"Control rats pre-treated with NIMO showed similar results (C(max): 4.5+/-0.8 microg ml(-1)) than those pre-treated with V. NIMO pre-treatment of MP rats showed higher PHT concentrations (C(max): 6.8+/-1.0 microg ml(-1), p<0.05) when compared with V pre-treated MP group.",Nimodipine restores the altered hippocampal phenytoin pharmacokinetics in a refractory epileptic model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17240061/),[μg] / [ml],6.8,101479,DB01373,Calcium
,12733857,elimination half-life,We found an elimination half-life of bromide in blood of approximately of 10 days.,Bromism from daily over intake of bromide salt. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12733857/),d,10,101698,DB01373,Calcium
,19275545,bioavailability,"Although oral levosimendan has high bioavailability (approximately equal to 85%), in clinical practice it has been hitherto administered intravenously.",Relationship between the pharmacokinetics of levosimendan and its effects on cardiovascular system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19275545/),%,85,102151,DB01373,Calcium
,19275545,total clearance,Levosimendan has total clearance 175-250 mL/h/kg and most importantly a short half-life (about 1.5 hours).,Relationship between the pharmacokinetics of levosimendan and its effects on cardiovascular system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19275545/),[ml] / [h·kg],175-250,102152,DB01373,Calcium
,19275545,half-life,Levosimendan has total clearance 175-250 mL/h/kg and most importantly a short half-life (about 1.5 hours).,Relationship between the pharmacokinetics of levosimendan and its effects on cardiovascular system. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19275545/),h,1.5,102153,DB01373,Calcium
,19275545,half life,"Therefore, this drug has a special pharmacokinetic interest: It is one of the few drugs used in cardiovascular medicine, whose prolonged action is not due to the drug itself but it is mainly due to its active metabolite OR-1896 (approximately 80 hours half life).",Relationship between the pharmacokinetics of levosimendan and its effects on cardiovascular system. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19275545/),h,80,102154,DB01373,Calcium
,27113864,shelf life,A stability analysis has also been carried out according to ICH guidelines (Q1AR2) and shelf life was found to be 1year and 4 months for the prepared formulation.,Revisiting bone targeting potential of novel hydroxyapatite based surface modified PLGA nanoparticles of risedronate: Pharmacokinetic and biochemical assessment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27113864/),year,1,102308,DB01373,Calcium
,27113864,shelf life,A stability analysis has also been carried out according to ICH guidelines (Q1AR2) and shelf life was found to be 1year and 4 months for the prepared formulation.,Revisiting bone targeting potential of novel hydroxyapatite based surface modified PLGA nanoparticles of risedronate: Pharmacokinetic and biochemical assessment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27113864/),month,4,102309,DB01373,Calcium
,25270056,flow rate,"After one-step protein precipitation with methanol, the chromatographic separation was carried out on an Ecosil C18 column (150mm×4.6mm, 5μm) with a gradient mobile phase consisting of methanol and 5mM ammonium formate at a flow rate of 0.5mL/min.",Quantitation of clevidipine in dog blood by liquid chromatography tandem mass spectrometry: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25270056/),[ml] / [min],0.5,102373,DB01373,Calcium
,25270056,flow rate,The validated method has been successfully applied to a pharmacokinetic study of clevidipine injection to 8 healthy Beagle dogs following intravenous infusion at a flow rate of 5mg/h for 0.5h.,Quantitation of clevidipine in dog blood by liquid chromatography tandem mass spectrometry: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25270056/),[mg] / [h],5,102374,DB01373,Calcium
,32453913,half-maximal inhibitory concentration,"In vitro, febuxostat inhibited the ATP-dependent uptake of rosuvastatin into BCRP-overexpressing membrane vesicles with a half-maximal inhibitory concentration of 0.35 µM, whereas allopurinol showed no inhibition with concentrations up to 200 µM.","Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32453913/),μM,0.35,102626,DB01373,Calcium
,22001996,50% inhibition concentration (IC(50)),"Baicalein inhibited CYP3A4 enzyme activity in a concentration-dependent manner, with a 50% inhibition concentration (IC(50)) of 9.2 μM.",Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: a possible role of P-glycoprotein and CYP3A4 inhibition by baicalein. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22001996/),μM,9.2,102968,DB01373,Calcium
,22001996,absolute bioavailability,"Consequently, the absolute bioavailability of nimodipine in the presence of baicalein (2 and 8 mg/kg) was 31.0-35.3%, which was significantly enhanced (p < 0.05 for 2 mg/kg; p < 0.01 for 8 mg/kg) compared to the oral control group (22.3%).",Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: a possible role of P-glycoprotein and CYP3A4 inhibition by baicalein. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22001996/),%,31.0-35.3,102969,DB01373,Calcium
,22001996,absolute bioavailability,"Consequently, the absolute bioavailability of nimodipine in the presence of baicalein (2 and 8 mg/kg) was 31.0-35.3%, which was significantly enhanced (p < 0.05 for 2 mg/kg; p < 0.01 for 8 mg/kg) compared to the oral control group (22.3%).",Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: a possible role of P-glycoprotein and CYP3A4 inhibition by baicalein. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22001996/),%,22.3,102970,DB01373,Calcium
,33293242,plasma elimination half-life,The plasma elimination half-life of caffeine in the newborn is approximately 100 h.,"Pharmacokinetics, pharmacodynamics and metabolism of caffeine in newborns. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33293242/),h,100,103059,DB01373,Calcium
,12412821,half-lives,"Zoledronic plasma disposition was multiphasic, with half-lives of 0.2 and 1.4 hours representing an early, rapid decline of concentrations from the end-of-infusion C(max) to < 1% of C(max) at 24 hours postdose and half-lives of 39 and 4526 hours describing subsequent phases of very low concentrations between days 2 and 28 postdose.",Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412821/),h,0.2,103122,DB01373,Calcium
,12412821,half-lives,"Zoledronic plasma disposition was multiphasic, with half-lives of 0.2 and 1.4 hours representing an early, rapid decline of concentrations from the end-of-infusion C(max) to < 1% of C(max) at 24 hours postdose and half-lives of 39 and 4526 hours describing subsequent phases of very low concentrations between days 2 and 28 postdose.",Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412821/),h,1.4,103123,DB01373,Calcium
,12412821,half-lives,"Zoledronic plasma disposition was multiphasic, with half-lives of 0.2 and 1.4 hours representing an early, rapid decline of concentrations from the end-of-infusion C(max) to < 1% of C(max) at 24 hours postdose and half-lives of 39 and 4526 hours describing subsequent phases of very low concentrations between days 2 and 28 postdose.",Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412821/),h,39,103124,DB01373,Calcium
,12412821,half-lives,"Zoledronic plasma disposition was multiphasic, with half-lives of 0.2 and 1.4 hours representing an early, rapid decline of concentrations from the end-of-infusion C(max) to < 1% of C(max) at 24 hours postdose and half-lives of 39 and 4526 hours describing subsequent phases of very low concentrations between days 2 and 28 postdose.",Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412821/),h,4526,103125,DB01373,Calcium
,12412821,AUC0-24 h ratio,AUC0-24 h and C(max) were dose proportional and showed little accumulation (AUC0-24 h ratio between the third and first dose was 1.28).,Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412821/),,1.28,103126,DB01373,Calcium
,12412821,Ae0-24 h,"Urinary excretion of zoledronic acid was independent of infusion duration, dose, or number of doses, showing average Ae0-24 h of 38% +/- 13%, 41% +/- 14%, and 37% +/- 17%, respectively, after 4, 8, and 16 mg.",Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412821/),%,38,103127,DB01373,Calcium
,12412821,Ae0-24 h,"Urinary excretion of zoledronic acid was independent of infusion duration, dose, or number of doses, showing average Ae0-24 h of 38% +/- 13%, 41% +/- 14%, and 37% +/- 17%, respectively, after 4, 8, and 16 mg.",Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412821/),%,41,103128,DB01373,Calcium
,12412821,Ae0-24 h,"Urinary excretion of zoledronic acid was independent of infusion duration, dose, or number of doses, showing average Ae0-24 h of 38% +/- 13%, 41% +/- 14%, and 37% +/- 17%, respectively, after 4, 8, and 16 mg.",Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412821/),%,37,103129,DB01373,Calcium
,12412821,Renal clearance (Ae0-24 h)/(AUC0-24 h),"Renal clearance (Ae0-24 h)/(AUC0-24 h) was on average 69 +/- 28,81 +/- 40, and 54 +/- 34 ml/min after 4,8, and 16 mg, respectively, and showed a moderate correlation (r = 0.5; p < 0.001) with creatinine clearance, which was 84 +/- 23, 82 +/- 25, and 80 +/- 40 ml/min for the dose groups at baseline.",Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412821/),[ml] / [min],69,103130,DB01373,Calcium
,12412821,Renal clearance (Ae0-24 h)/(AUC0-24 h),"Renal clearance (Ae0-24 h)/(AUC0-24 h) was on average 69 +/- 28,81 +/- 40, and 54 +/- 34 ml/min after 4,8, and 16 mg, respectively, and showed a moderate correlation (r = 0.5; p < 0.001) with creatinine clearance, which was 84 +/- 23, 82 +/- 25, and 80 +/- 40 ml/min for the dose groups at baseline.",Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412821/),[ml] / [min],81,103131,DB01373,Calcium
,12412821,Renal clearance (Ae0-24 h)/(AUC0-24 h),"Renal clearance (Ae0-24 h)/(AUC0-24 h) was on average 69 +/- 28,81 +/- 40, and 54 +/- 34 ml/min after 4,8, and 16 mg, respectively, and showed a moderate correlation (r = 0.5; p < 0.001) with creatinine clearance, which was 84 +/- 23, 82 +/- 25, and 80 +/- 40 ml/min for the dose groups at baseline.",Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412821/),[ml] / [min],54,103132,DB01373,Calcium
,20946924,EC(50),"There were linear and exponential relationships between conjugate MW with potency and efficacy respectively, however the largest MW conjugate still retained 70% of E(max) and an EC(50) of 3.7nM.",PK/PD modelling of comb-shaped PEGylated salmon calcitonin conjugates of differing molecular weights. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20946924/),nM,3.7,103844,DB01373,Calcium
,18793580,maximum plasma concentration (Cmax),The maximum plasma concentration (Cmax) of levosimendan increased from 17 to 23 ng/ml.,The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793580/),[ng] / [ml],17,104167,DB01373,Calcium
,18793580,maximum plasma concentration (Cmax),The maximum plasma concentration (Cmax) of levosimendan increased from 17 to 23 ng/ml.,The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793580/),[ng] / [ml],23,104168,DB01373,Calcium
,18793580,concentrations,"The mean concentrations of the metabolites OR-1855 and OR-1896 in plasma were 4.3 and 8.3 ng/ml, respectively.",The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793580/),[ng] / [ml],4.3,104169,DB01373,Calcium
,18793580,concentrations,"The mean concentrations of the metabolites OR-1855 and OR-1896 in plasma were 4.3 and 8.3 ng/ml, respectively.",The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793580/),[ng] / [ml],8.3,104170,DB01373,Calcium
,30917531,AUC,"On Day 112, the AUC of serum 25(OH)D concentration was 2499.4 ± 463.8 nmol/mL (7.8 ± 0.2 for LogAUC) for Group 1 and 2152.3 ± 479.8 nmol/mL (7.6 ± 0.2 for LogAUC) for Group 2.","Pharmacokinetics of a New Pharmaceutical Form of Vitamin D3 100,000 IU in Soft Capsule. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30917531/),[nM] / [ml],2499.4,104358,DB01373,Calcium
,30917531,AUC,"On Day 112, the AUC of serum 25(OH)D concentration was 2499.4 ± 463.8 nmol/mL (7.8 ± 0.2 for LogAUC) for Group 1 and 2152.3 ± 479.8 nmol/mL (7.6 ± 0.2 for LogAUC) for Group 2.","Pharmacokinetics of a New Pharmaceutical Form of Vitamin D3 100,000 IU in Soft Capsule. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30917531/),,7.8,104359,DB01373,Calcium
,30917531,AUC,"On Day 112, the AUC of serum 25(OH)D concentration was 2499.4 ± 463.8 nmol/mL (7.8 ± 0.2 for LogAUC) for Group 1 and 2152.3 ± 479.8 nmol/mL (7.6 ± 0.2 for LogAUC) for Group 2.","Pharmacokinetics of a New Pharmaceutical Form of Vitamin D3 100,000 IU in Soft Capsule. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30917531/),[nM] / [ml],2152.3,104360,DB01373,Calcium
,30917531,AUC,"On Day 112, the AUC of serum 25(OH)D concentration was 2499.4 ± 463.8 nmol/mL (7.8 ± 0.2 for LogAUC) for Group 1 and 2152.3 ± 479.8 nmol/mL (7.6 ± 0.2 for LogAUC) for Group 2.","Pharmacokinetics of a New Pharmaceutical Form of Vitamin D3 100,000 IU in Soft Capsule. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30917531/),,7.6,104361,DB01373,Calcium
,30917531,Tmax,Fourteen days were needed to reach Tmax by more than half the subjects in Group 1 compared to 45 days in Group 2.,"Pharmacokinetics of a New Pharmaceutical Form of Vitamin D3 100,000 IU in Soft Capsule. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30917531/),,45,104362,DB01373,Calcium
,29777569,clearance (CL,"As expected, HWL-066 revealed a lower clearance (CL = 0.23 L-1 hr-1 kg-1 ), higher maximum concentration (Cmax = 5907.47 μg/L), and longer half-life (T1/2 = 3.50 hr), resulting in a 2.8-fold higher exposure than GW9508.","Improving metabolic stability with deuterium: The discovery of HWL-066, a potent and long-acting free fatty acid receptor 1 agonists. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29777569/),1/[h·kg·l],0.23,104632,DB01373,Calcium
,29777569,maximum concentration (Cmax,"As expected, HWL-066 revealed a lower clearance (CL = 0.23 L-1 hr-1 kg-1 ), higher maximum concentration (Cmax = 5907.47 μg/L), and longer half-life (T1/2 = 3.50 hr), resulting in a 2.8-fold higher exposure than GW9508.","Improving metabolic stability with deuterium: The discovery of HWL-066, a potent and long-acting free fatty acid receptor 1 agonists. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29777569/),[μg] / [l],5907.47,104633,DB01373,Calcium
,29777569,half-life (T1/2,"As expected, HWL-066 revealed a lower clearance (CL = 0.23 L-1 hr-1 kg-1 ), higher maximum concentration (Cmax = 5907.47 μg/L), and longer half-life (T1/2 = 3.50 hr), resulting in a 2.8-fold higher exposure than GW9508.","Improving metabolic stability with deuterium: The discovery of HWL-066, a potent and long-acting free fatty acid receptor 1 agonists. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29777569/),h,3.50,104634,DB01373,Calcium
,22306039,d(mean),"The optimized formulation, MS5 (d(mean)=44.47 μm, %EE=98.73, %CDR=97.32 and followed zero order release) was developed into colon-targeted matrix tablet using calcium pectinate as the matrix.",Colonic luminal surface retention of meloxicam microsponges delivered by erosion based colon-targeted matrix tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22306039/),μm,44.47,104960,DB01373,Calcium
,22306039,lag time,"The pharmacokinetic evaluation of MS5T2 in rabbits, revealed appearance of drug appeared in plasma after a lag time of 7h; a t(max) of 30 h with Fr=61.047%, thus presenting a formulation suitable for targeted colonic delivery.",Colonic luminal surface retention of meloxicam microsponges delivered by erosion based colon-targeted matrix tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22306039/),h,7,104961,DB01373,Calcium
,22306039,t(max),"The pharmacokinetic evaluation of MS5T2 in rabbits, revealed appearance of drug appeared in plasma after a lag time of 7h; a t(max) of 30 h with Fr=61.047%, thus presenting a formulation suitable for targeted colonic delivery.",Colonic luminal surface retention of meloxicam microsponges delivered by erosion based colon-targeted matrix tablet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22306039/),h,30,104962,DB01373,Calcium
,22306039,Fr,"The pharmacokinetic evaluation of MS5T2 in rabbits, revealed appearance of drug appeared in plasma after a lag time of 7h; a t(max) of 30 h with Fr=61.047%, thus presenting a formulation suitable for targeted colonic delivery.",Colonic luminal surface retention of meloxicam microsponges delivered by erosion based colon-targeted matrix tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22306039/),%,61.047,104963,DB01373,Calcium
,19746842,amount of drug transported,"Furthermore, the amount of drug transported from the duodenum was reduced in GFJ treated rats compared to that of the control (1581.0 +/- 7.8 nM vs 1084.81 +/- 6.1 nM, respectively).",Influence of grapefruit juice on the pharmacokinetics of diltiazem in Wistar rats upon single and multiple dosage regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19746842/),nM,1581.0,105879,DB01373,Calcium
,19746842,amount of drug transported,"Furthermore, the amount of drug transported from the duodenum was reduced in GFJ treated rats compared to that of the control (1581.0 +/- 7.8 nM vs 1084.81 +/- 6.1 nM, respectively).",Influence of grapefruit juice on the pharmacokinetics of diltiazem in Wistar rats upon single and multiple dosage regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19746842/),nM,1084.81,105880,DB01373,Calcium
,19746842,amount,"The amount of drug transported from the duodenum was reduced in the presence of pravastatin, a specific OATP inhibitor (1581.0 +/- 7.8 nM to 1265.0 +/- 5.5 nM).",Influence of grapefruit juice on the pharmacokinetics of diltiazem in Wistar rats upon single and multiple dosage regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19746842/),nM,1581.0,105881,DB01373,Calcium
,19746842,amount,"The amount of drug transported from the duodenum was reduced in the presence of pravastatin, a specific OATP inhibitor (1581.0 +/- 7.8 nM to 1265.0 +/- 5.5 nM).",Influence of grapefruit juice on the pharmacokinetics of diltiazem in Wistar rats upon single and multiple dosage regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19746842/),nM,1265.0,105882,DB01373,Calcium
,29232954,oral bioavailability,The results revealed that the oral bioavailability of two selected AC-NPs formulations was 235% and 169% relative to Lipitor.,Efficacy and Safety Profiles of Oral Atorvastatin-Loaded Nanoparticles: Effect of Size Modulation on Biodistribution. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29232954/),%,235,106497,DB01373,Calcium
,29232954,oral bioavailability,The results revealed that the oral bioavailability of two selected AC-NPs formulations was 235% and 169% relative to Lipitor.,Efficacy and Safety Profiles of Oral Atorvastatin-Loaded Nanoparticles: Effect of Size Modulation on Biodistribution. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29232954/),%,169,106498,DB01373,Calcium
,22748108,T(1/2-α/β),"After IT bolus, LCSF ziconotide and inulin showed an initial peak and biphasic (distribution/elimination) clearance (ziconotide T(1/2-α/β) = 0.14 and 1.77 hours, and inulin T(1/2-α/β) = 0.16 and 3.88 hours, respectively).","Pharmacokinetic analysis of ziconotide (SNX-111), an intrathecal N-type calcium channel blocking analgesic, delivered by bolus and infusion in the dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22748108/),h,0.14,106725,DB01373,Calcium
,22748108,T(1/2-α/β),"After IT bolus, LCSF ziconotide and inulin showed an initial peak and biphasic (distribution/elimination) clearance (ziconotide T(1/2-α/β) = 0.14 and 1.77 hours, and inulin T(1/2-α/β) = 0.16 and 3.88 hours, respectively).","Pharmacokinetic analysis of ziconotide (SNX-111), an intrathecal N-type calcium channel blocking analgesic, delivered by bolus and infusion in the dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22748108/),h,1.77,106726,DB01373,Calcium
,22748108,T(1/2-α/β),"After IT bolus, LCSF ziconotide and inulin showed an initial peak and biphasic (distribution/elimination) clearance (ziconotide T(1/2-α/β) = 0.14 and 1.77 hours, and inulin T(1/2-α/β) = 0.16 and 3.88 hours, respectively).","Pharmacokinetic analysis of ziconotide (SNX-111), an intrathecal N-type calcium channel blocking analgesic, delivered by bolus and infusion in the dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22748108/),h,0.16,106727,DB01373,Calcium
,22748108,T(1/2-α/β),"After IT bolus, LCSF ziconotide and inulin showed an initial peak and biphasic (distribution/elimination) clearance (ziconotide T(1/2-α/β) = 0.14 and 1.77 hours, and inulin T(1/2-α/β) = 0.16 and 3.88 hours, respectively).","Pharmacokinetic analysis of ziconotide (SNX-111), an intrathecal N-type calcium channel blocking analgesic, delivered by bolus and infusion in the dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22748108/),h,3.88,106728,DB01373,Calcium
,22748108,concentration ratio,"The LCSF : plasma ziconotide concentration ratio was 20,000:1 at 30 min and 30:1 at eight hours.","Pharmacokinetic analysis of ziconotide (SNX-111), an intrathecal N-type calcium channel blocking analgesic, delivered by bolus and infusion in the dog. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22748108/),,"20,000",106729,DB01373,Calcium
,22748108,concentration ratio,"The LCSF : plasma ziconotide concentration ratio was 20,000:1 at 30 min and 30:1 at eight hours.","Pharmacokinetic analysis of ziconotide (SNX-111), an intrathecal N-type calcium channel blocking analgesic, delivered by bolus and infusion in the dog. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22748108/),,30,106730,DB01373,Calcium
,22748108,Terminal elimination T(1/2),Terminal elimination T(1/2) after termination of continuous infusion was 2.47 hours.,"Pharmacokinetic analysis of ziconotide (SNX-111), an intrathecal N-type calcium channel blocking analgesic, delivered by bolus and infusion in the dog. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22748108/),h,2.47,106731,DB01373,Calcium
,24290597,bioavailability,The geometric mean (range ± 1 SD) of heme Fe bioavailability before and after treatment was 16.5% (8.3-32.8) and 26% (15.5-43.6) for the Ca group and 21.8% (13.0-36.6) and 25.1% (16.5-38.3) for the P group.,One-month of calcium supplementation does not affect iron bioavailability: a randomized controlled trial. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24290597/),%,16.5,107085,DB01373,Calcium
,24290597,bioavailability,The geometric mean (range ± 1 SD) of heme Fe bioavailability before and after treatment was 16.5% (8.3-32.8) and 26% (15.5-43.6) for the Ca group and 21.8% (13.0-36.6) and 25.1% (16.5-38.3) for the P group.,One-month of calcium supplementation does not affect iron bioavailability: a randomized controlled trial. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24290597/),%,26,107086,DB01373,Calcium
,24290597,bioavailability,The geometric mean (range ± 1 SD) of heme Fe bioavailability before and after treatment was 16.5% (8.3-32.8) and 26% (15.5-43.6) for the Ca group and 21.8% (13.0-36.6) and 25.1% (16.5-38.3) for the P group.,One-month of calcium supplementation does not affect iron bioavailability: a randomized controlled trial. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24290597/),%,21.8,107087,DB01373,Calcium
,24290597,bioavailability,The geometric mean (range ± 1 SD) of heme Fe bioavailability before and after treatment was 16.5% (8.3-32.8) and 26% (15.5-43.6) for the Ca group and 21.8% (13.0-36.6) and 25.1% (16.5-38.3) for the P group.,One-month of calcium supplementation does not affect iron bioavailability: a randomized controlled trial. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24290597/),%,25.1,107088,DB01373,Calcium
,24290597,bioavailability,"Non-heme Fe bioavailability before and after treatment was 39.5% (19.9-78.7) and 34.1% (19.1-60.6) for the Ca group, and 44.6% (24.9-79.7) and 39.3% (24.3-63.4) for the P group.",One-month of calcium supplementation does not affect iron bioavailability: a randomized controlled trial. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24290597/),%,39.5,107089,DB01373,Calcium
,24290597,bioavailability,"Non-heme Fe bioavailability before and after treatment was 39.5% (19.9-78.7) and 34.1% (19.1-60.6) for the Ca group, and 44.6% (24.9-79.7) and 39.3% (24.3-63.4) for the P group.",One-month of calcium supplementation does not affect iron bioavailability: a randomized controlled trial. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24290597/),%,34.1,107090,DB01373,Calcium
,24290597,bioavailability,"Non-heme Fe bioavailability before and after treatment was 39.5% (19.9-78.7) and 34.1% (19.1-60.6) for the Ca group, and 44.6% (24.9-79.7) and 39.3% (24.3-63.4) for the P group.",One-month of calcium supplementation does not affect iron bioavailability: a randomized controlled trial. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24290597/),%,44.6,107091,DB01373,Calcium
,24290597,bioavailability,"Non-heme Fe bioavailability before and after treatment was 39.5% (19.9-78.7) and 34.1% (19.1-60.6) for the Ca group, and 44.6% (24.9-79.7) and 39.3% (24.3-63.4) for the P group.",One-month of calcium supplementation does not affect iron bioavailability: a randomized controlled trial. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24290597/),%,39.3,107092,DB01373,Calcium
,21456601,IC(50),The affinity of all radiopeptides was high with IC(50) values between 0.5 and 4.8 nM.,Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456601/),nM,0.5 and 4.8,107122,DB01373,Calcium
,22801271,C(max),"The main pharmacokinetic parameters of test and reference formulations were as follows: the values of C(max) for AT were (10.6 ± 11.9) µg/L and (10.6 ± 9.8) µg/L, t(1/2z) were (11.4 ± 3.9) h and (11.4 ± 5.3) h, AUC(0-t) were (54.2 ± 37.4) µg×h(-1)×L(-1) and (51.7 ± 34.1) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),[μg] / [l],10.6,108007,DB01373,Calcium
,22801271,C(max),"The main pharmacokinetic parameters of test and reference formulations were as follows: the values of C(max) for AT were (10.6 ± 11.9) µg/L and (10.6 ± 9.8) µg/L, t(1/2z) were (11.4 ± 3.9) h and (11.4 ± 5.3) h, AUC(0-t) were (54.2 ± 37.4) µg×h(-1)×L(-1) and (51.7 ± 34.1) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),[μg] / [l],10.6,108008,DB01373,Calcium
,22801271,t(1/2z),"The main pharmacokinetic parameters of test and reference formulations were as follows: the values of C(max) for AT were (10.6 ± 11.9) µg/L and (10.6 ± 9.8) µg/L, t(1/2z) were (11.4 ± 3.9) h and (11.4 ± 5.3) h, AUC(0-t) were (54.2 ± 37.4) µg×h(-1)×L(-1) and (51.7 ± 34.1) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),h,11.4,108009,DB01373,Calcium
,22801271,t(1/2z),"The main pharmacokinetic parameters of test and reference formulations were as follows: the values of C(max) for AT were (10.6 ± 11.9) µg/L and (10.6 ± 9.8) µg/L, t(1/2z) were (11.4 ± 3.9) h and (11.4 ± 5.3) h, AUC(0-t) were (54.2 ± 37.4) µg×h(-1)×L(-1) and (51.7 ± 34.1) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),h,11.4,108010,DB01373,Calcium
,22801271,AUC(0-t),"The main pharmacokinetic parameters of test and reference formulations were as follows: the values of C(max) for AT were (10.6 ± 11.9) µg/L and (10.6 ± 9.8) µg/L, t(1/2z) were (11.4 ± 3.9) h and (11.4 ± 5.3) h, AUC(0-t) were (54.2 ± 37.4) µg×h(-1)×L(-1) and (51.7 ± 34.1) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),[μg] / [h·l],54.2,108011,DB01373,Calcium
,22801271,AUC(0-t),"The main pharmacokinetic parameters of test and reference formulations were as follows: the values of C(max) for AT were (10.6 ± 11.9) µg/L and (10.6 ± 9.8) µg/L, t(1/2z) were (11.4 ± 3.9) h and (11.4 ± 5.3) h, AUC(0-t) were (54.2 ± 37.4) µg×h(-1)×L(-1) and (51.7 ± 34.1) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),[μg] / [h·l],51.7,108012,DB01373,Calcium
,22801271,C(max),"The values of C(max) for o-OAT were (7.8 ± 4.5) µg/L and (7.6 ± 4.3) µg/L, t(1/2z) were (12.3 ± 4.2) h and (11.9 ± 3.4) h, AUC(0-t) were (96.8 ± 48.2) µg×h(-1)×L(-1) and (92.3 ± 44.4) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),[μg] / [l],7.8,108013,DB01373,Calcium
,22801271,C(max),"The values of C(max) for o-OAT were (7.8 ± 4.5) µg/L and (7.6 ± 4.3) µg/L, t(1/2z) were (12.3 ± 4.2) h and (11.9 ± 3.4) h, AUC(0-t) were (96.8 ± 48.2) µg×h(-1)×L(-1) and (92.3 ± 44.4) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),[μg] / [l],7.6,108014,DB01373,Calcium
,22801271,t(1/2z),"The values of C(max) for o-OAT were (7.8 ± 4.5) µg/L and (7.6 ± 4.3) µg/L, t(1/2z) were (12.3 ± 4.2) h and (11.9 ± 3.4) h, AUC(0-t) were (96.8 ± 48.2) µg×h(-1)×L(-1) and (92.3 ± 44.4) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),h,12.3,108015,DB01373,Calcium
,22801271,t(1/2z),"The values of C(max) for o-OAT were (7.8 ± 4.5) µg/L and (7.6 ± 4.3) µg/L, t(1/2z) were (12.3 ± 4.2) h and (11.9 ± 3.4) h, AUC(0-t) were (96.8 ± 48.2) µg×h(-1)×L(-1) and (92.3 ± 44.4) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),h,11.9,108016,DB01373,Calcium
,22801271,AUC(0-t),"The values of C(max) for o-OAT were (7.8 ± 4.5) µg/L and (7.6 ± 4.3) µg/L, t(1/2z) were (12.3 ± 4.2) h and (11.9 ± 3.4) h, AUC(0-t) were (96.8 ± 48.2) µg×h(-1)×L(-1) and (92.3 ± 44.4) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),[μg] / [h·l],96.8,108017,DB01373,Calcium
,22801271,AUC(0-t),"The values of C(max) for o-OAT were (7.8 ± 4.5) µg/L and (7.6 ± 4.3) µg/L, t(1/2z) were (12.3 ± 4.2) h and (11.9 ± 3.4) h, AUC(0-t) were (96.8 ± 48.2) µg×h(-1)×L(-1) and (92.3 ± 44.4) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),[μg] / [h·l],92.3,108018,DB01373,Calcium
,22801271,C(max),"The values of C(max) for p-OAT were (0.5 ± 0.4) µg/L and (0.4 ± 0.3) µg/L, t(1/2z) were (18.4 ± 12.4) h and (23.3 ± 17.8) h, AUC(0-t) were (15.9 ± 12.3) µg×h(-1)×L(-1) and (13.8 ± 8.11) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),[μg] / [l],0.5,108019,DB01373,Calcium
,22801271,C(max),"The values of C(max) for p-OAT were (0.5 ± 0.4) µg/L and (0.4 ± 0.3) µg/L, t(1/2z) were (18.4 ± 12.4) h and (23.3 ± 17.8) h, AUC(0-t) were (15.9 ± 12.3) µg×h(-1)×L(-1) and (13.8 ± 8.11) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),[μg] / [l],0.4,108020,DB01373,Calcium
,22801271,t(1/2z),"The values of C(max) for p-OAT were (0.5 ± 0.4) µg/L and (0.4 ± 0.3) µg/L, t(1/2z) were (18.4 ± 12.4) h and (23.3 ± 17.8) h, AUC(0-t) were (15.9 ± 12.3) µg×h(-1)×L(-1) and (13.8 ± 8.11) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),h,18.4,108021,DB01373,Calcium
,22801271,t(1/2z),"The values of C(max) for p-OAT were (0.5 ± 0.4) µg/L and (0.4 ± 0.3) µg/L, t(1/2z) were (18.4 ± 12.4) h and (23.3 ± 17.8) h, AUC(0-t) were (15.9 ± 12.3) µg×h(-1)×L(-1) and (13.8 ± 8.11) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),h,23.3,108022,DB01373,Calcium
,22801271,AUC(0-t),"The values of C(max) for p-OAT were (0.5 ± 0.4) µg/L and (0.4 ± 0.3) µg/L, t(1/2z) were (18.4 ± 12.4) h and (23.3 ± 17.8) h, AUC(0-t) were (15.9 ± 12.3) µg×h(-1)×L(-1) and (13.8 ± 8.11) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),[μg] / [h·l],15.9,108023,DB01373,Calcium
,22801271,AUC(0-t),"The values of C(max) for p-OAT were (0.5 ± 0.4) µg/L and (0.4 ± 0.3) µg/L, t(1/2z) were (18.4 ± 12.4) h and (23.3 ± 17.8) h, AUC(0-t) were (15.9 ± 12.3) µg×h(-1)×L(-1) and (13.8 ± 8.11) µg×h(-1)×L(-1), respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),[μg] / [h·l],13.8,108024,DB01373,Calcium
,22801271,relative bioavailability,"The relative bioavailability of AT and o-OAT in test formulation were (105.3 ± 20.7)% and (107.8 ± 23.2)%, respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),%,105.3,108025,DB01373,Calcium
,22801271,relative bioavailability,"The relative bioavailability of AT and o-OAT in test formulation were (105.3 ± 20.7)% and (107.8 ± 23.2)%, respectively.",[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22801271/),%,107.8,108026,DB01373,Calcium
,16470916,maximal plasma concentration (C(max)),"The maximal plasma concentration (C(max)) of the three treated groups were 0.51, 0.70 and 0.81 microg/ml, respectively.",[Effect of kaempferol on the pharmacokinetics of nifedipine in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470916/),[μg] / [ml],0.51,108535,DB01373,Calcium
,16470916,maximal plasma concentration (C(max)),"The maximal plasma concentration (C(max)) of the three treated groups were 0.51, 0.70 and 0.81 microg/ml, respectively.",[Effect of kaempferol on the pharmacokinetics of nifedipine in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470916/),[μg] / [ml],0.70,108536,DB01373,Calcium
,16470916,maximal plasma concentration (C(max)),"The maximal plasma concentration (C(max)) of the three treated groups were 0.51, 0.70 and 0.81 microg/ml, respectively.",[Effect of kaempferol on the pharmacokinetics of nifedipine in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470916/),[μg] / [ml],0.81,108537,DB01373,Calcium
,16470916,area under the concentration-time curve (AUC(0-8)),"The area under the concentration-time curve (AUC(0-8)) were 1.81, 2.83 and 3.63 microg/(h.ml(-1)), respectively.",[Effect of kaempferol on the pharmacokinetics of nifedipine in rats]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470916/),[h·μg] / [ml],1.81,108538,DB01373,Calcium
,16470916,area under the concentration-time curve (AUC(0-8)),"The area under the concentration-time curve (AUC(0-8)) were 1.81, 2.83 and 3.63 microg/(h.ml(-1)), respectively.",[Effect of kaempferol on the pharmacokinetics of nifedipine in rats]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470916/),[h·μg] / [ml],2.83,108539,DB01373,Calcium
,16470916,area under the concentration-time curve (AUC(0-8)),"The area under the concentration-time curve (AUC(0-8)) were 1.81, 2.83 and 3.63 microg/(h.ml(-1)), respectively.",[Effect of kaempferol on the pharmacokinetics of nifedipine in rats]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470916/),[h·μg] / [ml],3.63,108540,DB01373,Calcium
,21882531,m/z,"Plasma samples were determined with LC-MS: the analyte and internal standard pitavastatin were both analyzed by MS in the ESI, m/z was 480.0 for rosuvastatin and 420.0 for the IS, separately.",[Effect of OATP1B1 521T --> C heterogenesis on pharmacokinetic characterstics of rosuvastatin in Chinese volunteers]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21882531/),,480.0,108922,DB01373,Calcium
,21882531,m/z,"Plasma samples were determined with LC-MS: the analyte and internal standard pitavastatin were both analyzed by MS in the ESI, m/z was 480.0 for rosuvastatin and 420.0 for the IS, separately.",[Effect of OATP1B1 521T --> C heterogenesis on pharmacokinetic characterstics of rosuvastatin in Chinese volunteers]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21882531/),,420.0,108923,DB01373,Calcium
,11549204,PRA,"PRA increased significantly following I alone (1.5-2.0 ng/ml/h), as well as combined with N (2.5 ng/ ml/h) or H (3.1 ng/ml/h).","Pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme inhibitor imidapril with hydrochlorothiazide, bisoprolol and nilvadipine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549204/),[ng] / [h·ml],1.5-2.0,109392,DB01373,Calcium
,11549204,PRA,"PRA increased significantly following I alone (1.5-2.0 ng/ml/h), as well as combined with N (2.5 ng/ ml/h) or H (3.1 ng/ml/h).","Pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme inhibitor imidapril with hydrochlorothiazide, bisoprolol and nilvadipine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549204/),[ng] / [h·ml],2.5,109393,DB01373,Calcium
,11549204,PRA,"PRA increased significantly following I alone (1.5-2.0 ng/ml/h), as well as combined with N (2.5 ng/ ml/h) or H (3.1 ng/ml/h).","Pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme inhibitor imidapril with hydrochlorothiazide, bisoprolol and nilvadipine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549204/),[ng] / [h·ml],3.1,109394,DB01373,Calcium
,12839868,Maximum binding,6. Maximum binding of (3)H-nitrendipine to cardiac cell membrane was significantly reduced from 63.2+/-2.5 fmol mg(-1) protein in controls to 46.4+/-2.0 in acute inflammation and from 66.8+/-2.2 fmol mg(-1) protein in controls to 42.2+/-2.0 in chronic inflammation.,"Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12839868/),[fmol] / [mg],63.2,109408,DB01373,Calcium
,12839868,Maximum binding,6. Maximum binding of (3)H-nitrendipine to cardiac cell membrane was significantly reduced from 63.2+/-2.5 fmol mg(-1) protein in controls to 46.4+/-2.0 in acute inflammation and from 66.8+/-2.2 fmol mg(-1) protein in controls to 42.2+/-2.0 in chronic inflammation.,"Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12839868/),[fmol] / [mg],46.4,109409,DB01373,Calcium
,12839868,Maximum binding,6. Maximum binding of (3)H-nitrendipine to cardiac cell membrane was significantly reduced from 63.2+/-2.5 fmol mg(-1) protein in controls to 46.4+/-2.0 in acute inflammation and from 66.8+/-2.2 fmol mg(-1) protein in controls to 42.2+/-2.0 in chronic inflammation.,"Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12839868/),[fmol] / [mg],66.8,109410,DB01373,Calcium
,12839868,Maximum binding,6. Maximum binding of (3)H-nitrendipine to cardiac cell membrane was significantly reduced from 63.2+/-2.5 fmol mg(-1) protein in controls to 46.4+/-2.0 in acute inflammation and from 66.8+/-2.2 fmol mg(-1) protein in controls to 42.2+/-2.0 in chronic inflammation.,"Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12839868/),,42.2,109411,DB01373,Calcium
,16280265,m/,Selected ion monitoring (SIM) in positive mode was used for analyte quantification at m/z 480.2 for nicardipine and m/z 256.4 for diphenhydramine.,Liquid chromatography-mass spectrometry method for the determination of nicardipine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16280265/),,480.2,109486,DB01373,Calcium
less,16280265,run time,The run time was less than 5 min.,Liquid chromatography-mass spectrometry method for the determination of nicardipine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16280265/),min,5,109487,DB01373,Calcium
,23681426,peak (Umax),"The peak (Umax) and the average (Uave) urinary excretion rate of alendronate and the time to reach Umax (Tmax) were 2.94 μg/h, 0.901 μg/h and 6.77 h, respectively.",Improved dosage form of the combined alendronate and calcitriol (Maxmarvil®) on the absorption of alendronate in Korean postmenopausal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681426/),[μg] / [h],2.94,109602,DB01373,Calcium
,23681426,Uave,"The peak (Umax) and the average (Uave) urinary excretion rate of alendronate and the time to reach Umax (Tmax) were 2.94 μg/h, 0.901 μg/h and 6.77 h, respectively.",Improved dosage form of the combined alendronate and calcitriol (Maxmarvil®) on the absorption of alendronate in Korean postmenopausal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681426/),[μg] / [h],2.94,109603,DB01373,Calcium
,23681426,urinary excretion rate,"The peak (Umax) and the average (Uave) urinary excretion rate of alendronate and the time to reach Umax (Tmax) were 2.94 μg/h, 0.901 μg/h and 6.77 h, respectively.",Improved dosage form of the combined alendronate and calcitriol (Maxmarvil®) on the absorption of alendronate in Korean postmenopausal women. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681426/),[μg] / [h],2.94,109604,DB01373,Calcium
,23681426,urinary excretion rate,"The peak (Umax) and the average (Uave) urinary excretion rate of alendronate and the time to reach Umax (Tmax) were 2.94 μg/h, 0.901 μg/h and 6.77 h, respectively.",Improved dosage form of the combined alendronate and calcitriol (Maxmarvil®) on the absorption of alendronate in Korean postmenopausal women. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681426/),[μg] / [h],0.901,109605,DB01373,Calcium
,23681426,time to reach Umax (Tmax),"The peak (Umax) and the average (Uave) urinary excretion rate of alendronate and the time to reach Umax (Tmax) were 2.94 μg/h, 0.901 μg/h and 6.77 h, respectively.",Improved dosage form of the combined alendronate and calcitriol (Maxmarvil®) on the absorption of alendronate in Korean postmenopausal women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681426/),h,6.77,109606,DB01373,Calcium
,23681426,total cumulative urinary excretion,"The total cumulative urinary excretion of alendronate (Ae₀₋₂₄ h) was 21.6 μg (0.432% of oral alendornate), which was similar to the reported values.",Improved dosage form of the combined alendronate and calcitriol (Maxmarvil®) on the absorption of alendronate in Korean postmenopausal women. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681426/),μg,21.6,109607,DB01373,Calcium
,23681426,total cumulative urinary excretion,"The total cumulative urinary excretion of alendronate (Ae₀₋₂₄ h) was 21.6 μg (0.432% of oral alendornate), which was similar to the reported values.",Improved dosage form of the combined alendronate and calcitriol (Maxmarvil®) on the absorption of alendronate in Korean postmenopausal women. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681426/),%,0.432,109608,DB01373,Calcium
,16084849,area under the curve from 0 to 24 hours (AUC),"Indinavir plus ritonavir increased the median amlodipine area under the curve from 0 to 24 hours (AUC) by 89.8%, from 122 to 230 ng.h/mL (n = 18, P < .0001), and increased the median diltiazem AUC by 26.5%, from 800 to 1060 ng.h/mL (n = 13, P = .06).",Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084849/),[h·ng] / [ml],122,109911,DB01373,Calcium
,16084849,area under the curve from 0 to 24 hours (AUC),"Indinavir plus ritonavir increased the median amlodipine area under the curve from 0 to 24 hours (AUC) by 89.8%, from 122 to 230 ng.h/mL (n = 18, P < .0001), and increased the median diltiazem AUC by 26.5%, from 800 to 1060 ng.h/mL (n = 13, P = .06).",Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084849/),[h·ng] / [ml],230,109912,DB01373,Calcium
,16084849,AUC,"Indinavir plus ritonavir increased the median amlodipine area under the curve from 0 to 24 hours (AUC) by 89.8%, from 122 to 230 ng.h/mL (n = 18, P < .0001), and increased the median diltiazem AUC by 26.5%, from 800 to 1060 ng.h/mL (n = 13, P = .06).",Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084849/),[h·ng] / [ml],800,109913,DB01373,Calcium
,17903476,m/z,"Quantification was performed using multiple reaction monitoring (MRM) of the transitions m/z 491.2-->122.1 and m/z 417.1-->122.1 for cilnidipine and for the IS, respectively.","Determination of cilnidipine, a new calcium antagonist, in human plasma using high performance liquid chromatography with tandem mass spectrometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17903476/),,491.2,109953,DB01373,Calcium
,17903476,m/z,"Quantification was performed using multiple reaction monitoring (MRM) of the transitions m/z 491.2-->122.1 and m/z 417.1-->122.1 for cilnidipine and for the IS, respectively.","Determination of cilnidipine, a new calcium antagonist, in human plasma using high performance liquid chromatography with tandem mass spectrometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17903476/),,122.1,109954,DB01373,Calcium
,17903476,m/z,"Quantification was performed using multiple reaction monitoring (MRM) of the transitions m/z 491.2-->122.1 and m/z 417.1-->122.1 for cilnidipine and for the IS, respectively.","Determination of cilnidipine, a new calcium antagonist, in human plasma using high performance liquid chromatography with tandem mass spectrometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17903476/),,417.1,109955,DB01373,Calcium
,17903476,m/z,"Quantification was performed using multiple reaction monitoring (MRM) of the transitions m/z 491.2-->122.1 and m/z 417.1-->122.1 for cilnidipine and for the IS, respectively.","Determination of cilnidipine, a new calcium antagonist, in human plasma using high performance liquid chromatography with tandem mass spectrometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17903476/),,122.1,109956,DB01373,Calcium
,17903476,analysis time,The analysis time for each run was 3.0 min.,"Determination of cilnidipine, a new calcium antagonist, in human plasma using high performance liquid chromatography with tandem mass spectrometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17903476/),min,3.0,109957,DB01373,Calcium
,17903476,recoveries,The recoveries were between 92.71% and 97.64%.,"Determination of cilnidipine, a new calcium antagonist, in human plasma using high performance liquid chromatography with tandem mass spectrometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17903476/),%,92.71,109958,DB01373,Calcium
,17903476,recoveries,The recoveries were between 92.71% and 97.64%.,"Determination of cilnidipine, a new calcium antagonist, in human plasma using high performance liquid chromatography with tandem mass spectrometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17903476/),%,97.64,109959,DB01373,Calcium
,26276253,absorption Tmax,F3 microspheres exhibited controlled and prolonged absorption Tmax of 4.0 vs.,In-vivo evaluation of clindamycin release from glyceryl monooleate-alginate microspheres by NIR spectroscopy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26276253/),,4.0,110048,DB01373,Calcium
,26276253,Cmax,1.0 and 0.5 h; Cmax of 2.37±0.3 vs.,In-vivo evaluation of clindamycin release from glyceryl monooleate-alginate microspheres by NIR spectroscopy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26276253/),,2.37,110049,DB01373,Calcium
,30243471,flow rate,An isocratic elution of samples was performed on capcell pak C8 DD S5 column (4.6mm×250mm particle size 5μm) column with mobile phase consisting 5mM Phosphate Buffer (pH 4.8 adjusted with dilute ortho-phosphoric acid solution): acetonitrile (25:75:v/v) delivered at flow rate 1.0mLmin-1.,Validated RP-HPLC method for quantification of felodipine in rabbit plasma: Application in a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30243471/),1/[mlmin],1.0,110394,DB01373,Calcium
,30243471,LODs,"LODs and LOQs for felodipine were found to be 0.055 and 0.201μgmL-1, respectively.",Validated RP-HPLC method for quantification of felodipine in rabbit plasma: Application in a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30243471/),1/[μgml],0.055,110395,DB01373,Calcium
,30243471,LOQs,"LODs and LOQs for felodipine were found to be 0.055 and 0.201μgmL-1, respectively.",Validated RP-HPLC method for quantification of felodipine in rabbit plasma: Application in a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30243471/),1/[μgml],0.201,110396,DB01373,Calcium
,16390562,elimination half-life,"When compared to the elimination half-life in an open breathing system (1.2 +/- 0.07 h), elimination half-life was longer with a closed system (6.4 +/- 0.9 h, P 0.05) when compared to a closed system.","Partial liquid ventilation: effects of closed breathing systems, heat-and-moisture-exchangers and sodalime absorbers on perfluorocarbon evaporation. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390562/),h,1.2,110586,DB01373,Calcium
,16390562,elimination half-life,"When compared to the elimination half-life in an open breathing system (1.2 +/- 0.07 h), elimination half-life was longer with a closed system (6.4 +/- 0.9 h, P 0.05) when compared to a closed system.","Partial liquid ventilation: effects of closed breathing systems, heat-and-moisture-exchangers and sodalime absorbers on perfluorocarbon evaporation. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390562/),h,6.4,110587,DB01373,Calcium
,17803059,Maximum plasma concentrations (Cmax),"Maximum plasma concentrations (Cmax) of 6,183.7 pg/ml (test) and 5,366.7 pg/ml (reference) were achieved.",Pharmacokinetics and bioequivalence study of a generic amlodipine tablet formulation in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803059/),[pg] / [ml],"6,183.7",110620,DB01373,Calcium
,17803059,Maximum plasma concentrations (Cmax),"Maximum plasma concentrations (Cmax) of 6,183.7 pg/ml (test) and 5,366.7 pg/ml (reference) were achieved.",Pharmacokinetics and bioequivalence study of a generic amlodipine tablet formulation in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803059/),[pg] / [ml],"5,366.7",110621,DB01373,Calcium
,17803059,Areas under the plasma concentration-time curve (AUC(0-infinity)),"Areas under the plasma concentration-time curve (AUC(0-infinity)) of 267,231.0 pg x h/ml (test) and 266,061.7 ng x h/ml (reference) were calculated.",Pharmacokinetics and bioequivalence study of a generic amlodipine tablet formulation in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803059/),[h·pg] / [ml],"267,231.0",110622,DB01373,Calcium
,17803059,Areas under the plasma concentration-time curve (AUC(0-infinity)),"Areas under the plasma concentration-time curve (AUC(0-infinity)) of 267,231.0 pg x h/ml (test) and 266,061.7 ng x h/ml (reference) were calculated.",Pharmacokinetics and bioequivalence study of a generic amlodipine tablet formulation in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803059/),[h·ng] / [ml],"266,061.7",110623,DB01373,Calcium
,17803059,tmax,The median tmax was 5.6 h (test) and 6.1 h (reference).,Pharmacokinetics and bioequivalence study of a generic amlodipine tablet formulation in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803059/),h,5.6,110624,DB01373,Calcium
,17803059,tmax,The median tmax was 5.6 h (test) and 6.1 h (reference).,Pharmacokinetics and bioequivalence study of a generic amlodipine tablet formulation in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803059/),h,6.1,110625,DB01373,Calcium
,17803059,Plasma elimination half-lives (t 1/2),Plasma elimination half-lives (t 1/2) were 46.46 h (test) and 45.34 h (reference).,Pharmacokinetics and bioequivalence study of a generic amlodipine tablet formulation in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803059/),h,46.46,110626,DB01373,Calcium
,17803059,Plasma elimination half-lives (t 1/2),Plasma elimination half-lives (t 1/2) were 46.46 h (test) and 45.34 h (reference).,Pharmacokinetics and bioequivalence study of a generic amlodipine tablet formulation in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803059/),h,45.34,110627,DB01373,Calcium
,21998684,t(1/2),"These principles allow fabrication of formulations that exhibit either a fast, second-order (t(1/2) ~1 h), or a slow, zero-order release rate (t(1/2) ~ 50 h) kinetics.",Fabrication principles and their contribution to the superior in vivo therapeutic efficacy of nano-liposomes remote loaded with glucocorticoids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21998684/),h,1,110829,DB01373,Calcium
,31990625,peak plasma concentration,"Results: Verapamil significantly increased the peak plasma concentration (from 91.97 ± 11.30 to 125.30 ± 13.50 ng/mL), and decrease the oral clearance (from 63.85 ± 10.79 to 32.95 ± 6.17 L/h/kg).",Effect of verapamil on the pharmacokinetics of hydroxycamptothecin and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31990625/),[ng] / [ml],91.97,111465,DB01373,Calcium
,31990625,peak plasma concentration,"Results: Verapamil significantly increased the peak plasma concentration (from 91.97 ± 11.30 to 125.30 ± 13.50 ng/mL), and decrease the oral clearance (from 63.85 ± 10.79 to 32.95 ± 6.17 L/h/kg).",Effect of verapamil on the pharmacokinetics of hydroxycamptothecin and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31990625/),[ng] / [ml],125.30,111466,DB01373,Calcium
,31990625,oral clearance,"Results: Verapamil significantly increased the peak plasma concentration (from 91.97 ± 11.30 to 125.30 ± 13.50 ng/mL), and decrease the oral clearance (from 63.85 ± 10.79 to 32.95 ± 6.17 L/h/kg).",Effect of verapamil on the pharmacokinetics of hydroxycamptothecin and its potential mechanism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31990625/),[l] / [h·kg],63.85,111467,DB01373,Calcium
,31990625,oral clearance,"Results: Verapamil significantly increased the peak plasma concentration (from 91.97 ± 11.30 to 125.30 ± 13.50 ng/mL), and decrease the oral clearance (from 63.85 ± 10.79 to 32.95 ± 6.17 L/h/kg).",Effect of verapamil on the pharmacokinetics of hydroxycamptothecin and its potential mechanism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31990625/),[l] / [h·kg],32.95,111468,DB01373,Calcium
,31990625,intrinsic clearance rate,The intrinsic clearance rate was also significantly decreased (from 39.49 ± 0.42 to 28.64 ± 0.30 μL/min/mg protein) by the preincubation of verapamil.,Effect of verapamil on the pharmacokinetics of hydroxycamptothecin and its potential mechanism. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31990625/),[μl] / [mg·min],39.49,111469,DB01373,Calcium
,31990625,intrinsic clearance rate,The intrinsic clearance rate was also significantly decreased (from 39.49 ± 0.42 to 28.64 ± 0.30 μL/min/mg protein) by the preincubation of verapamil.,Effect of verapamil on the pharmacokinetics of hydroxycamptothecin and its potential mechanism. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31990625/),[μl] / [mg·min],28.64,111470,DB01373,Calcium
,31990625,efflux ratio,"The results of Caco-2 cell transwell experiments showed the efflux of HCPT was inhibited by verapamil, as the efflux ratio decreased from 1.82 to 1.21.",Effect of verapamil on the pharmacokinetics of hydroxycamptothecin and its potential mechanism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31990625/),,1.82,111471,DB01373,Calcium
,31990625,efflux ratio,"The results of Caco-2 cell transwell experiments showed the efflux of HCPT was inhibited by verapamil, as the efflux ratio decreased from 1.82 to 1.21.",Effect of verapamil on the pharmacokinetics of hydroxycamptothecin and its potential mechanism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31990625/),,1.21,111472,DB01373,Calcium
,12506180,time to progression,"Median time to progression was 11.4 months (95% CI, 8.7 to 14 months), and median survival was 19.5 months (95% CI, 15.3 months to incalculable).",Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12506180/),month,11.4,111718,DB01373,Calcium
,12506180,survival,"Median time to progression was 11.4 months (95% CI, 8.7 to 14 months), and median survival was 19.5 months (95% CI, 15.3 months to incalculable).",Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12506180/),month,19.5,111719,DB01373,Calcium
,21493750,pK(I),"JNJ-26070109 expressed high affinity for human (pK(I) = 8.49 ± 0.13), rat (pK(I) = 7.99 ± 0.08), and dog (pK(I) = 7.70 ± 0.14) CCK2 receptors.","JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21493750/),,8.49,111862,DB01373,Calcium
,21493750,pK(I),"JNJ-26070109 expressed high affinity for human (pK(I) = 8.49 ± 0.13), rat (pK(I) = 7.99 ± 0.08), and dog (pK(I) = 7.70 ± 0.14) CCK2 receptors.","JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21493750/),,7.99,111863,DB01373,Calcium
,21493750,pK(I),"JNJ-26070109 expressed high affinity for human (pK(I) = 8.49 ± 0.13), rat (pK(I) = 7.99 ± 0.08), and dog (pK(I) = 7.70 ± 0.14) CCK2 receptors.","JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21493750/),,7.70,111864,DB01373,Calcium
,21493750,pK(B),"JNJ-26070109 behaved as a surmountable, competitive, antagonist of human CCK2 receptors in a calcium mobilization assay (pK(B) = 8.53 ± 0.05) and in pentagastrin-stimulated gastric acid secretion in the isolated, lumen-perfused, mouse stomach assay (pK(B) = 8.19 ± 0.13).","JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21493750/),,8.53,111865,DB01373,Calcium
,21493750,p,"JNJ-26070109 behaved as a surmountable, competitive, antagonist of human CCK2 receptors in a calcium mobilization assay (pK(B) = 8.53 ± 0.05) and in pentagastrin-stimulated gastric acid secretion in the isolated, lumen-perfused, mouse stomach assay (pK(B) = 8.19 ± 0.13).","JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21493750/),,8.19,111866,DB01373,Calcium
,21493750,%F,"JNJ-26070109 was shown to have high oral bioavailability (%F rat = 73 ± 16; %F dog = 92 ± 12) with half lives of 1.8 ± 0.3 and 1.2 ± 0.1 h in rat and dog, respectively.","JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21493750/),,73,111867,DB01373,Calcium
,21493750,%F,"JNJ-26070109 was shown to have high oral bioavailability (%F rat = 73 ± 16; %F dog = 92 ± 12) with half lives of 1.8 ± 0.3 and 1.2 ± 0.1 h in rat and dog, respectively.","JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21493750/),h,92,111868,DB01373,Calcium
,21493750,half lives,"JNJ-26070109 was shown to have high oral bioavailability (%F rat = 73 ± 16; %F dog = 92 ± 12) with half lives of 1.8 ± 0.3 and 1.2 ± 0.1 h in rat and dog, respectively.","JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21493750/),h,1.8,111869,DB01373,Calcium
,21493750,half lives,"JNJ-26070109 was shown to have high oral bioavailability (%F rat = 73 ± 16; %F dog = 92 ± 12) with half lives of 1.8 ± 0.3 and 1.2 ± 0.1 h in rat and dog, respectively.","JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21493750/),h,1.2,111870,DB01373,Calcium
,21493750,oral EC(50),"In conscious rat and dog chronic gastric fistula models of pentagastrin-stimulated acid secretion, JNJ-26070109 had oral EC(50) values of 1.5 and 0.26 μM, respectively.","JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21493750/),μM,1.5,111871,DB01373,Calcium
,21493750,oral EC(50),"In conscious rat and dog chronic gastric fistula models of pentagastrin-stimulated acid secretion, JNJ-26070109 had oral EC(50) values of 1.5 and 0.26 μM, respectively.","JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21493750/),μM,0.26,111872,DB01373,Calcium
,16002804,fractional absorption,Mean fractional absorption of calcium from tortillas prepared from the low-phytate maize (0.50 +/- 0.03) was significantly (P = 0.003) greater than that from tortillas prepared from the control maize (0.35 +/- 0.07).,Absorption of calcium from tortilla meals prepared from low-phytate maize. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16002804/),,0.50,112101,DB01373,Calcium
,16002804,fractional absorption,Mean fractional absorption of calcium from tortillas prepared from the low-phytate maize (0.50 +/- 0.03) was significantly (P = 0.003) greater than that from tortillas prepared from the control maize (0.35 +/- 0.07).,Absorption of calcium from tortilla meals prepared from low-phytate maize. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16002804/),,0.35,112102,DB01373,Calcium
,15610940,relative bioavailability,The relative bioavailability of the SR formulation was 55.5% of that of the IR formulation.,"Kinetic and cardiovascular comparison of immediate-release isradipine and sustained-release isradipine among non-treatment-seeking, cocaine-dependent individuals. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15610940/),%,55.5,112172,DB01373,Calcium
,24936240,oral bioavailability (F,"Further in vivo evaluations included pharmacokinetic experiments in rats and mice, where 15 was shown to have oral bioavailability (F = 63%) and resulted in the mobilization of white blood cells (WBCs) in a dose-dependent manner.",Discovery of tetrahydroisoquinoline-based CXCR4 antagonists. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24936240/),%,63,112606,DB01373,Calcium
,11785692,absolute bioavailability (BA),The liver had a high intrinsic capacity for clearing VL because the absolute bioavailability (BA) of VL was 21.7% after PV administration.,Differentiation of gut and hepatic first-pass effect of drugs: 1. Studies of verapamil in ported dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11785692/),%,21.7,112787,DB01373,Calcium
,11785692,BA,"The BA of VL after ID administration was 23.5%; therefore, intestinal absorption was complete and intestinal extraction was negligible (ER(GI) approximately 0).",Differentiation of gut and hepatic first-pass effect of drugs: 1. Studies of verapamil in ported dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11785692/),%,23.5,112788,DB01373,Calcium
over,16759733,gastric residence time (GRT),Prolonged gastric residence time (GRT) of over 6 h was achieved in all animals for calcium silicate based floating microspheres of Rg.,A novel calcium silicate based microspheres of repaglinide: in vivo investigations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16759733/),h,6,112799,DB01373,Calcium
,18771003,area under the plasma concentration versus time curve from time 0 h to 96 h (AUC(0-96),"After administration of a single dose of azelnidipine 8mg and 16 mg, respectively; the area under the plasma concentration versus time curve from time 0 h to 96 h (AUC(0-96) were (186 +/- 47) ng ml(-1) h, (429 +/- 145) ng ml(-1) h, respectively; clearance rate (CL/F) were (45.94 +/- 11.61), (42.11 +/- 14.23) L/h, respectively; peak plasma concentration Cmax were (8.66 +/- 1.15), (19.17 +/- 4.13) ng/ml, respectively; apparent volume of distribution (Vd) were (1749 +/- 964), (2480 +/- 2212) L, respectively; time to Cmax (Tmax) were (2.8 +/- 1.2), (3.0 +/- 0.9) h, respectively; elimination half-life (t(1/2beta)) were (22.8 +/- 2.4), (23.5 +/- 4.2) h, respectively; and MRT were (25.7 +/- 1.3), (26.2 +/- 2.2) h, respectively; The essential pharmacokinetic parameters after oral multiple doses (8 mg, q.d.) were as follows: (Cmax) ss, (15.04 +/- 2.27) ng/ml; (Tmax) ss, (2.38 +/- 0.92) h; (Cmin) ss, (3.83 +/- 0.94) ng/ml; C(av), (7.05 +/- 1.54) ng/ml; DF, (1.62 +/- 0.26); AUCss, (169.19 +/- 36.87) ng ml(-1) h.",Determination of azelnidipine by LC-ESI-MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771003/),[h·ng] / [ml],186,113069,DB01373,Calcium
,18771003,area under the plasma concentration versus time curve from time 0 h to 96 h (AUC(0-96),"After administration of a single dose of azelnidipine 8mg and 16 mg, respectively; the area under the plasma concentration versus time curve from time 0 h to 96 h (AUC(0-96) were (186 +/- 47) ng ml(-1) h, (429 +/- 145) ng ml(-1) h, respectively; clearance rate (CL/F) were (45.94 +/- 11.61), (42.11 +/- 14.23) L/h, respectively; peak plasma concentration Cmax were (8.66 +/- 1.15), (19.17 +/- 4.13) ng/ml, respectively; apparent volume of distribution (Vd) were (1749 +/- 964), (2480 +/- 2212) L, respectively; time to Cmax (Tmax) were (2.8 +/- 1.2), (3.0 +/- 0.9) h, respectively; elimination half-life (t(1/2beta)) were (22.8 +/- 2.4), (23.5 +/- 4.2) h, respectively; and MRT were (25.7 +/- 1.3), (26.2 +/- 2.2) h, respectively; The essential pharmacokinetic parameters after oral multiple doses (8 mg, q.d.) were as follows: (Cmax) ss, (15.04 +/- 2.27) ng/ml; (Tmax) ss, (2.38 +/- 0.92) h; (Cmin) ss, (3.83 +/- 0.94) ng/ml; C(av), (7.05 +/- 1.54) ng/ml; DF, (1.62 +/- 0.26); AUCss, (169.19 +/- 36.87) ng ml(-1) h.",Determination of azelnidipine by LC-ESI-MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771003/),[h·ng] / [ml],429,113070,DB01373,Calcium
,18771003,clearance rate (CL/F),"After administration of a single dose of azelnidipine 8mg and 16 mg, respectively; the area under the plasma concentration versus time curve from time 0 h to 96 h (AUC(0-96) were (186 +/- 47) ng ml(-1) h, (429 +/- 145) ng ml(-1) h, respectively; clearance rate (CL/F) were (45.94 +/- 11.61), (42.11 +/- 14.23) L/h, respectively; peak plasma concentration Cmax were (8.66 +/- 1.15), (19.17 +/- 4.13) ng/ml, respectively; apparent volume of distribution (Vd) were (1749 +/- 964), (2480 +/- 2212) L, respectively; time to Cmax (Tmax) were (2.8 +/- 1.2), (3.0 +/- 0.9) h, respectively; elimination half-life (t(1/2beta)) were (22.8 +/- 2.4), (23.5 +/- 4.2) h, respectively; and MRT were (25.7 +/- 1.3), (26.2 +/- 2.2) h, respectively; The essential pharmacokinetic parameters after oral multiple doses (8 mg, q.d.) were as follows: (Cmax) ss, (15.04 +/- 2.27) ng/ml; (Tmax) ss, (2.38 +/- 0.92) h; (Cmin) ss, (3.83 +/- 0.94) ng/ml; C(av), (7.05 +/- 1.54) ng/ml; DF, (1.62 +/- 0.26); AUCss, (169.19 +/- 36.87) ng ml(-1) h.",Determination of azelnidipine by LC-ESI-MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771003/),[l] / [h],45.94,113071,DB01373,Calcium
,18771003,clearance rate (CL/F),"After administration of a single dose of azelnidipine 8mg and 16 mg, respectively; the area under the plasma concentration versus time curve from time 0 h to 96 h (AUC(0-96) were (186 +/- 47) ng ml(-1) h, (429 +/- 145) ng ml(-1) h, respectively; clearance rate (CL/F) were (45.94 +/- 11.61), (42.11 +/- 14.23) L/h, respectively; peak plasma concentration Cmax were (8.66 +/- 1.15), (19.17 +/- 4.13) ng/ml, respectively; apparent volume of distribution (Vd) were (1749 +/- 964), (2480 +/- 2212) L, respectively; time to Cmax (Tmax) were (2.8 +/- 1.2), (3.0 +/- 0.9) h, respectively; elimination half-life (t(1/2beta)) were (22.8 +/- 2.4), (23.5 +/- 4.2) h, respectively; and MRT were (25.7 +/- 1.3), (26.2 +/- 2.2) h, respectively; The essential pharmacokinetic parameters after oral multiple doses (8 mg, q.d.) were as follows: (Cmax) ss, (15.04 +/- 2.27) ng/ml; (Tmax) ss, (2.38 +/- 0.92) h; (Cmin) ss, (3.83 +/- 0.94) ng/ml; C(av), (7.05 +/- 1.54) ng/ml; DF, (1.62 +/- 0.26); AUCss, (169.19 +/- 36.87) ng ml(-1) h.",Determination of azelnidipine by LC-ESI-MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771003/),[l] / [h],42.11,113072,DB01373,Calcium
,18771003,peak plasma concentration Cmax,"After administration of a single dose of azelnidipine 8mg and 16 mg, respectively; the area under the plasma concentration versus time curve from time 0 h to 96 h (AUC(0-96) were (186 +/- 47) ng ml(-1) h, (429 +/- 145) ng ml(-1) h, respectively; clearance rate (CL/F) were (45.94 +/- 11.61), (42.11 +/- 14.23) L/h, respectively; peak plasma concentration Cmax were (8.66 +/- 1.15), (19.17 +/- 4.13) ng/ml, respectively; apparent volume of distribution (Vd) were (1749 +/- 964), (2480 +/- 2212) L, respectively; time to Cmax (Tmax) were (2.8 +/- 1.2), (3.0 +/- 0.9) h, respectively; elimination half-life (t(1/2beta)) were (22.8 +/- 2.4), (23.5 +/- 4.2) h, respectively; and MRT were (25.7 +/- 1.3), (26.2 +/- 2.2) h, respectively; The essential pharmacokinetic parameters after oral multiple doses (8 mg, q.d.) were as follows: (Cmax) ss, (15.04 +/- 2.27) ng/ml; (Tmax) ss, (2.38 +/- 0.92) h; (Cmin) ss, (3.83 +/- 0.94) ng/ml; C(av), (7.05 +/- 1.54) ng/ml; DF, (1.62 +/- 0.26); AUCss, (169.19 +/- 36.87) ng ml(-1) h.",Determination of azelnidipine by LC-ESI-MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771003/),[ng] / [ml],8.66,113073,DB01373,Calcium
,18771003,peak plasma concentration Cmax,"After administration of a single dose of azelnidipine 8mg and 16 mg, respectively; the area under the plasma concentration versus time curve from time 0 h to 96 h (AUC(0-96) were (186 +/- 47) ng ml(-1) h, (429 +/- 145) ng ml(-1) h, respectively; clearance rate (CL/F) were (45.94 +/- 11.61), (42.11 +/- 14.23) L/h, respectively; peak plasma concentration Cmax were (8.66 +/- 1.15), (19.17 +/- 4.13) ng/ml, respectively; apparent volume of distribution (Vd) were (1749 +/- 964), (2480 +/- 2212) L, respectively; time to Cmax (Tmax) were (2.8 +/- 1.2), (3.0 +/- 0.9) h, respectively; elimination half-life (t(1/2beta)) were (22.8 +/- 2.4), (23.5 +/- 4.2) h, respectively; and MRT were (25.7 +/- 1.3), (26.2 +/- 2.2) h, respectively; The essential pharmacokinetic parameters after oral multiple doses (8 mg, q.d.) were as follows: (Cmax) ss, (15.04 +/- 2.27) ng/ml; (Tmax) ss, (2.38 +/- 0.92) h; (Cmin) ss, (3.83 +/- 0.94) ng/ml; C(av), (7.05 +/- 1.54) ng/ml; DF, (1.62 +/- 0.26); AUCss, (169.19 +/- 36.87) ng ml(-1) h.",Determination of azelnidipine by LC-ESI-MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771003/),[ng] / [ml],19.17,113074,DB01373,Calcium
,18771003,apparent volume of distribution (Vd),"After administration of a single dose of azelnidipine 8mg and 16 mg, respectively; the area under the plasma concentration versus time curve from time 0 h to 96 h (AUC(0-96) were (186 +/- 47) ng ml(-1) h, (429 +/- 145) ng ml(-1) h, respectively; clearance rate (CL/F) were (45.94 +/- 11.61), (42.11 +/- 14.23) L/h, respectively; peak plasma concentration Cmax were (8.66 +/- 1.15), (19.17 +/- 4.13) ng/ml, respectively; apparent volume of distribution (Vd) were (1749 +/- 964), (2480 +/- 2212) L, respectively; time to Cmax (Tmax) were (2.8 +/- 1.2), (3.0 +/- 0.9) h, respectively; elimination half-life (t(1/2beta)) were (22.8 +/- 2.4), (23.5 +/- 4.2) h, respectively; and MRT were (25.7 +/- 1.3), (26.2 +/- 2.2) h, respectively; The essential pharmacokinetic parameters after oral multiple doses (8 mg, q.d.) were as follows: (Cmax) ss, (15.04 +/- 2.27) ng/ml; (Tmax) ss, (2.38 +/- 0.92) h; (Cmin) ss, (3.83 +/- 0.94) ng/ml; C(av), (7.05 +/- 1.54) ng/ml; DF, (1.62 +/- 0.26); AUCss, (169.19 +/- 36.87) ng ml(-1) h.",Determination of azelnidipine by LC-ESI-MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771003/),l,1749,113075,DB01373,Calcium
,18771003,apparent volume of distribution (Vd),"After administration of a single dose of azelnidipine 8mg and 16 mg, respectively; the area under the plasma concentration versus time curve from time 0 h to 96 h (AUC(0-96) were (186 +/- 47) ng ml(-1) h, (429 +/- 145) ng ml(-1) h, respectively; clearance rate (CL/F) were (45.94 +/- 11.61), (42.11 +/- 14.23) L/h, respectively; peak plasma concentration Cmax were (8.66 +/- 1.15), (19.17 +/- 4.13) ng/ml, respectively; apparent volume of distribution (Vd) were (1749 +/- 964), (2480 +/- 2212) L, respectively; time to Cmax (Tmax) were (2.8 +/- 1.2), (3.0 +/- 0.9) h, respectively; elimination half-life (t(1/2beta)) were (22.8 +/- 2.4), (23.5 +/- 4.2) h, respectively; and MRT were (25.7 +/- 1.3), (26.2 +/- 2.2) h, respectively; The essential pharmacokinetic parameters after oral multiple doses (8 mg, q.d.) were as follows: (Cmax) ss, (15.04 +/- 2.27) ng/ml; (Tmax) ss, (2.38 +/- 0.92) h; (Cmin) ss, (3.83 +/- 0.94) ng/ml; C(av), (7.05 +/- 1.54) ng/ml; DF, (1.62 +/- 0.26); AUCss, (169.19 +/- 36.87) ng ml(-1) h.",Determination of azelnidipine by LC-ESI-MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771003/),l,2480,113076,DB01373,Calcium
,18771003,time to Cmax (Tmax),"After administration of a single dose of azelnidipine 8mg and 16 mg, respectively; the area under the plasma concentration versus time curve from time 0 h to 96 h (AUC(0-96) were (186 +/- 47) ng ml(-1) h, (429 +/- 145) ng ml(-1) h, respectively; clearance rate (CL/F) were (45.94 +/- 11.61), (42.11 +/- 14.23) L/h, respectively; peak plasma concentration Cmax were (8.66 +/- 1.15), (19.17 +/- 4.13) ng/ml, respectively; apparent volume of distribution (Vd) were (1749 +/- 964), (2480 +/- 2212) L, respectively; time to Cmax (Tmax) were (2.8 +/- 1.2), (3.0 +/- 0.9) h, respectively; elimination half-life (t(1/2beta)) were (22.8 +/- 2.4), (23.5 +/- 4.2) h, respectively; and MRT were (25.7 +/- 1.3), (26.2 +/- 2.2) h, respectively; The essential pharmacokinetic parameters after oral multiple doses (8 mg, q.d.) were as follows: (Cmax) ss, (15.04 +/- 2.27) ng/ml; (Tmax) ss, (2.38 +/- 0.92) h; (Cmin) ss, (3.83 +/- 0.94) ng/ml; C(av), (7.05 +/- 1.54) ng/ml; DF, (1.62 +/- 0.26); AUCss, (169.19 +/- 36.87) ng ml(-1) h.",Determination of azelnidipine by LC-ESI-MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771003/),h,2.8,113077,DB01373,Calcium
,18771003,time to Cmax (Tmax),"After administration of a single dose of azelnidipine 8mg and 16 mg, respectively; the area under the plasma concentration versus time curve from time 0 h to 96 h (AUC(0-96) were (186 +/- 47) ng ml(-1) h, (429 +/- 145) ng ml(-1) h, respectively; clearance rate (CL/F) were (45.94 +/- 11.61), (42.11 +/- 14.23) L/h, respectively; peak plasma concentration Cmax were (8.66 +/- 1.15), (19.17 +/- 4.13) ng/ml, respectively; apparent volume of distribution (Vd) were (1749 +/- 964), (2480 +/- 2212) L, respectively; time to Cmax (Tmax) were (2.8 +/- 1.2), (3.0 +/- 0.9) h, respectively; elimination half-life (t(1/2beta)) were (22.8 +/- 2.4), (23.5 +/- 4.2) h, respectively; and MRT were (25.7 +/- 1.3), (26.2 +/- 2.2) h, respectively; The essential pharmacokinetic parameters after oral multiple doses (8 mg, q.d.) were as follows: (Cmax) ss, (15.04 +/- 2.27) ng/ml; (Tmax) ss, (2.38 +/- 0.92) h; (Cmin) ss, (3.83 +/- 0.94) ng/ml; C(av), (7.05 +/- 1.54) ng/ml; DF, (1.62 +/- 0.26); AUCss, (169.19 +/- 36.87) ng ml(-1) h.",Determination of azelnidipine by LC-ESI-MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771003/),h,3.0,113078,DB01373,Calcium
,18771003,elimination half-life (t(1/2beta)),"After administration of a single dose of azelnidipine 8mg and 16 mg, respectively; the area under the plasma concentration versus time curve from time 0 h to 96 h (AUC(0-96) were (186 +/- 47) ng ml(-1) h, (429 +/- 145) ng ml(-1) h, respectively; clearance rate (CL/F) were (45.94 +/- 11.61), (42.11 +/- 14.23) L/h, respectively; peak plasma concentration Cmax were (8.66 +/- 1.15), (19.17 +/- 4.13) ng/ml, respectively; apparent volume of distribution (Vd) were (1749 +/- 964), (2480 +/- 2212) L, respectively; time to Cmax (Tmax) were (2.8 +/- 1.2), (3.0 +/- 0.9) h, respectively; elimination half-life (t(1/2beta)) were (22.8 +/- 2.4), (23.5 +/- 4.2) h, respectively; and MRT were (25.7 +/- 1.3), (26.2 +/- 2.2) h, respectively; The essential pharmacokinetic parameters after oral multiple doses (8 mg, q.d.) were as follows: (Cmax) ss, (15.04 +/- 2.27) ng/ml; (Tmax) ss, (2.38 +/- 0.92) h; (Cmin) ss, (3.83 +/- 0.94) ng/ml; C(av), (7.05 +/- 1.54) ng/ml; DF, (1.62 +/- 0.26); AUCss, (169.19 +/- 36.87) ng ml(-1) h.",Determination of azelnidipine by LC-ESI-MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771003/),,22.8,113079,DB01373,Calcium
,18771003,elimination half-life (t(1/2beta)),"After administration of a single dose of azelnidipine 8mg and 16 mg, respectively; the area under the plasma concentration versus time curve from time 0 h to 96 h (AUC(0-96) were (186 +/- 47) ng ml(-1) h, (429 +/- 145) ng ml(-1) h, respectively; clearance rate (CL/F) were (45.94 +/- 11.61), (42.11 +/- 14.23) L/h, respectively; peak plasma concentration Cmax were (8.66 +/- 1.15), (19.17 +/- 4.13) ng/ml, respectively; apparent volume of distribution (Vd) were (1749 +/- 964), (2480 +/- 2212) L, respectively; time to Cmax (Tmax) were (2.8 +/- 1.2), (3.0 +/- 0.9) h, respectively; elimination half-life (t(1/2beta)) were (22.8 +/- 2.4), (23.5 +/- 4.2) h, respectively; and MRT were (25.7 +/- 1.3), (26.2 +/- 2.2) h, respectively; The essential pharmacokinetic parameters after oral multiple doses (8 mg, q.d.) were as follows: (Cmax) ss, (15.04 +/- 2.27) ng/ml; (Tmax) ss, (2.38 +/- 0.92) h; (Cmin) ss, (3.83 +/- 0.94) ng/ml; C(av), (7.05 +/- 1.54) ng/ml; DF, (1.62 +/- 0.26); AUCss, (169.19 +/- 36.87) ng ml(-1) h.",Determination of azelnidipine by LC-ESI-MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771003/),,23.5,113080,DB01373,Calcium
,16033250,t(max),The mean values were as follows: t(max): 8.5 +/- 1.2 h; C(max): 36.55 +/- 6.76 ng/ml; AUC: 347.06 +/- 51.61 ng/h/ml; AUC 409.99 +/- 61.08 ng/h/ml; A(half-life): 2.26 +/- 0.36 h; D(half-life): 2.43 +/- 0.44 h; E(half-life): 4.62 +/- 0.79 h.,"Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16033250/),h,8.5,113252,DB01373,Calcium
,16033250,C(max),The mean values were as follows: t(max): 8.5 +/- 1.2 h; C(max): 36.55 +/- 6.76 ng/ml; AUC: 347.06 +/- 51.61 ng/h/ml; AUC 409.99 +/- 61.08 ng/h/ml; A(half-life): 2.26 +/- 0.36 h; D(half-life): 2.43 +/- 0.44 h; E(half-life): 4.62 +/- 0.79 h.,"Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16033250/),[ng] / [ml],36.55,113253,DB01373,Calcium
,16033250,AUC,The mean values were as follows: t(max): 8.5 +/- 1.2 h; C(max): 36.55 +/- 6.76 ng/ml; AUC: 347.06 +/- 51.61 ng/h/ml; AUC 409.99 +/- 61.08 ng/h/ml; A(half-life): 2.26 +/- 0.36 h; D(half-life): 2.43 +/- 0.44 h; E(half-life): 4.62 +/- 0.79 h.,"Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16033250/),[ng] / [h·ml],347.06,113254,DB01373,Calcium
,16033250,AUC,The mean values were as follows: t(max): 8.5 +/- 1.2 h; C(max): 36.55 +/- 6.76 ng/ml; AUC: 347.06 +/- 51.61 ng/h/ml; AUC 409.99 +/- 61.08 ng/h/ml; A(half-life): 2.26 +/- 0.36 h; D(half-life): 2.43 +/- 0.44 h; E(half-life): 4.62 +/- 0.79 h.,"Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16033250/),[ng] / [h·ml],409.99,113255,DB01373,Calcium
,16033250,A(half-life),The mean values were as follows: t(max): 8.5 +/- 1.2 h; C(max): 36.55 +/- 6.76 ng/ml; AUC: 347.06 +/- 51.61 ng/h/ml; AUC 409.99 +/- 61.08 ng/h/ml; A(half-life): 2.26 +/- 0.36 h; D(half-life): 2.43 +/- 0.44 h; E(half-life): 4.62 +/- 0.79 h.,"Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16033250/),h,2.26,113256,DB01373,Calcium
,16033250,D(half-life),The mean values were as follows: t(max): 8.5 +/- 1.2 h; C(max): 36.55 +/- 6.76 ng/ml; AUC: 347.06 +/- 51.61 ng/h/ml; AUC 409.99 +/- 61.08 ng/h/ml; A(half-life): 2.26 +/- 0.36 h; D(half-life): 2.43 +/- 0.44 h; E(half-life): 4.62 +/- 0.79 h.,"Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16033250/),h,2.43,113257,DB01373,Calcium
,16033250,E(half-life),The mean values were as follows: t(max): 8.5 +/- 1.2 h; C(max): 36.55 +/- 6.76 ng/ml; AUC: 347.06 +/- 51.61 ng/h/ml; AUC 409.99 +/- 61.08 ng/h/ml; A(half-life): 2.26 +/- 0.36 h; D(half-life): 2.43 +/- 0.44 h; E(half-life): 4.62 +/- 0.79 h.,"Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16033250/),h,4.62,113258,DB01373,Calcium
,21970310,clearance factor C(trough)-0.180,The full version of the final NONMEM® model was where CCB is 1 for concomitant administration of a CCB and is 0 otherwise; CHF is 1 for patients with CHF and is 0 otherwise; SEX is 0 for male and is 1 for female; and the elderly clearance factor C(trough)-0.180 is 1 for digoxin C(trough) <1.7 ng/mL.,Determination of digoxin clearance in Japanese elderly patients for optimization of drug therapy: a population pharmacokinetics analysis using nonlinear mixed-effects modelling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21970310/),,1,113291,DB01373,Calcium
<,21970310,C(trough),The full version of the final NONMEM® model was where CCB is 1 for concomitant administration of a CCB and is 0 otherwise; CHF is 1 for patients with CHF and is 0 otherwise; SEX is 0 for male and is 1 for female; and the elderly clearance factor C(trough)-0.180 is 1 for digoxin C(trough) <1.7 ng/mL.,Determination of digoxin clearance in Japanese elderly patients for optimization of drug therapy: a population pharmacokinetics analysis using nonlinear mixed-effects modelling. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21970310/),[ng] / [ml],1.7,113292,DB01373,Calcium
less,26594027,oral bioavailability (BA),"The oral bioavailability (BA) of risedronate sodium (RS), an antiresorptive agent, is less than 1% due to its low membrane permeability as well as the formation of non-absorbable complexes with multivalent cations such as calcium ion (Ca(2+)) in the gastrointestinal tract.","Enteric-coated tablet of risedronate sodium in combination with phytic acid, a natural chelating agent, for improved oral bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26594027/),%,1,113422,DB01373,Calcium
,25115037,Cmax,"Plasma concentrations after commercial pimobendan tablet suspension at 10 mg/kg reached a Cmax of 8.26 ng/mL at 3 hours with a terminal half-life of 2.1 hours, while concentrations after the bulk chemical suspension reached a Cmax of 1.28 ng/mL at 12 hours and had a terminal half-life of 2.3 hours.",Pharmacokinetics of single oral dose of pimobendan in Hispaniolan Amazon parrots (Amazona ventralis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25115037/),[ng] / [ml],8.26,113547,DB01373,Calcium
,25115037,terminal half-life,"Plasma concentrations after commercial pimobendan tablet suspension at 10 mg/kg reached a Cmax of 8.26 ng/mL at 3 hours with a terminal half-life of 2.1 hours, while concentrations after the bulk chemical suspension reached a Cmax of 1.28 ng/mL at 12 hours and had a terminal half-life of 2.3 hours.",Pharmacokinetics of single oral dose of pimobendan in Hispaniolan Amazon parrots (Amazona ventralis). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25115037/),h,2.1,113548,DB01373,Calcium
,25115037,Cmax,"Plasma concentrations after commercial pimobendan tablet suspension at 10 mg/kg reached a Cmax of 8.26 ng/mL at 3 hours with a terminal half-life of 2.1 hours, while concentrations after the bulk chemical suspension reached a Cmax of 1.28 ng/mL at 12 hours and had a terminal half-life of 2.3 hours.",Pharmacokinetics of single oral dose of pimobendan in Hispaniolan Amazon parrots (Amazona ventralis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25115037/),[ng] / [ml],1.28,113549,DB01373,Calcium
,25115037,terminal half-life,"Plasma concentrations after commercial pimobendan tablet suspension at 10 mg/kg reached a Cmax of 8.26 ng/mL at 3 hours with a terminal half-life of 2.1 hours, while concentrations after the bulk chemical suspension reached a Cmax of 1.28 ng/mL at 12 hours and had a terminal half-life of 2.3 hours.",Pharmacokinetics of single oral dose of pimobendan in Hispaniolan Amazon parrots (Amazona ventralis). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25115037/),h,2.3,113550,DB01373,Calcium
,17570622,peak plasma lanthanum concentration,"Following oral gavage of a single 1500 mg/kg dose, the peak plasma lanthanum concentration was 1.04+/-0.31 ng/mL, 8 h post-dose.",Systemic lanthanum is excreted in the bile of rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17570622/),[ng] / [ml],1.04,113742,DB01373,Calcium
,17570622,absolute oral bioavailability,Comparing plasma exposure after oral and intravenous administration of lanthanum yielded an absolute oral bioavailability of 0.0007%.,Systemic lanthanum is excreted in the bile of rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17570622/),%,0.0007,113743,DB01373,Calcium
,15556551,C(max),"The following differences (p < 0.05, Wilcoxon test) between (S) and (R) enantiomers were found (median): C(max) 2.071 ng mL(-1) versus 1.681 ng mL(-1); AUC(0-24)12.352 ng h mL(-1) versus 10.063 ng h mL(-1) and Cl/f 732.16 L h(-1) versus 1891.84 L h(-1).",Enantioselective pharmacokinetics of lercanidipine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556551/),[ng] / [ml],2.071,114812,DB01373,Calcium
,15556551,C(max),"The following differences (p < 0.05, Wilcoxon test) between (S) and (R) enantiomers were found (median): C(max) 2.071 ng mL(-1) versus 1.681 ng mL(-1); AUC(0-24)12.352 ng h mL(-1) versus 10.063 ng h mL(-1) and Cl/f 732.16 L h(-1) versus 1891.84 L h(-1).",Enantioselective pharmacokinetics of lercanidipine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556551/),[ng] / [ml],1.681,114813,DB01373,Calcium
,15556551,AUC(0-24),"The following differences (p < 0.05, Wilcoxon test) between (S) and (R) enantiomers were found (median): C(max) 2.071 ng mL(-1) versus 1.681 ng mL(-1); AUC(0-24)12.352 ng h mL(-1) versus 10.063 ng h mL(-1) and Cl/f 732.16 L h(-1) versus 1891.84 L h(-1).",Enantioselective pharmacokinetics of lercanidipine in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556551/),[h·ng] / [ml],12.352,114814,DB01373,Calcium
,15556551,AUC(0-24),"The following differences (p < 0.05, Wilcoxon test) between (S) and (R) enantiomers were found (median): C(max) 2.071 ng mL(-1) versus 1.681 ng mL(-1); AUC(0-24)12.352 ng h mL(-1) versus 10.063 ng h mL(-1) and Cl/f 732.16 L h(-1) versus 1891.84 L h(-1).",Enantioselective pharmacokinetics of lercanidipine in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556551/),[h·ng] / [ml],10.063,114815,DB01373,Calcium
,15556551,Cl/f,"The following differences (p < 0.05, Wilcoxon test) between (S) and (R) enantiomers were found (median): C(max) 2.071 ng mL(-1) versus 1.681 ng mL(-1); AUC(0-24)12.352 ng h mL(-1) versus 10.063 ng h mL(-1) and Cl/f 732.16 L h(-1) versus 1891.84 L h(-1).",Enantioselective pharmacokinetics of lercanidipine in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556551/),[l] / [h],732.16,114816,DB01373,Calcium
,15556551,Cl/f,"The following differences (p < 0.05, Wilcoxon test) between (S) and (R) enantiomers were found (median): C(max) 2.071 ng mL(-1) versus 1.681 ng mL(-1); AUC(0-24)12.352 ng h mL(-1) versus 10.063 ng h mL(-1) and Cl/f 732.16 L h(-1) versus 1891.84 L h(-1).",Enantioselective pharmacokinetics of lercanidipine in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556551/),[l] / [h],1891.84,114817,DB01373,Calcium
,24569459,t1/2,The mean t1/2 of KRN23 was 8-12 days after i.v. administration and 13-19 days after s.c. administration.,Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24569459/),d,8-12,116535,DB01373,Calcium
,24569459,t1/2,The mean t1/2 of KRN23 was 8-12 days after i.v. administration and 13-19 days after s.c. administration.,Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24569459/),d,13-19,116536,DB01373,Calcium
,20399994,C(max),"Geometric mean C(max) values for rosuvastatin after administration of single doses of rosuvastatin 5, 10, and 20 mg were 8.33, 10.76, and 19.17 ng/mL, respectively; the corresponding geometric mean AUC(0-t) values were 57.63, 88.89, and 163.87 ng .","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),[ng] / [ml],8.33,117127,DB01373,Calcium
,20399994,C(max),"Geometric mean C(max) values for rosuvastatin after administration of single doses of rosuvastatin 5, 10, and 20 mg were 8.33, 10.76, and 19.17 ng/mL, respectively; the corresponding geometric mean AUC(0-t) values were 57.63, 88.89, and 163.87 ng .","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),[ng] / [ml],10.76,117128,DB01373,Calcium
,20399994,C(max),"Geometric mean C(max) values for rosuvastatin after administration of single doses of rosuvastatin 5, 10, and 20 mg were 8.33, 10.76, and 19.17 ng/mL, respectively; the corresponding geometric mean AUC(0-t) values were 57.63, 88.89, and 163.87 ng .","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),[ng] / [ml],19.17,117129,DB01373,Calcium
,20399994,AUC(0-t),"Geometric mean C(max) values for rosuvastatin after administration of single doses of rosuvastatin 5, 10, and 20 mg were 8.33, 10.76, and 19.17 ng/mL, respectively; the corresponding geometric mean AUC(0-t) values were 57.63, 88.89, and 163.87 ng .","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),ng,57.63,117130,DB01373,Calcium
,20399994,AUC(0-t),"Geometric mean C(max) values for rosuvastatin after administration of single doses of rosuvastatin 5, 10, and 20 mg were 8.33, 10.76, and 19.17 ng/mL, respectively; the corresponding geometric mean AUC(0-t) values were 57.63, 88.89, and 163.87 ng .","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),ng,88.89,117131,DB01373,Calcium
,20399994,AUC(0-t),"Geometric mean C(max) values for rosuvastatin after administration of single doses of rosuvastatin 5, 10, and 20 mg were 8.33, 10.76, and 19.17 ng/mL, respectively; the corresponding geometric mean AUC(0-t) values were 57.63, 88.89, and 163.87 ng .","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),ng,163.87,117132,DB01373,Calcium
,20399994,C(max),"At steady state, values for C(max) were 8.31, 8.41, and 20.73 ng/mL; the corresponding geometric mean AUC values were 64.87, 77.29, and 178.64 ng .","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),[ng] / [ml],8.31,117133,DB01373,Calcium
,20399994,C(max),"At steady state, values for C(max) were 8.31, 8.41, and 20.73 ng/mL; the corresponding geometric mean AUC values were 64.87, 77.29, and 178.64 ng .","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),[ng] / [ml],8.41,117134,DB01373,Calcium
,20399994,C(max),"At steady state, values for C(max) were 8.31, 8.41, and 20.73 ng/mL; the corresponding geometric mean AUC values were 64.87, 77.29, and 178.64 ng .","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),[ng] / [ml],20.73,117135,DB01373,Calcium
,20399994,AUC,"At steady state, values for C(max) were 8.31, 8.41, and 20.73 ng/mL; the corresponding geometric mean AUC values were 64.87, 77.29, and 178.64 ng .","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),ng,64.87,117136,DB01373,Calcium
,20399994,AUC,"At steady state, values for C(max) were 8.31, 8.41, and 20.73 ng/mL; the corresponding geometric mean AUC values were 64.87, 77.29, and 178.64 ng .","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),ng,77.29,117137,DB01373,Calcium
,20399994,AUC,"At steady state, values for C(max) were 8.31, 8.41, and 20.73 ng/mL; the corresponding geometric mean AUC values were 64.87, 77.29, and 178.64 ng .","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),ng,178.64,117138,DB01373,Calcium
,20399994,accumulation ratios,"After administration of multiple doses of rosuvastatin 5, 10, and 20 mg, the accumulation ratios were 1.23, 0.95, and 1.23, respectively, indicating minimal accumulation of rosuvastatin.","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),,1.23,117139,DB01373,Calcium
,20399994,accumulation ratios,"After administration of multiple doses of rosuvastatin 5, 10, and 20 mg, the accumulation ratios were 1.23, 0.95, and 1.23, respectively, indicating minimal accumulation of rosuvastatin.","Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399994/),,0.95,117140,DB01373,Calcium
,22393830,disintegration time,"Apart from improved stability compared to pure AT, disintegration time of 27s, hardness of 5 kg and favorable mouth feel were achieved.","Preparation, physicochemical characteristics and bioavailability studies of an atorvastatin hydroxypropyl-beta-cyclodextrin complex. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22393830/),s,27,117215,DB01373,Calcium
,30092663,concentrations,"Amlodipine concentrations in the L. plantarum IS-10506 group were 4.95 ± 1.22, 8.71 ± 0.69, and 12.48 ± 2.53 ng/ml, and those in the control group were 1.69 ± 0.31, 3.89 ± 1.23, and 7.17 ± 1.85 ng/ml at 30, 60, and 120 minutes, respectively after administration of amlodipine.",Lactobacillus plantarum IS-10506 probiotic administration increases amlodipine absorption in a rabbit model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30092663/),[ng] / [ml],4.95,117619,DB01373,Calcium
,30092663,concentrations,"Amlodipine concentrations in the L. plantarum IS-10506 group were 4.95 ± 1.22, 8.71 ± 0.69, and 12.48 ± 2.53 ng/ml, and those in the control group were 1.69 ± 0.31, 3.89 ± 1.23, and 7.17 ± 1.85 ng/ml at 30, 60, and 120 minutes, respectively after administration of amlodipine.",Lactobacillus plantarum IS-10506 probiotic administration increases amlodipine absorption in a rabbit model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30092663/),[ng] / [ml],8.71,117620,DB01373,Calcium
,30092663,concentrations,"Amlodipine concentrations in the L. plantarum IS-10506 group were 4.95 ± 1.22, 8.71 ± 0.69, and 12.48 ± 2.53 ng/ml, and those in the control group were 1.69 ± 0.31, 3.89 ± 1.23, and 7.17 ± 1.85 ng/ml at 30, 60, and 120 minutes, respectively after administration of amlodipine.",Lactobacillus plantarum IS-10506 probiotic administration increases amlodipine absorption in a rabbit model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30092663/),[ng] / [ml],12.48,117621,DB01373,Calcium
,30092663,concentrations,"Amlodipine concentrations in the L. plantarum IS-10506 group were 4.95 ± 1.22, 8.71 ± 0.69, and 12.48 ± 2.53 ng/ml, and those in the control group were 1.69 ± 0.31, 3.89 ± 1.23, and 7.17 ± 1.85 ng/ml at 30, 60, and 120 minutes, respectively after administration of amlodipine.",Lactobacillus plantarum IS-10506 probiotic administration increases amlodipine absorption in a rabbit model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30092663/),[ng] / [ml],1.69,117622,DB01373,Calcium
,30092663,concentrations,"Amlodipine concentrations in the L. plantarum IS-10506 group were 4.95 ± 1.22, 8.71 ± 0.69, and 12.48 ± 2.53 ng/ml, and those in the control group were 1.69 ± 0.31, 3.89 ± 1.23, and 7.17 ± 1.85 ng/ml at 30, 60, and 120 minutes, respectively after administration of amlodipine.",Lactobacillus plantarum IS-10506 probiotic administration increases amlodipine absorption in a rabbit model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30092663/),[ng] / [ml],3.89,117623,DB01373,Calcium
,30092663,concentrations,"Amlodipine concentrations in the L. plantarum IS-10506 group were 4.95 ± 1.22, 8.71 ± 0.69, and 12.48 ± 2.53 ng/ml, and those in the control group were 1.69 ± 0.31, 3.89 ± 1.23, and 7.17 ± 1.85 ng/ml at 30, 60, and 120 minutes, respectively after administration of amlodipine.",Lactobacillus plantarum IS-10506 probiotic administration increases amlodipine absorption in a rabbit model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30092663/),[ng] / [ml],7.17,117624,DB01373,Calcium
,19652502,pD(2),"The pD(2) value in the absence and presence of HE (10 mg/ml) was 5.14+/-0.16 and 3.99+/-0.17, respectively.",Pharmacological effects of Hachi-mi-jio-gan extract (Harncare) on the contractile response and on pharmacologically relevant receptors in the rat bladder. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19652502/),,5.14,117809,DB01373,Calcium
,19652502,pD(2),"The pD(2) value in the absence and presence of HE (10 mg/ml) was 5.14+/-0.16 and 3.99+/-0.17, respectively.",Pharmacological effects of Hachi-mi-jio-gan extract (Harncare) on the contractile response and on pharmacologically relevant receptors in the rat bladder. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19652502/),,3.99,117810,DB01373,Calcium
,19652502,IC(50),"The respective IC(50) values were 6.85+/-0.94, 7.08+/-0.72 and 1.34+/-0.23 mg/ml.",Pharmacological effects of Hachi-mi-jio-gan extract (Harncare) on the contractile response and on pharmacologically relevant receptors in the rat bladder. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19652502/),[mg] / [ml],6.85,117811,DB01373,Calcium
,19652502,IC(50),"The respective IC(50) values were 6.85+/-0.94, 7.08+/-0.72 and 1.34+/-0.23 mg/ml.",Pharmacological effects of Hachi-mi-jio-gan extract (Harncare) on the contractile response and on pharmacologically relevant receptors in the rat bladder. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19652502/),[mg] / [ml],7.08,117812,DB01373,Calcium
,19652502,IC(50),"The respective IC(50) values were 6.85+/-0.94, 7.08+/-0.72 and 1.34+/-0.23 mg/ml.",Pharmacological effects of Hachi-mi-jio-gan extract (Harncare) on the contractile response and on pharmacologically relevant receptors in the rat bladder. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19652502/),[mg] / [ml],1.34,117813,DB01373,Calcium
less,26445481,oral bioavailability,"Although melatonin exhibits oncostatic properties such as antiproliferative effects, the oral bioavailability of this hormone is less than 20%.",The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445481/),%,20,118008,DB01373,Calcium
,26445481,viability rate,"MCF-7 cells incubated with melatonin adsorbed to PEG microspheres showed a lower viability rate (40.0 ± 8.3 with melatonin adsorbed to PEG microspheres compared to 54.1 ± 7.3 with melatonin; 81.8 ± 12.5 with PEG microsphere and 92.7 ± 4.1 with medium), increased spontaneous intracellular Ca2+ release (27.0 ± 8.6 with melatonin adsorbed to PEG microspheres compared to 21.5 ± 13.4 with melatonin; 10.1 ± 5.4 with PEG microsphere and 9.1 ± 5.6 with medium) and increased apoptosis index (51.2 ± 2.7 with melatonin adsorbed to PEG microspheres compared to 36.0 ± 2.1 with melatonin; 4.9 ± 0.5 with PEG microsphere and 3.1 ± 0.6 with medium).",The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445481/),,40.0,118009,DB01373,Calcium
,26445481,viability rate,"MCF-7 cells incubated with melatonin adsorbed to PEG microspheres showed a lower viability rate (40.0 ± 8.3 with melatonin adsorbed to PEG microspheres compared to 54.1 ± 7.3 with melatonin; 81.8 ± 12.5 with PEG microsphere and 92.7 ± 4.1 with medium), increased spontaneous intracellular Ca2+ release (27.0 ± 8.6 with melatonin adsorbed to PEG microspheres compared to 21.5 ± 13.4 with melatonin; 10.1 ± 5.4 with PEG microsphere and 9.1 ± 5.6 with medium) and increased apoptosis index (51.2 ± 2.7 with melatonin adsorbed to PEG microspheres compared to 36.0 ± 2.1 with melatonin; 4.9 ± 0.5 with PEG microsphere and 3.1 ± 0.6 with medium).",The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445481/),,54.1,118010,DB01373,Calcium
,26445481,viability rate,"MCF-7 cells incubated with melatonin adsorbed to PEG microspheres showed a lower viability rate (40.0 ± 8.3 with melatonin adsorbed to PEG microspheres compared to 54.1 ± 7.3 with melatonin; 81.8 ± 12.5 with PEG microsphere and 92.7 ± 4.1 with medium), increased spontaneous intracellular Ca2+ release (27.0 ± 8.6 with melatonin adsorbed to PEG microspheres compared to 21.5 ± 13.4 with melatonin; 10.1 ± 5.4 with PEG microsphere and 9.1 ± 5.6 with medium) and increased apoptosis index (51.2 ± 2.7 with melatonin adsorbed to PEG microspheres compared to 36.0 ± 2.1 with melatonin; 4.9 ± 0.5 with PEG microsphere and 3.1 ± 0.6 with medium).",The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445481/),,81.8,118011,DB01373,Calcium
,26445481,viability rate,"MCF-7 cells incubated with melatonin adsorbed to PEG microspheres showed a lower viability rate (40.0 ± 8.3 with melatonin adsorbed to PEG microspheres compared to 54.1 ± 7.3 with melatonin; 81.8 ± 12.5 with PEG microsphere and 92.7 ± 4.1 with medium), increased spontaneous intracellular Ca2+ release (27.0 ± 8.6 with melatonin adsorbed to PEG microspheres compared to 21.5 ± 13.4 with melatonin; 10.1 ± 5.4 with PEG microsphere and 9.1 ± 5.6 with medium) and increased apoptosis index (51.2 ± 2.7 with melatonin adsorbed to PEG microspheres compared to 36.0 ± 2.1 with melatonin; 4.9 ± 0.5 with PEG microsphere and 3.1 ± 0.6 with medium).",The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445481/),,92.7,118012,DB01373,Calcium
,26445481,spontaneous,"MCF-7 cells incubated with melatonin adsorbed to PEG microspheres showed a lower viability rate (40.0 ± 8.3 with melatonin adsorbed to PEG microspheres compared to 54.1 ± 7.3 with melatonin; 81.8 ± 12.5 with PEG microsphere and 92.7 ± 4.1 with medium), increased spontaneous intracellular Ca2+ release (27.0 ± 8.6 with melatonin adsorbed to PEG microspheres compared to 21.5 ± 13.4 with melatonin; 10.1 ± 5.4 with PEG microsphere and 9.1 ± 5.6 with medium) and increased apoptosis index (51.2 ± 2.7 with melatonin adsorbed to PEG microspheres compared to 36.0 ± 2.1 with melatonin; 4.9 ± 0.5 with PEG microsphere and 3.1 ± 0.6 with medium).",The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445481/),,27.0,118013,DB01373,Calcium
,26445481,spontaneous,"MCF-7 cells incubated with melatonin adsorbed to PEG microspheres showed a lower viability rate (40.0 ± 8.3 with melatonin adsorbed to PEG microspheres compared to 54.1 ± 7.3 with melatonin; 81.8 ± 12.5 with PEG microsphere and 92.7 ± 4.1 with medium), increased spontaneous intracellular Ca2+ release (27.0 ± 8.6 with melatonin adsorbed to PEG microspheres compared to 21.5 ± 13.4 with melatonin; 10.1 ± 5.4 with PEG microsphere and 9.1 ± 5.6 with medium) and increased apoptosis index (51.2 ± 2.7 with melatonin adsorbed to PEG microspheres compared to 36.0 ± 2.1 with melatonin; 4.9 ± 0.5 with PEG microsphere and 3.1 ± 0.6 with medium).",The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445481/),,21.5,118014,DB01373,Calcium
,26445481,spontaneous,"MCF-7 cells incubated with melatonin adsorbed to PEG microspheres showed a lower viability rate (40.0 ± 8.3 with melatonin adsorbed to PEG microspheres compared to 54.1 ± 7.3 with melatonin; 81.8 ± 12.5 with PEG microsphere and 92.7 ± 4.1 with medium), increased spontaneous intracellular Ca2+ release (27.0 ± 8.6 with melatonin adsorbed to PEG microspheres compared to 21.5 ± 13.4 with melatonin; 10.1 ± 5.4 with PEG microsphere and 9.1 ± 5.6 with medium) and increased apoptosis index (51.2 ± 2.7 with melatonin adsorbed to PEG microspheres compared to 36.0 ± 2.1 with melatonin; 4.9 ± 0.5 with PEG microsphere and 3.1 ± 0.6 with medium).",The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445481/),,10.1,118015,DB01373,Calcium
,26445481,spontaneous,"MCF-7 cells incubated with melatonin adsorbed to PEG microspheres showed a lower viability rate (40.0 ± 8.3 with melatonin adsorbed to PEG microspheres compared to 54.1 ± 7.3 with melatonin; 81.8 ± 12.5 with PEG microsphere and 92.7 ± 4.1 with medium), increased spontaneous intracellular Ca2+ release (27.0 ± 8.6 with melatonin adsorbed to PEG microspheres compared to 21.5 ± 13.4 with melatonin; 10.1 ± 5.4 with PEG microsphere and 9.1 ± 5.6 with medium) and increased apoptosis index (51.2 ± 2.7 with melatonin adsorbed to PEG microspheres compared to 36.0 ± 2.1 with melatonin; 4.9 ± 0.5 with PEG microsphere and 3.1 ± 0.6 with medium).",The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445481/),,9.1,118016,DB01373,Calcium
,26445481,apoptosis index,"MCF-7 cells incubated with melatonin adsorbed to PEG microspheres showed a lower viability rate (40.0 ± 8.3 with melatonin adsorbed to PEG microspheres compared to 54.1 ± 7.3 with melatonin; 81.8 ± 12.5 with PEG microsphere and 92.7 ± 4.1 with medium), increased spontaneous intracellular Ca2+ release (27.0 ± 8.6 with melatonin adsorbed to PEG microspheres compared to 21.5 ± 13.4 with melatonin; 10.1 ± 5.4 with PEG microsphere and 9.1 ± 5.6 with medium) and increased apoptosis index (51.2 ± 2.7 with melatonin adsorbed to PEG microspheres compared to 36.0 ± 2.1 with melatonin; 4.9 ± 0.5 with PEG microsphere and 3.1 ± 0.6 with medium).",The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445481/),,51.2,118017,DB01373,Calcium
,26445481,apoptosis index,"MCF-7 cells incubated with melatonin adsorbed to PEG microspheres showed a lower viability rate (40.0 ± 8.3 with melatonin adsorbed to PEG microspheres compared to 54.1 ± 7.3 with melatonin; 81.8 ± 12.5 with PEG microsphere and 92.7 ± 4.1 with medium), increased spontaneous intracellular Ca2+ release (27.0 ± 8.6 with melatonin adsorbed to PEG microspheres compared to 21.5 ± 13.4 with melatonin; 10.1 ± 5.4 with PEG microsphere and 9.1 ± 5.6 with medium) and increased apoptosis index (51.2 ± 2.7 with melatonin adsorbed to PEG microspheres compared to 36.0 ± 2.1 with melatonin; 4.9 ± 0.5 with PEG microsphere and 3.1 ± 0.6 with medium).",The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445481/),,36.0,118018,DB01373,Calcium
,26445481,apoptosis index,"MCF-7 cells incubated with melatonin adsorbed to PEG microspheres showed a lower viability rate (40.0 ± 8.3 with melatonin adsorbed to PEG microspheres compared to 54.1 ± 7.3 with melatonin; 81.8 ± 12.5 with PEG microsphere and 92.7 ± 4.1 with medium), increased spontaneous intracellular Ca2+ release (27.0 ± 8.6 with melatonin adsorbed to PEG microspheres compared to 21.5 ± 13.4 with melatonin; 10.1 ± 5.4 with PEG microsphere and 9.1 ± 5.6 with medium) and increased apoptosis index (51.2 ± 2.7 with melatonin adsorbed to PEG microspheres compared to 36.0 ± 2.1 with melatonin; 4.9 ± 0.5 with PEG microsphere and 3.1 ± 0.6 with medium).",The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445481/),,4.9,118019,DB01373,Calcium
,26445481,apoptosis index,"MCF-7 cells incubated with melatonin adsorbed to PEG microspheres showed a lower viability rate (40.0 ± 8.3 with melatonin adsorbed to PEG microspheres compared to 54.1 ± 7.3 with melatonin; 81.8 ± 12.5 with PEG microsphere and 92.7 ± 4.1 with medium), increased spontaneous intracellular Ca2+ release (27.0 ± 8.6 with melatonin adsorbed to PEG microspheres compared to 21.5 ± 13.4 with melatonin; 10.1 ± 5.4 with PEG microsphere and 9.1 ± 5.6 with medium) and increased apoptosis index (51.2 ± 2.7 with melatonin adsorbed to PEG microspheres compared to 36.0 ± 2.1 with melatonin; 4.9 ± 0.5 with PEG microsphere and 3.1 ± 0.6 with medium).",The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445481/),,3.1,118020,DB01373,Calcium
,25632296,"area under the curve of plasma concentration, τ","Zofenopril/zofenoprilat PK analysis showed higher area under the curve of plasma concentration, τ values (ng/ml x h) than ramipril/ramiprilat (zofenopril vs. ramipril, 84.25 ± 34.47 vs. 47.40 ± 21.30; and zofenoprilat vs. ramiprilat, 653.67 ± 174.91 vs. 182.26 ± 61.28).",A crossover randomized comparative study of zofenopril and ramipril on cough reflex and airway inflammation in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25632296/),[ng] / [h·ml],84.25,118464,DB01373,Calcium
,25632296,"area under the curve of plasma concentration, τ","Zofenopril/zofenoprilat PK analysis showed higher area under the curve of plasma concentration, τ values (ng/ml x h) than ramipril/ramiprilat (zofenopril vs. ramipril, 84.25 ± 34.47 vs. 47.40 ± 21.30; and zofenoprilat vs. ramiprilat, 653.67 ± 174.91 vs. 182.26 ± 61.28).",A crossover randomized comparative study of zofenopril and ramipril on cough reflex and airway inflammation in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25632296/),[ng] / [h·ml],47.40,118465,DB01373,Calcium
,25632296,"area under the curve of plasma concentration, τ","Zofenopril/zofenoprilat PK analysis showed higher area under the curve of plasma concentration, τ values (ng/ml x h) than ramipril/ramiprilat (zofenopril vs. ramipril, 84.25 ± 34.47 vs. 47.40 ± 21.30; and zofenoprilat vs. ramiprilat, 653.67 ± 174.91 vs. 182.26 ± 61.28).",A crossover randomized comparative study of zofenopril and ramipril on cough reflex and airway inflammation in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25632296/),[ng] / [h·ml],653.67,118466,DB01373,Calcium
,25632296,"area under the curve of plasma concentration, τ","Zofenopril/zofenoprilat PK analysis showed higher area under the curve of plasma concentration, τ values (ng/ml x h) than ramipril/ramiprilat (zofenopril vs. ramipril, 84.25 ± 34.47 vs. 47.40 ± 21.30; and zofenoprilat vs. ramiprilat, 653.67 ± 174.91 vs. 182.26 ± 61.28).",A crossover randomized comparative study of zofenopril and ramipril on cough reflex and airway inflammation in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25632296/),[ng] / [h·ml],182.26,118467,DB01373,Calcium
,33428168,absolute oral availability,"Following single doses, rosuvastatin has a mean absolute oral availability of 20%, an overall mean total clearance of 28.3 L/h and an average terminal elimination half-life of approximately 20 h.",Pharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33428168/),%,20,118477,DB01373,Calcium
,33428168,total clearance,"Following single doses, rosuvastatin has a mean absolute oral availability of 20%, an overall mean total clearance of 28.3 L/h and an average terminal elimination half-life of approximately 20 h.",Pharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33428168/),[l] / [h],28.3,118478,DB01373,Calcium
,33428168,terminal elimination half-life,"Following single doses, rosuvastatin has a mean absolute oral availability of 20%, an overall mean total clearance of 28.3 L/h and an average terminal elimination half-life of approximately 20 h.",Pharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33428168/),h,20,118479,DB01373,Calcium
,33428168,half-life,"The clinical relevance of the statistically significant drug interactions is yet to be investigated following repeated co-administration for at least 15 days, consistent with a half-life of low-density lipoprotein of 3 days.",Pharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33428168/),d,3,118480,DB01373,Calcium
,24316669,IC₅₀,"Among synthesized target compounds, 16g (IC₅₀ = 25.73 nM) and 16i (IC₅₀ = 25.53 nM) showed equivalent inhibitory activity against CCR5 to that of the positive control maraviroc (IC₅₀ = 25.43 nM) in calcium mobilization assay.","Design, synthesis, and biological evaluation of novel piperidine-4-carboxamide derivatives as potent CCR5 inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24316669/),nM,25.73,118508,DB01373,Calcium
,24316669,IC₅₀,"Among synthesized target compounds, 16g (IC₅₀ = 25.73 nM) and 16i (IC₅₀ = 25.53 nM) showed equivalent inhibitory activity against CCR5 to that of the positive control maraviroc (IC₅₀ = 25.43 nM) in calcium mobilization assay.","Design, synthesis, and biological evaluation of novel piperidine-4-carboxamide derivatives as potent CCR5 inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24316669/),nM,25.53,118509,DB01373,Calcium
,24316669,IC₅₀,"Among synthesized target compounds, 16g (IC₅₀ = 25.73 nM) and 16i (IC₅₀ = 25.53 nM) showed equivalent inhibitory activity against CCR5 to that of the positive control maraviroc (IC₅₀ = 25.43 nM) in calcium mobilization assay.","Design, synthesis, and biological evaluation of novel piperidine-4-carboxamide derivatives as potent CCR5 inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24316669/),nM,25.43,118510,DB01373,Calcium
,24316669,IC₅₀,"Two compounds, 16g and 16i, displayed antiviral activity with IC₅₀ values of 73.01 nM and 94.10 nM, respectively.","Design, synthesis, and biological evaluation of novel piperidine-4-carboxamide derivatives as potent CCR5 inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24316669/),nM,73.01,118511,DB01373,Calcium
,24316669,IC₅₀,"Two compounds, 16g and 16i, displayed antiviral activity with IC₅₀ values of 73.01 nM and 94.10 nM, respectively.","Design, synthesis, and biological evaluation of novel piperidine-4-carboxamide derivatives as potent CCR5 inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24316669/),nM,94.10,118512,DB01373,Calcium
,25544113,iron,"The geometric means of iron bioavailability (range±1SD) for iron alone, iron with phytic acid, iron with tannic acid, and iron with citrus pectin were 25.0% (11.9-52.0); 18.9% (9.9-35.8); 16.8% (8.7-32.3); and 21.1% (10.2-43.9), respectively (repeated-measures ANOVA, p<0.02 (Dunnett's post hoc: control vs tannic acid p<0.05).","Effect of phytic acid, tannic acid and pectin on fasting iron bioavailability both in the presence and absence of calcium. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544113/),%,25.0,119225,DB01373,Calcium
,25544113,bioavailability,"The geometric means of iron bioavailability (range±1SD) for iron alone, iron with phytic acid, iron with tannic acid, and iron with citrus pectin were 25.0% (11.9-52.0); 18.9% (9.9-35.8); 16.8% (8.7-32.3); and 21.1% (10.2-43.9), respectively (repeated-measures ANOVA, p<0.02 (Dunnett's post hoc: control vs tannic acid p<0.05).","Effect of phytic acid, tannic acid and pectin on fasting iron bioavailability both in the presence and absence of calcium. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544113/),%,25.0,119226,DB01373,Calcium
,25544113,bioavailability,"The geometric means of iron bioavailability (range±1SD) for iron alone, iron with phytic acid, iron with tannic acid, and iron with citrus pectin were 25.0% (11.9-52.0); 18.9% (9.9-35.8); 16.8% (8.7-32.3); and 21.1% (10.2-43.9), respectively (repeated-measures ANOVA, p<0.02 (Dunnett's post hoc: control vs tannic acid p<0.05).","Effect of phytic acid, tannic acid and pectin on fasting iron bioavailability both in the presence and absence of calcium. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544113/),%,18.9,119227,DB01373,Calcium
,25544113,bioavailability,"The geometric means of iron bioavailability (range±1SD) for iron alone, iron with phytic acid, iron with tannic acid, and iron with citrus pectin were 25.0% (11.9-52.0); 18.9% (9.9-35.8); 16.8% (8.7-32.3); and 21.1% (10.2-43.9), respectively (repeated-measures ANOVA, p<0.02 (Dunnett's post hoc: control vs tannic acid p<0.05).","Effect of phytic acid, tannic acid and pectin on fasting iron bioavailability both in the presence and absence of calcium. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544113/),%,16.8,119228,DB01373,Calcium
,25544113,bioavailability,"The geometric means of iron bioavailability (range±1SD) for iron alone, iron with phytic acid, iron with tannic acid, and iron with citrus pectin were 25.0% (11.9-52.0); 18.9% (9.9-35.8); 16.8% (8.7-32.3); and 21.1% (10.2-43.9), respectively (repeated-measures ANOVA, p<0.02 (Dunnett's post hoc: control vs tannic acid p<0.05).","Effect of phytic acid, tannic acid and pectin on fasting iron bioavailability both in the presence and absence of calcium. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544113/),%,21.1,119229,DB01373,Calcium
,25544113,iron bioavailability,"When 800mg of calcium was added (study B), iron bioavailability was 16.7% (10.1-27.5); 13.2% (7.1-24.6); 14.8% (8.8-25.1); and 12.6% (5.5-28.8), respectively (repeated-measures ANOVA, NS).","Effect of phytic acid, tannic acid and pectin on fasting iron bioavailability both in the presence and absence of calcium. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544113/),%,16.7,119230,DB01373,Calcium
,25544113,iron bioavailability,"When 800mg of calcium was added (study B), iron bioavailability was 16.7% (10.1-27.5); 13.2% (7.1-24.6); 14.8% (8.8-25.1); and 12.6% (5.5-28.8), respectively (repeated-measures ANOVA, NS).","Effect of phytic acid, tannic acid and pectin on fasting iron bioavailability both in the presence and absence of calcium. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544113/),%,13.2,119231,DB01373,Calcium
,25544113,iron bioavailability,"When 800mg of calcium was added (study B), iron bioavailability was 16.7% (10.1-27.5); 13.2% (7.1-24.6); 14.8% (8.8-25.1); and 12.6% (5.5-28.8), respectively (repeated-measures ANOVA, NS).","Effect of phytic acid, tannic acid and pectin on fasting iron bioavailability both in the presence and absence of calcium. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544113/),%,14.8,119232,DB01373,Calcium
,25544113,iron bioavailability,"When 800mg of calcium was added (study B), iron bioavailability was 16.7% (10.1-27.5); 13.2% (7.1-24.6); 14.8% (8.8-25.1); and 12.6% (5.5-28.8), respectively (repeated-measures ANOVA, NS).","Effect of phytic acid, tannic acid and pectin on fasting iron bioavailability both in the presence and absence of calcium. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544113/),%,12.6,119233,DB01373,Calcium
,15129990,bioavailability,"A bioavailability of ambroxol of approximately 64% of that of a commercially available formulation could be achieved from gels containing an identical dose of ambroxol formed in situ in the stomachs of rats, with appreciably lower peak plasma levels and a sustained release of drug over a period of at least 6 h.",Oral sustained delivery of ambroxol from in situ-gelling pectin formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15129990/),%,64,119526,DB01373,Calcium
,18004661,calcium retention,The calcium retention was higher in the femur of rats fed on the diet supplemented with Ca + Zn (221 +/- 13.61 mg/g) than the rats fed on the diet supplemented with Ca + Fe (219 +/- 18.92 mg/g).,"Bioavailability of calcium, iron and zinc fortified whole wheat flour chapatti. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18004661/),[mg] / [g],221,119593,DB01373,Calcium
,18004661,calcium retention,The calcium retention was higher in the femur of rats fed on the diet supplemented with Ca + Zn (221 +/- 13.61 mg/g) than the rats fed on the diet supplemented with Ca + Fe (219 +/- 18.92 mg/g).,"Bioavailability of calcium, iron and zinc fortified whole wheat flour chapatti. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18004661/),[mg] / [g],219,119594,DB01373,Calcium
,18004661,zinc content,"The iron in plasma, liver and femur ranged from 2.19 +/- 0.11 to 2.77 +/- 0.10 microg/ml, 203.5 +/- 13.24 to 251.5 +/- 17.19 microg/g and 43.5 +/- 1.05 to 52 +/- 2.07 microg/g while zinc content ranged from 1.31 +/- 0.089 to 1.55 +/- 0.114 microg/ml, 89.5 +/- 3.41 to 132 +/- 6.10 microg/g and 175 +/- 8.29 to 191 +/- 10.85 microg/g, respectively.","Bioavailability of calcium, iron and zinc fortified whole wheat flour chapatti. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18004661/),[μg] / [ml],1.31,119595,DB01373,Calcium
,18004661,zinc content,"The iron in plasma, liver and femur ranged from 2.19 +/- 0.11 to 2.77 +/- 0.10 microg/ml, 203.5 +/- 13.24 to 251.5 +/- 17.19 microg/g and 43.5 +/- 1.05 to 52 +/- 2.07 microg/g while zinc content ranged from 1.31 +/- 0.089 to 1.55 +/- 0.114 microg/ml, 89.5 +/- 3.41 to 132 +/- 6.10 microg/g and 175 +/- 8.29 to 191 +/- 10.85 microg/g, respectively.","Bioavailability of calcium, iron and zinc fortified whole wheat flour chapatti. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18004661/),[μg] / [ml],1.55,119596,DB01373,Calcium
,18004661,zinc content,"The iron in plasma, liver and femur ranged from 2.19 +/- 0.11 to 2.77 +/- 0.10 microg/ml, 203.5 +/- 13.24 to 251.5 +/- 17.19 microg/g and 43.5 +/- 1.05 to 52 +/- 2.07 microg/g while zinc content ranged from 1.31 +/- 0.089 to 1.55 +/- 0.114 microg/ml, 89.5 +/- 3.41 to 132 +/- 6.10 microg/g and 175 +/- 8.29 to 191 +/- 10.85 microg/g, respectively.","Bioavailability of calcium, iron and zinc fortified whole wheat flour chapatti. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18004661/),[μg] / [g],89.5,119597,DB01373,Calcium
,18004661,zinc content,"The iron in plasma, liver and femur ranged from 2.19 +/- 0.11 to 2.77 +/- 0.10 microg/ml, 203.5 +/- 13.24 to 251.5 +/- 17.19 microg/g and 43.5 +/- 1.05 to 52 +/- 2.07 microg/g while zinc content ranged from 1.31 +/- 0.089 to 1.55 +/- 0.114 microg/ml, 89.5 +/- 3.41 to 132 +/- 6.10 microg/g and 175 +/- 8.29 to 191 +/- 10.85 microg/g, respectively.","Bioavailability of calcium, iron and zinc fortified whole wheat flour chapatti. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18004661/),[μg] / [g],132,119598,DB01373,Calcium
,18004661,zinc content,"The iron in plasma, liver and femur ranged from 2.19 +/- 0.11 to 2.77 +/- 0.10 microg/ml, 203.5 +/- 13.24 to 251.5 +/- 17.19 microg/g and 43.5 +/- 1.05 to 52 +/- 2.07 microg/g while zinc content ranged from 1.31 +/- 0.089 to 1.55 +/- 0.114 microg/ml, 89.5 +/- 3.41 to 132 +/- 6.10 microg/g and 175 +/- 8.29 to 191 +/- 10.85 microg/g, respectively.","Bioavailability of calcium, iron and zinc fortified whole wheat flour chapatti. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18004661/),μ,175,119599,DB01373,Calcium
,18004661,zinc content,"The iron in plasma, liver and femur ranged from 2.19 +/- 0.11 to 2.77 +/- 0.10 microg/ml, 203.5 +/- 13.24 to 251.5 +/- 17.19 microg/g and 43.5 +/- 1.05 to 52 +/- 2.07 microg/g while zinc content ranged from 1.31 +/- 0.089 to 1.55 +/- 0.114 microg/ml, 89.5 +/- 3.41 to 132 +/- 6.10 microg/g and 175 +/- 8.29 to 191 +/- 10.85 microg/g, respectively.","Bioavailability of calcium, iron and zinc fortified whole wheat flour chapatti. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18004661/),μ,191,119600,DB01373,Calcium
,15333515,systemic clearance,The systemic clearance of propranolol (approximately 1.53 l/h/kg) suggested that the hepatic blood flow in CHPs is comparable to that in humans.,The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: model characterization and application. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15333515/),[l] / [h·kg],1.53,119920,DB01373,Calcium
,12362933,relative iron bioavailabilities,"The relative iron bioavailabilities (95% confidence intervals) for the calcium carbonate, calcium acetate, and sevelamer HCI treatments were 0.81 (0.70, 0.94), 0.73 (0.63, 0.85), and 0.90 (0.78, 1.05), respectively.",Effect of phosphate binders on supplemental iron absorption in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12362933/),,0.81,120485,DB01373,Calcium
,12362933,relative iron bioavailabilities,"The relative iron bioavailabilities (95% confidence intervals) for the calcium carbonate, calcium acetate, and sevelamer HCI treatments were 0.81 (0.70, 0.94), 0.73 (0.63, 0.85), and 0.90 (0.78, 1.05), respectively.",Effect of phosphate binders on supplemental iron absorption in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12362933/),,0.73,120486,DB01373,Calcium
,12362933,relative iron bioavailabilities,"The relative iron bioavailabilities (95% confidence intervals) for the calcium carbonate, calcium acetate, and sevelamer HCI treatments were 0.81 (0.70, 0.94), 0.73 (0.63, 0.85), and 0.90 (0.78, 1.05), respectively.",Effect of phosphate binders on supplemental iron absorption in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12362933/),,0.90,120487,DB01373,Calcium
,15563062,T1/2beta,"When m-Nif was intravenously administered, the plasma concentration-time curve was fit to a two-compartment model and T1/2beta was 117 min.",[Pharmacokinetics of m-nifedipine in Beagle dogs]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563062/),min,117,120762,DB01373,Calcium
,15563062,T1/2 (Ke),T1/2 (Ke) and Cmax were 147 min and 20 microg x L(-1); at the low dose of 1.152 mg x kg(-1).,[Pharmacokinetics of m-nifedipine in Beagle dogs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563062/),min,147,120763,DB01373,Calcium
,15563062,Cmax,T1/2 (Ke) and Cmax were 147 min and 20 microg x L(-1); at the low dose of 1.152 mg x kg(-1).,[Pharmacokinetics of m-nifedipine in Beagle dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563062/),[μg] / [l],20,120764,DB01373,Calcium
,15563062,T1/2 (Ke),T1/2 (Ke) was 122 min and Cmax was 36 microg x L(-1) at the middle dose of 3.456 mg x kg(-1).,[Pharmacokinetics of m-nifedipine in Beagle dogs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563062/),min,122,120765,DB01373,Calcium
,15563062,Cmax,T1/2 (Ke) was 122 min and Cmax was 36 microg x L(-1) at the middle dose of 3.456 mg x kg(-1).,[Pharmacokinetics of m-nifedipine in Beagle dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563062/),[μg] / [l],36,120766,DB01373,Calcium
,15563062,T1/2 (Ke),"T1/2 (Ke) was 144 min and Cmax was 69 microg x L(-1) at the high dose of 10.37 mg x kg(-1), respectively.",[Pharmacokinetics of m-nifedipine in Beagle dogs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563062/),min,144,120767,DB01373,Calcium
,15563062,Cmax,"T1/2 (Ke) was 144 min and Cmax was 69 microg x L(-1) at the high dose of 10.37 mg x kg(-1), respectively.",[Pharmacokinetics of m-nifedipine in Beagle dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563062/),[μg] / [l],69,120768,DB01373,Calcium
,25867662,peak plasma concentration,"For the 10 mg/kg study, the median peak plasma concentration and time to peak plasma concentration were 0.032 μg/mL and 2 hours, respectively.",Plasma Drug Concentrations of Orally Administered Rosuvastatin in Hispaniolan Amazon Parrots (Amazona ventralis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25867662/),[μg] / [ml],0.032,120957,DB01373,Calcium
,25867662,time to peak plasma concentration,"For the 10 mg/kg study, the median peak plasma concentration and time to peak plasma concentration were 0.032 μg/mL and 2 hours, respectively.",Plasma Drug Concentrations of Orally Administered Rosuvastatin in Hispaniolan Amazon Parrots (Amazona ventralis). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25867662/),h,2,120958,DB01373,Calcium
,17646091,absolute bioavailability,"While micronization increased the absolute bioavailability of the solid drug significantly compared to crude material (from nondetectable to 20%), cogrinding with specific excipients was able to almost double this improvement (up to 39%).","Cogrinding enhances the oral bioavailability of EMD 57033, a poorly water soluble drug, in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17646091/),%,20,120983,DB01373,Calcium
,17646091,absolute bioavailability,"While micronization increased the absolute bioavailability of the solid drug significantly compared to crude material (from nondetectable to 20%), cogrinding with specific excipients was able to almost double this improvement (up to 39%).","Cogrinding enhances the oral bioavailability of EMD 57033, a poorly water soluble drug, in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17646091/),,39,120984,DB01373,Calcium
,17646091,absolute bioavailability,"With an absolute bioavailability of 26%, spray-dried nanoparticular EMD 57033 failed to show the superior bioavailability that had been anticipated from in vitro data.","Cogrinding enhances the oral bioavailability of EMD 57033, a poorly water soluble drug, in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17646091/),%,26,120985,DB01373,Calcium
,17646091,absolute bioavailability,The control solution prepared with cyclodextrin was shown to have an absolute bioavailability of 57% (vs. i.v. infusion).,"Cogrinding enhances the oral bioavailability of EMD 57033, a poorly water soluble drug, in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17646091/),%,57,120986,DB01373,Calcium
,25760566,AUC0-24 hours,"Tenofovir geometric mean AUC0-24 hours, Cmax and C24 hours were 2.66 [90% confidence interval (CI) 2.49-2.84] μg hours/mL, 0.26 (0.24-0.29) μg/mL and 0.057 (0.052-0.062) μg/mL, respectively.","Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25760566/),[h·μg] / [ml],2.66,121062,DB01373,Calcium
,25760566,Cmax,"Tenofovir geometric mean AUC0-24 hours, Cmax and C24 hours were 2.66 [90% confidence interval (CI) 2.49-2.84] μg hours/mL, 0.26 (0.24-0.29) μg/mL and 0.057 (0.052-0.062) μg/mL, respectively.","Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25760566/),[μg] / [ml],0.26,121063,DB01373,Calcium
,25760566,C24 hours,"Tenofovir geometric mean AUC0-24 hours, Cmax and C24 hours were 2.66 [90% confidence interval (CI) 2.49-2.84] μg hours/mL, 0.26 (0.24-0.29) μg/mL and 0.057 (0.052-0.062) μg/mL, respectively.","Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25760566/),[μg] / [ml],0.057,121064,DB01373,Calcium
,26682194,percentage,"The percentage of 5-FU released at the end of 24 h from ECHC3 was 97.83 ± 0.12% in the presence of pectinase whereas in the control study, it was 40.08 ± 0.02%.",Factorial designed 5-fluorouracil-loaded microsponges and calcium pectinate beads plugged in hydroxypropyl methylcellulose capsules for colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26682194/),%,97.83,121093,DB01373,Calcium
,26682194,percentage,"The percentage of 5-FU released at the end of 24 h from ECHC3 was 97.83 ± 0.12% in the presence of pectinase whereas in the control study, it was 40.08 ± 0.02%.",Factorial designed 5-fluorouracil-loaded microsponges and calcium pectinate beads plugged in hydroxypropyl methylcellulose capsules for colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26682194/),%,40.08,121094,DB01373,Calcium
>,19373887,IC(50),"CP-100,356 was devoid of inhibition (IC(50) >50 microM) against major human P450 enzymes including P4503A4.","N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a ""chemical knock-out equivalent"" to assess the impact of efflux transporters on oral drug absorption in the rat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373887/),μM,50,121222,DB01373,Calcium
,19373887,IC(50),"In human MDR1-transfected MDCKII cells, CP-100,356 inhibited acetoxymethyl calcein (calcein-AM) uptake (IC(50) approximately 0.5 +/- 0.07 microM) and digoxin transport (IC(50) approximately 1.2 +/- 0.1 microM).","N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a ""chemical knock-out equivalent"" to assess the impact of efflux transporters on oral drug absorption in the rat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373887/),μM,0.5,121223,DB01373,Calcium
,19373887,IC(50),"In human MDR1-transfected MDCKII cells, CP-100,356 inhibited acetoxymethyl calcein (calcein-AM) uptake (IC(50) approximately 0.5 +/- 0.07 microM) and digoxin transport (IC(50) approximately 1.2 +/- 0.1 microM).","N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a ""chemical knock-out equivalent"" to assess the impact of efflux transporters on oral drug absorption in the rat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373887/),μM,1.2,121224,DB01373,Calcium
,19373887,IC(50),"Inhibition of prazosin transport (IC(50) approximately 1.5 +/- 0.3 microM) in human BCRP-transfected MDCKII cells by CP-100,356 confirmed the dual MDR1/BCRP inhibitory properties.","N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a ""chemical knock-out equivalent"" to assess the impact of efflux transporters on oral drug absorption in the rat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373887/),μM,1.5,121225,DB01373,Calcium
,19373887,IC(50),"CP-100,356 was a weak inhibitor of OATP1B1 (IC(50) approximately 66 +/- 1.1 microM) and was devoid of MRP2 inhibition (IC(50) >15 microM).","N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a ""chemical knock-out equivalent"" to assess the impact of efflux transporters on oral drug absorption in the rat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373887/),μM,66,121226,DB01373,Calcium
>,19373887,IC(50),"CP-100,356 was a weak inhibitor of OATP1B1 (IC(50) approximately 66 +/- 1.1 microM) and was devoid of MRP2 inhibition (IC(50) >15 microM).","N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a ""chemical knock-out equivalent"" to assess the impact of efflux transporters on oral drug absorption in the rat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373887/),μM,15,121227,DB01373,Calcium
,32317615,MST,PRCL-02 monotherapy only marginally prolonged graft survival (MST = 13.16 d; group 2) compared with untreated controls.,Targeting Calcium Release-activated Calcium Channel Is Not Sufficient to Prevent Rejection in Nonhuman Primate Kidney Transplantation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32317615/),d,13.16,121684,DB01373,Calcium
,19540208,K(i),"Using the CCRF-CEM T-cell line which expresses CXCR4 we have demonstrated that AMD3465 is an antagonist of SDF-1 ligand binding (K(i) of 41.7+/-1.2nM), and inhibits SDF-1 mediated signaling as shown by inhibition of GTP binding, calcium flux, and inhibition of chemotaxis.",Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19540208/),nM,41.7,121974,DB01373,Calcium
,19540208,terminal half-life,AMD3465 was cleared from dog plasma in a biphasic manner with a terminal half-life of 1.56-4.63h.,Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19540208/),h,1.56-4.63,121975,DB01373,Calcium
,19540208,bioavailability,Comparison of exposure to the intravenous and subcutaneous doses indicated 100% bioavailability following subcutaneous administration.,Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19540208/),%,100,121976,DB01373,Calcium
,17190374,AUC0-infinity,"After administering a single dose of each formulation, mean AUC0-infinity and Cmax values were 190.91+/-60.49 ng x h/ml and 3.87+/-1.04 ng/ml for the test formulation and 203.15+/-52.05 ng x h/ml and 4.01+/-0.60 ng/ml for the reference formulation, respectively.",Comparative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17190374/),[h·ng] / [ml],190.91,122461,DB01373,Calcium
,17190374,AUC0-infinity,"After administering a single dose of each formulation, mean AUC0-infinity and Cmax values were 190.91+/-60.49 ng x h/ml and 3.87+/-1.04 ng/ml for the test formulation and 203.15+/-52.05 ng x h/ml and 4.01+/-0.60 ng/ml for the reference formulation, respectively.",Comparative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17190374/),[h·ng] / [ml],203.15,122462,DB01373,Calcium
,17190374,Cmax,"After administering a single dose of each formulation, mean AUC0-infinity and Cmax values were 190.91+/-60.49 ng x h/ml and 3.87+/-1.04 ng/ml for the test formulation and 203.15+/-52.05 ng x h/ml and 4.01+/-0.60 ng/ml for the reference formulation, respectively.",Comparative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17190374/),[ng] / [ml],3.87,122463,DB01373,Calcium
,17190374,Cmax,"After administering a single dose of each formulation, mean AUC0-infinity and Cmax values were 190.91+/-60.49 ng x h/ml and 3.87+/-1.04 ng/ml for the test formulation and 203.15+/-52.05 ng x h/ml and 4.01+/-0.60 ng/ml for the reference formulation, respectively.",Comparative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17190374/),[ng] / [ml],4.01,122464,DB01373,Calcium
,19048790,Tmax,The Tmax of IBU-ISG and reference formulation were (1.8 +/- 0.6) and (0.4 +/- 0. 1) h.,[Preparation of in situ gel systems for the oral delivery of ibuprofen and its pharmacokinetics study in beagle dogs]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19048790/),h,1.8,122493,DB01373,Calcium
,19048790,Tmax,The Tmax of IBU-ISG and reference formulation were (1.8 +/- 0.6) and (0.4 +/- 0. 1) h.,[Preparation of in situ gel systems for the oral delivery of ibuprofen and its pharmacokinetics study in beagle dogs]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19048790/),h,0.4,122494,DB01373,Calcium
,19048790,Cmax,The Cmax values were (29.2 +/- 7.6) and (37.8 +/- 2.2) microg x mL(-1).,[Preparation of in situ gel systems for the oral delivery of ibuprofen and its pharmacokinetics study in beagle dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19048790/),[μg] / [ml],29.2,122495,DB01373,Calcium
,19048790,Cmax,The Cmax values were (29.2 +/- 7.6) and (37.8 +/- 2.2) microg x mL(-1).,[Preparation of in situ gel systems for the oral delivery of ibuprofen and its pharmacokinetics study in beagle dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19048790/),[μg] / [ml],37.8,122496,DB01373,Calcium
,19048790,T(1/2),"The T(1/2) were (2.3 +/- 0.5) and (2.0 +/- 0.9) h, and the AUC(0-t) were (131.0 +/- 38.6) and (117.3 +/- 23.1) microg x mL(-1) x h, respectively.",[Preparation of in situ gel systems for the oral delivery of ibuprofen and its pharmacokinetics study in beagle dogs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19048790/),h,2.3,122497,DB01373,Calcium
,19048790,T(1/2),"The T(1/2) were (2.3 +/- 0.5) and (2.0 +/- 0.9) h, and the AUC(0-t) were (131.0 +/- 38.6) and (117.3 +/- 23.1) microg x mL(-1) x h, respectively.",[Preparation of in situ gel systems for the oral delivery of ibuprofen and its pharmacokinetics study in beagle dogs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19048790/),h,2.0,122498,DB01373,Calcium
,19048790,AUC(0-t),"The T(1/2) were (2.3 +/- 0.5) and (2.0 +/- 0.9) h, and the AUC(0-t) were (131.0 +/- 38.6) and (117.3 +/- 23.1) microg x mL(-1) x h, respectively.",[Preparation of in situ gel systems for the oral delivery of ibuprofen and its pharmacokinetics study in beagle dogs]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19048790/),[h·μg] / [ml],131.0,122499,DB01373,Calcium
,19048790,AUC(0-t),"The T(1/2) were (2.3 +/- 0.5) and (2.0 +/- 0.9) h, and the AUC(0-t) were (131.0 +/- 38.6) and (117.3 +/- 23.1) microg x mL(-1) x h, respectively.",[Preparation of in situ gel systems for the oral delivery of ibuprofen and its pharmacokinetics study in beagle dogs]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19048790/),[h·μg] / [ml],117.3,122500,DB01373,Calcium
,32727577,half-life,"Study 1: esaxerenone peak plasma concentration (Cmax) and time to Cmax were unaltered by amlodipine coadministration, but mean half-life was slightly prolonged from 18.5 to 20.9 h.",Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32727577/),h,18,122698,DB01373,Calcium
,32727577,half-life,"Study 1: esaxerenone peak plasma concentration (Cmax) and time to Cmax were unaltered by amlodipine coadministration, but mean half-life was slightly prolonged from 18.5 to 20.9 h.",Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32727577/),h,20,122699,DB01373,Calcium
,26693836,EC50,"In particular, compound 4 (3-(benzyloxy)-5-chloro-N-(4-(piperidin-1-ylmethyl)phenyl)benzamide) displayed noteworthy inhibitory activity in the mitochondrial swelling assay (EC50 =280 nm), poor-to-very-good physicochemical as well as in vitro pharmacokinetic properties, and conferred very high calcium retention capacity to mitochondria.",N-Phenylbenzamides as Potent Inhibitors of the Mitochondrial Permeability Transition Pore. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26693836/),nm,280,123091,DB01373,Calcium
,23494963,accumulation ratio,"Little accumulation of rosuvastatin after repeated, once-daily dosing was observed; the geometric mean accumulation ratio for rosuvastatin was 1.37 (coefficient of variation = 36.4 %).",Pharmacokinetic and pharmacodynamic profile of rosuvastatin in patients with end-stage renal disease on chronic haemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23494963/),,1.37,123421,DB01373,Calcium
,27207183,Ki,"ZBH2012001 exhibited a moderate affinity to SERTs and NETs (Ki values were 35.3 ± 2.86 and 225 ± 26.0 nM, respectively); it had no effects on the DATs or the 16 other GPCRs or iron channels.","Antidepressant-like Effects of ZBH2012001, a Novel Potent Serotonin and Norepinephrine Reuptake Inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207183/),nM,35.3,123919,DB01373,Calcium
,27207183,Ki,"ZBH2012001 exhibited a moderate affinity to SERTs and NETs (Ki values were 35.3 ± 2.86 and 225 ± 26.0 nM, respectively); it had no effects on the DATs or the 16 other GPCRs or iron channels.","Antidepressant-like Effects of ZBH2012001, a Novel Potent Serotonin and Norepinephrine Reuptake Inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207183/),nM,225,123920,DB01373,Calcium
,27207183,absolute bioavailability,"The pharmacokinetic evaluation of ZBH2012001 indicated that the absolute bioavailability value was 60.5%, and the acute toxicity test indicated that LD50 of ZBH2012001 was 346 mg/kg.","Antidepressant-like Effects of ZBH2012001, a Novel Potent Serotonin and Norepinephrine Reuptake Inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207183/),%,60.5,123921,DB01373,Calcium
,27207183,LD50,"The pharmacokinetic evaluation of ZBH2012001 indicated that the absolute bioavailability value was 60.5%, and the acute toxicity test indicated that LD50 of ZBH2012001 was 346 mg/kg.","Antidepressant-like Effects of ZBH2012001, a Novel Potent Serotonin and Norepinephrine Reuptake Inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207183/),[mg] / [kg],346,123922,DB01373,Calcium
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,30,124537,DB01373,Calcium
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,24,124538,DB01373,Calcium
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,34,124539,DB01373,Calcium
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,27,124540,DB01373,Calcium
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,30,124541,DB01373,Calcium
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,37,124542,DB01373,Calcium
,19427587,AUC(0-infinity),"In subjects, AUC(0-infinity) and AUC(0-24h) were 267 and 246 pg h ml(-1), respectively.",Pharmacokinetics of oral calcitriol in healthy human based on the analysis with an enzyme immunoassay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19427587/),[h·pg] / [ml],267,125239,DB01373,Calcium
,19427587,AUC(0-24h),"In subjects, AUC(0-infinity) and AUC(0-24h) were 267 and 246 pg h ml(-1), respectively.",Pharmacokinetics of oral calcitriol in healthy human based on the analysis with an enzyme immunoassay. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19427587/),[h·pg] / [ml],246,125240,DB01373,Calcium
,19427587,C(max),The C(max) of calcitriol was measured at 3.4h after administration as 50.0 pg ml(-1).,Pharmacokinetics of oral calcitriol in healthy human based on the analysis with an enzyme immunoassay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19427587/),[pg] / [ml],50.0,125241,DB01373,Calcium
,16169030,Vmax,"For carboxylesterase-mediated deltamethrin metabolism in plasma, Vmax=325.3+/-53.4 nmol/h/ml and Km=165.4+/-41.9 microM.",Characterization of deltamethrin metabolism by rat plasma and liver microsomes. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16169030/),[nM] / [h·ml],325.3,125315,DB01373,Calcium
,16169030,Km,"For carboxylesterase-mediated deltamethrin metabolism in plasma, Vmax=325.3+/-53.4 nmol/h/ml and Km=165.4+/-41.9 microM.",Characterization of deltamethrin metabolism by rat plasma and liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16169030/),μM,165.4,125316,DB01373,Calcium
,16169030,Vmax,The rate constants for liver carboxylesterases were Vmax=1981.8+/-132.3 nmol/h/g liver and Km=172.5+/-22.5 microM.,Characterization of deltamethrin metabolism by rat plasma and liver microsomes. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16169030/),[nM] / [g·h],1981.8,125317,DB01373,Calcium
,16169030,Km,The rate constants for liver carboxylesterases were Vmax=1981.8+/-132.3 nmol/h/g liver and Km=172.5+/-22.5 microM.,Characterization of deltamethrin metabolism by rat plasma and liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16169030/),μM,172.5,125318,DB01373,Calcium
,16169030,Vmax,Liver microsomal CYP450-mediated biotransformation of deltamethrin was a higher capacity (Vmax=2611.3+/-134.1 nmol/h/g liver) and higher affinity (Km=74.9+/-5.9 microM) process than carboxylesterase (plasma or liver) detoxification.,Characterization of deltamethrin metabolism by rat plasma and liver microsomes. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16169030/),[nM] / [g·h],2611.3,125319,DB01373,Calcium
,16169030,Km,Liver microsomal CYP450-mediated biotransformation of deltamethrin was a higher capacity (Vmax=2611.3+/-134.1 nmol/h/g liver) and higher affinity (Km=74.9+/-5.9 microM) process than carboxylesterase (plasma or liver) detoxification.,Characterization of deltamethrin metabolism by rat plasma and liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16169030/),μM,74.9,125320,DB01373,Calcium
,24294925,encapsulation efficiency (EE),"Stable rolled-up layers as well as elongated structure of nanocochleates possessing particle size and encapsulation efficiency (EE) of 275 + 4 nm and 84.31 ± 2.52%, respectively were obtained.","Fisetin-loaded nanocochleates: formulation, characterisation, in vitro anticancer testing, bioavailability and biodistribution study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24294925/),%,84.31,125406,DB01373,Calcium
,23611748,TTP,"Adding 5 μg/ml FXIII-B at a concentration of 1U of FXIII-A increased the AUC for rFXIII(V34L) and cFXIII by approximately 20% and accelerated TTP from 27.3 to 20.8 min for cFVIII, indicating a supportive function of FXIII-B in orientating cFXIII-A for thrombin cleavage.",Factor XIIIa generation assay: a tool for studying factor XIII function in plasma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23611748/),min,27.3,125870,DB01373,Calcium
,23611748,TTP,"Adding 5 μg/ml FXIII-B at a concentration of 1U of FXIII-A increased the AUC for rFXIII(V34L) and cFXIII by approximately 20% and accelerated TTP from 27.3 to 20.8 min for cFVIII, indicating a supportive function of FXIII-B in orientating cFXIII-A for thrombin cleavage.",Factor XIIIa generation assay: a tool for studying factor XIII function in plasma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23611748/),min,20.8,125871,DB01373,Calcium
,19437082,serum C (max),"Calcium citrate resulted in a significantly higher serum C (max) (9.4 + 0.4 mg/dl vs. 9.2 + 0.3 mg/dl, p = 0.02) and serum AUC (55 + 2 mg/dl vs. 54 + 2 mg/dl, p = 0.02).",Comparison of the absorption of calcium carbonate and calcium citrate after Roux-en-Y gastric bypass. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19437082/),[mg] / [dl],9.4,125874,DB01373,Calcium
,19437082,serum C (max),"Calcium citrate resulted in a significantly higher serum C (max) (9.4 + 0.4 mg/dl vs. 9.2 + 0.3 mg/dl, p = 0.02) and serum AUC (55 + 2 mg/dl vs. 54 + 2 mg/dl, p = 0.02).",Comparison of the absorption of calcium carbonate and calcium citrate after Roux-en-Y gastric bypass. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19437082/),[mg] / [dl],9.2,125875,DB01373,Calcium
,19437082,serum AUC,"Calcium citrate resulted in a significantly higher serum C (max) (9.4 + 0.4 mg/dl vs. 9.2 + 0.3 mg/dl, p = 0.02) and serum AUC (55 + 2 mg/dl vs. 54 + 2 mg/dl, p = 0.02).",Comparison of the absorption of calcium carbonate and calcium citrate after Roux-en-Y gastric bypass. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19437082/),[mg] / [dl],55,125876,DB01373,Calcium
,19437082,serum AUC,"Calcium citrate resulted in a significantly higher serum C (max) (9.4 + 0.4 mg/dl vs. 9.2 + 0.3 mg/dl, p = 0.02) and serum AUC (55 + 2 mg/dl vs. 54 + 2 mg/dl, p = 0.02).",Comparison of the absorption of calcium carbonate and calcium citrate after Roux-en-Y gastric bypass. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19437082/),[mg] / [dl],54,125877,DB01373,Calcium
,19437082,AUC,"Calcium citrate resulted in a significantly lower PTH(min) (24 + 11 pg/ml vs. 30 + 13 pg/ml, p = 0.01) and a higher AUC (-32 + 51 pg/ml vs. -3 + 56 pg/ml, p = 0.04).",Comparison of the absorption of calcium carbonate and calcium citrate after Roux-en-Y gastric bypass. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19437082/),[pg] / [ml],-,125878,DB01373,Calcium
,19437082,AUC,"Calcium citrate resulted in a significantly lower PTH(min) (24 + 11 pg/ml vs. 30 + 13 pg/ml, p = 0.01) and a higher AUC (-32 + 51 pg/ml vs. -3 + 56 pg/ml, p = 0.04).",Comparison of the absorption of calcium carbonate and calcium citrate after Roux-en-Y gastric bypass. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19437082/),[pg] / [ml],32,125879,DB01373,Calcium
,19437082,AUC,"Calcium citrate resulted in a significantly lower PTH(min) (24 + 11 pg/ml vs. 30 + 13 pg/ml, p = 0.01) and a higher AUC (-32 + 51 pg/ml vs. -3 + 56 pg/ml, p = 0.04).",Comparison of the absorption of calcium carbonate and calcium citrate after Roux-en-Y gastric bypass. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19437082/),[pg] / [ml],-3,125880,DB01373,Calcium
,19437082,AUC,"There was a non-significant trend for higher urinary AUC in the calcium citrate group (76.13 + 36.39 mg/6 h vs. 66.04 + 40.82, p = 0.17).",Comparison of the absorption of calcium carbonate and calcium citrate after Roux-en-Y gastric bypass. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19437082/),[mg] / [6·h],76.13,125881,DB01373,Calcium
,19437082,AUC,"There was a non-significant trend for higher urinary AUC in the calcium citrate group (76.13 + 36.39 mg/6 h vs. 66.04 + 40.82, p = 0.17).",Comparison of the absorption of calcium carbonate and calcium citrate after Roux-en-Y gastric bypass. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19437082/),,66.04,125882,DB01373,Calcium
,26854158,half-lives,"The half-lives varied from 1.8 days to 4.5 days during the six cycles (patient 1), and from 1.5 days to 3.6 days (patient 2), respectively.",Evaluation of Alpha-Therapy with Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-the Role of Gamma Scintigraphy in Dosimetry and Pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26854158/),d,1.8,126053,DB01373,Calcium
,26854158,half-lives,"The half-lives varied from 1.8 days to 4.5 days during the six cycles (patient 1), and from 1.5 days to 3.6 days (patient 2), respectively.",Evaluation of Alpha-Therapy with Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-the Role of Gamma Scintigraphy in Dosimetry and Pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26854158/),d,4.5,126054,DB01373,Calcium
,26854158,half-lives,"The half-lives varied from 1.8 days to 4.5 days during the six cycles (patient 1), and from 1.5 days to 3.6 days (patient 2), respectively.",Evaluation of Alpha-Therapy with Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-the Role of Gamma Scintigraphy in Dosimetry and Pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26854158/),d,1.5,126055,DB01373,Calcium
,26854158,half-lives,"The half-lives varied from 1.8 days to 4.5 days during the six cycles (patient 1), and from 1.5 days to 3.6 days (patient 2), respectively.",Evaluation of Alpha-Therapy with Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-the Role of Gamma Scintigraphy in Dosimetry and Pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26854158/),d,3.6,126056,DB01373,Calcium
,16187976,C(max),"During verapamil co-administration, everolimus C(max) increased 2.3-fold (90% CI, 1.9, 2.7) from 21 +/- 8 to 47 +/- 18 ng ml(-1) and AUC increased 3.5-fold (90% CI, 3.1, 3.9) from 115 +/- 45 to 392 +/- 142 ng ml(-1) h.",Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[ng] / [ml],21,126057,DB01373,Calcium
,16187976,C(max),"During verapamil co-administration, everolimus C(max) increased 2.3-fold (90% CI, 1.9, 2.7) from 21 +/- 8 to 47 +/- 18 ng ml(-1) and AUC increased 3.5-fold (90% CI, 3.1, 3.9) from 115 +/- 45 to 392 +/- 142 ng ml(-1) h.",Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[ng] / [ml],47,126058,DB01373,Calcium
,16187976,AUC,"During verapamil co-administration, everolimus C(max) increased 2.3-fold (90% CI, 1.9, 2.7) from 21 +/- 8 to 47 +/- 18 ng ml(-1) and AUC increased 3.5-fold (90% CI, 3.1, 3.9) from 115 +/- 45 to 392 +/- 142 ng ml(-1) h.",Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[h·ng] / [ml],115,126059,DB01373,Calcium
,16187976,AUC,"During verapamil co-administration, everolimus C(max) increased 2.3-fold (90% CI, 1.9, 2.7) from 21 +/- 8 to 47 +/- 18 ng ml(-1) and AUC increased 3.5-fold (90% CI, 3.1, 3.9) from 115 +/- 45 to 392 +/- 142 ng ml(-1) h.",Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[h·ng] / [ml],392,126060,DB01373,Calcium
,16187976,half-life,Everolimus half-life was only prolonged to a minor extent (32 +/- 6 vs. 37 +/- 6 h).,Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),h,32,126061,DB01373,Calcium
,16187976,half-life,Everolimus half-life was only prolonged to a minor extent (32 +/- 6 vs. 37 +/- 6 h).,Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),h,37,126062,DB01373,Calcium
,16187976,predose,Verapamil predose concentrations doubled from 32 +/- 16 to 74 +/- 42 ng ml(-1) after single dose administration of everolimus.,Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[ng] / [ml],32,126063,DB01373,Calcium
,16187976,predose,Verapamil predose concentrations doubled from 32 +/- 16 to 74 +/- 42 ng ml(-1) after single dose administration of everolimus.,Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[ng] / [ml],74,126064,DB01373,Calcium
,16187976,concentrations,Verapamil predose concentrations doubled from 32 +/- 16 to 74 +/- 42 ng ml(-1) after single dose administration of everolimus.,Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[ng] / [ml],32,126065,DB01373,Calcium
,16187976,concentrations,Verapamil predose concentrations doubled from 32 +/- 16 to 74 +/- 42 ng ml(-1) after single dose administration of everolimus.,Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[ng] / [ml],74,126066,DB01373,Calcium
,29123380,entrapment efficiency,"Formulations (HS1-HS9) have shown entrapment efficiency between 83.50%±0.30% and 88.50%±0.25%, and optimum release was offered by formulation HS7 at both pH levels, ie, 1.2 (89%) and 7.4 (92%).",Development of β-cyclodextrin-based hydrogel microparticles for solubility enhancement of rosuvastatin: an in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29123380/),%,83.50,126283,DB01373,Calcium
,29123380,entrapment efficiency,"Formulations (HS1-HS9) have shown entrapment efficiency between 83.50%±0.30% and 88.50%±0.25%, and optimum release was offered by formulation HS7 at both pH levels, ie, 1.2 (89%) and 7.4 (92%).",Development of β-cyclodextrin-based hydrogel microparticles for solubility enhancement of rosuvastatin: an in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29123380/),%,88.50,126284,DB01373,Calcium
,29123380,zeta potential,The majority of microparticles had a particle size of less than 500 µm and zeta potential of -37 mV.,Development of β-cyclodextrin-based hydrogel microparticles for solubility enhancement of rosuvastatin: an in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29123380/),m,37,126285,DB01373,Calcium
,16413246,CL/F,The mean CL/F was 7.83 +/- 0.50 mL.min(-1).kg(-1) (LBW) in women compared with 6.31 +/- 1.01 in men and 8.68 +/- 1.00 mL.min(-1).,Population analyses of amlodipine in patients living in the community and patients living in nursing homes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413246/),[ml] / [kg·min],7.83,126414,DB01373,Calcium
,16413246,CL/F,The mean CL/F was 7.83 +/- 0.50 mL.min(-1).kg(-1) (LBW) in women compared with 6.31 +/- 1.01 in men and 8.68 +/- 1.00 mL.min(-1).,Population analyses of amlodipine in patients living in the community and patients living in nursing homes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413246/),[ml] / [min],6.31,126415,DB01373,Calcium
,16413246,CL/F,The mean CL/F was 7.83 +/- 0.50 mL.min(-1).kg(-1) (LBW) in women compared with 6.31 +/- 1.01 in men and 8.68 +/- 1.00 mL.min(-1).,Population analyses of amlodipine in patients living in the community and patients living in nursing homes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413246/),[ml] / [min],8.68,126416,DB01373,Calcium
,24170263,area under the plasma concentration versus time curve (AUC),"Calcium carbonate administration did not significantly affect the imatinib area under the plasma concentration versus time curve (AUC) (41.2 μg/mL h alone vs. 40.8 μg/mL h with calcium carbonate, P = 0.99), maximum plasma concentration (C(max)) (2.35 μg/mL alone vs. 2.39 μg/mL with calcium carbonate, P = 0.89).",Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24170263/),[μg] / [h·ml],41.2,127162,DB01373,Calcium
,24170263,area under the plasma concentration versus time curve (AUC),"Calcium carbonate administration did not significantly affect the imatinib area under the plasma concentration versus time curve (AUC) (41.2 μg/mL h alone vs. 40.8 μg/mL h with calcium carbonate, P = 0.99), maximum plasma concentration (C(max)) (2.35 μg/mL alone vs. 2.39 μg/mL with calcium carbonate, P = 0.89).",Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24170263/),[μg] / [h·ml],40.8,127163,DB01373,Calcium
,24170263,maximum plasma concentration (C(max)),"Calcium carbonate administration did not significantly affect the imatinib area under the plasma concentration versus time curve (AUC) (41.2 μg/mL h alone vs. 40.8 μg/mL h with calcium carbonate, P = 0.99), maximum plasma concentration (C(max)) (2.35 μg/mL alone vs. 2.39 μg/mL with calcium carbonate, P = 0.89).",Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24170263/),[μg] / [ml],2.35,127164,DB01373,Calcium
,24170263,maximum plasma concentration (C(max)),"Calcium carbonate administration did not significantly affect the imatinib area under the plasma concentration versus time curve (AUC) (41.2 μg/mL h alone vs. 40.8 μg/mL h with calcium carbonate, P = 0.99), maximum plasma concentration (C(max)) (2.35 μg/mL alone vs. 2.39 μg/mL with calcium carbonate, P = 0.89).",Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24170263/),[μg] / [ml],2.39,127165,DB01373,Calcium
,25960179,lag time,"The final formula of floating spheroids was optimized on the basis of shape (spherical), diameter (0.47 mm), lag time (20 s), and floating time (> 32 h).",Development and characterization of floating spheroids of atorvastatin calcium loaded NLC for enhancement of oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25960179/),s,20,127630,DB01373,Calcium
,15821819,half-life,The half-life of intravenous dalteparin is 77 minutes with slight dose-related variation.,High-dose intravenous dalteparin can be monitored effectively using standard coagulation times. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15821819/),min,77,128078,DB01373,Calcium
,28717974,time for 80% drug release (T80),"The optimized thiomeric microsphere formulation revealed 93.12% entrapment efficiency, time for 80% drug release (T80) of 358.1 min, and 88% mucoadhesion after 1 h.",Improvement of Oral Bioavailability of Lopinavir Without Co-administration of Ritonavir Using Microspheres of Thiolated Xyloglucan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28717974/),min,358.1,128438,DB01373,Calcium
,19533049,half-life,"Pharmacokinetic half-life of prednisolone is 2-3 h, indicating short pharmacodynamic effect duration.",Twice daily fractionated dose administration of prednisolone compared to standard once daily administration to patients with glomerulonephritis or with kidney transplants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19533049/),h,2-3,128507,DB01373,Calcium
,19813460,flow rate,"The mobile phase was 10 mmol/L ammonium acetate solution-methanol (30:70, v/v) at the flow rate of 0.2 mL/min.",Liquid chromatography-mass spectrometry method for the determination of amlodipine in human plasma and its application in a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19813460/),[ml] / [min],0.2,128543,DB01373,Calcium
,19813460,relative bioavailability,The relative bioavailability was 103.7 +/- 12.3%.,Liquid chromatography-mass spectrometry method for the determination of amlodipine in human plasma and its application in a bioequivalence study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19813460/),%,103.7,128544,DB01373,Calcium
,16631328,T50%s,"The in vitro release study showed that the T50%s were 3.2+/-0.1min for Sylysia 320, 4.6+/-0.2min for Florite RE, 13.7+/-0.1min for Neusilin US(2).",Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631328/),min,3.2,129892,DB01373,Calcium
,16631328,T50%s,"The in vitro release study showed that the T50%s were 3.2+/-0.1min for Sylysia 320, 4.6+/-0.2min for Florite RE, 13.7+/-0.1min for Neusilin US(2).",Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631328/),min,4.6,129893,DB01373,Calcium
,16631328,T50%s,"The in vitro release study showed that the T50%s were 3.2+/-0.1min for Sylysia 320, 4.6+/-0.2min for Florite RE, 13.7+/-0.1min for Neusilin US(2).",Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631328/),min,13.7,129894,DB01373,Calcium
,16631328,C(max),"The in vivo rat absorption study showed that Florite RE system had the highest C(max), 0.42+/-0.01IU/mL and AUC, 0.59+/-0.06IUh/mL, where plasma LMWH levels were measured as anti-Xa activity.",Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631328/),[iu] / [ml],0.42,129895,DB01373,Calcium
,16631328,AUC,"The in vivo rat absorption study showed that Florite RE system had the highest C(max), 0.42+/-0.01IU/mL and AUC, 0.59+/-0.06IUh/mL, where plasma LMWH levels were measured as anti-Xa activity.",Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631328/),[iuh] / [ml],0.59,129896,DB01373,Calcium
,16631328,C(max),"Other preparations had the C(max) and AUC, 0.12+/-0.01IU/mL and 0.15+/-0.02IUh/mL for Neusilin US(2) and 0.25+/-0.02IU/mL and 0.40+/-0.03IUh/mL for Sylysia 320, respectively.",Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631328/),[iu] / [ml],0.12,129897,DB01373,Calcium
,16631328,C(max),"Other preparations had the C(max) and AUC, 0.12+/-0.01IU/mL and 0.15+/-0.02IUh/mL for Neusilin US(2) and 0.25+/-0.02IU/mL and 0.40+/-0.03IUh/mL for Sylysia 320, respectively.",Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631328/),[iu] / [ml],0.25,129898,DB01373,Calcium
,16631328,AUC,"Other preparations had the C(max) and AUC, 0.12+/-0.01IU/mL and 0.15+/-0.02IUh/mL for Neusilin US(2) and 0.25+/-0.02IU/mL and 0.40+/-0.03IUh/mL for Sylysia 320, respectively.",Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631328/),[iuh] / [ml],0.15,129899,DB01373,Calcium
,16631328,AUC,"Other preparations had the C(max) and AUC, 0.12+/-0.01IU/mL and 0.15+/-0.02IUh/mL for Neusilin US(2) and 0.25+/-0.02IU/mL and 0.40+/-0.03IUh/mL for Sylysia 320, respectively.",Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631328/),[iuh] / [ml],0.40,129900,DB01373,Calcium
,16631328,bioavailability (BA),"The bioavailability (BA) of LMWH from the microporous calcium silicate preparation, Florite RE, was 18.8% in rats by comparing the AUC obtained after i.v. injection of LMWH, 40IU/kg to another group of rats.",Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631328/),%,18.8,129901,DB01373,Calcium
,16631328,C(max),"High plasma anti-Xa activity levels were obtained, i.e., the C(max) was 0.48+/-0.11IU/mL and AUC was 1.64+/-0.32IUh/mL.",Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631328/),[iu] / [ml],0.48,129902,DB01373,Calcium
,16631328,AUC,"High plasma anti-Xa activity levels were obtained, i.e., the C(max) was 0.48+/-0.11IU/mL and AUC was 1.64+/-0.32IUh/mL.",Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631328/),[iuh] / [ml],1.64,129903,DB01373,Calcium
,29019117,"unbound partitioning (Kpu,u)","In vivo unbound partitioning (Kpu,u) for rosuvastatin, bosentan, and metformin, calculated from total concentrations in the liver and plasma, were 243, 553, and 15, respectively.",Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Clearance and Liver Partitioning of OATP and OCT Substrates in Cynomolgus Monkeys. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29019117/),,243,129954,DB01373,Calcium
,29019117,"unbound partitioning (Kpu,u)","In vivo unbound partitioning (Kpu,u) for rosuvastatin, bosentan, and metformin, calculated from total concentrations in the liver and plasma, were 243, 553, and 15, respectively.",Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Clearance and Liver Partitioning of OATP and OCT Substrates in Cynomolgus Monkeys. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29019117/),,553,129955,DB01373,Calcium
,29019117,"unbound partitioning (Kpu,u)","In vivo unbound partitioning (Kpu,u) for rosuvastatin, bosentan, and metformin, calculated from total concentrations in the liver and plasma, were 243, 553, and 15, respectively.",Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Clearance and Liver Partitioning of OATP and OCT Substrates in Cynomolgus Monkeys. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29019117/),,15,129956,DB01373,Calcium
,14872555,Cmax,"The mean Cmax was 143.12+/-53.48 ng/ml, the mean AUC was 293.77+/-115.62 ng.h/ml, the mean T1/2 was 3.08+/-1.61 h, and the median value of Tmax was 0.61 h.",Pharmacokinetics of nifedipine in Taiwanese. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14872555/),[ng] / [ml],143.12,130187,DB01373,Calcium
,14872555,AUC,"The mean Cmax was 143.12+/-53.48 ng/ml, the mean AUC was 293.77+/-115.62 ng.h/ml, the mean T1/2 was 3.08+/-1.61 h, and the median value of Tmax was 0.61 h.",Pharmacokinetics of nifedipine in Taiwanese. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14872555/),[h·ng] / [ml],293.77,130188,DB01373,Calcium
,14872555,T1/2,"The mean Cmax was 143.12+/-53.48 ng/ml, the mean AUC was 293.77+/-115.62 ng.h/ml, the mean T1/2 was 3.08+/-1.61 h, and the median value of Tmax was 0.61 h.",Pharmacokinetics of nifedipine in Taiwanese. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14872555/),h,3.08,130189,DB01373,Calcium
,14872555,Tmax,"The mean Cmax was 143.12+/-53.48 ng/ml, the mean AUC was 293.77+/-115.62 ng.h/ml, the mean T1/2 was 3.08+/-1.61 h, and the median value of Tmax was 0.61 h.",Pharmacokinetics of nifedipine in Taiwanese. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14872555/),h,0.61,130190,DB01373,Calcium
,14872555,AUC distribution,"According to the antimode of AUC distribution of 22.5 ng.h/ml/mg proposed by Kleinbloesem, 69.7% of Taiwanese can be categorized as slow metabolizers.",Pharmacokinetics of nifedipine in Taiwanese. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14872555/),[h·ng] / [mg·ml],22.5,130191,DB01373,Calcium
,21437757,K(i),"The proposed model well characterized the data and provided compound specific estimates of the K(i) and cooperativity constant (α) of 1.47 ng/mL and 0.406, respectively.",Pharmacodynamic model of parathyroid hormone modulation by a negative allosteric modulator of the calcium-sensing receptor. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21437757/),[ng] / [ml],1.47,131355,DB01373,Calcium
,21437757,cooperativity constant (α),"The proposed model well characterized the data and provided compound specific estimates of the K(i) and cooperativity constant (α) of 1.47 ng/mL and 0.406, respectively.",Pharmacodynamic model of parathyroid hormone modulation by a negative allosteric modulator of the calcium-sensing receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21437757/),,0.406,131356,DB01373,Calcium
,15116058,inhibition constant,The in vitro results indicate that the maximum gemfibrozil inhibition of rosuvastatin OATP2-mediated uptake was 50%; the inhibition constant for the inhibitory process was 4.0 +/- 1.3 micromol/L.,The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15116058/),[μM] / [l],4.0,131878,DB01373,Calcium
,24037880,incre,"Steady-state increments computed from the model were 20.6 ± 17.1, 35.2 ± 14.6, and 51.3 ± 22.0 ng/mL, respectively.",25-Hydroxyvitamin D response to graded vitamin D₃ supplementation among obese adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24037880/),,20,132032,DB01373,Calcium
,24037880,incre,"Steady-state increments computed from the model were 20.6 ± 17.1, 35.2 ± 14.6, and 51.3 ± 22.0 ng/mL, respectively.",25-Hydroxyvitamin D response to graded vitamin D₃ supplementation among obese adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24037880/),,35.2,132033,DB01373,Calcium
,24037880,incre,"Steady-state increments computed from the model were 20.6 ± 17.1, 35.2 ± 14.6, and 51.3 ± 22.0 ng/mL, respectively.",25-Hydroxyvitamin D response to graded vitamin D₃ supplementation among obese adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24037880/),,51.3,132034,DB01373,Calcium
,18673251,absolute bioavailability,The absolute bioavailability for both formulations was ca. 60 %.,"Effect of para-sulfonato-calix[n]arenes on the solubility, chemical stability, and bioavailability of a water insoluble drug nifedipine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18673251/),%,60,132363,DB01373,Calcium
,12916003,T max,"After pulmonary administration of Technosphere/PTH(1 - 34), PTH(1 - 34) appeared in the serum with a faster concentration increase (T max: pulmonary 10 +/- 5 min vs. subcutaneous 28 +/- 8 min, p < 0.001) and with higher maximal concentrations (C max : pulmonary 309 +/- 215 pmol/l vs. subcutaneous 102 +/- 45 pmol/l, p < 0.05) as compared to the subcutaneous injection.",Pilot study with technosphere/PTH(1-34)--a new approach for effective pulmonary delivery of parathyroid hormone (1-34). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12916003/),min,10,132876,DB01373,Calcium
,12916003,T max,"After pulmonary administration of Technosphere/PTH(1 - 34), PTH(1 - 34) appeared in the serum with a faster concentration increase (T max: pulmonary 10 +/- 5 min vs. subcutaneous 28 +/- 8 min, p < 0.001) and with higher maximal concentrations (C max : pulmonary 309 +/- 215 pmol/l vs. subcutaneous 102 +/- 45 pmol/l, p < 0.05) as compared to the subcutaneous injection.",Pilot study with technosphere/PTH(1-34)--a new approach for effective pulmonary delivery of parathyroid hormone (1-34). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12916003/),min,28,132877,DB01373,Calcium
,12916003,maximal concentrations (C max,"After pulmonary administration of Technosphere/PTH(1 - 34), PTH(1 - 34) appeared in the serum with a faster concentration increase (T max: pulmonary 10 +/- 5 min vs. subcutaneous 28 +/- 8 min, p < 0.001) and with higher maximal concentrations (C max : pulmonary 309 +/- 215 pmol/l vs. subcutaneous 102 +/- 45 pmol/l, p < 0.05) as compared to the subcutaneous injection.",Pilot study with technosphere/PTH(1-34)--a new approach for effective pulmonary delivery of parathyroid hormone (1-34). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12916003/),[pM] / [l],309,132878,DB01373,Calcium
,12916003,maximal concentrations (C max,"After pulmonary administration of Technosphere/PTH(1 - 34), PTH(1 - 34) appeared in the serum with a faster concentration increase (T max: pulmonary 10 +/- 5 min vs. subcutaneous 28 +/- 8 min, p < 0.001) and with higher maximal concentrations (C max : pulmonary 309 +/- 215 pmol/l vs. subcutaneous 102 +/- 45 pmol/l, p < 0.05) as compared to the subcutaneous injection.",Pilot study with technosphere/PTH(1-34)--a new approach for effective pulmonary delivery of parathyroid hormone (1-34). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12916003/),[pM] / [l],102,132879,DB01373,Calcium
,12916003,relative bioavailability,The relative bioavailability of pulmonary Technosphere/PTH(1 - 34) was calculated to be 48 %.,Pilot study with technosphere/PTH(1-34)--a new approach for effective pulmonary delivery of parathyroid hormone (1-34). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12916003/),%,48,132880,DB01373,Calcium
,16841359,flow rate,"The chromatographic separation was performed on an Atlantis C18 column (2.1 mm x 150 mm, 5.0 microm) with a mobile phase consisting of 0.2% formic acid/methanol (30:70, v/v) at a flow rate of 0.20 mL/min.",Quantitative determination of rosuvastatin in human plasma by liquid chromatography with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16841359/),[ml] / [min],0.20,133213,DB01373,Calcium
,24875062,bioavailability,"The bioavailability of ENRO was 65.78 ± 7.81% and 47.99 ± 9.48% with ions and food, respectively.",Influence of oral co-administration of a preparation containing calcium and magnesium and food on enrofloxacin pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24875062/),%,65.78,134339,DB01373,Calcium
,24875062,bioavailability,"The bioavailability of ENRO was 65.78 ± 7.81% and 47.99 ± 9.48% with ions and food, respectively.",Influence of oral co-administration of a preparation containing calcium and magnesium and food on enrofloxacin pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24875062/),%,47.99,134340,DB01373,Calcium
,24875062,maximum concentration (Cmax),"The maximum concentration (Cmax) in plasma of animals exposed to ions reached 0.87 ± 0.26 μg/ml in a tmax of 2.07 ± 0.76 h; in animals which were fed while medicated, the analogous parameters were 0.36 ± 0.13 μg/ml and 8.06 ± 3.08 h.",Influence of oral co-administration of a preparation containing calcium and magnesium and food on enrofloxacin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24875062/),[μg] / [ml],0.87,134341,DB01373,Calcium
,24875062,tmax,"The maximum concentration (Cmax) in plasma of animals exposed to ions reached 0.87 ± 0.26 μg/ml in a tmax of 2.07 ± 0.76 h; in animals which were fed while medicated, the analogous parameters were 0.36 ± 0.13 μg/ml and 8.06 ± 3.08 h.",Influence of oral co-administration of a preparation containing calcium and magnesium and food on enrofloxacin pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24875062/),h,2.07,134342,DB01373,Calcium
,24875062,tmax,"The maximum concentration (Cmax) in plasma of animals exposed to ions reached 0.87 ± 0.26 μg/ml in a tmax of 2.07 ± 0.76 h; in animals which were fed while medicated, the analogous parameters were 0.36 ± 0.13 μg/ml and 8.06 ± 3.08 h.",Influence of oral co-administration of a preparation containing calcium and magnesium and food on enrofloxacin pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24875062/),[μg] / [ml],0.36,134343,DB01373,Calcium
,24875062,tmax,"The maximum concentration (Cmax) in plasma of animals exposed to ions reached 0.87 ± 0.26 μg/ml in a tmax of 2.07 ± 0.76 h; in animals which were fed while medicated, the analogous parameters were 0.36 ± 0.13 μg/ml and 8.06 ± 3.08 h.",Influence of oral co-administration of a preparation containing calcium and magnesium and food on enrofloxacin pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24875062/),h,8.06,134344,DB01373,Calcium
,18193692,recoveries,Sample preparation with this method yielded clean extracts and consistent recoveries: 91.39% for RST and 99.28% for IS.,Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for quantification of rosuvastatin in small volume human plasma samples and its application to a clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193692/),%,91.39,135206,DB01373,Calcium
,18193692,recoveries,Sample preparation with this method yielded clean extracts and consistent recoveries: 91.39% for RST and 99.28% for IS.,Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for quantification of rosuvastatin in small volume human plasma samples and its application to a clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193692/),%,99.28,135207,DB01373,Calcium
,18193692,total chromatographic run time,"The total chromatographic run time was 3.5 min and the elution of RST and IS occurred at 2.5 and 3.1 min, respectively; this was achieved with a mobile phase consisting of 0.05 mol/L formic acid: acetonitrile (20:80, v/v) at a flow rate of 0.50 ml/min on an Inertsil ODS-3 column (4.6 x 100 mm, 3.0 microm).",Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for quantification of rosuvastatin in small volume human plasma samples and its application to a clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193692/),min,3.5,135208,DB01373,Calcium
,18193692,flow rate,"The total chromatographic run time was 3.5 min and the elution of RST and IS occurred at 2.5 and 3.1 min, respectively; this was achieved with a mobile phase consisting of 0.05 mol/L formic acid: acetonitrile (20:80, v/v) at a flow rate of 0.50 ml/min on an Inertsil ODS-3 column (4.6 x 100 mm, 3.0 microm).",Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for quantification of rosuvastatin in small volume human plasma samples and its application to a clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193692/),[ml] / [min],0.50,135209,DB01373,Calcium
,27125455,Carr's index,"The resultant powders were free flowing with an angle of repose <40° and Carr's index 5-20%, regardless of the solid carrier types.",Development of a solidified self-microemulsifying drug delivery system (S-SMEDDS) for atorvastatin calcium with improved dissolution and bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27125455/),,5-20,135442,DB01373,Calcium
,27125455,relative BAs (RBAs),"The relative BAs (RBAs) of SMEDDS, S(M)-SMEDDS, and S(S)-SMEDDS were 345%, 216%, and 160%, respectively, compared to that of ATV suspension.",Development of a solidified self-microemulsifying drug delivery system (S-SMEDDS) for atorvastatin calcium with improved dissolution and bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27125455/),%,345,135443,DB01373,Calcium
,27125455,relative BAs (RBAs),"The relative BAs (RBAs) of SMEDDS, S(M)-SMEDDS, and S(S)-SMEDDS were 345%, 216%, and 160%, respectively, compared to that of ATV suspension.",Development of a solidified self-microemulsifying drug delivery system (S-SMEDDS) for atorvastatin calcium with improved dissolution and bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27125455/),%,216,135444,DB01373,Calcium
,27125455,relative BAs (RBAs),"The relative BAs (RBAs) of SMEDDS, S(M)-SMEDDS, and S(S)-SMEDDS were 345%, 216%, and 160%, respectively, compared to that of ATV suspension.",Development of a solidified self-microemulsifying drug delivery system (S-SMEDDS) for atorvastatin calcium with improved dissolution and bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27125455/),%,160,135445,DB01373,Calcium
,27125455,RBAs,"Additionally, at a reduced dose of ATV equivalent to 5mg/kg, the RBAs of S(M)-SMEDDS and S(S)-SMEDDS compared to that of SMEDDS were 101% and 65%, respectively.",Development of a solidified self-microemulsifying drug delivery system (S-SMEDDS) for atorvastatin calcium with improved dissolution and bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27125455/),%,101,135446,DB01373,Calcium
,27125455,RBAs,"Additionally, at a reduced dose of ATV equivalent to 5mg/kg, the RBAs of S(M)-SMEDDS and S(S)-SMEDDS compared to that of SMEDDS were 101% and 65%, respectively.",Development of a solidified self-microemulsifying drug delivery system (S-SMEDDS) for atorvastatin calcium with improved dissolution and bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27125455/),%,65,135447,DB01373,Calcium
,24900239,C max,"TTA-A8 recently progressed into human clinical trials, and in line with our predictions, preliminary studies (n = 12) with a 20 mg oral dose afforded a high C max of 1.82 ± 0.274 μM with an apparent terminal half-life of 3.0 ± 1.1 h.",Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24900239/),μM,1.82,135815,DB01373,Calcium
,24900239,apparent terminal half-life,"TTA-A8 recently progressed into human clinical trials, and in line with our predictions, preliminary studies (n = 12) with a 20 mg oral dose afforded a high C max of 1.82 ± 0.274 μM with an apparent terminal half-life of 3.0 ± 1.1 h.",Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24900239/),h,3.0,135816,DB01373,Calcium
,21395015,total clearance,"Systemic pharmacokinetic parameters determined in rats and rabbits, respectively, were as follows: total clearance, 18 and 15 ml/(min kg); steady state distribution volume, 330 and 880 ml/kg; mean retention time, 0.3 and 1.0 h; half-life, 0.73 and 2.3 h.",[Pharmacokinetics of n-(5-oxynicotinoyl)-L-glutamic acid calcium salt upon bolus administration in rats and rabbits: interspecies extrapolation]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395015/),[ml] / [kg·min],18,135922,DB01373,Calcium
,21395015,total clearance,"Systemic pharmacokinetic parameters determined in rats and rabbits, respectively, were as follows: total clearance, 18 and 15 ml/(min kg); steady state distribution volume, 330 and 880 ml/kg; mean retention time, 0.3 and 1.0 h; half-life, 0.73 and 2.3 h.",[Pharmacokinetics of n-(5-oxynicotinoyl)-L-glutamic acid calcium salt upon bolus administration in rats and rabbits: interspecies extrapolation]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395015/),[ml] / [kg·min],15,135923,DB01373,Calcium
,21395015,steady state distribution volume,"Systemic pharmacokinetic parameters determined in rats and rabbits, respectively, were as follows: total clearance, 18 and 15 ml/(min kg); steady state distribution volume, 330 and 880 ml/kg; mean retention time, 0.3 and 1.0 h; half-life, 0.73 and 2.3 h.",[Pharmacokinetics of n-(5-oxynicotinoyl)-L-glutamic acid calcium salt upon bolus administration in rats and rabbits: interspecies extrapolation]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395015/),[ml] / [kg],330,135924,DB01373,Calcium
,21395015,steady state distribution volume,"Systemic pharmacokinetic parameters determined in rats and rabbits, respectively, were as follows: total clearance, 18 and 15 ml/(min kg); steady state distribution volume, 330 and 880 ml/kg; mean retention time, 0.3 and 1.0 h; half-life, 0.73 and 2.3 h.",[Pharmacokinetics of n-(5-oxynicotinoyl)-L-glutamic acid calcium salt upon bolus administration in rats and rabbits: interspecies extrapolation]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395015/),[ml] / [kg],880,135925,DB01373,Calcium
,21395015,mean retention time,"Systemic pharmacokinetic parameters determined in rats and rabbits, respectively, were as follows: total clearance, 18 and 15 ml/(min kg); steady state distribution volume, 330 and 880 ml/kg; mean retention time, 0.3 and 1.0 h; half-life, 0.73 and 2.3 h.",[Pharmacokinetics of n-(5-oxynicotinoyl)-L-glutamic acid calcium salt upon bolus administration in rats and rabbits: interspecies extrapolation]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395015/),h,0.3,135926,DB01373,Calcium
,21395015,mean retention time,"Systemic pharmacokinetic parameters determined in rats and rabbits, respectively, were as follows: total clearance, 18 and 15 ml/(min kg); steady state distribution volume, 330 and 880 ml/kg; mean retention time, 0.3 and 1.0 h; half-life, 0.73 and 2.3 h.",[Pharmacokinetics of n-(5-oxynicotinoyl)-L-glutamic acid calcium salt upon bolus administration in rats and rabbits: interspecies extrapolation]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395015/),h,1.0,135927,DB01373,Calcium
,21395015,half-life,"Systemic pharmacokinetic parameters determined in rats and rabbits, respectively, were as follows: total clearance, 18 and 15 ml/(min kg); steady state distribution volume, 330 and 880 ml/kg; mean retention time, 0.3 and 1.0 h; half-life, 0.73 and 2.3 h.",[Pharmacokinetics of n-(5-oxynicotinoyl)-L-glutamic acid calcium salt upon bolus administration in rats and rabbits: interspecies extrapolation]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395015/),h,0.73,135928,DB01373,Calcium
,21395015,half-life,"Systemic pharmacokinetic parameters determined in rats and rabbits, respectively, were as follows: total clearance, 18 and 15 ml/(min kg); steady state distribution volume, 330 and 880 ml/kg; mean retention time, 0.3 and 1.0 h; half-life, 0.73 and 2.3 h.",[Pharmacokinetics of n-(5-oxynicotinoyl)-L-glutamic acid calcium salt upon bolus administration in rats and rabbits: interspecies extrapolation]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395015/),h,2.3,135929,DB01373,Calcium
,21395015,half-life,"Using the allometric approach to the interspecies extrapolation of the pharmacokinetic data, the half-life of ONG in humans is predicted to be 4 h.",[Pharmacokinetics of n-(5-oxynicotinoyl)-L-glutamic acid calcium salt upon bolus administration in rats and rabbits: interspecies extrapolation]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395015/),h,4,135930,DB01373,Calcium
,16784736,AUC(0-72),"The AUC(0-72) and AUC(0-infinity) of rosuvastatin were lower in the 421CC group than in the 421CA+421AA group (33.8+/-11.4 vs. 59.6+/-22.2 ng.h/ml, P=0.018; 34.9+/-11.9 vs. 62.2+/-23.5 ng.h/ml, P=0.018), respectively.",Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16784736/),[h·ng] / [ml],33.8,135939,DB01373,Calcium
,16784736,AUC(0-72),"The AUC(0-72) and AUC(0-infinity) of rosuvastatin were lower in the 421CC group than in the 421CA+421AA group (33.8+/-11.4 vs. 59.6+/-22.2 ng.h/ml, P=0.018; 34.9+/-11.9 vs. 62.2+/-23.5 ng.h/ml, P=0.018), respectively.",Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16784736/),[h·ng] / [ml],59.6,135940,DB01373,Calcium
,16784736,AUC(0-infinity),"The AUC(0-72) and AUC(0-infinity) of rosuvastatin were lower in the 421CC group than in the 421CA+421AA group (33.8+/-11.4 vs. 59.6+/-22.2 ng.h/ml, P=0.018; 34.9+/-11.9 vs. 62.2+/-23.5 ng.h/ml, P=0.018), respectively.",Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16784736/),[h·ng] / [ml],34.9,135941,DB01373,Calcium
,16784736,AUC(0-infinity),"The AUC(0-72) and AUC(0-infinity) of rosuvastatin were lower in the 421CC group than in the 421CA+421AA group (33.8+/-11.4 vs. 59.6+/-22.2 ng.h/ml, P=0.018; 34.9+/-11.9 vs. 62.2+/-23.5 ng.h/ml, P=0.018), respectively.",Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16784736/),[h·ng] / [ml],62.2,135942,DB01373,Calcium
,16784736,C(max),"The C(max) value was higher in the 421CA+421AA group than that in the 421CC group (9.9+/-5.4 vs. 5.1+/-2.4 ng/ml, P=0.048).",Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16784736/),[ng] / [ml],9.9,135943,DB01373,Calcium
,16784736,C(max),"The C(max) value was higher in the 421CA+421AA group than that in the 421CC group (9.9+/-5.4 vs. 5.1+/-2.4 ng/ml, P=0.048).",Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16784736/),[ng] / [ml],5.1,135944,DB01373,Calcium
,16784736,CL/F,"The CL/F value was lower in the 421CA+421AA group than that in the 421CC group (384.7+/-161.2 vs. 674.0+/-297.6 l/h, P=0.043).",Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16784736/),[l] / [h],384.7,135945,DB01373,Calcium
,16784736,CL/F,"The CL/F value was lower in the 421CA+421AA group than that in the 421CC group (384.7+/-161.2 vs. 674.0+/-297.6 l/h, P=0.043).",Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16784736/),[l] / [h],674.0,135946,DB01373,Calcium
,20166433,absolute bioavailability (A.B.),"Consequently, the absolute bioavailability (A.B.) of verapamil with simvastatin (7.3% at 0.3 mg/kg, 9.3% at 1.0 mg/kg) were significantly higher than those in the control group (P < 0.05, 5.2%).","Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166433/),%,7.3,136145,DB01373,Calcium
,20166433,absolute bioavailability (A.B.),"Consequently, the absolute bioavailability (A.B.) of verapamil with simvastatin (7.3% at 0.3 mg/kg, 9.3% at 1.0 mg/kg) were significantly higher than those in the control group (P < 0.05, 5.2%).","Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166433/),%,9.3,136146,DB01373,Calcium
,20166433,absolute bioavailability (A.B.),"Consequently, the absolute bioavailability (A.B.) of verapamil with simvastatin (7.3% at 0.3 mg/kg, 9.3% at 1.0 mg/kg) were significantly higher than those in the control group (P < 0.05, 5.2%).","Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166433/),%,5.2,136147,DB01373,Calcium
,28685495,relative bioavailability,"The relative bioavailability of rosuvastatin was essentially unchanged when administered with metformin in T1 and T2, but in T3 it increased to 152% for AUC0-tz (90% CI 135-171%) and 154% for C max (90% CI 132-180%).",Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685495/),%,152,136188,DB01373,Calcium
,28685495,relative bioavailability,"The relative bioavailability of rosuvastatin was essentially unchanged when administered with metformin in T1 and T2, but in T3 it increased to 152% for AUC0-tz (90% CI 135-171%) and 154% for C max (90% CI 132-180%).",Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685495/),%,154,136189,DB01373,Calcium
,22210034,limit of detection,"The assay was linear in the concentration range of 2-100 ng/mL in 1 mL of plasma with high precision and accuracy, and the limit of detection was 0.5 ng/mL.",Determination of alendronate in low volumes of plasma by column-switching high-performance liquid chromatography method and its application to pharmacokinetic studies in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210034/),[ng] / [ml],0.5,138912,DB01373,Calcium
,22210034,maximum alendronate plasma concentration (C(max)),"The mean value of maximum alendronate plasma concentration (C(max)) was 37.69 ng/mL, and the mean time to reach the C(max) (T(max)) was 1.08 h.",Determination of alendronate in low volumes of plasma by column-switching high-performance liquid chromatography method and its application to pharmacokinetic studies in human plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210034/),[ng] / [ml],37.69,138913,DB01373,Calcium
,22210034,time to reach the C(max) (T(max)),"The mean value of maximum alendronate plasma concentration (C(max)) was 37.69 ng/mL, and the mean time to reach the C(max) (T(max)) was 1.08 h.",Determination of alendronate in low volumes of plasma by column-switching high-performance liquid chromatography method and its application to pharmacokinetic studies in human plasma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210034/),h,1.08,138914,DB01373,Calcium
,22210034,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) and elimination half-life (T(1/2)) were 106.48 ng/mL/h and 1.66 h, respectively.",Determination of alendronate in low volumes of plasma by column-switching high-performance liquid chromatography method and its application to pharmacokinetic studies in human plasma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210034/),[ng] / [h·ml],106.48,138915,DB01373,Calcium
,22210034,elimination half-life (T(1/2)),"The area under the plasma concentration-time curve (AUC) and elimination half-life (T(1/2)) were 106.48 ng/mL/h and 1.66 h, respectively.",Determination of alendronate in low volumes of plasma by column-switching high-performance liquid chromatography method and its application to pharmacokinetic studies in human plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210034/),h,1.66,138916,DB01373,Calcium
,28156162,oral bioavailability,"NM has poor oral bioavailability (5-13%) due to its low aqueous solubility, and extensive first pass metabolism.",Contribution of both olfactory and systemic pathways for brain targeting of nimodipine-loaded lipo-pluronics micelles: in vitro characterization and in vivo biodistribution study after intranasal and intravenous delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28156162/),%,5-13,139520,DB01373,Calcium
,28156162,drug-targeting efficiency,The drug-targeting efficiency of NM to the brain after intranasal administration was calculated to be 1872.82%.,Contribution of both olfactory and systemic pathways for brain targeting of nimodipine-loaded lipo-pluronics micelles: in vitro characterization and in vivo biodistribution study after intranasal and intravenous delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28156162/),%,1872.82,139521,DB01373,Calcium
,34173263,Cmax,"The mean (range) for Cmax , Tmax and the terminal half-life were 515.6 (369.7-714.0) ng/ml, 8.67 (8.0 12.0) h, and 22.4 (18.3-42.5) h, respectively.",Pharmacokinetics of transdermal flunixin meglumine and effects on biomarkers of inflammation in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34173263/),[ng] / [ml],515.6,139546,DB01373,Calcium
,34173263,Tmax,"The mean (range) for Cmax , Tmax and the terminal half-life were 515.6 (369.7-714.0) ng/ml, 8.67 (8.0 12.0) h, and 22.4 (18.3-42.5) h, respectively.",Pharmacokinetics of transdermal flunixin meglumine and effects on biomarkers of inflammation in horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34173263/),h,8.67,139547,DB01373,Calcium
,34173263,terminal half-life,"The mean (range) for Cmax , Tmax and the terminal half-life were 515.6 (369.7-714.0) ng/ml, 8.67 (8.0 12.0) h, and 22.4 (18.3-42.5) h, respectively.",Pharmacokinetics of transdermal flunixin meglumine and effects on biomarkers of inflammation in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34173263/),h,22.4,139548,DB01373,Calcium
,23054989,zeta potential,The vesicles had a mean particle size of (163.8 ± 5.5) nm and a zeta potential of -74.5 ± 6.4 mV.,Preparation and characterization of stable pH-sensitive vesicles composed of α-tocopherol hemisuccinate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23054989/),mv,-,139756,DB01373,Calcium
,23054989,zeta potential,The vesicles had a mean particle size of (163.8 ± 5.5) nm and a zeta potential of -74.5 ± 6.4 mV.,Preparation and characterization of stable pH-sensitive vesicles composed of α-tocopherol hemisuccinate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23054989/),mv,74.5,139757,DB01373,Calcium
,21091728,peak (C(max) ),"After oral administration of carbasalate calcium, the plasma drug concentration for ASA, SA and GA reached a peak (C(max) ) of 8.88 ± 1.31, 42.6 ± 4.62 and 10.1 ± 2.16 μg/mL at 0.170, 2.00 and 2.00 h, respectively.",Analytical determination and pharmacokinetics of major metabolites of carbasalate calcium in broilers following oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21091728/),[μg] / [ml],8.88,139795,DB01373,Calcium
,21091728,peak (C(max) ),"After oral administration of carbasalate calcium, the plasma drug concentration for ASA, SA and GA reached a peak (C(max) ) of 8.88 ± 1.31, 42.6 ± 4.62 and 10.1 ± 2.16 μg/mL at 0.170, 2.00 and 2.00 h, respectively.",Analytical determination and pharmacokinetics of major metabolites of carbasalate calcium in broilers following oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21091728/),[μg] / [ml],42.6,139796,DB01373,Calcium
,21091728,peak (C(max) ),"After oral administration of carbasalate calcium, the plasma drug concentration for ASA, SA and GA reached a peak (C(max) ) of 8.88 ± 1.31, 42.6 ± 4.62 and 10.1 ± 2.16 μg/mL at 0.170, 2.00 and 2.00 h, respectively.",Analytical determination and pharmacokinetics of major metabolites of carbasalate calcium in broilers following oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21091728/),[μg] / [ml],10.1,139797,DB01373,Calcium
,21091728,terminal half-life (t(1/2λz) ),"The terminal half-life (t(1/2λz) ) of ASA, SA and GA was 11.2 ± 8.04, 23.7 ± 17.1 and 28.6 ± 4.90 h, respectively.",Analytical determination and pharmacokinetics of major metabolites of carbasalate calcium in broilers following oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21091728/),h,11.2,139798,DB01373,Calcium
,21091728,terminal half-life (t(1/2λz) ),"The terminal half-life (t(1/2λz) ) of ASA, SA and GA was 11.2 ± 8.04, 23.7 ± 17.1 and 28.6 ± 4.90 h, respectively.",Analytical determination and pharmacokinetics of major metabolites of carbasalate calcium in broilers following oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21091728/),h,23.7,139799,DB01373,Calcium
,21091728,terminal half-life (t(1/2λz) ),"The terminal half-life (t(1/2λz) ) of ASA, SA and GA was 11.2 ± 8.04, 23.7 ± 17.1 and 28.6 ± 4.90 h, respectively.",Analytical determination and pharmacokinetics of major metabolites of carbasalate calcium in broilers following oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21091728/),h,28.6,139800,DB01373,Calcium
,18432283,AUC,"The pharmacokinetics of verapamil was enantioselective in the control group, with a higher plasma proportion of the S-verapamil (AUC 250.8 versus 120.4 ng x h x mL(-1); p < or = 0.05, Wilcoxon test) and S-norverapamil (AUC 72.3 versus 52.3 ng x h x mL(-1); p < or = 0.05, Wilcoxon test).",Reduction of enantioselectivity in the kinetic disposition and metabolism of verapamil in rats exposed to toluene. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18432283/),[h·ng] / [ml],250.8,140111,DB01373,Calcium
,18432283,AUC,"The pharmacokinetics of verapamil was enantioselective in the control group, with a higher plasma proportion of the S-verapamil (AUC 250.8 versus 120.4 ng x h x mL(-1); p < or = 0.05, Wilcoxon test) and S-norverapamil (AUC 72.3 versus 52.3 ng x h x mL(-1); p < or = 0.05, Wilcoxon test).",Reduction of enantioselectivity in the kinetic disposition and metabolism of verapamil in rats exposed to toluene. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18432283/),[h·ng] / [ml],120.4,140112,DB01373,Calcium
,18432283,AUC,"The pharmacokinetics of verapamil was enantioselective in the control group, with a higher plasma proportion of the S-verapamil (AUC 250.8 versus 120.4 ng x h x mL(-1); p < or = 0.05, Wilcoxon test) and S-norverapamil (AUC 72.3 versus 52.3 ng x h x mL(-1); p < or = 0.05, Wilcoxon test).",Reduction of enantioselectivity in the kinetic disposition and metabolism of verapamil in rats exposed to toluene. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18432283/),[h·ng] / [ml],72.3,140113,DB01373,Calcium
,18432283,AUC,"The pharmacokinetics of verapamil was enantioselective in the control group, with a higher plasma proportion of the S-verapamil (AUC 250.8 versus 120.4 ng x h x mL(-1); p < or = 0.05, Wilcoxon test) and S-norverapamil (AUC 72.3 versus 52.3 ng x h x mL(-1); p < or = 0.05, Wilcoxon test).",Reduction of enantioselectivity in the kinetic disposition and metabolism of verapamil in rats exposed to toluene. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18432283/),[h·ng] / [ml],52.3,140114,DB01373,Calcium
,30141180,tmax,"Median plasma cinacalcet tmax was 1 h (range 0.5-4.0 h); mean (SD) Cmax and AUClast were 2.83 (1.98) ng/mL and 11.8 (8.74) h*ng/mL, respectively; mean (SD) half-life (t1/2) was 3.70 (2.57) h.","An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30141180/),h,1,140154,DB01373,Calcium
,30141180,Cmax,"Median plasma cinacalcet tmax was 1 h (range 0.5-4.0 h); mean (SD) Cmax and AUClast were 2.83 (1.98) ng/mL and 11.8 (8.74) h*ng/mL, respectively; mean (SD) half-life (t1/2) was 3.70 (2.57) h.","An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30141180/),[ng] / [ml],2.83,140155,DB01373,Calcium
,30141180,AUClast,"Median plasma cinacalcet tmax was 1 h (range 0.5-4.0 h); mean (SD) Cmax and AUClast were 2.83 (1.98) ng/mL and 11.8 (8.74) h*ng/mL, respectively; mean (SD) half-life (t1/2) was 3.70 (2.57) h.","An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30141180/),[h·ng] / [ml],11.8,140156,DB01373,Calcium
,30141180,half-life (t1/2),"Median plasma cinacalcet tmax was 1 h (range 0.5-4.0 h); mean (SD) Cmax and AUClast were 2.83 (1.98) ng/mL and 11.8 (8.74) h*ng/mL, respectively; mean (SD) half-life (t1/2) was 3.70 (2.57) h.","An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30141180/),h,3.70,140157,DB01373,Calcium
,16144752,extraction efficacy,The mean extraction efficacy was 90.6% and no interfering peaks of the blank plasma chromatograms were observed.,"HPLC method for analysis of a new 1,4-dihydropyridine: application to pharmacokinetic study in rabbit. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144752/),%,90.6,140178,DB01373,Calcium
,20572052,minimum Glu concentration,"Low cross-linking solution pH (1.5), minimum Glu concentration (2.5%) and cross-linking time (2 h) were crucial to exhibit colon-specific drug release.",Impact of glutaraldehyde on in vivo colon-specific release of resveratrol from biodegradable pectin-based formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20572052/),%,2.5,140819,DB01373,Calcium
,29440178,faa,The faa values obtained on the former assumption were 0.48-0.54.,Evaluation of Alteration in Hepatic and Intestinal BCRP Function In Vivo from ABCG2 c.421C>A Polymorphism Based on PBPK Analysis of Rosuvastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29440178/),,0.48-0.54,141299,DB01373,Calcium
,26539812,T1/2,"As a first step towards assessing the relevance of short-lived nuclides (half-life shorter than that of (10)C, T1/2 = 19 s) for in vivo dose delivery verification using beam-on PET, we measured their production in the stopping of 55 MeV protons in water, carbon, phosphorus and calcium",Short-lived positron emitters in beam-on PET imaging during proton therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26539812/),s,19,141391,DB01373,Calcium
,26539812,T1/2,"The most copiously produced short-lived nuclides and their production rates relative to the relevant long-lived nuclides are: (12)N (T1/2 = 11 ms) on carbon (9% of (11)C), (29)P (T1/2 = 4.1 s) on phosphorus (20% of (30)P) and (38m)K (T1/2 = 0.92 s) on calcium (113% of (38g)K).",Short-lived positron emitters in beam-on PET imaging during proton therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26539812/),ms,11,141392,DB01373,Calcium
,26539812,T1/2,"The most copiously produced short-lived nuclides and their production rates relative to the relevant long-lived nuclides are: (12)N (T1/2 = 11 ms) on carbon (9% of (11)C), (29)P (T1/2 = 4.1 s) on phosphorus (20% of (30)P) and (38m)K (T1/2 = 0.92 s) on calcium (113% of (38g)K).",Short-lived positron emitters in beam-on PET imaging during proton therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26539812/),s,4.1,141393,DB01373,Calcium
,26539812,T1/2,"The most copiously produced short-lived nuclides and their production rates relative to the relevant long-lived nuclides are: (12)N (T1/2 = 11 ms) on carbon (9% of (11)C), (29)P (T1/2 = 4.1 s) on phosphorus (20% of (30)P) and (38m)K (T1/2 = 0.92 s) on calcium (113% of (38g)K).",Short-lived positron emitters in beam-on PET imaging during proton therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26539812/),s,0.92,141394,DB01373,Calcium
,17213004,Cmax AUC from time 0 to the last available measurement (AUC(last)),"The mean (SD) values for Cmax AUC from time 0 to the last available measurement (AUC(last)), and AUC from 0 to infinity (AUC(0-infinity)) for the reference formulation (3.0 [0.6] ng/mL, 151.4 [35.7] ng x h/mL, and 175.3 [45.1] ng x h/mL, respectively) did not differ significantly from those for the test formulation (3.1 [0.6] ng/mL, 139.7 [40.3] ng x h/mL, and 161.7 [43.8] ng x h/mL, respectively).","Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213004/),[ng] / [ml],3.0,141563,DB01373,Calcium
,17213004,Cmax AUC from time 0 to the last available measurement (AUC(last)),"The mean (SD) values for Cmax AUC from time 0 to the last available measurement (AUC(last)), and AUC from 0 to infinity (AUC(0-infinity)) for the reference formulation (3.0 [0.6] ng/mL, 151.4 [35.7] ng x h/mL, and 175.3 [45.1] ng x h/mL, respectively) did not differ significantly from those for the test formulation (3.1 [0.6] ng/mL, 139.7 [40.3] ng x h/mL, and 161.7 [43.8] ng x h/mL, respectively).","Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213004/),[h·ng] / [ml],151.4,141564,DB01373,Calcium
,17213004,Cmax AUC from time 0 to the last available measurement (AUC(last)),"The mean (SD) values for Cmax AUC from time 0 to the last available measurement (AUC(last)), and AUC from 0 to infinity (AUC(0-infinity)) for the reference formulation (3.0 [0.6] ng/mL, 151.4 [35.7] ng x h/mL, and 175.3 [45.1] ng x h/mL, respectively) did not differ significantly from those for the test formulation (3.1 [0.6] ng/mL, 139.7 [40.3] ng x h/mL, and 161.7 [43.8] ng x h/mL, respectively).","Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213004/),[ng] / [ml],3.1,141565,DB01373,Calcium
,17213004,AUC from 0 to infinity (AUC(0-infinity)),"The mean (SD) values for Cmax AUC from time 0 to the last available measurement (AUC(last)), and AUC from 0 to infinity (AUC(0-infinity)) for the reference formulation (3.0 [0.6] ng/mL, 151.4 [35.7] ng x h/mL, and 175.3 [45.1] ng x h/mL, respectively) did not differ significantly from those for the test formulation (3.1 [0.6] ng/mL, 139.7 [40.3] ng x h/mL, and 161.7 [43.8] ng x h/mL, respectively).","Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213004/),[h·ng] / [ml],175.3,141566,DB01373,Calcium
,17213004,AUC from 0 to infinity (AUC(0-infinity)),"The mean (SD) values for Cmax AUC from time 0 to the last available measurement (AUC(last)), and AUC from 0 to infinity (AUC(0-infinity)) for the reference formulation (3.0 [0.6] ng/mL, 151.4 [35.7] ng x h/mL, and 175.3 [45.1] ng x h/mL, respectively) did not differ significantly from those for the test formulation (3.1 [0.6] ng/mL, 139.7 [40.3] ng x h/mL, and 161.7 [43.8] ng x h/mL, respectively).","Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213004/),[ng] / [ml],3.1,141567,DB01373,Calcium
,17213004,AUC from 0 to infinity (AUC(0-infinity)),"The mean (SD) values for Cmax AUC from time 0 to the last available measurement (AUC(last)), and AUC from 0 to infinity (AUC(0-infinity)) for the reference formulation (3.0 [0.6] ng/mL, 151.4 [35.7] ng x h/mL, and 175.3 [45.1] ng x h/mL, respectively) did not differ significantly from those for the test formulation (3.1 [0.6] ng/mL, 139.7 [40.3] ng x h/mL, and 161.7 [43.8] ng x h/mL, respectively).","Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213004/),[h·ng] / [ml],139.7,141568,DB01373,Calcium
,17213004,AUC from 0 to infinity (AUC(0-infinity)),"The mean (SD) values for Cmax AUC from time 0 to the last available measurement (AUC(last)), and AUC from 0 to infinity (AUC(0-infinity)) for the reference formulation (3.0 [0.6] ng/mL, 151.4 [35.7] ng x h/mL, and 175.3 [45.1] ng x h/mL, respectively) did not differ significantly from those for the test formulation (3.1 [0.6] ng/mL, 139.7 [40.3] ng x h/mL, and 161.7 [43.8] ng x h/mL, respectively).","Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213004/),[h·ng] / [ml],161.7,141569,DB01373,Calcium
,31852330,swelling index,"The swelling index and floating duration for the optimized formulation were 140.48 ± 0.57 and 8.53 ± 0.10 h, respectively.","Gastroretentive bilayer film for sustained release of atorvastatin calcium and immediate release of amlodipine besylate: pharmaceutical, pharmacokinetic evaluation, and IVIVC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31852330/),h,140.48,142329,DB01373,Calcium
,31852330,floating duration,"The swelling index and floating duration for the optimized formulation were 140.48 ± 0.57 and 8.53 ± 0.10 h, respectively.","Gastroretentive bilayer film for sustained release of atorvastatin calcium and immediate release of amlodipine besylate: pharmaceutical, pharmacokinetic evaluation, and IVIVC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31852330/),h,8.53,142330,DB01373,Calcium
,12680034,hardness,The compression force was adjusted to produce tablets with hardness value about 7.73 +/- 0.79 Kp.,In vitro--in vivo evaluation of tableted caseinchitosan microspheres containing diltiazem hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12680034/),k,7.73,143379,DB01373,Calcium
,12680034,maximum drug concentration (Cmax),The pharmacokinetic parameters including maximum drug concentration (Cmax) and time to reach that maximum (Tmax) were 106.24 +/- 17.96 ng.,In vitro--in vivo evaluation of tableted caseinchitosan microspheres containing diltiazem hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12680034/),ng,106.24,143380,DB01373,Calcium
,12680034,elimination half-lives,"The elimination half-lives were nearly the same for the commercial and the formulated tablets (8.22 +/- 4.19 and 7.95 +/- 4.28 hours, respectively).",In vitro--in vivo evaluation of tableted caseinchitosan microspheres containing diltiazem hydrochloride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12680034/),h,8.22,143381,DB01373,Calcium
,12680034,elimination half-lives,"The elimination half-lives were nearly the same for the commercial and the formulated tablets (8.22 +/- 4.19 and 7.95 +/- 4.28 hours, respectively).",In vitro--in vivo evaluation of tableted caseinchitosan microspheres containing diltiazem hydrochloride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12680034/),h,7.95,143382,DB01373,Calcium
,20137768,AUC(0-tlast),"Under fasting conditions total and maximum exposure, represented by geometric mean AUC(0-tlast)- and C(max)-values, respectively were 466.7 h*ng/ml (AUC(0-tlast)) and 21.9 ng/ml (C(max)) for Test and 507.8 h*ng/ml (AUC(0-tlast)) and 22.0 ng/ml (C(max)) for Reference tablets.",Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137768/),[h·ng] / [ml],466.7,143954,DB01373,Calcium
,20137768,C(max),"Under fasting conditions total and maximum exposure, represented by geometric mean AUC(0-tlast)- and C(max)-values, respectively were 466.7 h*ng/ml (AUC(0-tlast)) and 21.9 ng/ml (C(max)) for Test and 507.8 h*ng/ml (AUC(0-tlast)) and 22.0 ng/ml (C(max)) for Reference tablets.",Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137768/),[ng] / [ml],21.9,143955,DB01373,Calcium
,20137768,AUC(0-tlast),"Under fasting conditions total and maximum exposure, represented by geometric mean AUC(0-tlast)- and C(max)-values, respectively were 466.7 h*ng/ml (AUC(0-tlast)) and 21.9 ng/ml (C(max)) for Test and 507.8 h*ng/ml (AUC(0-tlast)) and 22.0 ng/ml (C(max)) for Reference tablets.",Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137768/),[h·ng] / [ml],507.8,143956,DB01373,Calcium
,20137768,C(max)),"Under fasting conditions total and maximum exposure, represented by geometric mean AUC(0-tlast)- and C(max)-values, respectively were 466.7 h*ng/ml (AUC(0-tlast)) and 21.9 ng/ml (C(max)) for Test and 507.8 h*ng/ml (AUC(0-tlast)) and 22.0 ng/ml (C(max)) for Reference tablets.",Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137768/),[ng] / [ml],22.0,143957,DB01373,Calcium
,20137768,AUC(0-tlast),"Both, total and maximum exposure, represented by geometric mean values for AUC(0-tlast) and C(max), were considerably lower (differences also statistically significant) after administration of Test with 481.8 h*ng/ml for AUC(0-tlast) and 25.3 ng/ml for C(max) in comparison to Reference tablets with 595.9 h*ng/ml for AUC(0-tlast) and 31.9 ng/ml for C(max).",Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137768/),[h·ng] / [ml],481.8,143958,DB01373,Calcium
,20137768,C(max),"Both, total and maximum exposure, represented by geometric mean values for AUC(0-tlast) and C(max), were considerably lower (differences also statistically significant) after administration of Test with 481.8 h*ng/ml for AUC(0-tlast) and 25.3 ng/ml for C(max) in comparison to Reference tablets with 595.9 h*ng/ml for AUC(0-tlast) and 31.9 ng/ml for C(max).",Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137768/),[ng] / [ml],25.3,143959,DB01373,Calcium
,20137768,AUC(0-tlast,"Both, total and maximum exposure, represented by geometric mean values for AUC(0-tlast) and C(max), were considerably lower (differences also statistically significant) after administration of Test with 481.8 h*ng/ml for AUC(0-tlast) and 25.3 ng/ml for C(max) in comparison to Reference tablets with 595.9 h*ng/ml for AUC(0-tlast) and 31.9 ng/ml for C(max).",Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137768/),[h·ng] / [ml],595.9,143960,DB01373,Calcium
,20137768,C(max),"Both, total and maximum exposure, represented by geometric mean values for AUC(0-tlast) and C(max), were considerably lower (differences also statistically significant) after administration of Test with 481.8 h*ng/ml for AUC(0-tlast) and 25.3 ng/ml for C(max) in comparison to Reference tablets with 595.9 h*ng/ml for AUC(0-tlast) and 31.9 ng/ml for C(max).",Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137768/),[ng] / [ml],31.9,143961,DB01373,Calcium
,26241752,oral bioavailability,"However, NM suffers from poor oral bioavailability (5-13%) due to its low aqueous solubility, extensive first pass metabolism and short elimination half-life (1-2h).","Novel self-assembled nano-tubular mixed micelles of Pluronics P123, Pluronic F127 and phosphatidylcholine for oral delivery of nimodipine: In vitro characterization, ex vivo transport and in vivo pharmacokinetic studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26241752/),%,5-13,144692,DB01373,Calcium
,26241752,elimination half-life,"However, NM suffers from poor oral bioavailability (5-13%) due to its low aqueous solubility, extensive first pass metabolism and short elimination half-life (1-2h).","Novel self-assembled nano-tubular mixed micelles of Pluronics P123, Pluronic F127 and phosphatidylcholine for oral delivery of nimodipine: In vitro characterization, ex vivo transport and in vivo pharmacokinetic studies. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26241752/),h,1-2,144693,DB01373,Calcium
,26241752,zeta potential,"The selected NM-loaded PPPMM, containing PC to Pluronics(®) molar ratio of 75:25, showed a drug payload, SE, micellar size and zeta potential of 1.06 ± 0.03 mg/mL, 99.2 ± 2.01%, 571.5 ± 11.87 nm and -31.2 ± 0.06 mv, respectively.","Novel self-assembled nano-tubular mixed micelles of Pluronics P123, Pluronic F127 and phosphatidylcholine for oral delivery of nimodipine: In vitro characterization, ex vivo transport and in vivo pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26241752/),mv,-31.2,144694,DB01373,Calcium
,26241752,bioavailability,The in vivo pharmacokinetic study showed greater bioavailability of NM in plasma (232%) and brain (208%) of rats from NM-loaded PPPMM compared to that of the drug solution due to the efficiency of flexible NTMM to enhance absorption of NM from the intestinal mucosa.,"Novel self-assembled nano-tubular mixed micelles of Pluronics P123, Pluronic F127 and phosphatidylcholine for oral delivery of nimodipine: In vitro characterization, ex vivo transport and in vivo pharmacokinetic studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26241752/),%,232,144695,DB01373,Calcium
,26241752,bioavailability,The in vivo pharmacokinetic study showed greater bioavailability of NM in plasma (232%) and brain (208%) of rats from NM-loaded PPPMM compared to that of the drug solution due to the efficiency of flexible NTMM to enhance absorption of NM from the intestinal mucosa.,"Novel self-assembled nano-tubular mixed micelles of Pluronics P123, Pluronic F127 and phosphatidylcholine for oral delivery of nimodipine: In vitro characterization, ex vivo transport and in vivo pharmacokinetic studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26241752/),%,208,144696,DB01373,Calcium
,19116379,total platinum concentration,"In guinea pig cochlea, total platinum concentration (0.12 vs 0.63 microg/kg, respectively, P = .008) and perilymphatic drug concentrations (238 vs 515 microM x minute, respectively, P < .001) were lower after intravenous oxaliplatin treatment (16.6 mg/kg) than after equimolar cisplatin treatment (12.5 mg/kg).",Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19116379/),[μg] / [kg],0.12,145807,DB01373,Calcium
,19116379,total platinum concentration,"In guinea pig cochlea, total platinum concentration (0.12 vs 0.63 microg/kg, respectively, P = .008) and perilymphatic drug concentrations (238 vs 515 microM x minute, respectively, P < .001) were lower after intravenous oxaliplatin treatment (16.6 mg/kg) than after equimolar cisplatin treatment (12.5 mg/kg).",Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19116379/),[μg] / [kg],0.63,145808,DB01373,Calcium
,25984962,AUC(0-12),"The estimated pharmacokinetic parameters of nifedipine showed a mean AUC(0-12) of 250.2ngh/mL, ClT/F of 89.2L/h, Vd/F of 600.0L and t1/2 5.1h.",Analysis of nifedipine in human plasma and amniotic fluid by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics in hypertensive pregnant women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25984962/),[ngh] / [ml],250.2,146168,DB01373,Calcium
,25984962,ClT/F,"The estimated pharmacokinetic parameters of nifedipine showed a mean AUC(0-12) of 250.2ngh/mL, ClT/F of 89.2L/h, Vd/F of 600.0L and t1/2 5.1h.",Analysis of nifedipine in human plasma and amniotic fluid by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics in hypertensive pregnant women. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25984962/),[l] / [h],89.2,146169,DB01373,Calcium
,25984962,Vd/F,"The estimated pharmacokinetic parameters of nifedipine showed a mean AUC(0-12) of 250.2ngh/mL, ClT/F of 89.2L/h, Vd/F of 600.0L and t1/2 5.1h.",Analysis of nifedipine in human plasma and amniotic fluid by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics in hypertensive pregnant women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25984962/),l,600.0,146170,DB01373,Calcium
,25984962,t1/2,"The estimated pharmacokinetic parameters of nifedipine showed a mean AUC(0-12) of 250.2ngh/mL, ClT/F of 89.2L/h, Vd/F of 600.0L and t1/2 5.1h.",Analysis of nifedipine in human plasma and amniotic fluid by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics in hypertensive pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25984962/),h,5.1,146171,DB01373,Calcium
,25984962,amniotic fluid/plasma concentration ratio,The mean amniotic fluid/plasma concentration ratio was 0.05.,Analysis of nifedipine in human plasma and amniotic fluid by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics in hypertensive pregnant women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25984962/),,0.05,146172,DB01373,Calcium
,18499371,AUC(0-infinity),"The results suggested that there was no significant difference in the areas under the plasma concentration-time curve and the mean peak concentration between NMD-SSC (AUC(0-infinity)=2488+/-433nghmL(-1), Cmax=321+/-78ngml(-1)) and Nimotop (AUC0-infinity=2272+/-398nghmL(-1), Cmax=293+/-73ngmL(-1)) (P>0.05).",Nimodipine semi-solid capsules containing solid dispersion for improving dissolution. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18499371/),1/[nghml],2488,146263,DB01373,Calcium
,18499371,Cmax,"The results suggested that there was no significant difference in the areas under the plasma concentration-time curve and the mean peak concentration between NMD-SSC (AUC(0-infinity)=2488+/-433nghmL(-1), Cmax=321+/-78ngml(-1)) and Nimotop (AUC0-infinity=2272+/-398nghmL(-1), Cmax=293+/-73ngmL(-1)) (P>0.05).",Nimodipine semi-solid capsules containing solid dispersion for improving dissolution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18499371/),1/[ngml],321,146264,DB01373,Calcium
,18499371,AUC0-infinity,"The results suggested that there was no significant difference in the areas under the plasma concentration-time curve and the mean peak concentration between NMD-SSC (AUC(0-infinity)=2488+/-433nghmL(-1), Cmax=321+/-78ngml(-1)) and Nimotop (AUC0-infinity=2272+/-398nghmL(-1), Cmax=293+/-73ngmL(-1)) (P>0.05).",Nimodipine semi-solid capsules containing solid dispersion for improving dissolution. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18499371/),1/[nghml],2272,146265,DB01373,Calcium
,18499371,Cmax,"The results suggested that there was no significant difference in the areas under the plasma concentration-time curve and the mean peak concentration between NMD-SSC (AUC(0-infinity)=2488+/-433nghmL(-1), Cmax=321+/-78ngml(-1)) and Nimotop (AUC0-infinity=2272+/-398nghmL(-1), Cmax=293+/-73ngmL(-1)) (P>0.05).",Nimodipine semi-solid capsules containing solid dispersion for improving dissolution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18499371/),1/[ngml],293,146266,DB01373,Calcium
,18499371,tmax,"However, the apparent rate of absorption of NMD from NMD-SSC (tmax=1.3h) was markedly faster than that from Nimotop (tmax=3.1h) (P<0.05), which indicates that as a fast release preparation, NMD-SSC is well absorbed.",Nimodipine semi-solid capsules containing solid dispersion for improving dissolution. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18499371/),h,1.3,146267,DB01373,Calcium
,18499371,tmax,"However, the apparent rate of absorption of NMD from NMD-SSC (tmax=1.3h) was markedly faster than that from Nimotop (tmax=3.1h) (P<0.05), which indicates that as a fast release preparation, NMD-SSC is well absorbed.",Nimodipine semi-solid capsules containing solid dispersion for improving dissolution. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18499371/),h,3.1,146268,DB01373,Calcium
,31188698,Cmax,"The results indicated that the Cmax increased from 36.84 ± 4.21 to 48.68 ± 6.35 ng/mL, and the AUC(0-t) increased from 135.82 ± 21.05 to 77.28 ± 12.92 ng h/mL, and t1/2 also increased from 2.62 ± 0.31 to 3.32 ± 0.57 h when GLT and AC were co-administered.",Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31188698/),[ng] / [ml],36.84,146673,DB01373,Calcium
,31188698,Cmax,"The results indicated that the Cmax increased from 36.84 ± 4.21 to 48.68 ± 6.35 ng/mL, and the AUC(0-t) increased from 135.82 ± 21.05 to 77.28 ± 12.92 ng h/mL, and t1/2 also increased from 2.62 ± 0.31 to 3.32 ± 0.57 h when GLT and AC were co-administered.",Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31188698/),[ng] / [ml],48.68,146674,DB01373,Calcium
,31188698,AUC(0-t),"The results indicated that the Cmax increased from 36.84 ± 4.21 to 48.68 ± 6.35 ng/mL, and the AUC(0-t) increased from 135.82 ± 21.05 to 77.28 ± 12.92 ng h/mL, and t1/2 also increased from 2.62 ± 0.31 to 3.32 ± 0.57 h when GLT and AC were co-administered.",Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31188698/),[h·ng] / [ml],135.82,146675,DB01373,Calcium
,31188698,AUC(0-t),"The results indicated that the Cmax increased from 36.84 ± 4.21 to 48.68 ± 6.35 ng/mL, and the AUC(0-t) increased from 135.82 ± 21.05 to 77.28 ± 12.92 ng h/mL, and t1/2 also increased from 2.62 ± 0.31 to 3.32 ± 0.57 h when GLT and AC were co-administered.",Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31188698/),[h·ng] / [ml],77.28,146676,DB01373,Calcium
,31188698,t1/2,"The results indicated that the Cmax increased from 36.84 ± 4.21 to 48.68 ± 6.35 ng/mL, and the AUC(0-t) increased from 135.82 ± 21.05 to 77.28 ± 12.92 ng h/mL, and t1/2 also increased from 2.62 ± 0.31 to 3.32 ± 0.57 h when GLT and AC were co-administered.",Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31188698/),h,2.62,146677,DB01373,Calcium
,31188698,t1/2,"The results indicated that the Cmax increased from 36.84 ± 4.21 to 48.68 ± 6.35 ng/mL, and the AUC(0-t) increased from 135.82 ± 21.05 to 77.28 ± 12.92 ng h/mL, and t1/2 also increased from 2.62 ± 0.31 to 3.32 ± 0.57 h when GLT and AC were co-administered.",Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31188698/),h,3.32,146678,DB01373,Calcium
,31188698,metabolic stability,The metabolic stability of AC was also increased (48.2 ± 6.7 vs. 36.7 ± 5.3 min) with the pre-treatment of GLT.,Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31188698/),min,48.2,146679,DB01373,Calcium
,31188698,metabolic stability,The metabolic stability of AC was also increased (48.2 ± 6.7 vs. 36.7 ± 5.3 min) with the pre-treatment of GLT.,Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31188698/),min,36.7,146680,DB01373,Calcium
,14744949,kinact,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),1/[min],0.39,146728,DB01373,Calcium
,14744949,kinact,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),μM,6.46,146729,DB01373,Calcium
,14744949,kinact,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),1/[min],0.64,146730,DB01373,Calcium
,14744949,kinact,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),1/[min],1.12,146731,DB01373,Calcium
,14744949,kinact,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),1/[min],0.07,146732,DB01373,Calcium
,14744949,KI,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),μM,6.46,146733,DB01373,Calcium
,14744949,KI,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),1/[min],1.12,146734,DB01373,Calcium
,14744949,KI,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),μM,5.89,146735,DB01373,Calcium
,14744949,KI,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),1/[min],0.07,146736,DB01373,Calcium
,14744949,KI,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),μM,7.93,146737,DB01373,Calcium
,14744949,unbound fraction,"The in vitro unbound fraction was 0.84 for S-verapamil, 0.68 for R-verapamil, and 0.84 for (+/-)-norverapamil.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),,0.84,146738,DB01373,Calcium
,14744949,unbound fraction,"The in vitro unbound fraction was 0.84 for S-verapamil, 0.68 for R-verapamil, and 0.84 for (+/-)-norverapamil.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),,0.68,146739,DB01373,Calcium
,14744949,fm,A mechanism-based pharmacokinetic model predicted that the oral area under the curve (AUC) of a CYP3A substrate that is eliminated completely (fm=1) by the hepatic CYP3A increased 1.6- to 2.2-fold after repeated oral administration of verapamil.,Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),,1,146740,DB01373,Calcium
,14744949,fm,"For midazolam (fm=0.9), a drug that undergoes extensive intestinal wall metabolism, the predicted increase in oral AUC was 3.2- to 4.5-fold.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),,0.9,146741,DB01373,Calcium
,22718749,limit of detection,"Calibration curves were constructed in concentration range of 0.01-20.0 ng/mL and limit of detection and limit of quantification values were found to be 0.68 and 2.30 pg/mL, respectively.",Determination of rosuvastatin at picogram level in serum by fluorimetric derivatization with 9-anthryldiazomethane using HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22718749/),[pg] / [ml],0.68,146836,DB01373,Calcium
,22718749,limit of quantification,"Calibration curves were constructed in concentration range of 0.01-20.0 ng/mL and limit of detection and limit of quantification values were found to be 0.68 and 2.30 pg/mL, respectively.",Determination of rosuvastatin at picogram level in serum by fluorimetric derivatization with 9-anthryldiazomethane using HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22718749/),[pg] / [ml],2.30,146837,DB01373,Calcium
,22718749,maximum plasma concentration,"To test suitability of the developed methods for clinic use, the pharmacokinetics of rosuvastatin were investigated after oral administration of a 20 mg rosuvastatin film tablet to a healthy volunteer and maximum plasma concentration, time to reach that concentration and elimination half life were found to be 17.5 ng/mL, 3.5 h and 18.09 h, respectively.",Determination of rosuvastatin at picogram level in serum by fluorimetric derivatization with 9-anthryldiazomethane using HPLC. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22718749/),[ng] / [ml],17.5,146838,DB01373,Calcium
,22718749,time to reach that concentration,"To test suitability of the developed methods for clinic use, the pharmacokinetics of rosuvastatin were investigated after oral administration of a 20 mg rosuvastatin film tablet to a healthy volunteer and maximum plasma concentration, time to reach that concentration and elimination half life were found to be 17.5 ng/mL, 3.5 h and 18.09 h, respectively.",Determination of rosuvastatin at picogram level in serum by fluorimetric derivatization with 9-anthryldiazomethane using HPLC. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22718749/),h,3.5,146839,DB01373,Calcium
,22718749,elimination half life,"To test suitability of the developed methods for clinic use, the pharmacokinetics of rosuvastatin were investigated after oral administration of a 20 mg rosuvastatin film tablet to a healthy volunteer and maximum plasma concentration, time to reach that concentration and elimination half life were found to be 17.5 ng/mL, 3.5 h and 18.09 h, respectively.",Determination of rosuvastatin at picogram level in serum by fluorimetric derivatization with 9-anthryldiazomethane using HPLC. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22718749/),h,18.09,146840,DB01373,Calcium
,12584860,RSD,"The within-day and between-days RSD (n = 5) were 5.25% and 8.97%, and the relative recoveries were 99.99% and 97.10% for R- and S-enantiomer, respectively.",[Studies on in-vivo process of the enantiomers of nicardipine in rabbit by coupled chiral and achiral HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584860/),%,5.25,147532,DB01373,Calcium
,12584860,RSD,"The within-day and between-days RSD (n = 5) were 5.25% and 8.97%, and the relative recoveries were 99.99% and 97.10% for R- and S-enantiomer, respectively.",[Studies on in-vivo process of the enantiomers of nicardipine in rabbit by coupled chiral and achiral HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584860/),%,8.97,147533,DB01373,Calcium
,12584860,relative recoveries,"The within-day and between-days RSD (n = 5) were 5.25% and 8.97%, and the relative recoveries were 99.99% and 97.10% for R- and S-enantiomer, respectively.",[Studies on in-vivo process of the enantiomers of nicardipine in rabbit by coupled chiral and achiral HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584860/),%,99.99,147534,DB01373,Calcium
,12584860,relative recoveries,"The within-day and between-days RSD (n = 5) were 5.25% and 8.97%, and the relative recoveries were 99.99% and 97.10% for R- and S-enantiomer, respectively.",[Studies on in-vivo process of the enantiomers of nicardipine in rabbit by coupled chiral and achiral HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584860/),%,97.10,147535,DB01373,Calcium
,12584860,Tmax,"The mean Tmax, Cmax and AUC values were (2.49 +/- 0.03) h, (134 +/- 2) ng.",[Studies on in-vivo process of the enantiomers of nicardipine in rabbit by coupled chiral and achiral HPLC]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584860/),h,2.49,147536,DB01373,Calcium
,19483319,bioavailability,"However, the decrease in bioavailability of ciprofloxacin was slight (15%) compared with that of tetracycline (30%).","Effect of a Kampo preparation, byakkokaninjinto, on pharmacokinetics of ciprofloxacin and tetracycline. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19483319/),%,15,147756,DB01373,Calcium
,19483319,bioavailability,"However, the decrease in bioavailability of ciprofloxacin was slight (15%) compared with that of tetracycline (30%).","Effect of a Kampo preparation, byakkokaninjinto, on pharmacokinetics of ciprofloxacin and tetracycline. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19483319/),%,30,147757,DB01373,Calcium
,28189955,detection limits,Linear calibration ranges were obtained in the range 0.05-2.0μgmL-1 for FLD and MET and 0.1-2.0μgmL-1 for RAM with detection limits of 0.013-0.031μgmL-1 for all the studied drug combinations.,Ultrasound assisted dispersive liquid-liquid microextraction coupled with high performance liquid chromatography designated for bioavailability studies of felodipine combinations in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28189955/),1/[μgml],0.013-0.031,147977,DB01373,Calcium
,18042475,C(max),"Geometric mean (SD) C(max) values of 10.22 (8.05), 25.86 (18.77), and 44.99 (17.99) ng/mL were achieved at a median T(max) of 2.5 hours after administration of single doses of 5, 10, and 20 mg of rosuvastatin, respectively; the corresponding geometric mean (SD) values of AUC(0-t) were 73.67 (48.78), 210.21 (178.70), and 303.81 (193.29) ng/mL . h(-1), and the mean (SD) apparent elimination t(1/2) values were 13.01 (8.68), 13.33 (5.21), and 15.40 (5.43) hours after administration.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [ml],10.22,148086,DB01373,Calcium
,18042475,C(max),"Geometric mean (SD) C(max) values of 10.22 (8.05), 25.86 (18.77), and 44.99 (17.99) ng/mL were achieved at a median T(max) of 2.5 hours after administration of single doses of 5, 10, and 20 mg of rosuvastatin, respectively; the corresponding geometric mean (SD) values of AUC(0-t) were 73.67 (48.78), 210.21 (178.70), and 303.81 (193.29) ng/mL . h(-1), and the mean (SD) apparent elimination t(1/2) values were 13.01 (8.68), 13.33 (5.21), and 15.40 (5.43) hours after administration.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [ml],25.86,148087,DB01373,Calcium
,18042475,C(max),"Geometric mean (SD) C(max) values of 10.22 (8.05), 25.86 (18.77), and 44.99 (17.99) ng/mL were achieved at a median T(max) of 2.5 hours after administration of single doses of 5, 10, and 20 mg of rosuvastatin, respectively; the corresponding geometric mean (SD) values of AUC(0-t) were 73.67 (48.78), 210.21 (178.70), and 303.81 (193.29) ng/mL . h(-1), and the mean (SD) apparent elimination t(1/2) values were 13.01 (8.68), 13.33 (5.21), and 15.40 (5.43) hours after administration.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [ml],44.99,148088,DB01373,Calcium
,18042475,T(max),"Geometric mean (SD) C(max) values of 10.22 (8.05), 25.86 (18.77), and 44.99 (17.99) ng/mL were achieved at a median T(max) of 2.5 hours after administration of single doses of 5, 10, and 20 mg of rosuvastatin, respectively; the corresponding geometric mean (SD) values of AUC(0-t) were 73.67 (48.78), 210.21 (178.70), and 303.81 (193.29) ng/mL . h(-1), and the mean (SD) apparent elimination t(1/2) values were 13.01 (8.68), 13.33 (5.21), and 15.40 (5.43) hours after administration.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),h,2.5,148089,DB01373,Calcium
,18042475,AUC(0-t),"Geometric mean (SD) C(max) values of 10.22 (8.05), 25.86 (18.77), and 44.99 (17.99) ng/mL were achieved at a median T(max) of 2.5 hours after administration of single doses of 5, 10, and 20 mg of rosuvastatin, respectively; the corresponding geometric mean (SD) values of AUC(0-t) were 73.67 (48.78), 210.21 (178.70), and 303.81 (193.29) ng/mL . h(-1), and the mean (SD) apparent elimination t(1/2) values were 13.01 (8.68), 13.33 (5.21), and 15.40 (5.43) hours after administration.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ml·ng] / [h],73.67,148090,DB01373,Calcium
,18042475,AUC(0-t),"Geometric mean (SD) C(max) values of 10.22 (8.05), 25.86 (18.77), and 44.99 (17.99) ng/mL were achieved at a median T(max) of 2.5 hours after administration of single doses of 5, 10, and 20 mg of rosuvastatin, respectively; the corresponding geometric mean (SD) values of AUC(0-t) were 73.67 (48.78), 210.21 (178.70), and 303.81 (193.29) ng/mL . h(-1), and the mean (SD) apparent elimination t(1/2) values were 13.01 (8.68), 13.33 (5.21), and 15.40 (5.43) hours after administration.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ml·ng] / [h],210.21,148091,DB01373,Calcium
,18042475,AUC(0-t),"Geometric mean (SD) C(max) values of 10.22 (8.05), 25.86 (18.77), and 44.99 (17.99) ng/mL were achieved at a median T(max) of 2.5 hours after administration of single doses of 5, 10, and 20 mg of rosuvastatin, respectively; the corresponding geometric mean (SD) values of AUC(0-t) were 73.67 (48.78), 210.21 (178.70), and 303.81 (193.29) ng/mL . h(-1), and the mean (SD) apparent elimination t(1/2) values were 13.01 (8.68), 13.33 (5.21), and 15.40 (5.43) hours after administration.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ml·ng] / [h],303.81,148092,DB01373,Calcium
,18042475,apparent elimination t(1/2),"Geometric mean (SD) C(max) values of 10.22 (8.05), 25.86 (18.77), and 44.99 (17.99) ng/mL were achieved at a median T(max) of 2.5 hours after administration of single doses of 5, 10, and 20 mg of rosuvastatin, respectively; the corresponding geometric mean (SD) values of AUC(0-t) were 73.67 (48.78), 210.21 (178.70), and 303.81 (193.29) ng/mL . h(-1), and the mean (SD) apparent elimination t(1/2) values were 13.01 (8.68), 13.33 (5.21), and 15.40 (5.43) hours after administration.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),h,13.01,148093,DB01373,Calcium
,18042475,apparent elimination t(1/2),"Geometric mean (SD) C(max) values of 10.22 (8.05), 25.86 (18.77), and 44.99 (17.99) ng/mL were achieved at a median T(max) of 2.5 hours after administration of single doses of 5, 10, and 20 mg of rosuvastatin, respectively; the corresponding geometric mean (SD) values of AUC(0-t) were 73.67 (48.78), 210.21 (178.70), and 303.81 (193.29) ng/mL . h(-1), and the mean (SD) apparent elimination t(1/2) values were 13.01 (8.68), 13.33 (5.21), and 15.40 (5.43) hours after administration.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),h,13.33,148094,DB01373,Calcium
,18042475,apparent elimination t(1/2),"Geometric mean (SD) C(max) values of 10.22 (8.05), 25.86 (18.77), and 44.99 (17.99) ng/mL were achieved at a median T(max) of 2.5 hours after administration of single doses of 5, 10, and 20 mg of rosuvastatin, respectively; the corresponding geometric mean (SD) values of AUC(0-t) were 73.67 (48.78), 210.21 (178.70), and 303.81 (193.29) ng/mL . h(-1), and the mean (SD) apparent elimination t(1/2) values were 13.01 (8.68), 13.33 (5.21), and 15.40 (5.43) hours after administration.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),h,15.40,148095,DB01373,Calcium
,18042475,C(max),"In men, the mean (SD) C(max) values were 7.57 (6.49), 20.43 (14.10), and 36.80 (15.64) ng/mL, and the mean (SD) AUC(0-t) values were 51.74 (33.92), 136.35 (97.18), and 232.25 (101.66) ng/mL x h(-1), with the 5-, 10-, and 20-mg doses of rosuvastatin, respectively.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [ml],7.57,148096,DB01373,Calcium
,18042475,C(max),"In men, the mean (SD) C(max) values were 7.57 (6.49), 20.43 (14.10), and 36.80 (15.64) ng/mL, and the mean (SD) AUC(0-t) values were 51.74 (33.92), 136.35 (97.18), and 232.25 (101.66) ng/mL x h(-1), with the 5-, 10-, and 20-mg doses of rosuvastatin, respectively.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [ml],20.43,148097,DB01373,Calcium
,18042475,C(max),"In men, the mean (SD) C(max) values were 7.57 (6.49), 20.43 (14.10), and 36.80 (15.64) ng/mL, and the mean (SD) AUC(0-t) values were 51.74 (33.92), 136.35 (97.18), and 232.25 (101.66) ng/mL x h(-1), with the 5-, 10-, and 20-mg doses of rosuvastatin, respectively.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [ml],36.80,148098,DB01373,Calcium
,18042475,AUC(0-t),"In men, the mean (SD) C(max) values were 7.57 (6.49), 20.43 (14.10), and 36.80 (15.64) ng/mL, and the mean (SD) AUC(0-t) values were 51.74 (33.92), 136.35 (97.18), and 232.25 (101.66) ng/mL x h(-1), with the 5-, 10-, and 20-mg doses of rosuvastatin, respectively.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ml·ng] / [h],51.74,148099,DB01373,Calcium
,18042475,AUC(0-t),"In men, the mean (SD) C(max) values were 7.57 (6.49), 20.43 (14.10), and 36.80 (15.64) ng/mL, and the mean (SD) AUC(0-t) values were 51.74 (33.92), 136.35 (97.18), and 232.25 (101.66) ng/mL x h(-1), with the 5-, 10-, and 20-mg doses of rosuvastatin, respectively.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ml·ng] / [h],136.35,148100,DB01373,Calcium
,18042475,AUC(0-t),"In men, the mean (SD) C(max) values were 7.57 (6.49), 20.43 (14.10), and 36.80 (15.64) ng/mL, and the mean (SD) AUC(0-t) values were 51.74 (33.92), 136.35 (97.18), and 232.25 (101.66) ng/mL x h(-1), with the 5-, 10-, and 20-mg doses of rosuvastatin, respectively.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ml·ng] / [h],232.25,148101,DB01373,Calcium
,18042475,C(max),"In women, the corresponding C(max) values were 13.40 (9.27), 32.44 (23.10), and 54.82 (16.78) ng/mL, and AUC(0-t) values were 99.99 (54.07), 298.85 (223.66), and 430.21 (194.61) ng/mL x h-1.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [ml],13.40,148102,DB01373,Calcium
,18042475,C(max),"In women, the corresponding C(max) values were 13.40 (9.27), 32.44 (23.10), and 54.82 (16.78) ng/mL, and AUC(0-t) values were 99.99 (54.07), 298.85 (223.66), and 430.21 (194.61) ng/mL x h-1.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [ml],32.44,148103,DB01373,Calcium
,18042475,C(max),"In women, the corresponding C(max) values were 13.40 (9.27), 32.44 (23.10), and 54.82 (16.78) ng/mL, and AUC(0-t) values were 99.99 (54.07), 298.85 (223.66), and 430.21 (194.61) ng/mL x h-1.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [ml],54.82,148104,DB01373,Calcium
,18042475,AUC(0-t),"In women, the corresponding C(max) values were 13.40 (9.27), 32.44 (23.10), and 54.82 (16.78) ng/mL, and AUC(0-t) values were 99.99 (54.07), 298.85 (223.66), and 430.21 (194.61) ng/mL x h-1.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [h·ml],99.99,148105,DB01373,Calcium
,18042475,AUC(0-t),"In women, the corresponding C(max) values were 13.40 (9.27), 32.44 (23.10), and 54.82 (16.78) ng/mL, and AUC(0-t) values were 99.99 (54.07), 298.85 (223.66), and 430.21 (194.61) ng/mL x h-1.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [h·ml],298.85,148106,DB01373,Calcium
,18042475,AUC(0-t),"In women, the corresponding C(max) values were 13.40 (9.27), 32.44 (23.10), and 54.82 (16.78) ng/mL, and AUC(0-t) values were 99.99 (54.07), 298.85 (223.66), and 430.21 (194.61) ng/mL x h-1.","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [h·ml],430.21,148107,DB01373,Calcium
,18042475,C(max),"However, C(max) and AUC(0-t) values of 0.82 ng/mL and 6.87 ng/mL x h-1, respectively, after oral administration of 10 mg of rosuvastatin in the fed state were significantly different from the corresponding values under fasting conditions (both, P < 0.05).","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [ml],0.82,148108,DB01373,Calcium
,18042475,AUC(0-t),"However, C(max) and AUC(0-t) values of 0.82 ng/mL and 6.87 ng/mL x h-1, respectively, after oral administration of 10 mg of rosuvastatin in the fed state were significantly different from the corresponding values under fasting conditions (both, P < 0.05).","Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042475/),[ng] / [h·ml],6.87,148109,DB01373,Calcium
,20953593,half-life,"The pharmacokinetics of teriparatide were characterized by rapid absorption (maximum concentration achieved within 30 min) and rapid elimination (half-life of 1 h), resulting in a total duration of exposure to the peptide of approximately 4 h.",Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20953593/),h,1,148812,DB01373,Calcium
,22993862,MPE,"MPE is 0.1% for scheme 6 and -0.6% for scheme 3, respectively.",[Modeling and simulation activities to design sampling scheme for population pharmacokinetic study on amlodipine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22993862/),%,0.1,150645,DB01373,Calcium
,22993862,MAPE,MAPE is 0.7% for both schemes.,[Modeling and simulation activities to design sampling scheme for population pharmacokinetic study on amlodipine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22993862/),,0,150646,DB01373,Calcium
,21737362,limit of detection (LOD),The limit of detection (LOD) was 2 ng mL(-1) (S/N = 3) with limit of quantification (LOQ) being 5 ng mL(-1).,Application of hollow fiber liquid phase microextraction coupled with high-performance liquid chromatography for the study of the osthole pharmacokinetics in cerebral ischemia hypoperfusion rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21737362/),[ng] / [ml],2,150665,DB01373,Calcium
,21737362,S/N,The limit of detection (LOD) was 2 ng mL(-1) (S/N = 3) with limit of quantification (LOQ) being 5 ng mL(-1).,Application of hollow fiber liquid phase microextraction coupled with high-performance liquid chromatography for the study of the osthole pharmacokinetics in cerebral ischemia hypoperfusion rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21737362/),,3,150666,DB01373,Calcium
,34286279,drug content,"The drug content of carbamazepine in CPH pectin formulations A and B was 95% and 96%, respectively.",A Pharmacokinetic Evaluation of a Pectin-Based Oral Multiparticulate Matrix Carrier of Carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286279/),,95,151380,DB01373,Calcium
,34286279,AUC0⟶36,"AUC0⟶36 (176.20 ± 7.97 µg.h/mL), C max (8.45 ± 0.71 μg/mL), T max (12 ± 1.28 h), and t 1/2 (13.75 ± 3.28 h) of formulation A showed a moderately enhanced and comparable pharmacokinetic profile to Tegretol CR® (AUC0⟶36: 155 ± 7.15 µg.h/mL, C max: 8.24 ± 0.45 μg/mL, T max: 8.0 ± 2.23 h, and t 1/2: 13.51 ± 2.87 h).",A Pharmacokinetic Evaluation of a Pectin-Based Oral Multiparticulate Matrix Carrier of Carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286279/),[h·μg] / [ml],176.20,151381,DB01373,Calcium
,34286279,C max,"AUC0⟶36 (176.20 ± 7.97 µg.h/mL), C max (8.45 ± 0.71 μg/mL), T max (12 ± 1.28 h), and t 1/2 (13.75 ± 3.28 h) of formulation A showed a moderately enhanced and comparable pharmacokinetic profile to Tegretol CR® (AUC0⟶36: 155 ± 7.15 µg.h/mL, C max: 8.24 ± 0.45 μg/mL, T max: 8.0 ± 2.23 h, and t 1/2: 13.51 ± 2.87 h).",A Pharmacokinetic Evaluation of a Pectin-Based Oral Multiparticulate Matrix Carrier of Carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286279/),[μg] / [ml],8.45,151382,DB01373,Calcium
,34286279,T max,"AUC0⟶36 (176.20 ± 7.97 µg.h/mL), C max (8.45 ± 0.71 μg/mL), T max (12 ± 1.28 h), and t 1/2 (13.75 ± 3.28 h) of formulation A showed a moderately enhanced and comparable pharmacokinetic profile to Tegretol CR® (AUC0⟶36: 155 ± 7.15 µg.h/mL, C max: 8.24 ± 0.45 μg/mL, T max: 8.0 ± 2.23 h, and t 1/2: 13.51 ± 2.87 h).",A Pharmacokinetic Evaluation of a Pectin-Based Oral Multiparticulate Matrix Carrier of Carbamazepine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286279/),h,12,151383,DB01373,Calcium
,34286279,t 1/2,"AUC0⟶36 (176.20 ± 7.97 µg.h/mL), C max (8.45 ± 0.71 μg/mL), T max (12 ± 1.28 h), and t 1/2 (13.75 ± 3.28 h) of formulation A showed a moderately enhanced and comparable pharmacokinetic profile to Tegretol CR® (AUC0⟶36: 155 ± 7.15 µg.h/mL, C max: 8.24 ± 0.45 μg/mL, T max: 8.0 ± 2.23 h, and t 1/2: 13.51 ± 2.87 h).",A Pharmacokinetic Evaluation of a Pectin-Based Oral Multiparticulate Matrix Carrier of Carbamazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286279/),h,13.75,151384,DB01373,Calcium
,34286279,AUC0⟶36,"AUC0⟶36 (176.20 ± 7.97 µg.h/mL), C max (8.45 ± 0.71 μg/mL), T max (12 ± 1.28 h), and t 1/2 (13.75 ± 3.28 h) of formulation A showed a moderately enhanced and comparable pharmacokinetic profile to Tegretol CR® (AUC0⟶36: 155 ± 7.15 µg.h/mL, C max: 8.24 ± 0.45 μg/mL, T max: 8.0 ± 2.23 h, and t 1/2: 13.51 ± 2.87 h).",A Pharmacokinetic Evaluation of a Pectin-Based Oral Multiparticulate Matrix Carrier of Carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286279/),[h·μg] / [ml],155,151385,DB01373,Calcium
,34286279,C max,"AUC0⟶36 (176.20 ± 7.97 µg.h/mL), C max (8.45 ± 0.71 μg/mL), T max (12 ± 1.28 h), and t 1/2 (13.75 ± 3.28 h) of formulation A showed a moderately enhanced and comparable pharmacokinetic profile to Tegretol CR® (AUC0⟶36: 155 ± 7.15 µg.h/mL, C max: 8.24 ± 0.45 μg/mL, T max: 8.0 ± 2.23 h, and t 1/2: 13.51 ± 2.87 h).",A Pharmacokinetic Evaluation of a Pectin-Based Oral Multiparticulate Matrix Carrier of Carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286279/),[μg] / [ml],8.24,151386,DB01373,Calcium
,34286279,T max,"AUC0⟶36 (176.20 ± 7.97 µg.h/mL), C max (8.45 ± 0.71 μg/mL), T max (12 ± 1.28 h), and t 1/2 (13.75 ± 3.28 h) of formulation A showed a moderately enhanced and comparable pharmacokinetic profile to Tegretol CR® (AUC0⟶36: 155 ± 7.15 µg.h/mL, C max: 8.24 ± 0.45 μg/mL, T max: 8.0 ± 2.23 h, and t 1/2: 13.51 ± 2.87 h).",A Pharmacokinetic Evaluation of a Pectin-Based Oral Multiparticulate Matrix Carrier of Carbamazepine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286279/),h,8.0,151387,DB01373,Calcium
,34286279,t 1/2,"AUC0⟶36 (176.20 ± 7.97 µg.h/mL), C max (8.45 ± 0.71 μg/mL), T max (12 ± 1.28 h), and t 1/2 (13.75 ± 3.28 h) of formulation A showed a moderately enhanced and comparable pharmacokinetic profile to Tegretol CR® (AUC0⟶36: 155 ± 7.15 µg.h/mL, C max: 8.24 ± 0.45 μg/mL, T max: 8.0 ± 2.23 h, and t 1/2: 13.51 ± 2.87 h).",A Pharmacokinetic Evaluation of a Pectin-Based Oral Multiparticulate Matrix Carrier of Carbamazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286279/),h,13.51,151388,DB01373,Calcium
,26406153,particle size,The particle size of optimum formulation was 22.8 ± 4.0 nm.,Design and evaluation of oral nanoemulsion drug delivery system of mebudipine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26406153/),,22.8,151552,DB01373,Calcium
,14512129,maximum plasma concentration (C(max)),"Geometric mean rosuvastatin maximum plasma concentration (C(max)) values of 3.75, 6.79, 10.3, and 30.1 ng/mL were achieved at a median time to C(max) of 5.0 hours after doses of 10, 20, 40, and 80 mg, respectively.","A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512129/),[ng] / [ml],3.75,152364,DB01373,Calcium
,14512129,maximum plasma concentration (C(max)),"Geometric mean rosuvastatin maximum plasma concentration (C(max)) values of 3.75, 6.79, 10.3, and 30.1 ng/mL were achieved at a median time to C(max) of 5.0 hours after doses of 10, 20, 40, and 80 mg, respectively.","A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512129/),[ng] / [ml],6.79,152365,DB01373,Calcium
,14512129,maximum plasma concentration (C(max)),"Geometric mean rosuvastatin maximum plasma concentration (C(max)) values of 3.75, 6.79, 10.3, and 30.1 ng/mL were achieved at a median time to C(max) of 5.0 hours after doses of 10, 20, 40, and 80 mg, respectively.","A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512129/),[ng] / [ml],10.3,152366,DB01373,Calcium
,14512129,maximum plasma concentration (C(max)),"Geometric mean rosuvastatin maximum plasma concentration (C(max)) values of 3.75, 6.79, 10.3, and 30.1 ng/mL were achieved at a median time to C(max) of 5.0 hours after doses of 10, 20, 40, and 80 mg, respectively.","A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512129/),[ng] / [ml],30.1,152367,DB01373,Calcium
,14512129,time to C(max),"Geometric mean rosuvastatin maximum plasma concentration (C(max)) values of 3.75, 6.79, 10.3, and 30.1 ng/mL were achieved at a median time to C(max) of 5.0 hours after doses of 10, 20, 40, and 80 mg, respectively.","A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512129/),h,5.0,152368,DB01373,Calcium
,14512129,area under the plasma concentration-time curve from time 0 to time of the last measurable concentration (AUC(0-t)),"The corresponding geometric mean values for rosuvastatin area under the plasma concentration-time curve from time 0 to time of the last measurable concentration (AUC(0-t)) were 31.6, 56.8, 98.2, and 268 ng.h/mL.","A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512129/),[h·ng] / [ml],31.6,152369,DB01373,Calcium
,14512129,area under the plasma concentration-time curve from time 0 to time of the last measurable concentration (AUC(0-t)),"The corresponding geometric mean values for rosuvastatin area under the plasma concentration-time curve from time 0 to time of the last measurable concentration (AUC(0-t)) were 31.6, 56.8, 98.2, and 268 ng.h/mL.","A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512129/),[h·ng] / [ml],56.8,152370,DB01373,Calcium
,14512129,area under the plasma concentration-time curve from time 0 to time of the last measurable concentration (AUC(0-t)),"The corresponding geometric mean values for rosuvastatin area under the plasma concentration-time curve from time 0 to time of the last measurable concentration (AUC(0-t)) were 31.6, 56.8, 98.2, and 268 ng.h/mL.","A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512129/),[h·ng] / [ml],98.2,152371,DB01373,Calcium
,14512129,area under the plasma concentration-time curve from time 0 to time of the last measurable concentration (AUC(0-t)),"The corresponding geometric mean values for rosuvastatin area under the plasma concentration-time curve from time 0 to time of the last measurable concentration (AUC(0-t)) were 31.6, 56.8, 98.2, and 268 ng.h/mL.","A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512129/),[h·ng] / [ml],268,152372,DB01373,Calcium
,31004346,terminal half-life,"The maximum plasma concentration (Cmax ) was reached within 3 to 4 hours (≤60 mg) and within 20 to 28 hours (>60 mg), and across all dose levels the terminal half-life (95% confidence interval) ranged from 36 (29-45) to 43 (22-86) hours.","First-in-man study of ACT-709478, a novel selective triple T-type calcium channel blocker. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31004346/),h,36,152994,DB01373,Calcium
,31004346,terminal half-life,"The maximum plasma concentration (Cmax ) was reached within 3 to 4 hours (≤60 mg) and within 20 to 28 hours (>60 mg), and across all dose levels the terminal half-life (95% confidence interval) ranged from 36 (29-45) to 43 (22-86) hours.","First-in-man study of ACT-709478, a novel selective triple T-type calcium channel blocker. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31004346/),h,43,152995,DB01373,Calcium
,18196225,heart rate nadir,"The daytime mean heart rate nadir was 15% lower when fingolimod was combined with atenolol (42 +/- 7 bpm) compared with fingolimod alone (51 +/- 9 bpm) yielding a combination/monotherapy ratio of 0.85 (90%CI, 0.79-0.92).",The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18196225/),bpm,42,153037,DB01373,Calcium
,18196225,heart rate nadir,"The daytime mean heart rate nadir was 15% lower when fingolimod was combined with atenolol (42 +/- 7 bpm) compared with fingolimod alone (51 +/- 9 bpm) yielding a combination/monotherapy ratio of 0.85 (90%CI, 0.79-0.92).",The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18196225/),bpm,51,153038,DB01373,Calcium
,18196225,heart rate nadir,The daytime mean heart rate nadir from fingolimod alone (55 +/- 5 bpm) was not altered when combined with diltiazem (56 +/- 8 bpm) yielding a ratio of 0.99 (0.94-1.05).,The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18196225/),bpm,55,153039,DB01373,Calcium
,18196225,heart rate nadir,The daytime mean heart rate nadir from fingolimod alone (55 +/- 5 bpm) was not altered when combined with diltiazem (56 +/- 8 bpm) yielding a ratio of 0.99 (0.94-1.05).,The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18196225/),bpm,56,153040,DB01373,Calcium
,15908031,percentage released,"In vitro release study showed that the percentage released of GM from each preparation per 2 h was 99.8+/-0.06% for Florite RE 10 mg, 96.7+/-1.16% for Florite RE 20 mg, 98.3+/-0.32% for Neusilin US2, and 94.4+/-0.23% for Sylysia 320.",Oral solid gentamicin preparation using emulsifier and adsorbent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908031/),%,99.8,153147,DB01373,Calcium
,15908031,percentage released,"In vitro release study showed that the percentage released of GM from each preparation per 2 h was 99.8+/-0.06% for Florite RE 10 mg, 96.7+/-1.16% for Florite RE 20 mg, 98.3+/-0.32% for Neusilin US2, and 94.4+/-0.23% for Sylysia 320.",Oral solid gentamicin preparation using emulsifier and adsorbent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908031/),%,96.7,153148,DB01373,Calcium
,15908031,percentage released,"In vitro release study showed that the percentage released of GM from each preparation per 2 h was 99.8+/-0.06% for Florite RE 10 mg, 96.7+/-1.16% for Florite RE 20 mg, 98.3+/-0.32% for Neusilin US2, and 94.4+/-0.23% for Sylysia 320.",Oral solid gentamicin preparation using emulsifier and adsorbent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908031/),%,98.3,153149,DB01373,Calcium
,15908031,percentage released,"In vitro release study showed that the percentage released of GM from each preparation per 2 h was 99.8+/-0.06% for Florite RE 10 mg, 96.7+/-1.16% for Florite RE 20 mg, 98.3+/-0.32% for Neusilin US2, and 94.4+/-0.23% for Sylysia 320.",Oral solid gentamicin preparation using emulsifier and adsorbent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908031/),%,94.4,153150,DB01373,Calcium
,15908031,T50%,"The T50% values were 0.35+/-0.05 h for Florite RE 10 mg, 0.34+/-0.03 h for Florite RE 20 mg, 0.26+/-0.03 h for Neusilin US2, and 0.15+/-0.01 h for Sylysia 320.",Oral solid gentamicin preparation using emulsifier and adsorbent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908031/),h,0.35,153151,DB01373,Calcium
,15908031,T50%,"The T50% values were 0.35+/-0.05 h for Florite RE 10 mg, 0.34+/-0.03 h for Florite RE 20 mg, 0.26+/-0.03 h for Neusilin US2, and 0.15+/-0.01 h for Sylysia 320.",Oral solid gentamicin preparation using emulsifier and adsorbent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908031/),h,0.34,153152,DB01373,Calcium
,15908031,T50%,"The T50% values were 0.35+/-0.05 h for Florite RE 10 mg, 0.34+/-0.03 h for Florite RE 20 mg, 0.26+/-0.03 h for Neusilin US2, and 0.15+/-0.01 h for Sylysia 320.",Oral solid gentamicin preparation using emulsifier and adsorbent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908031/),h,0.26,153153,DB01373,Calcium
,15908031,T50%,"The T50% values were 0.35+/-0.05 h for Florite RE 10 mg, 0.34+/-0.03 h for Florite RE 20 mg, 0.26+/-0.03 h for Neusilin US2, and 0.15+/-0.01 h for Sylysia 320.",Oral solid gentamicin preparation using emulsifier and adsorbent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908031/),h,0.15,153154,DB01373,Calcium
,15908031,C(max),The in vivo rat absorption study showed that Florite RE 10 mg preparation had the highest C(max) (2.14+/-0.67 microg/ml) and AUC (4.74+/-1.21 microg h/ml).,Oral solid gentamicin preparation using emulsifier and adsorbent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908031/),[μg] / [ml],2.14,153155,DB01373,Calcium
,15908031,AUC,The in vivo rat absorption study showed that Florite RE 10 mg preparation had the highest C(max) (2.14+/-0.67 microg/ml) and AUC (4.74+/-1.21 microg h/ml).,Oral solid gentamicin preparation using emulsifier and adsorbent. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908031/),[h·μg] / [ml],4.74,153156,DB01373,Calcium
,15908031,C(max),"Other preparations had C(max) and AUC of 0.69+/-0.10 microg/ml and 1.56+/-0.43 microg h/ml for Florite RE 20 mg, 1.07+/-0.31 microg/ml and 1.80+/-0.33 microg h/ml for Neusilin US2, and 0.99+/-0.21 microg/ml and 1.77+/-0.50 micorg h/ml for Sylysia 320, respectively.",Oral solid gentamicin preparation using emulsifier and adsorbent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908031/),[μg] / [ml],0.69,153157,DB01373,Calcium
,15908031,C(max),"Other preparations had C(max) and AUC of 0.69+/-0.10 microg/ml and 1.56+/-0.43 microg h/ml for Florite RE 20 mg, 1.07+/-0.31 microg/ml and 1.80+/-0.33 microg h/ml for Neusilin US2, and 0.99+/-0.21 microg/ml and 1.77+/-0.50 micorg h/ml for Sylysia 320, respectively.",Oral solid gentamicin preparation using emulsifier and adsorbent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908031/),[μg] / [ml],1.07,153158,DB01373,Calcium
,15908031,C(max),"Other preparations had C(max) and AUC of 0.69+/-0.10 microg/ml and 1.56+/-0.43 microg h/ml for Florite RE 20 mg, 1.07+/-0.31 microg/ml and 1.80+/-0.33 microg h/ml for Neusilin US2, and 0.99+/-0.21 microg/ml and 1.77+/-0.50 micorg h/ml for Sylysia 320, respectively.",Oral solid gentamicin preparation using emulsifier and adsorbent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908031/),[μg] / [ml],0.99,153159,DB01373,Calcium
,15908031,AUC,"Other preparations had C(max) and AUC of 0.69+/-0.10 microg/ml and 1.56+/-0.43 microg h/ml for Florite RE 20 mg, 1.07+/-0.31 microg/ml and 1.80+/-0.33 microg h/ml for Neusilin US2, and 0.99+/-0.21 microg/ml and 1.77+/-0.50 micorg h/ml for Sylysia 320, respectively.",Oral solid gentamicin preparation using emulsifier and adsorbent. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908031/),[h·μg] / [ml],1.56,153160,DB01373,Calcium
,15908031,AUC,"Other preparations had C(max) and AUC of 0.69+/-0.10 microg/ml and 1.56+/-0.43 microg h/ml for Florite RE 20 mg, 1.07+/-0.31 microg/ml and 1.80+/-0.33 microg h/ml for Neusilin US2, and 0.99+/-0.21 microg/ml and 1.77+/-0.50 micorg h/ml for Sylysia 320, respectively.",Oral solid gentamicin preparation using emulsifier and adsorbent. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908031/),[h·μg] / [ml],1.80,153161,DB01373,Calcium
,15908031,AUC,"Other preparations had C(max) and AUC of 0.69+/-0.10 microg/ml and 1.56+/-0.43 microg h/ml for Florite RE 20 mg, 1.07+/-0.31 microg/ml and 1.80+/-0.33 microg h/ml for Neusilin US2, and 0.99+/-0.21 microg/ml and 1.77+/-0.50 micorg h/ml for Sylysia 320, respectively.",Oral solid gentamicin preparation using emulsifier and adsorbent. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908031/),[μg] / [ml],0.99,153162,DB01373,Calcium
,15908031,AUC,"Other preparations had C(max) and AUC of 0.69+/-0.10 microg/ml and 1.56+/-0.43 microg h/ml for Florite RE 20 mg, 1.07+/-0.31 microg/ml and 1.80+/-0.33 microg h/ml for Neusilin US2, and 0.99+/-0.21 microg/ml and 1.77+/-0.50 micorg h/ml for Sylysia 320, respectively.",Oral solid gentamicin preparation using emulsifier and adsorbent. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908031/),[h·micorg] / [ml],1.77,153163,DB01373,Calcium
,15908031,bioavailability (BA),"The bioavailability (BA) of GM from the microporous calcium silicate preparation, Florite RE 10 mg, was 14.1% in rats, derived by comparing the AUC obtained after intravenous injection of GM, 1.0 mg/kg, to another group of rats.",Oral solid gentamicin preparation using emulsifier and adsorbent. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908031/),%,14.1,153164,DB01373,Calcium
,15908031,C(max),"High plasma GM levels were obtained (i.e., the C(max) was 1.26+/-0.20 microg/ml and the AUC was 2.59+/-0.33 microg h/ml).",Oral solid gentamicin preparation using emulsifier and adsorbent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908031/),[μg] / [ml],1.26,153165,DB01373,Calcium
,15908031,AUC,"High plasma GM levels were obtained (i.e., the C(max) was 1.26+/-0.20 microg/ml and the AUC was 2.59+/-0.33 microg h/ml).",Oral solid gentamicin preparation using emulsifier and adsorbent. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908031/),[h·μg] / [ml],2.59,153166,DB01373,Calcium
,31969307,Cmax,"The Cmax (29.07 ± 6.88 ng/mL), [AUC]xo (206.65 ± 55.27 ng/hr/mL) and CL/F (3275.26 ± 1072.87 mL/hr) were slightly higher in our study, whereas the values of Vd (19377.23 ± 9114.29 mL) and tmax (3.0 ± 0.46 hr) were comparatively smaller.",Rosuvastatin pharmacokinetics in Pakistani healthy volunteers in comparison with other population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969307/),[ng] / [ml],29.07,153204,DB01373,Calcium
,31969307,[AUC]xo,"The Cmax (29.07 ± 6.88 ng/mL), [AUC]xo (206.65 ± 55.27 ng/hr/mL) and CL/F (3275.26 ± 1072.87 mL/hr) were slightly higher in our study, whereas the values of Vd (19377.23 ± 9114.29 mL) and tmax (3.0 ± 0.46 hr) were comparatively smaller.",Rosuvastatin pharmacokinetics in Pakistani healthy volunteers in comparison with other population. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969307/),[ng] / [h·ml],206.65,153205,DB01373,Calcium
,31969307,CL/F,"The Cmax (29.07 ± 6.88 ng/mL), [AUC]xo (206.65 ± 55.27 ng/hr/mL) and CL/F (3275.26 ± 1072.87 mL/hr) were slightly higher in our study, whereas the values of Vd (19377.23 ± 9114.29 mL) and tmax (3.0 ± 0.46 hr) were comparatively smaller.",Rosuvastatin pharmacokinetics in Pakistani healthy volunteers in comparison with other population. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969307/),[ml] / [h],3275.26,153206,DB01373,Calcium
,31969307,Vd,"The Cmax (29.07 ± 6.88 ng/mL), [AUC]xo (206.65 ± 55.27 ng/hr/mL) and CL/F (3275.26 ± 1072.87 mL/hr) were slightly higher in our study, whereas the values of Vd (19377.23 ± 9114.29 mL) and tmax (3.0 ± 0.46 hr) were comparatively smaller.",Rosuvastatin pharmacokinetics in Pakistani healthy volunteers in comparison with other population. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969307/),ml,19377.23,153207,DB01373,Calcium
,31969307,tmax,"The Cmax (29.07 ± 6.88 ng/mL), [AUC]xo (206.65 ± 55.27 ng/hr/mL) and CL/F (3275.26 ± 1072.87 mL/hr) were slightly higher in our study, whereas the values of Vd (19377.23 ± 9114.29 mL) and tmax (3.0 ± 0.46 hr) were comparatively smaller.",Rosuvastatin pharmacokinetics in Pakistani healthy volunteers in comparison with other population. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969307/),h,3.0,153208,DB01373,Calcium
,15558528,oral clearance,"Median oral clearance ranged from 222 to 599 L/h, and median time after dosing when C max occurred ranged from 2 to 3 hours across all doses.","Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15558528/),[l] / [h],222 to 599,153700,DB01373,Calcium
,15558528,time after dosing when C max occurred,"Median oral clearance ranged from 222 to 599 L/h, and median time after dosing when C max occurred ranged from 2 to 3 hours across all doses.","Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15558528/),h,2 to 3,153701,DB01373,Calcium
,19821575,volume of distribution (V(dss),"The lack of a bone building effect for analogue 3 was attributed to the large volume of distribution (V(dss)(rat) = 11 L/kg), producing a protracted plasma PTH profile.",Antagonists of the calcium receptor. 2. Amino alcohol-based parathyroid hormone secretagogues. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19821575/),[l] / [kg],11,153980,DB01373,Calcium
,19821575,volume of distribution (V(dss)(12),Incorporation of a carboxylic acid functionality into the amino alcohol template led to the identification of 12 with a lower volume of distribution (V(dss)(12) = 1.18 L/kg) and a shorter half-life.,Antagonists of the calcium receptor. 2. Amino alcohol-based parathyroid hormone secretagogues. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19821575/),[l] / [kg],1.18,153981,DB01373,Calcium
,22784220,Peff,"Estimated Peff ranged 0.16-44.16 × 10(-4) cm/s, while reported fraction unbound to plasma proteins (fu) ranged 0.01-0.99 for the drugs under investigation.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),[cm] / [s],0.16-44.16 × 10(-4),154149,DB01373,Calcium
,22784220,fraction unbound to plasma proteins (fu),"Estimated Peff ranged 0.16-44.16 × 10(-4) cm/s, while reported fraction unbound to plasma proteins (fu) ranged 0.01-0.99 for the drugs under investigation.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),,0.01-0.99,154150,DB01373,Calcium
,22784220,Saliva/plasma concentrations ratios,"Saliva/plasma concentrations ratios ranged 0.11-13.4, in agreement with drug protein binding and permeability.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),,0.11-13.4,154151,DB01373,Calcium
,15607710,limit of detection,"The coefficient of variation of the precision of the assay was less than 8%, the assay accuracy was between 93.4 and 113.3%, and the limit of detection was 0.05 ng/ml for 1 ml of plasma.",Analysis of benidipine enantiomers in human plasma by liquid chromatography-mass spectrometry using a macrocyclic antibiotic (Vancomycin) chiral stationary phase column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15607710/),[ng] / [ml],0.05,154294,DB01373,Calcium
,11981071,bioavailability,"After oral administration of 1,25(OH)(2)D(3) the bioavailability of 1,25(OH)(2)D(3) was 70.6+/-5.8/72.2+/-4.8% in healthy volunteers/uraemic patients (n.s.).","Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981071/),%,70.6,154805,DB01373,Calcium
,11981071,bioavailability,"After oral administration of 1,25(OH)(2)D(3) the bioavailability of 1,25(OH)(2)D(3) was 70.6+/-5.8/72.2+/-4.8% in healthy volunteers/uraemic patients (n.s.).","Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981071/),%,72.2,154806,DB01373,Calcium
,11981071,volume of distribution,"After i.v. administration the volume of distribution of 1,25(OH)(2)D(3) was similar, 0.49+/-0.14 vs 0.27+/-0.06 l/kg in healthy volunteers vs uraemic patients (n.s.), while the metabolic clearance rate of 1,25(OH)(2)D(3) was 57% lower in the uraemic patients, 23.5+/-4.34 vs 10.1+/-1.35 ml/min in healthy volunteers vs uraemic patients, respectively (P<0.03).","Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981071/),[l] / [kg],0.49,154807,DB01373,Calcium
,11981071,volume of distribution,"After i.v. administration the volume of distribution of 1,25(OH)(2)D(3) was similar, 0.49+/-0.14 vs 0.27+/-0.06 l/kg in healthy volunteers vs uraemic patients (n.s.), while the metabolic clearance rate of 1,25(OH)(2)D(3) was 57% lower in the uraemic patients, 23.5+/-4.34 vs 10.1+/-1.35 ml/min in healthy volunteers vs uraemic patients, respectively (P<0.03).","Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981071/),[l] / [kg],0.27,154808,DB01373,Calcium
,11981071,metabolic clearance rate,"After i.v. administration the volume of distribution of 1,25(OH)(2)D(3) was similar, 0.49+/-0.14 vs 0.27+/-0.06 l/kg in healthy volunteers vs uraemic patients (n.s.), while the metabolic clearance rate of 1,25(OH)(2)D(3) was 57% lower in the uraemic patients, 23.5+/-4.34 vs 10.1+/-1.35 ml/min in healthy volunteers vs uraemic patients, respectively (P<0.03).","Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981071/),[ml] / [min],23.5,154809,DB01373,Calcium
,11981071,metabolic clearance rate,"After i.v. administration the volume of distribution of 1,25(OH)(2)D(3) was similar, 0.49+/-0.14 vs 0.27+/-0.06 l/kg in healthy volunteers vs uraemic patients (n.s.), while the metabolic clearance rate of 1,25(OH)(2)D(3) was 57% lower in the uraemic patients, 23.5+/-4.34 vs 10.1+/-1.35 ml/min in healthy volunteers vs uraemic patients, respectively (P<0.03).","Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981071/),[ml] / [min],10.1,154810,DB01373,Calcium
,11981071,bioavailability,"The bioavailability of 1,25(OH)(2)D(3) after i.v. administration of 1alpha(OH)D(3) was 42.4+/-11.0/42.0+/-2.0% in healthy volunteers/uraemic patients (n.s.); and after oral administration of 1alpha(OH)D(3) 42.0+/-2.0/29.8+/-3.1% in healthy volunteers/uraemic patients (n.s.).","Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981071/),%,42.4,154811,DB01373,Calcium
,11981071,bioavailability,"The bioavailability of 1,25(OH)(2)D(3) after i.v. administration of 1alpha(OH)D(3) was 42.4+/-11.0/42.0+/-2.0% in healthy volunteers/uraemic patients (n.s.); and after oral administration of 1alpha(OH)D(3) 42.0+/-2.0/29.8+/-3.1% in healthy volunteers/uraemic patients (n.s.).","Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981071/),%,42.0,154812,DB01373,Calcium
,11981071,bioavailability,"The bioavailability of 1,25(OH)(2)D(3) after i.v. administration of 1alpha(OH)D(3) was 42.4+/-11.0/42.0+/-2.0% in healthy volunteers/uraemic patients (n.s.); and after oral administration of 1alpha(OH)D(3) 42.0+/-2.0/29.8+/-3.1% in healthy volunteers/uraemic patients (n.s.).","Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981071/),%,29.8,154813,DB01373,Calcium
,27174018,IC50,"3. Inhibition study using rosuvastatin as the substrate in OATP1B1- and OATP1B3-transfected cells indicated that curcumin was an OATP1B1 and 1B3 inhibitor, with IC50 at 5.19 ± 0.05 and 3.68 ± 0.05 μM, respectively; the data for COG were 1.04 ± 0.01 and 1.08 ± 0.02 μM, respectively.",Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27174018/),μM,5.19,155201,DB01373,Calcium
,27174018,IC50,"3. Inhibition study using rosuvastatin as the substrate in OATP1B1- and OATP1B3-transfected cells indicated that curcumin was an OATP1B1 and 1B3 inhibitor, with IC50 at 5.19 ± 0.05 and 3.68 ± 0.05 μM, respectively; the data for COG were 1.04 ± 0.01 and 1.08 ± 0.02 μM, respectively.",Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27174018/),μM,3.68,155202,DB01373,Calcium
,27174018,IC50,"3. Inhibition study using rosuvastatin as the substrate in OATP1B1- and OATP1B3-transfected cells indicated that curcumin was an OATP1B1 and 1B3 inhibitor, with IC50 at 5.19 ± 0.05 and 3.68 ± 0.05 μM, respectively; the data for COG were 1.04 ± 0.01 and 1.08 ± 0.02 μM, respectively.",Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27174018/),μM,1.04,155203,DB01373,Calcium
,27174018,IC50,"3. Inhibition study using rosuvastatin as the substrate in OATP1B1- and OATP1B3-transfected cells indicated that curcumin was an OATP1B1 and 1B3 inhibitor, with IC50 at 5.19 ± 0.05 and 3.68 ± 0.05 μM, respectively; the data for COG were 1.04 ± 0.01 and 1.08 ± 0.02 μM, respectively.",Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27174018/),μM,1.08,155204,DB01373,Calcium
,17668921,bioavailability,"The MCH1 receptor antagonists 5m and (S)-6b show reasonable pharmacokinetic profiles (rat bioavailability = 48 and 81%, respectively).",Synthesis and SAR investigations for novel melanin-concentrating hormone 1 receptor (MCH1) antagonists Part 1. The discovery of arylacetamides as viable replacements for the dihydropyrimidinone moiety of an HTS hit. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17668921/),%,48,155639,DB01373,Calcium
,17668921,bioavailability,"The MCH1 receptor antagonists 5m and (S)-6b show reasonable pharmacokinetic profiles (rat bioavailability = 48 and 81%, respectively).",Synthesis and SAR investigations for novel melanin-concentrating hormone 1 receptor (MCH1) antagonists Part 1. The discovery of arylacetamides as viable replacements for the dihydropyrimidinone moiety of an HTS hit. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17668921/),%,81,155640,DB01373,Calcium
,17668921,minimum effective dose,"Compounds 5m and (S)-6b demonstrated the inhibition of a centrally administered MCH-evoked drinking effect, and compound 5m exhibited oral in vivo efficacy in the rat social interaction model of anxiety, with a minimum effective dose = 0.3 mg/kg.",Synthesis and SAR investigations for novel melanin-concentrating hormone 1 receptor (MCH1) antagonists Part 1. The discovery of arylacetamides as viable replacements for the dihydropyrimidinone moiety of an HTS hit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17668921/),[mg] / [kg],0.3,155641,DB01373,Calcium
,23484100,Tmax,"Fosteum and the Squadrito study formulation were equivalent for genistein Tmax (2 hrs), Cmax (0.7 μM), T1/2 (18 ± 6.9 versus 21 ± 4.9 hrs), and AUC (9221 ± 413 versus 9818 ± 1370 ng·hr/mL).",The steady-state serum concentration of genistein aglycone is affected by formulation: a bioequivalence study of bone products. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23484100/),h,2,156369,DB01373,Calcium
,23484100,Cmax,"Fosteum and the Squadrito study formulation were equivalent for genistein Tmax (2 hrs), Cmax (0.7 μM), T1/2 (18 ± 6.9 versus 21 ± 4.9 hrs), and AUC (9221 ± 413 versus 9818 ± 1370 ng·hr/mL).",The steady-state serum concentration of genistein aglycone is affected by formulation: a bioequivalence study of bone products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23484100/),μM,0.7,156370,DB01373,Calcium
,23484100,T1/2,"Fosteum and the Squadrito study formulation were equivalent for genistein Tmax (2 hrs), Cmax (0.7 μM), T1/2 (18 ± 6.9 versus 21 ± 4.9 hrs), and AUC (9221 ± 413 versus 9818 ± 1370 ng·hr/mL).",The steady-state serum concentration of genistein aglycone is affected by formulation: a bioequivalence study of bone products. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23484100/),h,18,156371,DB01373,Calcium
,23484100,T1/2,"Fosteum and the Squadrito study formulation were equivalent for genistein Tmax (2 hrs), Cmax (0.7 μM), T1/2 (18 ± 6.9 versus 21 ± 4.9 hrs), and AUC (9221 ± 413 versus 9818 ± 1370 ng·hr/mL).",The steady-state serum concentration of genistein aglycone is affected by formulation: a bioequivalence study of bone products. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23484100/),h,21,156372,DB01373,Calcium
,23484100,AUC,"Fosteum and the Squadrito study formulation were equivalent for genistein Tmax (2 hrs), Cmax (0.7 μM), T1/2 (18 ± 6.9 versus 21 ± 4.9 hrs), and AUC (9221 ± 413 versus 9818 ± 1370 ng·hr/mL).",The steady-state serum concentration of genistein aglycone is affected by formulation: a bioequivalence study of bone products. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23484100/),[h·ng] / [ml],9221,156373,DB01373,Calcium
,23484100,AUC,"Fosteum and the Squadrito study formulation were equivalent for genistein Tmax (2 hrs), Cmax (0.7 μM), T1/2 (18 ± 6.9 versus 21 ± 4.9 hrs), and AUC (9221 ± 413 versus 9818 ± 1370 ng·hr/mL).",The steady-state serum concentration of genistein aglycone is affected by formulation: a bioequivalence study of bone products. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23484100/),[h·ng] / [ml],9818,156374,DB01373,Calcium
,23484100,Tmax,"The OTC supplement's synthetically derived genistein, however, showed altered Tmax (6 hrs), Cmax (0.57 μ M), T1/2 (8.3 ± 1.9 hrs), and AUC (6474 ± 287 ng·hr/mL).",The steady-state serum concentration of genistein aglycone is affected by formulation: a bioequivalence study of bone products. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23484100/),h,6,156375,DB01373,Calcium
,23484100,Cmax,"The OTC supplement's synthetically derived genistein, however, showed altered Tmax (6 hrs), Cmax (0.57 μ M), T1/2 (8.3 ± 1.9 hrs), and AUC (6474 ± 287 ng·hr/mL).",The steady-state serum concentration of genistein aglycone is affected by formulation: a bioequivalence study of bone products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23484100/),M·μ,0.57,156376,DB01373,Calcium
,23484100,T1/2,"The OTC supplement's synthetically derived genistein, however, showed altered Tmax (6 hrs), Cmax (0.57 μ M), T1/2 (8.3 ± 1.9 hrs), and AUC (6474 ± 287 ng·hr/mL).",The steady-state serum concentration of genistein aglycone is affected by formulation: a bioequivalence study of bone products. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23484100/),h,8.3,156377,DB01373,Calcium
,23484100,AUC,"The OTC supplement's synthetically derived genistein, however, showed altered Tmax (6 hrs), Cmax (0.57 μ M), T1/2 (8.3 ± 1.9 hrs), and AUC (6474 ± 287 ng·hr/mL).",The steady-state serum concentration of genistein aglycone is affected by formulation: a bioequivalence study of bone products. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23484100/),[h·ng] / [ml],6474,156378,DB01373,Calcium
,31058419,AUCτ,"Losartan did not influence the exposure of amlodipine at steady-state (AUCτ , 165.15 ng h/mL [amlodipine alone] vs 172.36 ng h/mL [combination], P = 0.389) [geometric mean ratio (GMR) (90% confidence interval [CI]), 1.060 (0.954-1.178)].",Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058419/),[h·ng] / [ml],165.15,156995,DB01373,Calcium
,31058419,AUCτ,"Losartan did not influence the exposure of amlodipine at steady-state (AUCτ , 165.15 ng h/mL [amlodipine alone] vs 172.36 ng h/mL [combination], P = 0.389) [geometric mean ratio (GMR) (90% confidence interval [CI]), 1.060 (0.954-1.178)].",Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058419/),[h·ng] / [ml],172.36,156996,DB01373,Calcium
,31058419,AUCτ,"In addition, the exposure of EXP-3174 was not affected by amlodipine (AUCτ , 1159.46 ng h/mL vs 1105.10 ng h/mL, P = 0.295) (GMR [90% CI], 0.957 [0.891-1.027]).",Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058419/),[h·ng] / [ml],1159.46,156997,DB01373,Calcium
,31058419,AUCτ,"In addition, the exposure of EXP-3174 was not affected by amlodipine (AUCτ , 1159.46 ng h/mL vs 1105.10 ng h/mL, P = 0.295) (GMR [90% CI], 0.957 [0.891-1.027]).",Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058419/),[h·ng] / [ml],1105.10,156998,DB01373,Calcium
,31058419,AUCτ,"However, amlodipine significantly decreased the exposure of losartan at steady-state (AUCτ , 1241.50 ng h/mL vs 1082.02 ng h/mL, P = 0.006) (GMR [90% CI], 0.875 [0.813-0.942]) and increased oral clearance of losartan (84.65 L/h vs 97.26 L/h, P = 0.002).",Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058419/),[h·ng] / [ml],1241.50,156999,DB01373,Calcium
,31058419,AUCτ,"However, amlodipine significantly decreased the exposure of losartan at steady-state (AUCτ , 1241.50 ng h/mL vs 1082.02 ng h/mL, P = 0.006) (GMR [90% CI], 0.875 [0.813-0.942]) and increased oral clearance of losartan (84.65 L/h vs 97.26 L/h, P = 0.002).",Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058419/),[h·ng] / [ml],1082.02,157000,DB01373,Calcium
,31058419,oral clearance,"However, amlodipine significantly decreased the exposure of losartan at steady-state (AUCτ , 1241.50 ng h/mL vs 1082.02 ng h/mL, P = 0.006) (GMR [90% CI], 0.875 [0.813-0.942]) and increased oral clearance of losartan (84.65 L/h vs 97.26 L/h, P = 0.002).",Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058419/),[l] / [h],84.65,157001,DB01373,Calcium
,31058419,oral clearance,"However, amlodipine significantly decreased the exposure of losartan at steady-state (AUCτ , 1241.50 ng h/mL vs 1082.02 ng h/mL, P = 0.006) (GMR [90% CI], 0.875 [0.813-0.942]) and increased oral clearance of losartan (84.65 L/h vs 97.26 L/h, P = 0.002).",Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058419/),[l] / [h],97.26,157002,DB01373,Calcium
,23146221,cumulative urinary excretion percentages,"After receiving a single 4 mg oral dose of pitavastatin calcium, the average cumulative urinary excretion percentages of Pi and Pi-LAC in Chinese volunteers were (0.41 ± 0.16)% and (6.1 ± 5.0)%, respectively.",Simple LC-MS/MS methods for simultaneous determination of pitavastatin and its lactone metabolite in human plasma and urine involving a procedure for inhibiting the conversion of pitavastatin lactone to pitavastatin in plasma and its application to a pharmacokinetic study. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23146221/),%,0.41,157409,DB01373,Calcium
,23146221,cumulative urinary excretion percentages,"After receiving a single 4 mg oral dose of pitavastatin calcium, the average cumulative urinary excretion percentages of Pi and Pi-LAC in Chinese volunteers were (0.41 ± 0.16)% and (6.1 ± 5.0)%, respectively.",Simple LC-MS/MS methods for simultaneous determination of pitavastatin and its lactone metabolite in human plasma and urine involving a procedure for inhibiting the conversion of pitavastatin lactone to pitavastatin in plasma and its application to a pharmacokinetic study. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23146221/),%,6.1,157410,DB01373,Calcium
,31291476,half-life,"TransCon PTH demonstrated a half-life of 28 and 34 hours in rats and monkeys, respectively.","Design and Preclinical Development of TransCon PTH, an Investigational Sustained-Release PTH Replacement Therapy for Hypoparathyroidism. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31291476/),h,28,157631,DB01373,Calcium
,31291476,half-life,"TransCon PTH demonstrated a half-life of 28 and 34 hours in rats and monkeys, respectively.","Design and Preclinical Development of TransCon PTH, an Investigational Sustained-Release PTH Replacement Therapy for Hypoparathyroidism. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31291476/),h,34,157632,DB01373,Calcium
,14693307,peak plasma concentration (C(max)),The geometric mean peak plasma concentration (C(max)) of rosuvastatin was 6.06 ng/mL and was reached at a median of 5 hours after dosing.,"Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14693307/),[ng] / [ml],6.06,159222,DB01373,Calcium
,14693307,absolute bioavailability,"Given the absolute bioavailability (20%) and estimated absorption (approximately 50%) of rosuvastatin, this finding suggests that metabolism is a minor route of clearance for this agent.","Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14693307/),%,20,159223,DB01373,Calcium
,14693307,absorption,"Given the absolute bioavailability (20%) and estimated absorption (approximately 50%) of rosuvastatin, this finding suggests that metabolism is a minor route of clearance for this agent.","Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14693307/),%,50,159224,DB01373,Calcium
,17144644,bioavailable,"Pregabalin is rapidly absorbed with at least 90% bioavailable irrespective of dose, does not bind to plasma proteins and is excreted virtually unchanged by the kidneys.",[Pregabalin (Lyrica) and neuropathic pain syndromes]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17144644/),%,90,159783,DB01373,Calcium
,17515696,tmax,The mean tmax of cinacalcet was prolonged in fasting subjects (6 h) in relation to high-fat (4 h) and low-fat (3.5 h) fed subjects.,The pharmacokinetics of cinacalcet are unaffected following consumption of high- and low-fat meals. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17515696/),h,6,160126,DB01373,Calcium
,17515696,tmax,The mean tmax of cinacalcet was prolonged in fasting subjects (6 h) in relation to high-fat (4 h) and low-fat (3.5 h) fed subjects.,The pharmacokinetics of cinacalcet are unaffected following consumption of high- and low-fat meals. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17515696/),h,4,160127,DB01373,Calcium
,17515696,tmax,The mean tmax of cinacalcet was prolonged in fasting subjects (6 h) in relation to high-fat (4 h) and low-fat (3.5 h) fed subjects.,The pharmacokinetics of cinacalcet are unaffected following consumption of high- and low-fat meals. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17515696/),h,3.5,160128,DB01373,Calcium
,17667799,venous/capillary plasma concentration ratio,"The venous/capillary plasma concentration ratio was 1.00 [median value; interquartile range (IQR): 0.882-1.094]; for 85% of the data points the ratio was 0.8 to 1.2, independent of drug concentration.",Therapeutic drug monitoring of methotrexate on the pediatric oncology ward: can blood sampling from central venous accesses substitute for capillary finger punctures? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17667799/),,1,160432,DB01373,Calcium
,17236247,retention times,"The retention times of nitrendipine and internal standard (felodipine) were 5.0 min and 7.5 min, respectively.",Development and validation of a reversed-phase HPLC method for determination of nitrendipine in rat plasma: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17236247/),min,5.0,160632,DB01373,Calcium
,17236247,retention times,"The retention times of nitrendipine and internal standard (felodipine) were 5.0 min and 7.5 min, respectively.",Development and validation of a reversed-phase HPLC method for determination of nitrendipine in rat plasma: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17236247/),min,7.5,160633,DB01373,Calcium
,15907605,current,An average current of 0.43+/-0.01 mA was maintained during patch application.,In vivo iontophoretic delivery and pharmacokinetics of salmon calcitonin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907605/),ma,0.43,161011,DB01373,Calcium
,15907605,infusion rate,Iontophoretic patches delivered SCT at an average infusion rate of 177.9+/-58.7 ng/(min kg) and an average steady state concentration of 7.58+/-1.35 ng/ml was achieved.,In vivo iontophoretic delivery and pharmacokinetics of salmon calcitonin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907605/),[ng] / [kg·min],177.9,161012,DB01373,Calcium
,15907605,steady state concentration,Iontophoretic patches delivered SCT at an average infusion rate of 177.9+/-58.7 ng/(min kg) and an average steady state concentration of 7.58+/-1.35 ng/ml was achieved.,In vivo iontophoretic delivery and pharmacokinetics of salmon calcitonin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907605/),[ng] / [ml],7.58,161013,DB01373,Calcium
,15907605,Clearance,"Clearance and half-life of SCT after IV administration were found to be 16.8+/-0.9 ml/(min kg) and 33.5+/-3.3 min, respectively.",In vivo iontophoretic delivery and pharmacokinetics of salmon calcitonin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907605/),[ml] / [kg·min],16.8,161014,DB01373,Calcium
,15907605,half-life,"Clearance and half-life of SCT after IV administration were found to be 16.8+/-0.9 ml/(min kg) and 33.5+/-3.3 min, respectively.",In vivo iontophoretic delivery and pharmacokinetics of salmon calcitonin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907605/),min,33.5,161015,DB01373,Calcium
,25666686,saliva/plasma concentration ratio,"A correlation coefficient of 0.99 between saliva and plasma concentrations, and a saliva/plasma concentration ratio of 0.175 were observed.",Saliva versus plasma bioequivalence of rusovastatin in humans: validation of class III drugs of the salivary excretion classification system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25666686/),,0.175,161391,DB01373,Calcium
,32104340,en,"And the drug loading and encapsulation efficiency were about 8% and 71%, respectively.",The studies of PLGA nanoparticles loading atorvastatin calcium for oral administration in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32104340/),%,8,162085,DB01373,Calcium
,32104340,en,"And the drug loading and encapsulation efficiency were about 8% and 71%, respectively.",The studies of PLGA nanoparticles loading atorvastatin calcium for oral administration in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32104340/),%,71,162086,DB01373,Calcium
,17069421,run time,A run time of 3 min for each sample made it possible to analyze more than 250 human plasma samples per day.,Liquid chromatographic-electrospray tandem mass spectrometric method for the quantification of nimodipine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17069421/),min,3,162385,DB01373,Calcium
,16278401,C(max),"At the 165 microg dose, C(max) was 6.21 +/- 1.99 ng/mL, AUC(0-24) was 41.3 +/- 9.77 ng h/mL, AUC(0-infinity) was 55.4 +/- 8.44, and half-life (T(1/2)) was 16.2 hours.","Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16278401/),[ng] / [ml],6.21,163154,DB01373,Calcium
,16278401,AUC(0-24),"At the 165 microg dose, C(max) was 6.21 +/- 1.99 ng/mL, AUC(0-24) was 41.3 +/- 9.77 ng h/mL, AUC(0-infinity) was 55.4 +/- 8.44, and half-life (T(1/2)) was 16.2 hours.","Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16278401/),[h·ng] / [ml],41.3,163155,DB01373,Calcium
,16278401,AUC(0-infinity),"At the 165 microg dose, C(max) was 6.21 +/- 1.99 ng/mL, AUC(0-24) was 41.3 +/- 9.77 ng h/mL, AUC(0-infinity) was 55.4 +/- 8.44, and half-life (T(1/2)) was 16.2 hours.","Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16278401/),,55.4,163156,DB01373,Calcium
,16278401,half-life (T(1/2)),"At the 165 microg dose, C(max) was 6.21 +/- 1.99 ng/mL, AUC(0-24) was 41.3 +/- 9.77 ng h/mL, AUC(0-infinity) was 55.4 +/- 8.44, and half-life (T(1/2)) was 16.2 hours.","Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16278401/),h,16.2,163157,DB01373,Calcium
,32529303,oral bioavailability,"Felodipine (FLD), a dihydropyridine calcium channel blocker with excellent antihypertensive effect, is poorly soluble and undergoes extensive hepatic metabolism, which lead to poor oral bioavailability (about 15%) and limit its clinic application.",Enhanced Oral Bioavailability of Felodipine from Solid Lipid Nanoparticles Prepared Through Effervescent Dispersion Technique. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32529303/),%,15,164432,DB01373,Calcium
,32529303,zeta-potential,"The FLD-SLNs showed desired particle characteristics with particle size (198.15 ± 1.82 nm), poly dispersity index (0.26 ± 0.02), zeta-potential (- 25.53 ± 0.60 mV), entrapment efficiency (95.65 ± 0.70%), drug loading (2.33 ± 0.10%), and a spherical appearance.",Enhanced Oral Bioavailability of Felodipine from Solid Lipid Nanoparticles Prepared Through Effervescent Dispersion Technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32529303/),mv,- 25.53,164433,DB01373,Calcium
,32529303,en,"The FLD-SLNs showed desired particle characteristics with particle size (198.15 ± 1.82 nm), poly dispersity index (0.26 ± 0.02), zeta-potential (- 25.53 ± 0.60 mV), entrapment efficiency (95.65 ± 0.70%), drug loading (2.33 ± 0.10%), and a spherical appearance.",Enhanced Oral Bioavailability of Felodipine from Solid Lipid Nanoparticles Prepared Through Effervescent Dispersion Technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32529303/),,95.65,164434,DB01373,Calcium
greater,20704460,recovery,"The limit of quantitation for NF was 5 ng/mL in serum, and the recovery was greater than 90%.",Pharmacokinetics of a novel nifedipine and pH-sensitive N-succinyl chitosan/alginate hydrogel bead in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704460/),%,90,164908,DB01373,Calcium
,20704460,Cmax,"The mean Cmax was 320.2 ± 71.3 μg/L, the mean Tmax was 3.2 ± 0.5 hours, the mean t1/2 was 6.60 ± 2.17 hours, the mean AUC0-24 was 2.03 ± 0.25 mg h/L, the mean AUC0-∞ was 2.50 ± 0.36 mg h/L, the mean MRT0-24 was 8.57 ± 0.19 hours, and the mean MRT0-∞ was 15.2 ± 1.8 hours.",Pharmacokinetics of a novel nifedipine and pH-sensitive N-succinyl chitosan/alginate hydrogel bead in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704460/),[μg] / [l],320.2,164909,DB01373,Calcium
,20704460,Tmax,"The mean Cmax was 320.2 ± 71.3 μg/L, the mean Tmax was 3.2 ± 0.5 hours, the mean t1/2 was 6.60 ± 2.17 hours, the mean AUC0-24 was 2.03 ± 0.25 mg h/L, the mean AUC0-∞ was 2.50 ± 0.36 mg h/L, the mean MRT0-24 was 8.57 ± 0.19 hours, and the mean MRT0-∞ was 15.2 ± 1.8 hours.",Pharmacokinetics of a novel nifedipine and pH-sensitive N-succinyl chitosan/alginate hydrogel bead in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704460/),h,3.2,164910,DB01373,Calcium
,20704460,t1/2,"The mean Cmax was 320.2 ± 71.3 μg/L, the mean Tmax was 3.2 ± 0.5 hours, the mean t1/2 was 6.60 ± 2.17 hours, the mean AUC0-24 was 2.03 ± 0.25 mg h/L, the mean AUC0-∞ was 2.50 ± 0.36 mg h/L, the mean MRT0-24 was 8.57 ± 0.19 hours, and the mean MRT0-∞ was 15.2 ± 1.8 hours.",Pharmacokinetics of a novel nifedipine and pH-sensitive N-succinyl chitosan/alginate hydrogel bead in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704460/),h,6.60,164911,DB01373,Calcium
,20704460,AUC0-24,"The mean Cmax was 320.2 ± 71.3 μg/L, the mean Tmax was 3.2 ± 0.5 hours, the mean t1/2 was 6.60 ± 2.17 hours, the mean AUC0-24 was 2.03 ± 0.25 mg h/L, the mean AUC0-∞ was 2.50 ± 0.36 mg h/L, the mean MRT0-24 was 8.57 ± 0.19 hours, and the mean MRT0-∞ was 15.2 ± 1.8 hours.",Pharmacokinetics of a novel nifedipine and pH-sensitive N-succinyl chitosan/alginate hydrogel bead in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704460/),[h·mg] / [l],2.03,164912,DB01373,Calcium
,20704460,AUC0-∞,"The mean Cmax was 320.2 ± 71.3 μg/L, the mean Tmax was 3.2 ± 0.5 hours, the mean t1/2 was 6.60 ± 2.17 hours, the mean AUC0-24 was 2.03 ± 0.25 mg h/L, the mean AUC0-∞ was 2.50 ± 0.36 mg h/L, the mean MRT0-24 was 8.57 ± 0.19 hours, and the mean MRT0-∞ was 15.2 ± 1.8 hours.",Pharmacokinetics of a novel nifedipine and pH-sensitive N-succinyl chitosan/alginate hydrogel bead in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704460/),[h·mg] / [l],2.50,164913,DB01373,Calcium
,20704460,MRT0-24,"The mean Cmax was 320.2 ± 71.3 μg/L, the mean Tmax was 3.2 ± 0.5 hours, the mean t1/2 was 6.60 ± 2.17 hours, the mean AUC0-24 was 2.03 ± 0.25 mg h/L, the mean AUC0-∞ was 2.50 ± 0.36 mg h/L, the mean MRT0-24 was 8.57 ± 0.19 hours, and the mean MRT0-∞ was 15.2 ± 1.8 hours.",Pharmacokinetics of a novel nifedipine and pH-sensitive N-succinyl chitosan/alginate hydrogel bead in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704460/),h,8.57,164914,DB01373,Calcium
,20704460,MRT0-∞,"The mean Cmax was 320.2 ± 71.3 μg/L, the mean Tmax was 3.2 ± 0.5 hours, the mean t1/2 was 6.60 ± 2.17 hours, the mean AUC0-24 was 2.03 ± 0.25 mg h/L, the mean AUC0-∞ was 2.50 ± 0.36 mg h/L, the mean MRT0-24 was 8.57 ± 0.19 hours, and the mean MRT0-∞ was 15.2 ± 1.8 hours.",Pharmacokinetics of a novel nifedipine and pH-sensitive N-succinyl chitosan/alginate hydrogel bead in rabbits. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704460/),h,15.2,164915,DB01373,Calcium
,29051147,Michaelis-Menten constant,"We initially investigated the active transport of rosuvastatin into PXB cells, and found concentration-dependent uptake with a Michaelis-Menten constant value of 4.0 μmol/l and a Vmax value of 4.63 pmol/min per 106 cells.",Organic Anion-Transporting Polypeptide (OATP)-Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051147/),[μM] / [l],4.0,166789,DB01373,Calcium
,29051147,Vmax,"We initially investigated the active transport of rosuvastatin into PXB cells, and found concentration-dependent uptake with a Michaelis-Menten constant value of 4.0 μmol/l and a Vmax value of 4.63 pmol/min per 106 cells.",Organic Anion-Transporting Polypeptide (OATP)-Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051147/),[pM] / [106·cells·min],4.63,166790,DB01373,Calcium
,29051147,IC50,Cyclosporine A inhibited the uptake of rosuvastatin with an IC50 value of 0.21 μmol/l.,Organic Anion-Transporting Polypeptide (OATP)-Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051147/),[μM] / [l],0.21,166791,DB01373,Calcium
,31181484,flow rate,"The two analytes were extracted from plasma sample using acetonitrile-induced protein precipitation then separated on an Agilent Eclipse Plus ODS (4.6 × 100 mm, 3.5 μm) column by gradient elution using 6 mM ammonium formate/0.1% formic acid and ACN at a flow rate 0.4 mL min-1.",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),[ml] / [min],0.4,167338,DB01373,Calcium
,31181484,m/,"Multiple reaction monitoring in positive ion mode was used for quantification of precursor to production at m/z 492.1 → 206.9 for IRB, 482.1 → 258.1 for ROS, and 409.2 → 238.2 for the internal standard, amlodipine (AML).",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),,492.1,167339,DB01373,Calcium
,31181484,m/,"Multiple reaction monitoring in positive ion mode was used for quantification of precursor to production at m/z 492.1 → 206.9 for IRB, 482.1 → 258.1 for ROS, and 409.2 → 238.2 for the internal standard, amlodipine (AML).",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),,206,167340,DB01373,Calcium
,31181484,m/,"Multiple reaction monitoring in positive ion mode was used for quantification of precursor to production at m/z 492.1 → 206.9 for IRB, 482.1 → 258.1 for ROS, and 409.2 → 238.2 for the internal standard, amlodipine (AML).",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),,482.1,167341,DB01373,Calcium
,31181484,m/,"Multiple reaction monitoring in positive ion mode was used for quantification of precursor to production at m/z 492.1 → 206.9 for IRB, 482.1 → 258.1 for ROS, and 409.2 → 238.2 for the internal standard, amlodipine (AML).",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),,258.1,167342,DB01373,Calcium
,31181484,m/,"Multiple reaction monitoring in positive ion mode was used for quantification of precursor to production at m/z 492.1 → 206.9 for IRB, 482.1 → 258.1 for ROS, and 409.2 → 238.2 for the internal standard, amlodipine (AML).",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),,409.2,167343,DB01373,Calcium
,31181484,detection limits (S/N of 3),"Linearity was obeyed in the range of 1-10000 ng mL-1 and 1-5000 ng mL-1 with detection limits (S/N of 3) of 0.05 and 0.07 ng mL-1 for IRB and ROS, respectively.",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),[ng] / [ml],0.05,167344,DB01373,Calcium
,31181484,detection limits (S/N of 3),"Linearity was obeyed in the range of 1-10000 ng mL-1 and 1-5000 ng mL-1 with detection limits (S/N of 3) of 0.05 and 0.07 ng mL-1 for IRB and ROS, respectively.",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),[ng] / [ml],0.07,167345,DB01373,Calcium
,15531380,Cmax,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[ng] / [ml],7.8,167666,DB01373,Calcium
,15531380,Cmax,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[ng] / [ml],15.4,167667,DB01373,Calcium
,15531380,AUC0-6h,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[h·ng] / [ml],21.7,167668,DB01373,Calcium
,15531380,AUC0-6h,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[h·ng] / [ml],43.3,167669,DB01373,Calcium
,15531380,Cmax,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[ng] / [ml],74.2,167670,DB01373,Calcium
,15531380,Cmax,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[ng] / [ml],58.6,167671,DB01373,Calcium
,15531380,AUC0-6h,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[h·ng] / [ml],365,167672,DB01373,Calcium
,15531380,AUC0-6h,"After the combined treatment period, Cmax of HMG-CoA reductase inhibitor was elevated from 7.8 +/- 2.6 ng/ml to 15.4 +/- 7.9 ng/ml (P < 0.01) and AUC0-6h from 21.7 +/- 4.9 ng x hr/ml to 43.3 +/- 23.4 ng x hr/ml (P < 0.01), while Cmax of diltiazem was decreased from 74.2 +/- 36.4 ng/ml to 58.6 +/- 18.9 ng/ml (P < 0.05) and its AUC0-6h from 365 +/- 153 ng x hr/ml to 287 +/- 113 ng x hr/ml (P < 0.01).",Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531380/),[h·ng] / [ml],287,167673,DB01373,Calcium
,18176327,"area under the concentration time curve (AUC)[0,tau]","Geometric mean (+/-SD) rosuvastatin area under the concentration time curve (AUC)[0,tau] and maximum concentration (Cmax) were 47.6 ng.h/mL (+/-15.3) and 4.34 ng/mL (+/-1.8), respectively, when given alone versus 98.8 ng.h/mL (+/-65.5) and 20.2 ng/mL (+/-16.9) when combined with lopinavir/ritonavir (P < 0.0001).",Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18176327/),[h·ng] / [ml],47.6,168739,DB01373,Calcium
,18176327,"area under the concentration time curve (AUC)[0,tau]","Geometric mean (+/-SD) rosuvastatin area under the concentration time curve (AUC)[0,tau] and maximum concentration (Cmax) were 47.6 ng.h/mL (+/-15.3) and 4.34 ng/mL (+/-1.8), respectively, when given alone versus 98.8 ng.h/mL (+/-65.5) and 20.2 ng/mL (+/-16.9) when combined with lopinavir/ritonavir (P < 0.0001).",Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18176327/),[h·ng] / [ml],98.8,168740,DB01373,Calcium
,18176327,maximum concentration (Cmax),"Geometric mean (+/-SD) rosuvastatin area under the concentration time curve (AUC)[0,tau] and maximum concentration (Cmax) were 47.6 ng.h/mL (+/-15.3) and 4.34 ng/mL (+/-1.8), respectively, when given alone versus 98.8 ng.h/mL (+/-65.5) and 20.2 ng/mL (+/-16.9) when combined with lopinavir/ritonavir (P < 0.0001).",Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18176327/),[ng] / [ml],4.34,168741,DB01373,Calcium
,18176327,maximum concentration (Cmax),"Geometric mean (+/-SD) rosuvastatin area under the concentration time curve (AUC)[0,tau] and maximum concentration (Cmax) were 47.6 ng.h/mL (+/-15.3) and 4.34 ng/mL (+/-1.8), respectively, when given alone versus 98.8 ng.h/mL (+/-65.5) and 20.2 ng/mL (+/-16.9) when combined with lopinavir/ritonavir (P < 0.0001).",Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18176327/),[ng] / [ml],20.2,168742,DB01373,Calcium
,24989775,distribution t1/2,Drug concentration rose rapidly during the infusion and decreased rapidly initially (distribution t1/2 of 30 min) and then more slowly (terminal t1/2 of 5.6 h).,"GAL-021, a new intravenous BKCa-channel blocker, is well tolerated and stimulates ventilation in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24989775/),min,30,168772,DB01373,Calcium
,24989775,terminal t1/2,Drug concentration rose rapidly during the infusion and decreased rapidly initially (distribution t1/2 of 30 min) and then more slowly (terminal t1/2 of 5.6 h).,"GAL-021, a new intravenous BKCa-channel blocker, is well tolerated and stimulates ventilation in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24989775/),h,5.6,168773,DB01373,Calcium
,22339081,AUC0-24,"The pharmacokinetics parameters of DH sustained-release microspheres and reference tablet was AUC0-24 (ng · h · mL(-1)) 836.3 and 857.3, C(max) (ng · mL(-1)) 85.4 and 135.2, T(max) (h) 4.7 and 1.2.",In vitro and in vivo evaluation of a novel diltiazem hydrochloride polydispersity sustained-release system. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339081/),[h·ng] / [ml],836.3,168809,DB01373,Calcium
,22339081,AUC0-24,"The pharmacokinetics parameters of DH sustained-release microspheres and reference tablet was AUC0-24 (ng · h · mL(-1)) 836.3 and 857.3, C(max) (ng · mL(-1)) 85.4 and 135.2, T(max) (h) 4.7 and 1.2.",In vitro and in vivo evaluation of a novel diltiazem hydrochloride polydispersity sustained-release system. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339081/),[h·ng] / [ml],857.3,168810,DB01373,Calcium
,22339081,C(max),"The pharmacokinetics parameters of DH sustained-release microspheres and reference tablet was AUC0-24 (ng · h · mL(-1)) 836.3 and 857.3, C(max) (ng · mL(-1)) 85.4 and 135.2, T(max) (h) 4.7 and 1.2.",In vitro and in vivo evaluation of a novel diltiazem hydrochloride polydispersity sustained-release system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339081/),[ng] / [ml],85.4,168811,DB01373,Calcium
,22339081,C(max),"The pharmacokinetics parameters of DH sustained-release microspheres and reference tablet was AUC0-24 (ng · h · mL(-1)) 836.3 and 857.3, C(max) (ng · mL(-1)) 85.4 and 135.2, T(max) (h) 4.7 and 1.2.",In vitro and in vivo evaluation of a novel diltiazem hydrochloride polydispersity sustained-release system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339081/),[ng] / [ml],135.2,168812,DB01373,Calcium
,22339081,T(max),"The pharmacokinetics parameters of DH sustained-release microspheres and reference tablet was AUC0-24 (ng · h · mL(-1)) 836.3 and 857.3, C(max) (ng · mL(-1)) 85.4 and 135.2, T(max) (h) 4.7 and 1.2.",In vitro and in vivo evaluation of a novel diltiazem hydrochloride polydispersity sustained-release system. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339081/),h,4.7,168813,DB01373,Calcium
,22339081,T(max),"The pharmacokinetics parameters of DH sustained-release microspheres and reference tablet was AUC0-24 (ng · h · mL(-1)) 836.3 and 857.3, C(max) (ng · mL(-1)) 85.4 and 135.2, T(max) (h) 4.7 and 1.2.",In vitro and in vivo evaluation of a novel diltiazem hydrochloride polydispersity sustained-release system. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339081/),h,1.2,168814,DB01373,Calcium
,18563364,AUC0-48,"The mean AUC0-48, Cmax, Tlag and Tmax for the two types of tablets ranged from 41.5-53.6 microg.h/mL, 4.3-4.5 microg/mL, 2.0-2.5 h and 3.8-4.0 h, respectively.",Investigation of the relationship between in vitro and in vivo release behaviors of acamprosate from enteric-coated tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18563364/),[h·μg] / [ml],41.5-53.6,168928,DB01373,Calcium
,18563364,Cmax,"The mean AUC0-48, Cmax, Tlag and Tmax for the two types of tablets ranged from 41.5-53.6 microg.h/mL, 4.3-4.5 microg/mL, 2.0-2.5 h and 3.8-4.0 h, respectively.",Investigation of the relationship between in vitro and in vivo release behaviors of acamprosate from enteric-coated tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18563364/),[μg] / [ml],4.3-4.5,168929,DB01373,Calcium
,18563364,Tlag,"The mean AUC0-48, Cmax, Tlag and Tmax for the two types of tablets ranged from 41.5-53.6 microg.h/mL, 4.3-4.5 microg/mL, 2.0-2.5 h and 3.8-4.0 h, respectively.",Investigation of the relationship between in vitro and in vivo release behaviors of acamprosate from enteric-coated tablets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18563364/),[μg] / [ml],4.3-4.5,168930,DB01373,Calcium
,18563364,Tmax,"The mean AUC0-48, Cmax, Tlag and Tmax for the two types of tablets ranged from 41.5-53.6 microg.h/mL, 4.3-4.5 microg/mL, 2.0-2.5 h and 3.8-4.0 h, respectively.",Investigation of the relationship between in vitro and in vivo release behaviors of acamprosate from enteric-coated tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18563364/),h,3.8-4.0,168931,DB01373,Calcium
up to,31536764,relative oral bioavailability,The relative oral bioavailability was calculated to be up to 56% when DTX was loaded in nanoparticles from poly(anhydride)-mPEG2000 conjugate (DTX-NP-mPEG2).,Nanoparticles from Gantrez® AN-poly(ethylene glycol) conjugates as carriers for oral delivery of docetaxel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31536764/),%,56,169098,DB01373,Calcium
,15390088,C(max),"The following differences were observed between the (+)-(S) and (-)-(R)-FEN in the patients with rheumatoid arthritis (means 95% CI, Wilcoxon test, P < 0.05): C(max) 14.1 (12.5-15.8) versus 3.6 (2.5-4.7) microg/ml; AUC(ss) (0-8) 80.5 (67.3-93.7) versus 12.1 (8.8-15.4) microg.h/ml; Cl(T)/f 1.3 (1.0-1.5) versus 9.1 (6.5-11.8) l/h; and t(1/2) 3.1 (2.3-3.9) versus 1.2 (0.8-1.6) h.",Influence of rheumatoid arthritis in the enantioselective disposition of fenoprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15390088/),[μg] / [ml],14.1,169211,DB01373,Calcium
,15390088,C(max),"The following differences were observed between the (+)-(S) and (-)-(R)-FEN in the patients with rheumatoid arthritis (means 95% CI, Wilcoxon test, P < 0.05): C(max) 14.1 (12.5-15.8) versus 3.6 (2.5-4.7) microg/ml; AUC(ss) (0-8) 80.5 (67.3-93.7) versus 12.1 (8.8-15.4) microg.h/ml; Cl(T)/f 1.3 (1.0-1.5) versus 9.1 (6.5-11.8) l/h; and t(1/2) 3.1 (2.3-3.9) versus 1.2 (0.8-1.6) h.",Influence of rheumatoid arthritis in the enantioselective disposition of fenoprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15390088/),[μg] / [ml],3.6,169212,DB01373,Calcium
,15390088,AUC(ss) (0-8),"The following differences were observed between the (+)-(S) and (-)-(R)-FEN in the patients with rheumatoid arthritis (means 95% CI, Wilcoxon test, P < 0.05): C(max) 14.1 (12.5-15.8) versus 3.6 (2.5-4.7) microg/ml; AUC(ss) (0-8) 80.5 (67.3-93.7) versus 12.1 (8.8-15.4) microg.h/ml; Cl(T)/f 1.3 (1.0-1.5) versus 9.1 (6.5-11.8) l/h; and t(1/2) 3.1 (2.3-3.9) versus 1.2 (0.8-1.6) h.",Influence of rheumatoid arthritis in the enantioselective disposition of fenoprofen. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15390088/),[h·μg] / [ml],80.5,169213,DB01373,Calcium
,15390088,AUC(ss) (0-8),"The following differences were observed between the (+)-(S) and (-)-(R)-FEN in the patients with rheumatoid arthritis (means 95% CI, Wilcoxon test, P < 0.05): C(max) 14.1 (12.5-15.8) versus 3.6 (2.5-4.7) microg/ml; AUC(ss) (0-8) 80.5 (67.3-93.7) versus 12.1 (8.8-15.4) microg.h/ml; Cl(T)/f 1.3 (1.0-1.5) versus 9.1 (6.5-11.8) l/h; and t(1/2) 3.1 (2.3-3.9) versus 1.2 (0.8-1.6) h.",Influence of rheumatoid arthritis in the enantioselective disposition of fenoprofen. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15390088/),[h·μg] / [ml],12.1,169214,DB01373,Calcium
,15390088,Cl(T)/f,"The following differences were observed between the (+)-(S) and (-)-(R)-FEN in the patients with rheumatoid arthritis (means 95% CI, Wilcoxon test, P < 0.05): C(max) 14.1 (12.5-15.8) versus 3.6 (2.5-4.7) microg/ml; AUC(ss) (0-8) 80.5 (67.3-93.7) versus 12.1 (8.8-15.4) microg.h/ml; Cl(T)/f 1.3 (1.0-1.5) versus 9.1 (6.5-11.8) l/h; and t(1/2) 3.1 (2.3-3.9) versus 1.2 (0.8-1.6) h.",Influence of rheumatoid arthritis in the enantioselective disposition of fenoprofen. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15390088/),[l] / [h],1.3,169215,DB01373,Calcium
,15390088,Cl(T)/f,"The following differences were observed between the (+)-(S) and (-)-(R)-FEN in the patients with rheumatoid arthritis (means 95% CI, Wilcoxon test, P < 0.05): C(max) 14.1 (12.5-15.8) versus 3.6 (2.5-4.7) microg/ml; AUC(ss) (0-8) 80.5 (67.3-93.7) versus 12.1 (8.8-15.4) microg.h/ml; Cl(T)/f 1.3 (1.0-1.5) versus 9.1 (6.5-11.8) l/h; and t(1/2) 3.1 (2.3-3.9) versus 1.2 (0.8-1.6) h.",Influence of rheumatoid arthritis in the enantioselective disposition of fenoprofen. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15390088/),[l] / [h],9.1,169216,DB01373,Calcium
,15390088,t(1/2),"The following differences were observed between the (+)-(S) and (-)-(R)-FEN in the patients with rheumatoid arthritis (means 95% CI, Wilcoxon test, P < 0.05): C(max) 14.1 (12.5-15.8) versus 3.6 (2.5-4.7) microg/ml; AUC(ss) (0-8) 80.5 (67.3-93.7) versus 12.1 (8.8-15.4) microg.h/ml; Cl(T)/f 1.3 (1.0-1.5) versus 9.1 (6.5-11.8) l/h; and t(1/2) 3.1 (2.3-3.9) versus 1.2 (0.8-1.6) h.",Influence of rheumatoid arthritis in the enantioselective disposition of fenoprofen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15390088/),h,3.1,169217,DB01373,Calcium
,15390088,t(1/2),"The following differences were observed between the (+)-(S) and (-)-(R)-FEN in the patients with rheumatoid arthritis (means 95% CI, Wilcoxon test, P < 0.05): C(max) 14.1 (12.5-15.8) versus 3.6 (2.5-4.7) microg/ml; AUC(ss) (0-8) 80.5 (67.3-93.7) versus 12.1 (8.8-15.4) microg.h/ml; Cl(T)/f 1.3 (1.0-1.5) versus 9.1 (6.5-11.8) l/h; and t(1/2) 3.1 (2.3-3.9) versus 1.2 (0.8-1.6) h.",Influence of rheumatoid arthritis in the enantioselective disposition of fenoprofen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15390088/),h,1.2,169218,DB01373,Calcium
,15390088,Cl(T)/f,The Cl(T)/f of (-)-(R)-FEN was reduced in patients with rheumatoid arthritis when compared to healthy volunteers: 9.1 (6.5-11.8) versus 17.4 (13.9-20.9) l/h; P < 0.05 Mann-Whitney test.,Influence of rheumatoid arthritis in the enantioselective disposition of fenoprofen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15390088/),[l] / [h],9.1,169219,DB01373,Calcium
,15390088,Cl(T)/f,The Cl(T)/f of (-)-(R)-FEN was reduced in patients with rheumatoid arthritis when compared to healthy volunteers: 9.1 (6.5-11.8) versus 17.4 (13.9-20.9) l/h; P < 0.05 Mann-Whitney test.,Influence of rheumatoid arthritis in the enantioselective disposition of fenoprofen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15390088/),[l] / [h],17.4,169220,DB01373,Calcium
,11548856,compressibility,"The prepared granules showed good physical characteristics concerning the flow properties and compressibility, with the angles of repose in the range 29-31, and the compressibility indices ranged between 15% and 25%.",Excipient-excipient interaction in the design of sustained-release theophylline tablets: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11548856/),%,15,169221,DB01373,Calcium
,11548856,compressibility,"The prepared granules showed good physical characteristics concerning the flow properties and compressibility, with the angles of repose in the range 29-31, and the compressibility indices ranged between 15% and 25%.",Excipient-excipient interaction in the design of sustained-release theophylline tablets: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11548856/),%,25,169222,DB01373,Calcium
,11548856,friability,"The granules had low friability values (3.0%-4.2%), depending on SAL:CG ratios.",Excipient-excipient interaction in the design of sustained-release theophylline tablets: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11548856/),%,3.0,169223,DB01373,Calcium
,11548856,friability,"The granules had low friability values (3.0%-4.2%), depending on SAL:CG ratios.",Excipient-excipient interaction in the design of sustained-release theophylline tablets: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11548856/),%,4.2,169224,DB01373,Calcium
,11548856,bioavailability,The formulated tablets showed 104.65% bioavailability relative to that of the commercial tablets.,Excipient-excipient interaction in the design of sustained-release theophylline tablets: in vitro and in vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11548856/),%,104.65,169225,DB01373,Calcium
,24694186,pK(a),"pK(a) (7.49 ± 0.01), log P (5.10 ± 0.02) and intrinsic solubility (S0) (1.75 μg/ml) at 37 °C of JFD were obtained using potentiometric titration method.","Preformulation characterization and in vivo absorption in beagle dogs of JFD, a novel anti-obesity drug for oral delivery. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24694186/),,7.49,169923,DB01373,Calcium
,24694186,log P,"pK(a) (7.49 ± 0.01), log P (5.10 ± 0.02) and intrinsic solubility (S0) (1.75 μg/ml) at 37 °C of JFD were obtained using potentiometric titration method.","Preformulation characterization and in vivo absorption in beagle dogs of JFD, a novel anti-obesity drug for oral delivery. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24694186/),,5.10,169924,DB01373,Calcium
,24694186,intrinsic solubility (S0),"pK(a) (7.49 ± 0.01), log P (5.10 ± 0.02) and intrinsic solubility (S0) (1.75 μg/ml) at 37 °C of JFD were obtained using potentiometric titration method.","Preformulation characterization and in vivo absorption in beagle dogs of JFD, a novel anti-obesity drug for oral delivery. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24694186/),[μg] / [ml],1.75,169925,DB01373,Calcium
,24694186,T(max),"Further, JFD exhibited an acceptable pharmacokinetic profiling in beagle dogs and the pharmacokinetic parameters T(max), C(max), AUC(0-t) and absolute bioavailability were 1.60 ± 0.81 h, 0.78 ± 0.47 μg/ml, 3.77 ± 1.85 μg·h/ml and 52.30 ± 19.39%, respectively.","Preformulation characterization and in vivo absorption in beagle dogs of JFD, a novel anti-obesity drug for oral delivery. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24694186/),h,1.60,169926,DB01373,Calcium
,24694186,C(max),"Further, JFD exhibited an acceptable pharmacokinetic profiling in beagle dogs and the pharmacokinetic parameters T(max), C(max), AUC(0-t) and absolute bioavailability were 1.60 ± 0.81 h, 0.78 ± 0.47 μg/ml, 3.77 ± 1.85 μg·h/ml and 52.30 ± 19.39%, respectively.","Preformulation characterization and in vivo absorption in beagle dogs of JFD, a novel anti-obesity drug for oral delivery. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24694186/),[μg] / [ml],0.78,169927,DB01373,Calcium
,24694186,C(max),"Further, JFD exhibited an acceptable pharmacokinetic profiling in beagle dogs and the pharmacokinetic parameters T(max), C(max), AUC(0-t) and absolute bioavailability were 1.60 ± 0.81 h, 0.78 ± 0.47 μg/ml, 3.77 ± 1.85 μg·h/ml and 52.30 ± 19.39%, respectively.","Preformulation characterization and in vivo absorption in beagle dogs of JFD, a novel anti-obesity drug for oral delivery. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24694186/),[h·μg] / [ml],3.77,169928,DB01373,Calcium
,24694186,AUC(0-t),"Further, JFD exhibited an acceptable pharmacokinetic profiling in beagle dogs and the pharmacokinetic parameters T(max), C(max), AUC(0-t) and absolute bioavailability were 1.60 ± 0.81 h, 0.78 ± 0.47 μg/ml, 3.77 ± 1.85 μg·h/ml and 52.30 ± 19.39%, respectively.","Preformulation characterization and in vivo absorption in beagle dogs of JFD, a novel anti-obesity drug for oral delivery. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24694186/),[μg] / [ml],0.78,169929,DB01373,Calcium
,24694186,absolute bioavailability,"Further, JFD exhibited an acceptable pharmacokinetic profiling in beagle dogs and the pharmacokinetic parameters T(max), C(max), AUC(0-t) and absolute bioavailability were 1.60 ± 0.81 h, 0.78 ± 0.47 μg/ml, 3.77 ± 1.85 μg·h/ml and 52.30 ± 19.39%, respectively.","Preformulation characterization and in vivo absorption in beagle dogs of JFD, a novel anti-obesity drug for oral delivery. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24694186/),%,52.30,169930,DB01373,Calcium
,22928732,zeta potential,"High entrapment efficiency (>50%), desired particle size (<10 µm), high zeta potential values (-30.91 ± 3.06 to -34.65 ± 1.01 mV) and low polydispersity indices (0.61 ± 0.04 to 0.88 ± 0.05) were recorded in the prepared microspheres.",Enhanced oral bioavailability of calcium using bovine serum albumin microspheres. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22928732/),mv,30.91,170007,DB01373,Calcium
,22928732,zeta potential,"High entrapment efficiency (>50%), desired particle size (<10 µm), high zeta potential values (-30.91 ± 3.06 to -34.65 ± 1.01 mV) and low polydispersity indices (0.61 ± 0.04 to 0.88 ± 0.05) were recorded in the prepared microspheres.",Enhanced oral bioavailability of calcium using bovine serum albumin microspheres. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22928732/),mv,34.65,170008,DB01373,Calcium
,22928732,polydispersity in,"High entrapment efficiency (>50%), desired particle size (<10 µm), high zeta potential values (-30.91 ± 3.06 to -34.65 ± 1.01 mV) and low polydispersity indices (0.61 ± 0.04 to 0.88 ± 0.05) were recorded in the prepared microspheres.",Enhanced oral bioavailability of calcium using bovine serum albumin microspheres. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22928732/),,0.61,170009,DB01373,Calcium
,22928732,polydispersity in,"High entrapment efficiency (>50%), desired particle size (<10 µm), high zeta potential values (-30.91 ± 3.06 to -34.65 ± 1.01 mV) and low polydispersity indices (0.61 ± 0.04 to 0.88 ± 0.05) were recorded in the prepared microspheres.",Enhanced oral bioavailability of calcium using bovine serum albumin microspheres. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22928732/),,0.88,170010,DB01373,Calcium
,29932656,EC20,"Compound 14l exhibited a potent in vitro hPTHR1 agonist effect with EC20 of 3.0 μM and EC50 of 12 μM and showed excellent physicochemical properties, such as high solubility in fasted state simulated intestinal fluid and good metabolic stability in human liver microsomes.","Development of a Novel Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist (CH5447240), a Potent and Orally Available Small Molecule for Treatment of Hypoparathyroidism. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29932656/),μM,3.0,170045,DB01373,Calcium
,29932656,EC50,"Compound 14l exhibited a potent in vitro hPTHR1 agonist effect with EC20 of 3.0 μM and EC50 of 12 μM and showed excellent physicochemical properties, such as high solubility in fasted state simulated intestinal fluid and good metabolic stability in human liver microsomes.","Development of a Novel Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist (CH5447240), a Potent and Orally Available Small Molecule for Treatment of Hypoparathyroidism. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29932656/),μM,12,170046,DB01373,Calcium
,29932656,oral bioavailability,"Importantly, 14l showed 55% oral bioavailability and a significantly elevated serum calcium level in hypocalcemic model rats.","Development of a Novel Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist (CH5447240), a Potent and Orally Available Small Molecule for Treatment of Hypoparathyroidism. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29932656/),%,55,170047,DB01373,Calcium
,15230340,maximum concentration (Cmax),Mean CsA maximum concentration (Cmax) decreased from 0.4 +/- 0.1 microg/ml to 0.1 +/- 0.0 microg/mL in rats pretreated with 90 mg/kg diltiazem (p<0.05).,The interaction of the diltiazem with oral and intravenous cyclosporine in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15230340/),[μg] / [ml],0.4,170099,DB01373,Calcium
,15230340,maximum concentration (Cmax),Mean CsA maximum concentration (Cmax) decreased from 0.4 +/- 0.1 microg/ml to 0.1 +/- 0.0 microg/mL in rats pretreated with 90 mg/kg diltiazem (p<0.05).,The interaction of the diltiazem with oral and intravenous cyclosporine in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15230340/),[μg] / [ml],0.1,170100,DB01373,Calcium
,15230340,absolute bioavailability after oral administration (F,The absolute bioavailability after oral administration (F(p.o.)) in the 60 or 90 mg/kg diltiazem groups were lower than the control group (9.6% and 8.5% versus 22.6%).,The interaction of the diltiazem with oral and intravenous cyclosporine in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15230340/),%,9.6,170101,DB01373,Calcium
,15230340,absolute bioavailability after oral administration (F,The absolute bioavailability after oral administration (F(p.o.)) in the 60 or 90 mg/kg diltiazem groups were lower than the control group (9.6% and 8.5% versus 22.6%).,The interaction of the diltiazem with oral and intravenous cyclosporine in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15230340/),%,8.5,170102,DB01373,Calcium
,15230340,absolute bioavailability after oral administration (F,The absolute bioavailability after oral administration (F(p.o.)) in the 60 or 90 mg/kg diltiazem groups were lower than the control group (9.6% and 8.5% versus 22.6%).,The interaction of the diltiazem with oral and intravenous cyclosporine in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15230340/),%,22.6,170103,DB01373,Calcium
,11755750,Limit of quantification (LOQ),Limit of quantification (LOQ) was set at 0.25 nmol/l (0.10 microg/l).,Enantioselective determination of felodipine in human plasma by chiral normal-phase liquid chromatography and electrospray ionisation mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11755750/),[nM] / [l],0.25,170807,DB01373,Calcium
,11755750,Limit of quantification (LOQ),Limit of quantification (LOQ) was set at 0.25 nmol/l (0.10 microg/l).,Enantioselective determination of felodipine in human plasma by chiral normal-phase liquid chromatography and electrospray ionisation mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11755750/),μ,0.10,170808,DB01373,Calcium
,25652785,CSF/Plasma concentration ratio,CSF/Plasma concentration ratio of nimodipine after oral administration of 60 mg at 1 h was 0.013 ± 0.0005.,"Absorption, elimination and cerebrospinal fluid concentrations of nimodipine in healthy beagle dogs receiving human intravenous and oral formulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25652785/),,0.013,170942,DB01373,Calcium
,25652785,terminal elimination half-life,The mean terminal elimination half-life of nimodipine after i.v. bolus dose 0.72 mg was 1.8 h and mean plasma clearance was 40.3 and 3.4 l/h/kg.,"Absorption, elimination and cerebrospinal fluid concentrations of nimodipine in healthy beagle dogs receiving human intravenous and oral formulation. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25652785/),h,1.8,170943,DB01373,Calcium
,25652785,plasma clearance,The mean terminal elimination half-life of nimodipine after i.v. bolus dose 0.72 mg was 1.8 h and mean plasma clearance was 40.3 and 3.4 l/h/kg.,"Absorption, elimination and cerebrospinal fluid concentrations of nimodipine in healthy beagle dogs receiving human intravenous and oral formulation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25652785/),[l] / [h·kg],40.3,170944,DB01373,Calcium
,25652785,plasma clearance,The mean terminal elimination half-life of nimodipine after i.v. bolus dose 0.72 mg was 1.8 h and mean plasma clearance was 40.3 and 3.4 l/h/kg.,"Absorption, elimination and cerebrospinal fluid concentrations of nimodipine in healthy beagle dogs receiving human intravenous and oral formulation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25652785/),[l] / [h·kg],3.4,170945,DB01373,Calcium
,25652785,Absolute bioavailability,Absolute bioavailability was 22 %.,"Absorption, elimination and cerebrospinal fluid concentrations of nimodipine in healthy beagle dogs receiving human intravenous and oral formulation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25652785/),%,22,170946,DB01373,Calcium
,26650374,metabolic rate,"When ginkgolides B, bilobalide, or quercetin and amlodipine were co-incubated in the rat liver microsomes, the metabolic rate of amlodipine was prolonged to 533.1, 216.1 and 407.6 min, respectively, from 73.7 min.",Effect of Ginkgo Leaf Tablets on the Pharmacokinetics of Amlodipine in Rats. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26650374/),min,533.1,171132,DB01373,Calcium
,26650374,metabolic rate,"When ginkgolides B, bilobalide, or quercetin and amlodipine were co-incubated in the rat liver microsomes, the metabolic rate of amlodipine was prolonged to 533.1, 216.1 and 407.6 min, respectively, from 73.7 min.",Effect of Ginkgo Leaf Tablets on the Pharmacokinetics of Amlodipine in Rats. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26650374/),min,216.1,171133,DB01373,Calcium
,26650374,metabolic rate,"When ginkgolides B, bilobalide, or quercetin and amlodipine were co-incubated in the rat liver microsomes, the metabolic rate of amlodipine was prolonged to 533.1, 216.1 and 407.6 min, respectively, from 73.7 min.",Effect of Ginkgo Leaf Tablets on the Pharmacokinetics of Amlodipine in Rats. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26650374/),min,407.6,171134,DB01373,Calcium
,26650374,metabolic rate,"When ginkgolides B, bilobalide, or quercetin and amlodipine were co-incubated in the rat liver microsomes, the metabolic rate of amlodipine was prolonged to 533.1, 216.1 and 407.6 min, respectively, from 73.7 min.",Effect of Ginkgo Leaf Tablets on the Pharmacokinetics of Amlodipine in Rats. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26650374/),min,73.7,171135,DB01373,Calcium
,30050285,entrapment efficiency,The entrapment efficiency was 84.3%±1.3%.,Development of novel rosuvastatin nanostructured lipid carriers for oral delivery in an animal model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30050285/),%,84.3,171552,DB01373,Calcium
,27186665,particle,"The mean particle size, polydispersity index (PDI), zeta potential (ζ) and entrapment efficiency (%) of optimized NLC formulation was observed to be 150.3 ± 4.67 nm, 0.175 ± 0.022, -32.9 ± 1.36 mV and 84.95 ± 5.63%, respectively.",Improved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin-loaded nanostructured lipid carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27186665/),nm,150.3,171636,DB01373,Calcium
,27186665,polydispersity index (PDI),"The mean particle size, polydispersity index (PDI), zeta potential (ζ) and entrapment efficiency (%) of optimized NLC formulation was observed to be 150.3 ± 4.67 nm, 0.175 ± 0.022, -32.9 ± 1.36 mV and 84.95 ± 5.63%, respectively.",Improved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin-loaded nanostructured lipid carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27186665/),mv,0.175,171637,DB01373,Calcium
,27186665,zeta potential (ζ),"The mean particle size, polydispersity index (PDI), zeta potential (ζ) and entrapment efficiency (%) of optimized NLC formulation was observed to be 150.3 ± 4.67 nm, 0.175 ± 0.022, -32.9 ± 1.36 mV and 84.95 ± 5.63%, respectively.",Improved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin-loaded nanostructured lipid carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27186665/),mv,0.175,171638,DB01373,Calcium
,27186665,entrapment efficiency,"The mean particle size, polydispersity index (PDI), zeta potential (ζ) and entrapment efficiency (%) of optimized NLC formulation was observed to be 150.3 ± 4.67 nm, 0.175 ± 0.022, -32.9 ± 1.36 mV and 84.95 ± 5.63%, respectively.",Improved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin-loaded nanostructured lipid carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27186665/),mv,0.175,171639,DB01373,Calcium
,27186665,entrapment efficiency,"The mean particle size, polydispersity index (PDI), zeta potential (ζ) and entrapment efficiency (%) of optimized NLC formulation was observed to be 150.3 ± 4.67 nm, 0.175 ± 0.022, -32.9 ± 1.36 mV and 84.95 ± 5.63%, respectively.",Improved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin-loaded nanostructured lipid carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27186665/),mv,-,171640,DB01373,Calcium
,27186665,entrapment efficiency,"The mean particle size, polydispersity index (PDI), zeta potential (ζ) and entrapment efficiency (%) of optimized NLC formulation was observed to be 150.3 ± 4.67 nm, 0.175 ± 0.022, -32.9 ± 1.36 mV and 84.95 ± 5.63%, respectively.",Improved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin-loaded nanostructured lipid carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27186665/),mv,32.9,171641,DB01373,Calcium
,16615674,heart rate,"Her heart rate was 75 beats per minute, (bpm) and her blood pressure dropped from 70/50 to 50/00 mmHg.",Monitoring of verapamil enantiomers concentration in overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615674/),[beats] / [min],75,172338,DB01373,Calcium
,16615674,serum concentrations,"On admission, R-(+)- and S-(-)-verapamil serum concentrations were 2252 ng/ml and 810 ng/ ml, respectively.",Monitoring of verapamil enantiomers concentration in overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615674/),[ng] / [ml],2252,172339,DB01373,Calcium
,16615674,serum concentrations,"On admission, R-(+)- and S-(-)-verapamil serum concentrations were 2252 ng/ml and 810 ng/ ml, respectively.",Monitoring of verapamil enantiomers concentration in overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615674/),[ng] / [ml],810,172340,DB01373,Calcium
,16615674,Terminal elimination half-lives,"Terminal elimination half-lives were 18.7 (21.3) and 17.0 (18.5) hours, respectively, for R-(+)- and S-(-)-verapamil.",Monitoring of verapamil enantiomers concentration in overdose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615674/),h,18.7,172341,DB01373,Calcium
,16615674,Terminal elimination half-lives,"Terminal elimination half-lives were 18.7 (21.3) and 17.0 (18.5) hours, respectively, for R-(+)- and S-(-)-verapamil.",Monitoring of verapamil enantiomers concentration in overdose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615674/),h,17.0,172342,DB01373,Calcium
,17318527,AUC(0-4),"Nimodipine AUC values (expressed in mug min/ml) were lower in the eight SAH patients receiving enteral nimodipine [AUC(0-4) range: 0.13-5.4 (median: 0.32); AUC(24-28) range: 0.16-6.1 (0.71); AUC(72-76) range: 0.47-20.6 (1.9)] than in the nine patients receiving a continuous intravenous infusion of nimodipine [AUC(0-4) range: 2.4-4.9 (3.4), p=0.059; AUC(24-28) range: 4.7-10.3 (7.3), p=0.001; AUC(72-76) range: 3.4-8.6 (6.9), p=0.001].",Early-phase pharmacokinetics of enteral and parenteral nimodipine in patients with acute subarachnoid haemorrhage - a pilot study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318527/),[min·μg] / [ml],0.32,172619,DB01373,Calcium
,17318527,AUC(72-76),"Nimodipine AUC values (expressed in mug min/ml) were lower in the eight SAH patients receiving enteral nimodipine [AUC(0-4) range: 0.13-5.4 (median: 0.32); AUC(24-28) range: 0.16-6.1 (0.71); AUC(72-76) range: 0.47-20.6 (1.9)] than in the nine patients receiving a continuous intravenous infusion of nimodipine [AUC(0-4) range: 2.4-4.9 (3.4), p=0.059; AUC(24-28) range: 4.7-10.3 (7.3), p=0.001; AUC(72-76) range: 3.4-8.6 (6.9), p=0.001].",Early-phase pharmacokinetics of enteral and parenteral nimodipine in patients with acute subarachnoid haemorrhage - a pilot study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318527/),,3.4-8.6,172620,DB01373,Calcium
,18691988,t(1/2),"In the single-dose study, the mean t(1/2) for aranidipine 5, 10, and 20 mg was 3.0 (2.7), 2.7 (1.1), and 3.1 (2.2) hours, respectively; mean T(max) was 4.9 (0.4), 4.4 (1.0), and 4.3 (0.9) hours; mean C(max) was 1.1 (0.6), 2.4 (0.8), and 4.0 (2.0) microg/L; and mean AUC(last) was 4.1 (1.4), 10.3 (2.3), and 20.9 (4.2) microg .","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),h,3.0,172694,DB01373,Calcium
,18691988,t(1/2),"In the single-dose study, the mean t(1/2) for aranidipine 5, 10, and 20 mg was 3.0 (2.7), 2.7 (1.1), and 3.1 (2.2) hours, respectively; mean T(max) was 4.9 (0.4), 4.4 (1.0), and 4.3 (0.9) hours; mean C(max) was 1.1 (0.6), 2.4 (0.8), and 4.0 (2.0) microg/L; and mean AUC(last) was 4.1 (1.4), 10.3 (2.3), and 20.9 (4.2) microg .","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),h,2.7,172695,DB01373,Calcium
,18691988,t(1/2),"In the single-dose study, the mean t(1/2) for aranidipine 5, 10, and 20 mg was 3.0 (2.7), 2.7 (1.1), and 3.1 (2.2) hours, respectively; mean T(max) was 4.9 (0.4), 4.4 (1.0), and 4.3 (0.9) hours; mean C(max) was 1.1 (0.6), 2.4 (0.8), and 4.0 (2.0) microg/L; and mean AUC(last) was 4.1 (1.4), 10.3 (2.3), and 20.9 (4.2) microg .","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),h,3.1,172696,DB01373,Calcium
,18691988,T(max),"In the single-dose study, the mean t(1/2) for aranidipine 5, 10, and 20 mg was 3.0 (2.7), 2.7 (1.1), and 3.1 (2.2) hours, respectively; mean T(max) was 4.9 (0.4), 4.4 (1.0), and 4.3 (0.9) hours; mean C(max) was 1.1 (0.6), 2.4 (0.8), and 4.0 (2.0) microg/L; and mean AUC(last) was 4.1 (1.4), 10.3 (2.3), and 20.9 (4.2) microg .","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),h,4.9,172697,DB01373,Calcium
,18691988,T(max),"In the single-dose study, the mean t(1/2) for aranidipine 5, 10, and 20 mg was 3.0 (2.7), 2.7 (1.1), and 3.1 (2.2) hours, respectively; mean T(max) was 4.9 (0.4), 4.4 (1.0), and 4.3 (0.9) hours; mean C(max) was 1.1 (0.6), 2.4 (0.8), and 4.0 (2.0) microg/L; and mean AUC(last) was 4.1 (1.4), 10.3 (2.3), and 20.9 (4.2) microg .","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),h,4.4,172698,DB01373,Calcium
,18691988,T(max),"In the single-dose study, the mean t(1/2) for aranidipine 5, 10, and 20 mg was 3.0 (2.7), 2.7 (1.1), and 3.1 (2.2) hours, respectively; mean T(max) was 4.9 (0.4), 4.4 (1.0), and 4.3 (0.9) hours; mean C(max) was 1.1 (0.6), 2.4 (0.8), and 4.0 (2.0) microg/L; and mean AUC(last) was 4.1 (1.4), 10.3 (2.3), and 20.9 (4.2) microg .","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),h,4.3,172699,DB01373,Calcium
,18691988,C(max),"In the single-dose study, the mean t(1/2) for aranidipine 5, 10, and 20 mg was 3.0 (2.7), 2.7 (1.1), and 3.1 (2.2) hours, respectively; mean T(max) was 4.9 (0.4), 4.4 (1.0), and 4.3 (0.9) hours; mean C(max) was 1.1 (0.6), 2.4 (0.8), and 4.0 (2.0) microg/L; and mean AUC(last) was 4.1 (1.4), 10.3 (2.3), and 20.9 (4.2) microg .","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),[μg] / [l],1.1,172700,DB01373,Calcium
,18691988,C(max),"In the single-dose study, the mean t(1/2) for aranidipine 5, 10, and 20 mg was 3.0 (2.7), 2.7 (1.1), and 3.1 (2.2) hours, respectively; mean T(max) was 4.9 (0.4), 4.4 (1.0), and 4.3 (0.9) hours; mean C(max) was 1.1 (0.6), 2.4 (0.8), and 4.0 (2.0) microg/L; and mean AUC(last) was 4.1 (1.4), 10.3 (2.3), and 20.9 (4.2) microg .","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),[μg] / [l],2.4,172701,DB01373,Calcium
,18691988,C(max),"In the single-dose study, the mean t(1/2) for aranidipine 5, 10, and 20 mg was 3.0 (2.7), 2.7 (1.1), and 3.1 (2.2) hours, respectively; mean T(max) was 4.9 (0.4), 4.4 (1.0), and 4.3 (0.9) hours; mean C(max) was 1.1 (0.6), 2.4 (0.8), and 4.0 (2.0) microg/L; and mean AUC(last) was 4.1 (1.4), 10.3 (2.3), and 20.9 (4.2) microg .","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),[μg] / [l],4.0,172702,DB01373,Calcium
,18691988,AUC(last),"In the single-dose study, the mean t(1/2) for aranidipine 5, 10, and 20 mg was 3.0 (2.7), 2.7 (1.1), and 3.1 (2.2) hours, respectively; mean T(max) was 4.9 (0.4), 4.4 (1.0), and 4.3 (0.9) hours; mean C(max) was 1.1 (0.6), 2.4 (0.8), and 4.0 (2.0) microg/L; and mean AUC(last) was 4.1 (1.4), 10.3 (2.3), and 20.9 (4.2) microg .","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),μg,4.1,172703,DB01373,Calcium
,18691988,AUC(last),"In the single-dose study, the mean t(1/2) for aranidipine 5, 10, and 20 mg was 3.0 (2.7), 2.7 (1.1), and 3.1 (2.2) hours, respectively; mean T(max) was 4.9 (0.4), 4.4 (1.0), and 4.3 (0.9) hours; mean C(max) was 1.1 (0.6), 2.4 (0.8), and 4.0 (2.0) microg/L; and mean AUC(last) was 4.1 (1.4), 10.3 (2.3), and 20.9 (4.2) microg .","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),μg,10.3,172704,DB01373,Calcium
,18691988,AUC(last),"In the single-dose study, the mean t(1/2) for aranidipine 5, 10, and 20 mg was 3.0 (2.7), 2.7 (1.1), and 3.1 (2.2) hours, respectively; mean T(max) was 4.9 (0.4), 4.4 (1.0), and 4.3 (0.9) hours; mean C(max) was 1.1 (0.6), 2.4 (0.8), and 4.0 (2.0) microg/L; and mean AUC(last) was 4.1 (1.4), 10.3 (2.3), and 20.9 (4.2) microg .","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),μg,20.9,172705,DB01373,Calcium
,18691988,t(1/2),"For M-1, the corresponding values were 4.6 (1.0), 4.1 (0.5), and 4.1 (0.3) hours for t(1/2); 5.6 (2.0), 5.0 (1.6), and 5.0 (0.8) hours for T(max); 18.4 (0.6), 40.5 (10.0), and 39.2 (11.3) microg/L for C(max); and 143.5 (39.1), 304.5 (108.2), and 403.9 (73.5) microg . h/L for AUC(last).","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),h,4.6,172706,DB01373,Calcium
,18691988,t(1/2),"For M-1, the corresponding values were 4.6 (1.0), 4.1 (0.5), and 4.1 (0.3) hours for t(1/2); 5.6 (2.0), 5.0 (1.6), and 5.0 (0.8) hours for T(max); 18.4 (0.6), 40.5 (10.0), and 39.2 (11.3) microg/L for C(max); and 143.5 (39.1), 304.5 (108.2), and 403.9 (73.5) microg . h/L for AUC(last).","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),h,4.1,172707,DB01373,Calcium
,18691988,t(1/2),"For M-1, the corresponding values were 4.6 (1.0), 4.1 (0.5), and 4.1 (0.3) hours for t(1/2); 5.6 (2.0), 5.0 (1.6), and 5.0 (0.8) hours for T(max); 18.4 (0.6), 40.5 (10.0), and 39.2 (11.3) microg/L for C(max); and 143.5 (39.1), 304.5 (108.2), and 403.9 (73.5) microg . h/L for AUC(last).","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),h,4.1,172708,DB01373,Calcium
,18691988,T(max),"For M-1, the corresponding values were 4.6 (1.0), 4.1 (0.5), and 4.1 (0.3) hours for t(1/2); 5.6 (2.0), 5.0 (1.6), and 5.0 (0.8) hours for T(max); 18.4 (0.6), 40.5 (10.0), and 39.2 (11.3) microg/L for C(max); and 143.5 (39.1), 304.5 (108.2), and 403.9 (73.5) microg . h/L for AUC(last).","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),h,5.6,172709,DB01373,Calcium
,18691988,T(max),"For M-1, the corresponding values were 4.6 (1.0), 4.1 (0.5), and 4.1 (0.3) hours for t(1/2); 5.6 (2.0), 5.0 (1.6), and 5.0 (0.8) hours for T(max); 18.4 (0.6), 40.5 (10.0), and 39.2 (11.3) microg/L for C(max); and 143.5 (39.1), 304.5 (108.2), and 403.9 (73.5) microg . h/L for AUC(last).","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),h,5.0,172710,DB01373,Calcium
,18691988,T(max),"For M-1, the corresponding values were 4.6 (1.0), 4.1 (0.5), and 4.1 (0.3) hours for t(1/2); 5.6 (2.0), 5.0 (1.6), and 5.0 (0.8) hours for T(max); 18.4 (0.6), 40.5 (10.0), and 39.2 (11.3) microg/L for C(max); and 143.5 (39.1), 304.5 (108.2), and 403.9 (73.5) microg . h/L for AUC(last).","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),h,5.0,172711,DB01373,Calcium
,18691988,C(max),"For M-1, the corresponding values were 4.6 (1.0), 4.1 (0.5), and 4.1 (0.3) hours for t(1/2); 5.6 (2.0), 5.0 (1.6), and 5.0 (0.8) hours for T(max); 18.4 (0.6), 40.5 (10.0), and 39.2 (11.3) microg/L for C(max); and 143.5 (39.1), 304.5 (108.2), and 403.9 (73.5) microg . h/L for AUC(last).","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),[μg] / [l],18.4,172712,DB01373,Calcium
,18691988,C(max),"For M-1, the corresponding values were 4.6 (1.0), 4.1 (0.5), and 4.1 (0.3) hours for t(1/2); 5.6 (2.0), 5.0 (1.6), and 5.0 (0.8) hours for T(max); 18.4 (0.6), 40.5 (10.0), and 39.2 (11.3) microg/L for C(max); and 143.5 (39.1), 304.5 (108.2), and 403.9 (73.5) microg . h/L for AUC(last).","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),[μg] / [l],40.5,172713,DB01373,Calcium
,18691988,C(max),"For M-1, the corresponding values were 4.6 (1.0), 4.1 (0.5), and 4.1 (0.3) hours for t(1/2); 5.6 (2.0), 5.0 (1.6), and 5.0 (0.8) hours for T(max); 18.4 (0.6), 40.5 (10.0), and 39.2 (11.3) microg/L for C(max); and 143.5 (39.1), 304.5 (108.2), and 403.9 (73.5) microg . h/L for AUC(last).","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),[μg] / [l],39.2,172714,DB01373,Calcium
,18691988,C(max),"For M-1, the corresponding values were 4.6 (1.0), 4.1 (0.5), and 4.1 (0.3) hours for t(1/2); 5.6 (2.0), 5.0 (1.6), and 5.0 (0.8) hours for T(max); 18.4 (0.6), 40.5 (10.0), and 39.2 (11.3) microg/L for C(max); and 143.5 (39.1), 304.5 (108.2), and 403.9 (73.5) microg . h/L for AUC(last).","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),[h·μg] / [l],304.5,172715,DB01373,Calcium
,18691988,AUC(last,"For M-1, the corresponding values were 4.6 (1.0), 4.1 (0.5), and 4.1 (0.3) hours for t(1/2); 5.6 (2.0), 5.0 (1.6), and 5.0 (0.8) hours for T(max); 18.4 (0.6), 40.5 (10.0), and 39.2 (11.3) microg/L for C(max); and 143.5 (39.1), 304.5 (108.2), and 403.9 (73.5) microg . h/L for AUC(last).","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),[h·μg] / [l],143.5,172716,DB01373,Calcium
,18691988,AUC(last,"For M-1, the corresponding values were 4.6 (1.0), 4.1 (0.5), and 4.1 (0.3) hours for t(1/2); 5.6 (2.0), 5.0 (1.6), and 5.0 (0.8) hours for T(max); 18.4 (0.6), 40.5 (10.0), and 39.2 (11.3) microg/L for C(max); and 143.5 (39.1), 304.5 (108.2), and 403.9 (73.5) microg . h/L for AUC(last).","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),[h·μg] / [l],304.5,172717,DB01373,Calcium
,18691988,AUC(last,"For M-1, the corresponding values were 4.6 (1.0), 4.1 (0.5), and 4.1 (0.3) hours for t(1/2); 5.6 (2.0), 5.0 (1.6), and 5.0 (0.8) hours for T(max); 18.4 (0.6), 40.5 (10.0), and 39.2 (11.3) microg/L for C(max); and 143.5 (39.1), 304.5 (108.2), and 403.9 (73.5) microg . h/L for AUC(last).","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),[h·μg] / [l],403.9,172718,DB01373,Calcium
,18691988,t(1/2),"After multiple doses, the mean values for t(1/2), T(max), C(max), and AUC(0-infinity) for aranidipine 10 mg were 2.3 (0.9) hours, 5.0 (1.2) hours, 3.1 (1.1) microg/L, and 13.8 (3.6) microg .","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),h,2.3,172719,DB01373,Calcium
,18691988,T(max),"After multiple doses, the mean values for t(1/2), T(max), C(max), and AUC(0-infinity) for aranidipine 10 mg were 2.3 (0.9) hours, 5.0 (1.2) hours, 3.1 (1.1) microg/L, and 13.8 (3.6) microg .","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),h,5.0,172720,DB01373,Calcium
,18691988,C(max),"After multiple doses, the mean values for t(1/2), T(max), C(max), and AUC(0-infinity) for aranidipine 10 mg were 2.3 (0.9) hours, 5.0 (1.2) hours, 3.1 (1.1) microg/L, and 13.8 (3.6) microg .","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),h,5.0,172721,DB01373,Calcium
,18691988,AUC(0-infinity),"After multiple doses, the mean values for t(1/2), T(max), C(max), and AUC(0-infinity) for aranidipine 10 mg were 2.3 (0.9) hours, 5.0 (1.2) hours, 3.1 (1.1) microg/L, and 13.8 (3.6) microg .","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),μg,13.8,172722,DB01373,Calcium
,18691988,M-1,"The corresponding values for M-1 were 4.8 (0.9) hours, 5.7 (1.3) hours, 40.0 (11.3) microg/L, and 381.8 (161.2) microg .","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),h,4.8,172723,DB01373,Calcium
,18691988,M-1,"The corresponding values for M-1 were 4.8 (0.9) hours, 5.7 (1.3) hours, 40.0 (11.3) microg/L, and 381.8 (161.2) microg .","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),h,5.7,172724,DB01373,Calcium
,18691988,M-1,"The corresponding values for M-1 were 4.8 (0.9) hours, 5.7 (1.3) hours, 40.0 (11.3) microg/L, and 381.8 (161.2) microg .","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),[μg] / [l],40.0,172725,DB01373,Calcium
,18691988,M-1,"The corresponding values for M-1 were 4.8 (0.9) hours, 5.7 (1.3) hours, 40.0 (11.3) microg/L, and 381.8 (161.2) microg .","Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691988/),μg,381.8,172726,DB01373,Calcium
,16541405,linear dynamic,The assay exhibited a linear dynamic range of 2-500 ng/mL for fluvastatin in human plasma.,Liquid chromatography/negative ion electrospray tandem mass spectrometry method for the quantification of fluvastatin in human plasma: validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16541405/),[ng] / [ml],2-500,173102,DB01373,Calcium
,16541405,run time,A run time of 1.5 min for each sample made it possible to analyze more than 400 human plasma samples per day.,Liquid chromatography/negative ion electrospray tandem mass spectrometry method for the quantification of fluvastatin in human plasma: validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16541405/),min,1.5,173103,DB01373,Calcium
,20417274,zeta potential,"The particle size and zeta potential of nanocrystals were 209 nm (+/- 9 nm) and -13.9 mV (+/-1.9 mV), respectively.",Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20417274/),mv,-,173587,DB01373,Calcium
,20417274,zeta potential,"The particle size and zeta potential of nanocrystals were 209 nm (+/- 9 nm) and -13.9 mV (+/-1.9 mV), respectively.",Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20417274/),mv,13.9,173588,DB01373,Calcium
,26347996,peak concentration,"The results indicated that, when the rats were pretreated with verapamil, the peak concentration of pristimerin increased from 189.13 to 277.53 ng/mL (46.7%), and the AUC0-t increased by approximately 82.0%.",Influence of verapamil on pharmacokinetics of pristimerin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26347996/),[ng] / [ml],189.13,174289,DB01373,Calcium
,26347996,peak concentration,"The results indicated that, when the rats were pretreated with verapamil, the peak concentration of pristimerin increased from 189.13 to 277.53 ng/mL (46.7%), and the AUC0-t increased by approximately 82.0%.",Influence of verapamil on pharmacokinetics of pristimerin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26347996/),[ng] / [ml],277.53,174290,DB01373,Calcium
,30368658,maximum plasma concentration (Cmax),"Following a single oral dose of tylerdipine of 5-30 mg, the mean maximum plasma concentration (Cmax) increased from 0.9993 to 10.11 ng/ml; mean area under the plasma-concentration curve (AUC) from time zero to 72 h increased from 4.332 to 73.95 h·ng/ml.","Pharmacokinetics, Safety and Tolerability of Tylerdipine Hydrochloride, a Novel Dihydropyridine Dual L/T-type Calcium Channel Blocker, after Single and Multiple Oral Doses in Healthy Chinese Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30368658/),[ng] / [ml],0.9993,174596,DB01373,Calcium
,30368658,maximum plasma concentration (Cmax),"Following a single oral dose of tylerdipine of 5-30 mg, the mean maximum plasma concentration (Cmax) increased from 0.9993 to 10.11 ng/ml; mean area under the plasma-concentration curve (AUC) from time zero to 72 h increased from 4.332 to 73.95 h·ng/ml.","Pharmacokinetics, Safety and Tolerability of Tylerdipine Hydrochloride, a Novel Dihydropyridine Dual L/T-type Calcium Channel Blocker, after Single and Multiple Oral Doses in Healthy Chinese Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30368658/),[ng] / [ml],10.11,174597,DB01373,Calcium
,30368658,area under the plasma-concentration curve (AUC) from time zero to 72 h,"Following a single oral dose of tylerdipine of 5-30 mg, the mean maximum plasma concentration (Cmax) increased from 0.9993 to 10.11 ng/ml; mean area under the plasma-concentration curve (AUC) from time zero to 72 h increased from 4.332 to 73.95 h·ng/ml.","Pharmacokinetics, Safety and Tolerability of Tylerdipine Hydrochloride, a Novel Dihydropyridine Dual L/T-type Calcium Channel Blocker, after Single and Multiple Oral Doses in Healthy Chinese Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30368658/),[h·ng] / [ml],4.332,174598,DB01373,Calcium
,30368658,area under the plasma-concentration curve (AUC) from time zero to 72 h,"Following a single oral dose of tylerdipine of 5-30 mg, the mean maximum plasma concentration (Cmax) increased from 0.9993 to 10.11 ng/ml; mean area under the plasma-concentration curve (AUC) from time zero to 72 h increased from 4.332 to 73.95 h·ng/ml.","Pharmacokinetics, Safety and Tolerability of Tylerdipine Hydrochloride, a Novel Dihydropyridine Dual L/T-type Calcium Channel Blocker, after Single and Multiple Oral Doses in Healthy Chinese Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30368658/),[h·ng] / [ml],73.95,174599,DB01373,Calcium
less,30368658,accumulation ratios (RAUC),"Accumulation of tylerdipine was low, with accumulation ratios (RAUC) of less than 1.65.","Pharmacokinetics, Safety and Tolerability of Tylerdipine Hydrochloride, a Novel Dihydropyridine Dual L/T-type Calcium Channel Blocker, after Single and Multiple Oral Doses in Healthy Chinese Subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30368658/),,1.65,174600,DB01373,Calcium
,15689158,IC50,The 5-isoquinoline-containing compound 14a (hTRPV1 IC50 = 4 nM) exhibited 46% oral bioavailability and in vivo activity in animal models of visceral and inflammatory pain.,"Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15689158/),nM,4,174658,DB01373,Calcium
,15689158,oral bioavailability,The 5-isoquinoline-containing compound 14a (hTRPV1 IC50 = 4 nM) exhibited 46% oral bioavailability and in vivo activity in animal models of visceral and inflammatory pain.,"Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15689158/),%,46,174659,DB01373,Calcium
,15689158,IC50,"Pharmacokinetic and pharmacological properties of 14a are substantial improvements over the profile of the high-throughput screening hit 1 (hTRPV1 IC50 = 22 nM), which was not efficacious in animal pain models and was not orally bioavailable.","Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15689158/),nM,22,174660,DB01373,Calcium
,16806856,maximum concentration,"The study showed that there is a substantial and immediate transport of rosuvastatin into the human bile, with the maximum concentration appearing 42 min after dosing, 39,000+/-31,000 ng/ml.",Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16806856/),[ng] / [ml],"39,000",175221,DB01373,Calcium
,16806856,bile to plasma ratio,"At all time points the biliary concentration exceeded the plasma concentration, and the average bile to plasma ratio was 5200+/-9200 (range 89-33,900, median 2000).",Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16806856/),,5200,175222,DB01373,Calcium
,29517132,terminal half-life,The AZD5718 was rapidly absorbed and plasma concentrations declined biphasically with a mean terminal half-life of 10-12 h.,"Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5-Lipoxygenase Activating Protein Inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29517132/),h,10-12,175509,DB01373,Calcium
,21890509,width in time at half-maximal intensity,"Vehicle data were described by a baseline and a surge function; the surge peak was determined to be approximately 9.69 min by all approaches, and its width in time at half-maximal intensity was 5 min (1-min count and RTTE) or 10 min (5-min count).",Transient lower esophageal sphincter relaxation pharmacokinetic-pharmacodynamic modeling: count model and repeated time-to-event model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21890509/),min,5,176150,DB01373,Calcium
,21890509,width in time at half-maximal intensity,"Vehicle data were described by a baseline and a surge function; the surge peak was determined to be approximately 9.69 min by all approaches, and its width in time at half-maximal intensity was 5 min (1-min count and RTTE) or 10 min (5-min count).",Transient lower esophageal sphincter relaxation pharmacokinetic-pharmacodynamic modeling: count model and repeated time-to-event model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21890509/),,1,176151,DB01373,Calcium
,21890509,width in time at half-maximal intensity,"Vehicle data were described by a baseline and a surge function; the surge peak was determined to be approximately 9.69 min by all approaches, and its width in time at half-maximal intensity was 5 min (1-min count and RTTE) or 10 min (5-min count).",Transient lower esophageal sphincter relaxation pharmacokinetic-pharmacodynamic modeling: count model and repeated time-to-event model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21890509/),min,10,176152,DB01373,Calcium
,21890509,width in time at half-maximal intensity,"Vehicle data were described by a baseline and a surge function; the surge peak was determined to be approximately 9.69 min by all approaches, and its width in time at half-maximal intensity was 5 min (1-min count and RTTE) or 10 min (5-min count).",Transient lower esophageal sphincter relaxation pharmacokinetic-pharmacodynamic modeling: count model and repeated time-to-event model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21890509/),,5,176153,DB01373,Calcium
,21890509,IC(50),"TLESR inhibition by WIN55212-2 was described by an I(max) model, with an IC(50) of on average 2.39 nmol · l(-1).",Transient lower esophageal sphincter relaxation pharmacokinetic-pharmacodynamic modeling: count model and repeated time-to-event model. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21890509/),[nM] / [l],2.39,176154,DB01373,Calcium
,11805220,K(i),"SC-57461A (3-[methyl[3-[4-phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl) is a potent inhibitor of human recombinant LTA(4) hydrolase (epoxide hydrolase and aminopeptidase activities, K(i) values = 23 and 27 nM, respectively) as well as calcium ionophore-induced LTB(4) production in human whole blood (IC(50) = 49 nM).","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),nM,23,176267,DB01373,Calcium
,11805220,K(i),"SC-57461A (3-[methyl[3-[4-phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl) is a potent inhibitor of human recombinant LTA(4) hydrolase (epoxide hydrolase and aminopeptidase activities, K(i) values = 23 and 27 nM, respectively) as well as calcium ionophore-induced LTB(4) production in human whole blood (IC(50) = 49 nM).","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),nM,27,176268,DB01373,Calcium
,11805220,IC(50),"SC-57461A (3-[methyl[3-[4-phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl) is a potent inhibitor of human recombinant LTA(4) hydrolase (epoxide hydrolase and aminopeptidase activities, K(i) values = 23 and 27 nM, respectively) as well as calcium ionophore-induced LTB(4) production in human whole blood (IC(50) = 49 nM).","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),nM,49,176269,DB01373,Calcium
,11805220,ED(50),"Oral activity was evident from the ability of the compound to inhibit mouse ex vivo calcium ionophore-stimulated blood LTB(4) production with ED(50) values at 1.0 and 3.0 h of 0.2 and 0.8 mg/kg, respectively.","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),h,1.0,176270,DB01373,Calcium
,11805220,ED(50),"Oral activity was evident from the ability of the compound to inhibit mouse ex vivo calcium ionophore-stimulated blood LTB(4) production with ED(50) values at 1.0 and 3.0 h of 0.2 and 0.8 mg/kg, respectively.","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),h,3.0,176271,DB01373,Calcium
,11805220,ED(50),"Oral activity was evident from the ability of the compound to inhibit mouse ex vivo calcium ionophore-stimulated blood LTB(4) production with ED(50) values at 1.0 and 3.0 h of 0.2 and 0.8 mg/kg, respectively.","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),[mg] / [kg],0.2,176272,DB01373,Calcium
,11805220,ED(50),"Oral activity was evident from the ability of the compound to inhibit mouse ex vivo calcium ionophore-stimulated blood LTB(4) production with ED(50) values at 1.0 and 3.0 h of 0.2 and 0.8 mg/kg, respectively.","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),[mg] / [kg],0.8,176273,DB01373,Calcium
,11805220,ED(50),"In a rat model of ionophore-induced peritoneal eicosanoid production, SC-57461 inhibited LTB(4) production in a dose-dependent manner (ED(50) = 0.3-1 mg/kg) without affecting LTC(4) or 6-keto-prostaglandin F(1alpha) production.","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),[mg] / [kg],0.3-1,176274,DB01373,Calcium
,11805220,ED(90),"Oral pretreatment with SC-57461 in a rat reversed passive dermal Arthus model blocked LTB(4) production with an ED(90) value of 3 to 10 mg/kg, demonstrating good penetration of drug into skin.","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),[mg] / [kg],3 to 10,176275,DB01373,Calcium
,23649554,peak level,"PTH levels rose immediately, reaching a median peak level of 26.5 (interquartile range [IQR], 20.1-42.5) pmol/L 15 minutes following injection.",PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23649554/),[pM] / [l],26.5,176450,DB01373,Calcium
,23649554,plasma half-life,"Thereafter, levels gradually decreased until reaching predosing levels after 16 hours, with a plasma half-life of 2.2 (1.7-2.5) hours.",PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23649554/),h,2.2,176451,DB01373,Calcium
,30151212,time to maximum concentration,"After oral administration, mirogabalin was rapidly absorbed (time to maximum concentration, ∼1 hour) and eliminated through urine unchanged (61%-72% urinary excretion).","Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30151212/),h,∼1,176897,DB01373,Calcium
,33560891,Tmax,MT-1207 was rapidly absorbed (median Tmax: 0.5-1.25 h).,"Pharmacokinetics and pharmacodynamics of MT-1207, a novel multitarget blocker of α1 receptor, 5-HT2A receptor, and calcium channel, in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33560891/),h,0.5-1.25,176956,DB01373,Calcium
,33560891,t1/2,The mean t1/2 of MT-1207 was approximately 4-7 hours.,"Pharmacokinetics and pharmacodynamics of MT-1207, a novel multitarget blocker of α1 receptor, 5-HT2A receptor, and calcium channel, in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33560891/),h,4-7,176957,DB01373,Calcium
,16336286,peak plasma concentrations,"Benidipine reached mean peak plasma concentrations of 1.04 and 3.85 ng/mL at 0.5 and 0.75 h after 4 and 8 mg doses, respectively.",Pharmacokinetics and pharmacodynamics of benidipine using a slow receptor-binding model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16336286/),[ng] / [ml],1.04,177269,DB01373,Calcium
,16336286,peak plasma concentrations,"Benidipine reached mean peak plasma concentrations of 1.04 and 3.85 ng/mL at 0.5 and 0.75 h after 4 and 8 mg doses, respectively.",Pharmacokinetics and pharmacodynamics of benidipine using a slow receptor-binding model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16336286/),[ng] / [ml],3.85,177270,DB01373,Calcium
,16336286,maximal increases,"Maximal decreases in diastolic blood pressure with 4 and 8 mg of benidipine were 7.79 and 14.75 mmHg, respectively, and maximal increases in heart rate were 7.32 and 17.56 bpm, respectively.",Pharmacokinetics and pharmacodynamics of benidipine using a slow receptor-binding model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16336286/),bpm,7.32,177271,DB01373,Calcium
,16336286,maximal increases,"Maximal decreases in diastolic blood pressure with 4 and 8 mg of benidipine were 7.79 and 14.75 mmHg, respectively, and maximal increases in heart rate were 7.32 and 17.56 bpm, respectively.",Pharmacokinetics and pharmacodynamics of benidipine using a slow receptor-binding model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16336286/),bpm,17.56,177272,DB01373,Calcium
,16336286,heart rate,"Maximal decreases in diastolic blood pressure with 4 and 8 mg of benidipine were 7.79 and 14.75 mmHg, respectively, and maximal increases in heart rate were 7.32 and 17.56 bpm, respectively.",Pharmacokinetics and pharmacodynamics of benidipine using a slow receptor-binding model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16336286/),bpm,7.32,177273,DB01373,Calcium
,16336286,heart rate,"Maximal decreases in diastolic blood pressure with 4 and 8 mg of benidipine were 7.79 and 14.75 mmHg, respectively, and maximal increases in heart rate were 7.32 and 17.56 bpm, respectively.",Pharmacokinetics and pharmacodynamics of benidipine using a slow receptor-binding model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16336286/),bpm,17.56,177274,DB01373,Calcium
,24674989,flow rate,"Chromatographic separation was achieved on a reversed phase C18 column with a mobile phase consisted of a water mixture of 10mM potassium dihydrogen phosphate (pH=4.5):methanol (40:60, v/v), pumped at flow rate of 1.0mL/min, and detected at 303nm.",High performance liquid chromatographic method for the determination of cinepazide maleate and its application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24674989/),[ml] / [min],1.0,177442,DB01373,Calcium
>,17006328,EC50,"While FTY720-P activated both S1P1 and S1P3 receptors, KRP-203-P selectively activated S1P1, but not the S1P3 receptor (EC50:>1000 nM).","Use of sphingosine-1-phosphate 1 receptor agonist, KRP-203, in combination with a subtherapeutic dose of cyclosporine A for rat renal transplantation. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17006328/),nM,1000,177486,DB01373,Calcium
,17006328,survival time,"With a low dose of CsA (1 mg/kg/day), KRP-203 (0.3 mg/kg/day) significantly prolonged renal allograft survival (P<0.05, survival time: 9.8 days (CsA) vs. >27.4 days (CsA+KRP)).","Use of sphingosine-1-phosphate 1 receptor agonist, KRP-203, in combination with a subtherapeutic dose of cyclosporine A for rat renal transplantation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17006328/),d,9.8,177487,DB01373,Calcium
>,17006328,survival time,"With a low dose of CsA (1 mg/kg/day), KRP-203 (0.3 mg/kg/day) significantly prolonged renal allograft survival (P<0.05, survival time: 9.8 days (CsA) vs. >27.4 days (CsA+KRP)).","Use of sphingosine-1-phosphate 1 receptor agonist, KRP-203, in combination with a subtherapeutic dose of cyclosporine A for rat renal transplantation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17006328/),d,27.4,177488,DB01373,Calcium
,32361977,accumulation factor,The accumulation factor for multiple daily dosing was approximately 2.,"Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32361977/),,2,177782,DB01373,Calcium
,32361977,plasma half-life,"The geometric mean plasma half-life of IMU-838 at steady state was approximately 30 h, which supports its use for once-daily dosing regimen.","Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32361977/),h,30,177783,DB01373,Calcium
,22503212,T(max),The median T(max) value in each of the 3 dose groups was 6.0 hours.,"Pharmacokinetic and pharmacodynamic properties of the calcimimetic agent cinacalcet (KRN1493) in healthy male Korean subjects: a randomized, open-label, single ascending-dose, parallel-group study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22503212/),h,6.0,178000,DB01373,Calcium
,22503212,C(max),"Mean C(max) values in the 50-, 75-, and 100-mg dose groups were 12.0 (5.5), 17.2 (14.9), and 43.1 (15.5) μg/L; mean AUC(0-∞) values were 126.6 (56.4), 184.3 (87.9), and 417.4 (169.9) μg · h/L.","Pharmacokinetic and pharmacodynamic properties of the calcimimetic agent cinacalcet (KRN1493) in healthy male Korean subjects: a randomized, open-label, single ascending-dose, parallel-group study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22503212/),[μg] / [l],12.0,178001,DB01373,Calcium
,22503212,C(max),"Mean C(max) values in the 50-, 75-, and 100-mg dose groups were 12.0 (5.5), 17.2 (14.9), and 43.1 (15.5) μg/L; mean AUC(0-∞) values were 126.6 (56.4), 184.3 (87.9), and 417.4 (169.9) μg · h/L.","Pharmacokinetic and pharmacodynamic properties of the calcimimetic agent cinacalcet (KRN1493) in healthy male Korean subjects: a randomized, open-label, single ascending-dose, parallel-group study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22503212/),[μg] / [l],17.2,178002,DB01373,Calcium
,22503212,C(max),"Mean C(max) values in the 50-, 75-, and 100-mg dose groups were 12.0 (5.5), 17.2 (14.9), and 43.1 (15.5) μg/L; mean AUC(0-∞) values were 126.6 (56.4), 184.3 (87.9), and 417.4 (169.9) μg · h/L.","Pharmacokinetic and pharmacodynamic properties of the calcimimetic agent cinacalcet (KRN1493) in healthy male Korean subjects: a randomized, open-label, single ascending-dose, parallel-group study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22503212/),[μg] / [l],43.1,178003,DB01373,Calcium
,22503212,AUC(0-∞),"Mean C(max) values in the 50-, 75-, and 100-mg dose groups were 12.0 (5.5), 17.2 (14.9), and 43.1 (15.5) μg/L; mean AUC(0-∞) values were 126.6 (56.4), 184.3 (87.9), and 417.4 (169.9) μg · h/L.","Pharmacokinetic and pharmacodynamic properties of the calcimimetic agent cinacalcet (KRN1493) in healthy male Korean subjects: a randomized, open-label, single ascending-dose, parallel-group study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22503212/),[h·μg] / [l],126.6,178004,DB01373,Calcium
,22503212,AUC(0-∞),"Mean C(max) values in the 50-, 75-, and 100-mg dose groups were 12.0 (5.5), 17.2 (14.9), and 43.1 (15.5) μg/L; mean AUC(0-∞) values were 126.6 (56.4), 184.3 (87.9), and 417.4 (169.9) μg · h/L.","Pharmacokinetic and pharmacodynamic properties of the calcimimetic agent cinacalcet (KRN1493) in healthy male Korean subjects: a randomized, open-label, single ascending-dose, parallel-group study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22503212/),[h·μg] / [l],184.3,178005,DB01373,Calcium
,22503212,AUC(0-∞),"Mean C(max) values in the 50-, 75-, and 100-mg dose groups were 12.0 (5.5), 17.2 (14.9), and 43.1 (15.5) μg/L; mean AUC(0-∞) values were 126.6 (56.4), 184.3 (87.9), and 417.4 (169.9) μg · h/L.","Pharmacokinetic and pharmacodynamic properties of the calcimimetic agent cinacalcet (KRN1493) in healthy male Korean subjects: a randomized, open-label, single ascending-dose, parallel-group study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22503212/),[h·μg] / [l],417.4,178006,DB01373,Calcium
over,17523003,gastric residence time (GRT),Prolonged gastric residence time (GRT) of over 6 hr was achieved in all subjects for calcium silicate based floating granules of Rg.,Porous carrier based floating granular delivery system of repaglinide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523003/),h,6,178017,DB01373,Calcium
,33723919,terminal half-life,"The terminal half-life for CBD was 10.7 ± 3.61, 10.6 ± 3.84 and 9.88 ± 3.53 for 0.5, 1, and 2 mg/kg.",Pharmacokinetics and effects on arachidonic acid metabolism of low doses of cannabidiol following oral administration to horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33723919/),,10.7,179269,DB01373,Calcium
,33723919,terminal half-life,"The terminal half-life for CBD was 10.7 ± 3.61, 10.6 ± 3.84 and 9.88 ± 3.53 for 0.5, 1, and 2 mg/kg.",Pharmacokinetics and effects on arachidonic acid metabolism of low doses of cannabidiol following oral administration to horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33723919/),,10.6,179270,DB01373,Calcium
,33723919,terminal half-life,"The terminal half-life for CBD was 10.7 ± 3.61, 10.6 ± 3.84 and 9.88 ± 3.53 for 0.5, 1, and 2 mg/kg.",Pharmacokinetics and effects on arachidonic acid metabolism of low doses of cannabidiol following oral administration to horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33723919/),,9.88,179271,DB01373,Calcium
,23722358,flow rate,"The mobile phase consisted of a gradient mixture of 15 µmol/L ammonium acetate in water and in methanol, maintained at a flow rate of 0.4 mL/min.",Development and validation of a sensitive method for simultaneous determination of rosuvastatin and N-desmethyl rosuvastatin in human plasma using liquid chromatography/negative electrospray ionization/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23722358/),[ml] / [min],0.4,179423,DB01373,Calcium
,21771277,Cmax,"The pharmacokinetic parameters for rhPTH(1-84) and rhPTH(1-34) after subcutaneous administration of a single dose of 1.0, 2.0 and 4.0 μg/kg were as follows: Cmax = (110.54 ± 59.18), (149.70 ± 50.61) and (372.52± 94.96) pg/mL; (53.93±6.27), (61.12±11.28) and (89.04 ± 7.08) pg/mL, respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),[pg] / [ml],110.54,180349,DB01373,Calcium
,21771277,Cmax,"The pharmacokinetic parameters for rhPTH(1-84) and rhPTH(1-34) after subcutaneous administration of a single dose of 1.0, 2.0 and 4.0 μg/kg were as follows: Cmax = (110.54 ± 59.18), (149.70 ± 50.61) and (372.52± 94.96) pg/mL; (53.93±6.27), (61.12±11.28) and (89.04 ± 7.08) pg/mL, respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),[pg] / [ml],149.70,180350,DB01373,Calcium
,21771277,Cmax,"The pharmacokinetic parameters for rhPTH(1-84) and rhPTH(1-34) after subcutaneous administration of a single dose of 1.0, 2.0 and 4.0 μg/kg were as follows: Cmax = (110.54 ± 59.18), (149.70 ± 50.61) and (372.52± 94.96) pg/mL; (53.93±6.27), (61.12±11.28) and (89.04 ± 7.08) pg/mL, respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),[pg] / [ml],372.52,180351,DB01373,Calcium
,21771277,Cmax,"The pharmacokinetic parameters for rhPTH(1-84) and rhPTH(1-34) after subcutaneous administration of a single dose of 1.0, 2.0 and 4.0 μg/kg were as follows: Cmax = (110.54 ± 59.18), (149.70 ± 50.61) and (372.52± 94.96) pg/mL; (53.93±6.27), (61.12±11.28) and (89.04 ± 7.08) pg/mL, respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),[pg] / [ml],53.93,180352,DB01373,Calcium
,21771277,Cmax,"The pharmacokinetic parameters for rhPTH(1-84) and rhPTH(1-34) after subcutaneous administration of a single dose of 1.0, 2.0 and 4.0 μg/kg were as follows: Cmax = (110.54 ± 59.18), (149.70 ± 50.61) and (372.52± 94.96) pg/mL; (53.93±6.27), (61.12±11.28) and (89.04 ± 7.08) pg/mL, respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),[pg] / [ml],61.12,180353,DB01373,Calcium
,21771277,Cmax,"The pharmacokinetic parameters for rhPTH(1-84) and rhPTH(1-34) after subcutaneous administration of a single dose of 1.0, 2.0 and 4.0 μg/kg were as follows: Cmax = (110.54 ± 59.18), (149.70 ± 50.61) and (372.52± 94.96) pg/mL; (53.93±6.27), (61.12±11.28) and (89.04 ± 7.08) pg/mL, respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),[pg] / [ml],89.04,180354,DB01373,Calcium
,21771277,AUC0-10,"AUC0-10 = (268.87 ± 47.72), (538.93 ± 146.89) and (1364.11 ± 176.82) pg hr/mL; (197.20 ± 50.78), (207.15 ± 72.08) and (344.05 ± 77.06) pg hr/mL, respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),[h·pg] / [ml],268.87,180355,DB01373,Calcium
,21771277,AUC0-10,"AUC0-10 = (268.87 ± 47.72), (538.93 ± 146.89) and (1364.11 ± 176.82) pg hr/mL; (197.20 ± 50.78), (207.15 ± 72.08) and (344.05 ± 77.06) pg hr/mL, respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),[h·pg] / [ml],538.93,180356,DB01373,Calcium
,21771277,AUC0-10,"AUC0-10 = (268.87 ± 47.72), (538.93 ± 146.89) and (1364.11 ± 176.82) pg hr/mL; (197.20 ± 50.78), (207.15 ± 72.08) and (344.05 ± 77.06) pg hr/mL, respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),[h·pg] / [ml],1364.11,180357,DB01373,Calcium
,21771277,AUC0-10,"AUC0-10 = (268.87 ± 47.72), (538.93 ± 146.89) and (1364.11 ± 176.82) pg hr/mL; (197.20 ± 50.78), (207.15 ± 72.08) and (344.05 ± 77.06) pg hr/mL, respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),[h·pg] / [ml],197.20,180358,DB01373,Calcium
,21771277,AUC0-10,"AUC0-10 = (268.87 ± 47.72), (538.93 ± 146.89) and (1364.11 ± 176.82) pg hr/mL; (197.20 ± 50.78), (207.15 ± 72.08) and (344.05 ± 77.06) pg hr/mL, respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),[h·pg] / [ml],207.15,180359,DB01373,Calcium
,21771277,AUC0-10,"AUC0-10 = (268.87 ± 47.72), (538.93 ± 146.89) and (1364.11 ± 176.82) pg hr/mL; (197.20 ± 50.78), (207.15 ± 72.08) and (344.05 ± 77.06) pg hr/mL, respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),[h·pg] / [ml],344.05,180360,DB01373,Calcium
,21771277,t1/2,"t1/2 = (2.34 ± 1.93), (2.58 ± 1.18) and (2.74 ± 1.31) hr; (3.37 ± 1.82), (4.39 ± 3.79), and (3.99 ± 1.85) hr, respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),h,2.34,180361,DB01373,Calcium
,21771277,t1/2,"t1/2 = (2.34 ± 1.93), (2.58 ± 1.18) and (2.74 ± 1.31) hr; (3.37 ± 1.82), (4.39 ± 3.79), and (3.99 ± 1.85) hr, respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),h,2.58,180362,DB01373,Calcium
,21771277,t1/2,"t1/2 = (2.34 ± 1.93), (2.58 ± 1.18) and (2.74 ± 1.31) hr; (3.37 ± 1.82), (4.39 ± 3.79), and (3.99 ± 1.85) hr, respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),h,2.74,180363,DB01373,Calcium
,21771277,t1/2,"t1/2 = (2.34 ± 1.93), (2.58 ± 1.18) and (2.74 ± 1.31) hr; (3.37 ± 1.82), (4.39 ± 3.79), and (3.99 ± 1.85) hr, respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),h,3.37,180364,DB01373,Calcium
,21771277,t1/2,"t1/2 = (2.34 ± 1.93), (2.58 ± 1.18) and (2.74 ± 1.31) hr; (3.37 ± 1.82), (4.39 ± 3.79), and (3.99 ± 1.85) hr, respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),h,4.39,180365,DB01373,Calcium
,21771277,t1/2,"t1/2 = (2.34 ± 1.93), (2.58 ± 1.18) and (2.74 ± 1.31) hr; (3.37 ± 1.82), (4.39 ± 3.79), and (3.99 ± 1.85) hr, respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),h,3.99,180366,DB01373,Calcium
,21771277,Css_max,"The pharmacokinetic parameters for rhPTH(1-84) and rhPTH(1-34) after administration of multiple doses of 2.0 μg/kg were as follows: Css_max = (164.96 ± 52.61) and (75.05 ± 7.31) pg/mL; Css_min = (6.99 ± 7.73) and (2.05 ± 2.82) pg/mL; AUCss = (567.26 ± 118.41) and (306.02 ± 77.55) pg hr/mL; t1/2 = (1.81 ± 0.89) and (2.27 ± 1.11) hr; DF = (6.93 ± 2.64) and (6.00 ± 1.37), respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),[pg] / [ml],164.96,180367,DB01373,Calcium
,21771277,Css_max,"The pharmacokinetic parameters for rhPTH(1-84) and rhPTH(1-34) after administration of multiple doses of 2.0 μg/kg were as follows: Css_max = (164.96 ± 52.61) and (75.05 ± 7.31) pg/mL; Css_min = (6.99 ± 7.73) and (2.05 ± 2.82) pg/mL; AUCss = (567.26 ± 118.41) and (306.02 ± 77.55) pg hr/mL; t1/2 = (1.81 ± 0.89) and (2.27 ± 1.11) hr; DF = (6.93 ± 2.64) and (6.00 ± 1.37), respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),[pg] / [ml],75.05,180368,DB01373,Calcium
,21771277,Css_min,"The pharmacokinetic parameters for rhPTH(1-84) and rhPTH(1-34) after administration of multiple doses of 2.0 μg/kg were as follows: Css_max = (164.96 ± 52.61) and (75.05 ± 7.31) pg/mL; Css_min = (6.99 ± 7.73) and (2.05 ± 2.82) pg/mL; AUCss = (567.26 ± 118.41) and (306.02 ± 77.55) pg hr/mL; t1/2 = (1.81 ± 0.89) and (2.27 ± 1.11) hr; DF = (6.93 ± 2.64) and (6.00 ± 1.37), respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),[pg] / [ml],6.99,180369,DB01373,Calcium
,21771277,Css_min,"The pharmacokinetic parameters for rhPTH(1-84) and rhPTH(1-34) after administration of multiple doses of 2.0 μg/kg were as follows: Css_max = (164.96 ± 52.61) and (75.05 ± 7.31) pg/mL; Css_min = (6.99 ± 7.73) and (2.05 ± 2.82) pg/mL; AUCss = (567.26 ± 118.41) and (306.02 ± 77.55) pg hr/mL; t1/2 = (1.81 ± 0.89) and (2.27 ± 1.11) hr; DF = (6.93 ± 2.64) and (6.00 ± 1.37), respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),[pg] / [ml],2.05,180370,DB01373,Calcium
,21771277,AUCss,"The pharmacokinetic parameters for rhPTH(1-84) and rhPTH(1-34) after administration of multiple doses of 2.0 μg/kg were as follows: Css_max = (164.96 ± 52.61) and (75.05 ± 7.31) pg/mL; Css_min = (6.99 ± 7.73) and (2.05 ± 2.82) pg/mL; AUCss = (567.26 ± 118.41) and (306.02 ± 77.55) pg hr/mL; t1/2 = (1.81 ± 0.89) and (2.27 ± 1.11) hr; DF = (6.93 ± 2.64) and (6.00 ± 1.37), respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),[h·pg] / [ml],567.26,180371,DB01373,Calcium
,21771277,AUCss,"The pharmacokinetic parameters for rhPTH(1-84) and rhPTH(1-34) after administration of multiple doses of 2.0 μg/kg were as follows: Css_max = (164.96 ± 52.61) and (75.05 ± 7.31) pg/mL; Css_min = (6.99 ± 7.73) and (2.05 ± 2.82) pg/mL; AUCss = (567.26 ± 118.41) and (306.02 ± 77.55) pg hr/mL; t1/2 = (1.81 ± 0.89) and (2.27 ± 1.11) hr; DF = (6.93 ± 2.64) and (6.00 ± 1.37), respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),[h·pg] / [ml],306.02,180372,DB01373,Calcium
,21771277,t1/2,"The pharmacokinetic parameters for rhPTH(1-84) and rhPTH(1-34) after administration of multiple doses of 2.0 μg/kg were as follows: Css_max = (164.96 ± 52.61) and (75.05 ± 7.31) pg/mL; Css_min = (6.99 ± 7.73) and (2.05 ± 2.82) pg/mL; AUCss = (567.26 ± 118.41) and (306.02 ± 77.55) pg hr/mL; t1/2 = (1.81 ± 0.89) and (2.27 ± 1.11) hr; DF = (6.93 ± 2.64) and (6.00 ± 1.37), respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),h,1.81,180373,DB01373,Calcium
,21771277,t1/2,"The pharmacokinetic parameters for rhPTH(1-84) and rhPTH(1-34) after administration of multiple doses of 2.0 μg/kg were as follows: Css_max = (164.96 ± 52.61) and (75.05 ± 7.31) pg/mL; Css_min = (6.99 ± 7.73) and (2.05 ± 2.82) pg/mL; AUCss = (567.26 ± 118.41) and (306.02 ± 77.55) pg hr/mL; t1/2 = (1.81 ± 0.89) and (2.27 ± 1.11) hr; DF = (6.93 ± 2.64) and (6.00 ± 1.37), respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),h,2.27,180374,DB01373,Calcium
,21771277,DF,"The pharmacokinetic parameters for rhPTH(1-84) and rhPTH(1-34) after administration of multiple doses of 2.0 μg/kg were as follows: Css_max = (164.96 ± 52.61) and (75.05 ± 7.31) pg/mL; Css_min = (6.99 ± 7.73) and (2.05 ± 2.82) pg/mL; AUCss = (567.26 ± 118.41) and (306.02 ± 77.55) pg hr/mL; t1/2 = (1.81 ± 0.89) and (2.27 ± 1.11) hr; DF = (6.93 ± 2.64) and (6.00 ± 1.37), respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),,6.93,180375,DB01373,Calcium
,21771277,DF,"The pharmacokinetic parameters for rhPTH(1-84) and rhPTH(1-34) after administration of multiple doses of 2.0 μg/kg were as follows: Css_max = (164.96 ± 52.61) and (75.05 ± 7.31) pg/mL; Css_min = (6.99 ± 7.73) and (2.05 ± 2.82) pg/mL; AUCss = (567.26 ± 118.41) and (306.02 ± 77.55) pg hr/mL; t1/2 = (1.81 ± 0.89) and (2.27 ± 1.11) hr; DF = (6.93 ± 2.64) and (6.00 ± 1.37), respectively.","Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771277/),,6.00,180376,DB01373,Calcium
,28063122,terminal half-life,The terminal half-life of total C-14 in plasma was approximately 56 days.,Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28063122/),d,56,180589,DB01373,Calcium
,28063122,ratio of conjugation-deconjugation rate constants,The ratio of conjugation-deconjugation rate constants between etelcalcetide and biotransformed products was 11.3.,Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28063122/),,11.3,180590,DB01373,Calcium
,15991253,apparent volume of distribution,The apparent volume of distribution of (+/-)-DHP-014 was 2.0 L/kg in rats and was unchanged with increasing intravenous doses of (+/-)-DHP-014.,Pharmacokinetics and bioavailability of a newly synthesized dihydropyridine compound with multidrug resistance reversal activity. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15991253/),[l] / [kg],2.0,181681,DB01373,Calcium
,15991253,oral bioavailability,The estimated oral bioavailability of (+/-)-DHP-014 was 8.2%.,Pharmacokinetics and bioavailability of a newly synthesized dihydropyridine compound with multidrug resistance reversal activity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15991253/),%,8.2,181682,DB01373,Calcium
greater,21162117,Log P,MNP001 is a highly lipophilic compound with a Log P value greater than 4.,"Preclinical pharmacokinetics and metabolism of MNP001, a piperidine analog of 3-carbamyl compounds. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21162117/),,4,182161,DB01373,Calcium
,17090399,size,"Average size and zeta potential of SLNs of different lipids, with and without charge modifiers ranged from 101.9 +/- 3.0 to 123.5 +/- 3.0 nm and - 35.1 +/- 0.5 to +34.6 +/- 2.3 mV, respectively.","Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17090399/),nm,101.9,182785,DB01373,Calcium
,17090399,size,"Average size and zeta potential of SLNs of different lipids, with and without charge modifiers ranged from 101.9 +/- 3.0 to 123.5 +/- 3.0 nm and - 35.1 +/- 0.5 to +34.6 +/- 2.3 mV, respectively.","Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17090399/),nm,123.5,182786,DB01373,Calcium
,17090399,zeta potential,"Average size and zeta potential of SLNs of different lipids, with and without charge modifiers ranged from 101.9 +/- 3.0 to 123.5 +/- 3.0 nm and - 35.1 +/- 0.5 to +34.6 +/- 2.3 mV, respectively.","Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17090399/),nm,123.5,182787,DB01373,Calcium
,17090399,zeta potential,"Average size and zeta potential of SLNs of different lipids, with and without charge modifiers ranged from 101.9 +/- 3.0 to 123.5 +/- 3.0 nm and - 35.1 +/- 0.5 to +34.6 +/- 2.3 mV, respectively.","Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17090399/),m,35.1,182788,DB01373,Calcium
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,16.0,183649,DB01373,Calcium
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,43.5,183650,DB01373,Calcium
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,15.2,183651,DB01373,Calcium
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,28.4,183652,DB01373,Calcium
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,5.2,183653,DB01373,Calcium
,22167570,liver-to-plasma ratios,"In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug.","Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167570/),,6.3,183654,DB01373,Calcium
,25549928,Inhibitory concentration (IC50),Inhibitory concentration (IC50) was 12.1 μM.,"Effects of pioglitazone on the pharmacokinetics of nifedipine and its main metabolite, dehydronifedipine, in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25549928/),μM,12.1,183915,DB01373,Calcium
,25549928,absolute bioavailability (AB),"Consequently, the absolute bioavailability (AB) of nifedipine in the presence of pioglitazone (1.0 mg/kg) was significantly higher (25.3 %) than that of the control.","Effects of pioglitazone on the pharmacokinetics of nifedipine and its main metabolite, dehydronifedipine, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25549928/),%,25.3,183916,DB01373,Calcium
,18582256,maximum diltiazem concentration,The maximum diltiazem concentration (577 microg.l(-1)) was recorded 7 h post ingestion which was followed by an erratic and prolonged elimination phase.,Lessons learnt in the pharmacokinetic analysis of the effect of haemoperfusion for acute overdose with sustained-release diltiazem. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18582256/),[μg] / [l],577,184005,DB01373,Calcium
,18582256,maximum clearance,The maximum clearance of diltiazem due to haemoperfusion was calculated to be 19.4 and 15.1 ml.,Lessons learnt in the pharmacokinetic analysis of the effect of haemoperfusion for acute overdose with sustained-release diltiazem. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18582256/),ml,19.4,184006,DB01373,Calcium
,18582256,maximum clearance,The maximum clearance of diltiazem due to haemoperfusion was calculated to be 19.4 and 15.1 ml.,Lessons learnt in the pharmacokinetic analysis of the effect of haemoperfusion for acute overdose with sustained-release diltiazem. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18582256/),ml,15.1,184007,DB01373,Calcium
,24151144,particle size,"The mean particle size of PhytoSolve and PBF were 138.5 ± 9.0 and 74.4 ± 2.5 nm, respectively.",Improved oral bioavalability of mebudipine upon administration in PhytoSolve and Phosal-based formulation (PBF). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24151144/),nm,138.5,184065,DB01373,Calcium
,24151144,particle size,"The mean particle size of PhytoSolve and PBF were 138.5 ± 9.0 and 74.4 ± 2.5 nm, respectively.",Improved oral bioavalability of mebudipine upon administration in PhytoSolve and Phosal-based formulation (PBF). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24151144/),nm,74.4,184066,DB01373,Calcium
,21851289,C(max),"The C(max) and T(max) for OTSP and TMPP tablets were 213.06 ng/mL, 2.50 h and 3402.13 ng/mL, 0.33 h, respectively and the relative bioavailability of P3 was 97.18% compared with TMPP tablets.",Preparation and pharmacokinetics in beagle dogs of once-a-day tetramethylpyrazine phosphate sustained-release pellets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21851289/),[ng] / [ml],213.06,184301,DB01373,Calcium
,21851289,C(max),"The C(max) and T(max) for OTSP and TMPP tablets were 213.06 ng/mL, 2.50 h and 3402.13 ng/mL, 0.33 h, respectively and the relative bioavailability of P3 was 97.18% compared with TMPP tablets.",Preparation and pharmacokinetics in beagle dogs of once-a-day tetramethylpyrazine phosphate sustained-release pellets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21851289/),[ng] / [ml],3402.13,184302,DB01373,Calcium
,21851289,T(max),"The C(max) and T(max) for OTSP and TMPP tablets were 213.06 ng/mL, 2.50 h and 3402.13 ng/mL, 0.33 h, respectively and the relative bioavailability of P3 was 97.18% compared with TMPP tablets.",Preparation and pharmacokinetics in beagle dogs of once-a-day tetramethylpyrazine phosphate sustained-release pellets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21851289/),h,2.50,184303,DB01373,Calcium
,21851289,T(max),"The C(max) and T(max) for OTSP and TMPP tablets were 213.06 ng/mL, 2.50 h and 3402.13 ng/mL, 0.33 h, respectively and the relative bioavailability of P3 was 97.18% compared with TMPP tablets.",Preparation and pharmacokinetics in beagle dogs of once-a-day tetramethylpyrazine phosphate sustained-release pellets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21851289/),h,0.33,184304,DB01373,Calcium
,21851289,relative bioavailability,"The C(max) and T(max) for OTSP and TMPP tablets were 213.06 ng/mL, 2.50 h and 3402.13 ng/mL, 0.33 h, respectively and the relative bioavailability of P3 was 97.18% compared with TMPP tablets.",Preparation and pharmacokinetics in beagle dogs of once-a-day tetramethylpyrazine phosphate sustained-release pellets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21851289/),%,97.18,184305,DB01373,Calcium
,21986570,C(max),"In the single dose group, C(max) reached at 2.0 h and the mean t(1/2) was approximately 2.5 h.",Pharmacokinetics and safety of calcium L-threonate in healthy volunteers after single and multiple oral administrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21986570/),h,2.0,184356,DB01373,Calcium
,21986570,t(1/2),"In the single dose group, C(max) reached at 2.0 h and the mean t(1/2) was approximately 2.5 h.",Pharmacokinetics and safety of calcium L-threonate in healthy volunteers after single and multiple oral administrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21986570/),h,2.5,184357,DB01373,Calcium
,21986570,Cl/r,Cumulative urinary excretion of L-threonate over 24 h represented 5.9% of the administered dose with a mean Cl/r of 0.8 L/h.,Pharmacokinetics and safety of calcium L-threonate in healthy volunteers after single and multiple oral administrations. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21986570/),[l] / [h],0.8,184358,DB01373,Calcium
,29277683,"AUCELF to AUCu,plasma ratios","CIP concentrations in ELF were much higher after CIP-Cu microparticles IT administration compared to the other two formulations, with mean AUCELF to AUCu,plasma ratios equal to 1069, 203 and 9.8 after CIP-Cu microparticles, CIP-Ca microparticles and CIP solution pulmonary administration, respectively.",New aerosol formulation to control ciprofloxacin pulmonary concentration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29277683/),,1069,184887,DB01373,Calcium
,29277683,"AUCELF to AUCu,plasma ratios","CIP concentrations in ELF were much higher after CIP-Cu microparticles IT administration compared to the other two formulations, with mean AUCELF to AUCu,plasma ratios equal to 1069, 203 and 9.8 after CIP-Cu microparticles, CIP-Ca microparticles and CIP solution pulmonary administration, respectively.",New aerosol formulation to control ciprofloxacin pulmonary concentration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29277683/),,203,184888,DB01373,Calcium
,29277683,"AUCELF to AUCu,plasma ratios","CIP concentrations in ELF were much higher after CIP-Cu microparticles IT administration compared to the other two formulations, with mean AUCELF to AUCu,plasma ratios equal to 1069, 203 and 9.8 after CIP-Cu microparticles, CIP-Ca microparticles and CIP solution pulmonary administration, respectively.",New aerosol formulation to control ciprofloxacin pulmonary concentration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29277683/),,9.8,184889,DB01373,Calcium
,15911315,IC(50),We have discovered a novel NCX inhibitor (23 h) with an IC(50) value of 0.12 microM against reverse NCX.,Discovery of an N-(2-aminopyridin-4-ylmethyl)nicotinamide derivative: a potent and orally bioavailable NCX inhibitor. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15911315/),μM,0.12,185425,DB01373,Calcium
,17443134,oral clearance,There was a significantly higher oral clearance of R-verapamil (165.1+/-86.4 versus 91.2+/-36.5 l/h; P=0.009) and S-verapamil (919.4+/-517.4 versus 460.2+/-239.7 l/h; P=0.01) in CYP3A5 expressers compared to nonexpressers.,Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17443134/),[l] / [h],165.1,185656,DB01373,Calcium
,17443134,oral clearance,There was a significantly higher oral clearance of R-verapamil (165.1+/-86.4 versus 91.2+/-36.5 l/h; P=0.009) and S-verapamil (919.4+/-517.4 versus 460.2+/-239.7 l/h; P=0.01) in CYP3A5 expressers compared to nonexpressers.,Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17443134/),[l] / [h],91.2,185657,DB01373,Calcium
,17443134,oral clearance,There was a significantly higher oral clearance of R-verapamil (165.1+/-86.4 versus 91.2+/-36.5 l/h; P=0.009) and S-verapamil (919.4+/-517.4 versus 460.2+/-239.7 l/h; P=0.01) in CYP3A5 expressers compared to nonexpressers.,Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17443134/),[l] / [h],919.4,185658,DB01373,Calcium
,17443134,oral clearance,There was a significantly higher oral clearance of R-verapamil (165.1+/-86.4 versus 91.2+/-36.5 l/h; P=0.009) and S-verapamil (919.4+/-517.4 versus 460.2+/-239.7 l/h; P=0.01) in CYP3A5 expressers compared to nonexpressers.,Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17443134/),[l] / [h],460.2,185659,DB01373,Calcium
,18307734,bioavailability,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),%,2.6 and 5.0,185713,DB01373,Calcium
,18307734,IC50,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),[nM] / [l],0.6,185714,DB01373,Calcium
,18307734,plasma half-life,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),h,23-36,185715,DB01373,Calcium
,29472495,area under the concentration-time curve to the last sampling time (AUC0-12),"The area under the concentration-time curve to the last sampling time (AUC0-12) values for apixaban were not different between control and NAFLD subjects (671 and 545 ng/ml × hour, respectively; P = 0.15).",Apixaban and Rosuvas--tatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29472495/),[ng] / [h·ml],671,185762,DB01373,Calcium
,29472495,area under the concentration-time curve to the last sampling time (AUC0-12),"The area under the concentration-time curve to the last sampling time (AUC0-12) values for apixaban were not different between control and NAFLD subjects (671 and 545 ng/ml × hour, respectively; P = 0.15).",Apixaban and Rosuvas--tatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29472495/),[ng] / [h·ml],545,185763,DB01373,Calcium
,29472495,AUC0-12,"Similarly, the AUC0-12 values for rosuvastatin did not differ between the control and NAFLD groups (25.4 and 20.1 ng/ml × hour, respectively; P = 0.28).",Apixaban and Rosuvas--tatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29472495/),[ng] / [h·ml],25.4,185764,DB01373,Calcium
,29472495,AUC0-12,"Similarly, the AUC0-12 values for rosuvastatin did not differ between the control and NAFLD groups (25.4 and 20.1 ng/ml × hour, respectively; P = 0.28).",Apixaban and Rosuvas--tatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29472495/),[ng] / [h·ml],20.1,185765,DB01373,Calcium
,16038908,minimum detectable limit,The assay enables the measurement of amlodipine for therapeutic drug monitoring with a minimum detectable limit of 0.2 ng ml(-1).,Validated HPLC method for determination of amlodipine in human plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16038908/),[ng] / [ml],0.2,186004,DB01373,Calcium
,16038908,analytical recovery,"The method involves simple, one-step extraction procedure and analytical recovery was about 97%.",Validated HPLC method for determination of amlodipine in human plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16038908/),%,97,186005,DB01373,Calcium
,16038908,flow rate,"The mobile phase was a mixture of 0.01 M sodium dihydrogen phosphate buffer and acetonitrile (63:37, v/v) adjusted to pH 3.5 at a flow rate of 1.5 ml min(-1).",Validated HPLC method for determination of amlodipine in human plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16038908/),[ml] / [min],1.5,186006,DB01373,Calcium
,33313994,volume of distribution,The distribution of daptomycin is limited (volume of distribution of 0.1 L/kg in healthy volunteers) due to its negative charge at physiological pH and its high binding to plasma proteins (about 90%).,Clinical Pharmacokinetics of Daptomycin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33313994/),[l] / [kg],0.1,187050,DB01373,Calcium
not exceed,33313994,residual concentration,"A target for the ratio of the area under the curve to the minimum inhibitory concentration > 666 is usually recommended for clinical efficacy, whereas in order to limit the risk of undesirable muscular effects the residual concentration should not exceed 24.3 mg/L.",Clinical Pharmacokinetics of Daptomycin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33313994/),[mg] / [l],24.3,187051,DB01373,Calcium
,20297846,IC(50),"As a result of lead optimization, we identified (S)-N'-((1H-benzo[d]imidazol-2-yl)methyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine (AMD070) 2 as a potent and selective antagonist of CXCR4 with an IC(50) value of 13 nM in a CXCR4 125I-SDF inhibition binding assay.",Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20297846/),nM,13,187095,DB01373,Calcium
,20297846,IC(50),"Compound 2 inhibited the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC(50) of 2 and 26 nM, respectively, while remaining noncytotoxic to cells at concentrations exceeding 23 microM.",Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20297846/),nM,2,187096,DB01373,Calcium
,20297846,IC(50),"Compound 2 inhibited the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC(50) of 2 and 26 nM, respectively, while remaining noncytotoxic to cells at concentrations exceeding 23 microM.",Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20297846/),nM,26,187097,DB01373,Calcium
,27036206,Maximal tolerated dose (MTD),Maximal tolerated dose (MTD) was determined to be 1 mg/kg/day.,A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27036206/),[mg] / [d·kg],1,187610,DB01373,Calcium
,32436346,volume of distribution,"The volume of distribution, systemic clearance, and terminal half-life was 0.907 L/kg, 7.89 mL/h/kg, and 1.34 h, respectively.","Serum concentrations, pharmacokinetic/pharmacodynamic modeling, and effects of dexamethasone on inflammatory mediators following intravenous and oral administration to exercised horses. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32436346/),[l] / [kg],0.907,188074,DB01373,Calcium
,32436346,systemic clearance,"The volume of distribution, systemic clearance, and terminal half-life was 0.907 L/kg, 7.89 mL/h/kg, and 1.34 h, respectively.","Serum concentrations, pharmacokinetic/pharmacodynamic modeling, and effects of dexamethasone on inflammatory mediators following intravenous and oral administration to exercised horses. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32436346/),[ml] / [h·kg],7.89,188075,DB01373,Calcium
,32436346,terminal half-life,"The volume of distribution, systemic clearance, and terminal half-life was 0.907 L/kg, 7.89 mL/h/kg, and 1.34 h, respectively.","Serum concentrations, pharmacokinetic/pharmacodynamic modeling, and effects of dexamethasone on inflammatory mediators following intravenous and oral administration to exercised horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32436346/),h,1.34,188076,DB01373,Calcium
,32436346,IC50,The IC50 for cortisol suppression was 0.007 ng/mL.,"Serum concentrations, pharmacokinetic/pharmacodynamic modeling, and effects of dexamethasone on inflammatory mediators following intravenous and oral administration to exercised horses. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32436346/),[ng] / [ml],0.007,188077,DB01373,Calcium
,34008842,AUC,The PKS of 900 µg vitamin D3 revealed that malabsorptive patients had 64% lower AUC than healthy participants (1177 ± 425 vs. 3258 ± 496 ng · h/mL; P < 0.05).,"A pilot-randomized, double-blind crossover trial to evaluate the pharmacokinetics of orally administered 25-hydroxyvitamin D3 and vitamin D3 in healthy adults with differing BMI and in adults with intestinal malabsorption. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34008842/),[h·ng] / [ml],1177,188321,DB01373,Calcium
,34008842,AUC,The PKS of 900 µg vitamin D3 revealed that malabsorptive patients had 64% lower AUC than healthy participants (1177 ± 425 vs. 3258 ± 496 ng · h/mL; P < 0.05).,"A pilot-randomized, double-blind crossover trial to evaluate the pharmacokinetics of orally administered 25-hydroxyvitamin D3 and vitamin D3 in healthy adults with differing BMI and in adults with intestinal malabsorption. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34008842/),[h·ng] / [ml],3258,188322,DB01373,Calcium
,34008842,AUC,"The PKS of 900 µg vitamin D3 showed that the higher BMI group had 53% lower AUC than the lower BMI group (2089 ± 490 vs. 4427 ± 313 ng · h/mL; P < 0.05), whereas AUCs of 900 µg 25(OH)D3 were not significantly different between the 2 groups (P = 0.500).","A pilot-randomized, double-blind crossover trial to evaluate the pharmacokinetics of orally administered 25-hydroxyvitamin D3 and vitamin D3 in healthy adults with differing BMI and in adults with intestinal malabsorption. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34008842/),[h·ng] / [ml],2089,188323,DB01373,Calcium
,34008842,AUC,"The PKS of 900 µg vitamin D3 showed that the higher BMI group had 53% lower AUC than the lower BMI group (2089 ± 490 vs. 4427 ± 313 ng · h/mL; P < 0.05), whereas AUCs of 900 µg 25(OH)D3 were not significantly different between the 2 groups (P = 0.500).","A pilot-randomized, double-blind crossover trial to evaluate the pharmacokinetics of orally administered 25-hydroxyvitamin D3 and vitamin D3 in healthy adults with differing BMI and in adults with intestinal malabsorption. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34008842/),[h·ng] / [ml],4427,188324,DB01373,Calcium
,19659504,"AUC(ss,tau)","Mean olmesartan AUC(ss,tau) for olmesartan alone and with amlodipine were 2439 and 2388 ng h/mL and for olmesartan alone and with atenolol were 2340 and 2247 ng h/mL.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[h·ng] / [ml],2439,189018,DB01373,Calcium
,19659504,"AUC(ss,tau)","Mean olmesartan AUC(ss,tau) for olmesartan alone and with amlodipine were 2439 and 2388 ng h/mL and for olmesartan alone and with atenolol were 2340 and 2247 ng h/mL.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[h·ng] / [ml],2388,189019,DB01373,Calcium
,19659504,"AUC(ss,tau)","Mean olmesartan AUC(ss,tau) for olmesartan alone and with amlodipine were 2439 and 2388 ng h/mL and for olmesartan alone and with atenolol were 2340 and 2247 ng h/mL.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[h·ng] / [ml],2340,189020,DB01373,Calcium
,19659504,"AUC(ss,tau)","Mean olmesartan AUC(ss,tau) for olmesartan alone and with amlodipine were 2439 and 2388 ng h/mL and for olmesartan alone and with atenolol were 2340 and 2247 ng h/mL.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[h·ng] / [ml],2247,189021,DB01373,Calcium
,19659504,"C(ss,max)","Corresponding olmesartan C(ss,max) values were 465.7 and 439.5 ng/mL for amlodipine, and 447.4 and 423.8 ng/mL for atenolol.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[ng] / [ml],465.7,189022,DB01373,Calcium
,19659504,"C(ss,max)","Corresponding olmesartan C(ss,max) values were 465.7 and 439.5 ng/mL for amlodipine, and 447.4 and 423.8 ng/mL for atenolol.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[ng] / [ml],439.5,189023,DB01373,Calcium
,19659504,"C(ss,max)","Corresponding olmesartan C(ss,max) values were 465.7 and 439.5 ng/mL for amlodipine, and 447.4 and 423.8 ng/mL for atenolol.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[ng] / [ml],447.4,189024,DB01373,Calcium
,19659504,"C(ss,max)","Corresponding olmesartan C(ss,max) values were 465.7 and 439.5 ng/mL for amlodipine, and 447.4 and 423.8 ng/mL for atenolol.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[ng] / [ml],423.8,189025,DB01373,Calcium
,19659504,t(max),Median t(max) values for olmesartan were 1.5 h for each group in each study.,Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),h,1.5,189026,DB01373,Calcium
,23369879,constant flow rate,"Adequate chromatographic separation was achieved using Phenomenex Synergi 4u polar-RP 80A (150mm×4.6mm, 4μm) column in the isocratic elution mode and the eluent was water/methanol (14:86%, v/v) adjusted by trichloroacetic acid to pH 3.2 which was delivered isocratically at constant flow rate of 0.50mL/min.",Simultaneous determination of amlodipine and atorvastatin with its metabolites; ortho and para hydroxy atorvastatin; in human plasma by LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23369879/),[ml] / [min],0.50,189319,DB01373,Calcium
,25843024,pK(B),"In a calcium mobilization assay performed on CHONK1 cells Pronetupitant (100 nM, 15 min preincubation) behaved as an NK1 antagonist more potent than Netupitant (pK(B) 8.72 and 7.54, respectively).","In vitro and in vivo pharmacological characterization of Pronetupitant, a prodrug of the neurokinin 1 receptor antagonist Netupitant. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25843024/),,8.72,191617,DB01373,Calcium
,25843024,pK(B),"In a calcium mobilization assay performed on CHONK1 cells Pronetupitant (100 nM, 15 min preincubation) behaved as an NK1 antagonist more potent than Netupitant (pK(B) 8.72 and 7.54, respectively).","In vitro and in vivo pharmacological characterization of Pronetupitant, a prodrug of the neurokinin 1 receptor antagonist Netupitant. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25843024/),,7.54,191618,DB01373,Calcium
≈,25843024,pK(B),In the guinea pig ileum bioassay Pronetupitant antagonized the contractile effect of SP showing a similar potency as Netupitant (pK(B)≈9).,"In vitro and in vivo pharmacological characterization of Pronetupitant, a prodrug of the neurokinin 1 receptor antagonist Netupitant. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25843024/),,9,191619,DB01373,Calcium
,14677769,apparent association constant,"The solubility of nitrendipine increased linearly as a function of HP-beta-CD concentration, resulting in AL-type phase solubility diagram which revealed a formation of inclusion complex in a molar ratio of 1:1, with the apparent association constant of 108.3M(-1).",Improvement of dissolution and bioavailability of nitrendipine by inclusion in hydroxypropyl-beta-cyclodextrin. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14677769/),1/[M],108.3,191829,DB01373,Calcium
,12811362,area under the plasma concentration-time curve (AUC),"Grapefruit juice increased the mean felodipine area under the plasma concentration-time curve (AUC) (mean +/- SE, 55 +/- 9 nmol.","Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12811362/),nM,55,192683,DB01373,Calcium
,12811362,plasma peak drug concentration,"h/L; P <.05) and the plasma peak drug concentration (16 +/- 3 nmol/L versus 8 +/- 2 nmol/L, P <.05) and decreased the dehydrofelodipine/felodipine AUC ratio compared with those of water.","Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12811362/),[nM] / [l],16,192684,DB01373,Calcium
,12811362,plasma peak drug concentration,"h/L; P <.05) and the plasma peak drug concentration (16 +/- 3 nmol/L versus 8 +/- 2 nmol/L, P <.05) and decreased the dehydrofelodipine/felodipine AUC ratio compared with those of water.","Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12811362/),[nM] / [l],8,192685,DB01373,Calcium
,29322864,Cmax,"The results indicated that Cmax (23.87 ± 4.27 vs. 38.94 ± 5.32 ng/mL), AUC(0-t) (41.01 ± 11.32 vs. 77.28 ± 12.92 ng h/mL), and t1/2 (1.91 ± 0.18 vs. 2.74 ± 0.23 h) decreased significantly (p < 0.05) when DST and AC were co-administered, which suggested that DST might influence the pharmacokinetic behavior of AC when they are co-administered.",Effects of Danshen tablets on pharmacokinetics of atorvastatin calcium in rats and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29322864/),[ng] / [ml],23.87,192886,DB01373,Calcium
,29322864,Cmax,"The results indicated that Cmax (23.87 ± 4.27 vs. 38.94 ± 5.32 ng/mL), AUC(0-t) (41.01 ± 11.32 vs. 77.28 ± 12.92 ng h/mL), and t1/2 (1.91 ± 0.18 vs. 2.74 ± 0.23 h) decreased significantly (p < 0.05) when DST and AC were co-administered, which suggested that DST might influence the pharmacokinetic behavior of AC when they are co-administered.",Effects of Danshen tablets on pharmacokinetics of atorvastatin calcium in rats and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29322864/),[ng] / [ml],38.94,192887,DB01373,Calcium
,29322864,AUC(0-t),"The results indicated that Cmax (23.87 ± 4.27 vs. 38.94 ± 5.32 ng/mL), AUC(0-t) (41.01 ± 11.32 vs. 77.28 ± 12.92 ng h/mL), and t1/2 (1.91 ± 0.18 vs. 2.74 ± 0.23 h) decreased significantly (p < 0.05) when DST and AC were co-administered, which suggested that DST might influence the pharmacokinetic behavior of AC when they are co-administered.",Effects of Danshen tablets on pharmacokinetics of atorvastatin calcium in rats and its potential mechanism. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29322864/),[h·ng] / [ml],41.01,192888,DB01373,Calcium
,29322864,AUC(0-t),"The results indicated that Cmax (23.87 ± 4.27 vs. 38.94 ± 5.32 ng/mL), AUC(0-t) (41.01 ± 11.32 vs. 77.28 ± 12.92 ng h/mL), and t1/2 (1.91 ± 0.18 vs. 2.74 ± 0.23 h) decreased significantly (p < 0.05) when DST and AC were co-administered, which suggested that DST might influence the pharmacokinetic behavior of AC when they are co-administered.",Effects of Danshen tablets on pharmacokinetics of atorvastatin calcium in rats and its potential mechanism. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29322864/),[h·ng] / [ml],77.28,192889,DB01373,Calcium
,29322864,t1/2,"The results indicated that Cmax (23.87 ± 4.27 vs. 38.94 ± 5.32 ng/mL), AUC(0-t) (41.01 ± 11.32 vs. 77.28 ± 12.92 ng h/mL), and t1/2 (1.91 ± 0.18 vs. 2.74 ± 0.23 h) decreased significantly (p < 0.05) when DST and AC were co-administered, which suggested that DST might influence the pharmacokinetic behavior of AC when they are co-administered.",Effects of Danshen tablets on pharmacokinetics of atorvastatin calcium in rats and its potential mechanism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29322864/),h,1.91,192890,DB01373,Calcium
,29322864,t1/2,"The results indicated that Cmax (23.87 ± 4.27 vs. 38.94 ± 5.32 ng/mL), AUC(0-t) (41.01 ± 11.32 vs. 77.28 ± 12.92 ng h/mL), and t1/2 (1.91 ± 0.18 vs. 2.74 ± 0.23 h) decreased significantly (p < 0.05) when DST and AC were co-administered, which suggested that DST might influence the pharmacokinetic behavior of AC when they are co-administered.",Effects of Danshen tablets on pharmacokinetics of atorvastatin calcium in rats and its potential mechanism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29322864/),h,2.74,192891,DB01373,Calcium
,29322864,metabolic stability (t1/2),The metabolic stability (t1/2) of AC was also decreased (25.7 ± 5.2 vs. 42.5 ± 6.1) with the pretreatment of DST.,Effects of Danshen tablets on pharmacokinetics of atorvastatin calcium in rats and its potential mechanism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29322864/),,25.7,192892,DB01373,Calcium
,29322864,metabolic stability (t1/2),The metabolic stability (t1/2) of AC was also decreased (25.7 ± 5.2 vs. 42.5 ± 6.1) with the pretreatment of DST.,Effects of Danshen tablets on pharmacokinetics of atorvastatin calcium in rats and its potential mechanism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29322864/),,42.5,192893,DB01373,Calcium
,11737990,flow rate,"Mobile phase consisted of methanol (70%), water (25%) and acetonitril (5%) and its flow rate was 1 ml/min.",High performance liquid chromatography of mebudipine: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737990/),[ml] / [min],1,194350,DB01373,Calcium
>,11737990,extraction efficiency,The extraction efficiency was >90% and the minimum quantifiable concentration was 10 ng/ml (CV<10%).,High performance liquid chromatography of mebudipine: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737990/),%,90,194351,DB01373,Calcium
,11737990,minimum quantifiable concentration,The extraction efficiency was >90% and the minimum quantifiable concentration was 10 ng/ml (CV<10%).,High performance liquid chromatography of mebudipine: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737990/),[ng] / [ml],10,194352,DB01373,Calcium
,12817900,absolute bioavailability,For tablets being based on the thiomer/GSH system an absolute bioavailability of 19.9 +/- 9.3% (means +/- SD; n = 5) vs. intravenous injection could be achieved.,Development and in vivo evaluation of an oral delivery system for low molecular weight heparin based on thiolated polycarbophil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12817900/),%,19.9,194455,DB01373,Calcium
,26385444,IC50,26 exhibited IC50 on MLCK assay of 2.1±1.7 μM with selectivity of L-type calcium channels and comparative to Nifedipine.,"Design, synthesis and pharmacological evaluation of pyrimidobenzothiazole-3-carboxylate derivatives as selective L-type calcium channel blockers. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26385444/),μM,2.1,194550,DB01373,Calcium
,26385444,partition coefficient,It offered satisfactory physicochemical properties with partition coefficient of (ClogP) 4.64.,"Design, synthesis and pharmacological evaluation of pyrimidobenzothiazole-3-carboxylate derivatives as selective L-type calcium channel blockers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26385444/),,4.64,194551,DB01373,Calcium
,26385444,Cmax,Its pharmacokinetic profile is also good with Cmax at 0.40 μg/ml by oral route with Tmax reaching in 0.5 h which means in 30 min.,"Design, synthesis and pharmacological evaluation of pyrimidobenzothiazole-3-carboxylate derivatives as selective L-type calcium channel blockers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26385444/),[μg] / [ml],0.40,194552,DB01373,Calcium
,26385444,Tmax,Its pharmacokinetic profile is also good with Cmax at 0.40 μg/ml by oral route with Tmax reaching in 0.5 h which means in 30 min.,"Design, synthesis and pharmacological evaluation of pyrimidobenzothiazole-3-carboxylate derivatives as selective L-type calcium channel blockers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26385444/),h,0.5,194553,DB01373,Calcium
,26385444,t1/2,26 also exhibits superior t1/2 of 5.4 h and oral bioavailability of (F) 56.75% with an AUC0-∞ of 0.84 μg h/ml.,"Design, synthesis and pharmacological evaluation of pyrimidobenzothiazole-3-carboxylate derivatives as selective L-type calcium channel blockers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26385444/),h,5.4,194554,DB01373,Calcium
,26385444,oral bioavailability,26 also exhibits superior t1/2 of 5.4 h and oral bioavailability of (F) 56.75% with an AUC0-∞ of 0.84 μg h/ml.,"Design, synthesis and pharmacological evaluation of pyrimidobenzothiazole-3-carboxylate derivatives as selective L-type calcium channel blockers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26385444/),%,56.75,194555,DB01373,Calcium
,26385444,AUC0-∞,26 also exhibits superior t1/2 of 5.4 h and oral bioavailability of (F) 56.75% with an AUC0-∞ of 0.84 μg h/ml.,"Design, synthesis and pharmacological evaluation of pyrimidobenzothiazole-3-carboxylate derivatives as selective L-type calcium channel blockers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26385444/),[h·μg] / [ml],0.84,194556,DB01373,Calcium
,14609284,stability constant,The phase solubility studies indicated the formation of a N-betaCD inclusion complex with a stability constant of 121.9 M(-1).,Controlled release of nifedipine from mucoadhesive tablets of its inclusion complexes with beta-cyclodextrin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14609284/),1/[M],121.9,194561,DB01373,Calcium
,26099962,C max,"The C max (premenopausal = 58.2 ± 29.1, postmenopausal = 12.2 ± 3.1 ng/ml), [Formula: see text] (premenopausal = 272.6 ± 107.3 ng·h/ml, postmenopausal = 58.8 ± 16.6 ng·h/ml), and [Formula: see text] (premenopausal = 366.1 ± 169, postmenopausal = 66.4 ± 12.9 ng·h/ml) of rosuvastatin were significantly higher (p < 0.05) in premenopausal compared with postmenopausal women.",Impact of Menopause on Pharmacokinetics of Rosuvastatin Compared with Premenopausal Women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26099962/),[ng] / [ml],58.2,194741,DB01373,Calcium
,26099962,C max,"The C max (premenopausal = 58.2 ± 29.1, postmenopausal = 12.2 ± 3.1 ng/ml), [Formula: see text] (premenopausal = 272.6 ± 107.3 ng·h/ml, postmenopausal = 58.8 ± 16.6 ng·h/ml), and [Formula: see text] (premenopausal = 366.1 ± 169, postmenopausal = 66.4 ± 12.9 ng·h/ml) of rosuvastatin were significantly higher (p < 0.05) in premenopausal compared with postmenopausal women.",Impact of Menopause on Pharmacokinetics of Rosuvastatin Compared with Premenopausal Women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26099962/),[ng] / [ml],12.2,194742,DB01373,Calcium
,26099962,C max,"The C max (premenopausal = 58.2 ± 29.1, postmenopausal = 12.2 ± 3.1 ng/ml), [Formula: see text] (premenopausal = 272.6 ± 107.3 ng·h/ml, postmenopausal = 58.8 ± 16.6 ng·h/ml), and [Formula: see text] (premenopausal = 366.1 ± 169, postmenopausal = 66.4 ± 12.9 ng·h/ml) of rosuvastatin were significantly higher (p < 0.05) in premenopausal compared with postmenopausal women.",Impact of Menopause on Pharmacokinetics of Rosuvastatin Compared with Premenopausal Women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26099962/),[h·ng] / [ml],272.6,194743,DB01373,Calcium
,26099962,C max,"The C max (premenopausal = 58.2 ± 29.1, postmenopausal = 12.2 ± 3.1 ng/ml), [Formula: see text] (premenopausal = 272.6 ± 107.3 ng·h/ml, postmenopausal = 58.8 ± 16.6 ng·h/ml), and [Formula: see text] (premenopausal = 366.1 ± 169, postmenopausal = 66.4 ± 12.9 ng·h/ml) of rosuvastatin were significantly higher (p < 0.05) in premenopausal compared with postmenopausal women.",Impact of Menopause on Pharmacokinetics of Rosuvastatin Compared with Premenopausal Women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26099962/),[h·ng] / [ml],58.8,194744,DB01373,Calcium
,26099962,C max,"The C max (premenopausal = 58.2 ± 29.1, postmenopausal = 12.2 ± 3.1 ng/ml), [Formula: see text] (premenopausal = 272.6 ± 107.3 ng·h/ml, postmenopausal = 58.8 ± 16.6 ng·h/ml), and [Formula: see text] (premenopausal = 366.1 ± 169, postmenopausal = 66.4 ± 12.9 ng·h/ml) of rosuvastatin were significantly higher (p < 0.05) in premenopausal compared with postmenopausal women.",Impact of Menopause on Pharmacokinetics of Rosuvastatin Compared with Premenopausal Women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26099962/),[h·ng] / [ml],366.1,194745,DB01373,Calcium
,26099962,C max,"The C max (premenopausal = 58.2 ± 29.1, postmenopausal = 12.2 ± 3.1 ng/ml), [Formula: see text] (premenopausal = 272.6 ± 107.3 ng·h/ml, postmenopausal = 58.8 ± 16.6 ng·h/ml), and [Formula: see text] (premenopausal = 366.1 ± 169, postmenopausal = 66.4 ± 12.9 ng·h/ml) of rosuvastatin were significantly higher (p < 0.05) in premenopausal compared with postmenopausal women.",Impact of Menopause on Pharmacokinetics of Rosuvastatin Compared with Premenopausal Women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26099962/),[h·ng] / [ml],66.4,194746,DB01373,Calcium
,17803060,AUCt,"The mean AUCt, AUCinf, Cmax, and t(1/2) were 353.15 ng x h/mL, 417.86 ng x h/mL, 8.08 ng/mL, and 48.04 h, respectively, for the test drug and 359.99 ng x h x mL(-1), 408.23 ng x h/mL, 8.22 ng/mL, and 43.81 h, respectively, for the reference drug.",Comparative bioavailability cf two amlodipine formulation in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803060/),[h·ng] / [ml],353.15,194768,DB01373,Calcium
,17803060,AUCinf,"The mean AUCt, AUCinf, Cmax, and t(1/2) were 353.15 ng x h/mL, 417.86 ng x h/mL, 8.08 ng/mL, and 48.04 h, respectively, for the test drug and 359.99 ng x h x mL(-1), 408.23 ng x h/mL, 8.22 ng/mL, and 43.81 h, respectively, for the reference drug.",Comparative bioavailability cf two amlodipine formulation in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803060/),[h·ng] / [ml],417.86,194769,DB01373,Calcium
,17803060,Cmax,"The mean AUCt, AUCinf, Cmax, and t(1/2) were 353.15 ng x h/mL, 417.86 ng x h/mL, 8.08 ng/mL, and 48.04 h, respectively, for the test drug and 359.99 ng x h x mL(-1), 408.23 ng x h/mL, 8.22 ng/mL, and 43.81 h, respectively, for the reference drug.",Comparative bioavailability cf two amlodipine formulation in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803060/),[h·ng] / [ml],417.86,194770,DB01373,Calcium
,17803060,Cmax,"The mean AUCt, AUCinf, Cmax, and t(1/2) were 353.15 ng x h/mL, 417.86 ng x h/mL, 8.08 ng/mL, and 48.04 h, respectively, for the test drug and 359.99 ng x h x mL(-1), 408.23 ng x h/mL, 8.22 ng/mL, and 43.81 h, respectively, for the reference drug.",Comparative bioavailability cf two amlodipine formulation in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803060/),[ng] / [ml],8.08,194771,DB01373,Calcium
,17803060,t(1/2),"The mean AUCt, AUCinf, Cmax, and t(1/2) were 353.15 ng x h/mL, 417.86 ng x h/mL, 8.08 ng/mL, and 48.04 h, respectively, for the test drug and 359.99 ng x h x mL(-1), 408.23 ng x h/mL, 8.22 ng/mL, and 43.81 h, respectively, for the reference drug.",Comparative bioavailability cf two amlodipine formulation in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803060/),h,48.04,194772,DB01373,Calcium
,17803060,t(1/2),"The mean AUCt, AUCinf, Cmax, and t(1/2) were 353.15 ng x h/mL, 417.86 ng x h/mL, 8.08 ng/mL, and 48.04 h, respectively, for the test drug and 359.99 ng x h x mL(-1), 408.23 ng x h/mL, 8.22 ng/mL, and 43.81 h, respectively, for the reference drug.",Comparative bioavailability cf two amlodipine formulation in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803060/),h,43.81,194773,DB01373,Calcium
,17803060,Tmax,"The median Tmax of the test drug and reference drug were 8.0 h and 8.5 h, respectively.",Comparative bioavailability cf two amlodipine formulation in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803060/),h,8.0,194774,DB01373,Calcium
,17803060,Tmax,"The median Tmax of the test drug and reference drug were 8.0 h and 8.5 h, respectively.",Comparative bioavailability cf two amlodipine formulation in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803060/),h,8.5,194775,DB01373,Calcium
,19857105,half-lives,"The drug demonstrated tissue-specific half-lives of 15, 63, and 67 h, respectively.",Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19857105/),h,15,195393,DB01373,Calcium
,19857105,half-lives,"The drug demonstrated tissue-specific half-lives of 15, 63, and 67 h, respectively.",Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19857105/),h,63,195394,DB01373,Calcium
,19857105,half-lives,"The drug demonstrated tissue-specific half-lives of 15, 63, and 67 h, respectively.",Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19857105/),h,67,195395,DB01373,Calcium
,19857105,peak concentrations,"Azithromycin also distributed rapidly in the eyelids, reaching peak concentrations of 180 mug/g at the end of the 7-day treatment, and was eliminated with a half-life of 125 h.",Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19857105/),[μg] / [g],180,195396,DB01373,Calcium
,19857105,half-life,"Azithromycin also distributed rapidly in the eyelids, reaching peak concentrations of 180 mug/g at the end of the 7-day treatment, and was eliminated with a half-life of 125 h.",Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19857105/),h,125,195397,DB01373,Calcium
,24092617,C max,The mean C max was 0.034 ± 0.005 μg/mL (nitrendipine alone) and 0.054 ± 0.006 μg/mL (nitrendipine after pretreatment with silibinin).,Effect of silibinin on the pharmacokinetics of nitrendipine in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24092617/),[μg] / [ml],0.034,195703,DB01373,Calcium
,24092617,C max,The mean C max was 0.034 ± 0.005 μg/mL (nitrendipine alone) and 0.054 ± 0.006 μg/mL (nitrendipine after pretreatment with silibinin).,Effect of silibinin on the pharmacokinetics of nitrendipine in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24092617/),[μg] / [ml],0.054,195704,DB01373,Calcium
,12721338,IC50,"Similar to capsazepine, this compound inhibits capsaicin-induced activation of rat VR1 with an IC50 value of 35 nM.","N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12721338/),nM,35,195843,DB01373,Calcium
,12721338,IC50,"Interestingly however, BCTC also potently inhibits acid-induced activation of rat VR1 (IC50 value of 6.0 nM), whereas capsazepine is inactive.","N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12721338/),nM,6.0,195844,DB01373,Calcium
,12721338,plasma half-life,"BCTC was orally bioavailable in the rat, demonstrating a plasma half-life of approximately 1 h and significant penetration into the central nervous system.","N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12721338/),h,1,195845,DB01373,Calcium
,16095861,total run time,The total run time was 25 min.,High-performance liquid chromatography method for determining alendronate sodium in human plasma by detecting fluorescence: application to a pharmacokinetic study in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16095861/),min,25,196072,DB01373,Calcium
,16095861,maximum plasma concentration (C(max)),"Following the oral administration of 70 mg of alendronate sodium to volunteers, the maximum plasma concentration (C(max)) and elimination half-life were 40.94 +/- 19.60 ng/ml and 1.67 +/- 0.50 h, respectively.",High-performance liquid chromatography method for determining alendronate sodium in human plasma by detecting fluorescence: application to a pharmacokinetic study in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16095861/),[ng] / [ml],40.94,196073,DB01373,Calcium
,16095861,elimination half-life,"Following the oral administration of 70 mg of alendronate sodium to volunteers, the maximum plasma concentration (C(max)) and elimination half-life were 40.94 +/- 19.60 ng/ml and 1.67 +/- 0.50 h, respectively.",High-performance liquid chromatography method for determining alendronate sodium in human plasma by detecting fluorescence: application to a pharmacokinetic study in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16095861/),h,1.67,196074,DB01373,Calcium
,16143964,flow rate,"Ternary gradient elution at a flow rate of 1 mL/min was employed on an Intertisl ODS 3V column (4.6 x 250 mm, 5 microm) at ambient temperature.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),[ml] / [min],1,196690,DB01373,Calcium
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,7.5,196691,DB01373,Calcium
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,17.2,196692,DB01373,Calcium
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,21.6,196693,DB01373,Calcium
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,28.5,196694,DB01373,Calcium
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,33.5,196695,DB01373,Calcium
,16143964,Nominal retention times,"Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively.","Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143964/),min,35.5,196696,DB01373,Calcium
,24020431,maximum whole blood concentration (Cmax),"The results showed that encapsulation of curcumin significantly elevated its bioavailability and provided the highest maximum whole blood concentration (Cmax), 37 ± 28 ng/mL, in the experimental animals 45 ± 17 min (t(max)) after oral administration.",Elevating bioavailability of curcumin via encapsulation with a novel formulation of artificial oil bodies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24020431/),[ng] / [ml],37,196826,DB01373,Calcium
,24020431,t(max),"The results showed that encapsulation of curcumin significantly elevated its bioavailability and provided the highest maximum whole blood concentration (Cmax), 37 ± 28 ng/mL, in the experimental animals 45 ± 17 min (t(max)) after oral administration.",Elevating bioavailability of curcumin via encapsulation with a novel formulation of artificial oil bodies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24020431/),min,45,196827,DB01373,Calcium
,11772327,plasma half-life,"Rosuvastatin, like atorvastatin, has a plasma half-life of about 20 h and is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.",Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11772327/),h,20,197177,DB01373,Calcium
,29604372,oral bioavailability,"Pegylated nanoparticles (NMD-NP/PEG), with a size of 190 nm and a payload of 68 µg/mg, significantly improve the oral bioavailability of nimodipine; about 7-times higher than for the control drug solution (62% vs 9%).",Pegylated nanoparticles for the oral delivery of nimodipine: Pharmacokinetics and effect on the anxiety and cognition in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29604372/),%,62,197517,DB01373,Calcium
,29604372,oral bioavailability,"Pegylated nanoparticles (NMD-NP/PEG), with a size of 190 nm and a payload of 68 µg/mg, significantly improve the oral bioavailability of nimodipine; about 7-times higher than for the control drug solution (62% vs 9%).",Pegylated nanoparticles for the oral delivery of nimodipine: Pharmacokinetics and effect on the anxiety and cognition in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29604372/),%,9,197518,DB01373,Calcium
,19932750,gastric retention period,"Abdominal X-ray imaging of formula F10, loaded with barium sulfate, in six healthy volunteers revealed a mean gastric retention period of 5.50+/-0.77h.","Controlled-release effervescent floating matrix tablets of ciprofloxacin hydrochloride: development, optimization and in vitro-in vivo evaluation in healthy human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19932750/),h,5.50,197519,DB01373,Calcium
,19035878,absolute bioavailability (AB),"Consequently, the absolute bioavailability (AB) of diltiazem in the presence of resveratrol (2.5 and 10 mg/kg) was significantly (P < 0.05) higher (10.2-11.1%) than that of the control (6.9%).","Effects of resveratrol on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19035878/),%,10.2-11.1,197861,DB01373,Calcium
,19035878,absolute bioavailability (AB),"Consequently, the absolute bioavailability (AB) of diltiazem in the presence of resveratrol (2.5 and 10 mg/kg) was significantly (P < 0.05) higher (10.2-11.1%) than that of the control (6.9%).","Effects of resveratrol on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19035878/),%,6.9,197862,DB01373,Calcium
,28042936,peak plasma concentration (Cmax ),"The median pharmacokinetic parameters of CG were: peak plasma concentration (Cmax ) 26.41 ng ml-1 , time to reach Cmax (tmax ) 1.79 h, area under the plasma concentration vs. time curve from 0-12 h (AUC0-12 ) 235.99 ng.h ml-1 , half-life (t½) 4.34 h, volume of distribution divided by bioavailability (Vd/F) 560.96 l, and ClT /F 84.77 l h-1 .",Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28042936/),[ng] / [ml],26.41,197912,DB01373,Calcium
,28042936,time to reach Cmax (tmax ),"The median pharmacokinetic parameters of CG were: peak plasma concentration (Cmax ) 26.41 ng ml-1 , time to reach Cmax (tmax ) 1.79 h, area under the plasma concentration vs. time curve from 0-12 h (AUC0-12 ) 235.99 ng.h ml-1 , half-life (t½) 4.34 h, volume of distribution divided by bioavailability (Vd/F) 560.96 l, and ClT /F 84.77 l h-1 .",Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28042936/),h,1.79,197913,DB01373,Calcium
,28042936,area under the plasma concentration vs. time curve from 0-12 h (AUC0-12 ),"The median pharmacokinetic parameters of CG were: peak plasma concentration (Cmax ) 26.41 ng ml-1 , time to reach Cmax (tmax ) 1.79 h, area under the plasma concentration vs. time curve from 0-12 h (AUC0-12 ) 235.99 ng.h ml-1 , half-life (t½) 4.34 h, volume of distribution divided by bioavailability (Vd/F) 560.96 l, and ClT /F 84.77 l h-1 .",Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28042936/),[h·ng] / [ml],235.99,197914,DB01373,Calcium
,28042936,half-life (t½),"The median pharmacokinetic parameters of CG were: peak plasma concentration (Cmax ) 26.41 ng ml-1 , time to reach Cmax (tmax ) 1.79 h, area under the plasma concentration vs. time curve from 0-12 h (AUC0-12 ) 235.99 ng.h ml-1 , half-life (t½) 4.34 h, volume of distribution divided by bioavailability (Vd/F) 560.96 l, and ClT /F 84.77 l h-1 .",Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28042936/),h,4.34,197915,DB01373,Calcium
,28042936,volume of distribution divided by bioavailability (Vd/F),"The median pharmacokinetic parameters of CG were: peak plasma concentration (Cmax ) 26.41 ng ml-1 , time to reach Cmax (tmax ) 1.79 h, area under the plasma concentration vs. time curve from 0-12 h (AUC0-12 ) 235.99 ng.h ml-1 , half-life (t½) 4.34 h, volume of distribution divided by bioavailability (Vd/F) 560.96 l, and ClT /F 84.77 l h-1 .",Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28042936/),l,560.96,197916,DB01373,Calcium
,28042936,ClT /F,"The median pharmacokinetic parameters of CG were: peak plasma concentration (Cmax ) 26.41 ng ml-1 , time to reach Cmax (tmax ) 1.79 h, area under the plasma concentration vs. time curve from 0-12 h (AUC0-12 ) 235.99 ng.h ml-1 , half-life (t½) 4.34 h, volume of distribution divided by bioavailability (Vd/F) 560.96 l, and ClT /F 84.77 l h-1 .",Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28042936/),[l] / [h],84.77,197917,DB01373,Calcium
,28042936,Cmax,"The parameters for T2DM group were: Cmax 23.52 ng ml-1 , tmax 1.48 h, AUC0-12 202.23 ng.h ml-1 , t½ 5.00 h, Vd/F 609.40 l, and apparent total clearance (ClT /F) 98.94 l h-1 .",Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28042936/),[ng] / [ml],23.52,197918,DB01373,Calcium
,28042936,tmax,"The parameters for T2DM group were: Cmax 23.52 ng ml-1 , tmax 1.48 h, AUC0-12 202.23 ng.h ml-1 , t½ 5.00 h, Vd/F 609.40 l, and apparent total clearance (ClT /F) 98.94 l h-1 .",Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28042936/),h,1.48,197919,DB01373,Calcium
,28042936,AUC0-12,"The parameters for T2DM group were: Cmax 23.52 ng ml-1 , tmax 1.48 h, AUC0-12 202.23 ng.h ml-1 , t½ 5.00 h, Vd/F 609.40 l, and apparent total clearance (ClT /F) 98.94 l h-1 .",Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28042936/),[h·ng] / [ml],202.23,197920,DB01373,Calcium
,28042936,t½,"The parameters for T2DM group were: Cmax 23.52 ng ml-1 , tmax 1.48 h, AUC0-12 202.23 ng.h ml-1 , t½ 5.00 h, Vd/F 609.40 l, and apparent total clearance (ClT /F) 98.94 l h-1 .",Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28042936/),h,5.00,197921,DB01373,Calcium
,28042936,Vd/F,"The parameters for T2DM group were: Cmax 23.52 ng ml-1 , tmax 1.48 h, AUC0-12 202.23 ng.h ml-1 , t½ 5.00 h, Vd/F 609.40 l, and apparent total clearance (ClT /F) 98.94 l h-1 .",Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28042936/),l,609.40,197922,DB01373,Calcium
,28042936,apparent total clearance (ClT /F),"The parameters for T2DM group were: Cmax 23.52 ng ml-1 , tmax 1.48 h, AUC0-12 202.23 ng.h ml-1 , t½ 5.00 h, Vd/F 609.40 l, and apparent total clearance (ClT /F) 98.94 l h-1 .",Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28042936/),[l] / [h],98.94,197923,DB01373,Calcium
,25913252,elimination half-life time,"The present study demonstrated that PEGylation of NELL-1 significantly increases the elimination half-life time of the protein from 5.5 h to 15.5 h while distributing more than 2-3 times the amount of protein to bone tissues (femur, tibia, vertebrae, calvaria) in vivo when compared to naked NELL-1.",Pharmacokinetics and osteogenic potential of PEGylated NELL-1 in vivo after systemic administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913252/),h,5.5,198066,DB01373,Calcium
,25913252,elimination half-life time,"The present study demonstrated that PEGylation of NELL-1 significantly increases the elimination half-life time of the protein from 5.5 h to 15.5 h while distributing more than 2-3 times the amount of protein to bone tissues (femur, tibia, vertebrae, calvaria) in vivo when compared to naked NELL-1.",Pharmacokinetics and osteogenic potential of PEGylated NELL-1 in vivo after systemic administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913252/),h,15.5,198067,DB01373,Calcium
,24752908,systemic clearance,The systemic clearance of plasma AMG 416 was estimated to be 6.94 L/h.,"A pharmacokinetic/pharmacodynamic model for AMG 416, a novel calcimimetic peptide, following a single intravenous dose in healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24752908/),[l] / [h],6.94,198369,DB01373,Calcium
,24752908,maximum response Emax,"The maximum response Emax and the potency parameter EC50 were estimated to be 0.69 and 21.0 ng/mL, respectively.","A pharmacokinetic/pharmacodynamic model for AMG 416, a novel calcimimetic peptide, following a single intravenous dose in healthy subjects. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24752908/),[ng] / [ml],0.69,198370,DB01373,Calcium
,24752908,potency parameter,"The maximum response Emax and the potency parameter EC50 were estimated to be 0.69 and 21.0 ng/mL, respectively.","A pharmacokinetic/pharmacodynamic model for AMG 416, a novel calcimimetic peptide, following a single intravenous dose in healthy subjects. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24752908/),[ng] / [ml],0.69,198371,DB01373,Calcium
,24752908,EC50,"The maximum response Emax and the potency parameter EC50 were estimated to be 0.69 and 21.0 ng/mL, respectively.","A pharmacokinetic/pharmacodynamic model for AMG 416, a novel calcimimetic peptide, following a single intravenous dose in healthy subjects. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24752908/),[ng] / [ml],21.0,198372,DB01373,Calcium
,20481538,IC(50),"Compound 1 binds to human neurotensin receptors 1 and 2 with IC(50) of 10.6 and 54.2 nM, respectively, and tolerance to the compound in a rat pain model did not develop after 12 days of daily administration.","Identification and functional characterization of a stable, centrally active derivative of the neurotensin (8-13) fragment as a potential first-in-class analgesic. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20481538/),nM,10.6,199072,DB01373,Calcium
,20481538,IC(50),"Compound 1 binds to human neurotensin receptors 1 and 2 with IC(50) of 10.6 and 54.2 nM, respectively, and tolerance to the compound in a rat pain model did not develop after 12 days of daily administration.","Identification and functional characterization of a stable, centrally active derivative of the neurotensin (8-13) fragment as a potential first-in-class analgesic. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20481538/),nM,54.2,199073,DB01373,Calcium
,24521776,AUC0-12,"Everolimus AUC0-12 was not affected by concomitant rosuvastatin treatment, 80.3±21.3 μg*h/L before and 78.5±21.9 μg*h/L after, respectively (P=0.61).",More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521776/),[h·μg] / [l],80.3,199420,DB01373,Calcium
,24521776,AUC0-12,"Everolimus AUC0-12 was not affected by concomitant rosuvastatin treatment, 80.3±21.3 μg*h/L before and 78.5±21.9 μg*h/L after, respectively (P=0.61).",More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521776/),[h·μg] / [l],78.5,199421,DB01373,Calcium
,24521776,AUC0-24,"Mean rosuvastatin AUC0-24 was 157±61.7 ng*h/mL, approximately threefold higher than reported in the literature for nontransplants.",More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521776/),[h·ng] / [ml],157,199422,DB01373,Calcium
,16621934,E(H),"Fexofenadine had a low liver extraction (E(H); mean +/- S.E.M.), and the given doses of verapamil did not affect the E(H) (0.13 +/- 0.04, 0.16 +/- 0.03, and 0.12 +/- 0.02 for G1, G2, and G3, respectively) or biliary clearance.",First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16621934/),,0.13,200647,DB01373,Calcium
,16621934,E(H),"Fexofenadine had a low liver extraction (E(H); mean +/- S.E.M.), and the given doses of verapamil did not affect the E(H) (0.13 +/- 0.04, 0.16 +/- 0.03, and 0.12 +/- 0.02 for G1, G2, and G3, respectively) or biliary clearance.",First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16621934/),,0.16,200648,DB01373,Calcium
,16621934,E(H),"Fexofenadine had a low liver extraction (E(H); mean +/- S.E.M.), and the given doses of verapamil did not affect the E(H) (0.13 +/- 0.04, 0.16 +/- 0.03, and 0.12 +/- 0.02 for G1, G2, and G3, respectively) or biliary clearance.",First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16621934/),,0.12,200649,DB01373,Calcium
,17064199,area under the concentration-time curve from time zero extrapolated to infinity (AUC(0-infinity)),"The mean area under the concentration-time curve from time zero extrapolated to infinity (AUC(0-infinity)) for ICA-17043 increased in a dose-related manner (11,827, 19,697, and 30,676 ng.hr/ml for 50, 100, and 150 mg, respectively).",Dose-escalation study of ICA-17043 in patients with sickle cell disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17064199/),[h·ng] / [ml],"11,827",201640,DB01373,Calcium
,17064199,area under the concentration-time curve from time zero extrapolated to infinity (AUC(0-infinity)),"The mean area under the concentration-time curve from time zero extrapolated to infinity (AUC(0-infinity)) for ICA-17043 increased in a dose-related manner (11,827, 19,697, and 30,676 ng.hr/ml for 50, 100, and 150 mg, respectively).",Dose-escalation study of ICA-17043 in patients with sickle cell disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17064199/),[h·ng] / [ml],"19,697",201641,DB01373,Calcium
,17064199,area under the concentration-time curve from time zero extrapolated to infinity (AUC(0-infinity)),"The mean area under the concentration-time curve from time zero extrapolated to infinity (AUC(0-infinity)) for ICA-17043 increased in a dose-related manner (11,827, 19,697, and 30,676 ng.hr/ml for 50, 100, and 150 mg, respectively).",Dose-escalation study of ICA-17043 in patients with sickle cell disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17064199/),[h·ng] / [ml],"30,676",201642,DB01373,Calcium
,17064199,half-life,Overall mean half-life was 12.8 days.,Dose-escalation study of ICA-17043 in patients with sickle cell disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17064199/),d,12.8,201643,DB01373,Calcium
,17064199,peak plasma concentrations,"Mean peak plasma concentrations rose between the 50- and 100-mg dose levels but plateaued at 150 mg (59.1, 108.7, and 109.1 ng/ml, respectively).",Dose-escalation study of ICA-17043 in patients with sickle cell disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17064199/),[ng] / [ml],59.1,201644,DB01373,Calcium
,17064199,peak plasma concentrations,"Mean peak plasma concentrations rose between the 50- and 100-mg dose levels but plateaued at 150 mg (59.1, 108.7, and 109.1 ng/ml, respectively).",Dose-escalation study of ICA-17043 in patients with sickle cell disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17064199/),[ng] / [ml],108.7,201645,DB01373,Calcium
,17064199,peak plasma concentrations,"Mean peak plasma concentrations rose between the 50- and 100-mg dose levels but plateaued at 150 mg (59.1, 108.7, and 109.1 ng/ml, respectively).",Dose-escalation study of ICA-17043 in patients with sickle cell disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17064199/),[ng] / [ml],109.1,201646,DB01373,Calcium
,29752182,IC50,"The representative compound, a bicyclo[4.3.0]nonane derivative DS88790512, inhibited TRPC6 with an IC50 value of 11 nM.","Discovery of a bicyclo[4.3.0]nonane derivative DS88790512 as a potent, selective, and orally bioavailable blocker of transient receptor potential canonical 6 (TRPC6). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29752182/),nM,11,201842,DB01373,Calcium
,32603512,IC50,"In vitro, daridorexant inhibits BCRP with an IC50 of 3.0 μmol/L.",The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32603512/),[μM] / [l],3.0,202285,DB01373,Calcium
,14628452,Tmax,"The pharmacokinetic parameters Tmax, Cmax, AUC and CLs were: S-(-)-nimodipine (2.1 +/- 0.3) h, (197 +/- 5) microgram.L-1, (656 +/- 18) mL.min-1, (0.30 +/- 0.03) microgram.h.L-1, and R-(+)-nimodipine (1.7 +/- 0.5) h, (128 +/- 4) microgram.L-1, (381 +/- 4) mL.min-1, (0.53 +/- 0.03) microgram.",Studies on differences of pharmacokinetic behavior and tissue distribution of nimodipine and its two enantiomers in rats using achiral and chiral liquid chromatography. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628452/),h,2.1,202488,DB01373,Calcium
,14628452,CLs,"The pharmacokinetic parameters Tmax, Cmax, AUC and CLs were: S-(-)-nimodipine (2.1 +/- 0.3) h, (197 +/- 5) microgram.L-1, (656 +/- 18) mL.min-1, (0.30 +/- 0.03) microgram.h.L-1, and R-(+)-nimodipine (1.7 +/- 0.5) h, (128 +/- 4) microgram.L-1, (381 +/- 4) mL.min-1, (0.53 +/- 0.03) microgram.",Studies on differences of pharmacokinetic behavior and tissue distribution of nimodipine and its two enantiomers in rats using achiral and chiral liquid chromatography. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628452/),[h·μg] / [l],0.30,202489,DB01373,Calcium
,33860210,half-time,Quantification of the labels in bones indicated that free EP4 agonist (EP4a)(2a) was released from bone-bound 4 with a half-time of about 7 days.,"Design, Synthesis, Pharmacokinetics, and Biodistribution of a Series of Bone-Targeting EP4 Receptor Agonist Prodrugs for Treatment of Osteoporosis and Other Bone Conditions. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33860210/),d,7,203440,DB01373,Calcium
,20816731,bioavailability (BA),"The bioavailability (BA) of alendronate after intrapulmonary administration was 47% at a dose of 5 mg/kg, while the BA after oral administration was only 2.9% at a dose of 50 mg/kg in rats.","Absorption and safety of alendronate, a nitrogen-containing bisphosphonate, after intrapulmonary administration in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20816731/),%,47,203649,DB01373,Calcium
,20816731,bioavailability (BA),"The bioavailability (BA) of alendronate after intrapulmonary administration was 47% at a dose of 5 mg/kg, while the BA after oral administration was only 2.9% at a dose of 50 mg/kg in rats.","Absorption and safety of alendronate, a nitrogen-containing bisphosphonate, after intrapulmonary administration in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20816731/),%,2.9,203650,DB01373,Calcium
,20816731,BA,"The bioavailability (BA) of alendronate after intrapulmonary administration was 47% at a dose of 5 mg/kg, while the BA after oral administration was only 2.9% at a dose of 50 mg/kg in rats.","Absorption and safety of alendronate, a nitrogen-containing bisphosphonate, after intrapulmonary administration in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20816731/),%,2.9,203651,DB01373,Calcium
,23469685,Cmax,"ABCB1 haplotype (1236TT-2677TT-3435TT) carriers (n = 12) had obvious higher Cmax (11.16 +/- 3.10 microg x L(-1) vs 8.35 +/- 3.31 microg x L(-1), p < 0.05) and AUC(0-infinity) (86.61 +/- 24.32 microg x h x L(-1) vs 62.60 +/- 26.19 microg x h x L(-1), p < 0.05) compared to non-1236TT-2677TT-3435TT carriers (n = 24).","ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469685/),[μg] / [l],11.16,204280,DB01373,Calcium
,23469685,Cmax,"ABCB1 haplotype (1236TT-2677TT-3435TT) carriers (n = 12) had obvious higher Cmax (11.16 +/- 3.10 microg x L(-1) vs 8.35 +/- 3.31 microg x L(-1), p < 0.05) and AUC(0-infinity) (86.61 +/- 24.32 microg x h x L(-1) vs 62.60 +/- 26.19 microg x h x L(-1), p < 0.05) compared to non-1236TT-2677TT-3435TT carriers (n = 24).","ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469685/),[μg] / [l],8.35,204281,DB01373,Calcium
,23469685,AUC(0-infinity),"ABCB1 haplotype (1236TT-2677TT-3435TT) carriers (n = 12) had obvious higher Cmax (11.16 +/- 3.10 microg x L(-1) vs 8.35 +/- 3.31 microg x L(-1), p < 0.05) and AUC(0-infinity) (86.61 +/- 24.32 microg x h x L(-1) vs 62.60 +/- 26.19 microg x h x L(-1), p < 0.05) compared to non-1236TT-2677TT-3435TT carriers (n = 24).","ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469685/),[h·μg] / [l],86.61,204282,DB01373,Calcium
,23469685,AUC(0-infinity),"ABCB1 haplotype (1236TT-2677TT-3435TT) carriers (n = 12) had obvious higher Cmax (11.16 +/- 3.10 microg x L(-1) vs 8.35 +/- 3.31 microg x L(-1), p < 0.05) and AUC(0-infinity) (86.61 +/- 24.32 microg x h x L(-1) vs 62.60 +/- 26.19 microg x h x L(-1), p < 0.05) compared to non-1236TT-2677TT-3435TT carriers (n = 24).","ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469685/),[h·μg] / [l],62.60,204283,DB01373,Calcium
,23469685,Cmax,"Homozygotes (AA) carriers had obvious higher Cmax (12.20 +/- 4.09 microg x L(-1) vs 8.70 +/- 3.09 microg x L(-1), p < 0.05) and AUC(0-infinity) (98.74 +/- 25.36 microg x h x L(-1) vs 64.97 +/- 24.90 microg x h x L(-1), p < 0.05) values compared to heterozygotes (CA) and homozygotes (CC) carriers.","ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469685/),[μg] / [l],12.20,204284,DB01373,Calcium
,23469685,Cmax,"Homozygotes (AA) carriers had obvious higher Cmax (12.20 +/- 4.09 microg x L(-1) vs 8.70 +/- 3.09 microg x L(-1), p < 0.05) and AUC(0-infinity) (98.74 +/- 25.36 microg x h x L(-1) vs 64.97 +/- 24.90 microg x h x L(-1), p < 0.05) values compared to heterozygotes (CA) and homozygotes (CC) carriers.","ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469685/),[μg] / [l],8.70,204285,DB01373,Calcium
,23469685,AUC(0-infinity),"Homozygotes (AA) carriers had obvious higher Cmax (12.20 +/- 4.09 microg x L(-1) vs 8.70 +/- 3.09 microg x L(-1), p < 0.05) and AUC(0-infinity) (98.74 +/- 25.36 microg x h x L(-1) vs 64.97 +/- 24.90 microg x h x L(-1), p < 0.05) values compared to heterozygotes (CA) and homozygotes (CC) carriers.","ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469685/),[h·μg] / [l],98.74,204286,DB01373,Calcium
,23469685,AUC(0-infinity),"Homozygotes (AA) carriers had obvious higher Cmax (12.20 +/- 4.09 microg x L(-1) vs 8.70 +/- 3.09 microg x L(-1), p < 0.05) and AUC(0-infinity) (98.74 +/- 25.36 microg x h x L(-1) vs 64.97 +/- 24.90 microg x h x L(-1), p < 0.05) values compared to heterozygotes (CA) and homozygotes (CC) carriers.","ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23469685/),[h·μg] / [l],64.97,204287,DB01373,Calcium
,14558434,t1/2 beta,"Plasma concentrations of the unchanged drug after the intravenous injection of 0.2 mg/kg 14C-NS-7 decreased biexponentially, respective t1/2 beta values being 15.9 h in the male and 22.4 h in the female rats.","Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),h,15.9,204299,DB01373,Calcium
,14558434,t1/2 beta,"Plasma concentrations of the unchanged drug after the intravenous injection of 0.2 mg/kg 14C-NS-7 decreased biexponentially, respective t1/2 beta values being 15.9 h in the male and 22.4 h in the female rats.","Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),h,22.4,204300,DB01373,Calcium
,14558434,Urinary,Urinary and fecal excretions of radioactivity within 168 h of administration were 33.0 and 61.4% of the dose in the male and 35.0 and 53.2% in the female rats.,"Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),%,33.0,204301,DB01373,Calcium
,14558434,Urinary,Urinary and fecal excretions of radioactivity within 168 h of administration were 33.0 and 61.4% of the dose in the male and 35.0 and 53.2% in the female rats.,"Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),%,61.4,204302,DB01373,Calcium
,14558434,Urinary,Urinary and fecal excretions of radioactivity within 168 h of administration were 33.0 and 61.4% of the dose in the male and 35.0 and 53.2% in the female rats.,"Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),%,35.0,204303,DB01373,Calcium
,14558434,Urinary,Urinary and fecal excretions of radioactivity within 168 h of administration were 33.0 and 61.4% of the dose in the male and 35.0 and 53.2% in the female rats.,"Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),%,53.2,204304,DB01373,Calcium
,14558434,fecal excretions,Urinary and fecal excretions of radioactivity within 168 h of administration were 33.0 and 61.4% of the dose in the male and 35.0 and 53.2% in the female rats.,"Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),%,33.0,204305,DB01373,Calcium
,14558434,fecal excretions,Urinary and fecal excretions of radioactivity within 168 h of administration were 33.0 and 61.4% of the dose in the male and 35.0 and 53.2% in the female rats.,"Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),%,61.4,204306,DB01373,Calcium
,14558434,fecal excretions,Urinary and fecal excretions of radioactivity within 168 h of administration were 33.0 and 61.4% of the dose in the male and 35.0 and 53.2% in the female rats.,"Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),%,35.0,204307,DB01373,Calcium
,14558434,fecal excretions,Urinary and fecal excretions of radioactivity within 168 h of administration were 33.0 and 61.4% of the dose in the male and 35.0 and 53.2% in the female rats.,"Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),%,53.2,204308,DB01373,Calcium
,14558434,biliary excretions,"Within 24 h of administration, respective biliary excretions for the male and female rats were 26.1 and 11.9% of the dose.","Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),%,26.1,204309,DB01373,Calcium
,14558434,biliary excretions,"Within 24 h of administration, respective biliary excretions for the male and female rats were 26.1 and 11.9% of the dose.","Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),%,11.9,204310,DB01373,Calcium
,14558434,elimination half-life,The elimination half-life was 18 h for the dogs and 9.52 h for the monkeys.,"Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),h,18,204311,DB01373,Calcium
,14558434,elimination half-life,The elimination half-life was 18 h for the dogs and 9.52 h for the monkeys.,"Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),h,9.52,204312,DB01373,Calcium
,14558434,Urinary,"Urinary and fecal excretions of radioactivity within 168 h of administration were 24.2 and 70.0% of the dose for the dogs, and 63.3 and 24.8% for the monkeys.","Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),%,24.2,204313,DB01373,Calcium
,14558434,Urinary,"Urinary and fecal excretions of radioactivity within 168 h of administration were 24.2 and 70.0% of the dose for the dogs, and 63.3 and 24.8% for the monkeys.","Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),%,70.0,204314,DB01373,Calcium
,14558434,Urinary,"Urinary and fecal excretions of radioactivity within 168 h of administration were 24.2 and 70.0% of the dose for the dogs, and 63.3 and 24.8% for the monkeys.","Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),%,63.3,204315,DB01373,Calcium
,14558434,Urinary,"Urinary and fecal excretions of radioactivity within 168 h of administration were 24.2 and 70.0% of the dose for the dogs, and 63.3 and 24.8% for the monkeys.","Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),%,24.8,204316,DB01373,Calcium
,14558434,fecal excretions,"Urinary and fecal excretions of radioactivity within 168 h of administration were 24.2 and 70.0% of the dose for the dogs, and 63.3 and 24.8% for the monkeys.","Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),%,24.2,204317,DB01373,Calcium
,14558434,fecal excretions,"Urinary and fecal excretions of radioactivity within 168 h of administration were 24.2 and 70.0% of the dose for the dogs, and 63.3 and 24.8% for the monkeys.","Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),%,70.0,204318,DB01373,Calcium
,14558434,fecal excretions,"Urinary and fecal excretions of radioactivity within 168 h of administration were 24.2 and 70.0% of the dose for the dogs, and 63.3 and 24.8% for the monkeys.","Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),%,63.3,204319,DB01373,Calcium
,14558434,fecal excretions,"Urinary and fecal excretions of radioactivity within 168 h of administration were 24.2 and 70.0% of the dose for the dogs, and 63.3 and 24.8% for the monkeys.","Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),%,24.8,204320,DB01373,Calcium
,14558434,Binding,"Binding of 14C-NS-7 in the sera of rats, dogs, monkeys and humans was 90.7%, 73.5% 79.0% and 87.1%, respectively.","Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),%,90.7,204321,DB01373,Calcium
,14558434,Binding,"Binding of 14C-NS-7 in the sera of rats, dogs, monkeys and humans was 90.7%, 73.5% 79.0% and 87.1%, respectively.","Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),%,73.5,204322,DB01373,Calcium
,14558434,Binding,"Binding of 14C-NS-7 in the sera of rats, dogs, monkeys and humans was 90.7%, 73.5% 79.0% and 87.1%, respectively.","Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),%,79.0,204323,DB01373,Calcium
,14558434,Binding,"Binding of 14C-NS-7 in the sera of rats, dogs, monkeys and humans was 90.7%, 73.5% 79.0% and 87.1%, respectively.","Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),%,87.1,204324,DB01373,Calcium
,14558434,Binding,"Binding to human serum albumin, alpha 1-acid glycoprotein and lipoprotein was 56.2%, 45.4% and 79.5%, in the range of 4-40 ng/ml.","Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),%,56.2,204325,DB01373,Calcium
,14558434,Binding,"Binding to human serum albumin, alpha 1-acid glycoprotein and lipoprotein was 56.2%, 45.4% and 79.5%, in the range of 4-40 ng/ml.","Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),%,45.4,204326,DB01373,Calcium
,14558434,Binding,"Binding to human serum albumin, alpha 1-acid glycoprotein and lipoprotein was 56.2%, 45.4% and 79.5%, in the range of 4-40 ng/ml.","Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),%,79.5,204327,DB01373,Calcium
,14558434,Binding,"Binding to human serum albumin, alpha 1-acid glycoprotein and lipoprotein was 56.2%, 45.4% and 79.5%, in the range of 4-40 ng/ml.","Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),,4,204328,DB01373,Calcium
,14558434,In vivo binding,"In vivo binding in rat serum 5 min, 6 h and 24 h after the intravenous injection of 14C-NS-7(0.2 mg/kg) ranged from 89.6 to 90.6%.","Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14558434/),%,89.6,204329,DB01373,Calcium
,16759103,IC(50),"Optimization of the metabolic profile of early analogues led to the discovery of (2S,3S)-3-amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]pyridin-6-ylphenyl)butanamide (6), a potent, orally active DPP-4 inhibitor (IC(50) = 6.3 nM) with excellent selectivity, oral bioavailability in preclinical species, and in vivo efficacy in animal models.","(2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16759103/),nM,6.3,204739,DB01373,Calcium
,18318784,steady state oral clearance,"Cinacalcet steady state oral clearance was 131.1 +/- 20.9 l/h and 92.8 +/- 9.5 l/h (mean +/- SE) after 30 and 60 mg, respectively.",Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18318784/),[l] / [h],131.1,205447,DB01373,Calcium
,18318784,steady state oral clearance,"Cinacalcet steady state oral clearance was 131.1 +/- 20.9 l/h and 92.8 +/- 9.5 l/h (mean +/- SE) after 30 and 60 mg, respectively.",Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18318784/),[l] / [h],92.8,205448,DB01373,Calcium
,18318784,EC(50),"Cinacalcet and parathyroid hormone (PTH) concentrations showed an inverse correlation and were fitted to a simple E(max) model (E(max) = 80% reduction vs. baseline, EC(50) = 13 ng/mL).",Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18318784/),[ng] / [ml],13,205449,DB01373,Calcium
,18318784,fractional urinary excretion,"The 8-h fractional urinary excretion of calcium was increased after 60 mg cinacalcet (baseline 0.85 +/- 0.17%, 30 mg 1.53 +/- 0.35%, 60 mg 1.92 +/- 0.37%).",Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18318784/),%,0.85,205450,DB01373,Calcium
,18318784,fractional urinary excretion,"The 8-h fractional urinary excretion of calcium was increased after 60 mg cinacalcet (baseline 0.85 +/- 0.17%, 30 mg 1.53 +/- 0.35%, 60 mg 1.92 +/- 0.37%).",Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18318784/),%,1.53,205451,DB01373,Calcium
,18318784,fractional urinary excretion,"The 8-h fractional urinary excretion of calcium was increased after 60 mg cinacalcet (baseline 0.85 +/- 0.17%, 30 mg 1.53 +/- 0.35%, 60 mg 1.92 +/- 0.37%).",Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18318784/),%,1.92,205452,DB01373,Calcium
,14648609,fl ow-rate,"The use of methanol-water solution (containing 2.8 mm triethylamine, 80:20, v/v) as the mobile phase at a fl ow-rate of 1.2 mL/min enables the baseline separation of the drugs free from interferences with isocratic elution.",HPLC determination of diltiazem in human plasma and its application to pharmacokinetics in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14648609/),[ml] / [min],1.2,205887,DB01373,Calcium
,14648609,extraction recoveries,The extraction recoveries of diltiazem from spiked human plasma (n = 5) at three concentrations were 91.4-104.0%.,HPLC determination of diltiazem in human plasma and its application to pharmacokinetics in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14648609/),%,91.4-104.0,205888,DB01373,Calcium
,14648609,peak level,"The results showed that the peak level in plasma approximately averaged 118.5 +/- 14.3 ng/mL at 3.1 +/- 0.4 h, and the areas under the drug concentration curves (AUC) was 793.1 +/- 83.1 ng.h/mL.",HPLC determination of diltiazem in human plasma and its application to pharmacokinetics in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14648609/),[ng] / [ml],118.5,205889,DB01373,Calcium
,14648609,areas under the drug concentration curves (AUC),"The results showed that the peak level in plasma approximately averaged 118.5 +/- 14.3 ng/mL at 3.1 +/- 0.4 h, and the areas under the drug concentration curves (AUC) was 793.1 +/- 83.1 ng.h/mL.",HPLC determination of diltiazem in human plasma and its application to pharmacokinetics in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14648609/),[h·ng] / [ml],793.1,205890,DB01373,Calcium
,20706860,plasma concentration,"On day 45, sorafenib plasma concentration was stable (10.8 mg/L) before declining on days 60 and 75 (7.0 mg/L and 7.4 mg/L, respectively), which was probably related to an occurrence of grade-2 diarrhea.",Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20706860/),[mg] / [l],7.0,206263,DB01373,Calcium
,20706860,plasma concentration,"On day 45, sorafenib plasma concentration was stable (10.8 mg/L) before declining on days 60 and 75 (7.0 mg/L and 7.4 mg/L, respectively), which was probably related to an occurrence of grade-2 diarrhea.",Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20706860/),mg,7.4,206264,DB01373,Calcium
<,24065588,Δ r G,"The complex constant, K, was evaluated to be 10(9) orders of magnitude with Δ r G < 0.","Preparation, characterization, and evaluation of dipfluzine-benzoic acid co-crystals with improved physicochemical properties. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24065588/),,0,206692,DB01373,Calcium
,19773540,biliary recoveries,"The biliary recoveries of the administered rosuvastatin dose were 9.0 +/- 3.5 and 35.7 +/- 15.6% in TI and TIV, respectively.",Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773540/),%,9.0,206726,DB01373,Calcium
,19773540,biliary recoveries,"The biliary recoveries of the administered rosuvastatin dose were 9.0 +/- 3.5 and 35.7 +/- 15.6% in TI and TIV, respectively.",Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773540/),%,35.7,206727,DB01373,Calcium
,19773540,AUC(bile)/AUC(VH) ratio,"Rosuvastatin was highly transported into bile as shown by the median AUC(bile)/AUC(VH) ratio in TI of 1770 (1640-11,300).",Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773540/),,1770,206728,DB01373,Calcium
,19773540,hepatic,"However, cyclosporine significantly reduced the hepatic extraction of rosuvastatin (TI, 0.89 +/- 0.06; TII, 0.46 +/- 0.13) and increased the AUC(VP) and AUC(VH) by 1.6- and 9.1-fold, respectively.",Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773540/),,0.89,206729,DB01373,Calcium
,19773540,hepatic,"However, cyclosporine significantly reduced the hepatic extraction of rosuvastatin (TI, 0.89 +/- 0.06; TII, 0.46 +/- 0.13) and increased the AUC(VP) and AUC(VH) by 1.6- and 9.1-fold, respectively.",Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773540/),,0.46,206730,DB01373,Calcium
,15981945,terminal exponential half-life,The long terminal exponential half-life of risedronate (480 hours) has led to the development of a 35mg tablet for once-a-week administration.,Risedronate once a week. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15981945/),h,480,206746,DB01373,Calcium
,25480581,terminal half-life,"The terminal half-life was short (16.8 min), pointing out a rapid elimination after the end of the infusion.",Pharmacokinetics and tissue distribution of clevidipine and its metabolite in dogs and rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25480581/),min,16.8,207681,DB01373,Calcium
,25480581,total clearance,The total clearance was 5 mL/(min·kg).,Pharmacokinetics and tissue distribution of clevidipine and its metabolite in dogs and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25480581/),[ml] / [kg·min],5,207682,DB01373,Calcium
,31625026,oral bioavailability,Lercanidipine HCl (LER) is a vasoselective calcium-channel blocker that has a poor oral bioavailability of 10% due to its hepatic metabolism and low solubility.,"A novel transdermal nanoethosomal gel of lercanidipine HCl for treatment of hypertension: optimization using Box-Benkhen design, in vitro and in vivo characterization. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31625026/),%,10,207690,DB01373,Calcium
,31625026,vesicle size,Nanoethosomes showed a mean vesicle size between 210.87 and 400.57 nm and EE% ranging from 49.26 to 97.22%.,"A novel transdermal nanoethosomal gel of lercanidipine HCl for treatment of hypertension: optimization using Box-Benkhen design, in vitro and in vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31625026/),nm,210.87 and 400.57,207691,DB01373,Calcium
,31625026,EE%,Nanoethosomes showed a mean vesicle size between 210.87 and 400.57 nm and EE% ranging from 49.26 to 97.22%.,"A novel transdermal nanoethosomal gel of lercanidipine HCl for treatment of hypertension: optimization using Box-Benkhen design, in vitro and in vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31625026/),%,49.26 to 97.22,207692,DB01373,Calcium
,16371327,Peak plasma concentrations,"Peak plasma concentrations after normal consumption are usually around 50 microM, and half-lives for elimination range between 2.5-10 h.","Caffeine use in sports, pharmacokinetics in man, and cellular mechanisms of action. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16371327/),μM,50,207769,DB01373,Calcium
,16371327,half-lives for elimination,"Peak plasma concentrations after normal consumption are usually around 50 microM, and half-lives for elimination range between 2.5-10 h.","Caffeine use in sports, pharmacokinetics in man, and cellular mechanisms of action. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16371327/),h,2.5-10,207770,DB01373,Calcium
,29302210,Cmax,"The area under the curve (AUC) values of calcium ascorbate were 1.5-fold higher than those of ascorbic acid, and the Cmax value of calcium ascorbate (91.0 ng/ml) was higher than that of ascorbic acid (74.8 ng/ml).",Alleviation of ascorbic acid-induced gastric high acidity by calcium ascorbate in vitro and in vivo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29302210/),[ng] / [ml],91.0,207888,DB01373,Calcium
,29302210,Cmax,"The area under the curve (AUC) values of calcium ascorbate were 1.5-fold higher than those of ascorbic acid, and the Cmax value of calcium ascorbate (91.0 ng/ml) was higher than that of ascorbic acid (74.8 ng/ml).",Alleviation of ascorbic acid-induced gastric high acidity by calcium ascorbate in vitro and in vivo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29302210/),[ng] / [ml],74.8,207889,DB01373,Calcium
,19571520,Cmax,In vivo the plasma concentration of tetrandrine extended preparation given in dogs reached Cmax 2.67+/-0.69 microg/ml approximately at 5.67+/-0.58 h after oral administration.,Evaluation of tetrandrine sustained release calcium alginate gel beads in vitro and in vivo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19571520/),[μg] / [ml],2.67,208919,DB01373,Calcium
,19571520,AUC0-->24,"The AUC0-->24 and AUC0-->infinity were 24.64+/-6.77 mg.h/l and 29.75+/-5.30 mg.h/l, respectively.",Evaluation of tetrandrine sustained release calcium alginate gel beads in vitro and in vivo. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19571520/),[h·mg] / [l],24.64,208920,DB01373,Calcium
,19571520,AUC0-->infinity,"The AUC0-->24 and AUC0-->infinity were 24.64+/-6.77 mg.h/l and 29.75+/-5.30 mg.h/l, respectively.",Evaluation of tetrandrine sustained release calcium alginate gel beads in vitro and in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19571520/),[h·mg] / [l],29.75,208921,DB01373,Calcium
,19571520,elimination half-time,The elimination half-time was 9.6+/-2.40 h.,Evaluation of tetrandrine sustained release calcium alginate gel beads in vitro and in vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19571520/),h,9.6,208922,DB01373,Calcium
,21601627,encapsulation rates,"Particle size varied between 1.8 and 2.8mm and encapsulation rates between 27 and 30% for Ca- and Zn-pectinate beads, respectively.",Zinc-pectinate beads as an in vivo self-assembling system for pulsatile drug delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21601627/),%,27,208950,DB01373,Calcium
,21601627,encapsulation rates,"Particle size varied between 1.8 and 2.8mm and encapsulation rates between 27 and 30% for Ca- and Zn-pectinate beads, respectively.",Zinc-pectinate beads as an in vivo self-assembling system for pulsatile drug delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21601627/),%,30,208951,DB01373,Calcium
,21601627,t(max),In vivo Zn-pectinate beads (t(max): 12.0 ± 0.1h) led to a significant lag time for the theophylline absorption compared to Ca-pectinate (t(max): 6.0 ± 2.8h) or free theophylline (t(max): 2.5 ± 2.1h).,Zinc-pectinate beads as an in vivo self-assembling system for pulsatile drug delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21601627/),h,12.0,208952,DB01373,Calcium
,21601627,t(max),In vivo Zn-pectinate beads (t(max): 12.0 ± 0.1h) led to a significant lag time for the theophylline absorption compared to Ca-pectinate (t(max): 6.0 ± 2.8h) or free theophylline (t(max): 2.5 ± 2.1h).,Zinc-pectinate beads as an in vivo self-assembling system for pulsatile drug delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21601627/),h,6.0,208953,DB01373,Calcium
,21601627,t(max),In vivo Zn-pectinate beads (t(max): 12.0 ± 0.1h) led to a significant lag time for the theophylline absorption compared to Ca-pectinate (t(max): 6.0 ± 2.8h) or free theophylline (t(max): 2.5 ± 2.1h).,Zinc-pectinate beads as an in vivo self-assembling system for pulsatile drug delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21601627/),h,2.5,208954,DB01373,Calcium
,18501538,particle,"With the SAS process, the mean particle size and the specific surface area of amorphous atorvastatin were drastically changed to 68.7+/-15.8nm, 120.35+/-1.40m2/g and 95.7+/-12.2nm, 79.78+/-0.93m2/g from an acetone solution and a tetrahydrofuran solution, respectively and appeared to be associated with better performance in apparent solubility, dissolution and pharmacokinetic studies, compared with unprocessed crystalline atorvastatin.",Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18501538/),n,68.7,208984,DB01373,Calcium
,18501538,specific surface area,"With the SAS process, the mean particle size and the specific surface area of amorphous atorvastatin were drastically changed to 68.7+/-15.8nm, 120.35+/-1.40m2/g and 95.7+/-12.2nm, 79.78+/-0.93m2/g from an acetone solution and a tetrahydrofuran solution, respectively and appeared to be associated with better performance in apparent solubility, dissolution and pharmacokinetic studies, compared with unprocessed crystalline atorvastatin.",Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18501538/),[m2] / [g],120.35,208985,DB01373,Calcium
,18501538,specific surface area,"With the SAS process, the mean particle size and the specific surface area of amorphous atorvastatin were drastically changed to 68.7+/-15.8nm, 120.35+/-1.40m2/g and 95.7+/-12.2nm, 79.78+/-0.93m2/g from an acetone solution and a tetrahydrofuran solution, respectively and appeared to be associated with better performance in apparent solubility, dissolution and pharmacokinetic studies, compared with unprocessed crystalline atorvastatin.",Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18501538/),[m2] / [g],79.78,208986,DB01373,Calcium
,18501538,Oral AUC0-8h,"Oral AUC0-8h values in SD rats for crystalline and amorphous atorvastatin were as follow: 1121.4+/-212.0ngh/mL for crystalline atorvastatin, 3249.5+/-406.4ngh/mL and 3016.1+/-200.3ngh/mL for amorphous atorvastatin from an acetone solution and a tetrahydrofuran solution with SAS process, 2227.8+/-274.5 and 2099.9+/-339.2ngh/mL for amorphous atorvastatin from acetone and tetrahydrofuran with spray-drying.",Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18501538/),[ngh] / [ml],1121.4,208987,DB01373,Calcium
,18501538,Oral AUC0-8h,"Oral AUC0-8h values in SD rats for crystalline and amorphous atorvastatin were as follow: 1121.4+/-212.0ngh/mL for crystalline atorvastatin, 3249.5+/-406.4ngh/mL and 3016.1+/-200.3ngh/mL for amorphous atorvastatin from an acetone solution and a tetrahydrofuran solution with SAS process, 2227.8+/-274.5 and 2099.9+/-339.2ngh/mL for amorphous atorvastatin from acetone and tetrahydrofuran with spray-drying.",Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18501538/),[ngh] / [ml],3249.5,208988,DB01373,Calcium
,18501538,Oral AUC0-8h,"Oral AUC0-8h values in SD rats for crystalline and amorphous atorvastatin were as follow: 1121.4+/-212.0ngh/mL for crystalline atorvastatin, 3249.5+/-406.4ngh/mL and 3016.1+/-200.3ngh/mL for amorphous atorvastatin from an acetone solution and a tetrahydrofuran solution with SAS process, 2227.8+/-274.5 and 2099.9+/-339.2ngh/mL for amorphous atorvastatin from acetone and tetrahydrofuran with spray-drying.",Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18501538/),[ngh] / [ml],3016.1,208989,DB01373,Calcium
,18501538,Oral AUC0-8h,"Oral AUC0-8h values in SD rats for crystalline and amorphous atorvastatin were as follow: 1121.4+/-212.0ngh/mL for crystalline atorvastatin, 3249.5+/-406.4ngh/mL and 3016.1+/-200.3ngh/mL for amorphous atorvastatin from an acetone solution and a tetrahydrofuran solution with SAS process, 2227.8+/-274.5 and 2099.9+/-339.2ngh/mL for amorphous atorvastatin from acetone and tetrahydrofuran with spray-drying.",Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18501538/),[ngh] / [ml],2227.8,208990,DB01373,Calcium
,18501538,Oral AUC0-8h,"Oral AUC0-8h values in SD rats for crystalline and amorphous atorvastatin were as follow: 1121.4+/-212.0ngh/mL for crystalline atorvastatin, 3249.5+/-406.4ngh/mL and 3016.1+/-200.3ngh/mL for amorphous atorvastatin from an acetone solution and a tetrahydrofuran solution with SAS process, 2227.8+/-274.5 and 2099.9+/-339.2ngh/mL for amorphous atorvastatin from acetone and tetrahydrofuran with spray-drying.",Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18501538/),[ngh] / [ml],2099.9,208991,DB01373,Calcium
,18721002,maximum plasma concentrations (C(max)),"Mean (standard deviation) midazolam maximum plasma concentrations (C(max)) and area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)) were 9.31 (3.09) ng/mL and 24.1 (7.7) ng . h/mL, respectively, when administered in combination with cinacalcet, compared with 9.76 (2.81) ng/mL and 22.8 (6.1) ng . h/mL when administered alone.","Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18721002/),[ng] / [ml],9.31,209092,DB01373,Calcium
,18721002,maximum plasma concentrations (C(max)),"Mean (standard deviation) midazolam maximum plasma concentrations (C(max)) and area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)) were 9.31 (3.09) ng/mL and 24.1 (7.7) ng . h/mL, respectively, when administered in combination with cinacalcet, compared with 9.76 (2.81) ng/mL and 22.8 (6.1) ng . h/mL when administered alone.","Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18721002/),[ng] / [ml],9.76,209093,DB01373,Calcium
,18721002,area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)),"Mean (standard deviation) midazolam maximum plasma concentrations (C(max)) and area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)) were 9.31 (3.09) ng/mL and 24.1 (7.7) ng . h/mL, respectively, when administered in combination with cinacalcet, compared with 9.76 (2.81) ng/mL and 22.8 (6.1) ng . h/mL when administered alone.","Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18721002/),[h·ng] / [ml],24.1,209094,DB01373,Calcium
,18721002,area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)),"Mean (standard deviation) midazolam maximum plasma concentrations (C(max)) and area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)) were 9.31 (3.09) ng/mL and 24.1 (7.7) ng . h/mL, respectively, when administered in combination with cinacalcet, compared with 9.76 (2.81) ng/mL and 22.8 (6.1) ng . h/mL when administered alone.","Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18721002/),[h·ng] / [ml],22.8,209095,DB01373,Calcium
,20818832,absolute bioavailability,"The absolute bioavailability of gabapentin drops from 60% to 33% as the dosage increases from 900 to 3600 mg/day, while the absolute bioavailability of pregabalin remains at > or = 90% irrespective of the dosage.",A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20818832/),%,60,209278,DB01373,Calcium
,20818832,absolute bioavailability,"The absolute bioavailability of gabapentin drops from 60% to 33% as the dosage increases from 900 to 3600 mg/day, while the absolute bioavailability of pregabalin remains at > or = 90% irrespective of the dosage.",A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20818832/),%,33,209279,DB01373,Calcium
> or =,20818832,absolute bioavailability,"The absolute bioavailability of gabapentin drops from 60% to 33% as the dosage increases from 900 to 3600 mg/day, while the absolute bioavailability of pregabalin remains at > or = 90% irrespective of the dosage.",A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20818832/),%,90,209280,DB01373,Calcium
,20818832,elimination half-lives,"Both drugs are excreted renally, with elimination half-lives of approximately 6 hours.",A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20818832/),h,6,209281,DB01373,Calcium
,14508623,absolute bioavailability,"The relative bioavailability of nasally administered 2 IU/kg of mono-PEG2K-sCT was approximately 4-fold higher than nasally administrated unmodified sCT, and the absolute bioavailability was approximately 91% of intravenously injected sCT in 8 hr.",Intranasal delivery of PEGylated salmon calcitonins: hypocalcemic effects in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508623/),%,91,210071,DB01373,Calcium
,31023150,Partial metabolic clearance,Partial metabolic clearance of midazolam in palliative care patients was 31.7 ± 32.1 L/h.,Alteration of drug-metabolizing enzyme activity in palliative care patients: Microdosed assessment of cytochrome P450 3A. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31023150/),[l] / [h],31.7,210923,DB01373,Calcium
<,33502651,oral bioavailability,"Rosuvastatin is an efficient antihyperlipidemic agent; however, being a BCS class II molecule, it shows poor oral bioavailability of < 20%.","Oral Bioavailability Improvement of Tailored Rosuvastatin Loaded Niosomal Nanocarriers to Manage Ischemic Heart Disease: Optimization, Ex Vivo and In Vivo Studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33502651/),%,20,211513,DB01373,Calcium
,33502651,relative bioavailability,"The in vivo pharmacokinetic parameters in the rat model confirmed the improvement in the oral bioavailability with optimized rosuvastatin loaded niosomes (relative bioavailability = 2.01) in comparison to the rosuvastatin suspension, due to high surface area of niosomes and its lymphatic uptake via transcellular route.","Oral Bioavailability Improvement of Tailored Rosuvastatin Loaded Niosomal Nanocarriers to Manage Ischemic Heart Disease: Optimization, Ex Vivo and In Vivo Studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33502651/),,2.01,211514,DB01373,Calcium
,21879394,Oral bioavailability,Oral bioavailability of atorvastatin calcium (ATC) is very low (only 14%) due to instability and incomplete intestinal absorption and/or extensive gut wall extraction.,Enhanced bioavailability of atorvastatin calcium from stabilized gastric resident formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879394/),%,14,211547,DB01373,Calcium
,21879394,lag time,"The best formulation (F4) consisting of hypromellose, sodium bicarbonate, polyethylene oxide, docusate sodium, mannitol, crosscarmellose sodium, and magnesium stearate, gave floating lag time of 56 ± 4.16 s and good matrix integrity with in vitro dissolution of 98.2% in 12 h.",Enhanced bioavailability of atorvastatin calcium from stabilized gastric resident formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879394/),s,56,211548,DB01373,Calcium
,32613011,C max,"The C max values of OTC in OTC-CNP and free OTC treated group were 64.99 and 23.53 μg/ml, respectively.",Pharmacokinetics of Free Oxytetracycline and Oxytetracycline Loaded Cockle Shell Calcium Carbonate-Based Nanoparticle in BALB/c Mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32613011/),[μg] / [ml],64.99,211751,DB01373,Calcium
,32613011,C max,"The C max values of OTC in OTC-CNP and free OTC treated group were 64.99 and 23.53 μg/ml, respectively.",Pharmacokinetics of Free Oxytetracycline and Oxytetracycline Loaded Cockle Shell Calcium Carbonate-Based Nanoparticle in BALB/c Mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32613011/),[μg] / [ml],23.53,211752,DB01373,Calcium
,33196464,AUC,"RESULTSIn healthy women, the amplitude of luteinizing hormone (LH) rise was similar to that after KP54, but peaked later (21.4 vs. 4.7 hours; P = 0.0002), with correspondingly increased AUC of LH exposure (169.0 vs. 38.5 IU∙h/L; P = 0.0058).",Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33196464/),[iu∙h] / [l],169.0,212089,DB01373,Calcium
,33196464,AUC,"RESULTSIn healthy women, the amplitude of luteinizing hormone (LH) rise was similar to that after KP54, but peaked later (21.4 vs. 4.7 hours; P = 0.0002), with correspondingly increased AUC of LH exposure (169.0 vs. 38.5 IU∙h/L; P = 0.0058).",Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33196464/),[iu∙h] / [l],38.5,212090,DB01373,Calcium
,24870198,entrapment efficiency,"Developed beads possess drug release of 79-92%, entrapment efficiency of 65-89%, mucoadhesion of 61-89%.",Floating-bioadhesive gastroretentive Caesalpinia pulcherrima-based beads of amoxicillin trihydrate for Helicobacter pylori eradication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24870198/),%,65-89,212787,DB01373,Calcium
,32471106,Total cumulative doses,"Total cumulative doses were: 588,000 IU, 600,000 IU, 600,000 IU.",Pharmacokinetics of Oral Cholecalciferol in Healthy Subjects with Vitamin D Deficiency: A Randomized Open-Label Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32471106/),,"588,000",213481,DB01373,Calcium
,32471106,Total cumulative doses,"Total cumulative doses were: 588,000 IU, 600,000 IU, 600,000 IU.",Pharmacokinetics of Oral Cholecalciferol in Healthy Subjects with Vitamin D Deficiency: A Randomized Open-Label Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32471106/),,600,213482,DB01373,Calcium
,32471106,peak values,"mean 25 (OH)D plasma levels significantly increased from baseline 13.5 ± 3.7 ng/mL to peak values of 81.0 ± 15.0 ng/mL in Group A, 63.6 ± 7.9 ng/mL in Group B and 59.4 ± 12 ng/mL in Group C.",Pharmacokinetics of Oral Cholecalciferol in Healthy Subjects with Vitamin D Deficiency: A Randomized Open-Label Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32471106/),[ng] / [ml],81.0,213483,DB01373,Calcium
,32471106,peak values,"mean 25 (OH)D plasma levels significantly increased from baseline 13.5 ± 3.7 ng/mL to peak values of 81.0 ± 15.0 ng/mL in Group A, 63.6 ± 7.9 ng/mL in Group B and 59.4 ± 12 ng/mL in Group C.",Pharmacokinetics of Oral Cholecalciferol in Healthy Subjects with Vitamin D Deficiency: A Randomized Open-Label Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32471106/),[ng] / [ml],63.6,213484,DB01373,Calcium
,32471106,peak values,"mean 25 (OH)D plasma levels significantly increased from baseline 13.5 ± 3.7 ng/mL to peak values of 81.0 ± 15.0 ng/mL in Group A, 63.6 ± 7.9 ng/mL in Group B and 59.4 ± 12 ng/mL in Group C.",Pharmacokinetics of Oral Cholecalciferol in Healthy Subjects with Vitamin D Deficiency: A Randomized Open-Label Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32471106/),[ng] / [ml],59.4,213485,DB01373,Calcium
,23883365,Cmax,"The Cmax of felodipine was increased from 173.25 ± 14.65 to 275.61 ± 44.62 and 223.26 ± 26.35 to 561.32 ± 62.53 ng/mL in SDS and MDS, respectively, at the dose of naringenin 100 mg/kg.",Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883365/),[ng] / [ml],173.25,213747,DB01373,Calcium
,23883365,Cmax,"The Cmax of felodipine was increased from 173.25 ± 14.65 to 275.61 ± 44.62 and 223.26 ± 26.35 to 561.32 ± 62.53 ng/mL in SDS and MDS, respectively, at the dose of naringenin 100 mg/kg.",Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883365/),[ng] / [ml],275.61,213748,DB01373,Calcium
,23883365,Cmax,"The Cmax of felodipine was increased from 173.25 ± 14.65 to 275.61 ± 44.62 and 223.26 ± 26.35 to 561.32 ± 62.53 ng/mL in SDS and MDS, respectively, at the dose of naringenin 100 mg/kg.",Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883365/),[ng] / [ml],223.26,213749,DB01373,Calcium
,23883365,Cmax,"The Cmax of felodipine was increased from 173.25 ± 14.65 to 275.61 ± 44.62 and 223.26 ± 26.35 to 561.32 ± 62.53 ng/mL in SDS and MDS, respectively, at the dose of naringenin 100 mg/kg.",Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883365/),[ng] / [ml],561.32,213750,DB01373,Calcium
,23883365,AUCtotal,"The AUCtotal of felodipine was significantly (p < 0.001) increased from 2050.48 ± 60.57 to 3650.22 ± 78.61 and 3276.51 ± 325.61 to 7265.25 ± 536.11 (ng/mL/h) in SDS and MDS, respectively.",Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883365/),[ng] / [h·ml],2050.48,213751,DB01373,Calcium
,23883365,AUCtotal,"The AUCtotal of felodipine was significantly (p < 0.001) increased from 2050.48 ± 60.57 to 3650.22 ± 78.61 and 3276.51 ± 325.61 to 7265.25 ± 536.11 (ng/mL/h) in SDS and MDS, respectively.",Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883365/),[ng] / [h·ml],3650.22,213752,DB01373,Calcium
,23883365,AUCtotal,"The AUCtotal of felodipine was significantly (p < 0.001) increased from 2050.48 ± 60.57 to 3650.22 ± 78.61 and 3276.51 ± 325.61 to 7265.25 ± 536.11 (ng/mL/h) in SDS and MDS, respectively.",Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883365/),[ng] / [h·ml],3276.51,213753,DB01373,Calcium
,23883365,AUCtotal,"The AUCtotal of felodipine was significantly (p < 0.001) increased from 2050.48 ± 60.57 to 3650.22 ± 78.61 and 3276.51 ± 325.61 to 7265.25 ± 536.11 (ng/mL/h) in SDS and MDS, respectively.",Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883365/),[ng] / [h·ml],7265.25,213754,DB01373,Calcium
,25985569,AUC(o-72),"The AUC(o-72) and AUC(0 --> ∞) in subjects with NTCP c.800CT + TT genotype were 56% (162.64 ± 37.55 vs. 103.99 ± 28.15 ng x h/ml, P = 0.016) and 57% greater (178.51 ± 42.75 vs. 113.60 ± 33.73 ng x h/ml, P = 0.020) than those in the c.800CC wild-type subjects, respectively.",The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985569/),[h·ng] / [ml],162.64,213960,DB01373,Calcium
,25985569,AUC(o-72),"The AUC(o-72) and AUC(0 --> ∞) in subjects with NTCP c.800CT + TT genotype were 56% (162.64 ± 37.55 vs. 103.99 ± 28.15 ng x h/ml, P = 0.016) and 57% greater (178.51 ± 42.75 vs. 113.60 ± 33.73 ng x h/ml, P = 0.020) than those in the c.800CC wild-type subjects, respectively.",The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985569/),[h·ng] / [ml],103.99,213961,DB01373,Calcium
,25985569,AUC(o-72),"The AUC(o-72) and AUC(0 --> ∞) in subjects with NTCP c.800CT + TT genotype were 56% (162.64 ± 37.55 vs. 103.99 ± 28.15 ng x h/ml, P = 0.016) and 57% greater (178.51 ± 42.75 vs. 113.60 ± 33.73 ng x h/ml, P = 0.020) than those in the c.800CC wild-type subjects, respectively.",The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985569/),[h·ng] / [ml],178.51,213962,DB01373,Calcium
,25985569,AUC(0 --> ∞),"The AUC(o-72) and AUC(0 --> ∞) in subjects with NTCP c.800CT + TT genotype were 56% (162.64 ± 37.55 vs. 103.99 ± 28.15 ng x h/ml, P = 0.016) and 57% greater (178.51 ± 42.75 vs. 113.60 ± 33.73 ng x h/ml, P = 0.020) than those in the c.800CC wild-type subjects, respectively.",The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985569/),[h·ng] / [ml],103.99,213963,DB01373,Calcium
,25985569,AUC(0 --> ∞),"The AUC(o-72) and AUC(0 --> ∞) in subjects with NTCP c.800CT + TT genotype were 56% (162.64 ± 37.55 vs. 103.99 ± 28.15 ng x h/ml, P = 0.016) and 57% greater (178.51 ± 42.75 vs. 113.60 ± 33.73 ng x h/ml, P = 0.020) than those in the c.800CC wild-type subjects, respectively.",The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985569/),[h·ng] / [ml],178.51,213964,DB01373,Calcium
,25985569,AUC(0 --> ∞),"The AUC(o-72) and AUC(0 --> ∞) in subjects with NTCP c.800CT + TT genotype were 56% (162.64 ± 37.55 vs. 103.99 ± 28.15 ng x h/ml, P = 0.016) and 57% greater (178.51 ± 42.75 vs. 113.60 ± 33.73 ng x h/ml, P = 0.020) than those in the c.800CC wild-type subjects, respectively.",The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985569/),[h·ng] / [ml],113.60,213965,DB01373,Calcium
,25985569,C(max),"In the c.800CT + TT mutant group, the C(max) was about 78% higher than those in c.800CC genotype (14.31 ± 3.63 vs. 8.04 ± 1.72 ng x h/ml, P = 0.004).",The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985569/),[h·ng] / [ml],14.31,213966,DB01373,Calcium
,25985569,C(max),"In the c.800CT + TT mutant group, the C(max) was about 78% higher than those in c.800CC genotype (14.31 ± 3.63 vs. 8.04 ± 1.72 ng x h/ml, P = 0.004).",The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985569/),[h·ng] / [ml],8.04,213967,DB01373,Calcium
,25985569,oral clearance (CL/F),"The oral clearance (CL/F) of rosuvastatin in subjects with the c.800CT+TT genotype was only 63% of those in the c.800CC genotype (58.32 ± 12.16 vs. 93.04 ± 20.61 ng x h/ml, P = 0.009).",The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985569/),[h·ng] / [ml],58.32,213968,DB01373,Calcium
,25985569,oral clearance (CL/F),"The oral clearance (CL/F) of rosuvastatin in subjects with the c.800CT+TT genotype was only 63% of those in the c.800CC genotype (58.32 ± 12.16 vs. 93.04 ± 20.61 ng x h/ml, P = 0.009).",The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985569/),[h·ng] / [ml],93.04,213969,DB01373,Calcium
,12821462,maximum concentration of drug in serum (C(max)),"Data for 320 mg of gemifloxacin alone were as follows: maximum concentration of drug in serum (C(max)),13 microg/ml; half-life, 7.33 h; and area under the concentration-time curve from 0 h to infinity (AUC( infinity )), 6.79 microg.",Effect of calcium carbonate on bioavailability of orally administered gemifloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12821462/),[μg] / [ml],13,214196,DB01373,Calcium
,12821462,half-life,"Data for 320 mg of gemifloxacin alone were as follows: maximum concentration of drug in serum (C(max)),13 microg/ml; half-life, 7.33 h; and area under the concentration-time curve from 0 h to infinity (AUC( infinity )), 6.79 microg.",Effect of calcium carbonate on bioavailability of orally administered gemifloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12821462/),h,7.33,214197,DB01373,Calcium
,12821462,area under the concentration-time curve from 0 h to infinity (AUC( infinity )),"Data for 320 mg of gemifloxacin alone were as follows: maximum concentration of drug in serum (C(max)),13 microg/ml; half-life, 7.33 h; and area under the concentration-time curve from 0 h to infinity (AUC( infinity )), 6.79 microg.",Effect of calcium carbonate on bioavailability of orally administered gemifloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12821462/),μg,6.79,214198,DB01373,Calcium
,15693192,limit of detection,The limit of detection is 0.2 ng/mL.,High-performance liquid chromatography-electrospray ionization mass spectrometric determination of nisoldipine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15693192/),[ng] / [ml],0.2,214319,DB01373,Calcium
,25143371,relative bioavailability,"The relative bioavailability of CaHMB was 49%, 54%, and 27% greater than that of FAHMB for the 3 respective oral doses tested.",The relative bioavailability of the calcium salt of β-hydroxy-β-methylbutyrate is greater than that of the free fatty acid form in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25143371/),%,49,214803,DB01373,Calcium
,25143371,relative bioavailability,"The relative bioavailability of CaHMB was 49%, 54%, and 27% greater than that of FAHMB for the 3 respective oral doses tested.",The relative bioavailability of the calcium salt of β-hydroxy-β-methylbutyrate is greater than that of the free fatty acid form in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25143371/),%,54,214804,DB01373,Calcium
,25143371,relative bioavailability,"The relative bioavailability of CaHMB was 49%, 54%, and 27% greater than that of FAHMB for the 3 respective oral doses tested.",The relative bioavailability of the calcium salt of β-hydroxy-β-methylbutyrate is greater than that of the free fatty acid form in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25143371/),%,27,214805,DB01373,Calcium
,12769127,plasma half-life,"Rosuvastatin, like atorvastatin, has a plasma half-life of about 20 h and is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.",Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12769127/),h,20,214857,DB01373,Calcium
,17523760,terminal half-life (t((1/2)gamma)),"A terminal half-life (t((1/2)gamma)) of approximately 11 years, similar to that of calcium and other minerals in bone, was reported from an 18-month study of alendronic acid in postmenopausal women with osteoporosis.",Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523760/),years,11,214995,DB01373,Calcium
,17523760,t((1/2)gamma),"A mean t((1/2)gamma) of approximately 11 years was reported previously, based on analysis of data between days 240 and 540.",Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523760/),years,11,214996,DB01373,Calcium
,17523760,half-life,Recalculating the 'terminal' half-life of alendronic acid using only data from the first 30 days resulted in an 'observed' half-life of only 11 days.,Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523760/),d,11,214997,DB01373,Calcium
,14586383,effective jejunal permeability,"The mean (+/-SD) effective jejunal permeability values were 0.06 +/- 0.07. 10(-4) cm/s and 0.04 +/- 0.07. 10(-4) cm/s in the control and treatment periods, respectively.",Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586383/),[cm] / [s],0.06,215145,DB01373,Calcium
,14586383,effective jejunal permeability,"The mean (+/-SD) effective jejunal permeability values were 0.06 +/- 0.07. 10(-4) cm/s and 0.04 +/- 0.07. 10(-4) cm/s in the control and treatment periods, respectively.",Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586383/),[cm] / [s],0.04,215146,DB01373,Calcium
,14586383,apparent absorption rate constant into the systemic circulation,"However, verapamil increased the apparent absorption rate constant into the systemic circulation and the area under the plasma concentration-time curve for fexofenadine from 0.0030 +/- 0.0012 min(-1) to 0.0255 +/- 0.0103 min(-1) (P <.001) and from 161 +/- 181 ng/mL x min to 664 +/- 537 ng/mL x min (P <.01), respectively.",Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586383/),1/[min],0.0030,215147,DB01373,Calcium
,14586383,area under the plasma concentration-time curve,"However, verapamil increased the apparent absorption rate constant into the systemic circulation and the area under the plasma concentration-time curve for fexofenadine from 0.0030 +/- 0.0012 min(-1) to 0.0255 +/- 0.0103 min(-1) (P <.001) and from 161 +/- 181 ng/mL x min to 664 +/- 537 ng/mL x min (P <.01), respectively.",Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586383/),[ng] / [min·ml],161,215148,DB01373,Calcium
,14586383,area under the plasma concentration-time curve,"However, verapamil increased the apparent absorption rate constant into the systemic circulation and the area under the plasma concentration-time curve for fexofenadine from 0.0030 +/- 0.0012 min(-1) to 0.0255 +/- 0.0103 min(-1) (P <.001) and from 161 +/- 181 ng/mL x min to 664 +/- 537 ng/mL x min (P <.01), respectively.",Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586383/),[ng] / [min·ml],664,215149,DB01373,Calcium
,31994022,time to reach the maximum plasma concentration,ACT-709478 was absorbed with a time to reach the maximum plasma concentration of 3.5-4.0 h and eliminated with a half-life of 45-53 h.,"Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31994022/),h,3.5-4.0,215456,DB01373,Calcium
,31994022,half-life,ACT-709478 was absorbed with a time to reach the maximum plasma concentration of 3.5-4.0 h and eliminated with a half-life of 45-53 h.,"Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31994022/),h,45-53,215457,DB01373,Calcium
,16362456,Total urinary calcium excretion rates,"Total urinary calcium excretion rates (mmol/day) were as follows (mean +/- SD): placebo 4.41 +/- 2.17, milk 5.17 +/- 2.33, CaCO(3) 5.83 +/- 2.03, and CaCO(3 )+ D 6.06 +/- 2.46.","Bioavailability of calcium: comparison of calcium carbonate and milk and the effect of vitamin D, age, and sex using 24-hour urine calcium as a method. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16362456/),[mM] / [d],4.41,216425,DB01373,Calcium
,16362456,Total urinary calcium excretion rates,"Total urinary calcium excretion rates (mmol/day) were as follows (mean +/- SD): placebo 4.41 +/- 2.17, milk 5.17 +/- 2.33, CaCO(3) 5.83 +/- 2.03, and CaCO(3 )+ D 6.06 +/- 2.46.","Bioavailability of calcium: comparison of calcium carbonate and milk and the effect of vitamin D, age, and sex using 24-hour urine calcium as a method. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16362456/),[mM] / [d],5.17,216426,DB01373,Calcium
,16362456,Total urinary calcium excretion rates,"Total urinary calcium excretion rates (mmol/day) were as follows (mean +/- SD): placebo 4.41 +/- 2.17, milk 5.17 +/- 2.33, CaCO(3) 5.83 +/- 2.03, and CaCO(3 )+ D 6.06 +/- 2.46.","Bioavailability of calcium: comparison of calcium carbonate and milk and the effect of vitamin D, age, and sex using 24-hour urine calcium as a method. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16362456/),[mM] / [d],5.83,216427,DB01373,Calcium
,16362456,Total urinary calcium excretion rates,"Total urinary calcium excretion rates (mmol/day) were as follows (mean +/- SD): placebo 4.41 +/- 2.17, milk 5.17 +/- 2.33, CaCO(3) 5.83 +/- 2.03, and CaCO(3 )+ D 6.06 +/- 2.46.","Bioavailability of calcium: comparison of calcium carbonate and milk and the effect of vitamin D, age, and sex using 24-hour urine calcium as a method. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16362456/),[mM] / [d],6.06,216428,DB01373,Calcium
,16362456,calcium excretion,The increase in calcium excretion during the milk regimen was significant only for the old group: 0.96 vs. 0.28 mmol/day.,"Bioavailability of calcium: comparison of calcium carbonate and milk and the effect of vitamin D, age, and sex using 24-hour urine calcium as a method. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16362456/),[mM] / [d],0.96,216429,DB01373,Calcium
,16362456,calcium excretion,The increase in calcium excretion during the milk regimen was significant only for the old group: 0.96 vs. 0.28 mmol/day.,"Bioavailability of calcium: comparison of calcium carbonate and milk and the effect of vitamin D, age, and sex using 24-hour urine calcium as a method. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16362456/),[mM] / [d],0.28,216430,DB01373,Calcium
,15547050,C(max),Plasma formate concentrations increased briskly from 0.024 +/- 0.008 mM (endogenous formate) to reach C(max) (0.50 +/- 0.04 mM) at 60 min postdose and then declined with a half-life of 59 +/- 7 min.,Absorption and elimination of formate following oral administration of calcium formate in female human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15547050/),mM,0.50,216662,DB01373,Calcium
,15547050,half-life,Plasma formate concentrations increased briskly from 0.024 +/- 0.008 mM (endogenous formate) to reach C(max) (0.50 +/- 0.04 mM) at 60 min postdose and then declined with a half-life of 59 +/- 7 min.,Absorption and elimination of formate following oral administration of calcium formate in female human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15547050/),min,59,216663,DB01373,Calcium
,23911665,pEC50,NPS caused a concentration dependent mobilization of intracellular calcium in the three cell lines with high potency (pEC50 8.73-9.14).,In vitro and in vivo pharmacological characterization of the novel neuropeptide S receptor ligands QA1 and PI1. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23911665/),,8.73-9.14,217097,DB01373,Calcium
,23911665,pA2,PI1 displayed a competitive type of antagonism and lower values of potencies (pA2 7.74-8.45).,In vitro and in vivo pharmacological characterization of the novel neuropeptide S receptor ligands QA1 and PI1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23911665/),,7.74-8.45,217098,DB01373,Calcium
,23229796,bioavailability,The bioavailability of calcium L-threonate in 14 healthy Chinese subjects was 26.49 ± 9.39 %.,Calcium bioavailability of calcium L-threonate in healthy Chinese subjects measured with stable isotopes (⁴⁴Ca and ⁴²Ca). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23229796/),%,26.49,217266,DB01373,Calcium
,15918524,absolute bioavailability (F(A.B)),"The absolute bioavailability (F(A.B)) and the relative bioavailability (F(R.B)) of verapamil in the rabbits with hepatic failure were significantly higher (13.6-22.2% and 150-244%, respectively) than the control (9.1% and 100%, respectively).","Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918524/),%,13.6-22.2,217356,DB01373,Calcium
,15918524,absolute bioavailability (F(A.B)),"The absolute bioavailability (F(A.B)) and the relative bioavailability (F(R.B)) of verapamil in the rabbits with hepatic failure were significantly higher (13.6-22.2% and 150-244%, respectively) than the control (9.1% and 100%, respectively).","Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918524/),%,9.1,217357,DB01373,Calcium
,15918524,relative bioavailability (F(R.B)),"The absolute bioavailability (F(A.B)) and the relative bioavailability (F(R.B)) of verapamil in the rabbits with hepatic failure were significantly higher (13.6-22.2% and 150-244%, respectively) than the control (9.1% and 100%, respectively).","Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918524/),%,150-244,217358,DB01373,Calcium
,15918524,relative bioavailability (F(R.B)),"The absolute bioavailability (F(A.B)) and the relative bioavailability (F(R.B)) of verapamil in the rabbits with hepatic failure were significantly higher (13.6-22.2% and 150-244%, respectively) than the control (9.1% and 100%, respectively).","Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918524/),%,9.1,217359,DB01373,Calcium
,15918524,relative bioavailability (F(R.B)),"The absolute bioavailability (F(A.B)) and the relative bioavailability (F(R.B)) of verapamil in the rabbits with hepatic failure were significantly higher (13.6-22.2% and 150-244%, respectively) than the control (9.1% and 100%, respectively).","Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918524/),%,100,217360,DB01373,Calcium
less,27777389,absorption rates,"However, the absorption rates of orally ingested bisphosphonates are less than 1%.",[Pharmacokinetics of bisphosphonate.] ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27777389/),%,1,217647,DB01373,Calcium
,11836128,EC50,The aminoethyl analogue of the amide template 13 was a potent analgesic with an EC50=0.96 microg/kg in the AA-induced writhing test and with better in vivo stability than the parent phenol.,"Phenolic modification as an approach to improve the pharmacology of the 3-acyloxy-2-benzylpropyl homovanillic amides and thioureas, a promising class of vanilloid receptor agonists and analgesics. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11836128/),[μg] / [kg],0.96,217932,DB01373,Calcium
,25567367,K in,"The model estimated K in values in males and females were 10.2 and 7.13 μmol/h, respectively.","Population pharmacokinetics and exposure-uric acid analyses after single and multiple doses of ABT-639, a calcium channel blocker, in healthy volunteers. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567367/),[μM] / [h],10.2,218323,DB01373,Calcium
,25567367,K in,"The model estimated K in values in males and females were 10.2 and 7.13 μmol/h, respectively.","Population pharmacokinetics and exposure-uric acid analyses after single and multiple doses of ABT-639, a calcium channel blocker, in healthy volunteers. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567367/),[μM] / [h],7.13,218324,DB01373,Calcium
,25567367,K out,The model estimated K out was 0.033 1/h.,"Population pharmacokinetics and exposure-uric acid analyses after single and multiple doses of ABT-639, a calcium channel blocker, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567367/),[1] / [h],0.033,218325,DB01373,Calcium
,16353946,Half-lives,"Half-lives for dimer, heterotetramer, and monomer (3.33 hours, 2.83 days, and 3.94 hours for A(2), A(2)B(2), and B, respectively) were estimated, along with their variability in the population studied.",Population pharmacokinetics of recombinant factor XIII in cynomolgus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16353946/),h,3.33,219678,DB01373,Calcium
,16353946,Half-lives,"Half-lives for dimer, heterotetramer, and monomer (3.33 hours, 2.83 days, and 3.94 hours for A(2), A(2)B(2), and B, respectively) were estimated, along with their variability in the population studied.",Population pharmacokinetics of recombinant factor XIII in cynomolgus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16353946/),d,2.83,219679,DB01373,Calcium
,16353946,Half-lives,"Half-lives for dimer, heterotetramer, and monomer (3.33 hours, 2.83 days, and 3.94 hours for A(2), A(2)B(2), and B, respectively) were estimated, along with their variability in the population studied.",Population pharmacokinetics of recombinant factor XIII in cynomolgus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16353946/),h,3.94,219680,DB01373,Calcium
,27190106,absolute bioavailability,The absolute bioavailability of OTC in the group of birds exposed to higher ions concentration was reduced (8.68% ± 2.56) as compared to the control (13.71% ± 2.60).,Metal ion-oxytetracycline pharmacokinetic interactions after oral co-administration in broiler chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27190106/),%,8.68,219910,DB01373,Calcium
,27190106,absolute bioavailability,The absolute bioavailability of OTC in the group of birds exposed to higher ions concentration was reduced (8.68% ± 2.56) as compared to the control (13.71% ± 2.60).,Metal ion-oxytetracycline pharmacokinetic interactions after oral co-administration in broiler chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27190106/),%,13.71,219911,DB01373,Calcium
,27190106,area under the concentration-time curve from 0 to infinity,"Additionally, in this group, decrease in PK parameters such as: area under the concentration-time curve from 0 to infinity (15.36 μg × h/mL ± 4.36), from 0 to t (14.78 μg × h/mL ± 4.37), area under the first moment of curve from 0 to t (107.54 μg × h/mL ± 36.48), and maximum plasma concentration (2.13 μg/mL ± 0.32) were also observed.",Metal ion-oxytetracycline pharmacokinetic interactions after oral co-administration in broiler chickens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27190106/),[h·μg] / [ml],15.36,219912,DB01373,Calcium
,27190106,from,"Additionally, in this group, decrease in PK parameters such as: area under the concentration-time curve from 0 to infinity (15.36 μg × h/mL ± 4.36), from 0 to t (14.78 μg × h/mL ± 4.37), area under the first moment of curve from 0 to t (107.54 μg × h/mL ± 36.48), and maximum plasma concentration (2.13 μg/mL ± 0.32) were also observed.",Metal ion-oxytetracycline pharmacokinetic interactions after oral co-administration in broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27190106/),[h·μg] / [ml],14.78,219913,DB01373,Calcium
,27190106,0 to t,"Additionally, in this group, decrease in PK parameters such as: area under the concentration-time curve from 0 to infinity (15.36 μg × h/mL ± 4.36), from 0 to t (14.78 μg × h/mL ± 4.37), area under the first moment of curve from 0 to t (107.54 μg × h/mL ± 36.48), and maximum plasma concentration (2.13 μg/mL ± 0.32) were also observed.",Metal ion-oxytetracycline pharmacokinetic interactions after oral co-administration in broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27190106/),[h·μg] / [ml],14.78,219914,DB01373,Calcium
,27190106,area under the first moment of curve from 0 to t,"Additionally, in this group, decrease in PK parameters such as: area under the concentration-time curve from 0 to infinity (15.36 μg × h/mL ± 4.36), from 0 to t (14.78 μg × h/mL ± 4.37), area under the first moment of curve from 0 to t (107.54 μg × h/mL ± 36.48), and maximum plasma concentration (2.13 μg/mL ± 0.32) were also observed.",Metal ion-oxytetracycline pharmacokinetic interactions after oral co-administration in broiler chickens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27190106/),[h·μg] / [ml],107.54,219915,DB01373,Calcium
,27190106,maximum plasma concentration,"Additionally, in this group, decrease in PK parameters such as: area under the concentration-time curve from 0 to infinity (15.36 μg × h/mL ± 4.36), from 0 to t (14.78 μg × h/mL ± 4.37), area under the first moment of curve from 0 to t (107.54 μg × h/mL ± 36.48), and maximum plasma concentration (2.13 μg/mL ± 0.32) were also observed.",Metal ion-oxytetracycline pharmacokinetic interactions after oral co-administration in broiler chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27190106/),[μg] / [ml],2.13,219916,DB01373,Calcium
,19853420,C(max),"The mean C(max) of F2, F5, and Zovirax were 0.61+/-0.06, 0.73+/-0.07 and 0.92+/-0.21 microg/ml respectively.",Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853420/),[μg] / [ml],0.61,219981,DB01373,Calcium
,19853420,C(max),"The mean C(max) of F2, F5, and Zovirax were 0.61+/-0.06, 0.73+/-0.07 and 0.92+/-0.21 microg/ml respectively.",Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853420/),[μg] / [ml],0.73,219982,DB01373,Calcium
,19853420,C(max),"The mean C(max) of F2, F5, and Zovirax were 0.61+/-0.06, 0.73+/-0.07 and 0.92+/-0.21 microg/ml respectively.",Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853420/),[μg] / [ml],0.92,219983,DB01373,Calcium
,19853420,AUC(0-12),"Furthermore, the AUC(0-12) of F2 and F5 was significantly higher than that of Zovirax((R)) with values of 4.37+/-0.88, 5.14+/-0.87 and 3.21+/-0.53 microg/ml h respectively.",Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853420/),[μg] / [h·ml],4.37,219984,DB01373,Calcium
,19853420,AUC(0-12),"Furthermore, the AUC(0-12) of F2 and F5 was significantly higher than that of Zovirax((R)) with values of 4.37+/-0.88, 5.14+/-0.87 and 3.21+/-0.53 microg/ml h respectively.",Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853420/),[μg] / [h·ml],5.14,219985,DB01373,Calcium
,19853420,AUC(0-12),"Furthermore, the AUC(0-12) of F2 and F5 was significantly higher than that of Zovirax((R)) with values of 4.37+/-0.88, 5.14+/-0.87 and 3.21+/-0.53 microg/ml h respectively.",Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853420/),[μg] / [h·ml],3.21,219986,DB01373,Calcium
,19853420,relative bioavailability,The higher AUC(0-12) for both F2 and F5 reflected high relative bioavailability of 136.2% and 159.9% respectively compared to commercial ACV tablets.,Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853420/),%,136.2,219987,DB01373,Calcium
,19853420,relative bioavailability,The higher AUC(0-12) for both F2 and F5 reflected high relative bioavailability of 136.2% and 159.9% respectively compared to commercial ACV tablets.,Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853420/),%,159.9,219988,DB01373,Calcium
>,28987595,half-life,Fatty acid modification extended the half-life of native apelin-13 to >24 h in vitro.,"Acylated apelin-13 amide analogues exhibit enzyme resistance and prolonged insulin releasing, glucose lowering and anorexic properties. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28987595/),h,24,220632,DB01373,Calcium
,12370099,clearance rate [CL(S)],Nimodipine could increase clearance rate [CL(S)] from (20.8+/-1.5) to (31+/-11) mL/kg/s and reduce AUC of C(+/-)P(-)soman from (2.08+/-0.15) to (1.6+/-0.4) mg/s.,Influence of nimodipine on elimination of soman in rabbit blood and distribution of [3H]soman in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12370099/),[ml] / [kg·s],20.8,220882,DB01373,Calcium
,12370099,clearance rate [CL(S)],Nimodipine could increase clearance rate [CL(S)] from (20.8+/-1.5) to (31+/-11) mL/kg/s and reduce AUC of C(+/-)P(-)soman from (2.08+/-0.15) to (1.6+/-0.4) mg/s.,Influence of nimodipine on elimination of soman in rabbit blood and distribution of [3H]soman in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12370099/),[ml] / [kg·s],31,220883,DB01373,Calcium
,12370099,AUC,Nimodipine could increase clearance rate [CL(S)] from (20.8+/-1.5) to (31+/-11) mL/kg/s and reduce AUC of C(+/-)P(-)soman from (2.08+/-0.15) to (1.6+/-0.4) mg/s.,Influence of nimodipine on elimination of soman in rabbit blood and distribution of [3H]soman in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12370099/),[mg] / [s],2.08,220884,DB01373,Calcium
,12370099,AUC,Nimodipine could increase clearance rate [CL(S)] from (20.8+/-1.5) to (31+/-11) mL/kg/s and reduce AUC of C(+/-)P(-)soman from (2.08+/-0.15) to (1.6+/-0.4) mg/s.,Influence of nimodipine on elimination of soman in rabbit blood and distribution of [3H]soman in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12370099/),[mg] / [s],1.6,220885,DB01373,Calcium
,20171425,C(max),"For simvastatin acid, C(max) was significantly smaller (1.68 vs 3.62 ng/mL; P < 0.013) and T(max) and apparent t((1/2)) significantly longer (10.33 vs 4.04 hours [P < 0.001] and 11.41 vs 4.16 hours [P < 0.011]) for the CR formulation compared with the IR formulation, respectively, after the single-dose administration.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),[ng] / [ml],1.68,220946,DB01373,Calcium
,20171425,C(max),"For simvastatin acid, C(max) was significantly smaller (1.68 vs 3.62 ng/mL; P < 0.013) and T(max) and apparent t((1/2)) significantly longer (10.33 vs 4.04 hours [P < 0.001] and 11.41 vs 4.16 hours [P < 0.011]) for the CR formulation compared with the IR formulation, respectively, after the single-dose administration.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),[ng] / [ml],3.62,220947,DB01373,Calcium
,20171425,T(max),"For simvastatin acid, C(max) was significantly smaller (1.68 vs 3.62 ng/mL; P < 0.013) and T(max) and apparent t((1/2)) significantly longer (10.33 vs 4.04 hours [P < 0.001] and 11.41 vs 4.16 hours [P < 0.011]) for the CR formulation compared with the IR formulation, respectively, after the single-dose administration.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,10.33,220948,DB01373,Calcium
,20171425,T(max),"For simvastatin acid, C(max) was significantly smaller (1.68 vs 3.62 ng/mL; P < 0.013) and T(max) and apparent t((1/2)) significantly longer (10.33 vs 4.04 hours [P < 0.001] and 11.41 vs 4.16 hours [P < 0.011]) for the CR formulation compared with the IR formulation, respectively, after the single-dose administration.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,4.04,220949,DB01373,Calcium
,20171425,apparent t((1/2)),"For simvastatin acid, C(max) was significantly smaller (1.68 vs 3.62 ng/mL; P < 0.013) and T(max) and apparent t((1/2)) significantly longer (10.33 vs 4.04 hours [P < 0.001] and 11.41 vs 4.16 hours [P < 0.011]) for the CR formulation compared with the IR formulation, respectively, after the single-dose administration.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,4.04,220950,DB01373,Calcium
,20171425,apparent t((1/2)),"For simvastatin acid, C(max) was significantly smaller (1.68 vs 3.62 ng/mL; P < 0.013) and T(max) and apparent t((1/2)) significantly longer (10.33 vs 4.04 hours [P < 0.001] and 11.41 vs 4.16 hours [P < 0.011]) for the CR formulation compared with the IR formulation, respectively, after the single-dose administration.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,11.41,220951,DB01373,Calcium
,20171425,apparent t((1/2)),"For simvastatin acid, C(max) was significantly smaller (1.68 vs 3.62 ng/mL; P < 0.013) and T(max) and apparent t((1/2)) significantly longer (10.33 vs 4.04 hours [P < 0.001] and 11.41 vs 4.16 hours [P < 0.011]) for the CR formulation compared with the IR formulation, respectively, after the single-dose administration.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,4.16,220952,DB01373,Calcium
,20171425,C(max),"After the multiple-dose administration, for simvastatin acid, the C(max) for the CR formulation was significantly smaller (3.40 vs 5.16 ng/mL; P < 0.037), while the values for T(max) and apparent t((1/2)) were significantly longer (8.40 vs 4.57 hours and 13.09 vs 4.52 hours; both, P < 0.001) compared with the IR formulation.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),[ng] / [ml],3.40,220953,DB01373,Calcium
,20171425,C(max),"After the multiple-dose administration, for simvastatin acid, the C(max) for the CR formulation was significantly smaller (3.40 vs 5.16 ng/mL; P < 0.037), while the values for T(max) and apparent t((1/2)) were significantly longer (8.40 vs 4.57 hours and 13.09 vs 4.52 hours; both, P < 0.001) compared with the IR formulation.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),[ng] / [ml],5.16,220954,DB01373,Calcium
,20171425,T(max),"After the multiple-dose administration, for simvastatin acid, the C(max) for the CR formulation was significantly smaller (3.40 vs 5.16 ng/mL; P < 0.037), while the values for T(max) and apparent t((1/2)) were significantly longer (8.40 vs 4.57 hours and 13.09 vs 4.52 hours; both, P < 0.001) compared with the IR formulation.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,8.40,220955,DB01373,Calcium
,20171425,apparent t((1/2)),"After the multiple-dose administration, for simvastatin acid, the C(max) for the CR formulation was significantly smaller (3.40 vs 5.16 ng/mL; P < 0.037), while the values for T(max) and apparent t((1/2)) were significantly longer (8.40 vs 4.57 hours and 13.09 vs 4.52 hours; both, P < 0.001) compared with the IR formulation.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,4.57,220956,DB01373,Calcium
,20171425,apparent t((1/2)),"After the multiple-dose administration, for simvastatin acid, the C(max) for the CR formulation was significantly smaller (3.40 vs 5.16 ng/mL; P < 0.037), while the values for T(max) and apparent t((1/2)) were significantly longer (8.40 vs 4.57 hours and 13.09 vs 4.52 hours; both, P < 0.001) compared with the IR formulation.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,13.09,220957,DB01373,Calcium
,20171425,apparent t((1/2)),"After the multiple-dose administration, for simvastatin acid, the C(max) for the CR formulation was significantly smaller (3.40 vs 5.16 ng/mL; P < 0.037), while the values for T(max) and apparent t((1/2)) were significantly longer (8.40 vs 4.57 hours and 13.09 vs 4.52 hours; both, P < 0.001) compared with the IR formulation.","Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171425/),h,4.52,220958,DB01373,Calcium
,32141297,EC50,"Of these, 57, with EC50 = 145 nM and a solubility of 33 μM, showed high clearance in vivo but is a preferred tool in vitro.",Structure-Activity Relationship Studies of Tetrahydroquinolone Free Fatty Acid Receptor 3 Modulators. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32141297/),nM,145,221527,DB01373,Calcium
,32141297,solubility,"Of these, 57, with EC50 = 145 nM and a solubility of 33 μM, showed high clearance in vivo but is a preferred tool in vitro.",Structure-Activity Relationship Studies of Tetrahydroquinolone Free Fatty Acid Receptor 3 Modulators. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32141297/),μM,33,221528,DB01373,Calcium
,32141297,EC50,"In contrast, 63, with EC50 = 162 nM and a solubility of 9 μM, showed lower clearance and seems better suited for in vivo studies.",Structure-Activity Relationship Studies of Tetrahydroquinolone Free Fatty Acid Receptor 3 Modulators. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32141297/),nM,162,221529,DB01373,Calcium
,32141297,solubility,"In contrast, 63, with EC50 = 162 nM and a solubility of 9 μM, showed lower clearance and seems better suited for in vivo studies.",Structure-Activity Relationship Studies of Tetrahydroquinolone Free Fatty Acid Receptor 3 Modulators. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32141297/),μM,9,221530,DB01373,Calcium
≈,33822385,terminal elimination half-life,"Median terminal elimination half-life was ≈5 days following multiple-dose administration, with steady state achieved by approximately day 29.",Pharmacokinetics of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822385/),d,5,222752,DB01373,Calcium
,17470643,K(i),ELN441958 competitively inhibited the binding of the B(1) agonist ligand [(3)H]desArg(10)-kallidin ([(3)H]DAKD) to IMR-90 human fibroblast membranes with high affinity (K(i) = 0.26 +/- 0.02 nM).,"Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17470643/),nM,0.26,223016,DB01373,Calcium
,17470643,ED(50),"ELN441958 dose-dependently reduced carrageenan-induced thermal hyperalgesia in a rhesus monkey tail-withdrawal model, with an ED(50) approximately 3 mg/kg s.c.","Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17470643/),[mg] / [kg],3,223017,DB01373,Calcium
less,24012665,globule size,The globule size of the optimized system was less than 200nm which could be an acceptable nanoemulsion size range.,"Self nanoemulsifying drug delivery system (SNEDDS) of rosuvastatin calcium: design, formulation, bioavailability and pharmacokinetic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24012665/),nm,200,224754,DB01373,Calcium
,24012665,z,The zeta potential of the selected CN 7 SNEDDS formulation (cinnamon oil 30%; labrasol 60%; Capmul MCM C8 10%) was -29.5±0.63 with an average particle size distribution of 122nm.,"Self nanoemulsifying drug delivery system (SNEDDS) of rosuvastatin calcium: design, formulation, bioavailability and pharmacokinetic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24012665/),,-,224755,DB01373,Calcium
,24012665,z,The zeta potential of the selected CN 7 SNEDDS formulation (cinnamon oil 30%; labrasol 60%; Capmul MCM C8 10%) was -29.5±0.63 with an average particle size distribution of 122nm.,"Self nanoemulsifying drug delivery system (SNEDDS) of rosuvastatin calcium: design, formulation, bioavailability and pharmacokinetic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24012665/),,29.5,224756,DB01373,Calcium
,12296991,Excretion of radio,"3. Excretion of radioactivity was 98.0% of the dose in the faeces and 0.4% in the urine up to 168 h after oral administration in the intact rat, and was 55.1% in the bile and 0.5% in the urine up to 48 h post-dosing in the bile duct-cannulated rat.","Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12296991/),%,98.0,224758,DB01373,Calcium
,12296991,Excretion of radio,"3. Excretion of radioactivity was 98.0% of the dose in the faeces and 0.4% in the urine up to 168 h after oral administration in the intact rat, and was 55.1% in the bile and 0.5% in the urine up to 48 h post-dosing in the bile duct-cannulated rat.","Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12296991/),%,0.4,224759,DB01373,Calcium
,12296991,Excretion of radio,"3. Excretion of radioactivity was 98.0% of the dose in the faeces and 0.4% in the urine up to 168 h after oral administration in the intact rat, and was 55.1% in the bile and 0.5% in the urine up to 48 h post-dosing in the bile duct-cannulated rat.","Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12296991/),%,55.1,224760,DB01373,Calcium
,12296991,Excretion of radio,"3. Excretion of radioactivity was 98.0% of the dose in the faeces and 0.4% in the urine up to 168 h after oral administration in the intact rat, and was 55.1% in the bile and 0.5% in the urine up to 48 h post-dosing in the bile duct-cannulated rat.","Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12296991/),%,0.5,224761,DB01373,Calcium
,12296991,radioactivity concentration ratios,"4. In the tissue distribution study, the concentration of the radioactivity in the liver was markedly higher than those in the other tissues, and the radioactivity concentration ratios of the liver to the plasma were between 8 and 25 up to 48 h after oral administration.","Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12296991/),,8 and 25,224762,DB01373,Calcium
,24251972,T1/2,The observed T1/2 (8-9 h) for both conjugates was significantly lower than that observed for the PEGylated peptide (∼25 h).,Preparation and characterization of albumin conjugates of a truncated peptide YY analogue for half-life extension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24251972/),h,8-9,225357,DB01373,Calcium
,24251972,T1/2,The observed T1/2 (8-9 h) for both conjugates was significantly lower than that observed for the PEGylated peptide (∼25 h).,Preparation and characterization of albumin conjugates of a truncated peptide YY analogue for half-life extension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24251972/),h,∼25,225358,DB01373,Calcium
,11589462,m/z,"For the quantification of the nisoldipine enantiomers a GC-MS with an Ultra 1 Hewlett-Packard column was used with the detector operated in the single-ion monitoring mode with electron-impact ionization (m/z 371.35 and 270.20 for nisoldipine and m/z 360.00 for the internal standard, nitrendipine).",Enantioselective assay of nisoldipine in human plasma by chiral high-performance liquid chromatography combined with gas chromatographic-mass spectrometry: applications to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11589462/),,371.35,225426,DB01373,Calcium
,11589462,m/z,"For the quantification of the nisoldipine enantiomers a GC-MS with an Ultra 1 Hewlett-Packard column was used with the detector operated in the single-ion monitoring mode with electron-impact ionization (m/z 371.35 and 270.20 for nisoldipine and m/z 360.00 for the internal standard, nitrendipine).",Enantioselective assay of nisoldipine in human plasma by chiral high-performance liquid chromatography combined with gas chromatographic-mass spectrometry: applications to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11589462/),,270.20,225427,DB01373,Calcium
,11589462,m/z,"For the quantification of the nisoldipine enantiomers a GC-MS with an Ultra 1 Hewlett-Packard column was used with the detector operated in the single-ion monitoring mode with electron-impact ionization (m/z 371.35 and 270.20 for nisoldipine and m/z 360.00 for the internal standard, nitrendipine).",Enantioselective assay of nisoldipine in human plasma by chiral high-performance liquid chromatography combined with gas chromatographic-mass spectrometry: applications to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11589462/),,360.00,225428,DB01373,Calcium
,11589462,AUC(0-24) (+)/(-) ratio,The enantioselective pilot study on the kinetic disposition of nisoldipine administered in the racemic form to a hypertensive patient using a multiple dose regimen revealed the accumulation of the (+)-enantiomer with an AUC(0-24) (+)/(-) ratio of approximately 8.,Enantioselective assay of nisoldipine in human plasma by chiral high-performance liquid chromatography combined with gas chromatographic-mass spectrometry: applications to pharmacokinetics. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11589462/),,8,225429,DB01373,Calcium
,18023905,C(max),"Specifically, C(max) values increased on increasing PEG Mw, i.e., 78.1+/-21.1, 102.9+/-9.1, and 115.2+/-5.7 for 1, 2, 5 kDa, respectively, vs. 54.8+/-3.9 ng/mL for sCT.",Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18023905/),,78.1,225622,DB01373,Calcium
,18023905,C(max),"Specifically, C(max) values increased on increasing PEG Mw, i.e., 78.1+/-21.1, 102.9+/-9.1, and 115.2+/-5.7 for 1, 2, 5 kDa, respectively, vs. 54.8+/-3.9 ng/mL for sCT.",Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18023905/),[ng] / [ml],102.9,225623,DB01373,Calcium
,18023905,C(max),"Specifically, C(max) values increased on increasing PEG Mw, i.e., 78.1+/-21.1, 102.9+/-9.1, and 115.2+/-5.7 for 1, 2, 5 kDa, respectively, vs. 54.8+/-3.9 ng/mL for sCT.",Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18023905/),[ng] / [ml],115.2,225624,DB01373,Calcium
,18023905,C(max),"Specifically, C(max) values increased on increasing PEG Mw, i.e., 78.1+/-21.1, 102.9+/-9.1, and 115.2+/-5.7 for 1, 2, 5 kDa, respectively, vs. 54.8+/-3.9 ng/mL for sCT.",Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18023905/),[ng] / [ml],54.8,225625,DB01373,Calcium
,18023905,circulating t(1/2),"Their circulating t(1/2) values also increased to 53.9+/-6.0, 100.7+/-21.7, and 119.4+/-13.7 min, respectively, vs. 34.6+/-7.6 min for sCT.",Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18023905/),min,53.9,225626,DB01373,Calcium
,18023905,circulating t(1/2),"Their circulating t(1/2) values also increased to 53.9+/-6.0, 100.7+/-21.7, and 119.4+/-13.7 min, respectively, vs. 34.6+/-7.6 min for sCT.",Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18023905/),min,100.7,225627,DB01373,Calcium
,18023905,circulating t(1/2),"Their circulating t(1/2) values also increased to 53.9+/-6.0, 100.7+/-21.7, and 119.4+/-13.7 min, respectively, vs. 34.6+/-7.6 min for sCT.",Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18023905/),min,119.4,225628,DB01373,Calcium
,18023905,circulating t(1/2),"Their circulating t(1/2) values also increased to 53.9+/-6.0, 100.7+/-21.7, and 119.4+/-13.7 min, respectively, vs. 34.6+/-7.6 min for sCT.",Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18023905/),min,34.6,225629,DB01373,Calcium
,30932720,zeta potential,"The particle size, zeta potential and entrapment efficiency of the optimized nanoparticles were found to be 204.90 ± 64 nm, -11.58 ± 4.80 mV, and 88.33 ± 3.74%, respectively.",Design and development of bioinspired calcium phosphate nanoparticles of MTX: pharmacodynamic and pharmacokinetic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30932720/),m,-,225656,DB01373,Calcium
,30932720,entrapment efficiency,"The particle size, zeta potential and entrapment efficiency of the optimized nanoparticles were found to be 204.90 ± 64 nm, -11.58 ± 4.80 mV, and 88.33 ± 3.74%, respectively.",Design and development of bioinspired calcium phosphate nanoparticles of MTX: pharmacodynamic and pharmacokinetic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30932720/),m,11.58,225657,DB01373,Calcium
,30932720,entrapment efficiency,"The particle size, zeta potential and entrapment efficiency of the optimized nanoparticles were found to be 204.90 ± 64 nm, -11.58 ± 4.80 mV, and 88.33 ± 3.74%, respectively.",Design and development of bioinspired calcium phosphate nanoparticles of MTX: pharmacodynamic and pharmacokinetic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30932720/),%,88.33,225658,DB01373,Calcium
,21998019,limit of detection,The assay limit of detection was 25 pg ml(-1) and the effective working range at relative standard deviations (RSD) of ≤ 5% was 40-2000 pg ml(-1).,Validated enzyme-linked immunosorbent assay for determination of rosuvastatin in plasma at picogram level. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21998019/),[pg] / [ml],25,226327,DB01373,Calcium
,21998019,Analytical recovery,Analytical recovery of ROS from spiked plasma was 96.2 - 104.8 ± 2.12 - 5.42%.,Validated enzyme-linked immunosorbent assay for determination of rosuvastatin in plasma at picogram level. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21998019/),%,96.2 - 104.8,226328,DB01373,Calcium
,27777391,tmax,"Pharmakokinetic(PK)study after a single Teriparatide injection of the daily dose in healthy Japanese postmenopausal women(n=18)revealed very rapid achievement of peak blood level(median of tmax=0.25 hr)followed by fast disappearance from the blood(mean t1/2=0.708 hr, n=17).","[Relationship of pharmacokinetics, changes of bone turnover markers and BMD/fractures efficacy during treatment with anabolic agents;Teriparatide daily and once weekly subcutaneous injections.] ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27777391/),h,0.25,226406,DB01373,Calcium
,27777391,t1/2,"Pharmakokinetic(PK)study after a single Teriparatide injection of the daily dose in healthy Japanese postmenopausal women(n=18)revealed very rapid achievement of peak blood level(median of tmax=0.25 hr)followed by fast disappearance from the blood(mean t1/2=0.708 hr, n=17).","[Relationship of pharmacokinetics, changes of bone turnover markers and BMD/fractures efficacy during treatment with anabolic agents;Teriparatide daily and once weekly subcutaneous injections.] ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27777391/),h,0.708,226407,DB01373,Calcium
,27777391,tmax,"PK study after injection of the higher weekly dose in healthy Japanese postmenopausal women(n=10)revealed a relatively slow achievement of the peak blood level(mean tmax=0.875 hr)compared to daily injections, followed by relatively slow disappearance from the blood(mean t1/2=1.295 hr).","[Relationship of pharmacokinetics, changes of bone turnover markers and BMD/fractures efficacy during treatment with anabolic agents;Teriparatide daily and once weekly subcutaneous injections.] ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27777391/),h,0.875,226408,DB01373,Calcium
,27777391,t1/2,"PK study after injection of the higher weekly dose in healthy Japanese postmenopausal women(n=10)revealed a relatively slow achievement of the peak blood level(mean tmax=0.875 hr)compared to daily injections, followed by relatively slow disappearance from the blood(mean t1/2=1.295 hr).","[Relationship of pharmacokinetics, changes of bone turnover markers and BMD/fractures efficacy during treatment with anabolic agents;Teriparatide daily and once weekly subcutaneous injections.] ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27777391/),h,1.295,226409,DB01373,Calcium
,19474787,transport ratio,"In MDCKII-ABCG2 cells, atorvastatin transport was increased in the apical direction as compared with vector control cells (transport ratio 1.9 +/- 0.1 vs. 1.1 +/- 0.1).",ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19474787/),,1.9,226634,DB01373,Calcium
,19474787,transport ratio,"In MDCKII-ABCG2 cells, atorvastatin transport was increased in the apical direction as compared with vector control cells (transport ratio 1.9 +/- 0.1 vs. 1.1 +/- 0.1).",ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19474787/),,1.1,226635,DB01373,Calcium
,26669888,C max,"Additionally, the silybin-loaded calcium phosphate microparticle compared with the free silybin showed a prolonged 72-h release in vitro and a higher C max (418.5 ± 23.7 ng mL(-1)) with 167.5% oral relative bioavailability.",In Vitro Release and Bioavailability of Silybin from Micelle-Templated Porous Calcium Phosphate Microparticles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669888/),[ng] / [ml],418.5,227156,DB01373,Calcium
,26669888,oral relative bioavailability,"Additionally, the silybin-loaded calcium phosphate microparticle compared with the free silybin showed a prolonged 72-h release in vitro and a higher C max (418.5 ± 23.7 ng mL(-1)) with 167.5% oral relative bioavailability.",In Vitro Release and Bioavailability of Silybin from Micelle-Templated Porous Calcium Phosphate Microparticles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26669888/),%,167.5,227157,DB01373,Calcium
,12445025,Cmax,"The Cmax values were 4.58 vs 4.54 ng ml-1, and AUC(0,24 h) values were 40.1 vs 42.7 ng ml-1 h, following morning and evening administration, respectively.","Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445025/),[ng] / [ml],4.58,229847,DB01373,Calcium
,12445025,Cmax,"The Cmax values were 4.58 vs 4.54 ng ml-1, and AUC(0,24 h) values were 40.1 vs 42.7 ng ml-1 h, following morning and evening administration, respectively.","Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445025/),[ng] / [ml],4.54,229848,DB01373,Calcium
,12445025,"AUC(0,24 h)","The Cmax values were 4.58 vs 4.54 ng ml-1, and AUC(0,24 h) values were 40.1 vs 42.7 ng ml-1 h, following morning and evening administration, respectively.","Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445025/),[h·ng] / [ml],40.1,229849,DB01373,Calcium
,12445025,"AUC(0,24 h)","The Cmax values were 4.58 vs 4.54 ng ml-1, and AUC(0,24 h) values were 40.1 vs 42.7 ng ml-1 h, following morning and evening administration, respectively.","Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445025/),[h·ng] / [ml],42.7,229850,DB01373,Calcium
,31655025,pIC50,"Among the compounds tested, the S-enantiomer of the m-chlorophenyl compound (S-Y048) was the most potent, with an pIC50 of about 10.8 for inhibition of 5-oxo-ETE-induced calcium mobilization in human neutrophils.",Novel highly potent OXE receptor antagonists with prolonged plasma lifetimes that are converted to active metabolites in vivo in monkeys. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31655025/),,10.8,229987,DB01373,Calcium
over,31655025,half-life,"When administered orally to cynomolgus monkeys, S-Y048 rapidly appeared in the blood and had a half-life in plasma of over 7 hr, considerably longer than any of the other OXE analogues tested.",Novel highly potent OXE receptor antagonists with prolonged plasma lifetimes that are converted to active metabolites in vivo in monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31655025/),h,7,229988,DB01373,Calcium
,12210048,release rate,The release rate of testosterone from optimal WFCs (3/8-in. diameter) per unit surface area was 5.6 microg x cm(2) x mL(-1) x min(-1) and was zero-order.,Transmucosal delivery of testosterone in rabbits using novel bi-layer mucoadhesive wax-film composite disks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12210048/),[cm(2·μg] / [min·ml],5.6,230463,DB01373,Calcium
,12210048,C(max),"Rabbits (n = 3) injected intravenously had C(max) and area under the curve values of 1200 +/- 46 ng/mL, and 48,227 +/- 12,995 ng x min/mL, respectively.",Transmucosal delivery of testosterone in rabbits using novel bi-layer mucoadhesive wax-film composite disks. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12210048/),[ng] / [ml],1200,230464,DB01373,Calcium
,12210048,area under the curve,"Rabbits (n = 3) injected intravenously had C(max) and area under the curve values of 1200 +/- 46 ng/mL, and 48,227 +/- 12,995 ng x min/mL, respectively.",Transmucosal delivery of testosterone in rabbits using novel bi-layer mucoadhesive wax-film composite disks. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12210048/),[min·ng] / [ml],"48,227",230465,DB01373,Calcium
,12210048,C(max),"Rabbits (n = 3) dosed via the buccal pouch had C(max), T(max), and area under the curve values of 127 +/- 13 ng/mL, 200 +/- 35 min, and 24,221 +/- 1543 ng x min/mL.",Transmucosal delivery of testosterone in rabbits using novel bi-layer mucoadhesive wax-film composite disks. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12210048/),[ng] / [ml],127,230466,DB01373,Calcium
,12210048,T(max),"Rabbits (n = 3) dosed via the buccal pouch had C(max), T(max), and area under the curve values of 127 +/- 13 ng/mL, 200 +/- 35 min, and 24,221 +/- 1543 ng x min/mL.",Transmucosal delivery of testosterone in rabbits using novel bi-layer mucoadhesive wax-film composite disks. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12210048/),min,200,230467,DB01373,Calcium
,12210048,area under the curve,"Rabbits (n = 3) dosed via the buccal pouch had C(max), T(max), and area under the curve values of 127 +/- 13 ng/mL, 200 +/- 35 min, and 24,221 +/- 1543 ng x min/mL.",Transmucosal delivery of testosterone in rabbits using novel bi-layer mucoadhesive wax-film composite disks. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12210048/),[min·ng] / [ml],"24,221",230468,DB01373,Calcium
,12210048,relative bioavailability,The relative bioavailability for rabbits treated with the WFC was 50.2 +/- 3.2% with a coefficient of variation of 6.4%.,Transmucosal delivery of testosterone in rabbits using novel bi-layer mucoadhesive wax-film composite disks. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12210048/),%,50.2,230469,DB01373,Calcium
,30229512,half-life,Navicixizumab's half-life was 11.4 days and there was a moderate (29%) incidence of anti-drug antibody formation.,A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30229512/),d,11.4,230544,DB01373,Calcium
,29243231,Ki,Estimated rifampicin in vivo unbound OATP Ki (0.13 μM) using CPI data was 2-fold lower relative to rosuvastatin.,Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and Simulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29243231/),μM,0.13,230892,DB01373,Calcium
,19492813,IC(50),Functional screening of the former SmithKline Beecham compound collection against the human calcium receptor (CaR) resulted in the identification of the amino alcohol-based hit 2 (IC(50) = 11 microM).,Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19492813/),μM,11,231277,DB01373,Calcium
,19492813,volume of distribution,"Pharmacokinetic characterization of 38 in the rat revealed that this molecule had a large volume of distribution (11 L/kg), which resulted in a prolonged systemic exposure, protracted increases in the plasma levels of PTH, and an overall lack of net bone formation effect in a rodent model of osteoporosis.",Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19492813/),[l] / [kg],11,231278,DB01373,Calcium
,18343242,AUC(0-last),"Geometric mean of AUC(0-last)(test, 504.21 h x ng/mL; reference, 361.28 h x ng/mL) was significantly higher for the test product, with a point estimate of 140% and a corresponding 90% CI of 121% to 161%.",Comparison of two marketed nifedipine modified-release formulations: an exploratory clinical food interaction study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18343242/),[h·ng] / [ml],504.21,231330,DB01373,Calcium
,18343242,AUC(0-last),"Geometric mean of AUC(0-last)(test, 504.21 h x ng/mL; reference, 361.28 h x ng/mL) was significantly higher for the test product, with a point estimate of 140% and a corresponding 90% CI of 121% to 161%.",Comparison of two marketed nifedipine modified-release formulations: an exploratory clinical food interaction study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18343242/),[h·ng] / [ml],361.28,231331,DB01373,Calcium
,18343242,Cmax,"For the comparison of Cmax values, geometric means were: test, 76.46 ng/mL; reference, 19.20 ng/mL, with a point estimate of 398% and a CI of 316% to 503%.",Comparison of two marketed nifedipine modified-release formulations: an exploratory clinical food interaction study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18343242/),[ng] / [ml],76.46,231332,DB01373,Calcium
,18343242,Cmax,"For the comparison of Cmax values, geometric means were: test, 76.46 ng/mL; reference, 19.20 ng/mL, with a point estimate of 398% and a CI of 316% to 503%.",Comparison of two marketed nifedipine modified-release formulations: an exploratory clinical food interaction study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18343242/),[ng] / [ml],19.20,231333,DB01373,Calcium
,15793802,relative bioavailability,"With the delivery system containing 3 kDa LMWH (279 IU) a relative bioavailability of 19.1% was achieved, offering a significantly (p < 0.05) better bioavailability than the control system displaying a relative bioavailability of 8.1% The 6 kDa LMWH (300 IU) formulation displayed a relative bioavailability of 10.7% in contrast to the control displaying a relative bioavailability of 2.1%.",Oral heparin delivery: design and in vivo evaluation of a stomach-targeted mucoadhesive delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15793802/),%,19.1,232105,DB01373,Calcium
,15793802,relative bioavailability,"With the delivery system containing 3 kDa LMWH (279 IU) a relative bioavailability of 19.1% was achieved, offering a significantly (p < 0.05) better bioavailability than the control system displaying a relative bioavailability of 8.1% The 6 kDa LMWH (300 IU) formulation displayed a relative bioavailability of 10.7% in contrast to the control displaying a relative bioavailability of 2.1%.",Oral heparin delivery: design and in vivo evaluation of a stomach-targeted mucoadhesive delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15793802/),%,8.1,232106,DB01373,Calcium
,15793802,relative bioavailability,"With the delivery system containing 3 kDa LMWH (279 IU) a relative bioavailability of 19.1% was achieved, offering a significantly (p < 0.05) better bioavailability than the control system displaying a relative bioavailability of 8.1% The 6 kDa LMWH (300 IU) formulation displayed a relative bioavailability of 10.7% in contrast to the control displaying a relative bioavailability of 2.1%.",Oral heparin delivery: design and in vivo evaluation of a stomach-targeted mucoadhesive delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15793802/),%,10.7,232107,DB01373,Calcium
,15793802,relative bioavailability,"With the delivery system containing 3 kDa LMWH (279 IU) a relative bioavailability of 19.1% was achieved, offering a significantly (p < 0.05) better bioavailability than the control system displaying a relative bioavailability of 8.1% The 6 kDa LMWH (300 IU) formulation displayed a relative bioavailability of 10.7% in contrast to the control displaying a relative bioavailability of 2.1%.",Oral heparin delivery: design and in vivo evaluation of a stomach-targeted mucoadhesive delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15793802/),%,2.1,232108,DB01373,Calcium
,17066293,MTD,The MTD for weekly DN-101 was established as 45 mug.,"Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17066293/),μg,45,232515,DB01373,Calcium
,19192440,half-life,"Its unique pharmacokinetic profile as an oral drug with long half-life (2-7 weeks), low cost, and low induction of extrapyramidal symptoms warrants further investigation, particularly in psychiatric patients with low adherence to treatment.",Is flunarizine a long-acting oral atypical antipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19192440/),weeks,2-7,233080,DB01373,Calcium
,25581635,Plasma clearance,Plasma clearance (interindividual variability) was 0.564 L/h (14.0%CV).,"Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25581635/),[l] / [h],0.564,233229,DB01373,Calcium
,25581635,clearance,The hemodialysis clearance was 22.2 L/h.,"Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25581635/),[l] / [h],22.2,233230,DB01373,Calcium
,25581635,volume of distribution at steady-state,The volume of distribution at steady-state was approximately 624 L (82%CV).,"Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25581635/),l,624,233231,DB01373,Calcium
,25581635,time to achieve 90% steady-state pre,"The mean time to achieve 90% steady-state predialysis concentrations with 3- and 6-hour hemodialysis TIW was 46 and 32 days, respectively.","Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25581635/),d,46,233232,DB01373,Calcium
,25581635,time to achieve 90% steady-state pre,"The mean time to achieve 90% steady-state predialysis concentrations with 3- and 6-hour hemodialysis TIW was 46 and 32 days, respectively.","Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25581635/),d,32,233233,DB01373,Calcium
,29860181,flow rate,"Stereoselective separation was performed on CHIRALCEL OZ-RH column (150 mm × 4.6 mm i.d., 5 μm) with acetonitrile-water (10 mM ammonium acetate, 0.5% ammonia solution) (95:5, v/v) at a flow rate of 0.5 mL/min.",Validated LC-MS/MS method for the determination of amlodipine enantiomers in rat plasma and its application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29860181/),[ml] / [min],0.5,233363,DB01373,Calcium
,29860181,m/,Multiple reaction monitoring was selected with the transition of the m/z 409.1 → 238.0 for amlodipine enantiomers and m/z 237.0 → 194.1 for carbamazepine (IS) respectively.,Validated LC-MS/MS method for the determination of amlodipine enantiomers in rat plasma and its application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29860181/),,409.1,233364,DB01373,Calcium
,29860181,m/,Multiple reaction monitoring was selected with the transition of the m/z 409.1 → 238.0 for amlodipine enantiomers and m/z 237.0 → 194.1 for carbamazepine (IS) respectively.,Validated LC-MS/MS method for the determination of amlodipine enantiomers in rat plasma and its application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29860181/),,238.0,233365,DB01373,Calcium
,29860181,m/z,Multiple reaction monitoring was selected with the transition of the m/z 409.1 → 238.0 for amlodipine enantiomers and m/z 237.0 → 194.1 for carbamazepine (IS) respectively.,Validated LC-MS/MS method for the determination of amlodipine enantiomers in rat plasma and its application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29860181/),,237.0,233366,DB01373,Calcium
,29860181,m/z,Multiple reaction monitoring was selected with the transition of the m/z 409.1 → 238.0 for amlodipine enantiomers and m/z 237.0 → 194.1 for carbamazepine (IS) respectively.,Validated LC-MS/MS method for the determination of amlodipine enantiomers in rat plasma and its application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29860181/),,194.1,233367,DB01373,Calcium
,18093252,time of peak nifedipine concentrations,"Plasma NE was higher in the Coracten- (480 +/- 38.3 pg ml(-1)) than N-GITS-treated patients (343 +/- 75.0 pg ml(-1)) at the time of peak nifedipine concentrations (4 and 5 h, respectively) and their change from baseline was significantly (P = 0.0046) different.",Formulation of long-acting nifedipine tablets influences the heart rate and sympathetic nervous system response in hypertensive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18093252/),h,4,233599,DB01373,Calcium
,18093252,time of peak nifedipine concentrations,"Plasma NE was higher in the Coracten- (480 +/- 38.3 pg ml(-1)) than N-GITS-treated patients (343 +/- 75.0 pg ml(-1)) at the time of peak nifedipine concentrations (4 and 5 h, respectively) and their change from baseline was significantly (P = 0.0046) different.",Formulation of long-acting nifedipine tablets influences the heart rate and sympathetic nervous system response in hypertensive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18093252/),h,5,233600,DB01373,Calcium
,29423833,oral bioavailability,"The oral bioavailability of felodipine (FEL) is very low, i.e., about 15%.",Assessment of improved buccal permeation and bioavailability of felodipine microemulsion-based cross-linked polycarbophil gel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29423833/),%,15,234444,DB01373,Calcium
,29423833,J,"The optimized buccal gel (MEF-PCP1) showed significantly higher (p < 0.01) permeation flux (J = 0.44 ± 0.16 mg/cm2/h), when compared with the drug suspension (J = 0.17 ± 0.14 mg/cm2/h).",Assessment of improved buccal permeation and bioavailability of felodipine microemulsion-based cross-linked polycarbophil gel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29423833/),[mg] / [cm2·h],0.44,234445,DB01373,Calcium
,29423833,J,"The optimized buccal gel (MEF-PCP1) showed significantly higher (p < 0.01) permeation flux (J = 0.44 ± 0.16 mg/cm2/h), when compared with the drug suspension (J = 0.17 ± 0.14 mg/cm2/h).",Assessment of improved buccal permeation and bioavailability of felodipine microemulsion-based cross-linked polycarbophil gel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29423833/),[mg] / [cm2·h],0.17,234446,DB01373,Calcium
,29423833,spreadability,"The texture profile analysis of MEF-PCP1 was performed which showed spreadability (3.2 mJ), extrudability (151.8 mJ), hardness (13.8 g), and adhesiveness (41.0 g), and results indicated good spreadability and adhesiveness.",Assessment of improved buccal permeation and bioavailability of felodipine microemulsion-based cross-linked polycarbophil gel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29423833/),mj,3.2,234447,DB01373,Calcium
,29423833,extrudability,"The texture profile analysis of MEF-PCP1 was performed which showed spreadability (3.2 mJ), extrudability (151.8 mJ), hardness (13.8 g), and adhesiveness (41.0 g), and results indicated good spreadability and adhesiveness.",Assessment of improved buccal permeation and bioavailability of felodipine microemulsion-based cross-linked polycarbophil gel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29423833/),mj,151.8,234448,DB01373,Calcium
,29423833,Cmax,The Cmax value 9.21 ± 2.88 μg/ml of MEF-PCP1 gel was found to be significantly higher (P < 0.01) compared to the same dose administered by oral route (Cmax value 3.51 ± 1.74 μg/ml).,Assessment of improved buccal permeation and bioavailability of felodipine microemulsion-based cross-linked polycarbophil gel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29423833/),[μg] / [ml],9.21,234449,DB01373,Calcium
,29423833,Cmax,The Cmax value 9.21 ± 2.88 μg/ml of MEF-PCP1 gel was found to be significantly higher (P < 0.01) compared to the same dose administered by oral route (Cmax value 3.51 ± 1.74 μg/ml).,Assessment of improved buccal permeation and bioavailability of felodipine microemulsion-based cross-linked polycarbophil gel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29423833/),[μg] / [ml],3.51,234450,DB01373,Calcium
,29423833,relative bioavailability (Fr),The relative bioavailability (Fr) of the optimized MEF-PCP1 buccal gel was about 397.39% higher than that of oral route.,Assessment of improved buccal permeation and bioavailability of felodipine microemulsion-based cross-linked polycarbophil gel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29423833/),%,397.39,234451,DB01373,Calcium
,29204927,oral bioavailability,"The oral bioavailability of felodipine, a dihydropyridine calcium channel antagonist, is about 15%.",Augmented bioavailability of felodipine through an α-linolenic acid-based microemulsion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29204927/),%,15,234801,DB01373,Calcium
,29204927,apparent permeability coefficients (Papp),"The optimized felodipine-loaded microemulsion showed significantly higher (P < 0.05) apparent permeability coefficients (Papp) at 7.918 × 10-5 cm/s after 1 h, when compared with conventional formulations that are marketed tablet, drug oily solution, and drug emulsion, which showed a maximum Papp of 3.013, 4.428, and 5.335 × 10-5 cm/s, respectively.",Augmented bioavailability of felodipine through an α-linolenic acid-based microemulsion. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29204927/),[cm] / [s],7.918 × 10-5,234802,DB01373,Calcium
,29204927,maximum Papp,"The optimized felodipine-loaded microemulsion showed significantly higher (P < 0.05) apparent permeability coefficients (Papp) at 7.918 × 10-5 cm/s after 1 h, when compared with conventional formulations that are marketed tablet, drug oily solution, and drug emulsion, which showed a maximum Papp of 3.013, 4.428, and 5.335 × 10-5 cm/s, respectively.",Augmented bioavailability of felodipine through an α-linolenic acid-based microemulsion. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29204927/),[cm] / [s],3.013,234803,DB01373,Calcium
,29204927,maximum Papp,"The optimized felodipine-loaded microemulsion showed significantly higher (P < 0.05) apparent permeability coefficients (Papp) at 7.918 × 10-5 cm/s after 1 h, when compared with conventional formulations that are marketed tablet, drug oily solution, and drug emulsion, which showed a maximum Papp of 3.013, 4.428, and 5.335 × 10-5 cm/s, respectively.",Augmented bioavailability of felodipine through an α-linolenic acid-based microemulsion. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29204927/),[cm] / [s],4.428,234804,DB01373,Calcium
,29204927,maximum Papp,"The optimized felodipine-loaded microemulsion showed significantly higher (P < 0.05) apparent permeability coefficients (Papp) at 7.918 × 10-5 cm/s after 1 h, when compared with conventional formulations that are marketed tablet, drug oily solution, and drug emulsion, which showed a maximum Papp of 3.013, 4.428, and 5.335 × 10-5 cm/s, respectively.",Augmented bioavailability of felodipine through an α-linolenic acid-based microemulsion. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29204927/),[cm] / [s],5.335 × 10-5,234805,DB01373,Calcium
,29204927,C max,The optimized felodipine-loaded microemulsion showed significantly higher (p < 0.01) C max (7.12 ± 1.04 μg/ml) than marketed tablets (2.44 ± 1.03 μg/ml).,Augmented bioavailability of felodipine through an α-linolenic acid-based microemulsion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29204927/),[μg] / [ml],7.12,234806,DB01373,Calcium
,29204927,C max,The optimized felodipine-loaded microemulsion showed significantly higher (p < 0.01) C max (7.12 ± 1.04 μg/ml) than marketed tablets (2.44 ± 1.03 μg/ml).,Augmented bioavailability of felodipine through an α-linolenic acid-based microemulsion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29204927/),[μg] / [ml],2.44,234807,DB01373,Calcium
,29204927,AUClast,It was found that AUClast obtained from the optimized felodipine-loaded microemulsion (84.53 ± 10.73 μg h/ml) was significantly higher (p < 0.01) than the marketed tablet (27.41 ± 5.54 μg h/ml).,Augmented bioavailability of felodipine through an α-linolenic acid-based microemulsion. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29204927/),[h·μg] / [ml],84.53,234808,DB01373,Calcium
,29204927,AUClast,It was found that AUClast obtained from the optimized felodipine-loaded microemulsion (84.53 ± 10.73 μg h/ml) was significantly higher (p < 0.01) than the marketed tablet (27.41 ± 5.54 μg h/ml).,Augmented bioavailability of felodipine through an α-linolenic acid-based microemulsion. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29204927/),[h·μg] / [ml],27.41,234809,DB01373,Calcium
,29204927,relative bioavailability (Fr),The relative bioavailability (Fr) of the optimized felodipine-loaded microemulsion was about 308.3% higher than that of the marketed formulation.,Augmented bioavailability of felodipine through an α-linolenic acid-based microemulsion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29204927/),%,308.3,234810,DB01373,Calcium
,24793535,Tmax,"After single and multiple subcutaneous administration of rhPTH(1-34), the drug was rapidly absorbed, with a Tmax of 20 to 30 minutes, and rapidly cleared from the plasma, with a t½ of 47.2 to 60.6 minutes.","Safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human parathyroid hormone (1-34) in healthy Chinese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24793535/),min,20 to 30,235171,DB01373,Calcium
,24793535,t½,"After single and multiple subcutaneous administration of rhPTH(1-34), the drug was rapidly absorbed, with a Tmax of 20 to 30 minutes, and rapidly cleared from the plasma, with a t½ of 47.2 to 60.6 minutes.","Safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human parathyroid hormone (1-34) in healthy Chinese subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24793535/),min,47.2 to 60.6,235172,DB01373,Calcium
,23268736,peak rise,"Mean peak rise in serum 25-hydroxyvitamin D concentration above baseline was similar in non-pregnant and pregnant women (28 nmol/L and 32 nmol/L, respectively).","Pharmacokinetics of a single oral dose of vitamin D3 (70,000 IU) in pregnant and non-pregnant women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23268736/),,28,235339,DB01373,Calcium
,23268736,peak rise,"Mean peak rise in serum 25-hydroxyvitamin D concentration above baseline was similar in non-pregnant and pregnant women (28 nmol/L and 32 nmol/L, respectively).","Pharmacokinetics of a single oral dose of vitamin D3 (70,000 IU) in pregnant and non-pregnant women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23268736/),,32,235340,DB01373,Calcium
,19566113,absolute bioavailability,"The absolute bioavailability is 20-25%, and administration of cinacalcet with low- or high-fat meals increases exposure (area under the plasma concentration-time curve from time zero to infinity [AUC(infinity)]) 1.5- to 1.8-fold.",Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566113/),%,20-25,235608,DB01373,Calcium
,19566113,terminal elimination half-life,"The terminal elimination half-life is 30-40 hours, and steady-state concentrations are achieved within 7 days.",Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566113/),h,30-40,235609,DB01373,Calcium
,11550166,elimination half-life,The median elimination half-life of amifostine (9.3 minutes) and WR-1065 (15 minutes) was much shorter than the disulfide metabolites (74.4 minutes).,"Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11550166/),min,9.3,235654,DB01373,Calcium
,11550166,elimination half-life,The median elimination half-life of amifostine (9.3 minutes) and WR-1065 (15 minutes) was much shorter than the disulfide metabolites (74.4 minutes).,"Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11550166/),min,15,235655,DB01373,Calcium
,11550166,elimination half-life,The median elimination half-life of amifostine (9.3 minutes) and WR-1065 (15 minutes) was much shorter than the disulfide metabolites (74.4 minutes).,"Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11550166/),min,74.4,235656,DB01373,Calcium
,33081067,area under the curve (AUC0-t),A significant difference in the area under the curve (AUC0-t) was observed for group 4 (6.78 ± 4.24 h*ng/mL) in comparison with group 2 (12.83 ± 4.19 h*ng/mL).,Calcination Improves the In Vivo Efficacy of a Montmorillonite Clay to Bind Aflatoxin G1 in Broiler Chickens: A Toxicokinetic Approach. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33081067/),[h·ng] / [ml],6.78,236008,DB01373,Calcium
,33081067,area under the curve (AUC0-t),A significant difference in the area under the curve (AUC0-t) was observed for group 4 (6.78 ± 4.24 h*ng/mL) in comparison with group 2 (12.83 ± 4.19 h*ng/mL).,Calcination Improves the In Vivo Efficacy of a Montmorillonite Clay to Bind Aflatoxin G1 in Broiler Chickens: A Toxicokinetic Approach. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33081067/),[h·ng] / [ml],12.83,236009,DB01373,Calcium
,33081067,oral bioavailability,"A significant reduction of the oral bioavailability of AFG1 was observed for group 4 (7.61 ± 4.76%) compared with group 2 (14.40 ± 4.70%), while no significant effect was observed of CP.",Calcination Improves the In Vivo Efficacy of a Montmorillonite Clay to Bind Aflatoxin G1 in Broiler Chickens: A Toxicokinetic Approach. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33081067/),%,7.61,236010,DB01373,Calcium
,33081067,oral bioavailability,"A significant reduction of the oral bioavailability of AFG1 was observed for group 4 (7.61 ± 4.76%) compared with group 2 (14.40 ± 4.70%), while no significant effect was observed of CP.",Calcination Improves the In Vivo Efficacy of a Montmorillonite Clay to Bind Aflatoxin G1 in Broiler Chickens: A Toxicokinetic Approach. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33081067/),%,14.40,236011,DB01373,Calcium
,26934925,recovery,"The 24-h recovery of risedronate from evian® (0.32±0.02% [mean±standard deviation (S.D.)], n=4) and Contrex(®) (0.22±0.05%) mineral waters was significantly lower than that from tap water (0.47±0.04%, p<0.01).",Interaction between Bisphosphonates and Mineral Water: Study of Oral Risedronate Absorption in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26934925/),%,0.32,236378,DB01373,Calcium
,26934925,recovery,"The 24-h recovery of risedronate from evian® (0.32±0.02% [mean±standard deviation (S.D.)], n=4) and Contrex(®) (0.22±0.05%) mineral waters was significantly lower than that from tap water (0.47±0.04%, p<0.01).",Interaction between Bisphosphonates and Mineral Water: Study of Oral Risedronate Absorption in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26934925/),%,0.22,236379,DB01373,Calcium
,26934925,recovery,"The 24-h recovery of risedronate from evian® (0.32±0.02% [mean±standard deviation (S.D.)], n=4) and Contrex(®) (0.22±0.05%) mineral waters was significantly lower than that from tap water (0.47±0.04%, p<0.01).",Interaction between Bisphosphonates and Mineral Water: Study of Oral Risedronate Absorption in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26934925/),%,0.47,236380,DB01373,Calcium
,26934925,Absorption,"Absorption of risedronate in calcium chloride and magnesium chloride aqueous solutions of the same hardness (822 mg/L) was 54% (0.27±0.04%) and 12% (0.51±0.08%) lower, respectively, compared with ultrapure water; suggesting that absorption of risedronate declines as the calcium concentration of mineral waters increases.",Interaction between Bisphosphonates and Mineral Water: Study of Oral Risedronate Absorption in Rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26934925/),%,54,236381,DB01373,Calcium
,26934925,Absorption,"Absorption of risedronate in calcium chloride and magnesium chloride aqueous solutions of the same hardness (822 mg/L) was 54% (0.27±0.04%) and 12% (0.51±0.08%) lower, respectively, compared with ultrapure water; suggesting that absorption of risedronate declines as the calcium concentration of mineral waters increases.",Interaction between Bisphosphonates and Mineral Water: Study of Oral Risedronate Absorption in Rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26934925/),%,0.27,236382,DB01373,Calcium
,26934925,Absorption,"Absorption of risedronate in calcium chloride and magnesium chloride aqueous solutions of the same hardness (822 mg/L) was 54% (0.27±0.04%) and 12% (0.51±0.08%) lower, respectively, compared with ultrapure water; suggesting that absorption of risedronate declines as the calcium concentration of mineral waters increases.",Interaction between Bisphosphonates and Mineral Water: Study of Oral Risedronate Absorption in Rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26934925/),%,12,236383,DB01373,Calcium
,26934925,Absorption,"Absorption of risedronate in calcium chloride and magnesium chloride aqueous solutions of the same hardness (822 mg/L) was 54% (0.27±0.04%) and 12% (0.51±0.08%) lower, respectively, compared with ultrapure water; suggesting that absorption of risedronate declines as the calcium concentration of mineral waters increases.",Interaction between Bisphosphonates and Mineral Water: Study of Oral Risedronate Absorption in Rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26934925/),%,0.51,236384,DB01373,Calcium
,24023367,Km,"Membrane vesicle experiments revealed that RSV is a substrate of MRP4 (Km = 21 ± 7 µM, Vmax = 1140 ± 210 pmol/min per milligram of protein).",Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24023367/),μM,21,236646,DB01373,Calcium
,24023367,Vmax,"Membrane vesicle experiments revealed that RSV is a substrate of MRP4 (Km = 21 ± 7 µM, Vmax = 1140 ± 210 pmol/min per milligram of protein).",Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24023367/),[pM] / [milligram·min],1140,236647,DB01373,Calcium
,12221061,ED50,"In sinus rhythm dogs, peak AERP changes resulting from intravenous KB infusion ranged from (mean+/-SEM) 4.4+/-0.4% (1 mg/kg) to 14.8+/-2.6% (5 mg/kg; ED50=1.9 mg/kg).","Kb-R7943 prevents acute, atrial fibrillation-induced shortening of atrial refractoriness in anesthetized dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12221061/),[mg] / [kg],1.9,238470,DB01373,Calcium
,12221061,Plasma drug concentration,Plasma drug concentration peaked at the end of KB infusions (30.86+/-3.26 nmol/L; n=4 dogs) and declined to 0.56+/-0.19 nmol/L after 100 minutes.,"Kb-R7943 prevents acute, atrial fibrillation-induced shortening of atrial refractoriness in anesthetized dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12221061/),[nM] / [l],30.86,238471,DB01373,Calcium
,12221061,Plasma drug concentration,Plasma drug concentration peaked at the end of KB infusions (30.86+/-3.26 nmol/L; n=4 dogs) and declined to 0.56+/-0.19 nmol/L after 100 minutes.,"Kb-R7943 prevents acute, atrial fibrillation-induced shortening of atrial refractoriness in anesthetized dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12221061/),[nM] / [l],0.56,238472,DB01373,Calcium
,12221061,tissue-to-plasma drug concentration gradient,The cardiac tissue-to-plasma drug concentration gradient averaged approximately 40 at 100 minutes after start of KB infusion.,"Kb-R7943 prevents acute, atrial fibrillation-induced shortening of atrial refractoriness in anesthetized dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12221061/),,40,238473,DB01373,Calcium
,21940716,oral clearance,Paricalcitol pharmacokinetics were similar following intravenous and oral administration with mean oral clearance of 1.75 L/h and bioavailability of 75.1%.,Exposure-clinical response analysis of paricalcitol in patients with chronic kidney disease (stage 5) on hemodialysis or peritoneal dialysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21940716/),[l] / [h],1.75,238693,DB01373,Calcium
,21940716,bioavailability,Paricalcitol pharmacokinetics were similar following intravenous and oral administration with mean oral clearance of 1.75 L/h and bioavailability of 75.1%.,Exposure-clinical response analysis of paricalcitol in patients with chronic kidney disease (stage 5) on hemodialysis or peritoneal dialysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21940716/),%,75.1,238694,DB01373,Calcium
,33123800,IC50,Scutellarin inhibited hOATP1B3- and rOATP1B2-mediated rosuvastatin uptake (IC50: 45.54 ± 6.67 μM and 27.58 ± 3.97 μM) in vitro in a concentration-dependent manner.,Scutellarin is Highly Likely to be Responsible for Drug-Drug Interactions Mediated by Hepatic Organic Anion-Transporting Polypeptide1B3. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33123800/),μM,45.54,238735,DB01373,Calcium
,33123800,IC50,Scutellarin inhibited hOATP1B3- and rOATP1B2-mediated rosuvastatin uptake (IC50: 45.54 ± 6.67 μM and 27.58 ± 3.97 μM) in vitro in a concentration-dependent manner.,Scutellarin is Highly Likely to be Responsible for Drug-Drug Interactions Mediated by Hepatic Organic Anion-Transporting Polypeptide1B3. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33123800/),μM,27.58,238736,DB01373,Calcium
,15285332,bioavailability,"A bioavailability of approximately 96% of that of a paracetamol solution could be achieved from gels containing an identical dose of drug formed in situ in the stomachs of rats, with appreciably lower peak plasma levels and a sustained release of drug over a period of at least 6 h.",In situ gelling pectin formulations for oral sustained delivery of paracetamol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15285332/),%,96,239448,DB01373,Calcium
,11777750,maximum plasma concentration (C(max)),Mean value of maximum plasma concentration (C(max)) of V for floating pellets was 28.27 ng ml(-1) and t(max) 3.75 h.,Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11777750/),[ng] / [ml],28.27,239455,DB01373,Calcium
,11777750,t(max),Mean value of maximum plasma concentration (C(max)) of V for floating pellets was 28.27 ng ml(-1) and t(max) 3.75 h.,Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11777750/),h,3.75,239456,DB01373,Calcium
,11777750,"area under the concentrations versus time, AUC(0-infinity)","The value of the area under the concentrations versus time, AUC(0-infinity) was calculated as 364.65 ng ml(-1) h, biological half-lives of the absorption and elimination (t(0.5el)) phase were 0.5 h and 10.68 h, respectively.",Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11777750/),[h·ng] / [ml],364.65,239457,DB01373,Calcium
,11777750,biological half-lives of the absorption,"The value of the area under the concentrations versus time, AUC(0-infinity) was calculated as 364.65 ng ml(-1) h, biological half-lives of the absorption and elimination (t(0.5el)) phase were 0.5 h and 10.68 h, respectively.",Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11777750/),h,0.5,239458,DB01373,Calcium
,11777750,elimination (t(0.5el)) phase,"The value of the area under the concentrations versus time, AUC(0-infinity) was calculated as 364.65 ng ml(-1) h, biological half-lives of the absorption and elimination (t(0.5el)) phase were 0.5 h and 10.68 h, respectively.",Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11777750/),h,0.5,239459,DB01373,Calcium
,11777750,elimination (t(0.5el)) phase,"The value of the area under the concentrations versus time, AUC(0-infinity) was calculated as 364.65 ng ml(-1) h, biological half-lives of the absorption and elimination (t(0.5el)) phase were 0.5 h and 10.68 h, respectively.",Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11777750/),h,10.68,239460,DB01373,Calcium
,25782422,elimination half-life,"According to raw data, the elimination half-life of 25OHD was 84 and 111 days under D2 and D3 supplementation, respectively; after subtracting the placebo values, the corresponding figures were 33 and 82 days.",Vitamin D3 seems more appropriate than D2 to sustain adequate levels of 25OHD: a pharmacokinetic approach. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25782422/),d,84,239510,DB01373,Calcium
,25782422,elimination half-life,"According to raw data, the elimination half-life of 25OHD was 84 and 111 days under D2 and D3 supplementation, respectively; after subtracting the placebo values, the corresponding figures were 33 and 82 days.",Vitamin D3 seems more appropriate than D2 to sustain adequate levels of 25OHD: a pharmacokinetic approach. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25782422/),d,111,239511,DB01373,Calcium
,25782422,elimination half-life,"According to raw data, the elimination half-life of 25OHD was 84 and 111 days under D2 and D3 supplementation, respectively; after subtracting the placebo values, the corresponding figures were 33 and 82 days.",Vitamin D3 seems more appropriate than D2 to sustain adequate levels of 25OHD: a pharmacokinetic approach. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25782422/),d,33,239512,DB01373,Calcium
,25782422,elimination half-life,"According to raw data, the elimination half-life of 25OHD was 84 and 111 days under D2 and D3 supplementation, respectively; after subtracting the placebo values, the corresponding figures were 33 and 82 days.",Vitamin D3 seems more appropriate than D2 to sustain adequate levels of 25OHD: a pharmacokinetic approach. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25782422/),d,82,239513,DB01373,Calcium
,31173966,half-life,"A single bolus intravenous injection of CBD resulted in a half-life of 3.9 h, mean residence time of 3.3 h, and oral bioavailability of about 8.6%.",Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31173966/),h,3.9,240620,DB01373,Calcium
,31173966,mean residence time,"A single bolus intravenous injection of CBD resulted in a half-life of 3.9 h, mean residence time of 3.3 h, and oral bioavailability of about 8.6%.",Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31173966/),h,3.3,240621,DB01373,Calcium
,31173966,oral bioavailability,"A single bolus intravenous injection of CBD resulted in a half-life of 3.9 h, mean residence time of 3.3 h, and oral bioavailability of about 8.6%.",Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31173966/),%,8.6,240622,DB01373,Calcium
,27569392,Tmax,The intervention markedly increased the blood 25(OH)D3 levels within the first five days (mean Tmax=5.1±2.1 d) and sustained an optimal circulating level of 25(OH)D3 (≥30 ng/mL) for 56 d.,Pharmacokinetics and effects of demographic factors on blood 25(OH)D3 levels after a single orally administered high dose of vitamin D3. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27569392/),d,5.1,240846,DB01373,Calcium
,27401407,entrapment,Optimized CaP-AmB-NPs exhibited higher entrapment (71.1 ± 6.68%) of AmB.,Bioinspired Calcium Phosphate Nanoparticles Featuring as Efficient Carrier and Prompter for Macrophage Intervention in Experimental Leishmaniasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27401407/),%,71.1,240919,DB01373,Calcium
,16877419,C(max),Values of C(max) displayed a large interindividual variance and ranged from 0 ng/mL to 57.5 ng/mL.,Nimodipine plasma concentration and retinal blood flow in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16877419/),[ng] / [ml],0,240985,DB01373,Calcium
,16877419,C(max),Values of C(max) displayed a large interindividual variance and ranged from 0 ng/mL to 57.5 ng/mL.,Nimodipine plasma concentration and retinal blood flow in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16877419/),[ng] / [ml],57.5,240986,DB01373,Calcium
,16877419,maximum nimodipine plasma concentrations (C(max)),"On average, maximum nimodipine plasma concentrations (C(max)) were 16.6 +/- 14.9 ng/mL and 12.0 +/- 10.3 ng/mL at day 1 and day 5, respectively (P = 0.068).",Nimodipine plasma concentration and retinal blood flow in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16877419/),[ng] / [ml],16.6,240987,DB01373,Calcium
,16877419,maximum nimodipine plasma concentrations (C(max)),"On average, maximum nimodipine plasma concentrations (C(max)) were 16.6 +/- 14.9 ng/mL and 12.0 +/- 10.3 ng/mL at day 1 and day 5, respectively (P = 0.068).",Nimodipine plasma concentration and retinal blood flow in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16877419/),[ng] / [ml],12.0,240988,DB01373,Calcium
,16877419,t(max),"They were observed at 81 +/- 50 and at 93 +/- 40 minutes (t(max)) after the administration of nimodipine at day 1 and day 5, respectively (P = 0.43).",Nimodipine plasma concentration and retinal blood flow in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16877419/),min,81,240989,DB01373,Calcium
,16877419,t(max),"They were observed at 81 +/- 50 and at 93 +/- 40 minutes (t(max)) after the administration of nimodipine at day 1 and day 5, respectively (P = 0.43).",Nimodipine plasma concentration and retinal blood flow in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16877419/),min,93,240990,DB01373,Calcium
,17014999,T(max),"WIN55,212-2 was absorbed more rapidly (T(max)=0.2-0.3h) than Delta(9)-THC (T(max)=1.5-1.6h) and to a higher extent than Delta(9)-THC.","Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014999/),h,0.2-0.3,241047,DB01373,Calcium
,17014999,T(max),"WIN55,212-2 was absorbed more rapidly (T(max)=0.2-0.3h) than Delta(9)-THC (T(max)=1.5-1.6h) and to a higher extent than Delta(9)-THC.","Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014999/),h,1.5-1.6,241048,DB01373,Calcium
,17014999,absolute bioavailability (F(abs)),"Furthermore, it had no significant effect on the absolute bioavailability (F(abs)): F(abs)=6.4+/-2.4% and 9.1+/-3.0% for Delta(9)-THC in propylene glycol, with and without ethanol, respectively.","Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014999/),%,6.4,241049,DB01373,Calcium
,17014999,F(abs),"Furthermore, it had no significant effect on the absolute bioavailability (F(abs)): F(abs)=6.4+/-2.4% and 9.1+/-3.0% for Delta(9)-THC in propylene glycol, with and without ethanol, respectively.","Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014999/),%,6.4,241050,DB01373,Calcium
,17014999,F(abs),"Furthermore, it had no significant effect on the absolute bioavailability (F(abs)): F(abs)=6.4+/-2.4% and 9.1+/-3.0% for Delta(9)-THC in propylene glycol, with and without ethanol, respectively.","Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014999/),%,9.1,241051,DB01373,Calcium
,17014999,F(abs),"For WIN55,212-2, F(abs)=49.9+/-6.9% (propylene glycol alone) and 56.6+/-14.1% (propylene glycol with 10% ethanol).","Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014999/),%,49.9,241052,DB01373,Calcium
,17014999,F(abs),"For WIN55,212-2, F(abs)=49.9+/-6.9% (propylene glycol alone) and 56.6+/-14.1% (propylene glycol with 10% ethanol).","Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014999/),%,56.6,241053,DB01373,Calcium
more,33314326,half-life,Elimination was slow with a half-life of more than 80 h.,"A first-in-human study to evaluate the safety, tolerability and pharmacokinetics of RP3128, an oral calcium release-activated calcium (CRAC) channel modulator in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33314326/),h,80,241138,DB01373,Calcium
,12845505,Cmax,"The mean values of the single-dose pharmacokinetic parameters were as follows: Cmax 3.83 microg l(-1), tmax 5.01, AUC(0-24) 59.90 microg l(-1) h, kel 0.0177 h(-1).",Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845505/),[μg] / [l],3.83,241139,DB01373,Calcium
,12845505,tmax,"The mean values of the single-dose pharmacokinetic parameters were as follows: Cmax 3.83 microg l(-1), tmax 5.01, AUC(0-24) 59.90 microg l(-1) h, kel 0.0177 h(-1).",Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845505/),,5.01,241140,DB01373,Calcium
,12845505,AUC(0-24),"The mean values of the single-dose pharmacokinetic parameters were as follows: Cmax 3.83 microg l(-1), tmax 5.01, AUC(0-24) 59.90 microg l(-1) h, kel 0.0177 h(-1).",Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845505/),[h·μg] / [l],59.90,241141,DB01373,Calcium
,12845505,kel,"The mean values of the single-dose pharmacokinetic parameters were as follows: Cmax 3.83 microg l(-1), tmax 5.01, AUC(0-24) 59.90 microg l(-1) h, kel 0.0177 h(-1).",Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845505/),1/[h],0.0177,241142,DB01373,Calcium
,12845505,accumulation index,The mean accumulation index on the basis of AUC(0-24) was calculated as 3.70.,Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845505/),,3.70,241143,DB01373,Calcium
,19135377,EC(50),"Indeed, the 3-methoxy-4-methylsulfonylaminophenyl analog (1) was modestly (2.5-fold) more potent than RTX, with an EC(50)=0.106 nM.",Non-vanillyl resiniferatoxin analogues as potent and metabolically stable transient receptor potential vanilloid 1 agonists. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135377/),nM,0.106,241814,DB01373,Calcium
,17178265,oral clearance,"The difference in the oral clearance of amlodipine approached statistical significance between the 2 major genotype groups, with CYP3A5*1 carriers (27.0 +/- 8.2 L/h) showing 20% lower clearance than CYP3A5*3/*3 carriers (32.4 +/- 10.2 L/h) (P = .063).",Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178265/),[l] / [h],27.0,242101,DB01373,Calcium
,17178265,area under the plasma concentration-time curve,"However, the mean area under the plasma concentration-time curve of amlodipine was 200.9 +/- 61.9 ng . h/mL for CYP3A5*1 carriers and 167.6 +/- 45.0 ng . h/mL for CYP3A5*3/*3 carriers (P = .029).",Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178265/),[h·ng] / [ml],200.9,242102,DB01373,Calcium
,17178265,area under the plasma concentration-time curve,"However, the mean area under the plasma concentration-time curve of amlodipine was 200.9 +/- 61.9 ng . h/mL for CYP3A5*1 carriers and 167.6 +/- 45.0 ng . h/mL for CYP3A5*3/*3 carriers (P = .029).",Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178265/),[h·ng] / [ml],167.6,242103,DB01373,Calcium
,17178265,peak plasma concentration,"Moreover, the peak plasma concentration was significantly higher in CYP3A5*1 carriers (3.8 +/- 1.1 ng/mL) than in CYP3A5*3/*3 carriers (3.1 +/- 0.8 ng/mL) (P = .037).",Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178265/),[ng] / [ml],3.8,242104,DB01373,Calcium
,17178265,peak plasma concentration,"Moreover, the peak plasma concentration was significantly higher in CYP3A5*1 carriers (3.8 +/- 1.1 ng/mL) than in CYP3A5*3/*3 carriers (3.1 +/- 0.8 ng/mL) (P = .037).",Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178265/),[ng] / [ml],3.1,242105,DB01373,Calcium
,17328247,absolute bioavailability,"Consequently, absolute bioavailability values of diltiazem pretreated with atorvastatin (8.4-10.6%)were significantly higher (p < 0.05) than that in the control group (6.6%).","Effect of atorvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17328247/),%,8.4-10.6,242817,DB01373,Calcium
,17328247,absolute bioavailability,"Consequently, absolute bioavailability values of diltiazem pretreated with atorvastatin (8.4-10.6%)were significantly higher (p < 0.05) than that in the control group (6.6%).","Effect of atorvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17328247/),%,6.6,242818,DB01373,Calcium
,15338848,peak plasma concentrations,Mean peak plasma concentrations ranging from 51+/-51-110+/-59 pg/ml were observed 36-54 minutes after administration.,Pharmacokinetics of modified oral calcitonin product in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15338848/),[pg] / [ml],51,243103,DB01373,Calcium
,15338848,peak plasma concentrations,Mean peak plasma concentrations ranging from 51+/-51-110+/-59 pg/ml were observed 36-54 minutes after administration.,Pharmacokinetics of modified oral calcitonin product in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15338848/),[pg] / [ml],110,243104,DB01373,Calcium
,15338848,terminal elimination half-lives,Mean terminal elimination half-lives ranged from 54-76 minutes.,Pharmacokinetics of modified oral calcitonin product in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15338848/),min,54-76,243105,DB01373,Calcium
,19110105,flow rate,The effluent was monitored by UV detector at 240 nm and at a flow rate of 1.0 mL min(-1).,Development of high performance liquid chromatography method for lacidipine in rabbit serum: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19110105/),[ml] / [min],1.0,243382,DB01373,Calcium
,32827673,zeta potential,"The prepared chitosomes illustrated an average particle size of 342.22 ± 2.90 nm, a zeta potential value of +28.87 ± 1.39 mV and a drug entrapment efficiency of 94.59 ± 1.62%.","Rosuvastatin lyophilized tablets loaded with flexible chitosomes for improved drug bioavailability, anti-hyperlipidemic and anti-oxidant activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32827673/),mv,28.87,243687,DB01373,Calcium
,32827673,entrapment efficiency,"The prepared chitosomes illustrated an average particle size of 342.22 ± 2.90 nm, a zeta potential value of +28.87 ± 1.39 mV and a drug entrapment efficiency of 94.59 ± 1.62%.","Rosuvastatin lyophilized tablets loaded with flexible chitosomes for improved drug bioavailability, anti-hyperlipidemic and anti-oxidant activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32827673/),%,94.59,243688,DB01373,Calcium
,32827673,disintegration time,The developed tablets showed an acceptable quality control characteristics and in vivo disintegration time of 1.48 ± 0.439 min.,"Rosuvastatin lyophilized tablets loaded with flexible chitosomes for improved drug bioavailability, anti-hyperlipidemic and anti-oxidant activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32827673/),min,1.48,243689,DB01373,Calcium
more,32827673,relative bioavailability,"The chitosomes based tablets demonstrated higher relative bioavailability by more than 30% and 36% when compared with the corresponding pure rosuvastatin and the marketed drug tablets, respectively.","Rosuvastatin lyophilized tablets loaded with flexible chitosomes for improved drug bioavailability, anti-hyperlipidemic and anti-oxidant activity. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32827673/),%,30,243690,DB01373,Calcium
,32827673,relative bioavailability,"The chitosomes based tablets demonstrated higher relative bioavailability by more than 30% and 36% when compared with the corresponding pure rosuvastatin and the marketed drug tablets, respectively.","Rosuvastatin lyophilized tablets loaded with flexible chitosomes for improved drug bioavailability, anti-hyperlipidemic and anti-oxidant activity. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32827673/),%,36,243691,DB01373,Calcium
,20012601,relative bioavailability,"Consequently, the relative bioavailability of verapamil was also significantly increased (by 76.5%).",Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20012601/),%,76.5,243714,DB01373,Calcium
,16253731,Basal,Basal (0.09 +/- 0.03 versus 0.12 +/- 0.03 mmol/L; P = not significant) and peak citrate concentrations were similar in both groups (1.24 +/- 0.42 versus 1.19 +/- 0.33 mmol/L; P = not significant).,Citrate kinetics in patients receiving long-term hemodialysis therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16253731/),[mM] / [l],0.09,243762,DB01373,Calcium
,16253731,Basal,Basal (0.09 +/- 0.03 versus 0.12 +/- 0.03 mmol/L; P = not significant) and peak citrate concentrations were similar in both groups (1.24 +/- 0.42 versus 1.19 +/- 0.33 mmol/L; P = not significant).,Citrate kinetics in patients receiving long-term hemodialysis therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16253731/),[mM] / [l],0.12,243763,DB01373,Calcium
,16253731,peak citrate concentrations,Basal (0.09 +/- 0.03 versus 0.12 +/- 0.03 mmol/L; P = not significant) and peak citrate concentrations were similar in both groups (1.24 +/- 0.42 versus 1.19 +/- 0.33 mmol/L; P = not significant).,Citrate kinetics in patients receiving long-term hemodialysis therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16253731/),[mM] / [l],1.24,243764,DB01373,Calcium
,16253731,peak citrate concentrations,Basal (0.09 +/- 0.03 versus 0.12 +/- 0.03 mmol/L; P = not significant) and peak citrate concentrations were similar in both groups (1.24 +/- 0.42 versus 1.19 +/- 0.33 mmol/L; P = not significant).,Citrate kinetics in patients receiving long-term hemodialysis therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16253731/),[mM] / [l],1.19,243765,DB01373,Calcium
,16253731,Citrate clearance,Citrate clearance was similar in patients with renal failure (0.31 +/- 0.06 L/min) and controls (0.35 +/- 0.11 L/min; P = 0.47).,Citrate kinetics in patients receiving long-term hemodialysis therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16253731/),[l] / [min],0.31,243766,DB01373,Calcium
,16253731,Citrate clearance,Citrate clearance was similar in patients with renal failure (0.31 +/- 0.06 L/min) and controls (0.35 +/- 0.11 L/min; P = 0.47).,Citrate kinetics in patients receiving long-term hemodialysis therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16253731/),[l] / [min],0.35,243767,DB01373,Calcium
,17940637,elimination half-life,It has a mean elimination half-life of 6.3 hours.,"Pregabalin: its efficacy, safety and tolerability profile in generalized anxiety. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17940637/),h,6.3,244022,DB01373,Calcium
,24424300,m,"After a single liquid-liquid extraction, the assay was performed by using a C18 column and positive electrospray ionisation mode (ESI) in the multiple reaction monitoring (MRM) mode with transitions of m/z 417.3→167.3, 251.2→165.2, 199.1→121.3, and 183.2→105.1 for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),,417.3,244252,DB01373,Calcium
,24424300,m,"After a single liquid-liquid extraction, the assay was performed by using a C18 column and positive electrospray ionisation mode (ESI) in the multiple reaction monitoring (MRM) mode with transitions of m/z 417.3→167.3, 251.2→165.2, 199.1→121.3, and 183.2→105.1 for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),,251.2,244253,DB01373,Calcium
,24424300,m,"After a single liquid-liquid extraction, the assay was performed by using a C18 column and positive electrospray ionisation mode (ESI) in the multiple reaction monitoring (MRM) mode with transitions of m/z 417.3→167.3, 251.2→165.2, 199.1→121.3, and 183.2→105.1 for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),,199.1,244254,DB01373,Calcium
,24424300,m,"After a single liquid-liquid extraction, the assay was performed by using a C18 column and positive electrospray ionisation mode (ESI) in the multiple reaction monitoring (MRM) mode with transitions of m/z 417.3→167.3, 251.2→165.2, 199.1→121.3, and 183.2→105.1 for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),,183.2,244255,DB01373,Calcium
higher,24424300,extraction recoveries,The extraction recoveries of their three concentrations for Dip and its three metabolites were all higher than 71.9%.,Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),%,71.9,244256,DB01373,Calcium
,24424300,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),[ng] / [ml],59,244257,DB01373,Calcium
,24424300,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),[ng] / [ml],37,244258,DB01373,Calcium
,24424300,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),[ng] / [ml],3,244259,DB01373,Calcium
,24424300,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),[ng] / [ml],55,244260,DB01373,Calcium
,24424300,time to maximum plasma concentration (Tmax),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),min,65,244261,DB01373,Calcium
,24424300,time to maximum plasma concentration (Tmax),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),min,95,244262,DB01373,Calcium
,24424300,time to maximum plasma concentration (Tmax),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),min,190,244263,DB01373,Calcium
,24424300,time to maximum plasma concentration (Tmax),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),min,90,244264,DB01373,Calcium
,24424300,areas under the concentration-time curves (AUC0→∞),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),[min·ng] / [ml],17573,244265,DB01373,Calcium
,24424300,areas under the concentration-time curves (AUC0→∞),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),[min·ng] / [ml],8328,244266,DB01373,Calcium
,24424300,areas under the concentration-time curves (AUC0→∞),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),[min·ng] / [ml],5602,244267,DB01373,Calcium
,24424300,areas under the concentration-time curves (AUC0→∞),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),[min·ng] / [ml],16101,244268,DB01373,Calcium
,24424300,half-life (t1/2),"The half-life (t1/2) of Dip, M1, M2, and M5 were 329±15, 767±75, 2364±434, and 378±36 min, respectively, which indicated that Dip and M5 were eliminated quickly.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),min,329,244269,DB01373,Calcium
,24424300,half-life (t1/2),"The half-life (t1/2) of Dip, M1, M2, and M5 were 329±15, 767±75, 2364±434, and 378±36 min, respectively, which indicated that Dip and M5 were eliminated quickly.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),min,767,244270,DB01373,Calcium
,24424300,half-life (t1/2),"The half-life (t1/2) of Dip, M1, M2, and M5 were 329±15, 767±75, 2364±434, and 378±36 min, respectively, which indicated that Dip and M5 were eliminated quickly.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),min,2364,244271,DB01373,Calcium
,24424300,half-life (t1/2),"The half-life (t1/2) of Dip, M1, M2, and M5 were 329±15, 767±75, 2364±434, and 378±36 min, respectively, which indicated that Dip and M5 were eliminated quickly.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),min,378,244272,DB01373,Calcium
,16669860,peak plasma concentration,The median (minimum-maximum) peak plasma concentration of diltiazem was 727 (539-976) ng/mL.,Pharmacokinetics of the calcium-channel blocker diltiazem after a single intravenous dose in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669860/),[ng] / [ml],727,244371,DB01373,Calcium
,16669860,distribution half-life,"The distribution half-life was 12 (6-23) min, the terminal half-life was 93 (73-161) min, the mean residence time was 125 (99-206) min, total plasma clearance was 14.4 (10.4-18.6) mL/kg/min, and the volume of distribution at steady-state was 1.84 (1.46-2.51) L/kg.",Pharmacokinetics of the calcium-channel blocker diltiazem after a single intravenous dose in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669860/),min,12,244372,DB01373,Calcium
,16669860,terminal half-life,"The distribution half-life was 12 (6-23) min, the terminal half-life was 93 (73-161) min, the mean residence time was 125 (99-206) min, total plasma clearance was 14.4 (10.4-18.6) mL/kg/min, and the volume of distribution at steady-state was 1.84 (1.46-2.51) L/kg.",Pharmacokinetics of the calcium-channel blocker diltiazem after a single intravenous dose in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669860/),min,93,244373,DB01373,Calcium
,16669860,mean residence time,"The distribution half-life was 12 (6-23) min, the terminal half-life was 93 (73-161) min, the mean residence time was 125 (99-206) min, total plasma clearance was 14.4 (10.4-18.6) mL/kg/min, and the volume of distribution at steady-state was 1.84 (1.46-2.51) L/kg.",Pharmacokinetics of the calcium-channel blocker diltiazem after a single intravenous dose in horses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669860/),min,125,244374,DB01373,Calcium
,16669860,total plasma clearance,"The distribution half-life was 12 (6-23) min, the terminal half-life was 93 (73-161) min, the mean residence time was 125 (99-206) min, total plasma clearance was 14.4 (10.4-18.6) mL/kg/min, and the volume of distribution at steady-state was 1.84 (1.46-2.51) L/kg.",Pharmacokinetics of the calcium-channel blocker diltiazem after a single intravenous dose in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669860/),[ml] / [kg·min],14.4,244375,DB01373,Calcium
,16669860,volume of distribution at steady-state,"The distribution half-life was 12 (6-23) min, the terminal half-life was 93 (73-161) min, the mean residence time was 125 (99-206) min, total plasma clearance was 14.4 (10.4-18.6) mL/kg/min, and the volume of distribution at steady-state was 1.84 (1.46-2.51) L/kg.",Pharmacokinetics of the calcium-channel blocker diltiazem after a single intravenous dose in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669860/),[l] / [kg],1.84,244376,DB01373,Calcium
,16898076,peak plasma verapamil concentrations,"New retard tablets produced peak plasma verapamil concentrations of 81.34+/-5.69microg/l, time to peak plasma concentrations of 4.91+/-0.89h and an AUC (0-24h) of 1291+/-103.4h x microg/l, with a terminal phase half-life of 55.1+/-14.9h.",Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898076/),[μg] / [l],81.34,244468,DB01373,Calcium
,16898076,time to peak plasma concentrations,"New retard tablets produced peak plasma verapamil concentrations of 81.34+/-5.69microg/l, time to peak plasma concentrations of 4.91+/-0.89h and an AUC (0-24h) of 1291+/-103.4h x microg/l, with a terminal phase half-life of 55.1+/-14.9h.",Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898076/),h,4.91,244469,DB01373,Calcium
,16898076,AUC (0-24h),"New retard tablets produced peak plasma verapamil concentrations of 81.34+/-5.69microg/l, time to peak plasma concentrations of 4.91+/-0.89h and an AUC (0-24h) of 1291+/-103.4h x microg/l, with a terminal phase half-life of 55.1+/-14.9h.",Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898076/),[h·μg] / [l],1291,244470,DB01373,Calcium
,16898076,terminal phase half-life,"New retard tablets produced peak plasma verapamil concentrations of 81.34+/-5.69microg/l, time to peak plasma concentrations of 4.91+/-0.89h and an AUC (0-24h) of 1291+/-103.4h x microg/l, with a terminal phase half-life of 55.1+/-14.9h.",Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898076/),h,55.1,244471,DB01373,Calcium
,16898076,terminal plasma half-life,After intravenous administration verapamil exhibited biphasic elimination kinetics with a terminal plasma half-life of 2.36+/-0.42h and systemic clearance of 34.32+/-5.81 l/h.,Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898076/),h,2.36,244472,DB01373,Calcium
,16898076,systemic clearance,After intravenous administration verapamil exhibited biphasic elimination kinetics with a terminal plasma half-life of 2.36+/-0.42h and systemic clearance of 34.32+/-5.81 l/h.,Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898076/),[l] / [h],34.32,244473,DB01373,Calcium
,16898076,Bioavailability,Bioavailability of the new peroral retard formulation ranged from 19.49+/-4.41% to 67.69+/-11.70%.,Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898076/),%,19.49,244474,DB01373,Calcium
,16898076,Bioavailability,Bioavailability of the new peroral retard formulation ranged from 19.49+/-4.41% to 67.69+/-11.70%.,Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898076/),%,67.69,244475,DB01373,Calcium
,16898076,Input rates,Input rates for the new verapamil retard formulation ranged from 0.77+/-0.20mg/h to 5.57+/-1.58mg/h.,Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898076/),[mg] / [h],0.77,244476,DB01373,Calcium
,16898076,Input rates,Input rates for the new verapamil retard formulation ranged from 0.77+/-0.20mg/h to 5.57+/-1.58mg/h.,Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898076/),[mg] / [h],5.57,244477,DB01373,Calcium
,17691921,peak plasma concentration,"The geometric mean and 90% confidence intervals of pharmacokinetic parameters for human oral felodipine with G, P, H and W were respectively as follows: peak plasma concentration (nmol.L(-1)), 37 (32-44), 25 (21-29), 19 (16-22) and 18 (15-21); area under the plasma concentration-time curve (nmol.h.L(-1)), 118 (103-136), 84 (73-97), 64 (56-74) and 59 (51-68).",Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17691921/),[nM] / [l],37,244832,DB01373,Calcium
,17691921,peak plasma concentration,"The geometric mean and 90% confidence intervals of pharmacokinetic parameters for human oral felodipine with G, P, H and W were respectively as follows: peak plasma concentration (nmol.L(-1)), 37 (32-44), 25 (21-29), 19 (16-22) and 18 (15-21); area under the plasma concentration-time curve (nmol.h.L(-1)), 118 (103-136), 84 (73-97), 64 (56-74) and 59 (51-68).",Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17691921/),[nM] / [l],25,244833,DB01373,Calcium
,17691921,peak plasma concentration,"The geometric mean and 90% confidence intervals of pharmacokinetic parameters for human oral felodipine with G, P, H and W were respectively as follows: peak plasma concentration (nmol.L(-1)), 37 (32-44), 25 (21-29), 19 (16-22) and 18 (15-21); area under the plasma concentration-time curve (nmol.h.L(-1)), 118 (103-136), 84 (73-97), 64 (56-74) and 59 (51-68).",Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17691921/),[nM] / [l],19,244834,DB01373,Calcium
,17691921,peak plasma concentration,"The geometric mean and 90% confidence intervals of pharmacokinetic parameters for human oral felodipine with G, P, H and W were respectively as follows: peak plasma concentration (nmol.L(-1)), 37 (32-44), 25 (21-29), 19 (16-22) and 18 (15-21); area under the plasma concentration-time curve (nmol.h.L(-1)), 118 (103-136), 84 (73-97), 64 (56-74) and 59 (51-68).",Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17691921/),[nM] / [l],18,244835,DB01373,Calcium
,17691921,area under the plasma concentration-time curve,"The geometric mean and 90% confidence intervals of pharmacokinetic parameters for human oral felodipine with G, P, H and W were respectively as follows: peak plasma concentration (nmol.L(-1)), 37 (32-44), 25 (21-29), 19 (16-22) and 18 (15-21); area under the plasma concentration-time curve (nmol.h.L(-1)), 118 (103-136), 84 (73-97), 64 (56-74) and 59 (51-68).",Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17691921/),[h·nM] / [l],118,244836,DB01373,Calcium
,17691921,area under the plasma concentration-time curve,"The geometric mean and 90% confidence intervals of pharmacokinetic parameters for human oral felodipine with G, P, H and W were respectively as follows: peak plasma concentration (nmol.L(-1)), 37 (32-44), 25 (21-29), 19 (16-22) and 18 (15-21); area under the plasma concentration-time curve (nmol.h.L(-1)), 118 (103-136), 84 (73-97), 64 (56-74) and 59 (51-68).",Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17691921/),[h·nM] / [l],84,244837,DB01373,Calcium
,17691921,area under the plasma concentration-time curve,"The geometric mean and 90% confidence intervals of pharmacokinetic parameters for human oral felodipine with G, P, H and W were respectively as follows: peak plasma concentration (nmol.L(-1)), 37 (32-44), 25 (21-29), 19 (16-22) and 18 (15-21); area under the plasma concentration-time curve (nmol.h.L(-1)), 118 (103-136), 84 (73-97), 64 (56-74) and 59 (51-68).",Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17691921/),[h·nM] / [l],64,244838,DB01373,Calcium
,17691921,area under the plasma concentration-time curve,"The geometric mean and 90% confidence intervals of pharmacokinetic parameters for human oral felodipine with G, P, H and W were respectively as follows: peak plasma concentration (nmol.L(-1)), 37 (32-44), 25 (21-29), 19 (16-22) and 18 (15-21); area under the plasma concentration-time curve (nmol.h.L(-1)), 118 (103-136), 84 (73-97), 64 (56-74) and 59 (51-68).",Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17691921/),[h·nM] / [l],59,244839,DB01373,Calcium
,17331337,entrapment efficacy,"The particle size distribution, zeta-potential and entrapment efficacy were found to be 198.7+/-54.0 nm, -26.4 mV and 96.2%, respectively.","Formulation, preparation and evaluation of flunarizine-loaded lipid microspheres. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331337/),,96,245264,DB01373,Calcium
,17331337,AUC(0-t),"The pharmacokinetic parameters were as follows: AUC(0-t) 6.13 mug.h mL(-1), t(1/2) 5.32 h and Ke 0.16 L h(-1).","Formulation, preparation and evaluation of flunarizine-loaded lipid microspheres. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331337/),[h·μg] / [ml],6.13,245265,DB01373,Calcium
,17331337,t(1/2),"The pharmacokinetic parameters were as follows: AUC(0-t) 6.13 mug.h mL(-1), t(1/2) 5.32 h and Ke 0.16 L h(-1).","Formulation, preparation and evaluation of flunarizine-loaded lipid microspheres. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331337/),h,5.32,245266,DB01373,Calcium
,17331337,Ke,"The pharmacokinetic parameters were as follows: AUC(0-t) 6.13 mug.h mL(-1), t(1/2) 5.32 h and Ke 0.16 L h(-1).","Formulation, preparation and evaluation of flunarizine-loaded lipid microspheres. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331337/),[l] / [h],0.16,245267,DB01373,Calcium
,23319300,entrapment efficiency (EE%),"The average diameter was 378.6±26.5 nm in distilled water with entrapment efficiency (EE%) of 84.7±5.9%, while the average diameter was 316.9±34.6 nm in 0.1 M hydrochloric acid solution with EE% of 72.8±4.7%.","Liquid proliposomes of nimodipine drug delivery system: preparation, characterization, and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23319300/),%,84,245517,DB01373,Calcium
,23319300,EE%,"The average diameter was 378.6±26.5 nm in distilled water with entrapment efficiency (EE%) of 84.7±5.9%, while the average diameter was 316.9±34.6 nm in 0.1 M hydrochloric acid solution with EE% of 72.8±4.7%.","Liquid proliposomes of nimodipine drug delivery system: preparation, characterization, and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23319300/),%,72.8,245518,DB01373,Calcium
,23319300,time of peak concentration,"In vivo experiments, areas under the plasma level-time curve of NPSC and nimodipine-hydrated liposomes increased 2.41 and 2.34 times more than that of nimodipine soft capsules, peak concentration increased 2.87 and 2.92 times, time of peak concentration from 0.75 to 2 and 1 h, respectively.","Liquid proliposomes of nimodipine drug delivery system: preparation, characterization, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23319300/),h,0.75,245519,DB01373,Calcium
,23319300,time of peak concentration,"In vivo experiments, areas under the plasma level-time curve of NPSC and nimodipine-hydrated liposomes increased 2.41 and 2.34 times more than that of nimodipine soft capsules, peak concentration increased 2.87 and 2.92 times, time of peak concentration from 0.75 to 2 and 1 h, respectively.","Liquid proliposomes of nimodipine drug delivery system: preparation, characterization, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23319300/),h,2,245520,DB01373,Calcium
,23319300,time of peak concentration,"In vivo experiments, areas under the plasma level-time curve of NPSC and nimodipine-hydrated liposomes increased 2.41 and 2.34 times more than that of nimodipine soft capsules, peak concentration increased 2.87 and 2.92 times, time of peak concentration from 0.75 to 2 and 1 h, respectively.","Liquid proliposomes of nimodipine drug delivery system: preparation, characterization, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23319300/),h,1,245521,DB01373,Calcium
,11695851,plasma protein binding,"2. The extent of plasma protein binding of MA4, PB and MTX was approximately 96, 95 and 65%, respectively, and it did not differ significantly between the male and female rat.",Sex-related differences in the renal disposition of the acidic metabolite of clentiazem in rat. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695851/),%,96,245576,DB01373,Calcium
,11695851,plasma protein binding,"2. The extent of plasma protein binding of MA4, PB and MTX was approximately 96, 95 and 65%, respectively, and it did not differ significantly between the male and female rat.",Sex-related differences in the renal disposition of the acidic metabolite of clentiazem in rat. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695851/),%,95,245577,DB01373,Calcium
,11695851,plasma protein binding,"2. The extent of plasma protein binding of MA4, PB and MTX was approximately 96, 95 and 65%, respectively, and it did not differ significantly between the male and female rat.",Sex-related differences in the renal disposition of the acidic metabolite of clentiazem in rat. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695851/),%,65,245578,DB01373,Calcium
,11695851,CLrf/GFR,The CLrf/GFR for MTX was approximately 2.5 but did not differ significantly between the male and female.,Sex-related differences in the renal disposition of the acidic metabolite of clentiazem in rat. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695851/),,2.5,245579,DB01373,Calcium
,11716045,maximum,"When 1,000 microg of levothyroxine alone was given to subjects, the maximum average total T4 absorption was 837 microg (83.7% of the dose ingested) at 120 minutes.",The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11716045/),μg,837,245768,DB01373,Calcium
,11716045,total T4 absorption,"When 1,000 microg of levothyroxine alone was given to subjects, the maximum average total T4 absorption was 837 microg (83.7% of the dose ingested) at 120 minutes.",The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11716045/),μg,837,245769,DB01373,Calcium
,11716045,maximum,"When levothyroxine was coadministered with 2.0 g of calcium (as calcium carbonate), the maximum average T4 absorption decreased to 579 microg (57.9% of the dose ingested) at 240 minutes.",The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11716045/),μg,579,245770,DB01373,Calcium
,11716045,T4 absorption,"When levothyroxine was coadministered with 2.0 g of calcium (as calcium carbonate), the maximum average T4 absorption decreased to 579 microg (57.9% of the dose ingested) at 240 minutes.",The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11716045/),μg,579,245771,DB01373,Calcium
,24140353,time to reach the maximum mAb serum concentration (Tmax),"As compared to the liquid formulation the hydrogel formulations led to lower mAb serum levels, and the in situ forming system to a shift in the time to reach the maximum mAb serum concentration (Tmax) from 2 to 4 days.","Pharmacokinetics, biocompatibility and bioavailability of a controlled release monoclonal antibody formulation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24140353/),d,2,245877,DB01373,Calcium
,24140353,time to reach the maximum mAb serum concentration (Tmax),"As compared to the liquid formulation the hydrogel formulations led to lower mAb serum levels, and the in situ forming system to a shift in the time to reach the maximum mAb serum concentration (Tmax) from 2 to 4 days.","Pharmacokinetics, biocompatibility and bioavailability of a controlled release monoclonal antibody formulation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24140353/),d,4,245878,DB01373,Calcium
,31141832,flow rate,"Adequate separation for both analytes was achieved with a Waters C18 column (250 × 4.6 mm, 5 μm) using acetonitrile-5 mm sodium acetate buffer (70:30, v/v; pH adjusted to 3.5 with acetic acid) as a mobile phase at a flow rate of 1.0 mL/min and wavelength of 254 nm.","A simple, rapid and fully validated HPLC method for simultaneous quantitative bio-analysis of rosuvastatin and candesartan in rat plasma: Application to pharmacokinetic interaction study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31141832/),[ml] / [min],1.0,246051,DB01373,Calcium
,14704918,Area under the curve (AUC),"Vitreal pharmacokinetic parameters of quinidine in the presence of verapamil, i.e., Area under the curve (AUC) (39.27 +/- 6.47 min.","Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14704918/),min,39.27,246287,DB01373,Calcium
,14704918,maximum concentration achieved (Cmax),"microg/ml), maximum concentration achieved (Cmax) (0.095 +/- 0.011 microg/ml), vitreal elimination half-life (231.96 +/- 10.77 min), vitreal permeation half-life (16.57 +/- 6.96 min) were significantly different from the control values (19.21 +/- 3.73 min.","Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14704918/),[μg] / [ml],0.095,246288,DB01373,Calcium
,14704918,elimination half-life,"microg/ml), maximum concentration achieved (Cmax) (0.095 +/- 0.011 microg/ml), vitreal elimination half-life (231.96 +/- 10.77 min), vitreal permeation half-life (16.57 +/- 6.96 min) were significantly different from the control values (19.21 +/- 3.73 min.","Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14704918/),min,231.96,246289,DB01373,Calcium
,14704918,permeation half-life,"microg/ml), maximum concentration achieved (Cmax) (0.095 +/- 0.011 microg/ml), vitreal elimination half-life (231.96 +/- 10.77 min), vitreal permeation half-life (16.57 +/- 6.96 min) were significantly different from the control values (19.21 +/- 3.73 min.","Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14704918/),min,16.57,246290,DB01373,Calcium
,14704918,permeation half-life,"microg/ml), maximum concentration achieved (Cmax) (0.095 +/- 0.011 microg/ml), vitreal elimination half-life (231.96 +/- 10.77 min), vitreal permeation half-life (16.57 +/- 6.96 min) were significantly different from the control values (19.21 +/- 3.73 min.","Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14704918/),min,19.21,246291,DB01373,Calcium
,16854634,run time,"The chromatographic run time was 11min per injection, with retention time of 3.6, 10.2 and 6.8min for azelnidipine, M-1 and M-2, respectively.",Simultaneous determination of azelnidipine and two metabolites in human plasma using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16854634/),[min] / [injection],11,246671,DB01373,Calcium
,16854634,retention time,"The chromatographic run time was 11min per injection, with retention time of 3.6, 10.2 and 6.8min for azelnidipine, M-1 and M-2, respectively.",Simultaneous determination of azelnidipine and two metabolites in human plasma using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16854634/),min,3.6,246672,DB01373,Calcium
,16854634,retention time,"The chromatographic run time was 11min per injection, with retention time of 3.6, 10.2 and 6.8min for azelnidipine, M-1 and M-2, respectively.",Simultaneous determination of azelnidipine and two metabolites in human plasma using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16854634/),min,10.2,246673,DB01373,Calcium
,16854634,retention time,"The chromatographic run time was 11min per injection, with retention time of 3.6, 10.2 and 6.8min for azelnidipine, M-1 and M-2, respectively.",Simultaneous determination of azelnidipine and two metabolites in human plasma using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16854634/),min,6.8,246674,DB01373,Calcium
,16854634,overall recoveries,"The overall recoveries for azelnidipine, M-1 and M-2 were 68.8-78.6%, 54.3-62.9% and 80.4-89.7%, respectively.",Simultaneous determination of azelnidipine and two metabolites in human plasma using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16854634/),%,68.8-78.6,246675,DB01373,Calcium
,16854634,overall recoveries,"The overall recoveries for azelnidipine, M-1 and M-2 were 68.8-78.6%, 54.3-62.9% and 80.4-89.7%, respectively.",Simultaneous determination of azelnidipine and two metabolites in human plasma using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16854634/),%,54.3-62.9,246676,DB01373,Calcium
,16854634,overall recoveries,"The overall recoveries for azelnidipine, M-1 and M-2 were 68.8-78.6%, 54.3-62.9% and 80.4-89.7%, respectively.",Simultaneous determination of azelnidipine and two metabolites in human plasma using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16854634/),%,80.4-89.7,246677,DB01373,Calcium
,26350588,steady-state cerebral arterial concentrations,"According to our simulations, continuous IA nimodipine infusion at 2 mg/h and 1 mg/h resulted in steady-state cerebral arterial concentrations of about 200 ng/ml and 100 ng/ml assuming an ICA blood flow of 200 ml/min and a clearance of 70 l/h.",Pharmacokinetic Modeling of Intra-arterial Nimodipine Therapy for Subarachnoid Hemorrhage-Related Cerebral Vasospasm. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350588/),[ng] / [ml],200,246872,DB01373,Calcium
,26350588,steady-state cerebral arterial concentrations,"According to our simulations, continuous IA nimodipine infusion at 2 mg/h and 1 mg/h resulted in steady-state cerebral arterial concentrations of about 200 ng/ml and 100 ng/ml assuming an ICA blood flow of 200 ml/min and a clearance of 70 l/h.",Pharmacokinetic Modeling of Intra-arterial Nimodipine Therapy for Subarachnoid Hemorrhage-Related Cerebral Vasospasm. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350588/),[ng] / [ml],100,246873,DB01373,Calcium
,26350588,blood flow,"According to our simulations, continuous IA nimodipine infusion at 2 mg/h and 1 mg/h resulted in steady-state cerebral arterial concentrations of about 200 ng/ml and 100 ng/ml assuming an ICA blood flow of 200 ml/min and a clearance of 70 l/h.",Pharmacokinetic Modeling of Intra-arterial Nimodipine Therapy for Subarachnoid Hemorrhage-Related Cerebral Vasospasm. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350588/),[ml] / [min],200,246874,DB01373,Calcium
,26350588,clearance,"According to our simulations, continuous IA nimodipine infusion at 2 mg/h and 1 mg/h resulted in steady-state cerebral arterial concentrations of about 200 ng/ml and 100 ng/ml assuming an ICA blood flow of 200 ml/min and a clearance of 70 l/h.",Pharmacokinetic Modeling of Intra-arterial Nimodipine Therapy for Subarachnoid Hemorrhage-Related Cerebral Vasospasm. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350588/),[l] / [h],70,246875,DB01373,Calcium
,31342792,incorporation capacity,The physicochemical studies showed that the RCa/CD complexes were well incorporated into CPNs resulted in nanosized particles (215.22 and 189.13 nm) with homogenous size distribution (PDI: 0.203 and 0.182) with relatively high incorporation capacity (76.11 and 68.18%) for the CPN1 and CPN2 formulations respectively.,"Preparation, characterization and pharmacokinetic evaluation of rosuvastatin calcium incorporated cyclodextrin-polyanhydride nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31342792/),%,76.11,247946,DB01373,Calcium
,31342792,incorporation capacity,The physicochemical studies showed that the RCa/CD complexes were well incorporated into CPNs resulted in nanosized particles (215.22 and 189.13 nm) with homogenous size distribution (PDI: 0.203 and 0.182) with relatively high incorporation capacity (76.11 and 68.18%) for the CPN1 and CPN2 formulations respectively.,"Preparation, characterization and pharmacokinetic evaluation of rosuvastatin calcium incorporated cyclodextrin-polyanhydride nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31342792/),%,68.18,247947,DB01373,Calcium
,31342792,Papp,"According to permeability studies, pure RCa had lowest permeability data (3.08 × 10-7 cm⋅s-1 Papp value) while CPNs gained higher permeability data (1.36 × 10-5 and 1.12 × 10-5 cm⋅s-1 Papp values) for the CPN1 and CPN2 formulations respectively.","Preparation, characterization and pharmacokinetic evaluation of rosuvastatin calcium incorporated cyclodextrin-polyanhydride nanoparticles. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31342792/),[cm] / [s],3.08 × 10-7,247948,DB01373,Calcium
,31342792,Papp,"According to permeability studies, pure RCa had lowest permeability data (3.08 × 10-7 cm⋅s-1 Papp value) while CPNs gained higher permeability data (1.36 × 10-5 and 1.12 × 10-5 cm⋅s-1 Papp values) for the CPN1 and CPN2 formulations respectively.","Preparation, characterization and pharmacokinetic evaluation of rosuvastatin calcium incorporated cyclodextrin-polyanhydride nanoparticles. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31342792/),[cm] / [s],1.36 × 10-5,247949,DB01373,Calcium
,31342792,Papp,"According to permeability studies, pure RCa had lowest permeability data (3.08 × 10-7 cm⋅s-1 Papp value) while CPNs gained higher permeability data (1.36 × 10-5 and 1.12 × 10-5 cm⋅s-1 Papp values) for the CPN1 and CPN2 formulations respectively.","Preparation, characterization and pharmacokinetic evaluation of rosuvastatin calcium incorporated cyclodextrin-polyanhydride nanoparticles. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31342792/),[cm] / [s],1.12 × 10-5,247950,DB01373,Calcium
,23122405,gradient flow rate,The whole analysis lasted for 10.5min and the gradient flow rate was 0.25mL/min constantly.,Determination of piperphentonamine and metabolites M1 and M6 in human plasma and urine by LC/MS/MS and its application in a pharmacokinetics study in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23122405/),[ml] / [min],0.25,248244,DB01373,Calcium
,23122405,m/z ratios,"The results were that the m/z ratios of monitored precursor ions and product ions of PPTA, M1 and M6 were 354.0→191.8, 356.0→148.7 and 358.0→148.7, respectively.",Determination of piperphentonamine and metabolites M1 and M6 in human plasma and urine by LC/MS/MS and its application in a pharmacokinetics study in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23122405/),,354.0,248245,DB01373,Calcium
,23122405,m/z ratios,"The results were that the m/z ratios of monitored precursor ions and product ions of PPTA, M1 and M6 were 354.0→191.8, 356.0→148.7 and 358.0→148.7, respectively.",Determination of piperphentonamine and metabolites M1 and M6 in human plasma and urine by LC/MS/MS and its application in a pharmacokinetics study in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23122405/),,191.8,248246,DB01373,Calcium
,23122405,m/z ratios,"The results were that the m/z ratios of monitored precursor ions and product ions of PPTA, M1 and M6 were 354.0→191.8, 356.0→148.7 and 358.0→148.7, respectively.",Determination of piperphentonamine and metabolites M1 and M6 in human plasma and urine by LC/MS/MS and its application in a pharmacokinetics study in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23122405/),,356.0,248247,DB01373,Calcium
,23122405,m/z ratios,"The results were that the m/z ratios of monitored precursor ions and product ions of PPTA, M1 and M6 were 354.0→191.8, 356.0→148.7 and 358.0→148.7, respectively.",Determination of piperphentonamine and metabolites M1 and M6 in human plasma and urine by LC/MS/MS and its application in a pharmacokinetics study in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23122405/),,148.7,248248,DB01373,Calcium
,23122405,m/z ratios,"The results were that the m/z ratios of monitored precursor ions and product ions of PPTA, M1 and M6 were 354.0→191.8, 356.0→148.7 and 358.0→148.7, respectively.",Determination of piperphentonamine and metabolites M1 and M6 in human plasma and urine by LC/MS/MS and its application in a pharmacokinetics study in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23122405/),,358.0,248249,DB01373,Calcium
,23122405,m/z ratios,"The results were that the m/z ratios of monitored precursor ions and product ions of PPTA, M1 and M6 were 354.0→191.8, 356.0→148.7 and 358.0→148.7, respectively.",Determination of piperphentonamine and metabolites M1 and M6 in human plasma and urine by LC/MS/MS and its application in a pharmacokinetics study in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23122405/),,148.7,248250,DB01373,Calcium
,19446150,visible detection,"The visible detection of the method was in the range of 0.2 to 32.0 ng/mL, and the lower limit of quantification for amlodipine was 0.2 ng/mL.","Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446150/),[ng] / [ml],0.2 to 32.0,248619,DB01373,Calcium
,19446150,C(max),"The mean (SD) C(max), T(max), AUC(0-t), and AUC(0-infinity)) values after administration of the test and reference formulations, respectively, were as follows: 5.46 (1.13) versus 5.88 (1.24) ng/mL, 7.70 (2.08) versus 9.20 (4.18) hours, 284.56 (77.59) versus 311.34 (75.97) ng/mL/h, and 331.37 (111.03) versus 358.74 (101.10) ng/mL/h.","Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446150/),[ng] / [ml],5.46,248620,DB01373,Calcium
,19446150,T(max),"The mean (SD) C(max), T(max), AUC(0-t), and AUC(0-infinity)) values after administration of the test and reference formulations, respectively, were as follows: 5.46 (1.13) versus 5.88 (1.24) ng/mL, 7.70 (2.08) versus 9.20 (4.18) hours, 284.56 (77.59) versus 311.34 (75.97) ng/mL/h, and 331.37 (111.03) versus 358.74 (101.10) ng/mL/h.","Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446150/),[ng] / [ml],5.88,248621,DB01373,Calcium
,19446150,T(max),"The mean (SD) C(max), T(max), AUC(0-t), and AUC(0-infinity)) values after administration of the test and reference formulations, respectively, were as follows: 5.46 (1.13) versus 5.88 (1.24) ng/mL, 7.70 (2.08) versus 9.20 (4.18) hours, 284.56 (77.59) versus 311.34 (75.97) ng/mL/h, and 331.37 (111.03) versus 358.74 (101.10) ng/mL/h.","Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446150/),h,7.70,248622,DB01373,Calcium
,19446150,AUC(0-t),"The mean (SD) C(max), T(max), AUC(0-t), and AUC(0-infinity)) values after administration of the test and reference formulations, respectively, were as follows: 5.46 (1.13) versus 5.88 (1.24) ng/mL, 7.70 (2.08) versus 9.20 (4.18) hours, 284.56 (77.59) versus 311.34 (75.97) ng/mL/h, and 331.37 (111.03) versus 358.74 (101.10) ng/mL/h.","Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446150/),[ng] / [ml],5.88,248623,DB01373,Calcium
,19446150,AUC(0-t),"The mean (SD) C(max), T(max), AUC(0-t), and AUC(0-infinity)) values after administration of the test and reference formulations, respectively, were as follows: 5.46 (1.13) versus 5.88 (1.24) ng/mL, 7.70 (2.08) versus 9.20 (4.18) hours, 284.56 (77.59) versus 311.34 (75.97) ng/mL/h, and 331.37 (111.03) versus 358.74 (101.10) ng/mL/h.","Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446150/),h,7.70,248624,DB01373,Calcium
,19446150,AUC(0-infinity)),"The mean (SD) C(max), T(max), AUC(0-t), and AUC(0-infinity)) values after administration of the test and reference formulations, respectively, were as follows: 5.46 (1.13) versus 5.88 (1.24) ng/mL, 7.70 (2.08) versus 9.20 (4.18) hours, 284.56 (77.59) versus 311.34 (75.97) ng/mL/h, and 331.37 (111.03) versus 358.74 (101.10) ng/mL/h.","Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446150/),[ng] / [h·ml],284.56,248625,DB01373,Calcium
,19446150,AUC(0-infinity)),"The mean (SD) C(max), T(max), AUC(0-t), and AUC(0-infinity)) values after administration of the test and reference formulations, respectively, were as follows: 5.46 (1.13) versus 5.88 (1.24) ng/mL, 7.70 (2.08) versus 9.20 (4.18) hours, 284.56 (77.59) versus 311.34 (75.97) ng/mL/h, and 331.37 (111.03) versus 358.74 (101.10) ng/mL/h.","Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446150/),[ng] / [h·ml],331.37,248626,DB01373,Calcium
,19446150,AUC(0-infinity)),"The mean (SD) C(max), T(max), AUC(0-t), and AUC(0-infinity)) values after administration of the test and reference formulations, respectively, were as follows: 5.46 (1.13) versus 5.88 (1.24) ng/mL, 7.70 (2.08) versus 9.20 (4.18) hours, 284.56 (77.59) versus 311.34 (75.97) ng/mL/h, and 331.37 (111.03) versus 358.74 (101.10) ng/mL/h.","Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446150/),[ng] / [h·ml],358.74,248627,DB01373,Calcium
,19446150,t(1/2),The mean (SD) t(1/2) was 38.52 (10.51) hours for the test formulation and 38.75 (7.07) hours for the reference formulation.,"Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446150/),h,38.52,248628,DB01373,Calcium
,19446150,t(1/2),The mean (SD) t(1/2) was 38.52 (10.51) hours for the test formulation and 38.75 (7.07) hours for the reference formulation.,"Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446150/),h,38.75,248629,DB01373,Calcium
,19446150,relative bioavailability,The relative bioavailability of the test formulation was 90.9% by mean AUC(0-t) and 91.2% by mean AUC(0-infinity).,"Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446150/),%,90.9,248630,DB01373,Calcium
,19446150,relative bioavailability,The relative bioavailability of the test formulation was 90.9% by mean AUC(0-t) and 91.2% by mean AUC(0-infinity).,"Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446150/),%,91.2,248631,DB01373,Calcium
,23096939,apparent clearance (CL/F),"The typical values with interindividual variability for apparent clearance (CL/F) and apparent volume of distribution (V/F) were 8.9 L h(-1) (43.2 %) and 420 L (65.8 %), respectively.",Population pharmacokinetics of digoxin in elderly patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23096939/),[l] / [h],8.9,248836,DB01373,Calcium
,23096939,apparent volume of distribution (V/F),"The typical values with interindividual variability for apparent clearance (CL/F) and apparent volume of distribution (V/F) were 8.9 L h(-1) (43.2 %) and 420 L (65.8 %), respectively.",Population pharmacokinetics of digoxin in elderly patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23096939/),l,420,248837,DB01373,Calcium
,29196024,bioavailability,Raloxifene HCl (RH) has poor water solubility and due to its extensive first pass metabolism; its bioavailability is only 2%.,"Poly(methyl vinyl ether-co-maleic acid) for enhancement of solubility, oral bioavailability and anti-osteoporotic effects of raloxifene hydrochloride. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29196024/),%,2,249498,DB01373,Calcium
,22282953,m,Detection was performed by a triple-quadrupole mass spectrometry with positive electrospray ionization (ESI) as source ionization in multiple-reaction monitoring (MRM) mode at m/z 361.0 --> 315.0 for NTD and m/z 260.2 --> 116.0 for IS.,Ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of nitrendipine in dog plasma and its application to a pharmacokinetic study of a solid self-emulsifying pellet formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22282953/),,260.2,249764,DB01373,Calcium
,22282953,extraction recoveries,"The mean extraction recoveries of NTD and IS were 90.2% and 82.4%, respectively.",Ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of nitrendipine in dog plasma and its application to a pharmacokinetic study of a solid self-emulsifying pellet formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22282953/),%,90.2,249765,DB01373,Calcium
,22282953,extraction recoveries,"The mean extraction recoveries of NTD and IS were 90.2% and 82.4%, respectively.",Ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of nitrendipine in dog plasma and its application to a pharmacokinetic study of a solid self-emulsifying pellet formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22282953/),%,82.4,249766,DB01373,Calcium
,32476084,flow-rate,"As a result, excellent IVIVC for solid dispersions and crude drug (r2 = 0.9352-0.9916) was obtained for the dissolution rate determined with flow-through cell open-loop system in phosphate buffer solution with 0.1% (w/v) polysorbate 80 at pH 6.5, the flow-rate of 4 mL/min.",In Vitro-In Vivo Correlation for Solid Dispersion of a Poorly Water-Soluble Drug Efonidipine Hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32476084/),[ml] / [min],4,250538,DB01373,Calcium
,15511691,half-life,"It is rapidly and completely absorbed and has a long half-life (63-69h in healthy volunteers) which allows twice-daily, or even once-daily, dosing.","Zonisamide: chemistry, mechanism of action, and pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15511691/),h,63-69,250903,DB01373,Calcium
,15608078,pK(i),"ABT-239 binds to recombinant human and rat H3 receptors with high affinity, with pK(i) values of 9.4 and 8.9, respectively, and is over 1000-fold selective versus human H1, H2, and H4 histamine receptors.",Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15608078/),,9.4,251428,DB01373,Calcium
,15608078,pK(i),"ABT-239 binds to recombinant human and rat H3 receptors with high affinity, with pK(i) values of 9.4 and 8.9, respectively, and is over 1000-fold selective versus human H1, H2, and H4 histamine receptors.",Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15608078/),,8.9,251429,DB01373,Calcium
,15608078,pK(b),"ABT-239 is a potent H3 receptor antagonist at recombinant human and rat receptors, reversing agonist-induced changes in cAMP formation (pK(b) = 7.9 and 7.6, respectively), guanosine 5'-O-(3-[35S]thio) triphosphate ([35S]GTPgammaS) binding (pK(b) = 9.0 and 8.3, respectively), and calcium mobilization (human pK(b) = 7.9).",Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15608078/),,7.9,251430,DB01373,Calcium
,15608078,pK(b),"ABT-239 is a potent H3 receptor antagonist at recombinant human and rat receptors, reversing agonist-induced changes in cAMP formation (pK(b) = 7.9 and 7.6, respectively), guanosine 5'-O-(3-[35S]thio) triphosphate ([35S]GTPgammaS) binding (pK(b) = 9.0 and 8.3, respectively), and calcium mobilization (human pK(b) = 7.9).",Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15608078/),,7.6,251431,DB01373,Calcium
,15608078,pK(b),"ABT-239 is a potent H3 receptor antagonist at recombinant human and rat receptors, reversing agonist-induced changes in cAMP formation (pK(b) = 7.9 and 7.6, respectively), guanosine 5'-O-(3-[35S]thio) triphosphate ([35S]GTPgammaS) binding (pK(b) = 9.0 and 8.3, respectively), and calcium mobilization (human pK(b) = 7.9).",Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15608078/),,9.0,251432,DB01373,Calcium
,15608078,pK(b),"ABT-239 is a potent H3 receptor antagonist at recombinant human and rat receptors, reversing agonist-induced changes in cAMP formation (pK(b) = 7.9 and 7.6, respectively), guanosine 5'-O-(3-[35S]thio) triphosphate ([35S]GTPgammaS) binding (pK(b) = 9.0 and 8.3, respectively), and calcium mobilization (human pK(b) = 7.9).",Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15608078/),,8.3,251433,DB01373,Calcium
,15608078,pEC50,"Additionally, ABT-239 is a potent inverse agonist, inhibiting constitutive [35S]GTPgammaS binding at both rat and human H3 receptors with respective pEC50 values of 8.9 and 8.2.",Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15608078/),,8.9,251434,DB01373,Calcium
,15608078,pEC50,"Additionally, ABT-239 is a potent inverse agonist, inhibiting constitutive [35S]GTPgammaS binding at both rat and human H3 receptors with respective pEC50 values of 8.9 and 8.2.",Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15608078/),,8.2,251435,DB01373,Calcium
,15608078,t1/2,"ABT-239 demonstrates good pharmacokinetic characteristics in rat, dog, and monkey with t1/2 values ranging from 4 to 29 h, corresponding with clearance values and metabolic turnover in liver microsomes from these species, and good oral bioavailability ranging from 52 to 89%.",Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15608078/),h,4 to 29,251436,DB01373,Calcium
,15608078,oral bioavailability,"ABT-239 demonstrates good pharmacokinetic characteristics in rat, dog, and monkey with t1/2 values ranging from 4 to 29 h, corresponding with clearance values and metabolic turnover in liver microsomes from these species, and good oral bioavailability ranging from 52 to 89%.",Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15608078/),%,52 to 89,251437,DB01373,Calcium
,24036846,area under the plasma concentration versus time curve,"Calcium supplementation did not significantly affect nilotinib pharmacokinetic parameters including area under the plasma concentration versus time curve (18.4 μg/mL h alone vs. 16.9 μg/mL h with calcium carbonate, p = 0.83; 80 % power); maximum plasma concentration (C(max)) (0.670 μg/mL alone vs. 6.18 μg/mL with calcium carbonate, p = 0.97); or half-life (18.9 h alone vs. 17.2 h with calcium carbonate, p = 0.18).",Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24036846/),[μg] / [h·ml],18.4,251791,DB01373,Calcium
,24036846,area under the plasma concentration versus time curve,"Calcium supplementation did not significantly affect nilotinib pharmacokinetic parameters including area under the plasma concentration versus time curve (18.4 μg/mL h alone vs. 16.9 μg/mL h with calcium carbonate, p = 0.83; 80 % power); maximum plasma concentration (C(max)) (0.670 μg/mL alone vs. 6.18 μg/mL with calcium carbonate, p = 0.97); or half-life (18.9 h alone vs. 17.2 h with calcium carbonate, p = 0.18).",Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24036846/),[μg] / [h·ml],16.9,251792,DB01373,Calcium
,24036846,maximum plasma concentration (C(max)),"Calcium supplementation did not significantly affect nilotinib pharmacokinetic parameters including area under the plasma concentration versus time curve (18.4 μg/mL h alone vs. 16.9 μg/mL h with calcium carbonate, p = 0.83; 80 % power); maximum plasma concentration (C(max)) (0.670 μg/mL alone vs. 6.18 μg/mL with calcium carbonate, p = 0.97); or half-life (18.9 h alone vs. 17.2 h with calcium carbonate, p = 0.18).",Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24036846/),[μg] / [ml],0.670,251793,DB01373,Calcium
,24036846,maximum plasma concentration (C(max)),"Calcium supplementation did not significantly affect nilotinib pharmacokinetic parameters including area under the plasma concentration versus time curve (18.4 μg/mL h alone vs. 16.9 μg/mL h with calcium carbonate, p = 0.83; 80 % power); maximum plasma concentration (C(max)) (0.670 μg/mL alone vs. 6.18 μg/mL with calcium carbonate, p = 0.97); or half-life (18.9 h alone vs. 17.2 h with calcium carbonate, p = 0.18).",Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24036846/),[μg] / [ml],6.18,251794,DB01373,Calcium
,24036846,half-life,"Calcium supplementation did not significantly affect nilotinib pharmacokinetic parameters including area under the plasma concentration versus time curve (18.4 μg/mL h alone vs. 16.9 μg/mL h with calcium carbonate, p = 0.83; 80 % power); maximum plasma concentration (C(max)) (0.670 μg/mL alone vs. 6.18 μg/mL with calcium carbonate, p = 0.97); or half-life (18.9 h alone vs. 17.2 h with calcium carbonate, p = 0.18).",Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24036846/),h,18.9,251795,DB01373,Calcium
,24036846,half-life,"Calcium supplementation did not significantly affect nilotinib pharmacokinetic parameters including area under the plasma concentration versus time curve (18.4 μg/mL h alone vs. 16.9 μg/mL h with calcium carbonate, p = 0.83; 80 % power); maximum plasma concentration (C(max)) (0.670 μg/mL alone vs. 6.18 μg/mL with calcium carbonate, p = 0.97); or half-life (18.9 h alone vs. 17.2 h with calcium carbonate, p = 0.18).",Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24036846/),h,17.2,251796,DB01373,Calcium
,16496492,AUC,"AUC medians (with 95% binomial confidence bounds) for control, EDTA, EDTA + AC groups, respectively, for 12 hr were: 2813 (2298, 3561), 2570 (1669, 3476), and 2654 (2125, 3600); and for 24 hr were: 4083 (3488,5314), 4139 (2666, 5547), and 4274 (3336, 5577).",Effect of oral calcium disodium EDTA on iron absorption in a human model of iron overdose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16496492/),,2813,252516,DB01373,Calcium
,16496492,AUC,"AUC medians (with 95% binomial confidence bounds) for control, EDTA, EDTA + AC groups, respectively, for 12 hr were: 2813 (2298, 3561), 2570 (1669, 3476), and 2654 (2125, 3600); and for 24 hr were: 4083 (3488,5314), 4139 (2666, 5547), and 4274 (3336, 5577).",Effect of oral calcium disodium EDTA on iron absorption in a human model of iron overdose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16496492/),,"2298, 3561",252517,DB01373,Calcium
,16496492,AUC,"AUC medians (with 95% binomial confidence bounds) for control, EDTA, EDTA + AC groups, respectively, for 12 hr were: 2813 (2298, 3561), 2570 (1669, 3476), and 2654 (2125, 3600); and for 24 hr were: 4083 (3488,5314), 4139 (2666, 5547), and 4274 (3336, 5577).",Effect of oral calcium disodium EDTA on iron absorption in a human model of iron overdose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16496492/),,2570,252518,DB01373,Calcium
,16496492,AUC,"AUC medians (with 95% binomial confidence bounds) for control, EDTA, EDTA + AC groups, respectively, for 12 hr were: 2813 (2298, 3561), 2570 (1669, 3476), and 2654 (2125, 3600); and for 24 hr were: 4083 (3488,5314), 4139 (2666, 5547), and 4274 (3336, 5577).",Effect of oral calcium disodium EDTA on iron absorption in a human model of iron overdose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16496492/),,"1669, 3476",252519,DB01373,Calcium
,16496492,AUC,"AUC medians (with 95% binomial confidence bounds) for control, EDTA, EDTA + AC groups, respectively, for 12 hr were: 2813 (2298, 3561), 2570 (1669, 3476), and 2654 (2125, 3600); and for 24 hr were: 4083 (3488,5314), 4139 (2666, 5547), and 4274 (3336, 5577).",Effect of oral calcium disodium EDTA on iron absorption in a human model of iron overdose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16496492/),,2654,252520,DB01373,Calcium
,16496492,AUC,"AUC medians (with 95% binomial confidence bounds) for control, EDTA, EDTA + AC groups, respectively, for 12 hr were: 2813 (2298, 3561), 2570 (1669, 3476), and 2654 (2125, 3600); and for 24 hr were: 4083 (3488,5314), 4139 (2666, 5547), and 4274 (3336, 5577).",Effect of oral calcium disodium EDTA on iron absorption in a human model of iron overdose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16496492/),,2125,252521,DB01373,Calcium
,16496492,AUC,"AUC medians (with 95% binomial confidence bounds) for control, EDTA, EDTA + AC groups, respectively, for 12 hr were: 2813 (2298, 3561), 2570 (1669, 3476), and 2654 (2125, 3600); and for 24 hr were: 4083 (3488,5314), 4139 (2666, 5547), and 4274 (3336, 5577).",Effect of oral calcium disodium EDTA on iron absorption in a human model of iron overdose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16496492/),,4083,252522,DB01373,Calcium
,16496492,AUC,"AUC medians (with 95% binomial confidence bounds) for control, EDTA, EDTA + AC groups, respectively, for 12 hr were: 2813 (2298, 3561), 2570 (1669, 3476), and 2654 (2125, 3600); and for 24 hr were: 4083 (3488,5314), 4139 (2666, 5547), and 4274 (3336, 5577).",Effect of oral calcium disodium EDTA on iron absorption in a human model of iron overdose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16496492/),,4139,252523,DB01373,Calcium
,16496492,AUC,"AUC medians (with 95% binomial confidence bounds) for control, EDTA, EDTA + AC groups, respectively, for 12 hr were: 2813 (2298, 3561), 2570 (1669, 3476), and 2654 (2125, 3600); and for 24 hr were: 4083 (3488,5314), 4139 (2666, 5547), and 4274 (3336, 5577).",Effect of oral calcium disodium EDTA on iron absorption in a human model of iron overdose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16496492/),,4274,252524,DB01373,Calcium
,28261841,retention times,"The retention times achieved were 1.36, 1.23, 1.24 min and 1.34 min for PPF, 5-OH PPF, NDP and IS (carbamazepine), respectively.","A sensitive quantitative assay for the determination of propafenone and two metabolites, 5-hydroxypropafenone and N-depropylpropafenone, in human K2EDTA plasma using LC-MS/MS with ESI operated in positive mode. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28261841/),min,1.36,252731,DB01373,Calcium
,28261841,retention times,"The retention times achieved were 1.36, 1.23, 1.24 min and 1.34 min for PPF, 5-OH PPF, NDP and IS (carbamazepine), respectively.","A sensitive quantitative assay for the determination of propafenone and two metabolites, 5-hydroxypropafenone and N-depropylpropafenone, in human K2EDTA plasma using LC-MS/MS with ESI operated in positive mode. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28261841/),min,1.23,252732,DB01373,Calcium
,28261841,retention times,"The retention times achieved were 1.36, 1.23, 1.24 min and 1.34 min for PPF, 5-OH PPF, NDP and IS (carbamazepine), respectively.","A sensitive quantitative assay for the determination of propafenone and two metabolites, 5-hydroxypropafenone and N-depropylpropafenone, in human K2EDTA plasma using LC-MS/MS with ESI operated in positive mode. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28261841/),min,1.24,252733,DB01373,Calcium
,28261841,retention times,"The retention times achieved were 1.36, 1.23, 1.24 min and 1.34 min for PPF, 5-OH PPF, NDP and IS (carbamazepine), respectively.","A sensitive quantitative assay for the determination of propafenone and two metabolites, 5-hydroxypropafenone and N-depropylpropafenone, in human K2EDTA plasma using LC-MS/MS with ESI operated in positive mode. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28261841/),min,1.34,252734,DB01373,Calcium
,29948984,entrapment efficiency,"Results revealed that the optimized MTG microsponge was successfully formulated with high production yield (61.61% ± 0.6), entrapment efficiency (77.7% ±1.37), and particle size of 192.76 μm and it remained buoyant over simulated gastric fluid for 24 h with high percentage of in vitro buoyancy (91.01% ± 2.5).",Gastroretentive Microsponge as a Promising Tool for Prolonging the Release of Mitiglinide Calcium in Type-2 Diabetes Mellitus: Optimization and Pharmacokinetics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29948984/),%,77.7,253630,DB01373,Calcium
,29948984,cumulative % release,"Moreover, it sustained the in vitro drug release with cumulative % release of 83.74 ± 1.5 after 24 h.",Gastroretentive Microsponge as a Promising Tool for Prolonging the Release of Mitiglinide Calcium in Type-2 Diabetes Mellitus: Optimization and Pharmacokinetics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29948984/),,83.74,253631,DB01373,Calcium
,21401341,relative bioavailability,The pharmacokinetics and biodistribution studies of the optimized radiolabeled formulation (99mTc-labeled) in mice (p.o.) demonstrated a relative bioavailability of 475% against AB suspension.,Design and development of nanoemulsion drug delivery system of amlodipine besilate for improvement of oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21401341/),%,475,253646,DB01373,Calcium
,21401341,drug targeting index,"In almost all the tested organs, the uptake of AB from NE was significantly higher (p < 0.05) than AB suspension especially in heart with a drug targeting index of 44.1%, also confirming the efficacy of nanosized formulation at therapeutic site.",Design and development of nanoemulsion drug delivery system of amlodipine besilate for improvement of oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21401341/),%,44.1,253647,DB01373,Calcium
,14743973,T(1/2),The brain T(1/2) in rat treated with ery(75.0 min) and CsA(79.0 min) were larger than that (44.2 min) in rats NMD alone.,Effect of P-glycoprotein inhibitors erythromycin and cyclosporin A on brain pharmacokinetics of nimodipine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14743973/),min,75.0,254714,DB01373,Calcium
,14743973,T(1/2),The brain T(1/2) in rat treated with ery(75.0 min) and CsA(79.0 min) were larger than that (44.2 min) in rats NMD alone.,Effect of P-glycoprotein inhibitors erythromycin and cyclosporin A on brain pharmacokinetics of nimodipine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14743973/),min,79.0,254715,DB01373,Calcium
,14743973,T(1/2),The brain T(1/2) in rat treated with ery(75.0 min) and CsA(79.0 min) were larger than that (44.2 min) in rats NMD alone.,Effect of P-glycoprotein inhibitors erythromycin and cyclosporin A on brain pharmacokinetics of nimodipine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14743973/),min,44.2,254716,DB01373,Calcium
,15734899,area under the plasma concentration-time curve (0-270 min),"The mean increment in area under the plasma concentration-time curve (0-270 min) for serum calcium after calcium formate (378 mg . min/dl) was double that for calcium citrate (178 mg . min/dl; p < 0.01), whereas the latter was only modestly greater than either placebo (107; p < 0.05) or calcium carbonate (91; p < 0.05).","Relative bioavailability of calcium from calcium formate, calcium citrate, and calcium carbonate. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15734899/),[mg·min] / [dl],378,255483,DB01373,Calcium
,15734899,area under the plasma concentration-time curve (0-270 min),"The mean increment in area under the plasma concentration-time curve (0-270 min) for serum calcium after calcium formate (378 mg . min/dl) was double that for calcium citrate (178 mg . min/dl; p < 0.01), whereas the latter was only modestly greater than either placebo (107; p < 0.05) or calcium carbonate (91; p < 0.05).","Relative bioavailability of calcium from calcium formate, calcium citrate, and calcium carbonate. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15734899/),[mg·min] / [dl],178,255484,DB01373,Calcium
,20678686,C(max),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [ml],8.78,255520,DB01373,Calcium
,20678686,C(max),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [ml],10.76,255521,DB01373,Calcium
,20678686,AUC(0-t),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [ml],10.76,255522,DB01373,Calcium
,20678686,AUC(0-t),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [h·ml],38.22,255523,DB01373,Calcium
,20678686,AUC(0-t),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [h·ml],42.73,255524,DB01373,Calcium
,20678686,AUC(0-t),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [h·ml],47.32,255525,DB01373,Calcium
,20678686,AUC(0-infinity)),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [h·ml],42.73,255526,DB01373,Calcium
,20678686,AUC(0-infinity)),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [h·ml],44.51,255527,DB01373,Calcium
,20678686,AUC(0-infinity)),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [ml],5.78,255528,DB01373,Calcium
,20678686,AUC(0-infinity)),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [ml],5.77,255529,DB01373,Calcium
,20678686,AUC(0-infinity)),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [h·ml],47.32,255530,DB01373,Calcium
,20678686,AUC(0-infinity)),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [h·ml],48.47,255531,DB01373,Calcium
,20678686,AUC(0-infinity)),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [h·ml],52.36,255532,DB01373,Calcium
,20678686,AUC(0-infinity)),"The mean values of C(max), AUC(0-t), and AUC(0-infinity)) for the test and reference formulations of atorvastatin (8.78 and 10.76 ng/mL, 38.22 and 40.02 ng/mL/h, 42.73 and 44.51 ng/mL/h, respectively) and ortho-hydroxy-atorvastatin (5.78 and 5.77 ng/mL, 47.32 and 48.47 ng/mL/h, 52.36 and 53.14 ng/mL/h) were not significantly different.","Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678686/),[ng] / [h·ml],53.14,255533,DB01373,Calcium
,17652181,K(i),"In vitro study has demonstrated that cinacalcet is a potent inhibitor of cytochrome P450 (CYP) 2D6 with a K(i) value of 0.087 micromol/L, which is comparable to the well-known potent CYP2D6 inhibitor, quinidine (0.064 micromol/L).","Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17652181/),[μM] / [l],0.087,255651,DB01373,Calcium
,17652181,K(i),"In vitro study has demonstrated that cinacalcet is a potent inhibitor of cytochrome P450 (CYP) 2D6 with a K(i) value of 0.087 micromol/L, which is comparable to the well-known potent CYP2D6 inhibitor, quinidine (0.064 micromol/L).","Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17652181/),[μM] / [l],0.064,255652,DB01373,Calcium
,11996822,C(max),"For buccal formulation the average values of C(max) and AUC(0-24 h) for verapamil were much higher than for the reference Staveran tablets and amounted to 51.28 and 320.23 ng/ml h, respectively.",Pharmacokinetics of verapamil and its metabolite norverapamil from a buccal drug formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996822/),[ng] / [h·ml],51.28,256007,DB01373,Calcium
,11996822,AUC(0-24 h),"For buccal formulation the average values of C(max) and AUC(0-24 h) for verapamil were much higher than for the reference Staveran tablets and amounted to 51.28 and 320.23 ng/ml h, respectively.",Pharmacokinetics of verapamil and its metabolite norverapamil from a buccal drug formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996822/),[ng] / [h·ml],320.23,256008,DB01373,Calcium
,18691987,AUC(0-infinity),The mean AUC(0-infinity) of rosuvastatin was 95.8% (110.4 [41.4] vs 115.3 [30.9] ng/mL . h(-1)) of the corresponding value during the placebo phase (P = NS).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),[ml·ng] / [h],95,256281,DB01373,Calcium
,18691987,AUC(0-infinity),The mean AUC(0-infinity) of rosuvastatin was 95.8% (110.4 [41.4] vs 115.3 [30.9] ng/mL . h(-1)) of the corresponding value during the placebo phase (P = NS).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),[ml·ng] / [h],110.4,256282,DB01373,Calcium
,18691987,AUC(0-infinity),The mean AUC(0-infinity) of rosuvastatin was 95.8% (110.4 [41.4] vs 115.3 [30.9] ng/mL . h(-1)) of the corresponding value during the placebo phase (P = NS).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),[ml·ng] / [h],115.3,256283,DB01373,Calcium
,18691987,C(max),There was no statistically significant difference in either C(max) or t(1/2) of rosuvastatin between the rifampicin-treated and placebo groups (18.5 [6.3] vs 16.5 [5.5] ng/mL; 12.8 [3.0] vs 13.3 [2.8] h).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),[ng] / [ml],18.5,256284,DB01373,Calcium
,18691987,C(max),There was no statistically significant difference in either C(max) or t(1/2) of rosuvastatin between the rifampicin-treated and placebo groups (18.5 [6.3] vs 16.5 [5.5] ng/mL; 12.8 [3.0] vs 13.3 [2.8] h).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),[ng] / [ml],16.5,256285,DB01373,Calcium
,18691987,t(1/2),There was no statistically significant difference in either C(max) or t(1/2) of rosuvastatin between the rifampicin-treated and placebo groups (18.5 [6.3] vs 16.5 [5.5] ng/mL; 12.8 [3.0] vs 13.3 [2.8] h).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),h,12.8,256286,DB01373,Calcium
,18691987,t(1/2),There was no statistically significant difference in either C(max) or t(1/2) of rosuvastatin between the rifampicin-treated and placebo groups (18.5 [6.3] vs 16.5 [5.5] ng/mL; 12.8 [3.0] vs 13.3 [2.8] h).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),h,13.3,256287,DB01373,Calcium
,18691987,oral clearance,The oral clearance of rosuvastatin was not significantly affected by rifampicin pretreatment either (0.4 [0.3] vs 0.3 [0.2] L . h; P = 0.072).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),h·l,0.4,256288,DB01373,Calcium
,18691987,oral clearance,The oral clearance of rosuvastatin was not significantly affected by rifampicin pretreatment either (0.4 [0.3] vs 0.3 [0.2] L . h; P = 0.072).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),h·l,0.3,256289,DB01373,Calcium
,16832615,bioavailability,"The predicted bioavailability of the p.o. 25, 50, 100 and 400 mg doses of talinolol was 64, 76, 85, 94%, respectively.",In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16832615/),%,64,256572,DB01373,Calcium
,16832615,bioavailability,"The predicted bioavailability of the p.o. 25, 50, 100 and 400 mg doses of talinolol was 64, 76, 85, 94%, respectively.",In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16832615/),%,76,256573,DB01373,Calcium
,16832615,bioavailability,"The predicted bioavailability of the p.o. 25, 50, 100 and 400 mg doses of talinolol was 64, 76, 85, 94%, respectively.",In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16832615/),%,85,256574,DB01373,Calcium
,16832615,bioavailability,"The predicted bioavailability of the p.o. 25, 50, 100 and 400 mg doses of talinolol was 64, 76, 85, 94%, respectively.",In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16832615/),%,94,256575,DB01373,Calcium
,16832615,EC50,"For all simulations, EC50 was 114 nM and E0 was 83 bpm.",In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16832615/),nM,114,256576,DB01373,Calcium
,16832615,E0,"For all simulations, EC50 was 114 nM and E0 was 83 bpm.",In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16832615/),bpm,83,256577,DB01373,Calcium
,15592332,C max,"Bergamottin measured in plasma after administration of 6 and 12 mg produced C max values of 2.1 and 5.9 ng/mL, respectively, and times to reach C max of 0.8 and 1.1 hours, respectively.",Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592332/),[ng] / [ml],2.1,257055,DB01373,Calcium
,15592332,C max,"Bergamottin measured in plasma after administration of 6 and 12 mg produced C max values of 2.1 and 5.9 ng/mL, respectively, and times to reach C max of 0.8 and 1.1 hours, respectively.",Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592332/),[ng] / [ml],5.9,257056,DB01373,Calcium
,15592332,times to reach C max,"Bergamottin measured in plasma after administration of 6 and 12 mg produced C max values of 2.1 and 5.9 ng/mL, respectively, and times to reach C max of 0.8 and 1.1 hours, respectively.",Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592332/),h,0.8,257057,DB01373,Calcium
,15592332,times to reach C max,"Bergamottin measured in plasma after administration of 6 and 12 mg produced C max values of 2.1 and 5.9 ng/mL, respectively, and times to reach C max of 0.8 and 1.1 hours, respectively.",Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592332/),h,1.1,257058,DB01373,Calcium
,20108648,tmax,"The main pharmacokinetic parameters of the 333, 666 and 1322 mg regimen groups were as follows: tmax 7.5 +/- 2.6 h, 7.4 +/- 2.2 h, 8.1 +/- 3.1 h, Cmax 134.8 +/- 103.9 ng/mL, 297.5 +/- 188.1 ng/mL, 385.4 +/- 155.7 ng/mL, t1/2 13.3 +/- 11.4 h, 17.9 +/- 18.1 h, 15.1 +/- 9.1 h, AUC(0-t) 1772 +/- 1323 ng x h/mL, 3709 +/- 1195 ng x h/mL, 6421 +/- 2486 ng x h/mL, respectively.",Pharmacokinetics of acamprosate calcium in healthy Chinese subjects after oral administration of three dosage levels. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108648/),h,7.5,257136,DB01373,Calcium
,20108648,tmax,"The main pharmacokinetic parameters of the 333, 666 and 1322 mg regimen groups were as follows: tmax 7.5 +/- 2.6 h, 7.4 +/- 2.2 h, 8.1 +/- 3.1 h, Cmax 134.8 +/- 103.9 ng/mL, 297.5 +/- 188.1 ng/mL, 385.4 +/- 155.7 ng/mL, t1/2 13.3 +/- 11.4 h, 17.9 +/- 18.1 h, 15.1 +/- 9.1 h, AUC(0-t) 1772 +/- 1323 ng x h/mL, 3709 +/- 1195 ng x h/mL, 6421 +/- 2486 ng x h/mL, respectively.",Pharmacokinetics of acamprosate calcium in healthy Chinese subjects after oral administration of three dosage levels. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108648/),h,7.4,257137,DB01373,Calcium
,20108648,tmax,"The main pharmacokinetic parameters of the 333, 666 and 1322 mg regimen groups were as follows: tmax 7.5 +/- 2.6 h, 7.4 +/- 2.2 h, 8.1 +/- 3.1 h, Cmax 134.8 +/- 103.9 ng/mL, 297.5 +/- 188.1 ng/mL, 385.4 +/- 155.7 ng/mL, t1/2 13.3 +/- 11.4 h, 17.9 +/- 18.1 h, 15.1 +/- 9.1 h, AUC(0-t) 1772 +/- 1323 ng x h/mL, 3709 +/- 1195 ng x h/mL, 6421 +/- 2486 ng x h/mL, respectively.",Pharmacokinetics of acamprosate calcium in healthy Chinese subjects after oral administration of three dosage levels. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108648/),h,8.1,257138,DB01373,Calcium
,20108648,Cmax,"The main pharmacokinetic parameters of the 333, 666 and 1322 mg regimen groups were as follows: tmax 7.5 +/- 2.6 h, 7.4 +/- 2.2 h, 8.1 +/- 3.1 h, Cmax 134.8 +/- 103.9 ng/mL, 297.5 +/- 188.1 ng/mL, 385.4 +/- 155.7 ng/mL, t1/2 13.3 +/- 11.4 h, 17.9 +/- 18.1 h, 15.1 +/- 9.1 h, AUC(0-t) 1772 +/- 1323 ng x h/mL, 3709 +/- 1195 ng x h/mL, 6421 +/- 2486 ng x h/mL, respectively.",Pharmacokinetics of acamprosate calcium in healthy Chinese subjects after oral administration of three dosage levels. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108648/),[ng] / [ml],134.8,257139,DB01373,Calcium
,20108648,Cmax,"The main pharmacokinetic parameters of the 333, 666 and 1322 mg regimen groups were as follows: tmax 7.5 +/- 2.6 h, 7.4 +/- 2.2 h, 8.1 +/- 3.1 h, Cmax 134.8 +/- 103.9 ng/mL, 297.5 +/- 188.1 ng/mL, 385.4 +/- 155.7 ng/mL, t1/2 13.3 +/- 11.4 h, 17.9 +/- 18.1 h, 15.1 +/- 9.1 h, AUC(0-t) 1772 +/- 1323 ng x h/mL, 3709 +/- 1195 ng x h/mL, 6421 +/- 2486 ng x h/mL, respectively.",Pharmacokinetics of acamprosate calcium in healthy Chinese subjects after oral administration of three dosage levels. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108648/),[ng] / [ml],297.5,257140,DB01373,Calcium
,20108648,Cmax,"The main pharmacokinetic parameters of the 333, 666 and 1322 mg regimen groups were as follows: tmax 7.5 +/- 2.6 h, 7.4 +/- 2.2 h, 8.1 +/- 3.1 h, Cmax 134.8 +/- 103.9 ng/mL, 297.5 +/- 188.1 ng/mL, 385.4 +/- 155.7 ng/mL, t1/2 13.3 +/- 11.4 h, 17.9 +/- 18.1 h, 15.1 +/- 9.1 h, AUC(0-t) 1772 +/- 1323 ng x h/mL, 3709 +/- 1195 ng x h/mL, 6421 +/- 2486 ng x h/mL, respectively.",Pharmacokinetics of acamprosate calcium in healthy Chinese subjects after oral administration of three dosage levels. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108648/),[ng] / [ml],385.4,257141,DB01373,Calcium
,20108648,t1/2,"The main pharmacokinetic parameters of the 333, 666 and 1322 mg regimen groups were as follows: tmax 7.5 +/- 2.6 h, 7.4 +/- 2.2 h, 8.1 +/- 3.1 h, Cmax 134.8 +/- 103.9 ng/mL, 297.5 +/- 188.1 ng/mL, 385.4 +/- 155.7 ng/mL, t1/2 13.3 +/- 11.4 h, 17.9 +/- 18.1 h, 15.1 +/- 9.1 h, AUC(0-t) 1772 +/- 1323 ng x h/mL, 3709 +/- 1195 ng x h/mL, 6421 +/- 2486 ng x h/mL, respectively.",Pharmacokinetics of acamprosate calcium in healthy Chinese subjects after oral administration of three dosage levels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108648/),h,13.3,257142,DB01373,Calcium
,20108648,t1/2,"The main pharmacokinetic parameters of the 333, 666 and 1322 mg regimen groups were as follows: tmax 7.5 +/- 2.6 h, 7.4 +/- 2.2 h, 8.1 +/- 3.1 h, Cmax 134.8 +/- 103.9 ng/mL, 297.5 +/- 188.1 ng/mL, 385.4 +/- 155.7 ng/mL, t1/2 13.3 +/- 11.4 h, 17.9 +/- 18.1 h, 15.1 +/- 9.1 h, AUC(0-t) 1772 +/- 1323 ng x h/mL, 3709 +/- 1195 ng x h/mL, 6421 +/- 2486 ng x h/mL, respectively.",Pharmacokinetics of acamprosate calcium in healthy Chinese subjects after oral administration of three dosage levels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108648/),h,17.9,257143,DB01373,Calcium
,20108648,t1/2,"The main pharmacokinetic parameters of the 333, 666 and 1322 mg regimen groups were as follows: tmax 7.5 +/- 2.6 h, 7.4 +/- 2.2 h, 8.1 +/- 3.1 h, Cmax 134.8 +/- 103.9 ng/mL, 297.5 +/- 188.1 ng/mL, 385.4 +/- 155.7 ng/mL, t1/2 13.3 +/- 11.4 h, 17.9 +/- 18.1 h, 15.1 +/- 9.1 h, AUC(0-t) 1772 +/- 1323 ng x h/mL, 3709 +/- 1195 ng x h/mL, 6421 +/- 2486 ng x h/mL, respectively.",Pharmacokinetics of acamprosate calcium in healthy Chinese subjects after oral administration of three dosage levels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108648/),h,15.1,257144,DB01373,Calcium
,20108648,AUC(0-t),"The main pharmacokinetic parameters of the 333, 666 and 1322 mg regimen groups were as follows: tmax 7.5 +/- 2.6 h, 7.4 +/- 2.2 h, 8.1 +/- 3.1 h, Cmax 134.8 +/- 103.9 ng/mL, 297.5 +/- 188.1 ng/mL, 385.4 +/- 155.7 ng/mL, t1/2 13.3 +/- 11.4 h, 17.9 +/- 18.1 h, 15.1 +/- 9.1 h, AUC(0-t) 1772 +/- 1323 ng x h/mL, 3709 +/- 1195 ng x h/mL, 6421 +/- 2486 ng x h/mL, respectively.",Pharmacokinetics of acamprosate calcium in healthy Chinese subjects after oral administration of three dosage levels. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108648/),[h·ng] / [ml],1772,257145,DB01373,Calcium
,20108648,AUC(0-t),"The main pharmacokinetic parameters of the 333, 666 and 1322 mg regimen groups were as follows: tmax 7.5 +/- 2.6 h, 7.4 +/- 2.2 h, 8.1 +/- 3.1 h, Cmax 134.8 +/- 103.9 ng/mL, 297.5 +/- 188.1 ng/mL, 385.4 +/- 155.7 ng/mL, t1/2 13.3 +/- 11.4 h, 17.9 +/- 18.1 h, 15.1 +/- 9.1 h, AUC(0-t) 1772 +/- 1323 ng x h/mL, 3709 +/- 1195 ng x h/mL, 6421 +/- 2486 ng x h/mL, respectively.",Pharmacokinetics of acamprosate calcium in healthy Chinese subjects after oral administration of three dosage levels. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108648/),[h·ng] / [ml],3709,257146,DB01373,Calcium
,20108648,AUC(0-t),"The main pharmacokinetic parameters of the 333, 666 and 1322 mg regimen groups were as follows: tmax 7.5 +/- 2.6 h, 7.4 +/- 2.2 h, 8.1 +/- 3.1 h, Cmax 134.8 +/- 103.9 ng/mL, 297.5 +/- 188.1 ng/mL, 385.4 +/- 155.7 ng/mL, t1/2 13.3 +/- 11.4 h, 17.9 +/- 18.1 h, 15.1 +/- 9.1 h, AUC(0-t) 1772 +/- 1323 ng x h/mL, 3709 +/- 1195 ng x h/mL, 6421 +/- 2486 ng x h/mL, respectively.",Pharmacokinetics of acamprosate calcium in healthy Chinese subjects after oral administration of three dosage levels. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108648/),[h·ng] / [ml],6421,257147,DB01373,Calcium
,34315767,half-life,"The PK of dilpacimab showed a half-life ranging from 4.9 to 9.5 days, and biomarker analysis demonstrated that the drug bound to both VEGF and DLL4 targets.","Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34315767/),d,4.9 to 9.5,259056,DB01373,Calcium
,23627065,polydispersity index,Results showed better self-nanoemulsifying ability of systems containing triacetin compared to Transcutol P. SNEDDS formed uni-modal nanoemulsion droplet size distributions with droplet size less than 50 nm and polydispersity index values ranging from 0.127 to 0.275.,Enhancement of human oral bioavailability and in vitro antitumor activity of rosuvastatin via spray dried self-nanoemulsifying drug delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23627065/),,0.127 to 0.275,259057,DB01373,Calcium
,23627065,IC50,The anticancer effect of rosuvastatin was enhanced when incorporated in SNEDDS (IC50 value decreased from 4 to 3 microg/ml) due to the increase in penetration of SNEDDS inside the cells.,Enhancement of human oral bioavailability and in vitro antitumor activity of rosuvastatin via spray dried self-nanoemulsifying drug delivery system. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23627065/),[μg] / [ml],4,259058,DB01373,Calcium
,23627065,IC50,The anticancer effect of rosuvastatin was enhanced when incorporated in SNEDDS (IC50 value decreased from 4 to 3 microg/ml) due to the increase in penetration of SNEDDS inside the cells.,Enhancement of human oral bioavailability and in vitro antitumor activity of rosuvastatin via spray dried self-nanoemulsifying drug delivery system. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23627065/),[μg] / [ml],3,259059,DB01373,Calcium
,23627065,relative bioavailability,The relative bioavailability for SNEDDS tablets compared to the commercial tablets was 167%.,Enhancement of human oral bioavailability and in vitro antitumor activity of rosuvastatin via spray dried self-nanoemulsifying drug delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23627065/),%,167,259060,DB01373,Calcium
,23863489,Maximum circuit concentrations (Cmax),"Maximum circuit concentrations (Cmax) at 2 minutes for albumin were 3.5, 2.65 and 4.85 mg/l, for blood were 4.5, 6.5 and 5.55 mg/l and for Hartmann's were 1.65, 2.95 and 3.65 mg/l for 6 kg, 20 kg and 50 kg models.","Ceftriaxone pharmacokinetic properties during continuous veno-veno haemofiltration using an in vitro adult, paediatric and neonatal model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23863489/),[mg] / [l],3.5,262345,DB01373,Calcium
,23863489,Maximum circuit concentrations (Cmax),"Maximum circuit concentrations (Cmax) at 2 minutes for albumin were 3.5, 2.65 and 4.85 mg/l, for blood were 4.5, 6.5 and 5.55 mg/l and for Hartmann's were 1.65, 2.95 and 3.65 mg/l for 6 kg, 20 kg and 50 kg models.","Ceftriaxone pharmacokinetic properties during continuous veno-veno haemofiltration using an in vitro adult, paediatric and neonatal model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23863489/),[mg] / [l],2.65,262346,DB01373,Calcium
,23863489,Maximum circuit concentrations (Cmax),"Maximum circuit concentrations (Cmax) at 2 minutes for albumin were 3.5, 2.65 and 4.85 mg/l, for blood were 4.5, 6.5 and 5.55 mg/l and for Hartmann's were 1.65, 2.95 and 3.65 mg/l for 6 kg, 20 kg and 50 kg models.","Ceftriaxone pharmacokinetic properties during continuous veno-veno haemofiltration using an in vitro adult, paediatric and neonatal model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23863489/),[mg] / [l],4.85,262347,DB01373,Calcium
,23863489,Maximum circuit concentrations (Cmax),"Maximum circuit concentrations (Cmax) at 2 minutes for albumin were 3.5, 2.65 and 4.85 mg/l, for blood were 4.5, 6.5 and 5.55 mg/l and for Hartmann's were 1.65, 2.95 and 3.65 mg/l for 6 kg, 20 kg and 50 kg models.","Ceftriaxone pharmacokinetic properties during continuous veno-veno haemofiltration using an in vitro adult, paediatric and neonatal model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23863489/),[mg] / [l],4.5,262348,DB01373,Calcium
,23863489,Maximum circuit concentrations (Cmax),"Maximum circuit concentrations (Cmax) at 2 minutes for albumin were 3.5, 2.65 and 4.85 mg/l, for blood were 4.5, 6.5 and 5.55 mg/l and for Hartmann's were 1.65, 2.95 and 3.65 mg/l for 6 kg, 20 kg and 50 kg models.","Ceftriaxone pharmacokinetic properties during continuous veno-veno haemofiltration using an in vitro adult, paediatric and neonatal model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23863489/),[mg] / [l],6.5,262349,DB01373,Calcium
,23863489,Maximum circuit concentrations (Cmax),"Maximum circuit concentrations (Cmax) at 2 minutes for albumin were 3.5, 2.65 and 4.85 mg/l, for blood were 4.5, 6.5 and 5.55 mg/l and for Hartmann's were 1.65, 2.95 and 3.65 mg/l for 6 kg, 20 kg and 50 kg models.","Ceftriaxone pharmacokinetic properties during continuous veno-veno haemofiltration using an in vitro adult, paediatric and neonatal model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23863489/),[mg] / [l],5.55,262350,DB01373,Calcium
,23863489,Maximum circuit concentrations (Cmax),"Maximum circuit concentrations (Cmax) at 2 minutes for albumin were 3.5, 2.65 and 4.85 mg/l, for blood were 4.5, 6.5 and 5.55 mg/l and for Hartmann's were 1.65, 2.95 and 3.65 mg/l for 6 kg, 20 kg and 50 kg models.","Ceftriaxone pharmacokinetic properties during continuous veno-veno haemofiltration using an in vitro adult, paediatric and neonatal model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23863489/),[mg] / [l],1.65,262351,DB01373,Calcium
,23863489,Maximum circuit concentrations (Cmax),"Maximum circuit concentrations (Cmax) at 2 minutes for albumin were 3.5, 2.65 and 4.85 mg/l, for blood were 4.5, 6.5 and 5.55 mg/l and for Hartmann's were 1.65, 2.95 and 3.65 mg/l for 6 kg, 20 kg and 50 kg models.","Ceftriaxone pharmacokinetic properties during continuous veno-veno haemofiltration using an in vitro adult, paediatric and neonatal model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23863489/),[mg] / [l],2.95,262352,DB01373,Calcium
,23863489,Maximum circuit concentrations (Cmax),"Maximum circuit concentrations (Cmax) at 2 minutes for albumin were 3.5, 2.65 and 4.85 mg/l, for blood were 4.5, 6.5 and 5.55 mg/l and for Hartmann's were 1.65, 2.95 and 3.65 mg/l for 6 kg, 20 kg and 50 kg models.","Ceftriaxone pharmacokinetic properties during continuous veno-veno haemofiltration using an in vitro adult, paediatric and neonatal model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23863489/),[mg] / [l],3.65,262353,DB01373,Calcium
,23863489,T1/2,"The sieving coefficients (Sc) from blood (ratio of mean concentrations in the ultrafiltrate/circuits samples) were 0.31 and 0.51 with T1/2 (the half life) 62 and 20 minutes in the 6 kg and the 20 kg circuits, respectively.","Ceftriaxone pharmacokinetic properties during continuous veno-veno haemofiltration using an in vitro adult, paediatric and neonatal model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23863489/),min,62,262354,DB01373,Calcium
,23863489,T1/2,"The sieving coefficients (Sc) from blood (ratio of mean concentrations in the ultrafiltrate/circuits samples) were 0.31 and 0.51 with T1/2 (the half life) 62 and 20 minutes in the 6 kg and the 20 kg circuits, respectively.","Ceftriaxone pharmacokinetic properties during continuous veno-veno haemofiltration using an in vitro adult, paediatric and neonatal model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23863489/),min,20,262355,DB01373,Calcium
,21441129,Q(b),"The modeled prescriptions varied HD time from 12 to 40 h/wk over three to six sessions (Q(b) 200 to 400 ml/min, Q(d) 500 to 800 ml/min), and continuous venovenous hemodialysis at low flow rates (Q(b) 100 to 200 ml/min, Q(d) 35 to 50 ml/min), using high-flux polysulfone hemofilters.",Simulation-based sodium thiosulfate dosing strategies for the treatment of calciphylaxis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21441129/),[ml] / [min],200 to 400,262874,DB01373,Calcium
,21441129,Q(d),"The modeled prescriptions varied HD time from 12 to 40 h/wk over three to six sessions (Q(b) 200 to 400 ml/min, Q(d) 500 to 800 ml/min), and continuous venovenous hemodialysis at low flow rates (Q(b) 100 to 200 ml/min, Q(d) 35 to 50 ml/min), using high-flux polysulfone hemofilters.",Simulation-based sodium thiosulfate dosing strategies for the treatment of calciphylaxis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21441129/),[ml] / [min],500 to 800,262875,DB01373,Calcium
,21441129,Q(b),"The modeled prescriptions varied HD time from 12 to 40 h/wk over three to six sessions (Q(b) 200 to 400 ml/min, Q(d) 500 to 800 ml/min), and continuous venovenous hemodialysis at low flow rates (Q(b) 100 to 200 ml/min, Q(d) 35 to 50 ml/min), using high-flux polysulfone hemofilters.",Simulation-based sodium thiosulfate dosing strategies for the treatment of calciphylaxis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21441129/),[ml] / [min],100 to 200,262876,DB01373,Calcium
,21441129,Q(d),"The modeled prescriptions varied HD time from 12 to 40 h/wk over three to six sessions (Q(b) 200 to 400 ml/min, Q(d) 500 to 800 ml/min), and continuous venovenous hemodialysis at low flow rates (Q(b) 100 to 200 ml/min, Q(d) 35 to 50 ml/min), using high-flux polysulfone hemofilters.",Simulation-based sodium thiosulfate dosing strategies for the treatment of calciphylaxis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21441129/),[ml] / [min],35 to 50,262877,DB01373,Calcium
,23878324,half maximal effective concentration,"In this study, we evaluated the anti-Cryptosporidium activity of a novel CDPK1 inhibitor, 1294, and demonstrated that 1294 significantly reduces parasite infection in vitro, with a half maximal effective concentration of 100 nM.",A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23878324/),nM,100,262927,DB01373,Calcium
,20585842,absolute bioavailability,"From the simulated T(50%) values (50% dissolution time), the dissolution rates of crystals with particle sizes of 200 nm, 620 nm, 2.7 microm, 4.1 microm and 20.2 microm were calculated to be 5.1 x 10(4), 1.0 x 10(4), 237, 64 and 11-fold greater than that of the raw crystals and resulted in absolute bioavailability of 61.4% 51.5%, 29.4%, 26.7%, 24.7%, respectively.",Effect of crystal size on the in vitro dissolution and oral absorption of nitrendipine in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20585842/),%,61.4,263302,DB01373,Calcium
,20585842,absolute bioavailability,"From the simulated T(50%) values (50% dissolution time), the dissolution rates of crystals with particle sizes of 200 nm, 620 nm, 2.7 microm, 4.1 microm and 20.2 microm were calculated to be 5.1 x 10(4), 1.0 x 10(4), 237, 64 and 11-fold greater than that of the raw crystals and resulted in absolute bioavailability of 61.4% 51.5%, 29.4%, 26.7%, 24.7%, respectively.",Effect of crystal size on the in vitro dissolution and oral absorption of nitrendipine in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20585842/),%,51.5,263303,DB01373,Calcium
,20585842,absolute bioavailability,"From the simulated T(50%) values (50% dissolution time), the dissolution rates of crystals with particle sizes of 200 nm, 620 nm, 2.7 microm, 4.1 microm and 20.2 microm were calculated to be 5.1 x 10(4), 1.0 x 10(4), 237, 64 and 11-fold greater than that of the raw crystals and resulted in absolute bioavailability of 61.4% 51.5%, 29.4%, 26.7%, 24.7%, respectively.",Effect of crystal size on the in vitro dissolution and oral absorption of nitrendipine in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20585842/),%,29.4,263304,DB01373,Calcium
,20585842,absolute bioavailability,"From the simulated T(50%) values (50% dissolution time), the dissolution rates of crystals with particle sizes of 200 nm, 620 nm, 2.7 microm, 4.1 microm and 20.2 microm were calculated to be 5.1 x 10(4), 1.0 x 10(4), 237, 64 and 11-fold greater than that of the raw crystals and resulted in absolute bioavailability of 61.4% 51.5%, 29.4%, 26.7%, 24.7%, respectively.",Effect of crystal size on the in vitro dissolution and oral absorption of nitrendipine in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20585842/),%,26.7,263305,DB01373,Calcium
,20585842,absolute bioavailability,"From the simulated T(50%) values (50% dissolution time), the dissolution rates of crystals with particle sizes of 200 nm, 620 nm, 2.7 microm, 4.1 microm and 20.2 microm were calculated to be 5.1 x 10(4), 1.0 x 10(4), 237, 64 and 11-fold greater than that of the raw crystals and resulted in absolute bioavailability of 61.4% 51.5%, 29.4%, 26.7%, 24.7%, respectively.",Effect of crystal size on the in vitro dissolution and oral absorption of nitrendipine in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20585842/),%,24.7,263306,DB01373,Calcium
,26356646,bioconcentration factor (BCF),"The bioconcentration factor (BCF) of diltiazem was relatively low (0.5-194) in analysed tissues, following the order kidney > liver > muscle > blood plasma.","Bioconcentration, metabolism and half-life time of the human therapeutic drug diltiazem in rainbow trout Oncorhynchus mykiss. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356646/),,0.5-194,264529,DB01373,Calcium
,26356646,half-life,"The half-life of diltiazem in liver, kidney, and muscle was 1.5 h, 6.2 h, and 49 h, respectively.","Bioconcentration, metabolism and half-life time of the human therapeutic drug diltiazem in rainbow trout Oncorhynchus mykiss. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356646/),h,1.5,264530,DB01373,Calcium
,26356646,half-life,"The half-life of diltiazem in liver, kidney, and muscle was 1.5 h, 6.2 h, and 49 h, respectively.","Bioconcentration, metabolism and half-life time of the human therapeutic drug diltiazem in rainbow trout Oncorhynchus mykiss. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356646/),h,6.2,264531,DB01373,Calcium
,26356646,half-life,"The half-life of diltiazem in liver, kidney, and muscle was 1.5 h, 6.2 h, and 49 h, respectively.","Bioconcentration, metabolism and half-life time of the human therapeutic drug diltiazem in rainbow trout Oncorhynchus mykiss. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356646/),h,49,264532,DB01373,Calcium
,26356646,rate of metabolism,"The rate of metabolism for diltiazem in liver, kidney, muscle, and blood plasma was estimated to be 85 ± 9%, 64 ± 14%, 46 ± 6%, and 41 ± 8%, respectively.","Bioconcentration, metabolism and half-life time of the human therapeutic drug diltiazem in rainbow trout Oncorhynchus mykiss. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356646/),%,85,264533,DB01373,Calcium
,26356646,rate of metabolism,"The rate of metabolism for diltiazem in liver, kidney, muscle, and blood plasma was estimated to be 85 ± 9%, 64 ± 14%, 46 ± 6%, and 41 ± 8%, respectively.","Bioconcentration, metabolism and half-life time of the human therapeutic drug diltiazem in rainbow trout Oncorhynchus mykiss. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356646/),%,64,264534,DB01373,Calcium
,26356646,rate of metabolism,"The rate of metabolism for diltiazem in liver, kidney, muscle, and blood plasma was estimated to be 85 ± 9%, 64 ± 14%, 46 ± 6%, and 41 ± 8%, respectively.","Bioconcentration, metabolism and half-life time of the human therapeutic drug diltiazem in rainbow trout Oncorhynchus mykiss. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356646/),%,46,264535,DB01373,Calcium
,26356646,rate of metabolism,"The rate of metabolism for diltiazem in liver, kidney, muscle, and blood plasma was estimated to be 85 ± 9%, 64 ± 14%, 46 ± 6%, and 41 ± 8%, respectively.","Bioconcentration, metabolism and half-life time of the human therapeutic drug diltiazem in rainbow trout Oncorhynchus mykiss. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356646/),%,41,264536,DB01373,Calcium
,18661531,Maximum FD(4) concentration,Maximum FD(4) concentration in blood of the patch system was 46.1 +/- 8.9 ng/mL and was reached 3 h after administration.,Design and in vivo evaluation of a patch system based on thiolated polymers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18661531/),[ng] / [ml],46.1,266014,DB01373,Calcium
,18661531,c(max),In contrast c(max) of control tablets displayed 50.5 +/- 14.9 ng/mL after 2 h and the absorption of FD(4) after administration in oral solution was negligible.,Design and in vivo evaluation of a patch system based on thiolated polymers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18661531/),[ng] / [ml],50.5,266015,DB01373,Calcium
,18661531,absolute bioavailability,The absolute bioavailability of orally administered patch systems and control tablets was 0.54% and 0.32% respectively.,Design and in vivo evaluation of a patch system based on thiolated polymers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18661531/),%,0.54,266016,DB01373,Calcium
,18661531,absolute bioavailability,The absolute bioavailability of orally administered patch systems and control tablets was 0.54% and 0.32% respectively.,Design and in vivo evaluation of a patch system based on thiolated polymers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18661531/),%,0.32,266017,DB01373,Calcium
,18417431,recoveries,The recoveries of liquid-liquid extraction method were 58.3-62.6% for FK506 and 50.4-58.8% for DTZ.,Rapid and simultaneous determination of tacrolimus (FK506) and diltiazem in human whole blood by liquid chromatography-tandem mass spectrometry: application to a clinical drug-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18417431/),%,58.3-62.6,266552,DB01373,Calcium
,18417431,recoveries,The recoveries of liquid-liquid extraction method were 58.3-62.6% for FK506 and 50.4-58.8% for DTZ.,Rapid and simultaneous determination of tacrolimus (FK506) and diltiazem in human whole blood by liquid chromatography-tandem mass spectrometry: application to a clinical drug-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18417431/),%,50.4-58.8,266553,DB01373,Calcium
,15222726,elimination half-life (t1/2),The mean elimination half-life (t1/2) for the test (40 h) and the reference (44 h) were within the values previously reported.,Bioequivalence study of generic amlodipine in healthy Thai male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15222726/),h,40,267120,DB01373,Calcium
,15222726,elimination half-life (t1/2),The mean elimination half-life (t1/2) for the test (40 h) and the reference (44 h) were within the values previously reported.,Bioequivalence study of generic amlodipine in healthy Thai male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15222726/),h,44,267121,DB01373,Calcium
,15222726,tmax,"Although the tmax of the test (5 h) was faster than the reference (6 h), the mean (90% CI) of the AUC(0-infinity) and Cmax ratios Test/Reference were 0.91 (0.87-0.97) and 1.01 (0.93-1.09), respectively.",Bioequivalence study of generic amlodipine in healthy Thai male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15222726/),h,5,267122,DB01373,Calcium
,15222726,tmax,"Although the tmax of the test (5 h) was faster than the reference (6 h), the mean (90% CI) of the AUC(0-infinity) and Cmax ratios Test/Reference were 0.91 (0.87-0.97) and 1.01 (0.93-1.09), respectively.",Bioequivalence study of generic amlodipine in healthy Thai male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15222726/),h,6,267123,DB01373,Calcium
,12489980,C(max),"After repeated 2, 4 and 6 mg doses of lacidipine, geometric least square mean values (95% CI) were 1.76 (1.46-2.12), 3.56 (2.96-4.29) and 5.23 (4.34--6.30) microg/L for C(max) and 5.29 (4.57-6.11), 11.42 (9.87-13.20) and 17.55 (15.18-20.29) microg x h/L for AUC over the administration interval at steady state (AUC(tau)), respectively.",Dose linearity of lacidipine pharmacokinetics after single and repeated oral doses in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12489980/),[μg] / [l],1.76,267636,DB01373,Calcium
,12489980,C(max),"After repeated 2, 4 and 6 mg doses of lacidipine, geometric least square mean values (95% CI) were 1.76 (1.46-2.12), 3.56 (2.96-4.29) and 5.23 (4.34--6.30) microg/L for C(max) and 5.29 (4.57-6.11), 11.42 (9.87-13.20) and 17.55 (15.18-20.29) microg x h/L for AUC over the administration interval at steady state (AUC(tau)), respectively.",Dose linearity of lacidipine pharmacokinetics after single and repeated oral doses in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12489980/),[μg] / [l],3.56,267637,DB01373,Calcium
,12489980,C(max),"After repeated 2, 4 and 6 mg doses of lacidipine, geometric least square mean values (95% CI) were 1.76 (1.46-2.12), 3.56 (2.96-4.29) and 5.23 (4.34--6.30) microg/L for C(max) and 5.29 (4.57-6.11), 11.42 (9.87-13.20) and 17.55 (15.18-20.29) microg x h/L for AUC over the administration interval at steady state (AUC(tau)), respectively.",Dose linearity of lacidipine pharmacokinetics after single and repeated oral doses in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12489980/),[μg] / [l],5.23,267638,DB01373,Calcium
,12489980,AUC over,"After repeated 2, 4 and 6 mg doses of lacidipine, geometric least square mean values (95% CI) were 1.76 (1.46-2.12), 3.56 (2.96-4.29) and 5.23 (4.34--6.30) microg/L for C(max) and 5.29 (4.57-6.11), 11.42 (9.87-13.20) and 17.55 (15.18-20.29) microg x h/L for AUC over the administration interval at steady state (AUC(tau)), respectively.",Dose linearity of lacidipine pharmacokinetics after single and repeated oral doses in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12489980/),[h·μg] / [l],5.29,267639,DB01373,Calcium
,12489980,AUC over,"After repeated 2, 4 and 6 mg doses of lacidipine, geometric least square mean values (95% CI) were 1.76 (1.46-2.12), 3.56 (2.96-4.29) and 5.23 (4.34--6.30) microg/L for C(max) and 5.29 (4.57-6.11), 11.42 (9.87-13.20) and 17.55 (15.18-20.29) microg x h/L for AUC over the administration interval at steady state (AUC(tau)), respectively.",Dose linearity of lacidipine pharmacokinetics after single and repeated oral doses in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12489980/),[h·μg] / [l],11.42,267640,DB01373,Calcium
,12489980,AUC over,"After repeated 2, 4 and 6 mg doses of lacidipine, geometric least square mean values (95% CI) were 1.76 (1.46-2.12), 3.56 (2.96-4.29) and 5.23 (4.34--6.30) microg/L for C(max) and 5.29 (4.57-6.11), 11.42 (9.87-13.20) and 17.55 (15.18-20.29) microg x h/L for AUC over the administration interval at steady state (AUC(tau)), respectively.",Dose linearity of lacidipine pharmacokinetics after single and repeated oral doses in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12489980/),[h·μg] / [l],17.55,267641,DB01373,Calcium
,12489980,half-life,Mean half-life ranged between 13.2 hours and 18.7 hours.,Dose linearity of lacidipine pharmacokinetics after single and repeated oral doses in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12489980/),h,13.2,267642,DB01373,Calcium
,12489980,half-life,Mean half-life ranged between 13.2 hours and 18.7 hours.,Dose linearity of lacidipine pharmacokinetics after single and repeated oral doses in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12489980/),h,18.7,267643,DB01373,Calcium
,32557653,clearance (CL/F),"Cyclosporine clearance (CL/F) was estimated as 15.1 L/h, and volume of distribution (V/F) was 108 L.",Population Pharmacokinetic Modeling of Cyclosporine Among Malaysian Renal Transplant Patients: An Evaluation of Methods to Handle Missing Doses in Conventional Drug-Monitoring Data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32557653/),[l] / [h],15.1,267789,DB01373,Calcium
,32557653,volume of distribution (V/F),"Cyclosporine clearance (CL/F) was estimated as 15.1 L/h, and volume of distribution (V/F) was 108 L.",Population Pharmacokinetic Modeling of Cyclosporine Among Malaysian Renal Transplant Patients: An Evaluation of Methods to Handle Missing Doses in Conventional Drug-Monitoring Data. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32557653/),l,108,267790,DB01373,Calcium
,28025964,AUC<sub>last</sub>,"The extent of exposure in terms of AUC<sub>last</sub> amounted to 26,018.3 - 3,580.8 µg×h/L for the test formulation and 25,680.2 ± 3,083.6 µg×h/L for the reference formulation.",Bioequivalence of two formulations of pregabalin 150-mg capsules under fasting conditions in healthy male subjects . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28025964/),[h·μg] / [l],"26,018.3 - 3,580.8",267899,DB01373,Calcium
,28025964,AUC<sub>last</sub>,"The extent of exposure in terms of AUC<sub>last</sub> amounted to 26,018.3 - 3,580.8 µg×h/L for the test formulation and 25,680.2 ± 3,083.6 µg×h/L for the reference formulation.",Bioequivalence of two formulations of pregabalin 150-mg capsules under fasting conditions in healthy male subjects . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28025964/),[h·μg] / [l],"25,680.2",267900,DB01373,Calcium
,28025964,C<sub>max</sub>,"C<sub>max</sub> reached values of 4,782.7 ± 1,124.2 µg/L and 4,654.0 ± 911.4 µg/L for the test product and reference product, respectively.",Bioequivalence of two formulations of pregabalin 150-mg capsules under fasting conditions in healthy male subjects . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28025964/),[μg] / [l],"4,782.7",267901,DB01373,Calcium
,28025964,C<sub>max</sub>,"C<sub>max</sub> reached values of 4,782.7 ± 1,124.2 µg/L and 4,654.0 ± 911.4 µg/L for the test product and reference product, respectively.",Bioequivalence of two formulations of pregabalin 150-mg capsules under fasting conditions in healthy male subjects . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28025964/),[μg] / [l],"4,654.0",267902,DB01373,Calcium
,32014599,Papp,The SLN2 formulation showed the best cytotoxicity test results and had medium permeability (Papp 5.72 × 10-6 cm sec-1) while pure RCa resulted in low permeability (Papp 3.08 × 10-7 cm sec-1).,Physicochemical characterization and pharmacokinetic evaluation of rosuvastatin calcium incorporated solid lipid nanoparticles. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014599/),[cm] / [s],5.72 × 10-6,268139,DB01373,Calcium
,32014599,Papp,The SLN2 formulation showed the best cytotoxicity test results and had medium permeability (Papp 5.72 × 10-6 cm sec-1) while pure RCa resulted in low permeability (Papp 3.08 × 10-7 cm sec-1).,Physicochemical characterization and pharmacokinetic evaluation of rosuvastatin calcium incorporated solid lipid nanoparticles. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014599/),[cm] / [s],3.08 × 10-7,268140,DB01373,Calcium
over,17233542,gastric residence time,Prolonged gastric residence time of over 6 hours was achieved in all rabbits for calcium silicate-based floating microspheres of orlistat.,Evaluation of porous carrier-based floating orlistat microspheres for gastric delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17233542/),h,6,268821,DB01373,Calcium
,20519143,EC50,Oral administration of AM803 (1 mg/kg) resulted in sustained inhibition of ex vivo ionophore-challenged whole blood LTB4 biosynthesis with >90% inhibition for up to 12 h and an EC50 of approximately 7 nM.,"Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20519143/),nM,7,269260,DB01373,Calcium
,20519143,ED50s,"When rat lungs were challenged in vivo with calcium-ionophore, AM803 inhibited LTB4 and cysteinyl leukotriene (CysLT) production with ED50s of 0.12 mg/kg and 0.37 mg/kg, respectively.","Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20519143/),[mg] / [kg],0.12,269261,DB01373,Calcium
,20519143,ED50s,"When rat lungs were challenged in vivo with calcium-ionophore, AM803 inhibited LTB4 and cysteinyl leukotriene (CysLT) production with ED50s of 0.12 mg/kg and 0.37 mg/kg, respectively.","Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20519143/),[mg] / [kg],0.37,269262,DB01373,Calcium
,11923060,ratio of C(max),The mean ratio of C(max) was 235% comparing CORAL with Adalat OROS under these conditions.,Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11923060/),,235,269602,DB01373,Calcium
,12523672,C(max),"Rabbits injected intravenously had C(max), Cls, Vss, and AUC(0-inf) values of 75.1 +/- 6.5 ng/mL, 20.7 +/- 3.3 mL/min, 637 +/- 141 mL, and 1925 +/- 237 ng*min/mL, respectively.",Buccal transmucosal delivery of calcitonin in rabbits using thin-film composites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12523672/),[ng] / [ml],75.1,270413,DB01373,Calcium
,12523672,Cls,"Rabbits injected intravenously had C(max), Cls, Vss, and AUC(0-inf) values of 75.1 +/- 6.5 ng/mL, 20.7 +/- 3.3 mL/min, 637 +/- 141 mL, and 1925 +/- 237 ng*min/mL, respectively.",Buccal transmucosal delivery of calcitonin in rabbits using thin-film composites. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12523672/),[ml] / [min],20.7,270414,DB01373,Calcium
,12523672,Cls,"Rabbits injected intravenously had C(max), Cls, Vss, and AUC(0-inf) values of 75.1 +/- 6.5 ng/mL, 20.7 +/- 3.3 mL/min, 637 +/- 141 mL, and 1925 +/- 237 ng*min/mL, respectively.",Buccal transmucosal delivery of calcitonin in rabbits using thin-film composites. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12523672/),ml,637,270415,DB01373,Calcium
,12523672,Vss,"Rabbits injected intravenously had C(max), Cls, Vss, and AUC(0-inf) values of 75.1 +/- 6.5 ng/mL, 20.7 +/- 3.3 mL/min, 637 +/- 141 mL, and 1925 +/- 237 ng*min/mL, respectively.",Buccal transmucosal delivery of calcitonin in rabbits using thin-film composites. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12523672/),[ml] / [min],20.7,270416,DB01373,Calcium
,12523672,Vss,"Rabbits injected intravenously had C(max), Cls, Vss, and AUC(0-inf) values of 75.1 +/- 6.5 ng/mL, 20.7 +/- 3.3 mL/min, 637 +/- 141 mL, and 1925 +/- 237 ng*min/mL, respectively.",Buccal transmucosal delivery of calcitonin in rabbits using thin-film composites. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12523672/),ml,637,270417,DB01373,Calcium
,12523672,AUC(0-inf),"Rabbits injected intravenously had C(max), Cls, Vss, and AUC(0-inf) values of 75.1 +/- 6.5 ng/mL, 20.7 +/- 3.3 mL/min, 637 +/- 141 mL, and 1925 +/- 237 ng*min/mL, respectively.",Buccal transmucosal delivery of calcitonin in rabbits using thin-film composites. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12523672/),[min·ng] / [ml],1925,270418,DB01373,Calcium
,12523672,C(max) Cls,"Rabbits dosed via the buccal route had C(max) Cls, and AUC(0-400 min values of 4.6 +/- 1.6 ng/mL, 22.0 +/- 5.9 mL/min, and 842.9 +/- 209.7 ng*min/mL, respectively.",Buccal transmucosal delivery of calcitonin in rabbits using thin-film composites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12523672/),[ng] / [ml],4.6,270419,DB01373,Calcium
,12523672,AUC(0-400 min,"Rabbits dosed via the buccal route had C(max) Cls, and AUC(0-400 min values of 4.6 +/- 1.6 ng/mL, 22.0 +/- 5.9 mL/min, and 842.9 +/- 209.7 ng*min/mL, respectively.",Buccal transmucosal delivery of calcitonin in rabbits using thin-film composites. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12523672/),[min·ng] / [ml],842.9,270420,DB01373,Calcium
,12523672,relative bioavailability,The relative bioavailability for rabbits treated with the TFCs was 43.8 +/- 10.9% with a CV of 24.9%.,Buccal transmucosal delivery of calcitonin in rabbits using thin-film composites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12523672/),%,43.8,270421,DB01373,Calcium
,23311987,entrapment efficiency,"The entrapment efficiency of KEM was 94 ± 2% and the cumulative %KEM released from LBL-KEM was 19.2 and 63.5% at pH 1.4 and 7.4, respectively, after 24 h.",Osteogenic efficacy enhancement of kaempferol through an engineered layer-by-layer matrix: a study in ovariectomized rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23311987/),%,94,271290,DB01373,Calcium
,23311987,cumulative %,"The entrapment efficiency of KEM was 94 ± 2% and the cumulative %KEM released from LBL-KEM was 19.2 and 63.5% at pH 1.4 and 7.4, respectively, after 24 h.",Osteogenic efficacy enhancement of kaempferol through an engineered layer-by-layer matrix: a study in ovariectomized rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23311987/),%,19.2,271291,DB01373,Calcium
,23311987,cumulative %,"The entrapment efficiency of KEM was 94 ± 2% and the cumulative %KEM released from LBL-KEM was 19.2 and 63.5% at pH 1.4 and 7.4, respectively, after 24 h.",Osteogenic efficacy enhancement of kaempferol through an engineered layer-by-layer matrix: a study in ovariectomized rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23311987/),%,63.5,271292,DB01373,Calcium
,23311987,ζ-potential,A final ζ-potential of -8.9 mV was obtained after terminal surface modification with sodium deoxycholate.,Osteogenic efficacy enhancement of kaempferol through an engineered layer-by-layer matrix: a study in ovariectomized rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23311987/),mv,-8.9,271293,DB01373,Calcium
,23311987,area under the KEM serum concentration curve,"The area under the KEM serum concentration curve following oral administration of LBL-KEM to rats was 2479 ± 682 ng·h/ml, nearly twofold higher than free KEM.",Osteogenic efficacy enhancement of kaempferol through an engineered layer-by-layer matrix: a study in ovariectomized rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23311987/),[h·ng] / [ml],2479,271294,DB01373,Calcium
,26047011,entrapment efficiencies,"The candidate drugs encapsulated inside PLGA showed entrapment efficiencies ranging from 30%, 33.5% and 32% for hydrochlorothiazide, candesartan and amlodipine respectively.","Development of Sustained Release ""NanoFDC (Fixed Dose Combination)"" for Hypertension - An Experimental Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26047011/),%,30,271417,DB01373,Calcium
,26047011,entrapment efficiencies,"The candidate drugs encapsulated inside PLGA showed entrapment efficiencies ranging from 30%, 33.5% and 32% for hydrochlorothiazide, candesartan and amlodipine respectively.","Development of Sustained Release ""NanoFDC (Fixed Dose Combination)"" for Hypertension - An Experimental Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26047011/),%,33.5,271418,DB01373,Calcium
,26047011,entrapment efficiencies,"The candidate drugs encapsulated inside PLGA showed entrapment efficiencies ranging from 30%, 33.5% and 32% for hydrochlorothiazide, candesartan and amlodipine respectively.","Development of Sustained Release ""NanoFDC (Fixed Dose Combination)"" for Hypertension - An Experimental Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26047011/),%,32,271419,DB01373,Calcium
,26047011,MRT,"In pharmacokinetic analysis a sustained-release for 6 days and significant increase in the mean residence time (MRT), as compared to the respective free drugs was noted [MRT of amlodipine, hydrochlorothiazide and candesartan changed from 8.9 to 80.59 hours, 11 to 69.20 hours and 9 to 101.49 hours respectively].","Development of Sustained Release ""NanoFDC (Fixed Dose Combination)"" for Hypertension - An Experimental Study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26047011/),h,8.9 to 80.59,271420,DB01373,Calcium
,26047011,MRT,"In pharmacokinetic analysis a sustained-release for 6 days and significant increase in the mean residence time (MRT), as compared to the respective free drugs was noted [MRT of amlodipine, hydrochlorothiazide and candesartan changed from 8.9 to 80.59 hours, 11 to 69.20 hours and 9 to 101.49 hours respectively].","Development of Sustained Release ""NanoFDC (Fixed Dose Combination)"" for Hypertension - An Experimental Study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26047011/),h,11 to 69.20,271421,DB01373,Calcium
,26047011,MRT,"In pharmacokinetic analysis a sustained-release for 6 days and significant increase in the mean residence time (MRT), as compared to the respective free drugs was noted [MRT of amlodipine, hydrochlorothiazide and candesartan changed from 8.9 to 80.59 hours, 11 to 69.20 hours and 9 to 101.49 hours respectively].","Development of Sustained Release ""NanoFDC (Fixed Dose Combination)"" for Hypertension - An Experimental Study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26047011/),h,9 to 101.49,271422,DB01373,Calcium
,21495269,flow rate,"The mobile phase was consisted of acetonitrile-5 mM ammonium acetate (52:48, v/v), delivered at flow rate of 1 mL/min.",Bioequivalence of nifedipine softgel and capsule in healthy Chinese volunteers by liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21495269/),[ml] / [min],1,271762,DB01373,Calcium
,28344015,systemic availability,"Atorvastatin calcium (ATV), a cholesterol-lowering agent, suffers from poor systemic availability (14%) after oral administration in addition to other side effects on the gastrointestinal tract, liver and muscle.",Transdermal delivery of atorvastatin calcium from novel nanovesicular systems using polyethylene glycol fatty acid esters: Ameliorated effect without liver toxicity in poloxamer 407-induced hyperlipidemic rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28344015/),%,14,272369,DB01373,Calcium
,28344015,entrapment efficiency (EE%),The results revealed high ATV entrapment efficiency (EE%) ranging from 55.62 to 83.91%.,Transdermal delivery of atorvastatin calcium from novel nanovesicular systems using polyethylene glycol fatty acid esters: Ameliorated effect without liver toxicity in poloxamer 407-induced hyperlipidemic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28344015/),%,55.62 to 83.91,272370,DB01373,Calcium
,16817815,peak insulin,Insulin responses were higher in patients (peak insulin 96.33 +/- 9.71 mU/l) in relation to values found in controls (58.11 +/- 9.03 mU/l; P < 0.01).,Growth hormone and insulin-like growth factor binding protein-1 responses to oral glucose in patients with primary hyperparathyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16817815/),[mu] / [l],96.33,272890,DB01373,Calcium
,16817815,peak insulin,Insulin responses were higher in patients (peak insulin 96.33 +/- 9.71 mU/l) in relation to values found in controls (58.11 +/- 9.03 mU/l; P < 0.01).,Growth hormone and insulin-like growth factor binding protein-1 responses to oral glucose in patients with primary hyperparathyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16817815/),[mu] / [l],58.11,272891,DB01373,Calcium
,16817815,minimum concentration,"The minimum concentration of IGFBP-1 and the area under the curve (AUC) of IGFBP-1 after OGTT were higher after parathyroidectomy (3.34 +/- 0.69 microg/l and 8.94 +/- 1.72 microg x h/l, respectively) than at diagnosis (2.19 +/- 0.42 microg/l and 6.74 +/- 1.28 microg x h/l, respectively; P < 0.05).",Growth hormone and insulin-like growth factor binding protein-1 responses to oral glucose in patients with primary hyperparathyroidism. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16817815/),[μg] / [l],3.34,272892,DB01373,Calcium
,16817815,minimum concentration,"The minimum concentration of IGFBP-1 and the area under the curve (AUC) of IGFBP-1 after OGTT were higher after parathyroidectomy (3.34 +/- 0.69 microg/l and 8.94 +/- 1.72 microg x h/l, respectively) than at diagnosis (2.19 +/- 0.42 microg/l and 6.74 +/- 1.28 microg x h/l, respectively; P < 0.05).",Growth hormone and insulin-like growth factor binding protein-1 responses to oral glucose in patients with primary hyperparathyroidism. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16817815/),[μg] / [l],2.19,272893,DB01373,Calcium
,16817815,area under the curve (AUC),"The minimum concentration of IGFBP-1 and the area under the curve (AUC) of IGFBP-1 after OGTT were higher after parathyroidectomy (3.34 +/- 0.69 microg/l and 8.94 +/- 1.72 microg x h/l, respectively) than at diagnosis (2.19 +/- 0.42 microg/l and 6.74 +/- 1.28 microg x h/l, respectively; P < 0.05).",Growth hormone and insulin-like growth factor binding protein-1 responses to oral glucose in patients with primary hyperparathyroidism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16817815/),[h·μg] / [l],8.94,272894,DB01373,Calcium
,16817815,area under the curve (AUC),"The minimum concentration of IGFBP-1 and the area under the curve (AUC) of IGFBP-1 after OGTT were higher after parathyroidectomy (3.34 +/- 0.69 microg/l and 8.94 +/- 1.72 microg x h/l, respectively) than at diagnosis (2.19 +/- 0.42 microg/l and 6.74 +/- 1.28 microg x h/l, respectively; P < 0.05).",Growth hormone and insulin-like growth factor binding protein-1 responses to oral glucose in patients with primary hyperparathyroidism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16817815/),[h·μg] / [l],6.74,272895,DB01373,Calcium
,26082816,Tmax,"Following a single dose of 1 mg, 2 mg, and 4 mg, the mean (SD) Tmax values were 0.63 (0.17) hours, 0.65 (0.17) hours, and 0.79 (0.36) hours, respectively; the corresponding Cmax values were 66.80 (16.32) ng/mL, 106.09 (31.59) ng/mL, and 232.91 (66.42) ng/mL, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),h,0.63,274053,DB01373,Calcium
,26082816,Tmax,"Following a single dose of 1 mg, 2 mg, and 4 mg, the mean (SD) Tmax values were 0.63 (0.17) hours, 0.65 (0.17) hours, and 0.79 (0.36) hours, respectively; the corresponding Cmax values were 66.80 (16.32) ng/mL, 106.09 (31.59) ng/mL, and 232.91 (66.42) ng/mL, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),h,0.65,274054,DB01373,Calcium
,26082816,Tmax,"Following a single dose of 1 mg, 2 mg, and 4 mg, the mean (SD) Tmax values were 0.63 (0.17) hours, 0.65 (0.17) hours, and 0.79 (0.36) hours, respectively; the corresponding Cmax values were 66.80 (16.32) ng/mL, 106.09 (31.59) ng/mL, and 232.91 (66.42) ng/mL, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),h,0.79,274055,DB01373,Calcium
,26082816,Cmax,"Following a single dose of 1 mg, 2 mg, and 4 mg, the mean (SD) Tmax values were 0.63 (0.17) hours, 0.65 (0.17) hours, and 0.79 (0.36) hours, respectively; the corresponding Cmax values were 66.80 (16.32) ng/mL, 106.09 (31.59) ng/mL, and 232.91 (66.42) ng/mL, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),[ng] / [ml],66.80,274056,DB01373,Calcium
,26082816,Cmax,"Following a single dose of 1 mg, 2 mg, and 4 mg, the mean (SD) Tmax values were 0.63 (0.17) hours, 0.65 (0.17) hours, and 0.79 (0.36) hours, respectively; the corresponding Cmax values were 66.80 (16.32) ng/mL, 106.09 (31.59) ng/mL, and 232.91 (66.42) ng/mL, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),[ng] / [ml],106.09,274057,DB01373,Calcium
,26082816,Cmax,"Following a single dose of 1 mg, 2 mg, and 4 mg, the mean (SD) Tmax values were 0.63 (0.17) hours, 0.65 (0.17) hours, and 0.79 (0.36) hours, respectively; the corresponding Cmax values were 66.80 (16.32) ng/mL, 106.09 (31.59) ng/mL, and 232.91 (66.42) ng/mL, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),[ng] / [ml],232.91,274058,DB01373,Calcium
,26082816,AUC0-36,"AUC0-36 values were 190.04 (38.97) ng/mL/h, 307.87 (57.94) ng/mL/h, and 785.10 (166.08) ng/mL/h, respectively, whereas t1/2 values were 10.99 (2.70) hours, 9.52 (2.58) hours, and 10.38 (4.28) hours, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),[ng] / [h·ml],190.04,274059,DB01373,Calcium
,26082816,AUC0-36,"AUC0-36 values were 190.04 (38.97) ng/mL/h, 307.87 (57.94) ng/mL/h, and 785.10 (166.08) ng/mL/h, respectively, whereas t1/2 values were 10.99 (2.70) hours, 9.52 (2.58) hours, and 10.38 (4.28) hours, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),[ng] / [h·ml],307.87,274060,DB01373,Calcium
,26082816,AUC0-36,"AUC0-36 values were 190.04 (38.97) ng/mL/h, 307.87 (57.94) ng/mL/h, and 785.10 (166.08) ng/mL/h, respectively, whereas t1/2 values were 10.99 (2.70) hours, 9.52 (2.58) hours, and 10.38 (4.28) hours, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),[ng] / [h·ml],785.10,274061,DB01373,Calcium
,26082816,t1/2,"AUC0-36 values were 190.04 (38.97) ng/mL/h, 307.87 (57.94) ng/mL/h, and 785.10 (166.08) ng/mL/h, respectively, whereas t1/2 values were 10.99 (2.70) hours, 9.52 (2.58) hours, and 10.38 (4.28) hours, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),h,10.99,274062,DB01373,Calcium
,26082816,t1/2,"AUC0-36 values were 190.04 (38.97) ng/mL/h, 307.87 (57.94) ng/mL/h, and 785.10 (166.08) ng/mL/h, respectively, whereas t1/2 values were 10.99 (2.70) hours, 9.52 (2.58) hours, and 10.38 (4.28) hours, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),h,9.52,274063,DB01373,Calcium
,26082816,t1/2,"AUC0-36 values were 190.04 (38.97) ng/mL/h, 307.87 (57.94) ng/mL/h, and 785.10 (166.08) ng/mL/h, respectively, whereas t1/2 values were 10.99 (2.70) hours, 9.52 (2.58) hours, and 10.38 (4.28) hours, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),h,10.38,274064,DB01373,Calcium
,26082816,Tmax,"In the multiple-dose study, a rapid absorption (Tmax of 0.68 [0.20] hours) and marked peak concentration of 90.99 (36.88) ng/mL were observed.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),h,0.68,274065,DB01373,Calcium
,26082816,peak concentration,"In the multiple-dose study, a rapid absorption (Tmax of 0.68 [0.20] hours) and marked peak concentration of 90.99 (36.88) ng/mL were observed.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),[ng] / [ml],90.99,274066,DB01373,Calcium
,26082816,AUC0-48,"AUC0-48 and AUCss were 306.28 (130.02) ng/mL/h and 256.16 (116.34) ng/mL/h, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),[ng] / [h·ml],306.28,274067,DB01373,Calcium
,26082816,AUCss,"AUC0-48 and AUCss were 306.28 (130.02) ng/mL/h and 256.16 (116.34) ng/mL/h, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),[ng] / [h·ml],256.16,274068,DB01373,Calcium
,26082816,elimination half-life,"The elimination half-life after multiple dosing was significantly prolonged, which amounted to 13.31 (2.58) hours.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),h,13.31,274069,DB01373,Calcium
